Key Fields

Sequence Number:

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number:

CIBMTR Research ID:

Event date: __ __ __ __ - __ __- __ __

Primary Disease for HCT / Cellular Therapy Questions: 1 - 2

Date of diagnosis of primary disease for HCT / cellular therapy:1 __ __ __ __ - __ __- __ __

What was the primary disease for which the HCT / cellular therapy was performed?2

Acute myelogenous leukemia (AML or ANLL) (10)

Acute lymphoblastic leukemia (ALL) (20)

Acute leukemia of ambiguous lineage and other myeloid neoplasms (80)

Chronic myelogenous leukemia (CML) (40)

Myelodysplastic (MDS) / myeloproliferative (MPN) diseases (50) (Please classify all preleukemias) (If recipient has transformed to AML, indicate AML as the primary disease)

Other leukemia (30) (includes CLL)

Hodgkin lymphoma (150)

Non-Hodgkin lymphoma (100)

Multiple myeloma / plasma cell disorder (PCD) (170)

Solid tumors (200)

Severe aplastic anemia (300) (If the recipient developed MDS or AML, indicate MDS or AML as the primary disease)

Inherited abnormalities of erythrocyte differentiation or function (310)

Disorders of the immune system (400)

Inherited abnormalities of platelets (500)

Inherited disorders of metabolism (520)

Histiocytic disorders (570)

Autoimmune diseases (600)

Other disease (900)

Acute Myelogenous Leukemia (AML) Questions: 3 - 89

Specify the AML classification3

Did AML transform from MDS or MPN?4

yes - Also complete MDS Disease Classification questions

no

Is the disease (AML) therapy related?

yes no Unknown

5

Did the recipient have a predisposing condition?

yes no Unknown

6

Specify condition7

Bloom syndrome

Down syndrome

Fanconi anemia

Dyskeratosis congenita

Other condition

Specify other condition:8

Were cytogenetics tested (karyotyping or FISH)? (at diagnosis)

yes no Unknown

9

Were cytogenetics tested via FISH? (at diagnosis)

Yes No

10

Results of tests11

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities12

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

13

Specify other abnormality:14

Were cytogenetics tested via karyotyping? (at diagnosis)

Yes No

15

Results of tests16

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities17

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

18

Specify other abnormality:19

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

20

Were tests for molecular markers performed? (e.g. PCR, NGS) (at diagnosis)

yes no Unknown

21

CEBPA

Positive Negative Not Done

22

Specify CEBPA mutation23

Biallelic (homozygous)

Monoallelic (heterozygous)

Unknown

FLT3 – D835 point mutation

Positive Negative Not Done

24

FLT3 – ITD mutation

Positive Negative Not Done

25

FLT3 - ITD allelic ratio

Known Unknown

26

Specify FLT3 - ITD allelic ratio:27

IDH1

Positive Negative Not Done

28

IDH2

Positive Negative Not Done

29

KIT

Positive Negative Not Done

30

NPM1

Positive Negative Not Done

31

Other Molecular Marker (1) Questions: 32 - 33

Other molecular marker

Positive Negative Not Done

32

Specify other molecular marker:33

Were cytogenetics tested (karyotyping or FISH)? (between diagnosis and last evaluation)

yes no Unknown

34

Were cytogenetics tested via FISH? (between diagnosis and last evaluation)

Yes No

35

Results of tests36

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities37

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

38

Specify other abnormality:39

Were cytogenetics tested via karyotyping? (between diagnosis and last evaluation)

Yes No

40

Results of tests41

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities42

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

43

Specify other abnormality:44

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

45

Were tests for molecular markers performed? (e.g. PCR, NGS) (between diagnosis and last evaluation)

yes no Unknown

46

CEBPA

Positive Negative Not Done

47

Specify CEBPA mutation48

Biallelic (homozygous)

Monoallelic (heterozygous)

Unknown

FLT3 – D835 point mutation

Positive Negative Not Done

49

FLT3 – ITD mutation

Positive Negative Not Done

50

FLT3 - ITD allelic ratio

Known Unknown

51

Specify FLT3 - ITD allelic ratio:52

IDH1

Positive Negative Not Done

53

IDH2

Positive Negative Not Done

54

KIT

Positive Negative Not Done

55

NPM1

Positive Negative Not Done

56

Other Molecular Marker (1) Questions: 57 - 58

Other molecular marker

Positive Negative Not Done

57

Specify other molecular marker:58

Were cytogenetics tested (karyotyping or FISH)? (at last evaluation)

yes no Unknown

59

Were cytogenetics tested via FISH? (at last evaluation)

Yes No

60

Results of tests61

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities62

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

63

Specify other abnormality:64

Were cytogenetics tested via karyotyping? (at last evaluation)

Yes No

65

Results of tests66

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities67

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

68

Specify other abnormality:69

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

70

Were tests for molecular markers performed? (e.g. PCR, NGS) (at last evaluation)

yes no Unknown

71

CEBPA

Positive Negative Not Done

72

Specify CEBPA mutation73

Biallelic (homozygous)

Monoallelic (heterozygous)

Unknown

FLT3 – D835 point mutation

Positive Negative Not Done

74

FLT3 – ITD mutation

Positive Negative Not Done

75

FLT3 - ITD allelic ratio

Known Unknown

76

Specify FLT3 - ITD allelic ratio:77

IDH1

Positive Negative Not Done

78

IDH2

Positive Negative Not Done

79

KIT

Positive Negative Not Done

80

NPM1

Positive Negative Not Done

81

Other Molecular Marker (1) Questions: 82 - 83

Other molecular marker

Positive Negative Not Done

82

Specify other molecular marker:83

Did the recipient have central nervous system leukemia at any time prior to the start of the preparative regimen / infusion?

yes no Unknown

84

What was the disease status (based on hematological test results)?85

Primary induction failure

1st complete remission (no previous bone marrow or extramedullary relapse) (include CRi)

2nd complete remission

≥3rd complete remission

1st relapse

2nd relapse

≥3rd relapse

No treatment

How many cycles of induction therapy were required to achieve 1st complete remission? (includes CRi)

1 2 ≥ 3

86

Was the recipient in remission by flow cytometry?

Yes No Unknown Not applicable

87

Date of most recent relapse:88 __ __ __ __ - __ __- __ __

Date assessed:89 __ __ __ __ - __ __- __ __

Acute Lymphoblastic Leukemia (ALL) Questions: 90 - 151

Specify ALL classification90

Did the recipient have a predisposing condition?

yes no Unknown

91

Specify condition92

Aplastic anemia - Also complete CIBMTR Form 2028 - APL

Bloom syndrome

Down syndrome

Fanconi anemia - Also complete CIBMTR Form 2029 - FAN

Other condition

Specify other condition:93

Were tyrosine kinase inhibitors given for therapy at any time prior to the start of the preparative regimen / infusion? (e.g. imatinib mesylate, dasatinib, etc.)

yes no

94

Were cytogenetics tested (karyotyping or FISH)? (at diagnosis)

yes no Unknown

95

Were cytogenetics tested via FISH? (at diagnosis)

Yes No

96

Results of tests97

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities98

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

99

Specify other abnormality:100

Were cytogenetics tested via karyotyping? (at diagnosis)

Yes No

101

Results of tests102

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities103

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

104

Specify other abnormality:105

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

106

Were tests for molecular markers performed? (e.g. PCR, NGS) (at diagnosis)

yes no Unknown

107

BCR / ABL

Positive Negative Not Done

108

TEL-AML / AML1

Positive Negative Not Done

109

Other Molecular Marker (1) Questions: 110 - 111

Other molecular marker

Positive Negative Not Done

110

Specify other molecular marker:111

Were cytogenetics tested (karyotyping or FISH)? (between diagnosis and last evaluation)

yes no Unknown

112

Were cytogenetics tested via FISH? (between diagnosis and last evaluation)

Yes No

113

Results of tests114

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities115

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

116

Specify other abnormality:117

Were cytogenetics tested via karyotyping? (between diagnosis and last evaluation)

Yes No

118

Results of tests119

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities120

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

121

Specify other abnormality:122

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

123

Were tests for molecular markers performed? (e.g. PCR, NGS) (between diagnosis and last evaluation)

yes no Unknown

124

BCR / ABL

Positive Negative Not Done

125

TEL-AML / AML1

Positive Negative Not Done

126

Other Molecular Marker (1) Questions: 127 - 128

Other molecular marker

Positive Negative Not Done

127

Specify other molecular marker:128

Were cytogenetics tested (karyotyping or FISH)? (at last evaluation)

yes no Unknown

129

Were cytogenetics tested via FISH? (at last evaluation)

Yes No

130

Results of tests131

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities132

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

133

Specify other abnormality:134

Were cytogenetics tested via karyotyping? (at last evaluation)

Yes No

135

Results of tests136

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities137

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

138

Specify other abnormality:139

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

140

Were tests for molecular markers performed? (e.g. PCR, NGS) (at last evaluation)

yes no Unknown

141

BCR / ABL

Positive Negative Not Done

142

TEL-AML / AML1

Positive Negative Not Done

143

Other Molecular Marker (1) Questions: 144 - 145

Other molecular marker

Positive Negative Not Done

144

Specify other molecular marker:145

Did the recipient have central nervous system leukemia at any time prior to the start of the preparative regimen / infusion?

yes no Unknown

146

What was the disease status (based on hematological test results)?147

Primary induction failure

1st complete remission (no previous marrow or extramedullary relapse) (include CRi)

2nd complete remission

≥3rd complete remission

1st relapse

2nd relapse

≥3rd relapse

No treatment

How many cycles of induction therapy were required to achieve 1st complete remission? (include CRi)

1 2 ≥ 3

148

Was the recipient in remission by flow cytometry?

Yes No Unknown Not applicable

149

Date of most recent relapse:150 __ __ __ __ - __ __- __ __

Date assessed:151 __ __ __ __ - __ __- __ __

Acute Leukemias of Ambiguous Lineage and Other Myeloid Neoplasms Questions: 152 - 155

Specify acute leukemias of ambiguous lineage and other myeloid neoplasm classification152

Blastic plasmacytoid dendritic cell neoplasm (296)

Acute undifferentiated leukemia (31)

Mixed phenotype acute leukemia (MPAL) with t(9;22)(q34.1;q11.2); BCR-ABL1 (84)

Mixed phenotype acute leukemia with t(v; 11q23.3); KMT2A rearranged (85)

Mixed phenotype acute leukemia, B/myeloid, NOS (86)

Mixed phenotype acute leukemia, T/myeloid, NOS (87)

Other acute leukemia of ambiguous lineage or myeloid neoplasm (88)

Specify other acute leukemia of ambiguous lineage or myeloid neoplasm:153

What was the disease status (based on hematological test results)?154

Primary induction failure

1st complete remission (no previous marrow or extramedullary relapse)

2nd complete remission

≥3rd complete remission

1st relapse

2nd relapse

≥3rd relapse

No treatment

Date assessed:155 __ __ __ __ - __ __- __ __

Chronic Myelogenous Leukemia (CML) Questions: 156 - 166

Was therapy given prior to this HCT?

yes no

156

Combination chemotherapy

yes no

157

Hydroxyurea (Droxia, Hydrea)

yes no

158

Tyrosine kinase inhibitor (e.g. imatinib mesylate, dasatinib, nilotinib)

yes no

159

Interferon­α (Intron, Roferon) (includes PEG)

yes no

160

Other therapy

yes no

161

Specify other therapy:162

What was the disease status?163

Complete hematologic response (CHR)

Chronic phase

Accelerated phase

Blast phase

Specify level of response164

No cytogenetic response (No CyR)

Minimal cytogenetic response

Minor cytogenetic response

Partial cytogenetic response (PCyR)

Complete cytogenetic response (CCyR)

Major molecular remission (MMR)

Complete molecular remission (CMR)

Number

1st 2nd 3rd or higher

165

Date assessed:166 __ __ __ __ - __ __- __ __

Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases Questions: 167 - 260

What was the MDS / MPN subtype at diagnosis? - If transformed to AML, indicate AML as primary disease; also complete AML Disease Classification
questions

167

Was the disease (MDS/MPN) therapy related?

yes no Unknown

168

Did the recipient have a predisposing condition?

yes no Unknown

169

Specify condition

Aplastic Anemia Bloom syndrome Down syndrome Fanconi anemia Other condition

170

Specify other condition:171

WBC

Known Unknown

172

173 x 109/L (x 103/mm3)

x 106/L

Hemoglobin

Known Unknown

174

175 g/dL g/L mmol/L

Was RBC transfused ≤ 30 days before date of test?

Yes No

176

Platelets

Known Unknown

177

178 x 109/L (x 103/mm3)

x 106/L

Were platelets transfused ≤ 7 days before date of test?

Yes No

179

Neutrophils

Known Unknown

180

181 %

Blasts in bone marrow

Known Unknown

182

183 %

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

184

Results of tests185

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities186

One (1)

Two (2)

Three (3)

Four or more (4 or more)

–5

yes no

187

-7

yes no

188

–13

yes no

189

–20

yes no

190

–Y

yes no

191

+8

yes no

192

+19

yes no

193

t(1;3)

yes no

194

t(2;11)

yes no

195

t(3;3)

yes no

196

t(3;21)

yes no

197

t(6;9)

yes no

198

t(11;16)

yes no

199

del(3q) / 3q–

yes no

200

del(5q) / 5q-

yes no

201

del(7q) / 7q–

yes no

202

del(9q) / 9q–

yes no

203

del(11q) / 11q–

yes no

204

del(12p) / 12p–

yes no

205

del(13q) / 13q-

yes no

206

del(20q) / 20q–

yes no

207

inv(3)

yes no

208

i17q

yes no

209

Other abnormality

yes no

210

Specify other abnormality:211

Did the recipient progress or transform to a different MDS / MPN subtype between diagnosis and the start of the preparative regimen?

yes no

212

Specify the MDS / MPN classification after transformation:213

Specify the date of the most recent transformation:214 __ __ __ __ - __ __- __ __

Date of MDS diagnosis:215 __ __ __ __ - __ __- __ __

WBC

Known Unknown

216

217 x 109/L (x 103/mm3)

x 106/L

Hemoglobin

Known Unknown

218

219 g/dL g/L mmol/L

Was RBC transfused ≤ 30 days before date of test?

Yes No

220

Platelets

Known Unknown

221

222 x 109/L (x 103/mm3)

x 106/L

Were platelets transfused ≤ 7 days before date of test?

Yes No

223

Neutrophils

Known Unknown

224

225 %

Blasts in bone marrow

Known Unknown

226

227 %

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

228

Results of tests229

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities230

One (1)

Two (2)

Three (3)

Four or more (4 or more)

–5

yes no

231

-7

yes no

232

–13

yes no

233

–20

yes no

234

–Y

yes no

235

+8

yes no

236

+19

yes no

237

t(1;3)

yes no

238

t(2;11)

yes no

239

t(3;3)

yes no

240

t(3;21)

yes no

241

t(6;9)

yes no

242

t(11;16)

yes no

243

del(3q) / 3q–

yes no

244

del(5q) / 5q-

yes no

245

del(7q) / 7q–

yes no

246

del(9q) / 9q–

yes no

247

del(11q) / 11q–

yes no

248

del(12p) / 12p–

yes no

249

del(13q) / 13q-

yes no

250

del(20q) / 20q–

yes no

251

inv(3)

yes no

252

i17q

yes no

253

Other abnormality

yes no

254

Specify other abnormality:255

What was the disease status?256

Complete
remission

(CR)

– requires all of the following, maintained for ≥ 4 weeks: * bone marrow evaluation: <  5% myeloblasts with normal maturation of all cell lines *
peripheral blood evaluation: hemoglobin ≥ 11 g/dL untransfused and without erythropoietin support; ANC ≥ 1000/mm3  without myeloid growth factor
support; platelets ≥ 100 x 109/L without thrombopoietic support; 0% blasts

Hematologic

improvement
(HI)

– requires one measurement of the following, maintained for ≥ 8 weeks without ongoing cytotoxic therapy; specify which cell line was measured to
determine HI response: * HI­E – hemoglobin increase of ≥ 1.5 g/dL untransfused; for RBC transfusions performed for Hgb ≤ 9.0, reduction in RBC
units transfused in 8 weeks by ≥ 4 units compared to the pre­treatment transfusion number in 8 weeks * HI­P – for pre­treatment platelet count of > 20
x 109/L, platelet absolute increase of ≥ 30 x 109/L; for pre-treatment platelet count of < 20 x 109/L, platelet absolute increase of ≥ 20 x 109/L and ≥
100% from pre­treatment level  * HI­N – neutrophil count increase of ≥ 100% from pre­treatment level and an absolute increase of ≥ 500/mm3

No response (NR) / stable disease (SD) – does not meet the criteria for at least HI, but no evidence of disease progression

Progression from
hematologic improvement

(Prog from HI)

– requires at least one of the following, in the absence of another explanation (e.g., infection, bleeding, ongoing chemotherapy, etc.): *
≥ 50% reduction from maximum response levels in granulocytes or platelets * reduction in hemoglobin by ≥ 1.5 g/dL *transfusion
dependence

Relapse from complete

remission (Rel from CR)

– requires at least one of the following: * return to pre­treatment bone marrow blast percentage * decrease of ≥ 50% from maximum
response levels in granulocytes or platelets * transfusion dependence, or hemoglobin level ≥ 1.5 g/dL lower than prior to therapy

Not assessed

Specify the cell line examined to determine HI status257

HI-
E

– hemoglobin increase of ≥ 1.5 g/dL untransfused; for RBC transfusions performed for Hgb ≤ 9.0, reduction in RBC units transfused in 8 weeks by ≥ 4
units compared to the pre-treatment transfusion number in 8 weeks

HI-
P

– for pre­treatment platelet count of > 20 x 109/L, platelet absolute increase of ≥ 30 x 109/L; for pre-treatment platelet count of < 20 x 109/L, platelet
absolute increase of ≥ 20 x 109/L and ≥ 100% from pre­treatment level 

HI-N – neutrophil count increase of ≥ 100% from pre­treatment level and an absolute increase of ≥ 500/mm3

Date of progression:258 __ __ __ __ - __ __- __ __

Date of relapse:259 __ __ __ __ - __ __- __ __

Date assessed:260 __ __ __ __ - __ __- __ __

Other Leukemia (OL) Questions: 261 - 267

Specify the other leukemia classification261

Specify other leukemia:262

Was any 17p abnormality detected?

yes no

263

Did a histologic transformation to diffuse large B-cell lymphoma (Richter syndrome) occur at any time after CLL diagnosis?264

yes - Also complete NHL Disease Classification questions

no

What was the disease status? (Atypical CML)265

Primary induction failure

1st complete remission (no previous bone marrow or extramedullary relapse)

2nd complete remission

≥3rd complete remission

1st relapse

2nd relapse

≥3rd relapse

No treatment

What was the disease status? (CLL, PLL, Hairy cell leukemia)266

Complete remission (CR)

Partial remission (PR)

Stable disease (SD)

Progressive disease (Prog)

Untreated

Not assessed

Date assessed:267 __ __ __ __ - __ __- __ __

Hodgkin and Non-Hodgkin Lymphoma Questions: 268 - 285

Specify the lymphoma histology (at infusion)268

Specify other lymphoma histology:269

Assignment of DLBCL (germinal center B-cell type vs. activated B-cell type) subtype was based on270

Immunohistochemistry (e.g. Han's algorithm)

Gene expression profile

Unknown method

Is the lymphoma histology reported at transplant a transformation from CLL?

yes no

271

Was any 17p abnormality detected?

yes no

272

Is the lymphoma histology reported at transplant a transformation from a different lymphoma histology? (Not CLL)

Yes No

273

Specify the original lymphoma histology (prior to transformation)274

Specify other lymphoma histology:275

Date of original lymphoma diagnosis:276 __ __ __ __ - __ __- __ __ (report the date of diagnosis of original lymphoma subtype)

Was a PET (or PET/CT) scan performed? (at last evaluation prior to the start of the preparative regimen / infusion)

yes no

277

Was the PET (or PET/CT) scan positive for lymphoma involvement at any disease site?

yes no

278

Date of PET scan

Known Unknown

279

Date of PET (or PET/CT) scan:280 __ __ __ __ - __ __- __ __

Deauville (five-point) score of the PET (or PET/CT) scan

Known Unknown

281

Scale282

1 - no uptake or residual uptake

2 - slight uptake, but below blood pool (mediastinum)

3 - uptake above mediastinal, but below or equal to uptake in the liver

4 - uptake slightly to moderately higher than liver

5 - markedly increased uptake or any new lesions

What was the disease status?283

Total number of lines of therapy received

1 line 2 lines 3+ lines

284

Date assessed:285 __ __ __ __ - __ __- __ __

Multiple Myeloma / Plasma Cell Disorder (PCD) Questions: 286 - 317

Specify the multiple myeloma/plasma cell disorder (PCD) classification286

Specify other plasma cell disorder:287

Light chain

kappa lambda

288

What was the Durie-Salmon staging? (at diagnosis)289

Stage
I

(All of the following: Hgb > 10g/dL; serum calcium normal or <10.5 mg/dL; bone x-ray normal bone structure (scale 0), or solitary bone plasmacytoma
only; low M-component production rates IgG< 5g/dL, IgA < 3g/dL; urine light chain M-component on electrophoresis <4 g/24h)

Stage II (Fitting neither Stage I or III) 

Stage
III

(One or more of the following: Hgb < 8.5 g/dL; serum calcium > 12 mg/dL; advanced lytic bone lesions (scale 3); high M-component production rates
IgG > 7g/dL, IgA > 5 g/dL; Bence Jones protein > 12g/24h)

Unknown

What was the Durie-Salmon sub classification? (at diagnosis)290

A - relatively normal renal function (serum creatinine < 2.0 mg/dL)

B ­ abnormal renal function (serum creatinine ≥ 2.0 mg/dL)

Serum β2­microglobulin:291 μg/dL mg/L nmol/L

Serum albumin:292 g/dL g/L

Stage293

1 (β2 ­mic < 3.5, S. albumin ≥3.5)

2 (Not fitting stage 1 or 3)

3 (β2­mic ≥ 5.5; S. albumin ­)

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

294

Results of tests295

Abnormalities identified

No evaluable metaphases

No abnormalities

+3

yes no

296

+5

yes no

297

+7

yes no

298

+9

yes no

299

+11

yes no

300

+15

yes no

301

+19

yes no

302

t(4;14)

yes no

303

t(6;14)

yes no

304

t(11;14)

yes no

305

t(14;16)

yes no

306

t(14;20)

yes no

307

del(13q) / 13q-

yes no

308

del (17p) / 17p-

yes no

309

Hyperdiploid (>50)

yes no

310

Hypodiploid (<46)

yes no

311

Any abnormality at 1q

yes no

312

Any abnormality at 1p

yes no

313

Other abnormality

yes no

314

Specify other abnormality:315

What was the disease status?316

Stringent
complete

remission
(sCR)

- CR as defined, plus: normal free light chain ratio, and absence of clonal cells in the bone marrow by immunohistochemistry of immunofluorescence
(confirmation with repeat bone marrow biopsy not needed). (Presence and/or absence of clonal cells is based upon the Κ/λ ratio. An abnormal Κ/λ ratio by
immunohistochemistry and/or immunofluorescence requires a minimum of 100 plasma cells for analysis.  An abnormal ratio reflecting the presence of
an abnormal clone is Κ/λ of > 4:1 or < 1:2.) sCR requires two consecutive assessments made at any time before the institution of any new therapy, and
no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy sCR
requirements. 

Complete
remission

(CR)

- negative immunofixation on serum and urine samples, and disappearance of any soft tissue plasmacytomas, and < 5% plasma cells in the bone
marrow (confirmation with repeat bone marrow biopsy not needed).  CR requires two consecutive assessments made at any time before the institution

of any new therapy, and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not
required to satisfy CR requirements. 

Near
complete
remission
(nCR)

- serum and urine M-protein detectable by immunoelectrophoresis (IFE), but not on electrophoresis (negative SPEP & UPEP); < 5% plasma cells in
bone marrow.  nCR requires two consecutive assessments made at any time before the initiation of any new therapy, and no known evidence of
progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy nCR requirements. 

Very good
partial
remission
(VGPR)

­ serum and urine M­protein detectable by immunofixation but not on electrophoresis, or ≥ 90% reduction in serum M­protein and urine M­protein level <
100 mg/24 hours.  VGPR requires two consecutive assessments made at any time before the institution of any new therapy, and no known evidence of
progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy VGPR requirements.

Partial
remission
(PR)

­ ≥ 50% reduction in serum M­protein, and reduction in 24­hour urinary M­protein by ≥ 90% or to < 200 mg/24 hours.  If the serum and urine M­protein are
unmeasurable (i.e., do not meet any of the following criteria: • serum M­protein ≥ 1 g/dL.  Urine M­protein ≥ 200 mg/24 hours • serum free light chain
assay shows involved level ≥ 10 mg/dL, provided serum free light chain ratio is abnormal), a ≥ 50% decrease in the difference between involved and
uninvolved free light chain levels is required in place of the M-protein criteria.  If serum and urine M-protein are unmeasurable, and serum free light assay
is also unmeasurable, a ≥ 50% reduction in plasma cells is required in place of M­protein, provided the baseline bone marrow plasma cell percentage
was ≥ 30%. In addition to the above listed criteria, a ≥ 50% reduction in the size of soft tissue plasmacytomas is also required, if present at baseline. PR
requires two consecutive assessments made at any time before the institution of any new therapy, and no known evidence of progressive or new bone
lesions if radiographic studies were performed; radiographic studies are not required to satisfy PR requirements. 

Stable
disease
(SD)

- not meeting the criteria for CR, VGPR, PR or PD.  SD requires two consecutive assessments made at any time before the institution of any new therapy,
and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy SD
requirements.

Progressive
disease
(PD)

­ requires any one or more of the following:  Increase of ≥ 25% from baseline in:  serum M­component and/or (absolute increase ≥ 0.5 g/dL) (for
progressive disease, serum M­component increases of ≥ 1 g/dL are sufficient to define relapse if the starting M­component is ≥ 5 g/dL).  Urine M­
component and/or (absolute increase ≥ 200 mg/24 hours) for recipients without measurable serum and urine M­protein levels: the difference between
involved and uninvolved free light chain levels (absolute increase > 10 mg/dL).  Bone marrow plasma cell percentage (absolute percentage ≥ 10%)
(relapse from CR has a 5% cutoff vs. 10% for other categories of relapse) definite development of new bone lesions or soft tissue plasmacytomas, or
definite increase in the size of any existing  bone lesions or soft tissue plasmacytomas. Development of hypercalcemia (corrected serum calcium >
11.5 mg/dL or 2.65 mmol) that can be attributed solely to the plasma cell proliferative disorder.  PD requires two consecutive assessments made at
any time before classification as disease progression, and/or the institution of any new therapy.

Relapse
from CR
(Rel)
(untreated)

­ requires one or more of the following: reappearance of serum or urine M­protein by immunofixation or electrophoresis development of ≥ 5% plasma
cells in the bone marrow (relapse from CR has a 5% cutoff vs. 10% for other categories of relapse) appearance of any other sign of progression (e.g.,
new plasmacytoma, lytic bone lesion, hypercalcemia).  Rel requires two consecutive assessments made at any time before classification as relapse,
and/or the institution of any new therapy.

Unknown

Not applicable (Amyloidosis with no evidence of myeloma)

Date assessed:317 __ __ __ __ - __ __- __ __

Solid Tumors Questions: 318 - 319

Specify the solid tumor classification318

Specify other solid tumor:319

Severe Aplastic Anemia Questions: 320 - 321

Specify the severe aplastic anemia classification320

Specify other acquired cytopenic syndrome:321

Inherited Abnormalities of Erythrocyte Differentiation or Function Questions: 322 - 324

Specify the inherited abnormalities of erythrocyte differentiation or function classification322

Specify other constitutional anemia:323

Specify other hemoglobinopathy:324

Disorders of the Immune System Questions: 325 - 327

Specify disorder of immune system classification325

Specify other SCID:326

Specify other immunodeficiency:327

Inherited Abnormalities of Platelets Questions: 328 - 329

Specify inherited abnormalities of platelets classification328

Congenital amegakaryocytosis / congenital thrombocytopenia (501)

Glanzmann thrombasthenia (502)

Other inherited platelet abnormality (509)

Specify other inherited platelet abnormality:329

Inherited Disorders of Metabolism Questions: 330 - 331

Specify inherited disorders of metabolism classification330

Specify other inherited metabolic disorder:331

Histiocytic Disorders Questions: 332 - 333

Specify histiocytic disorder classification332

Specify other histiocytic disorder:333

Autoimmune Diseases Questions: 334 - 341

Specify autoimmune disease classification334

Specify other arthritis:335

Specify other juvenile idiopathic arthritis (JIA):336

Specify other connective tissue disease:337

Specify other vasculitis:338

Specify other autoimmune neurological disorder:339

Specify other autoimmune cytopenia:340

Specify other autoimmune bowel disorder:341

Other Disease Questions: 342 - 342

Specify other disease:342

First Name:

Last Name:

E-mail address:

Date: __ __ __ __ - __ __- __ __

OMB No: 0915-0310

Expiration Date: 1/31/2020

Public Burden Statement:  An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control
number.  The OMB control number for this project is 0915-0310.  Public reporting burden for this collection of information is estimated to average 1.0 hours per response, including the
time for reviewing instructions, searching existing data sources, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other
aspect of this collection of information, including suggestions for reducing this burden, to HRSA Reports Clearance Officer, 5600 Fishers Lane, Room 10-29, Rockville, Maryland, 20857.

Labs at diagnosis

Specify cytogenetic abnormalities identified at diagnosis:

Specify cytogenetic abnormalities identified at diagnosis:

Specify molecular markers identified at diagnosis:

Labs between diagnosis and last evaluation:

Specify cytogenetic abnormalities identified between diagnosis and last evaluation:

Specify cytogenetic abnormalities identified between diagnosis and last evaluation:

Specify molecular markers identified between diagnosis and last evaluation:

Labs at last evaluation:

Specify cytogenetic abnormalities identified at last evaluation:

Specify cytogenetic abnormalities identified at last evaluation:

Specify molecular markers identified at last evaluation:

CNS Leukemia

Status at transplantation:

Laboratory studies at diagnosis:

Specify cytogenetic abnormalities identified at diagnosis:

Specify cytogenetic abnormalities identified at diagnosis:

Specify molecular markers identified at diagnosis:

Laboratory studies between diagnosis and last evaluation:

Specify cytogenetic abnormalities identified between diagnosis and last evaluation:

Specify cytogenetic abnormalities identified between diagnosis and last evaluation:

Specify molecular markers identified between diagnosis and last evaluation:

Laboratory studies at last evaluation:

Specify cytogenetic abnormalities identified at last evaluation:

Specify cytogenetic abnormalities identified at last evaluation:

Specify molecular markers identified at last evaluation:

CNS Leukemia

Status at transplantation:

Status at transplantation:

Laboratory studies at diagnosis of MDS:

Specify abnormalities identified at diagnosis:

Monosomy

Trisomy

Translocation

Deletion

Inversion

Other

Laboratory studies at last evaluation prior to the start of the preparative regimen:

Specify cytogenetic abnormalities identified at last evaluation prior to the start of the preparative regimen:

Monosomy

Trisomy

Translocation

Deletion

Inversion

Other

Status at transplantation:

Status at transplantation:

Status at transplantation / infusion:

I.S.S.:

Specify cytogenetic abnormalities identified at any time prior to the start of the preparative regimen:

Trisomy

Translocation

Deletion

Other

Status at transplantation:

Center: CRID: 

Form 2402 R3.0: Disease Classification

CIBMTR Form 2402 revision 3.0 last updated Monday, January 29, 2018
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 1 / 26



Key Fields

Sequence Number:

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number:

CIBMTR Research ID:

Event date: __ __ __ __ - __ __- __ __

Primary Disease for HCT / Cellular Therapy Questions: 1 - 2

Date of diagnosis of primary disease for HCT / cellular therapy:1 __ __ __ __ - __ __- __ __

What was the primary disease for which the HCT / cellular therapy was performed?2

Acute myelogenous leukemia (AML or ANLL) (10)

Acute lymphoblastic leukemia (ALL) (20)

Acute leukemia of ambiguous lineage and other myeloid neoplasms (80)

Chronic myelogenous leukemia (CML) (40)

Myelodysplastic (MDS) / myeloproliferative (MPN) diseases (50) (Please classify all preleukemias) (If recipient has transformed to AML, indicate AML as the primary disease)

Other leukemia (30) (includes CLL)

Hodgkin lymphoma (150)

Non-Hodgkin lymphoma (100)

Multiple myeloma / plasma cell disorder (PCD) (170)

Solid tumors (200)

Severe aplastic anemia (300) (If the recipient developed MDS or AML, indicate MDS or AML as the primary disease)

Inherited abnormalities of erythrocyte differentiation or function (310)

Disorders of the immune system (400)

Inherited abnormalities of platelets (500)

Inherited disorders of metabolism (520)

Histiocytic disorders (570)

Autoimmune diseases (600)

Other disease (900)

Acute Myelogenous Leukemia (AML) Questions: 3 - 89

Specify the AML classification3

Did AML transform from MDS or MPN?4

yes - Also complete MDS Disease Classification questions

no

Is the disease (AML) therapy related?

yes no Unknown

5

Did the recipient have a predisposing condition?

yes no Unknown

6

Specify condition7

Bloom syndrome

Down syndrome

Fanconi anemia

Dyskeratosis congenita

Other condition

Specify other condition:8

Were cytogenetics tested (karyotyping or FISH)? (at diagnosis)

yes no Unknown

9

Were cytogenetics tested via FISH? (at diagnosis)

Yes No

10

Results of tests11

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities12

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

13

Specify other abnormality:14

Were cytogenetics tested via karyotyping? (at diagnosis)

Yes No

15

Results of tests16

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities17

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

18

Specify other abnormality:19

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

20

Were tests for molecular markers performed? (e.g. PCR, NGS) (at diagnosis)

yes no Unknown

21

CEBPA

Positive Negative Not Done

22

Specify CEBPA mutation23

Biallelic (homozygous)

Monoallelic (heterozygous)

Unknown

FLT3 – D835 point mutation

Positive Negative Not Done

24

FLT3 – ITD mutation

Positive Negative Not Done

25

FLT3 - ITD allelic ratio

Known Unknown

26

Specify FLT3 - ITD allelic ratio:27

IDH1

Positive Negative Not Done

28

IDH2

Positive Negative Not Done

29

KIT

Positive Negative Not Done

30

NPM1

Positive Negative Not Done

31

Other Molecular Marker (1) Questions: 32 - 33

Other molecular marker

Positive Negative Not Done

32

Specify other molecular marker:33

Were cytogenetics tested (karyotyping or FISH)? (between diagnosis and last evaluation)

yes no Unknown

34

Were cytogenetics tested via FISH? (between diagnosis and last evaluation)

Yes No

35

Results of tests36

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities37

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

38

Specify other abnormality:39

Were cytogenetics tested via karyotyping? (between diagnosis and last evaluation)

Yes No

40

Results of tests41

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities42

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

43

Specify other abnormality:44

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

45

Were tests for molecular markers performed? (e.g. PCR, NGS) (between diagnosis and last evaluation)

yes no Unknown

46

CEBPA

Positive Negative Not Done

47

Specify CEBPA mutation48

Biallelic (homozygous)

Monoallelic (heterozygous)

Unknown

FLT3 – D835 point mutation

Positive Negative Not Done

49

FLT3 – ITD mutation

Positive Negative Not Done

50

FLT3 - ITD allelic ratio

Known Unknown

51

Specify FLT3 - ITD allelic ratio:52

IDH1

Positive Negative Not Done

53

IDH2

Positive Negative Not Done

54

KIT

Positive Negative Not Done

55

NPM1

Positive Negative Not Done

56

Other Molecular Marker (1) Questions: 57 - 58

Other molecular marker

Positive Negative Not Done

57

Specify other molecular marker:58

Were cytogenetics tested (karyotyping or FISH)? (at last evaluation)

yes no Unknown

59

Were cytogenetics tested via FISH? (at last evaluation)

Yes No

60

Results of tests61

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities62

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

63

Specify other abnormality:64

Were cytogenetics tested via karyotyping? (at last evaluation)

Yes No

65

Results of tests66

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities67

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

68

Specify other abnormality:69

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

70

Were tests for molecular markers performed? (e.g. PCR, NGS) (at last evaluation)

yes no Unknown

71

CEBPA

Positive Negative Not Done

72

Specify CEBPA mutation73

Biallelic (homozygous)

Monoallelic (heterozygous)

Unknown

FLT3 – D835 point mutation

Positive Negative Not Done

74

FLT3 – ITD mutation

Positive Negative Not Done

75

FLT3 - ITD allelic ratio

Known Unknown

76

Specify FLT3 - ITD allelic ratio:77

IDH1

Positive Negative Not Done

78

IDH2

Positive Negative Not Done

79

KIT

Positive Negative Not Done

80

NPM1

Positive Negative Not Done

81

Other Molecular Marker (1) Questions: 82 - 83

Other molecular marker

Positive Negative Not Done

82

Specify other molecular marker:83

Did the recipient have central nervous system leukemia at any time prior to the start of the preparative regimen / infusion?

yes no Unknown

84

What was the disease status (based on hematological test results)?85

Primary induction failure

1st complete remission (no previous bone marrow or extramedullary relapse) (include CRi)

2nd complete remission

≥3rd complete remission

1st relapse

2nd relapse

≥3rd relapse

No treatment

How many cycles of induction therapy were required to achieve 1st complete remission? (includes CRi)

1 2 ≥ 3

86

Was the recipient in remission by flow cytometry?

Yes No Unknown Not applicable

87

Date of most recent relapse:88 __ __ __ __ - __ __- __ __

Date assessed:89 __ __ __ __ - __ __- __ __

Acute Lymphoblastic Leukemia (ALL) Questions: 90 - 151

Specify ALL classification90

Did the recipient have a predisposing condition?

yes no Unknown

91

Specify condition92

Aplastic anemia - Also complete CIBMTR Form 2028 - APL

Bloom syndrome

Down syndrome

Fanconi anemia - Also complete CIBMTR Form 2029 - FAN

Other condition

Specify other condition:93

Were tyrosine kinase inhibitors given for therapy at any time prior to the start of the preparative regimen / infusion? (e.g. imatinib mesylate, dasatinib, etc.)

yes no

94

Were cytogenetics tested (karyotyping or FISH)? (at diagnosis)

yes no Unknown

95

Were cytogenetics tested via FISH? (at diagnosis)

Yes No

96

Results of tests97

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities98

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

99

Specify other abnormality:100

Were cytogenetics tested via karyotyping? (at diagnosis)

Yes No

101

Results of tests102

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities103

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

104

Specify other abnormality:105

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

106

Were tests for molecular markers performed? (e.g. PCR, NGS) (at diagnosis)

yes no Unknown

107

BCR / ABL

Positive Negative Not Done

108

TEL-AML / AML1

Positive Negative Not Done

109

Other Molecular Marker (1) Questions: 110 - 111

Other molecular marker

Positive Negative Not Done

110

Specify other molecular marker:111

Were cytogenetics tested (karyotyping or FISH)? (between diagnosis and last evaluation)

yes no Unknown

112

Were cytogenetics tested via FISH? (between diagnosis and last evaluation)

Yes No

113

Results of tests114

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities115

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

116

Specify other abnormality:117

Were cytogenetics tested via karyotyping? (between diagnosis and last evaluation)

Yes No

118

Results of tests119

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities120

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

121

Specify other abnormality:122

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

123

Were tests for molecular markers performed? (e.g. PCR, NGS) (between diagnosis and last evaluation)

yes no Unknown

124

BCR / ABL

Positive Negative Not Done

125

TEL-AML / AML1

Positive Negative Not Done

126

Other Molecular Marker (1) Questions: 127 - 128

Other molecular marker

Positive Negative Not Done

127

Specify other molecular marker:128

Were cytogenetics tested (karyotyping or FISH)? (at last evaluation)

yes no Unknown

129

Were cytogenetics tested via FISH? (at last evaluation)

Yes No

130

Results of tests131

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities132

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

133

Specify other abnormality:134

Were cytogenetics tested via karyotyping? (at last evaluation)

Yes No

135

Results of tests136

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities137

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

138

Specify other abnormality:139

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

140

Were tests for molecular markers performed? (e.g. PCR, NGS) (at last evaluation)

yes no Unknown

141

BCR / ABL

Positive Negative Not Done

142

TEL-AML / AML1

Positive Negative Not Done

143

Other Molecular Marker (1) Questions: 144 - 145

Other molecular marker

Positive Negative Not Done

144

Specify other molecular marker:145

Did the recipient have central nervous system leukemia at any time prior to the start of the preparative regimen / infusion?

yes no Unknown

146

What was the disease status (based on hematological test results)?147

Primary induction failure

1st complete remission (no previous marrow or extramedullary relapse) (include CRi)

2nd complete remission

≥3rd complete remission

1st relapse

2nd relapse

≥3rd relapse

No treatment

How many cycles of induction therapy were required to achieve 1st complete remission? (include CRi)

1 2 ≥ 3

148

Was the recipient in remission by flow cytometry?

Yes No Unknown Not applicable

149

Date of most recent relapse:150 __ __ __ __ - __ __- __ __

Date assessed:151 __ __ __ __ - __ __- __ __

Acute Leukemias of Ambiguous Lineage and Other Myeloid Neoplasms Questions: 152 - 155

Specify acute leukemias of ambiguous lineage and other myeloid neoplasm classification152

Blastic plasmacytoid dendritic cell neoplasm (296)

Acute undifferentiated leukemia (31)

Mixed phenotype acute leukemia (MPAL) with t(9;22)(q34.1;q11.2); BCR-ABL1 (84)

Mixed phenotype acute leukemia with t(v; 11q23.3); KMT2A rearranged (85)

Mixed phenotype acute leukemia, B/myeloid, NOS (86)

Mixed phenotype acute leukemia, T/myeloid, NOS (87)

Other acute leukemia of ambiguous lineage or myeloid neoplasm (88)

Specify other acute leukemia of ambiguous lineage or myeloid neoplasm:153

What was the disease status (based on hematological test results)?154

Primary induction failure

1st complete remission (no previous marrow or extramedullary relapse)

2nd complete remission

≥3rd complete remission

1st relapse

2nd relapse

≥3rd relapse

No treatment

Date assessed:155 __ __ __ __ - __ __- __ __

Chronic Myelogenous Leukemia (CML) Questions: 156 - 166

Was therapy given prior to this HCT?

yes no

156

Combination chemotherapy

yes no

157

Hydroxyurea (Droxia, Hydrea)

yes no

158

Tyrosine kinase inhibitor (e.g. imatinib mesylate, dasatinib, nilotinib)

yes no

159

Interferon­α (Intron, Roferon) (includes PEG)

yes no

160

Other therapy

yes no

161

Specify other therapy:162

What was the disease status?163

Complete hematologic response (CHR)

Chronic phase

Accelerated phase

Blast phase

Specify level of response164

No cytogenetic response (No CyR)

Minimal cytogenetic response

Minor cytogenetic response

Partial cytogenetic response (PCyR)

Complete cytogenetic response (CCyR)

Major molecular remission (MMR)

Complete molecular remission (CMR)

Number

1st 2nd 3rd or higher

165

Date assessed:166 __ __ __ __ - __ __- __ __

Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases Questions: 167 - 260

What was the MDS / MPN subtype at diagnosis? - If transformed to AML, indicate AML as primary disease; also complete AML Disease Classification
questions

167

Was the disease (MDS/MPN) therapy related?

yes no Unknown

168

Did the recipient have a predisposing condition?

yes no Unknown

169

Specify condition

Aplastic Anemia Bloom syndrome Down syndrome Fanconi anemia Other condition

170

Specify other condition:171

WBC

Known Unknown

172

173 x 109/L (x 103/mm3)

x 106/L

Hemoglobin

Known Unknown

174

175 g/dL g/L mmol/L

Was RBC transfused ≤ 30 days before date of test?

Yes No

176

Platelets

Known Unknown

177

178 x 109/L (x 103/mm3)

x 106/L

Were platelets transfused ≤ 7 days before date of test?

Yes No

179

Neutrophils

Known Unknown

180

181 %

Blasts in bone marrow

Known Unknown

182

183 %

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

184

Results of tests185

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities186

One (1)

Two (2)

Three (3)

Four or more (4 or more)

–5

yes no

187

-7

yes no

188

–13

yes no

189

–20

yes no

190

–Y

yes no

191

+8

yes no

192

+19

yes no

193

t(1;3)

yes no

194

t(2;11)

yes no

195

t(3;3)

yes no

196

t(3;21)

yes no

197

t(6;9)

yes no

198

t(11;16)

yes no

199

del(3q) / 3q–

yes no

200

del(5q) / 5q-

yes no

201

del(7q) / 7q–

yes no

202

del(9q) / 9q–

yes no

203

del(11q) / 11q–

yes no

204

del(12p) / 12p–

yes no

205

del(13q) / 13q-

yes no

206

del(20q) / 20q–

yes no

207

inv(3)

yes no

208

i17q

yes no

209

Other abnormality

yes no

210

Specify other abnormality:211

Did the recipient progress or transform to a different MDS / MPN subtype between diagnosis and the start of the preparative regimen?

yes no

212

Specify the MDS / MPN classification after transformation:213

Specify the date of the most recent transformation:214 __ __ __ __ - __ __- __ __

Date of MDS diagnosis:215 __ __ __ __ - __ __- __ __

WBC

Known Unknown

216

217 x 109/L (x 103/mm3)

x 106/L

Hemoglobin

Known Unknown

218

219 g/dL g/L mmol/L

Was RBC transfused ≤ 30 days before date of test?

Yes No

220

Platelets

Known Unknown

221

222 x 109/L (x 103/mm3)

x 106/L

Were platelets transfused ≤ 7 days before date of test?

Yes No

223

Neutrophils

Known Unknown

224

225 %

Blasts in bone marrow

Known Unknown

226

227 %

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

228

Results of tests229

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities230

One (1)

Two (2)

Three (3)

Four or more (4 or more)

–5

yes no

231

-7

yes no

232

–13

yes no

233

–20

yes no

234

–Y

yes no

235

+8

yes no

236

+19

yes no

237

t(1;3)

yes no

238

t(2;11)

yes no

239

t(3;3)

yes no

240

t(3;21)

yes no

241

t(6;9)

yes no

242

t(11;16)

yes no

243

del(3q) / 3q–

yes no

244

del(5q) / 5q-

yes no

245

del(7q) / 7q–

yes no

246

del(9q) / 9q–

yes no

247

del(11q) / 11q–

yes no

248

del(12p) / 12p–

yes no

249

del(13q) / 13q-

yes no

250

del(20q) / 20q–

yes no

251

inv(3)

yes no

252

i17q

yes no

253

Other abnormality

yes no

254

Specify other abnormality:255

What was the disease status?256

Complete
remission

(CR)

– requires all of the following, maintained for ≥ 4 weeks: * bone marrow evaluation: <  5% myeloblasts with normal maturation of all cell lines *
peripheral blood evaluation: hemoglobin ≥ 11 g/dL untransfused and without erythropoietin support; ANC ≥ 1000/mm3  without myeloid growth factor
support; platelets ≥ 100 x 109/L without thrombopoietic support; 0% blasts

Hematologic

improvement
(HI)

– requires one measurement of the following, maintained for ≥ 8 weeks without ongoing cytotoxic therapy; specify which cell line was measured to
determine HI response: * HI­E – hemoglobin increase of ≥ 1.5 g/dL untransfused; for RBC transfusions performed for Hgb ≤ 9.0, reduction in RBC
units transfused in 8 weeks by ≥ 4 units compared to the pre­treatment transfusion number in 8 weeks * HI­P – for pre­treatment platelet count of > 20
x 109/L, platelet absolute increase of ≥ 30 x 109/L; for pre-treatment platelet count of < 20 x 109/L, platelet absolute increase of ≥ 20 x 109/L and ≥
100% from pre­treatment level  * HI­N – neutrophil count increase of ≥ 100% from pre­treatment level and an absolute increase of ≥ 500/mm3

No response (NR) / stable disease (SD) – does not meet the criteria for at least HI, but no evidence of disease progression

Progression from
hematologic improvement

(Prog from HI)

– requires at least one of the following, in the absence of another explanation (e.g., infection, bleeding, ongoing chemotherapy, etc.): *
≥ 50% reduction from maximum response levels in granulocytes or platelets * reduction in hemoglobin by ≥ 1.5 g/dL *transfusion
dependence

Relapse from complete

remission (Rel from CR)

– requires at least one of the following: * return to pre­treatment bone marrow blast percentage * decrease of ≥ 50% from maximum
response levels in granulocytes or platelets * transfusion dependence, or hemoglobin level ≥ 1.5 g/dL lower than prior to therapy

Not assessed

Specify the cell line examined to determine HI status257

HI-
E

– hemoglobin increase of ≥ 1.5 g/dL untransfused; for RBC transfusions performed for Hgb ≤ 9.0, reduction in RBC units transfused in 8 weeks by ≥ 4
units compared to the pre-treatment transfusion number in 8 weeks

HI-
P

– for pre­treatment platelet count of > 20 x 109/L, platelet absolute increase of ≥ 30 x 109/L; for pre-treatment platelet count of < 20 x 109/L, platelet
absolute increase of ≥ 20 x 109/L and ≥ 100% from pre­treatment level 

HI-N – neutrophil count increase of ≥ 100% from pre­treatment level and an absolute increase of ≥ 500/mm3

Date of progression:258 __ __ __ __ - __ __- __ __

Date of relapse:259 __ __ __ __ - __ __- __ __

Date assessed:260 __ __ __ __ - __ __- __ __

Other Leukemia (OL) Questions: 261 - 267

Specify the other leukemia classification261

Specify other leukemia:262

Was any 17p abnormality detected?

yes no

263

Did a histologic transformation to diffuse large B-cell lymphoma (Richter syndrome) occur at any time after CLL diagnosis?264

yes - Also complete NHL Disease Classification questions

no

What was the disease status? (Atypical CML)265

Primary induction failure

1st complete remission (no previous bone marrow or extramedullary relapse)

2nd complete remission

≥3rd complete remission

1st relapse

2nd relapse

≥3rd relapse

No treatment

What was the disease status? (CLL, PLL, Hairy cell leukemia)266

Complete remission (CR)

Partial remission (PR)

Stable disease (SD)

Progressive disease (Prog)

Untreated

Not assessed

Date assessed:267 __ __ __ __ - __ __- __ __

Hodgkin and Non-Hodgkin Lymphoma Questions: 268 - 285

Specify the lymphoma histology (at infusion)268

Specify other lymphoma histology:269

Assignment of DLBCL (germinal center B-cell type vs. activated B-cell type) subtype was based on270

Immunohistochemistry (e.g. Han's algorithm)

Gene expression profile

Unknown method

Is the lymphoma histology reported at transplant a transformation from CLL?

yes no

271

Was any 17p abnormality detected?

yes no

272

Is the lymphoma histology reported at transplant a transformation from a different lymphoma histology? (Not CLL)

Yes No

273

Specify the original lymphoma histology (prior to transformation)274

Specify other lymphoma histology:275

Date of original lymphoma diagnosis:276 __ __ __ __ - __ __- __ __ (report the date of diagnosis of original lymphoma subtype)

Was a PET (or PET/CT) scan performed? (at last evaluation prior to the start of the preparative regimen / infusion)

yes no

277

Was the PET (or PET/CT) scan positive for lymphoma involvement at any disease site?

yes no

278

Date of PET scan

Known Unknown

279

Date of PET (or PET/CT) scan:280 __ __ __ __ - __ __- __ __

Deauville (five-point) score of the PET (or PET/CT) scan

Known Unknown

281

Scale282

1 - no uptake or residual uptake

2 - slight uptake, but below blood pool (mediastinum)

3 - uptake above mediastinal, but below or equal to uptake in the liver

4 - uptake slightly to moderately higher than liver

5 - markedly increased uptake or any new lesions

What was the disease status?283

Total number of lines of therapy received

1 line 2 lines 3+ lines

284

Date assessed:285 __ __ __ __ - __ __- __ __

Multiple Myeloma / Plasma Cell Disorder (PCD) Questions: 286 - 317

Specify the multiple myeloma/plasma cell disorder (PCD) classification286

Specify other plasma cell disorder:287

Light chain

kappa lambda

288

What was the Durie-Salmon staging? (at diagnosis)289

Stage
I

(All of the following: Hgb > 10g/dL; serum calcium normal or <10.5 mg/dL; bone x-ray normal bone structure (scale 0), or solitary bone plasmacytoma
only; low M-component production rates IgG< 5g/dL, IgA < 3g/dL; urine light chain M-component on electrophoresis <4 g/24h)

Stage II (Fitting neither Stage I or III) 

Stage
III

(One or more of the following: Hgb < 8.5 g/dL; serum calcium > 12 mg/dL; advanced lytic bone lesions (scale 3); high M-component production rates
IgG > 7g/dL, IgA > 5 g/dL; Bence Jones protein > 12g/24h)

Unknown

What was the Durie-Salmon sub classification? (at diagnosis)290

A - relatively normal renal function (serum creatinine < 2.0 mg/dL)

B ­ abnormal renal function (serum creatinine ≥ 2.0 mg/dL)

Serum β2­microglobulin:291 μg/dL mg/L nmol/L

Serum albumin:292 g/dL g/L

Stage293

1 (β2 ­mic < 3.5, S. albumin ≥3.5)

2 (Not fitting stage 1 or 3)

3 (β2­mic ≥ 5.5; S. albumin ­)

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

294

Results of tests295

Abnormalities identified

No evaluable metaphases

No abnormalities

+3

yes no

296

+5

yes no

297

+7

yes no

298

+9

yes no

299

+11

yes no

300

+15

yes no

301

+19

yes no

302

t(4;14)

yes no

303

t(6;14)

yes no

304

t(11;14)

yes no

305

t(14;16)

yes no

306

t(14;20)

yes no

307

del(13q) / 13q-

yes no

308

del (17p) / 17p-

yes no

309

Hyperdiploid (>50)

yes no

310

Hypodiploid (<46)

yes no

311

Any abnormality at 1q

yes no

312

Any abnormality at 1p

yes no

313

Other abnormality

yes no

314

Specify other abnormality:315

What was the disease status?316

Stringent
complete

remission
(sCR)

- CR as defined, plus: normal free light chain ratio, and absence of clonal cells in the bone marrow by immunohistochemistry of immunofluorescence
(confirmation with repeat bone marrow biopsy not needed). (Presence and/or absence of clonal cells is based upon the Κ/λ ratio. An abnormal Κ/λ ratio by
immunohistochemistry and/or immunofluorescence requires a minimum of 100 plasma cells for analysis.  An abnormal ratio reflecting the presence of
an abnormal clone is Κ/λ of > 4:1 or < 1:2.) sCR requires two consecutive assessments made at any time before the institution of any new therapy, and
no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy sCR
requirements. 

Complete
remission

(CR)

- negative immunofixation on serum and urine samples, and disappearance of any soft tissue plasmacytomas, and < 5% plasma cells in the bone
marrow (confirmation with repeat bone marrow biopsy not needed).  CR requires two consecutive assessments made at any time before the institution

of any new therapy, and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not
required to satisfy CR requirements. 

Near
complete
remission
(nCR)

- serum and urine M-protein detectable by immunoelectrophoresis (IFE), but not on electrophoresis (negative SPEP & UPEP); < 5% plasma cells in
bone marrow.  nCR requires two consecutive assessments made at any time before the initiation of any new therapy, and no known evidence of
progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy nCR requirements. 

Very good
partial
remission
(VGPR)

­ serum and urine M­protein detectable by immunofixation but not on electrophoresis, or ≥ 90% reduction in serum M­protein and urine M­protein level <
100 mg/24 hours.  VGPR requires two consecutive assessments made at any time before the institution of any new therapy, and no known evidence of
progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy VGPR requirements.

Partial
remission
(PR)

­ ≥ 50% reduction in serum M­protein, and reduction in 24­hour urinary M­protein by ≥ 90% or to < 200 mg/24 hours.  If the serum and urine M­protein are
unmeasurable (i.e., do not meet any of the following criteria: • serum M­protein ≥ 1 g/dL.  Urine M­protein ≥ 200 mg/24 hours • serum free light chain
assay shows involved level ≥ 10 mg/dL, provided serum free light chain ratio is abnormal), a ≥ 50% decrease in the difference between involved and
uninvolved free light chain levels is required in place of the M-protein criteria.  If serum and urine M-protein are unmeasurable, and serum free light assay
is also unmeasurable, a ≥ 50% reduction in plasma cells is required in place of M­protein, provided the baseline bone marrow plasma cell percentage
was ≥ 30%. In addition to the above listed criteria, a ≥ 50% reduction in the size of soft tissue plasmacytomas is also required, if present at baseline. PR
requires two consecutive assessments made at any time before the institution of any new therapy, and no known evidence of progressive or new bone
lesions if radiographic studies were performed; radiographic studies are not required to satisfy PR requirements. 

Stable
disease
(SD)

- not meeting the criteria for CR, VGPR, PR or PD.  SD requires two consecutive assessments made at any time before the institution of any new therapy,
and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy SD
requirements.

Progressive
disease
(PD)

­ requires any one or more of the following:  Increase of ≥ 25% from baseline in:  serum M­component and/or (absolute increase ≥ 0.5 g/dL) (for
progressive disease, serum M­component increases of ≥ 1 g/dL are sufficient to define relapse if the starting M­component is ≥ 5 g/dL).  Urine M­
component and/or (absolute increase ≥ 200 mg/24 hours) for recipients without measurable serum and urine M­protein levels: the difference between
involved and uninvolved free light chain levels (absolute increase > 10 mg/dL).  Bone marrow plasma cell percentage (absolute percentage ≥ 10%)
(relapse from CR has a 5% cutoff vs. 10% for other categories of relapse) definite development of new bone lesions or soft tissue plasmacytomas, or
definite increase in the size of any existing  bone lesions or soft tissue plasmacytomas. Development of hypercalcemia (corrected serum calcium >
11.5 mg/dL or 2.65 mmol) that can be attributed solely to the plasma cell proliferative disorder.  PD requires two consecutive assessments made at
any time before classification as disease progression, and/or the institution of any new therapy.

Relapse
from CR
(Rel)
(untreated)

­ requires one or more of the following: reappearance of serum or urine M­protein by immunofixation or electrophoresis development of ≥ 5% plasma
cells in the bone marrow (relapse from CR has a 5% cutoff vs. 10% for other categories of relapse) appearance of any other sign of progression (e.g.,
new plasmacytoma, lytic bone lesion, hypercalcemia).  Rel requires two consecutive assessments made at any time before classification as relapse,
and/or the institution of any new therapy.

Unknown

Not applicable (Amyloidosis with no evidence of myeloma)

Date assessed:317 __ __ __ __ - __ __- __ __

Solid Tumors Questions: 318 - 319

Specify the solid tumor classification318

Specify other solid tumor:319

Severe Aplastic Anemia Questions: 320 - 321

Specify the severe aplastic anemia classification320

Specify other acquired cytopenic syndrome:321

Inherited Abnormalities of Erythrocyte Differentiation or Function Questions: 322 - 324

Specify the inherited abnormalities of erythrocyte differentiation or function classification322

Specify other constitutional anemia:323

Specify other hemoglobinopathy:324

Disorders of the Immune System Questions: 325 - 327

Specify disorder of immune system classification325

Specify other SCID:326

Specify other immunodeficiency:327

Inherited Abnormalities of Platelets Questions: 328 - 329

Specify inherited abnormalities of platelets classification328

Congenital amegakaryocytosis / congenital thrombocytopenia (501)

Glanzmann thrombasthenia (502)

Other inherited platelet abnormality (509)

Specify other inherited platelet abnormality:329

Inherited Disorders of Metabolism Questions: 330 - 331

Specify inherited disorders of metabolism classification330

Specify other inherited metabolic disorder:331

Histiocytic Disorders Questions: 332 - 333

Specify histiocytic disorder classification332

Specify other histiocytic disorder:333

Autoimmune Diseases Questions: 334 - 341

Specify autoimmune disease classification334

Specify other arthritis:335

Specify other juvenile idiopathic arthritis (JIA):336

Specify other connective tissue disease:337

Specify other vasculitis:338

Specify other autoimmune neurological disorder:339

Specify other autoimmune cytopenia:340

Specify other autoimmune bowel disorder:341

Other Disease Questions: 342 - 342

Specify other disease:342

First Name:

Last Name:

E-mail address:

Date: __ __ __ __ - __ __- __ __

OMB No: 0915-0310

Expiration Date: 1/31/2020

Public Burden Statement:  An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control
number.  The OMB control number for this project is 0915-0310.  Public reporting burden for this collection of information is estimated to average 1.0 hours per response, including the
time for reviewing instructions, searching existing data sources, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other
aspect of this collection of information, including suggestions for reducing this burden, to HRSA Reports Clearance Officer, 5600 Fishers Lane, Room 10-29, Rockville, Maryland, 20857.

Labs at diagnosis

Specify cytogenetic abnormalities identified at diagnosis:

Specify cytogenetic abnormalities identified at diagnosis:

Specify molecular markers identified at diagnosis:

Labs between diagnosis and last evaluation:

Specify cytogenetic abnormalities identified between diagnosis and last evaluation:

Specify cytogenetic abnormalities identified between diagnosis and last evaluation:

Specify molecular markers identified between diagnosis and last evaluation:

Labs at last evaluation:

Specify cytogenetic abnormalities identified at last evaluation:

Specify cytogenetic abnormalities identified at last evaluation:

Specify molecular markers identified at last evaluation:

CNS Leukemia

Status at transplantation:

Laboratory studies at diagnosis:

Specify cytogenetic abnormalities identified at diagnosis:

Specify cytogenetic abnormalities identified at diagnosis:

Specify molecular markers identified at diagnosis:

Laboratory studies between diagnosis and last evaluation:

Specify cytogenetic abnormalities identified between diagnosis and last evaluation:

Specify cytogenetic abnormalities identified between diagnosis and last evaluation:

Specify molecular markers identified between diagnosis and last evaluation:

Laboratory studies at last evaluation:

Specify cytogenetic abnormalities identified at last evaluation:

Specify cytogenetic abnormalities identified at last evaluation:

Specify molecular markers identified at last evaluation:

CNS Leukemia

Status at transplantation:

Status at transplantation:

Laboratory studies at diagnosis of MDS:

Specify abnormalities identified at diagnosis:

Monosomy

Trisomy

Translocation

Deletion

Inversion

Other

Laboratory studies at last evaluation prior to the start of the preparative regimen:

Specify cytogenetic abnormalities identified at last evaluation prior to the start of the preparative regimen:

Monosomy

Trisomy

Translocation

Deletion

Inversion

Other

Status at transplantation:

Status at transplantation:

Status at transplantation / infusion:

I.S.S.:

Specify cytogenetic abnormalities identified at any time prior to the start of the preparative regimen:

Trisomy

Translocation

Deletion

Other

Status at transplantation:

Center: CRID: 

Form 2402 R3.0: Disease Classification

CIBMTR Form 2402 revision 3.0 last updated Monday, January 29, 2018
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 2 / 26



Key Fields

Sequence Number:

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number:

CIBMTR Research ID:

Event date: __ __ __ __ - __ __- __ __

Primary Disease for HCT / Cellular Therapy Questions: 1 - 2

Date of diagnosis of primary disease for HCT / cellular therapy:1 __ __ __ __ - __ __- __ __

What was the primary disease for which the HCT / cellular therapy was performed?2

Acute myelogenous leukemia (AML or ANLL) (10)

Acute lymphoblastic leukemia (ALL) (20)

Acute leukemia of ambiguous lineage and other myeloid neoplasms (80)

Chronic myelogenous leukemia (CML) (40)

Myelodysplastic (MDS) / myeloproliferative (MPN) diseases (50) (Please classify all preleukemias) (If recipient has transformed to AML, indicate AML as the primary disease)

Other leukemia (30) (includes CLL)

Hodgkin lymphoma (150)

Non-Hodgkin lymphoma (100)

Multiple myeloma / plasma cell disorder (PCD) (170)

Solid tumors (200)

Severe aplastic anemia (300) (If the recipient developed MDS or AML, indicate MDS or AML as the primary disease)

Inherited abnormalities of erythrocyte differentiation or function (310)

Disorders of the immune system (400)

Inherited abnormalities of platelets (500)

Inherited disorders of metabolism (520)

Histiocytic disorders (570)

Autoimmune diseases (600)

Other disease (900)

Acute Myelogenous Leukemia (AML) Questions: 3 - 89

Specify the AML classification3

Did AML transform from MDS or MPN?4

yes - Also complete MDS Disease Classification questions

no

Is the disease (AML) therapy related?

yes no Unknown

5

Did the recipient have a predisposing condition?

yes no Unknown

6

Specify condition7

Bloom syndrome

Down syndrome

Fanconi anemia

Dyskeratosis congenita

Other condition

Specify other condition:8

Were cytogenetics tested (karyotyping or FISH)? (at diagnosis)

yes no Unknown

9

Were cytogenetics tested via FISH? (at diagnosis)

Yes No

10

Results of tests11

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities12

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

13

Specify other abnormality:14

Were cytogenetics tested via karyotyping? (at diagnosis)

Yes No

15

Results of tests16

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities17

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

18

Specify other abnormality:19

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

20

Were tests for molecular markers performed? (e.g. PCR, NGS) (at diagnosis)

yes no Unknown

21

CEBPA

Positive Negative Not Done

22

Specify CEBPA mutation23

Biallelic (homozygous)

Monoallelic (heterozygous)

Unknown

FLT3 – D835 point mutation

Positive Negative Not Done

24

FLT3 – ITD mutation

Positive Negative Not Done

25

FLT3 - ITD allelic ratio

Known Unknown

26

Specify FLT3 - ITD allelic ratio:27

IDH1

Positive Negative Not Done

28

IDH2

Positive Negative Not Done

29

KIT

Positive Negative Not Done

30

NPM1

Positive Negative Not Done

31

Other Molecular Marker (1) Questions: 32 - 33

Other molecular marker

Positive Negative Not Done

32

Specify other molecular marker:33

Were cytogenetics tested (karyotyping or FISH)? (between diagnosis and last evaluation)

yes no Unknown

34

Were cytogenetics tested via FISH? (between diagnosis and last evaluation)

Yes No

35

Results of tests36

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities37

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

38

Specify other abnormality:39

Were cytogenetics tested via karyotyping? (between diagnosis and last evaluation)

Yes No

40

Results of tests41

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities42

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

43

Specify other abnormality:44

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

45

Were tests for molecular markers performed? (e.g. PCR, NGS) (between diagnosis and last evaluation)

yes no Unknown

46

CEBPA

Positive Negative Not Done

47

Specify CEBPA mutation48

Biallelic (homozygous)

Monoallelic (heterozygous)

Unknown

FLT3 – D835 point mutation

Positive Negative Not Done

49

FLT3 – ITD mutation

Positive Negative Not Done

50

FLT3 - ITD allelic ratio

Known Unknown

51

Specify FLT3 - ITD allelic ratio:52

IDH1

Positive Negative Not Done

53

IDH2

Positive Negative Not Done

54

KIT

Positive Negative Not Done

55

NPM1

Positive Negative Not Done

56

Other Molecular Marker (1) Questions: 57 - 58

Other molecular marker

Positive Negative Not Done

57

Specify other molecular marker:58

Were cytogenetics tested (karyotyping or FISH)? (at last evaluation)

yes no Unknown

59

Were cytogenetics tested via FISH? (at last evaluation)

Yes No

60

Results of tests61

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities62

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

63

Specify other abnormality:64

Were cytogenetics tested via karyotyping? (at last evaluation)

Yes No

65

Results of tests66

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities67

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

68

Specify other abnormality:69

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

70

Were tests for molecular markers performed? (e.g. PCR, NGS) (at last evaluation)

yes no Unknown

71

CEBPA

Positive Negative Not Done

72

Specify CEBPA mutation73

Biallelic (homozygous)

Monoallelic (heterozygous)

Unknown

FLT3 – D835 point mutation

Positive Negative Not Done

74

FLT3 – ITD mutation

Positive Negative Not Done

75

FLT3 - ITD allelic ratio

Known Unknown

76

Specify FLT3 - ITD allelic ratio:77

IDH1

Positive Negative Not Done

78

IDH2

Positive Negative Not Done

79

KIT

Positive Negative Not Done

80

NPM1

Positive Negative Not Done

81

Other Molecular Marker (1) Questions: 82 - 83

Other molecular marker

Positive Negative Not Done

82

Specify other molecular marker:83

Did the recipient have central nervous system leukemia at any time prior to the start of the preparative regimen / infusion?

yes no Unknown

84

What was the disease status (based on hematological test results)?85

Primary induction failure

1st complete remission (no previous bone marrow or extramedullary relapse) (include CRi)

2nd complete remission

≥3rd complete remission

1st relapse

2nd relapse

≥3rd relapse

No treatment

How many cycles of induction therapy were required to achieve 1st complete remission? (includes CRi)

1 2 ≥ 3

86

Was the recipient in remission by flow cytometry?

Yes No Unknown Not applicable

87

Date of most recent relapse:88 __ __ __ __ - __ __- __ __

Date assessed:89 __ __ __ __ - __ __- __ __

Acute Lymphoblastic Leukemia (ALL) Questions: 90 - 151

Specify ALL classification90

Did the recipient have a predisposing condition?

yes no Unknown

91

Specify condition92

Aplastic anemia - Also complete CIBMTR Form 2028 - APL

Bloom syndrome

Down syndrome

Fanconi anemia - Also complete CIBMTR Form 2029 - FAN

Other condition

Specify other condition:93

Were tyrosine kinase inhibitors given for therapy at any time prior to the start of the preparative regimen / infusion? (e.g. imatinib mesylate, dasatinib, etc.)

yes no

94

Were cytogenetics tested (karyotyping or FISH)? (at diagnosis)

yes no Unknown

95

Were cytogenetics tested via FISH? (at diagnosis)

Yes No

96

Results of tests97

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities98

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

99

Specify other abnormality:100

Were cytogenetics tested via karyotyping? (at diagnosis)

Yes No

101

Results of tests102

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities103

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

104

Specify other abnormality:105

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

106

Were tests for molecular markers performed? (e.g. PCR, NGS) (at diagnosis)

yes no Unknown

107

BCR / ABL

Positive Negative Not Done

108

TEL-AML / AML1

Positive Negative Not Done

109

Other Molecular Marker (1) Questions: 110 - 111

Other molecular marker

Positive Negative Not Done

110

Specify other molecular marker:111

Were cytogenetics tested (karyotyping or FISH)? (between diagnosis and last evaluation)

yes no Unknown

112

Were cytogenetics tested via FISH? (between diagnosis and last evaluation)

Yes No

113

Results of tests114

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities115

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

116

Specify other abnormality:117

Were cytogenetics tested via karyotyping? (between diagnosis and last evaluation)

Yes No

118

Results of tests119

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities120

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

121

Specify other abnormality:122

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

123

Were tests for molecular markers performed? (e.g. PCR, NGS) (between diagnosis and last evaluation)

yes no Unknown

124

BCR / ABL

Positive Negative Not Done

125

TEL-AML / AML1

Positive Negative Not Done

126

Other Molecular Marker (1) Questions: 127 - 128

Other molecular marker

Positive Negative Not Done

127

Specify other molecular marker:128

Were cytogenetics tested (karyotyping or FISH)? (at last evaluation)

yes no Unknown

129

Were cytogenetics tested via FISH? (at last evaluation)

Yes No

130

Results of tests131

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities132

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

133

Specify other abnormality:134

Were cytogenetics tested via karyotyping? (at last evaluation)

Yes No

135

Results of tests136

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities137

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

138

Specify other abnormality:139

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

140

Were tests for molecular markers performed? (e.g. PCR, NGS) (at last evaluation)

yes no Unknown

141

BCR / ABL

Positive Negative Not Done

142

TEL-AML / AML1

Positive Negative Not Done

143

Other Molecular Marker (1) Questions: 144 - 145

Other molecular marker

Positive Negative Not Done

144

Specify other molecular marker:145

Did the recipient have central nervous system leukemia at any time prior to the start of the preparative regimen / infusion?

yes no Unknown

146

What was the disease status (based on hematological test results)?147

Primary induction failure

1st complete remission (no previous marrow or extramedullary relapse) (include CRi)

2nd complete remission

≥3rd complete remission

1st relapse

2nd relapse

≥3rd relapse

No treatment

How many cycles of induction therapy were required to achieve 1st complete remission? (include CRi)

1 2 ≥ 3

148

Was the recipient in remission by flow cytometry?

Yes No Unknown Not applicable

149

Date of most recent relapse:150 __ __ __ __ - __ __- __ __

Date assessed:151 __ __ __ __ - __ __- __ __

Acute Leukemias of Ambiguous Lineage and Other Myeloid Neoplasms Questions: 152 - 155

Specify acute leukemias of ambiguous lineage and other myeloid neoplasm classification152

Blastic plasmacytoid dendritic cell neoplasm (296)

Acute undifferentiated leukemia (31)

Mixed phenotype acute leukemia (MPAL) with t(9;22)(q34.1;q11.2); BCR-ABL1 (84)

Mixed phenotype acute leukemia with t(v; 11q23.3); KMT2A rearranged (85)

Mixed phenotype acute leukemia, B/myeloid, NOS (86)

Mixed phenotype acute leukemia, T/myeloid, NOS (87)

Other acute leukemia of ambiguous lineage or myeloid neoplasm (88)

Specify other acute leukemia of ambiguous lineage or myeloid neoplasm:153

What was the disease status (based on hematological test results)?154

Primary induction failure

1st complete remission (no previous marrow or extramedullary relapse)

2nd complete remission

≥3rd complete remission

1st relapse

2nd relapse

≥3rd relapse

No treatment

Date assessed:155 __ __ __ __ - __ __- __ __

Chronic Myelogenous Leukemia (CML) Questions: 156 - 166

Was therapy given prior to this HCT?

yes no

156

Combination chemotherapy

yes no

157

Hydroxyurea (Droxia, Hydrea)

yes no

158

Tyrosine kinase inhibitor (e.g. imatinib mesylate, dasatinib, nilotinib)

yes no

159

Interferon­α (Intron, Roferon) (includes PEG)

yes no

160

Other therapy

yes no

161

Specify other therapy:162

What was the disease status?163

Complete hematologic response (CHR)

Chronic phase

Accelerated phase

Blast phase

Specify level of response164

No cytogenetic response (No CyR)

Minimal cytogenetic response

Minor cytogenetic response

Partial cytogenetic response (PCyR)

Complete cytogenetic response (CCyR)

Major molecular remission (MMR)

Complete molecular remission (CMR)

Number

1st 2nd 3rd or higher

165

Date assessed:166 __ __ __ __ - __ __- __ __

Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases Questions: 167 - 260

What was the MDS / MPN subtype at diagnosis? - If transformed to AML, indicate AML as primary disease; also complete AML Disease Classification
questions

167

Was the disease (MDS/MPN) therapy related?

yes no Unknown

168

Did the recipient have a predisposing condition?

yes no Unknown

169

Specify condition

Aplastic Anemia Bloom syndrome Down syndrome Fanconi anemia Other condition

170

Specify other condition:171

WBC

Known Unknown

172

173 x 109/L (x 103/mm3)

x 106/L

Hemoglobin

Known Unknown

174

175 g/dL g/L mmol/L

Was RBC transfused ≤ 30 days before date of test?

Yes No

176

Platelets

Known Unknown

177

178 x 109/L (x 103/mm3)

x 106/L

Were platelets transfused ≤ 7 days before date of test?

Yes No

179

Neutrophils

Known Unknown

180

181 %

Blasts in bone marrow

Known Unknown

182

183 %

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

184

Results of tests185

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities186

One (1)

Two (2)

Three (3)

Four or more (4 or more)

–5

yes no

187

-7

yes no

188

–13

yes no

189

–20

yes no

190

–Y

yes no

191

+8

yes no

192

+19

yes no

193

t(1;3)

yes no

194

t(2;11)

yes no

195

t(3;3)

yes no

196

t(3;21)

yes no

197

t(6;9)

yes no

198

t(11;16)

yes no

199

del(3q) / 3q–

yes no

200

del(5q) / 5q-

yes no

201

del(7q) / 7q–

yes no

202

del(9q) / 9q–

yes no

203

del(11q) / 11q–

yes no

204

del(12p) / 12p–

yes no

205

del(13q) / 13q-

yes no

206

del(20q) / 20q–

yes no

207

inv(3)

yes no

208

i17q

yes no

209

Other abnormality

yes no

210

Specify other abnormality:211

Did the recipient progress or transform to a different MDS / MPN subtype between diagnosis and the start of the preparative regimen?

yes no

212

Specify the MDS / MPN classification after transformation:213

Specify the date of the most recent transformation:214 __ __ __ __ - __ __- __ __

Date of MDS diagnosis:215 __ __ __ __ - __ __- __ __

WBC

Known Unknown

216

217 x 109/L (x 103/mm3)

x 106/L

Hemoglobin

Known Unknown

218

219 g/dL g/L mmol/L

Was RBC transfused ≤ 30 days before date of test?

Yes No

220

Platelets

Known Unknown

221

222 x 109/L (x 103/mm3)

x 106/L

Were platelets transfused ≤ 7 days before date of test?

Yes No

223

Neutrophils

Known Unknown

224

225 %

Blasts in bone marrow

Known Unknown

226

227 %

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

228

Results of tests229

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities230

One (1)

Two (2)

Three (3)

Four or more (4 or more)

–5

yes no

231

-7

yes no

232

–13

yes no

233

–20

yes no

234

–Y

yes no

235

+8

yes no

236

+19

yes no

237

t(1;3)

yes no

238

t(2;11)

yes no

239

t(3;3)

yes no

240

t(3;21)

yes no

241

t(6;9)

yes no

242

t(11;16)

yes no

243

del(3q) / 3q–

yes no

244

del(5q) / 5q-

yes no

245

del(7q) / 7q–

yes no

246

del(9q) / 9q–

yes no

247

del(11q) / 11q–

yes no

248

del(12p) / 12p–

yes no

249

del(13q) / 13q-

yes no

250

del(20q) / 20q–

yes no

251

inv(3)

yes no

252

i17q

yes no

253

Other abnormality

yes no

254

Specify other abnormality:255

What was the disease status?256

Complete
remission

(CR)

– requires all of the following, maintained for ≥ 4 weeks: * bone marrow evaluation: <  5% myeloblasts with normal maturation of all cell lines *
peripheral blood evaluation: hemoglobin ≥ 11 g/dL untransfused and without erythropoietin support; ANC ≥ 1000/mm3  without myeloid growth factor
support; platelets ≥ 100 x 109/L without thrombopoietic support; 0% blasts

Hematologic

improvement
(HI)

– requires one measurement of the following, maintained for ≥ 8 weeks without ongoing cytotoxic therapy; specify which cell line was measured to
determine HI response: * HI­E – hemoglobin increase of ≥ 1.5 g/dL untransfused; for RBC transfusions performed for Hgb ≤ 9.0, reduction in RBC
units transfused in 8 weeks by ≥ 4 units compared to the pre­treatment transfusion number in 8 weeks * HI­P – for pre­treatment platelet count of > 20
x 109/L, platelet absolute increase of ≥ 30 x 109/L; for pre-treatment platelet count of < 20 x 109/L, platelet absolute increase of ≥ 20 x 109/L and ≥
100% from pre­treatment level  * HI­N – neutrophil count increase of ≥ 100% from pre­treatment level and an absolute increase of ≥ 500/mm3

No response (NR) / stable disease (SD) – does not meet the criteria for at least HI, but no evidence of disease progression

Progression from
hematologic improvement

(Prog from HI)

– requires at least one of the following, in the absence of another explanation (e.g., infection, bleeding, ongoing chemotherapy, etc.): *
≥ 50% reduction from maximum response levels in granulocytes or platelets * reduction in hemoglobin by ≥ 1.5 g/dL *transfusion
dependence

Relapse from complete

remission (Rel from CR)

– requires at least one of the following: * return to pre­treatment bone marrow blast percentage * decrease of ≥ 50% from maximum
response levels in granulocytes or platelets * transfusion dependence, or hemoglobin level ≥ 1.5 g/dL lower than prior to therapy

Not assessed

Specify the cell line examined to determine HI status257

HI-
E

– hemoglobin increase of ≥ 1.5 g/dL untransfused; for RBC transfusions performed for Hgb ≤ 9.0, reduction in RBC units transfused in 8 weeks by ≥ 4
units compared to the pre-treatment transfusion number in 8 weeks

HI-
P

– for pre­treatment platelet count of > 20 x 109/L, platelet absolute increase of ≥ 30 x 109/L; for pre-treatment platelet count of < 20 x 109/L, platelet
absolute increase of ≥ 20 x 109/L and ≥ 100% from pre­treatment level 

HI-N – neutrophil count increase of ≥ 100% from pre­treatment level and an absolute increase of ≥ 500/mm3

Date of progression:258 __ __ __ __ - __ __- __ __

Date of relapse:259 __ __ __ __ - __ __- __ __

Date assessed:260 __ __ __ __ - __ __- __ __

Other Leukemia (OL) Questions: 261 - 267

Specify the other leukemia classification261

Specify other leukemia:262

Was any 17p abnormality detected?

yes no

263

Did a histologic transformation to diffuse large B-cell lymphoma (Richter syndrome) occur at any time after CLL diagnosis?264

yes - Also complete NHL Disease Classification questions

no

What was the disease status? (Atypical CML)265

Primary induction failure

1st complete remission (no previous bone marrow or extramedullary relapse)

2nd complete remission

≥3rd complete remission

1st relapse

2nd relapse

≥3rd relapse

No treatment

What was the disease status? (CLL, PLL, Hairy cell leukemia)266

Complete remission (CR)

Partial remission (PR)

Stable disease (SD)

Progressive disease (Prog)

Untreated

Not assessed

Date assessed:267 __ __ __ __ - __ __- __ __

Hodgkin and Non-Hodgkin Lymphoma Questions: 268 - 285

Specify the lymphoma histology (at infusion)268

Specify other lymphoma histology:269

Assignment of DLBCL (germinal center B-cell type vs. activated B-cell type) subtype was based on270

Immunohistochemistry (e.g. Han's algorithm)

Gene expression profile

Unknown method

Is the lymphoma histology reported at transplant a transformation from CLL?

yes no

271

Was any 17p abnormality detected?

yes no

272

Is the lymphoma histology reported at transplant a transformation from a different lymphoma histology? (Not CLL)

Yes No

273

Specify the original lymphoma histology (prior to transformation)274

Specify other lymphoma histology:275

Date of original lymphoma diagnosis:276 __ __ __ __ - __ __- __ __ (report the date of diagnosis of original lymphoma subtype)

Was a PET (or PET/CT) scan performed? (at last evaluation prior to the start of the preparative regimen / infusion)

yes no

277

Was the PET (or PET/CT) scan positive for lymphoma involvement at any disease site?

yes no

278

Date of PET scan

Known Unknown

279

Date of PET (or PET/CT) scan:280 __ __ __ __ - __ __- __ __

Deauville (five-point) score of the PET (or PET/CT) scan

Known Unknown

281

Scale282

1 - no uptake or residual uptake

2 - slight uptake, but below blood pool (mediastinum)

3 - uptake above mediastinal, but below or equal to uptake in the liver

4 - uptake slightly to moderately higher than liver

5 - markedly increased uptake or any new lesions

What was the disease status?283

Total number of lines of therapy received

1 line 2 lines 3+ lines

284

Date assessed:285 __ __ __ __ - __ __- __ __

Multiple Myeloma / Plasma Cell Disorder (PCD) Questions: 286 - 317

Specify the multiple myeloma/plasma cell disorder (PCD) classification286

Specify other plasma cell disorder:287

Light chain

kappa lambda

288

What was the Durie-Salmon staging? (at diagnosis)289

Stage
I

(All of the following: Hgb > 10g/dL; serum calcium normal or <10.5 mg/dL; bone x-ray normal bone structure (scale 0), or solitary bone plasmacytoma
only; low M-component production rates IgG< 5g/dL, IgA < 3g/dL; urine light chain M-component on electrophoresis <4 g/24h)

Stage II (Fitting neither Stage I or III) 

Stage
III

(One or more of the following: Hgb < 8.5 g/dL; serum calcium > 12 mg/dL; advanced lytic bone lesions (scale 3); high M-component production rates
IgG > 7g/dL, IgA > 5 g/dL; Bence Jones protein > 12g/24h)

Unknown

What was the Durie-Salmon sub classification? (at diagnosis)290

A - relatively normal renal function (serum creatinine < 2.0 mg/dL)

B ­ abnormal renal function (serum creatinine ≥ 2.0 mg/dL)

Serum β2­microglobulin:291 μg/dL mg/L nmol/L

Serum albumin:292 g/dL g/L

Stage293

1 (β2 ­mic < 3.5, S. albumin ≥3.5)

2 (Not fitting stage 1 or 3)

3 (β2­mic ≥ 5.5; S. albumin ­)

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

294

Results of tests295

Abnormalities identified

No evaluable metaphases

No abnormalities

+3

yes no

296

+5

yes no

297

+7

yes no

298

+9

yes no

299

+11

yes no

300

+15

yes no

301

+19

yes no

302

t(4;14)

yes no

303

t(6;14)

yes no

304

t(11;14)

yes no

305

t(14;16)

yes no

306

t(14;20)

yes no

307

del(13q) / 13q-

yes no

308

del (17p) / 17p-

yes no

309

Hyperdiploid (>50)

yes no

310

Hypodiploid (<46)

yes no

311

Any abnormality at 1q

yes no

312

Any abnormality at 1p

yes no

313

Other abnormality

yes no

314

Specify other abnormality:315

What was the disease status?316

Stringent
complete

remission
(sCR)

- CR as defined, plus: normal free light chain ratio, and absence of clonal cells in the bone marrow by immunohistochemistry of immunofluorescence
(confirmation with repeat bone marrow biopsy not needed). (Presence and/or absence of clonal cells is based upon the Κ/λ ratio. An abnormal Κ/λ ratio by
immunohistochemistry and/or immunofluorescence requires a minimum of 100 plasma cells for analysis.  An abnormal ratio reflecting the presence of
an abnormal clone is Κ/λ of > 4:1 or < 1:2.) sCR requires two consecutive assessments made at any time before the institution of any new therapy, and
no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy sCR
requirements. 

Complete
remission

(CR)

- negative immunofixation on serum and urine samples, and disappearance of any soft tissue plasmacytomas, and < 5% plasma cells in the bone
marrow (confirmation with repeat bone marrow biopsy not needed).  CR requires two consecutive assessments made at any time before the institution

of any new therapy, and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not
required to satisfy CR requirements. 

Near
complete
remission
(nCR)

- serum and urine M-protein detectable by immunoelectrophoresis (IFE), but not on electrophoresis (negative SPEP & UPEP); < 5% plasma cells in
bone marrow.  nCR requires two consecutive assessments made at any time before the initiation of any new therapy, and no known evidence of
progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy nCR requirements. 

Very good
partial
remission
(VGPR)

­ serum and urine M­protein detectable by immunofixation but not on electrophoresis, or ≥ 90% reduction in serum M­protein and urine M­protein level <
100 mg/24 hours.  VGPR requires two consecutive assessments made at any time before the institution of any new therapy, and no known evidence of
progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy VGPR requirements.

Partial
remission
(PR)

­ ≥ 50% reduction in serum M­protein, and reduction in 24­hour urinary M­protein by ≥ 90% or to < 200 mg/24 hours.  If the serum and urine M­protein are
unmeasurable (i.e., do not meet any of the following criteria: • serum M­protein ≥ 1 g/dL.  Urine M­protein ≥ 200 mg/24 hours • serum free light chain
assay shows involved level ≥ 10 mg/dL, provided serum free light chain ratio is abnormal), a ≥ 50% decrease in the difference between involved and
uninvolved free light chain levels is required in place of the M-protein criteria.  If serum and urine M-protein are unmeasurable, and serum free light assay
is also unmeasurable, a ≥ 50% reduction in plasma cells is required in place of M­protein, provided the baseline bone marrow plasma cell percentage
was ≥ 30%. In addition to the above listed criteria, a ≥ 50% reduction in the size of soft tissue plasmacytomas is also required, if present at baseline. PR
requires two consecutive assessments made at any time before the institution of any new therapy, and no known evidence of progressive or new bone
lesions if radiographic studies were performed; radiographic studies are not required to satisfy PR requirements. 

Stable
disease
(SD)

- not meeting the criteria for CR, VGPR, PR or PD.  SD requires two consecutive assessments made at any time before the institution of any new therapy,
and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy SD
requirements.

Progressive
disease
(PD)

­ requires any one or more of the following:  Increase of ≥ 25% from baseline in:  serum M­component and/or (absolute increase ≥ 0.5 g/dL) (for
progressive disease, serum M­component increases of ≥ 1 g/dL are sufficient to define relapse if the starting M­component is ≥ 5 g/dL).  Urine M­
component and/or (absolute increase ≥ 200 mg/24 hours) for recipients without measurable serum and urine M­protein levels: the difference between
involved and uninvolved free light chain levels (absolute increase > 10 mg/dL).  Bone marrow plasma cell percentage (absolute percentage ≥ 10%)
(relapse from CR has a 5% cutoff vs. 10% for other categories of relapse) definite development of new bone lesions or soft tissue plasmacytomas, or
definite increase in the size of any existing  bone lesions or soft tissue plasmacytomas. Development of hypercalcemia (corrected serum calcium >
11.5 mg/dL or 2.65 mmol) that can be attributed solely to the plasma cell proliferative disorder.  PD requires two consecutive assessments made at
any time before classification as disease progression, and/or the institution of any new therapy.

Relapse
from CR
(Rel)
(untreated)

­ requires one or more of the following: reappearance of serum or urine M­protein by immunofixation or electrophoresis development of ≥ 5% plasma
cells in the bone marrow (relapse from CR has a 5% cutoff vs. 10% for other categories of relapse) appearance of any other sign of progression (e.g.,
new plasmacytoma, lytic bone lesion, hypercalcemia).  Rel requires two consecutive assessments made at any time before classification as relapse,
and/or the institution of any new therapy.

Unknown

Not applicable (Amyloidosis with no evidence of myeloma)

Date assessed:317 __ __ __ __ - __ __- __ __

Solid Tumors Questions: 318 - 319

Specify the solid tumor classification318

Specify other solid tumor:319

Severe Aplastic Anemia Questions: 320 - 321

Specify the severe aplastic anemia classification320

Specify other acquired cytopenic syndrome:321

Inherited Abnormalities of Erythrocyte Differentiation or Function Questions: 322 - 324

Specify the inherited abnormalities of erythrocyte differentiation or function classification322

Specify other constitutional anemia:323

Specify other hemoglobinopathy:324

Disorders of the Immune System Questions: 325 - 327

Specify disorder of immune system classification325

Specify other SCID:326

Specify other immunodeficiency:327

Inherited Abnormalities of Platelets Questions: 328 - 329

Specify inherited abnormalities of platelets classification328

Congenital amegakaryocytosis / congenital thrombocytopenia (501)

Glanzmann thrombasthenia (502)

Other inherited platelet abnormality (509)

Specify other inherited platelet abnormality:329

Inherited Disorders of Metabolism Questions: 330 - 331

Specify inherited disorders of metabolism classification330

Specify other inherited metabolic disorder:331

Histiocytic Disorders Questions: 332 - 333

Specify histiocytic disorder classification332

Specify other histiocytic disorder:333

Autoimmune Diseases Questions: 334 - 341

Specify autoimmune disease classification334

Specify other arthritis:335

Specify other juvenile idiopathic arthritis (JIA):336

Specify other connective tissue disease:337

Specify other vasculitis:338

Specify other autoimmune neurological disorder:339

Specify other autoimmune cytopenia:340

Specify other autoimmune bowel disorder:341

Other Disease Questions: 342 - 342

Specify other disease:342

First Name:

Last Name:

E-mail address:

Date: __ __ __ __ - __ __- __ __

OMB No: 0915-0310

Expiration Date: 1/31/2020

Public Burden Statement:  An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control
number.  The OMB control number for this project is 0915-0310.  Public reporting burden for this collection of information is estimated to average 1.0 hours per response, including the
time for reviewing instructions, searching existing data sources, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other
aspect of this collection of information, including suggestions for reducing this burden, to HRSA Reports Clearance Officer, 5600 Fishers Lane, Room 10-29, Rockville, Maryland, 20857.

Labs at diagnosis

Specify cytogenetic abnormalities identified at diagnosis:

Specify cytogenetic abnormalities identified at diagnosis:

Specify molecular markers identified at diagnosis:

Labs between diagnosis and last evaluation:

Specify cytogenetic abnormalities identified between diagnosis and last evaluation:

Specify cytogenetic abnormalities identified between diagnosis and last evaluation:

Specify molecular markers identified between diagnosis and last evaluation:

Labs at last evaluation:

Specify cytogenetic abnormalities identified at last evaluation:

Specify cytogenetic abnormalities identified at last evaluation:

Specify molecular markers identified at last evaluation:

CNS Leukemia

Status at transplantation:

Laboratory studies at diagnosis:

Specify cytogenetic abnormalities identified at diagnosis:

Specify cytogenetic abnormalities identified at diagnosis:

Specify molecular markers identified at diagnosis:

Laboratory studies between diagnosis and last evaluation:

Specify cytogenetic abnormalities identified between diagnosis and last evaluation:

Specify cytogenetic abnormalities identified between diagnosis and last evaluation:

Specify molecular markers identified between diagnosis and last evaluation:

Laboratory studies at last evaluation:

Specify cytogenetic abnormalities identified at last evaluation:

Specify cytogenetic abnormalities identified at last evaluation:

Specify molecular markers identified at last evaluation:

CNS Leukemia

Status at transplantation:

Status at transplantation:

Laboratory studies at diagnosis of MDS:

Specify abnormalities identified at diagnosis:

Monosomy

Trisomy

Translocation

Deletion

Inversion

Other

Laboratory studies at last evaluation prior to the start of the preparative regimen:

Specify cytogenetic abnormalities identified at last evaluation prior to the start of the preparative regimen:

Monosomy

Trisomy

Translocation

Deletion

Inversion

Other

Status at transplantation:

Status at transplantation:

Status at transplantation / infusion:

I.S.S.:

Specify cytogenetic abnormalities identified at any time prior to the start of the preparative regimen:

Trisomy

Translocation

Deletion

Other

Status at transplantation:

Center: CRID: 

Form 2402 R3.0: Disease Classification

CIBMTR Form 2402 revision 3.0 last updated Monday, January 29, 2018
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 3 / 26



Key Fields

Sequence Number:

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number:

CIBMTR Research ID:

Event date: __ __ __ __ - __ __- __ __

Primary Disease for HCT / Cellular Therapy Questions: 1 - 2

Date of diagnosis of primary disease for HCT / cellular therapy:1 __ __ __ __ - __ __- __ __

What was the primary disease for which the HCT / cellular therapy was performed?2

Acute myelogenous leukemia (AML or ANLL) (10)

Acute lymphoblastic leukemia (ALL) (20)

Acute leukemia of ambiguous lineage and other myeloid neoplasms (80)

Chronic myelogenous leukemia (CML) (40)

Myelodysplastic (MDS) / myeloproliferative (MPN) diseases (50) (Please classify all preleukemias) (If recipient has transformed to AML, indicate AML as the primary disease)

Other leukemia (30) (includes CLL)

Hodgkin lymphoma (150)

Non-Hodgkin lymphoma (100)

Multiple myeloma / plasma cell disorder (PCD) (170)

Solid tumors (200)

Severe aplastic anemia (300) (If the recipient developed MDS or AML, indicate MDS or AML as the primary disease)

Inherited abnormalities of erythrocyte differentiation or function (310)

Disorders of the immune system (400)

Inherited abnormalities of platelets (500)

Inherited disorders of metabolism (520)

Histiocytic disorders (570)

Autoimmune diseases (600)

Other disease (900)

Acute Myelogenous Leukemia (AML) Questions: 3 - 89

Specify the AML classification3

Did AML transform from MDS or MPN?4

yes - Also complete MDS Disease Classification questions

no

Is the disease (AML) therapy related?

yes no Unknown

5

Did the recipient have a predisposing condition?

yes no Unknown

6

Specify condition7

Bloom syndrome

Down syndrome

Fanconi anemia

Dyskeratosis congenita

Other condition

Specify other condition:8

Were cytogenetics tested (karyotyping or FISH)? (at diagnosis)

yes no Unknown

9

Were cytogenetics tested via FISH? (at diagnosis)

Yes No

10

Results of tests11

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities12

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

13

Specify other abnormality:14

Were cytogenetics tested via karyotyping? (at diagnosis)

Yes No

15

Results of tests16

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities17

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

18

Specify other abnormality:19

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

20

Were tests for molecular markers performed? (e.g. PCR, NGS) (at diagnosis)

yes no Unknown

21

CEBPA

Positive Negative Not Done

22

Specify CEBPA mutation23

Biallelic (homozygous)

Monoallelic (heterozygous)

Unknown

FLT3 – D835 point mutation

Positive Negative Not Done

24

FLT3 – ITD mutation

Positive Negative Not Done

25

FLT3 - ITD allelic ratio

Known Unknown

26

Specify FLT3 - ITD allelic ratio:27

IDH1

Positive Negative Not Done

28

IDH2

Positive Negative Not Done

29

KIT

Positive Negative Not Done

30

NPM1

Positive Negative Not Done

31

Other Molecular Marker (1) Questions: 32 - 33

Other molecular marker

Positive Negative Not Done

32

Specify other molecular marker:33

Were cytogenetics tested (karyotyping or FISH)? (between diagnosis and last evaluation)

yes no Unknown

34

Were cytogenetics tested via FISH? (between diagnosis and last evaluation)

Yes No

35

Results of tests36

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities37

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

38

Specify other abnormality:39

Were cytogenetics tested via karyotyping? (between diagnosis and last evaluation)

Yes No

40

Results of tests41

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities42

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

43

Specify other abnormality:44

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

45

Were tests for molecular markers performed? (e.g. PCR, NGS) (between diagnosis and last evaluation)

yes no Unknown

46

CEBPA

Positive Negative Not Done

47

Specify CEBPA mutation48

Biallelic (homozygous)

Monoallelic (heterozygous)

Unknown

FLT3 – D835 point mutation

Positive Negative Not Done

49

FLT3 – ITD mutation

Positive Negative Not Done

50

FLT3 - ITD allelic ratio

Known Unknown

51

Specify FLT3 - ITD allelic ratio:52

IDH1

Positive Negative Not Done

53

IDH2

Positive Negative Not Done

54

KIT

Positive Negative Not Done

55

NPM1

Positive Negative Not Done

56

Other Molecular Marker (1) Questions: 57 - 58

Other molecular marker

Positive Negative Not Done

57

Specify other molecular marker:58

Were cytogenetics tested (karyotyping or FISH)? (at last evaluation)

yes no Unknown

59

Were cytogenetics tested via FISH? (at last evaluation)

Yes No

60

Results of tests61

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities62

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

63

Specify other abnormality:64

Were cytogenetics tested via karyotyping? (at last evaluation)

Yes No

65

Results of tests66

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities67

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

68

Specify other abnormality:69

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

70

Were tests for molecular markers performed? (e.g. PCR, NGS) (at last evaluation)

yes no Unknown

71

CEBPA

Positive Negative Not Done

72

Specify CEBPA mutation73

Biallelic (homozygous)

Monoallelic (heterozygous)

Unknown

FLT3 – D835 point mutation

Positive Negative Not Done

74

FLT3 – ITD mutation

Positive Negative Not Done

75

FLT3 - ITD allelic ratio

Known Unknown

76

Specify FLT3 - ITD allelic ratio:77

IDH1

Positive Negative Not Done

78

IDH2

Positive Negative Not Done

79

KIT

Positive Negative Not Done

80

NPM1

Positive Negative Not Done

81

Other Molecular Marker (1) Questions: 82 - 83

Other molecular marker

Positive Negative Not Done

82

Specify other molecular marker:83

Did the recipient have central nervous system leukemia at any time prior to the start of the preparative regimen / infusion?

yes no Unknown

84

What was the disease status (based on hematological test results)?85

Primary induction failure

1st complete remission (no previous bone marrow or extramedullary relapse) (include CRi)

2nd complete remission

≥3rd complete remission

1st relapse

2nd relapse

≥3rd relapse

No treatment

How many cycles of induction therapy were required to achieve 1st complete remission? (includes CRi)

1 2 ≥ 3

86

Was the recipient in remission by flow cytometry?

Yes No Unknown Not applicable

87

Date of most recent relapse:88 __ __ __ __ - __ __- __ __

Date assessed:89 __ __ __ __ - __ __- __ __

Acute Lymphoblastic Leukemia (ALL) Questions: 90 - 151

Specify ALL classification90

Did the recipient have a predisposing condition?

yes no Unknown

91

Specify condition92

Aplastic anemia - Also complete CIBMTR Form 2028 - APL

Bloom syndrome

Down syndrome

Fanconi anemia - Also complete CIBMTR Form 2029 - FAN

Other condition

Specify other condition:93

Were tyrosine kinase inhibitors given for therapy at any time prior to the start of the preparative regimen / infusion? (e.g. imatinib mesylate, dasatinib, etc.)

yes no

94

Were cytogenetics tested (karyotyping or FISH)? (at diagnosis)

yes no Unknown

95

Were cytogenetics tested via FISH? (at diagnosis)

Yes No

96

Results of tests97

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities98

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

99

Specify other abnormality:100

Were cytogenetics tested via karyotyping? (at diagnosis)

Yes No

101

Results of tests102

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities103

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

104

Specify other abnormality:105

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

106

Were tests for molecular markers performed? (e.g. PCR, NGS) (at diagnosis)

yes no Unknown

107

BCR / ABL

Positive Negative Not Done

108

TEL-AML / AML1

Positive Negative Not Done

109

Other Molecular Marker (1) Questions: 110 - 111

Other molecular marker

Positive Negative Not Done

110

Specify other molecular marker:111

Were cytogenetics tested (karyotyping or FISH)? (between diagnosis and last evaluation)

yes no Unknown

112

Were cytogenetics tested via FISH? (between diagnosis and last evaluation)

Yes No

113

Results of tests114

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities115

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

116

Specify other abnormality:117

Were cytogenetics tested via karyotyping? (between diagnosis and last evaluation)

Yes No

118

Results of tests119

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities120

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

121

Specify other abnormality:122

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

123

Were tests for molecular markers performed? (e.g. PCR, NGS) (between diagnosis and last evaluation)

yes no Unknown

124

BCR / ABL

Positive Negative Not Done

125

TEL-AML / AML1

Positive Negative Not Done

126

Other Molecular Marker (1) Questions: 127 - 128

Other molecular marker

Positive Negative Not Done

127

Specify other molecular marker:128

Were cytogenetics tested (karyotyping or FISH)? (at last evaluation)

yes no Unknown

129

Were cytogenetics tested via FISH? (at last evaluation)

Yes No

130

Results of tests131

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities132

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

133

Specify other abnormality:134

Were cytogenetics tested via karyotyping? (at last evaluation)

Yes No

135

Results of tests136

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities137

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

138

Specify other abnormality:139

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

140

Were tests for molecular markers performed? (e.g. PCR, NGS) (at last evaluation)

yes no Unknown

141

BCR / ABL

Positive Negative Not Done

142

TEL-AML / AML1

Positive Negative Not Done

143

Other Molecular Marker (1) Questions: 144 - 145

Other molecular marker

Positive Negative Not Done

144

Specify other molecular marker:145

Did the recipient have central nervous system leukemia at any time prior to the start of the preparative regimen / infusion?

yes no Unknown

146

What was the disease status (based on hematological test results)?147

Primary induction failure

1st complete remission (no previous marrow or extramedullary relapse) (include CRi)

2nd complete remission

≥3rd complete remission

1st relapse

2nd relapse

≥3rd relapse

No treatment

How many cycles of induction therapy were required to achieve 1st complete remission? (include CRi)

1 2 ≥ 3

148

Was the recipient in remission by flow cytometry?

Yes No Unknown Not applicable

149

Date of most recent relapse:150 __ __ __ __ - __ __- __ __

Date assessed:151 __ __ __ __ - __ __- __ __

Acute Leukemias of Ambiguous Lineage and Other Myeloid Neoplasms Questions: 152 - 155

Specify acute leukemias of ambiguous lineage and other myeloid neoplasm classification152

Blastic plasmacytoid dendritic cell neoplasm (296)

Acute undifferentiated leukemia (31)

Mixed phenotype acute leukemia (MPAL) with t(9;22)(q34.1;q11.2); BCR-ABL1 (84)

Mixed phenotype acute leukemia with t(v; 11q23.3); KMT2A rearranged (85)

Mixed phenotype acute leukemia, B/myeloid, NOS (86)

Mixed phenotype acute leukemia, T/myeloid, NOS (87)

Other acute leukemia of ambiguous lineage or myeloid neoplasm (88)

Specify other acute leukemia of ambiguous lineage or myeloid neoplasm:153

What was the disease status (based on hematological test results)?154

Primary induction failure

1st complete remission (no previous marrow or extramedullary relapse)

2nd complete remission

≥3rd complete remission

1st relapse

2nd relapse

≥3rd relapse

No treatment

Date assessed:155 __ __ __ __ - __ __- __ __

Chronic Myelogenous Leukemia (CML) Questions: 156 - 166

Was therapy given prior to this HCT?

yes no

156

Combination chemotherapy

yes no

157

Hydroxyurea (Droxia, Hydrea)

yes no

158

Tyrosine kinase inhibitor (e.g. imatinib mesylate, dasatinib, nilotinib)

yes no

159

Interferon­α (Intron, Roferon) (includes PEG)

yes no

160

Other therapy

yes no

161

Specify other therapy:162

What was the disease status?163

Complete hematologic response (CHR)

Chronic phase

Accelerated phase

Blast phase

Specify level of response164

No cytogenetic response (No CyR)

Minimal cytogenetic response

Minor cytogenetic response

Partial cytogenetic response (PCyR)

Complete cytogenetic response (CCyR)

Major molecular remission (MMR)

Complete molecular remission (CMR)

Number

1st 2nd 3rd or higher

165

Date assessed:166 __ __ __ __ - __ __- __ __

Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases Questions: 167 - 260

What was the MDS / MPN subtype at diagnosis? - If transformed to AML, indicate AML as primary disease; also complete AML Disease Classification
questions

167

Was the disease (MDS/MPN) therapy related?

yes no Unknown

168

Did the recipient have a predisposing condition?

yes no Unknown

169

Specify condition

Aplastic Anemia Bloom syndrome Down syndrome Fanconi anemia Other condition

170

Specify other condition:171

WBC

Known Unknown

172

173 x 109/L (x 103/mm3)

x 106/L

Hemoglobin

Known Unknown

174

175 g/dL g/L mmol/L

Was RBC transfused ≤ 30 days before date of test?

Yes No

176

Platelets

Known Unknown

177

178 x 109/L (x 103/mm3)

x 106/L

Were platelets transfused ≤ 7 days before date of test?

Yes No

179

Neutrophils

Known Unknown

180

181 %

Blasts in bone marrow

Known Unknown

182

183 %

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

184

Results of tests185

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities186

One (1)

Two (2)

Three (3)

Four or more (4 or more)

–5

yes no

187

-7

yes no

188

–13

yes no

189

–20

yes no

190

–Y

yes no

191

+8

yes no

192

+19

yes no

193

t(1;3)

yes no

194

t(2;11)

yes no

195

t(3;3)

yes no

196

t(3;21)

yes no

197

t(6;9)

yes no

198

t(11;16)

yes no

199

del(3q) / 3q–

yes no

200

del(5q) / 5q-

yes no

201

del(7q) / 7q–

yes no

202

del(9q) / 9q–

yes no

203

del(11q) / 11q–

yes no

204

del(12p) / 12p–

yes no

205

del(13q) / 13q-

yes no

206

del(20q) / 20q–

yes no

207

inv(3)

yes no

208

i17q

yes no

209

Other abnormality

yes no

210

Specify other abnormality:211

Did the recipient progress or transform to a different MDS / MPN subtype between diagnosis and the start of the preparative regimen?

yes no

212

Specify the MDS / MPN classification after transformation:213

Specify the date of the most recent transformation:214 __ __ __ __ - __ __- __ __

Date of MDS diagnosis:215 __ __ __ __ - __ __- __ __

WBC

Known Unknown

216

217 x 109/L (x 103/mm3)

x 106/L

Hemoglobin

Known Unknown

218

219 g/dL g/L mmol/L

Was RBC transfused ≤ 30 days before date of test?

Yes No

220

Platelets

Known Unknown

221

222 x 109/L (x 103/mm3)

x 106/L

Were platelets transfused ≤ 7 days before date of test?

Yes No

223

Neutrophils

Known Unknown

224

225 %

Blasts in bone marrow

Known Unknown

226

227 %

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

228

Results of tests229

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities230

One (1)

Two (2)

Three (3)

Four or more (4 or more)

–5

yes no

231

-7

yes no

232

–13

yes no

233

–20

yes no

234

–Y

yes no

235

+8

yes no

236

+19

yes no

237

t(1;3)

yes no

238

t(2;11)

yes no

239

t(3;3)

yes no

240

t(3;21)

yes no

241

t(6;9)

yes no

242

t(11;16)

yes no

243

del(3q) / 3q–

yes no

244

del(5q) / 5q-

yes no

245

del(7q) / 7q–

yes no

246

del(9q) / 9q–

yes no

247

del(11q) / 11q–

yes no

248

del(12p) / 12p–

yes no

249

del(13q) / 13q-

yes no

250

del(20q) / 20q–

yes no

251

inv(3)

yes no

252

i17q

yes no

253

Other abnormality

yes no

254

Specify other abnormality:255

What was the disease status?256

Complete
remission

(CR)

– requires all of the following, maintained for ≥ 4 weeks: * bone marrow evaluation: <  5% myeloblasts with normal maturation of all cell lines *
peripheral blood evaluation: hemoglobin ≥ 11 g/dL untransfused and without erythropoietin support; ANC ≥ 1000/mm3  without myeloid growth factor
support; platelets ≥ 100 x 109/L without thrombopoietic support; 0% blasts

Hematologic

improvement
(HI)

– requires one measurement of the following, maintained for ≥ 8 weeks without ongoing cytotoxic therapy; specify which cell line was measured to
determine HI response: * HI­E – hemoglobin increase of ≥ 1.5 g/dL untransfused; for RBC transfusions performed for Hgb ≤ 9.0, reduction in RBC
units transfused in 8 weeks by ≥ 4 units compared to the pre­treatment transfusion number in 8 weeks * HI­P – for pre­treatment platelet count of > 20
x 109/L, platelet absolute increase of ≥ 30 x 109/L; for pre-treatment platelet count of < 20 x 109/L, platelet absolute increase of ≥ 20 x 109/L and ≥
100% from pre­treatment level  * HI­N – neutrophil count increase of ≥ 100% from pre­treatment level and an absolute increase of ≥ 500/mm3

No response (NR) / stable disease (SD) – does not meet the criteria for at least HI, but no evidence of disease progression

Progression from
hematologic improvement

(Prog from HI)

– requires at least one of the following, in the absence of another explanation (e.g., infection, bleeding, ongoing chemotherapy, etc.): *
≥ 50% reduction from maximum response levels in granulocytes or platelets * reduction in hemoglobin by ≥ 1.5 g/dL *transfusion
dependence

Relapse from complete

remission (Rel from CR)

– requires at least one of the following: * return to pre­treatment bone marrow blast percentage * decrease of ≥ 50% from maximum
response levels in granulocytes or platelets * transfusion dependence, or hemoglobin level ≥ 1.5 g/dL lower than prior to therapy

Not assessed

Specify the cell line examined to determine HI status257

HI-
E

– hemoglobin increase of ≥ 1.5 g/dL untransfused; for RBC transfusions performed for Hgb ≤ 9.0, reduction in RBC units transfused in 8 weeks by ≥ 4
units compared to the pre-treatment transfusion number in 8 weeks

HI-
P

– for pre­treatment platelet count of > 20 x 109/L, platelet absolute increase of ≥ 30 x 109/L; for pre-treatment platelet count of < 20 x 109/L, platelet
absolute increase of ≥ 20 x 109/L and ≥ 100% from pre­treatment level 

HI-N – neutrophil count increase of ≥ 100% from pre­treatment level and an absolute increase of ≥ 500/mm3

Date of progression:258 __ __ __ __ - __ __- __ __

Date of relapse:259 __ __ __ __ - __ __- __ __

Date assessed:260 __ __ __ __ - __ __- __ __

Other Leukemia (OL) Questions: 261 - 267

Specify the other leukemia classification261

Specify other leukemia:262

Was any 17p abnormality detected?

yes no

263

Did a histologic transformation to diffuse large B-cell lymphoma (Richter syndrome) occur at any time after CLL diagnosis?264

yes - Also complete NHL Disease Classification questions

no

What was the disease status? (Atypical CML)265

Primary induction failure

1st complete remission (no previous bone marrow or extramedullary relapse)

2nd complete remission

≥3rd complete remission

1st relapse

2nd relapse

≥3rd relapse

No treatment

What was the disease status? (CLL, PLL, Hairy cell leukemia)266

Complete remission (CR)

Partial remission (PR)

Stable disease (SD)

Progressive disease (Prog)

Untreated

Not assessed

Date assessed:267 __ __ __ __ - __ __- __ __

Hodgkin and Non-Hodgkin Lymphoma Questions: 268 - 285

Specify the lymphoma histology (at infusion)268

Specify other lymphoma histology:269

Assignment of DLBCL (germinal center B-cell type vs. activated B-cell type) subtype was based on270

Immunohistochemistry (e.g. Han's algorithm)

Gene expression profile

Unknown method

Is the lymphoma histology reported at transplant a transformation from CLL?

yes no

271

Was any 17p abnormality detected?

yes no

272

Is the lymphoma histology reported at transplant a transformation from a different lymphoma histology? (Not CLL)

Yes No

273

Specify the original lymphoma histology (prior to transformation)274

Specify other lymphoma histology:275

Date of original lymphoma diagnosis:276 __ __ __ __ - __ __- __ __ (report the date of diagnosis of original lymphoma subtype)

Was a PET (or PET/CT) scan performed? (at last evaluation prior to the start of the preparative regimen / infusion)

yes no

277

Was the PET (or PET/CT) scan positive for lymphoma involvement at any disease site?

yes no

278

Date of PET scan

Known Unknown

279

Date of PET (or PET/CT) scan:280 __ __ __ __ - __ __- __ __

Deauville (five-point) score of the PET (or PET/CT) scan

Known Unknown

281

Scale282

1 - no uptake or residual uptake

2 - slight uptake, but below blood pool (mediastinum)

3 - uptake above mediastinal, but below or equal to uptake in the liver

4 - uptake slightly to moderately higher than liver

5 - markedly increased uptake or any new lesions

What was the disease status?283

Total number of lines of therapy received

1 line 2 lines 3+ lines

284

Date assessed:285 __ __ __ __ - __ __- __ __

Multiple Myeloma / Plasma Cell Disorder (PCD) Questions: 286 - 317

Specify the multiple myeloma/plasma cell disorder (PCD) classification286

Specify other plasma cell disorder:287

Light chain

kappa lambda

288

What was the Durie-Salmon staging? (at diagnosis)289

Stage
I

(All of the following: Hgb > 10g/dL; serum calcium normal or <10.5 mg/dL; bone x-ray normal bone structure (scale 0), or solitary bone plasmacytoma
only; low M-component production rates IgG< 5g/dL, IgA < 3g/dL; urine light chain M-component on electrophoresis <4 g/24h)

Stage II (Fitting neither Stage I or III) 

Stage
III

(One or more of the following: Hgb < 8.5 g/dL; serum calcium > 12 mg/dL; advanced lytic bone lesions (scale 3); high M-component production rates
IgG > 7g/dL, IgA > 5 g/dL; Bence Jones protein > 12g/24h)

Unknown

What was the Durie-Salmon sub classification? (at diagnosis)290

A - relatively normal renal function (serum creatinine < 2.0 mg/dL)

B ­ abnormal renal function (serum creatinine ≥ 2.0 mg/dL)

Serum β2­microglobulin:291 μg/dL mg/L nmol/L

Serum albumin:292 g/dL g/L

Stage293

1 (β2 ­mic < 3.5, S. albumin ≥3.5)

2 (Not fitting stage 1 or 3)

3 (β2­mic ≥ 5.5; S. albumin ­)

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

294

Results of tests295

Abnormalities identified

No evaluable metaphases

No abnormalities

+3

yes no

296

+5

yes no

297

+7

yes no

298

+9

yes no

299

+11

yes no

300

+15

yes no

301

+19

yes no

302

t(4;14)

yes no

303

t(6;14)

yes no

304

t(11;14)

yes no

305

t(14;16)

yes no

306

t(14;20)

yes no

307

del(13q) / 13q-

yes no

308

del (17p) / 17p-

yes no

309

Hyperdiploid (>50)

yes no

310

Hypodiploid (<46)

yes no

311

Any abnormality at 1q

yes no

312

Any abnormality at 1p

yes no

313

Other abnormality

yes no

314

Specify other abnormality:315

What was the disease status?316

Stringent
complete

remission
(sCR)

- CR as defined, plus: normal free light chain ratio, and absence of clonal cells in the bone marrow by immunohistochemistry of immunofluorescence
(confirmation with repeat bone marrow biopsy not needed). (Presence and/or absence of clonal cells is based upon the Κ/λ ratio. An abnormal Κ/λ ratio by
immunohistochemistry and/or immunofluorescence requires a minimum of 100 plasma cells for analysis.  An abnormal ratio reflecting the presence of
an abnormal clone is Κ/λ of > 4:1 or < 1:2.) sCR requires two consecutive assessments made at any time before the institution of any new therapy, and
no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy sCR
requirements. 

Complete
remission

(CR)

- negative immunofixation on serum and urine samples, and disappearance of any soft tissue plasmacytomas, and < 5% plasma cells in the bone
marrow (confirmation with repeat bone marrow biopsy not needed).  CR requires two consecutive assessments made at any time before the institution

of any new therapy, and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not
required to satisfy CR requirements. 

Near
complete
remission
(nCR)

- serum and urine M-protein detectable by immunoelectrophoresis (IFE), but not on electrophoresis (negative SPEP & UPEP); < 5% plasma cells in
bone marrow.  nCR requires two consecutive assessments made at any time before the initiation of any new therapy, and no known evidence of
progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy nCR requirements. 

Very good
partial
remission
(VGPR)

­ serum and urine M­protein detectable by immunofixation but not on electrophoresis, or ≥ 90% reduction in serum M­protein and urine M­protein level <
100 mg/24 hours.  VGPR requires two consecutive assessments made at any time before the institution of any new therapy, and no known evidence of
progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy VGPR requirements.

Partial
remission
(PR)

­ ≥ 50% reduction in serum M­protein, and reduction in 24­hour urinary M­protein by ≥ 90% or to < 200 mg/24 hours.  If the serum and urine M­protein are
unmeasurable (i.e., do not meet any of the following criteria: • serum M­protein ≥ 1 g/dL.  Urine M­protein ≥ 200 mg/24 hours • serum free light chain
assay shows involved level ≥ 10 mg/dL, provided serum free light chain ratio is abnormal), a ≥ 50% decrease in the difference between involved and
uninvolved free light chain levels is required in place of the M-protein criteria.  If serum and urine M-protein are unmeasurable, and serum free light assay
is also unmeasurable, a ≥ 50% reduction in plasma cells is required in place of M­protein, provided the baseline bone marrow plasma cell percentage
was ≥ 30%. In addition to the above listed criteria, a ≥ 50% reduction in the size of soft tissue plasmacytomas is also required, if present at baseline. PR
requires two consecutive assessments made at any time before the institution of any new therapy, and no known evidence of progressive or new bone
lesions if radiographic studies were performed; radiographic studies are not required to satisfy PR requirements. 

Stable
disease
(SD)

- not meeting the criteria for CR, VGPR, PR or PD.  SD requires two consecutive assessments made at any time before the institution of any new therapy,
and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy SD
requirements.

Progressive
disease
(PD)

­ requires any one or more of the following:  Increase of ≥ 25% from baseline in:  serum M­component and/or (absolute increase ≥ 0.5 g/dL) (for
progressive disease, serum M­component increases of ≥ 1 g/dL are sufficient to define relapse if the starting M­component is ≥ 5 g/dL).  Urine M­
component and/or (absolute increase ≥ 200 mg/24 hours) for recipients without measurable serum and urine M­protein levels: the difference between
involved and uninvolved free light chain levels (absolute increase > 10 mg/dL).  Bone marrow plasma cell percentage (absolute percentage ≥ 10%)
(relapse from CR has a 5% cutoff vs. 10% for other categories of relapse) definite development of new bone lesions or soft tissue plasmacytomas, or
definite increase in the size of any existing  bone lesions or soft tissue plasmacytomas. Development of hypercalcemia (corrected serum calcium >
11.5 mg/dL or 2.65 mmol) that can be attributed solely to the plasma cell proliferative disorder.  PD requires two consecutive assessments made at
any time before classification as disease progression, and/or the institution of any new therapy.

Relapse
from CR
(Rel)
(untreated)

­ requires one or more of the following: reappearance of serum or urine M­protein by immunofixation or electrophoresis development of ≥ 5% plasma
cells in the bone marrow (relapse from CR has a 5% cutoff vs. 10% for other categories of relapse) appearance of any other sign of progression (e.g.,
new plasmacytoma, lytic bone lesion, hypercalcemia).  Rel requires two consecutive assessments made at any time before classification as relapse,
and/or the institution of any new therapy.

Unknown

Not applicable (Amyloidosis with no evidence of myeloma)

Date assessed:317 __ __ __ __ - __ __- __ __

Solid Tumors Questions: 318 - 319

Specify the solid tumor classification318

Specify other solid tumor:319

Severe Aplastic Anemia Questions: 320 - 321

Specify the severe aplastic anemia classification320

Specify other acquired cytopenic syndrome:321

Inherited Abnormalities of Erythrocyte Differentiation or Function Questions: 322 - 324

Specify the inherited abnormalities of erythrocyte differentiation or function classification322

Specify other constitutional anemia:323

Specify other hemoglobinopathy:324

Disorders of the Immune System Questions: 325 - 327

Specify disorder of immune system classification325

Specify other SCID:326

Specify other immunodeficiency:327

Inherited Abnormalities of Platelets Questions: 328 - 329

Specify inherited abnormalities of platelets classification328

Congenital amegakaryocytosis / congenital thrombocytopenia (501)

Glanzmann thrombasthenia (502)

Other inherited platelet abnormality (509)

Specify other inherited platelet abnormality:329

Inherited Disorders of Metabolism Questions: 330 - 331

Specify inherited disorders of metabolism classification330

Specify other inherited metabolic disorder:331

Histiocytic Disorders Questions: 332 - 333

Specify histiocytic disorder classification332

Specify other histiocytic disorder:333

Autoimmune Diseases Questions: 334 - 341

Specify autoimmune disease classification334

Specify other arthritis:335

Specify other juvenile idiopathic arthritis (JIA):336

Specify other connective tissue disease:337

Specify other vasculitis:338

Specify other autoimmune neurological disorder:339

Specify other autoimmune cytopenia:340

Specify other autoimmune bowel disorder:341

Other Disease Questions: 342 - 342

Specify other disease:342

First Name:

Last Name:

E-mail address:

Date: __ __ __ __ - __ __- __ __

OMB No: 0915-0310

Expiration Date: 1/31/2020

Public Burden Statement:  An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control
number.  The OMB control number for this project is 0915-0310.  Public reporting burden for this collection of information is estimated to average 1.0 hours per response, including the
time for reviewing instructions, searching existing data sources, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other
aspect of this collection of information, including suggestions for reducing this burden, to HRSA Reports Clearance Officer, 5600 Fishers Lane, Room 10-29, Rockville, Maryland, 20857.

Labs at diagnosis

Specify cytogenetic abnormalities identified at diagnosis:

Specify cytogenetic abnormalities identified at diagnosis:

Specify molecular markers identified at diagnosis:

Labs between diagnosis and last evaluation:

Specify cytogenetic abnormalities identified between diagnosis and last evaluation:

Specify cytogenetic abnormalities identified between diagnosis and last evaluation:

Specify molecular markers identified between diagnosis and last evaluation:

Labs at last evaluation:

Specify cytogenetic abnormalities identified at last evaluation:

Specify cytogenetic abnormalities identified at last evaluation:

Specify molecular markers identified at last evaluation:

CNS Leukemia

Status at transplantation:

Laboratory studies at diagnosis:

Specify cytogenetic abnormalities identified at diagnosis:

Specify cytogenetic abnormalities identified at diagnosis:

Specify molecular markers identified at diagnosis:

Laboratory studies between diagnosis and last evaluation:

Specify cytogenetic abnormalities identified between diagnosis and last evaluation:

Specify cytogenetic abnormalities identified between diagnosis and last evaluation:

Specify molecular markers identified between diagnosis and last evaluation:

Laboratory studies at last evaluation:

Specify cytogenetic abnormalities identified at last evaluation:

Specify cytogenetic abnormalities identified at last evaluation:

Specify molecular markers identified at last evaluation:

CNS Leukemia

Status at transplantation:

Status at transplantation:

Laboratory studies at diagnosis of MDS:

Specify abnormalities identified at diagnosis:

Monosomy

Trisomy

Translocation

Deletion

Inversion

Other

Laboratory studies at last evaluation prior to the start of the preparative regimen:

Specify cytogenetic abnormalities identified at last evaluation prior to the start of the preparative regimen:

Monosomy

Trisomy

Translocation

Deletion

Inversion

Other

Status at transplantation:

Status at transplantation:

Status at transplantation / infusion:

I.S.S.:

Specify cytogenetic abnormalities identified at any time prior to the start of the preparative regimen:

Trisomy

Translocation

Deletion

Other

Status at transplantation:

Center: CRID: 

Form 2402 R3.0: Disease Classification

CIBMTR Form 2402 revision 3.0 last updated Monday, January 29, 2018
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 4 / 26



Key Fields

Sequence Number:

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number:

CIBMTR Research ID:

Event date: __ __ __ __ - __ __- __ __

Primary Disease for HCT / Cellular Therapy Questions: 1 - 2

Date of diagnosis of primary disease for HCT / cellular therapy:1 __ __ __ __ - __ __- __ __

What was the primary disease for which the HCT / cellular therapy was performed?2

Acute myelogenous leukemia (AML or ANLL) (10)

Acute lymphoblastic leukemia (ALL) (20)

Acute leukemia of ambiguous lineage and other myeloid neoplasms (80)

Chronic myelogenous leukemia (CML) (40)

Myelodysplastic (MDS) / myeloproliferative (MPN) diseases (50) (Please classify all preleukemias) (If recipient has transformed to AML, indicate AML as the primary disease)

Other leukemia (30) (includes CLL)

Hodgkin lymphoma (150)

Non-Hodgkin lymphoma (100)

Multiple myeloma / plasma cell disorder (PCD) (170)

Solid tumors (200)

Severe aplastic anemia (300) (If the recipient developed MDS or AML, indicate MDS or AML as the primary disease)

Inherited abnormalities of erythrocyte differentiation or function (310)

Disorders of the immune system (400)

Inherited abnormalities of platelets (500)

Inherited disorders of metabolism (520)

Histiocytic disorders (570)

Autoimmune diseases (600)

Other disease (900)

Acute Myelogenous Leukemia (AML) Questions: 3 - 89

Specify the AML classification3

Did AML transform from MDS or MPN?4

yes - Also complete MDS Disease Classification questions

no

Is the disease (AML) therapy related?

yes no Unknown

5

Did the recipient have a predisposing condition?

yes no Unknown

6

Specify condition7

Bloom syndrome

Down syndrome

Fanconi anemia

Dyskeratosis congenita

Other condition

Specify other condition:8

Were cytogenetics tested (karyotyping or FISH)? (at diagnosis)

yes no Unknown

9

Were cytogenetics tested via FISH? (at diagnosis)

Yes No

10

Results of tests11

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities12

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

13

Specify other abnormality:14

Were cytogenetics tested via karyotyping? (at diagnosis)

Yes No

15

Results of tests16

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities17

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

18

Specify other abnormality:19

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

20

Were tests for molecular markers performed? (e.g. PCR, NGS) (at diagnosis)

yes no Unknown

21

CEBPA

Positive Negative Not Done

22

Specify CEBPA mutation23

Biallelic (homozygous)

Monoallelic (heterozygous)

Unknown

FLT3 – D835 point mutation

Positive Negative Not Done

24

FLT3 – ITD mutation

Positive Negative Not Done

25

FLT3 - ITD allelic ratio

Known Unknown

26

Specify FLT3 - ITD allelic ratio:27

IDH1

Positive Negative Not Done

28

IDH2

Positive Negative Not Done

29

KIT

Positive Negative Not Done

30

NPM1

Positive Negative Not Done

31

Other Molecular Marker (1) Questions: 32 - 33

Other molecular marker

Positive Negative Not Done

32

Specify other molecular marker:33

Were cytogenetics tested (karyotyping or FISH)? (between diagnosis and last evaluation)

yes no Unknown

34

Were cytogenetics tested via FISH? (between diagnosis and last evaluation)

Yes No

35

Results of tests36

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities37

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

38

Specify other abnormality:39

Were cytogenetics tested via karyotyping? (between diagnosis and last evaluation)

Yes No

40

Results of tests41

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities42

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

43

Specify other abnormality:44

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

45

Were tests for molecular markers performed? (e.g. PCR, NGS) (between diagnosis and last evaluation)

yes no Unknown

46

CEBPA

Positive Negative Not Done

47

Specify CEBPA mutation48

Biallelic (homozygous)

Monoallelic (heterozygous)

Unknown

FLT3 – D835 point mutation

Positive Negative Not Done

49

FLT3 – ITD mutation

Positive Negative Not Done

50

FLT3 - ITD allelic ratio

Known Unknown

51

Specify FLT3 - ITD allelic ratio:52

IDH1

Positive Negative Not Done

53

IDH2

Positive Negative Not Done

54

KIT

Positive Negative Not Done

55

NPM1

Positive Negative Not Done

56

Other Molecular Marker (1) Questions: 57 - 58

Other molecular marker

Positive Negative Not Done

57

Specify other molecular marker:58

Were cytogenetics tested (karyotyping or FISH)? (at last evaluation)

yes no Unknown

59

Were cytogenetics tested via FISH? (at last evaluation)

Yes No

60

Results of tests61

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities62

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

63

Specify other abnormality:64

Were cytogenetics tested via karyotyping? (at last evaluation)

Yes No

65

Results of tests66

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities67

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

68

Specify other abnormality:69

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

70

Were tests for molecular markers performed? (e.g. PCR, NGS) (at last evaluation)

yes no Unknown

71

CEBPA

Positive Negative Not Done

72

Specify CEBPA mutation73

Biallelic (homozygous)

Monoallelic (heterozygous)

Unknown

FLT3 – D835 point mutation

Positive Negative Not Done

74

FLT3 – ITD mutation

Positive Negative Not Done

75

FLT3 - ITD allelic ratio

Known Unknown

76

Specify FLT3 - ITD allelic ratio:77

IDH1

Positive Negative Not Done

78

IDH2

Positive Negative Not Done

79

KIT

Positive Negative Not Done

80

NPM1

Positive Negative Not Done

81

Other Molecular Marker (1) Questions: 82 - 83

Other molecular marker

Positive Negative Not Done

82

Specify other molecular marker:83

Did the recipient have central nervous system leukemia at any time prior to the start of the preparative regimen / infusion?

yes no Unknown

84

What was the disease status (based on hematological test results)?85

Primary induction failure

1st complete remission (no previous bone marrow or extramedullary relapse) (include CRi)

2nd complete remission

≥3rd complete remission

1st relapse

2nd relapse

≥3rd relapse

No treatment

How many cycles of induction therapy were required to achieve 1st complete remission? (includes CRi)

1 2 ≥ 3

86

Was the recipient in remission by flow cytometry?

Yes No Unknown Not applicable

87

Date of most recent relapse:88 __ __ __ __ - __ __- __ __

Date assessed:89 __ __ __ __ - __ __- __ __

Acute Lymphoblastic Leukemia (ALL) Questions: 90 - 151

Specify ALL classification90

Did the recipient have a predisposing condition?

yes no Unknown

91

Specify condition92

Aplastic anemia - Also complete CIBMTR Form 2028 - APL

Bloom syndrome

Down syndrome

Fanconi anemia - Also complete CIBMTR Form 2029 - FAN

Other condition

Specify other condition:93

Were tyrosine kinase inhibitors given for therapy at any time prior to the start of the preparative regimen / infusion? (e.g. imatinib mesylate, dasatinib, etc.)

yes no

94

Were cytogenetics tested (karyotyping or FISH)? (at diagnosis)

yes no Unknown

95

Were cytogenetics tested via FISH? (at diagnosis)

Yes No

96

Results of tests97

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities98

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

99

Specify other abnormality:100

Were cytogenetics tested via karyotyping? (at diagnosis)

Yes No

101

Results of tests102

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities103

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

104

Specify other abnormality:105

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

106

Were tests for molecular markers performed? (e.g. PCR, NGS) (at diagnosis)

yes no Unknown

107

BCR / ABL

Positive Negative Not Done

108

TEL-AML / AML1

Positive Negative Not Done

109

Other Molecular Marker (1) Questions: 110 - 111

Other molecular marker

Positive Negative Not Done

110

Specify other molecular marker:111

Were cytogenetics tested (karyotyping or FISH)? (between diagnosis and last evaluation)

yes no Unknown

112

Were cytogenetics tested via FISH? (between diagnosis and last evaluation)

Yes No

113

Results of tests114

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities115

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

116

Specify other abnormality:117

Were cytogenetics tested via karyotyping? (between diagnosis and last evaluation)

Yes No

118

Results of tests119

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities120

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

121

Specify other abnormality:122

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

123

Were tests for molecular markers performed? (e.g. PCR, NGS) (between diagnosis and last evaluation)

yes no Unknown

124

BCR / ABL

Positive Negative Not Done

125

TEL-AML / AML1

Positive Negative Not Done

126

Other Molecular Marker (1) Questions: 127 - 128

Other molecular marker

Positive Negative Not Done

127

Specify other molecular marker:128

Were cytogenetics tested (karyotyping or FISH)? (at last evaluation)

yes no Unknown

129

Were cytogenetics tested via FISH? (at last evaluation)

Yes No

130

Results of tests131

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities132

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

133

Specify other abnormality:134

Were cytogenetics tested via karyotyping? (at last evaluation)

Yes No

135

Results of tests136

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities137

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

138

Specify other abnormality:139

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

140

Were tests for molecular markers performed? (e.g. PCR, NGS) (at last evaluation)

yes no Unknown

141

BCR / ABL

Positive Negative Not Done

142

TEL-AML / AML1

Positive Negative Not Done

143

Other Molecular Marker (1) Questions: 144 - 145

Other molecular marker

Positive Negative Not Done

144

Specify other molecular marker:145

Did the recipient have central nervous system leukemia at any time prior to the start of the preparative regimen / infusion?

yes no Unknown

146

What was the disease status (based on hematological test results)?147

Primary induction failure

1st complete remission (no previous marrow or extramedullary relapse) (include CRi)

2nd complete remission

≥3rd complete remission

1st relapse

2nd relapse

≥3rd relapse

No treatment

How many cycles of induction therapy were required to achieve 1st complete remission? (include CRi)

1 2 ≥ 3

148

Was the recipient in remission by flow cytometry?

Yes No Unknown Not applicable

149

Date of most recent relapse:150 __ __ __ __ - __ __- __ __

Date assessed:151 __ __ __ __ - __ __- __ __

Acute Leukemias of Ambiguous Lineage and Other Myeloid Neoplasms Questions: 152 - 155

Specify acute leukemias of ambiguous lineage and other myeloid neoplasm classification152

Blastic plasmacytoid dendritic cell neoplasm (296)

Acute undifferentiated leukemia (31)

Mixed phenotype acute leukemia (MPAL) with t(9;22)(q34.1;q11.2); BCR-ABL1 (84)

Mixed phenotype acute leukemia with t(v; 11q23.3); KMT2A rearranged (85)

Mixed phenotype acute leukemia, B/myeloid, NOS (86)

Mixed phenotype acute leukemia, T/myeloid, NOS (87)

Other acute leukemia of ambiguous lineage or myeloid neoplasm (88)

Specify other acute leukemia of ambiguous lineage or myeloid neoplasm:153

What was the disease status (based on hematological test results)?154

Primary induction failure

1st complete remission (no previous marrow or extramedullary relapse)

2nd complete remission

≥3rd complete remission

1st relapse

2nd relapse

≥3rd relapse

No treatment

Date assessed:155 __ __ __ __ - __ __- __ __

Chronic Myelogenous Leukemia (CML) Questions: 156 - 166

Was therapy given prior to this HCT?

yes no

156

Combination chemotherapy

yes no

157

Hydroxyurea (Droxia, Hydrea)

yes no

158

Tyrosine kinase inhibitor (e.g. imatinib mesylate, dasatinib, nilotinib)

yes no

159

Interferon­α (Intron, Roferon) (includes PEG)

yes no

160

Other therapy

yes no

161

Specify other therapy:162

What was the disease status?163

Complete hematologic response (CHR)

Chronic phase

Accelerated phase

Blast phase

Specify level of response164

No cytogenetic response (No CyR)

Minimal cytogenetic response

Minor cytogenetic response

Partial cytogenetic response (PCyR)

Complete cytogenetic response (CCyR)

Major molecular remission (MMR)

Complete molecular remission (CMR)

Number

1st 2nd 3rd or higher

165

Date assessed:166 __ __ __ __ - __ __- __ __

Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases Questions: 167 - 260

What was the MDS / MPN subtype at diagnosis? - If transformed to AML, indicate AML as primary disease; also complete AML Disease Classification
questions

167

Was the disease (MDS/MPN) therapy related?

yes no Unknown

168

Did the recipient have a predisposing condition?

yes no Unknown

169

Specify condition

Aplastic Anemia Bloom syndrome Down syndrome Fanconi anemia Other condition

170

Specify other condition:171

WBC

Known Unknown

172

173 x 109/L (x 103/mm3)

x 106/L

Hemoglobin

Known Unknown

174

175 g/dL g/L mmol/L

Was RBC transfused ≤ 30 days before date of test?

Yes No

176

Platelets

Known Unknown

177

178 x 109/L (x 103/mm3)

x 106/L

Were platelets transfused ≤ 7 days before date of test?

Yes No

179

Neutrophils

Known Unknown

180

181 %

Blasts in bone marrow

Known Unknown

182

183 %

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

184

Results of tests185

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities186

One (1)

Two (2)

Three (3)

Four or more (4 or more)

–5

yes no

187

-7

yes no

188

–13

yes no

189

–20

yes no

190

–Y

yes no

191

+8

yes no

192

+19

yes no

193

t(1;3)

yes no

194

t(2;11)

yes no

195

t(3;3)

yes no

196

t(3;21)

yes no

197

t(6;9)

yes no

198

t(11;16)

yes no

199

del(3q) / 3q–

yes no

200

del(5q) / 5q-

yes no

201

del(7q) / 7q–

yes no

202

del(9q) / 9q–

yes no

203

del(11q) / 11q–

yes no

204

del(12p) / 12p–

yes no

205

del(13q) / 13q-

yes no

206

del(20q) / 20q–

yes no

207

inv(3)

yes no

208

i17q

yes no

209

Other abnormality

yes no

210

Specify other abnormality:211

Did the recipient progress or transform to a different MDS / MPN subtype between diagnosis and the start of the preparative regimen?

yes no

212

Specify the MDS / MPN classification after transformation:213

Specify the date of the most recent transformation:214 __ __ __ __ - __ __- __ __

Date of MDS diagnosis:215 __ __ __ __ - __ __- __ __

WBC

Known Unknown

216

217 x 109/L (x 103/mm3)

x 106/L

Hemoglobin

Known Unknown

218

219 g/dL g/L mmol/L

Was RBC transfused ≤ 30 days before date of test?

Yes No

220

Platelets

Known Unknown

221

222 x 109/L (x 103/mm3)

x 106/L

Were platelets transfused ≤ 7 days before date of test?

Yes No

223

Neutrophils

Known Unknown

224

225 %

Blasts in bone marrow

Known Unknown

226

227 %

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

228

Results of tests229

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities230

One (1)

Two (2)

Three (3)

Four or more (4 or more)

–5

yes no

231

-7

yes no

232

–13

yes no

233

–20

yes no

234

–Y

yes no

235

+8

yes no

236

+19

yes no

237

t(1;3)

yes no

238

t(2;11)

yes no

239

t(3;3)

yes no

240

t(3;21)

yes no

241

t(6;9)

yes no

242

t(11;16)

yes no

243

del(3q) / 3q–

yes no

244

del(5q) / 5q-

yes no

245

del(7q) / 7q–

yes no

246

del(9q) / 9q–

yes no

247

del(11q) / 11q–

yes no

248

del(12p) / 12p–

yes no

249

del(13q) / 13q-

yes no

250

del(20q) / 20q–

yes no

251

inv(3)

yes no

252

i17q

yes no

253

Other abnormality

yes no

254

Specify other abnormality:255

What was the disease status?256

Complete

remission
(CR)

– requires all of the following, maintained for ≥ 4 weeks: * bone marrow evaluation: <  5% myeloblasts with normal maturation of all cell lines *
peripheral blood evaluation: hemoglobin ≥ 11 g/dL untransfused and without erythropoietin support; ANC ≥ 1000/mm3  without myeloid growth factor
support; platelets ≥ 100 x 109/L without thrombopoietic support; 0% blasts

Hematologic
improvement

(HI)

– requires one measurement of the following, maintained for ≥ 8 weeks without ongoing cytotoxic therapy; specify which cell line was measured to
determine HI response: * HI­E – hemoglobin increase of ≥ 1.5 g/dL untransfused; for RBC transfusions performed for Hgb ≤ 9.0, reduction in RBC
units transfused in 8 weeks by ≥ 4 units compared to the pre­treatment transfusion number in 8 weeks * HI­P – for pre­treatment platelet count of > 20
x 109/L, platelet absolute increase of ≥ 30 x 109/L; for pre-treatment platelet count of < 20 x 109/L, platelet absolute increase of ≥ 20 x 109/L and ≥
100% from pre­treatment level  * HI­N – neutrophil count increase of ≥ 100% from pre­treatment level and an absolute increase of ≥ 500/mm3

No response (NR) / stable disease (SD) – does not meet the criteria for at least HI, but no evidence of disease progression

Progression from

hematologic improvement
(Prog from HI)

– requires at least one of the following, in the absence of another explanation (e.g., infection, bleeding, ongoing chemotherapy, etc.): *
≥ 50% reduction from maximum response levels in granulocytes or platelets * reduction in hemoglobin by ≥ 1.5 g/dL *transfusion
dependence

Relapse from complete
remission (Rel from CR)

– requires at least one of the following: * return to pre­treatment bone marrow blast percentage * decrease of ≥ 50% from maximum
response levels in granulocytes or platelets * transfusion dependence, or hemoglobin level ≥ 1.5 g/dL lower than prior to therapy

Not assessed

Specify the cell line examined to determine HI status257

HI-

E

– hemoglobin increase of ≥ 1.5 g/dL untransfused; for RBC transfusions performed for Hgb ≤ 9.0, reduction in RBC units transfused in 8 weeks by ≥ 4
units compared to the pre-treatment transfusion number in 8 weeks

HI-

P

– for pre­treatment platelet count of > 20 x 109/L, platelet absolute increase of ≥ 30 x 109/L; for pre-treatment platelet count of < 20 x 109/L, platelet
absolute increase of ≥ 20 x 109/L and ≥ 100% from pre­treatment level 

HI-N – neutrophil count increase of ≥ 100% from pre­treatment level and an absolute increase of ≥ 500/mm3

Date of progression:258 __ __ __ __ - __ __- __ __

Date of relapse:259 __ __ __ __ - __ __- __ __

Date assessed:260 __ __ __ __ - __ __- __ __

Other Leukemia (OL) Questions: 261 - 267

Specify the other leukemia classification261

Specify other leukemia:262

Was any 17p abnormality detected?

yes no

263

Did a histologic transformation to diffuse large B-cell lymphoma (Richter syndrome) occur at any time after CLL diagnosis?264

yes - Also complete NHL Disease Classification questions

no

What was the disease status? (Atypical CML)265

Primary induction failure

1st complete remission (no previous bone marrow or extramedullary relapse)

2nd complete remission

≥3rd complete remission

1st relapse

2nd relapse

≥3rd relapse

No treatment

What was the disease status? (CLL, PLL, Hairy cell leukemia)266

Complete remission (CR)

Partial remission (PR)

Stable disease (SD)

Progressive disease (Prog)

Untreated

Not assessed

Date assessed:267 __ __ __ __ - __ __- __ __

Hodgkin and Non-Hodgkin Lymphoma Questions: 268 - 285

Specify the lymphoma histology (at infusion)268

Specify other lymphoma histology:269

Assignment of DLBCL (germinal center B-cell type vs. activated B-cell type) subtype was based on270

Immunohistochemistry (e.g. Han's algorithm)

Gene expression profile

Unknown method

Is the lymphoma histology reported at transplant a transformation from CLL?

yes no

271

Was any 17p abnormality detected?

yes no

272

Is the lymphoma histology reported at transplant a transformation from a different lymphoma histology? (Not CLL)

Yes No

273

Specify the original lymphoma histology (prior to transformation)274

Specify other lymphoma histology:275

Date of original lymphoma diagnosis:276 __ __ __ __ - __ __- __ __ (report the date of diagnosis of original lymphoma subtype)

Was a PET (or PET/CT) scan performed? (at last evaluation prior to the start of the preparative regimen / infusion)

yes no

277

Was the PET (or PET/CT) scan positive for lymphoma involvement at any disease site?

yes no

278

Date of PET scan

Known Unknown

279

Date of PET (or PET/CT) scan:280 __ __ __ __ - __ __- __ __

Deauville (five-point) score of the PET (or PET/CT) scan

Known Unknown

281

Scale282

1 - no uptake or residual uptake

2 - slight uptake, but below blood pool (mediastinum)

3 - uptake above mediastinal, but below or equal to uptake in the liver

4 - uptake slightly to moderately higher than liver

5 - markedly increased uptake or any new lesions

What was the disease status?283

Total number of lines of therapy received

1 line 2 lines 3+ lines

284

Date assessed:285 __ __ __ __ - __ __- __ __

Multiple Myeloma / Plasma Cell Disorder (PCD) Questions: 286 - 317

Specify the multiple myeloma/plasma cell disorder (PCD) classification286

Specify other plasma cell disorder:287

Light chain

kappa lambda

288

What was the Durie-Salmon staging? (at diagnosis)289

Stage
I

(All of the following: Hgb > 10g/dL; serum calcium normal or <10.5 mg/dL; bone x-ray normal bone structure (scale 0), or solitary bone plasmacytoma
only; low M-component production rates IgG< 5g/dL, IgA < 3g/dL; urine light chain M-component on electrophoresis <4 g/24h)

Stage II (Fitting neither Stage I or III) 

Stage
III

(One or more of the following: Hgb < 8.5 g/dL; serum calcium > 12 mg/dL; advanced lytic bone lesions (scale 3); high M-component production rates
IgG > 7g/dL, IgA > 5 g/dL; Bence Jones protein > 12g/24h)

Unknown

What was the Durie-Salmon sub classification? (at diagnosis)290

A - relatively normal renal function (serum creatinine < 2.0 mg/dL)

B ­ abnormal renal function (serum creatinine ≥ 2.0 mg/dL)

Serum β2­microglobulin:291 μg/dL mg/L nmol/L

Serum albumin:292 g/dL g/L

Stage293

1 (β2 ­mic < 3.5, S. albumin ≥3.5)

2 (Not fitting stage 1 or 3)

3 (β2­mic ≥ 5.5; S. albumin ­)

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

294

Results of tests295

Abnormalities identified

No evaluable metaphases

No abnormalities

+3

yes no

296

+5

yes no

297

+7

yes no

298

+9

yes no

299

+11

yes no

300

+15

yes no

301

+19

yes no

302

t(4;14)

yes no

303

t(6;14)

yes no

304

t(11;14)

yes no

305

t(14;16)

yes no

306

t(14;20)

yes no

307

del(13q) / 13q-

yes no

308

del (17p) / 17p-

yes no

309

Hyperdiploid (>50)

yes no

310

Hypodiploid (<46)

yes no

311

Any abnormality at 1q

yes no

312

Any abnormality at 1p

yes no

313

Other abnormality

yes no

314

Specify other abnormality:315

What was the disease status?316

Stringent

complete
remission

(sCR)

- CR as defined, plus: normal free light chain ratio, and absence of clonal cells in the bone marrow by immunohistochemistry of immunofluorescence

(confirmation with repeat bone marrow biopsy not needed). (Presence and/or absence of clonal cells is based upon the Κ/λ ratio. An abnormal Κ/λ ratio by
immunohistochemistry and/or immunofluorescence requires a minimum of 100 plasma cells for analysis.  An abnormal ratio reflecting the presence of

an abnormal clone is Κ/λ of > 4:1 or < 1:2.) sCR requires two consecutive assessments made at any time before the institution of any new therapy, and
no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy sCR

requirements. 

Complete

remission
(CR)

- negative immunofixation on serum and urine samples, and disappearance of any soft tissue plasmacytomas, and < 5% plasma cells in the bone

marrow (confirmation with repeat bone marrow biopsy not needed).  CR requires two consecutive assessments made at any time before the institution
of any new therapy, and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not

required to satisfy CR requirements. 

Near
complete
remission
(nCR)

- serum and urine M-protein detectable by immunoelectrophoresis (IFE), but not on electrophoresis (negative SPEP & UPEP); < 5% plasma cells in
bone marrow.  nCR requires two consecutive assessments made at any time before the initiation of any new therapy, and no known evidence of
progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy nCR requirements. 

Very good
partial
remission
(VGPR)

­ serum and urine M­protein detectable by immunofixation but not on electrophoresis, or ≥ 90% reduction in serum M­protein and urine M­protein level <
100 mg/24 hours.  VGPR requires two consecutive assessments made at any time before the institution of any new therapy, and no known evidence of
progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy VGPR requirements.

Partial
remission
(PR)

­ ≥ 50% reduction in serum M­protein, and reduction in 24­hour urinary M­protein by ≥ 90% or to < 200 mg/24 hours.  If the serum and urine M­protein are
unmeasurable (i.e., do not meet any of the following criteria: • serum M­protein ≥ 1 g/dL.  Urine M­protein ≥ 200 mg/24 hours • serum free light chain
assay shows involved level ≥ 10 mg/dL, provided serum free light chain ratio is abnormal), a ≥ 50% decrease in the difference between involved and
uninvolved free light chain levels is required in place of the M-protein criteria.  If serum and urine M-protein are unmeasurable, and serum free light assay
is also unmeasurable, a ≥ 50% reduction in plasma cells is required in place of M­protein, provided the baseline bone marrow plasma cell percentage
was ≥ 30%. In addition to the above listed criteria, a ≥ 50% reduction in the size of soft tissue plasmacytomas is also required, if present at baseline. PR
requires two consecutive assessments made at any time before the institution of any new therapy, and no known evidence of progressive or new bone
lesions if radiographic studies were performed; radiographic studies are not required to satisfy PR requirements. 

Stable
disease
(SD)

- not meeting the criteria for CR, VGPR, PR or PD.  SD requires two consecutive assessments made at any time before the institution of any new therapy,
and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy SD
requirements.

Progressive
disease
(PD)

­ requires any one or more of the following:  Increase of ≥ 25% from baseline in:  serum M­component and/or (absolute increase ≥ 0.5 g/dL) (for
progressive disease, serum M­component increases of ≥ 1 g/dL are sufficient to define relapse if the starting M­component is ≥ 5 g/dL).  Urine M­
component and/or (absolute increase ≥ 200 mg/24 hours) for recipients without measurable serum and urine M­protein levels: the difference between
involved and uninvolved free light chain levels (absolute increase > 10 mg/dL).  Bone marrow plasma cell percentage (absolute percentage ≥ 10%)
(relapse from CR has a 5% cutoff vs. 10% for other categories of relapse) definite development of new bone lesions or soft tissue plasmacytomas, or
definite increase in the size of any existing  bone lesions or soft tissue plasmacytomas. Development of hypercalcemia (corrected serum calcium >
11.5 mg/dL or 2.65 mmol) that can be attributed solely to the plasma cell proliferative disorder.  PD requires two consecutive assessments made at
any time before classification as disease progression, and/or the institution of any new therapy.

Relapse
from CR
(Rel)
(untreated)

­ requires one or more of the following: reappearance of serum or urine M­protein by immunofixation or electrophoresis development of ≥ 5% plasma
cells in the bone marrow (relapse from CR has a 5% cutoff vs. 10% for other categories of relapse) appearance of any other sign of progression (e.g.,
new plasmacytoma, lytic bone lesion, hypercalcemia).  Rel requires two consecutive assessments made at any time before classification as relapse,
and/or the institution of any new therapy.

Unknown

Not applicable (Amyloidosis with no evidence of myeloma)

Date assessed:317 __ __ __ __ - __ __- __ __

Solid Tumors Questions: 318 - 319

Specify the solid tumor classification318

Specify other solid tumor:319

Severe Aplastic Anemia Questions: 320 - 321

Specify the severe aplastic anemia classification320

Specify other acquired cytopenic syndrome:321

Inherited Abnormalities of Erythrocyte Differentiation or Function Questions: 322 - 324

Specify the inherited abnormalities of erythrocyte differentiation or function classification322

Specify other constitutional anemia:323

Specify other hemoglobinopathy:324

Disorders of the Immune System Questions: 325 - 327

Specify disorder of immune system classification325

Specify other SCID:326

Specify other immunodeficiency:327

Inherited Abnormalities of Platelets Questions: 328 - 329

Specify inherited abnormalities of platelets classification328

Congenital amegakaryocytosis / congenital thrombocytopenia (501)

Glanzmann thrombasthenia (502)

Other inherited platelet abnormality (509)

Specify other inherited platelet abnormality:329

Inherited Disorders of Metabolism Questions: 330 - 331

Specify inherited disorders of metabolism classification330

Specify other inherited metabolic disorder:331

Histiocytic Disorders Questions: 332 - 333

Specify histiocytic disorder classification332

Specify other histiocytic disorder:333

Autoimmune Diseases Questions: 334 - 341

Specify autoimmune disease classification334

Specify other arthritis:335

Specify other juvenile idiopathic arthritis (JIA):336

Specify other connective tissue disease:337

Specify other vasculitis:338

Specify other autoimmune neurological disorder:339

Specify other autoimmune cytopenia:340

Specify other autoimmune bowel disorder:341

Other Disease Questions: 342 - 342

Specify other disease:342

First Name:

Last Name:

E-mail address:

Date: __ __ __ __ - __ __- __ __

OMB No: 0915-0310

Expiration Date: 1/31/2020

Public Burden Statement:  An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control
number.  The OMB control number for this project is 0915-0310.  Public reporting burden for this collection of information is estimated to average 1.0 hours per response, including the
time for reviewing instructions, searching existing data sources, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other
aspect of this collection of information, including suggestions for reducing this burden, to HRSA Reports Clearance Officer, 5600 Fishers Lane, Room 10-29, Rockville, Maryland, 20857.

Labs at diagnosis

Specify cytogenetic abnormalities identified at diagnosis:

Specify cytogenetic abnormalities identified at diagnosis:

Specify molecular markers identified at diagnosis:

Labs between diagnosis and last evaluation:

Specify cytogenetic abnormalities identified between diagnosis and last evaluation:

Specify cytogenetic abnormalities identified between diagnosis and last evaluation:

Specify molecular markers identified between diagnosis and last evaluation:

Labs at last evaluation:

Specify cytogenetic abnormalities identified at last evaluation:

Specify cytogenetic abnormalities identified at last evaluation:

Specify molecular markers identified at last evaluation:

CNS Leukemia

Status at transplantation:

Laboratory studies at diagnosis:

Specify cytogenetic abnormalities identified at diagnosis:

Specify cytogenetic abnormalities identified at diagnosis:

Specify molecular markers identified at diagnosis:

Laboratory studies between diagnosis and last evaluation:

Specify cytogenetic abnormalities identified between diagnosis and last evaluation:

Specify cytogenetic abnormalities identified between diagnosis and last evaluation:

Specify molecular markers identified between diagnosis and last evaluation:

Laboratory studies at last evaluation:

Specify cytogenetic abnormalities identified at last evaluation:

Specify cytogenetic abnormalities identified at last evaluation:

Specify molecular markers identified at last evaluation:

CNS Leukemia

Status at transplantation:

Status at transplantation:

Laboratory studies at diagnosis of MDS:

Specify abnormalities identified at diagnosis:

Monosomy

Trisomy

Translocation

Deletion

Inversion

Other

Laboratory studies at last evaluation prior to the start of the preparative regimen:

Specify cytogenetic abnormalities identified at last evaluation prior to the start of the preparative regimen:

Monosomy

Trisomy

Translocation

Deletion

Inversion

Other

Status at transplantation:

Status at transplantation:

Status at transplantation / infusion:

I.S.S.:

Specify cytogenetic abnormalities identified at any time prior to the start of the preparative regimen:

Trisomy

Translocation

Deletion

Other

Status at transplantation:

Center: CRID: 

Form 2402 R3.0: Disease Classification

CIBMTR Form 2402 revision 3.0 last updated Monday, January 29, 2018
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 5 / 26



Key Fields

Sequence Number:

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number:

CIBMTR Research ID:

Event date: __ __ __ __ - __ __- __ __

Primary Disease for HCT / Cellular Therapy Questions: 1 - 2

Date of diagnosis of primary disease for HCT / cellular therapy:1 __ __ __ __ - __ __- __ __

What was the primary disease for which the HCT / cellular therapy was performed?2

Acute myelogenous leukemia (AML or ANLL) (10)

Acute lymphoblastic leukemia (ALL) (20)

Acute leukemia of ambiguous lineage and other myeloid neoplasms (80)

Chronic myelogenous leukemia (CML) (40)

Myelodysplastic (MDS) / myeloproliferative (MPN) diseases (50) (Please classify all preleukemias) (If recipient has transformed to AML, indicate AML as the primary disease)

Other leukemia (30) (includes CLL)

Hodgkin lymphoma (150)

Non-Hodgkin lymphoma (100)

Multiple myeloma / plasma cell disorder (PCD) (170)

Solid tumors (200)

Severe aplastic anemia (300) (If the recipient developed MDS or AML, indicate MDS or AML as the primary disease)

Inherited abnormalities of erythrocyte differentiation or function (310)

Disorders of the immune system (400)

Inherited abnormalities of platelets (500)

Inherited disorders of metabolism (520)

Histiocytic disorders (570)

Autoimmune diseases (600)

Other disease (900)

Acute Myelogenous Leukemia (AML) Questions: 3 - 89

Specify the AML classification3

Did AML transform from MDS or MPN?4

yes - Also complete MDS Disease Classification questions

no

Is the disease (AML) therapy related?

yes no Unknown

5

Did the recipient have a predisposing condition?

yes no Unknown

6

Specify condition7

Bloom syndrome

Down syndrome

Fanconi anemia

Dyskeratosis congenita

Other condition

Specify other condition:8

Were cytogenetics tested (karyotyping or FISH)? (at diagnosis)

yes no Unknown

9

Were cytogenetics tested via FISH? (at diagnosis)

Yes No

10

Results of tests11

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities12

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

13

Specify other abnormality:14

Were cytogenetics tested via karyotyping? (at diagnosis)

Yes No

15

Results of tests16

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities17

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

18

Specify other abnormality:19

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

20

Were tests for molecular markers performed? (e.g. PCR, NGS) (at diagnosis)

yes no Unknown

21

CEBPA

Positive Negative Not Done

22

Specify CEBPA mutation23

Biallelic (homozygous)

Monoallelic (heterozygous)

Unknown

FLT3 – D835 point mutation

Positive Negative Not Done

24

FLT3 – ITD mutation

Positive Negative Not Done

25

FLT3 - ITD allelic ratio

Known Unknown

26

Specify FLT3 - ITD allelic ratio:27

IDH1

Positive Negative Not Done

28

IDH2

Positive Negative Not Done

29

KIT

Positive Negative Not Done

30

NPM1

Positive Negative Not Done

31

Other Molecular Marker (1) Questions: 32 - 33

Other molecular marker

Positive Negative Not Done

32

Specify other molecular marker:33

Were cytogenetics tested (karyotyping or FISH)? (between diagnosis and last evaluation)

yes no Unknown

34

Were cytogenetics tested via FISH? (between diagnosis and last evaluation)

Yes No

35

Results of tests36

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities37

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

38

Specify other abnormality:39

Were cytogenetics tested via karyotyping? (between diagnosis and last evaluation)

Yes No

40

Results of tests41

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities42

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

43

Specify other abnormality:44

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

45

Were tests for molecular markers performed? (e.g. PCR, NGS) (between diagnosis and last evaluation)

yes no Unknown

46

CEBPA

Positive Negative Not Done

47

Specify CEBPA mutation48

Biallelic (homozygous)

Monoallelic (heterozygous)

Unknown

FLT3 – D835 point mutation

Positive Negative Not Done

49

FLT3 – ITD mutation

Positive Negative Not Done

50

FLT3 - ITD allelic ratio

Known Unknown

51

Specify FLT3 - ITD allelic ratio:52

IDH1

Positive Negative Not Done

53

IDH2

Positive Negative Not Done

54

KIT

Positive Negative Not Done

55

NPM1

Positive Negative Not Done

56

Other Molecular Marker (1) Questions: 57 - 58

Other molecular marker

Positive Negative Not Done

57

Specify other molecular marker:58

Were cytogenetics tested (karyotyping or FISH)? (at last evaluation)

yes no Unknown

59

Were cytogenetics tested via FISH? (at last evaluation)

Yes No

60

Results of tests61

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities62

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

63

Specify other abnormality:64

Were cytogenetics tested via karyotyping? (at last evaluation)

Yes No

65

Results of tests66

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities67

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

68

Specify other abnormality:69

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

70

Were tests for molecular markers performed? (e.g. PCR, NGS) (at last evaluation)

yes no Unknown

71

CEBPA

Positive Negative Not Done

72

Specify CEBPA mutation73

Biallelic (homozygous)

Monoallelic (heterozygous)

Unknown

FLT3 – D835 point mutation

Positive Negative Not Done

74

FLT3 – ITD mutation

Positive Negative Not Done

75

FLT3 - ITD allelic ratio

Known Unknown

76

Specify FLT3 - ITD allelic ratio:77

IDH1

Positive Negative Not Done

78

IDH2

Positive Negative Not Done

79

KIT

Positive Negative Not Done

80

NPM1

Positive Negative Not Done

81

Other Molecular Marker (1) Questions: 82 - 83

Other molecular marker

Positive Negative Not Done

82

Specify other molecular marker:83

Did the recipient have central nervous system leukemia at any time prior to the start of the preparative regimen / infusion?

yes no Unknown

84

What was the disease status (based on hematological test results)?85

Primary induction failure

1st complete remission (no previous bone marrow or extramedullary relapse) (include CRi)

2nd complete remission

≥3rd complete remission

1st relapse

2nd relapse

≥3rd relapse

No treatment

How many cycles of induction therapy were required to achieve 1st complete remission? (includes CRi)

1 2 ≥ 3

86

Was the recipient in remission by flow cytometry?

Yes No Unknown Not applicable

87

Date of most recent relapse:88 __ __ __ __ - __ __- __ __

Date assessed:89 __ __ __ __ - __ __- __ __

Acute Lymphoblastic Leukemia (ALL) Questions: 90 - 151

Specify ALL classification90

Did the recipient have a predisposing condition?

yes no Unknown

91

Specify condition92

Aplastic anemia - Also complete CIBMTR Form 2028 - APL

Bloom syndrome

Down syndrome

Fanconi anemia - Also complete CIBMTR Form 2029 - FAN

Other condition

Specify other condition:93

Were tyrosine kinase inhibitors given for therapy at any time prior to the start of the preparative regimen / infusion? (e.g. imatinib mesylate, dasatinib, etc.)

yes no

94

Were cytogenetics tested (karyotyping or FISH)? (at diagnosis)

yes no Unknown

95

Were cytogenetics tested via FISH? (at diagnosis)

Yes No

96

Results of tests97

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities98

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

99

Specify other abnormality:100

Were cytogenetics tested via karyotyping? (at diagnosis)

Yes No

101

Results of tests102

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities103

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

104

Specify other abnormality:105

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

106

Were tests for molecular markers performed? (e.g. PCR, NGS) (at diagnosis)

yes no Unknown

107

BCR / ABL

Positive Negative Not Done

108

TEL-AML / AML1

Positive Negative Not Done

109

Other Molecular Marker (1) Questions: 110 - 111

Other molecular marker

Positive Negative Not Done

110

Specify other molecular marker:111

Were cytogenetics tested (karyotyping or FISH)? (between diagnosis and last evaluation)

yes no Unknown

112

Were cytogenetics tested via FISH? (between diagnosis and last evaluation)

Yes No

113

Results of tests114

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities115

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

116

Specify other abnormality:117

Were cytogenetics tested via karyotyping? (between diagnosis and last evaluation)

Yes No

118

Results of tests119

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities120

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

121

Specify other abnormality:122

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

123

Were tests for molecular markers performed? (e.g. PCR, NGS) (between diagnosis and last evaluation)

yes no Unknown

124

BCR / ABL

Positive Negative Not Done

125

TEL-AML / AML1

Positive Negative Not Done

126

Other Molecular Marker (1) Questions: 127 - 128

Other molecular marker

Positive Negative Not Done

127

Specify other molecular marker:128

Were cytogenetics tested (karyotyping or FISH)? (at last evaluation)

yes no Unknown

129

Were cytogenetics tested via FISH? (at last evaluation)

Yes No

130

Results of tests131

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities132

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

133

Specify other abnormality:134

Were cytogenetics tested via karyotyping? (at last evaluation)

Yes No

135

Results of tests136

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities137

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

138

Specify other abnormality:139

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

140

Were tests for molecular markers performed? (e.g. PCR, NGS) (at last evaluation)

yes no Unknown

141

BCR / ABL

Positive Negative Not Done

142

TEL-AML / AML1

Positive Negative Not Done

143

Other Molecular Marker (1) Questions: 144 - 145

Other molecular marker

Positive Negative Not Done

144

Specify other molecular marker:145

Did the recipient have central nervous system leukemia at any time prior to the start of the preparative regimen / infusion?

yes no Unknown

146

What was the disease status (based on hematological test results)?147

Primary induction failure

1st complete remission (no previous marrow or extramedullary relapse) (include CRi)

2nd complete remission

≥3rd complete remission

1st relapse

2nd relapse

≥3rd relapse

No treatment

How many cycles of induction therapy were required to achieve 1st complete remission? (include CRi)

1 2 ≥ 3

148

Was the recipient in remission by flow cytometry?

Yes No Unknown Not applicable

149

Date of most recent relapse:150 __ __ __ __ - __ __- __ __

Date assessed:151 __ __ __ __ - __ __- __ __

Acute Leukemias of Ambiguous Lineage and Other Myeloid Neoplasms Questions: 152 - 155

Specify acute leukemias of ambiguous lineage and other myeloid neoplasm classification152

Blastic plasmacytoid dendritic cell neoplasm (296)

Acute undifferentiated leukemia (31)

Mixed phenotype acute leukemia (MPAL) with t(9;22)(q34.1;q11.2); BCR-ABL1 (84)

Mixed phenotype acute leukemia with t(v; 11q23.3); KMT2A rearranged (85)

Mixed phenotype acute leukemia, B/myeloid, NOS (86)

Mixed phenotype acute leukemia, T/myeloid, NOS (87)

Other acute leukemia of ambiguous lineage or myeloid neoplasm (88)

Specify other acute leukemia of ambiguous lineage or myeloid neoplasm:153

What was the disease status (based on hematological test results)?154

Primary induction failure

1st complete remission (no previous marrow or extramedullary relapse)

2nd complete remission

≥3rd complete remission

1st relapse

2nd relapse

≥3rd relapse

No treatment

Date assessed:155 __ __ __ __ - __ __- __ __

Chronic Myelogenous Leukemia (CML) Questions: 156 - 166

Was therapy given prior to this HCT?

yes no

156

Combination chemotherapy

yes no

157

Hydroxyurea (Droxia, Hydrea)

yes no

158

Tyrosine kinase inhibitor (e.g. imatinib mesylate, dasatinib, nilotinib)

yes no

159

Interferon­α (Intron, Roferon) (includes PEG)

yes no

160

Other therapy

yes no

161

Specify other therapy:162

What was the disease status?163

Complete hematologic response (CHR)

Chronic phase

Accelerated phase

Blast phase

Specify level of response164

No cytogenetic response (No CyR)

Minimal cytogenetic response

Minor cytogenetic response

Partial cytogenetic response (PCyR)

Complete cytogenetic response (CCyR)

Major molecular remission (MMR)

Complete molecular remission (CMR)

Number

1st 2nd 3rd or higher

165

Date assessed:166 __ __ __ __ - __ __- __ __

Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases Questions: 167 - 260

What was the MDS / MPN subtype at diagnosis? - If transformed to AML, indicate AML as primary disease; also complete AML Disease Classification
questions

167

Was the disease (MDS/MPN) therapy related?

yes no Unknown

168

Did the recipient have a predisposing condition?

yes no Unknown

169

Specify condition

Aplastic Anemia Bloom syndrome Down syndrome Fanconi anemia Other condition

170

Specify other condition:171

WBC

Known Unknown

172

173 x 109/L (x 103/mm3)

x 106/L

Hemoglobin

Known Unknown

174

175 g/dL g/L mmol/L

Was RBC transfused ≤ 30 days before date of test?

Yes No

176

Platelets

Known Unknown

177

178 x 109/L (x 103/mm3)

x 106/L

Were platelets transfused ≤ 7 days before date of test?

Yes No

179

Neutrophils

Known Unknown

180

181 %

Blasts in bone marrow

Known Unknown

182

183 %

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

184

Results of tests185

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities186

One (1)

Two (2)

Three (3)

Four or more (4 or more)

–5

yes no

187

-7

yes no

188

–13

yes no

189

–20

yes no

190

–Y

yes no

191

+8

yes no

192

+19

yes no

193

t(1;3)

yes no

194

t(2;11)

yes no

195

t(3;3)

yes no

196

t(3;21)

yes no

197

t(6;9)

yes no

198

t(11;16)

yes no

199

del(3q) / 3q–

yes no

200

del(5q) / 5q-

yes no

201

del(7q) / 7q–

yes no

202

del(9q) / 9q–

yes no

203

del(11q) / 11q–

yes no

204

del(12p) / 12p–

yes no

205

del(13q) / 13q-

yes no

206

del(20q) / 20q–

yes no

207

inv(3)

yes no

208

i17q

yes no

209

Other abnormality

yes no

210

Specify other abnormality:211

Did the recipient progress or transform to a different MDS / MPN subtype between diagnosis and the start of the preparative regimen?

yes no

212

Specify the MDS / MPN classification after transformation:213

Specify the date of the most recent transformation:214 __ __ __ __ - __ __- __ __

Date of MDS diagnosis:215 __ __ __ __ - __ __- __ __

WBC

Known Unknown

216

217 x 109/L (x 103/mm3)

x 106/L

Hemoglobin

Known Unknown

218

219 g/dL g/L mmol/L

Was RBC transfused ≤ 30 days before date of test?

Yes No

220

Platelets

Known Unknown

221

222 x 109/L (x 103/mm3)

x 106/L

Were platelets transfused ≤ 7 days before date of test?

Yes No

223

Neutrophils

Known Unknown

224

225 %

Blasts in bone marrow

Known Unknown

226

227 %

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

228

Results of tests229

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities230

One (1)

Two (2)

Three (3)

Four or more (4 or more)

–5

yes no

231

-7

yes no

232

–13

yes no

233

–20

yes no

234

–Y

yes no

235

+8

yes no

236

+19

yes no

237

t(1;3)

yes no

238

t(2;11)

yes no

239

t(3;3)

yes no

240

t(3;21)

yes no

241

t(6;9)

yes no

242

t(11;16)

yes no

243

del(3q) / 3q–

yes no

244

del(5q) / 5q-

yes no

245

del(7q) / 7q–

yes no

246

del(9q) / 9q–

yes no

247

del(11q) / 11q–

yes no

248

del(12p) / 12p–

yes no

249

del(13q) / 13q-

yes no

250

del(20q) / 20q–

yes no

251

inv(3)

yes no

252

i17q

yes no

253

Other abnormality

yes no

254

Specify other abnormality:255

What was the disease status?256

Complete

remission
(CR)

– requires all of the following, maintained for ≥ 4 weeks: * bone marrow evaluation: <  5% myeloblasts with normal maturation of all cell lines *
peripheral blood evaluation: hemoglobin ≥ 11 g/dL untransfused and without erythropoietin support; ANC ≥ 1000/mm3  without myeloid growth factor
support; platelets ≥ 100 x 109/L without thrombopoietic support; 0% blasts

Hematologic
improvement

(HI)

– requires one measurement of the following, maintained for ≥ 8 weeks without ongoing cytotoxic therapy; specify which cell line was measured to
determine HI response: * HI­E – hemoglobin increase of ≥ 1.5 g/dL untransfused; for RBC transfusions performed for Hgb ≤ 9.0, reduction in RBC
units transfused in 8 weeks by ≥ 4 units compared to the pre­treatment transfusion number in 8 weeks * HI­P – for pre­treatment platelet count of > 20
x 109/L, platelet absolute increase of ≥ 30 x 109/L; for pre-treatment platelet count of < 20 x 109/L, platelet absolute increase of ≥ 20 x 109/L and ≥
100% from pre­treatment level  * HI­N – neutrophil count increase of ≥ 100% from pre­treatment level and an absolute increase of ≥ 500/mm3

No response (NR) / stable disease (SD) – does not meet the criteria for at least HI, but no evidence of disease progression

Progression from

hematologic improvement
(Prog from HI)

– requires at least one of the following, in the absence of another explanation (e.g., infection, bleeding, ongoing chemotherapy, etc.): *
≥ 50% reduction from maximum response levels in granulocytes or platelets * reduction in hemoglobin by ≥ 1.5 g/dL *transfusion
dependence

Relapse from complete
remission (Rel from CR)

– requires at least one of the following: * return to pre­treatment bone marrow blast percentage * decrease of ≥ 50% from maximum
response levels in granulocytes or platelets * transfusion dependence, or hemoglobin level ≥ 1.5 g/dL lower than prior to therapy

Not assessed

Specify the cell line examined to determine HI status257

HI-

E

– hemoglobin increase of ≥ 1.5 g/dL untransfused; for RBC transfusions performed for Hgb ≤ 9.0, reduction in RBC units transfused in 8 weeks by ≥ 4
units compared to the pre-treatment transfusion number in 8 weeks

HI-

P

– for pre­treatment platelet count of > 20 x 109/L, platelet absolute increase of ≥ 30 x 109/L; for pre-treatment platelet count of < 20 x 109/L, platelet
absolute increase of ≥ 20 x 109/L and ≥ 100% from pre­treatment level 

HI-N – neutrophil count increase of ≥ 100% from pre­treatment level and an absolute increase of ≥ 500/mm3

Date of progression:258 __ __ __ __ - __ __- __ __

Date of relapse:259 __ __ __ __ - __ __- __ __

Date assessed:260 __ __ __ __ - __ __- __ __

Other Leukemia (OL) Questions: 261 - 267

Specify the other leukemia classification261

Specify other leukemia:262

Was any 17p abnormality detected?

yes no

263

Did a histologic transformation to diffuse large B-cell lymphoma (Richter syndrome) occur at any time after CLL diagnosis?264

yes - Also complete NHL Disease Classification questions

no

What was the disease status? (Atypical CML)265

Primary induction failure

1st complete remission (no previous bone marrow or extramedullary relapse)

2nd complete remission

≥3rd complete remission

1st relapse

2nd relapse

≥3rd relapse

No treatment

What was the disease status? (CLL, PLL, Hairy cell leukemia)266

Complete remission (CR)

Partial remission (PR)

Stable disease (SD)

Progressive disease (Prog)

Untreated

Not assessed

Date assessed:267 __ __ __ __ - __ __- __ __

Hodgkin and Non-Hodgkin Lymphoma Questions: 268 - 285

Specify the lymphoma histology (at infusion)268

Specify other lymphoma histology:269

Assignment of DLBCL (germinal center B-cell type vs. activated B-cell type) subtype was based on270

Immunohistochemistry (e.g. Han's algorithm)

Gene expression profile

Unknown method

Is the lymphoma histology reported at transplant a transformation from CLL?

yes no

271

Was any 17p abnormality detected?

yes no

272

Is the lymphoma histology reported at transplant a transformation from a different lymphoma histology? (Not CLL)

Yes No

273

Specify the original lymphoma histology (prior to transformation)274

Specify other lymphoma histology:275

Date of original lymphoma diagnosis:276 __ __ __ __ - __ __- __ __ (report the date of diagnosis of original lymphoma subtype)

Was a PET (or PET/CT) scan performed? (at last evaluation prior to the start of the preparative regimen / infusion)

yes no

277

Was the PET (or PET/CT) scan positive for lymphoma involvement at any disease site?

yes no

278

Date of PET scan

Known Unknown

279

Date of PET (or PET/CT) scan:280 __ __ __ __ - __ __- __ __

Deauville (five-point) score of the PET (or PET/CT) scan

Known Unknown

281

Scale282

1 - no uptake or residual uptake

2 - slight uptake, but below blood pool (mediastinum)

3 - uptake above mediastinal, but below or equal to uptake in the liver

4 - uptake slightly to moderately higher than liver

5 - markedly increased uptake or any new lesions

What was the disease status?283

Total number of lines of therapy received

1 line 2 lines 3+ lines

284

Date assessed:285 __ __ __ __ - __ __- __ __

Multiple Myeloma / Plasma Cell Disorder (PCD) Questions: 286 - 317

Specify the multiple myeloma/plasma cell disorder (PCD) classification286

Specify other plasma cell disorder:287

Light chain

kappa lambda

288

What was the Durie-Salmon staging? (at diagnosis)289

Stage
I

(All of the following: Hgb > 10g/dL; serum calcium normal or <10.5 mg/dL; bone x-ray normal bone structure (scale 0), or solitary bone plasmacytoma
only; low M-component production rates IgG< 5g/dL, IgA < 3g/dL; urine light chain M-component on electrophoresis <4 g/24h)

Stage II (Fitting neither Stage I or III) 

Stage
III

(One or more of the following: Hgb < 8.5 g/dL; serum calcium > 12 mg/dL; advanced lytic bone lesions (scale 3); high M-component production rates
IgG > 7g/dL, IgA > 5 g/dL; Bence Jones protein > 12g/24h)

Unknown

What was the Durie-Salmon sub classification? (at diagnosis)290

A - relatively normal renal function (serum creatinine < 2.0 mg/dL)

B ­ abnormal renal function (serum creatinine ≥ 2.0 mg/dL)

Serum β2­microglobulin:291 μg/dL mg/L nmol/L

Serum albumin:292 g/dL g/L

Stage293

1 (β2 ­mic < 3.5, S. albumin ≥3.5)

2 (Not fitting stage 1 or 3)

3 (β2­mic ≥ 5.5; S. albumin ­)

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

294

Results of tests295

Abnormalities identified

No evaluable metaphases

No abnormalities

+3

yes no

296

+5

yes no

297

+7

yes no

298

+9

yes no

299

+11

yes no

300

+15

yes no

301

+19

yes no

302

t(4;14)

yes no

303

t(6;14)

yes no

304

t(11;14)

yes no

305

t(14;16)

yes no

306

t(14;20)

yes no

307

del(13q) / 13q-

yes no

308

del (17p) / 17p-

yes no

309

Hyperdiploid (>50)

yes no

310

Hypodiploid (<46)

yes no

311

Any abnormality at 1q

yes no

312

Any abnormality at 1p

yes no

313

Other abnormality

yes no

314

Specify other abnormality:315

What was the disease status?316

Stringent

complete
remission

(sCR)

- CR as defined, plus: normal free light chain ratio, and absence of clonal cells in the bone marrow by immunohistochemistry of immunofluorescence

(confirmation with repeat bone marrow biopsy not needed). (Presence and/or absence of clonal cells is based upon the Κ/λ ratio. An abnormal Κ/λ ratio by
immunohistochemistry and/or immunofluorescence requires a minimum of 100 plasma cells for analysis.  An abnormal ratio reflecting the presence of

an abnormal clone is Κ/λ of > 4:1 or < 1:2.) sCR requires two consecutive assessments made at any time before the institution of any new therapy, and
no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy sCR

requirements. 

Complete

remission
(CR)

- negative immunofixation on serum and urine samples, and disappearance of any soft tissue plasmacytomas, and < 5% plasma cells in the bone

marrow (confirmation with repeat bone marrow biopsy not needed).  CR requires two consecutive assessments made at any time before the institution
of any new therapy, and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not

required to satisfy CR requirements. 

Near
complete
remission
(nCR)

- serum and urine M-protein detectable by immunoelectrophoresis (IFE), but not on electrophoresis (negative SPEP & UPEP); < 5% plasma cells in
bone marrow.  nCR requires two consecutive assessments made at any time before the initiation of any new therapy, and no known evidence of
progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy nCR requirements. 

Very good
partial
remission
(VGPR)

­ serum and urine M­protein detectable by immunofixation but not on electrophoresis, or ≥ 90% reduction in serum M­protein and urine M­protein level <
100 mg/24 hours.  VGPR requires two consecutive assessments made at any time before the institution of any new therapy, and no known evidence of
progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy VGPR requirements.

Partial
remission
(PR)

­ ≥ 50% reduction in serum M­protein, and reduction in 24­hour urinary M­protein by ≥ 90% or to < 200 mg/24 hours.  If the serum and urine M­protein are
unmeasurable (i.e., do not meet any of the following criteria: • serum M­protein ≥ 1 g/dL.  Urine M­protein ≥ 200 mg/24 hours • serum free light chain
assay shows involved level ≥ 10 mg/dL, provided serum free light chain ratio is abnormal), a ≥ 50% decrease in the difference between involved and
uninvolved free light chain levels is required in place of the M-protein criteria.  If serum and urine M-protein are unmeasurable, and serum free light assay
is also unmeasurable, a ≥ 50% reduction in plasma cells is required in place of M­protein, provided the baseline bone marrow plasma cell percentage
was ≥ 30%. In addition to the above listed criteria, a ≥ 50% reduction in the size of soft tissue plasmacytomas is also required, if present at baseline. PR
requires two consecutive assessments made at any time before the institution of any new therapy, and no known evidence of progressive or new bone
lesions if radiographic studies were performed; radiographic studies are not required to satisfy PR requirements. 

Stable
disease
(SD)

- not meeting the criteria for CR, VGPR, PR or PD.  SD requires two consecutive assessments made at any time before the institution of any new therapy,
and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy SD
requirements.

Progressive
disease
(PD)

­ requires any one or more of the following:  Increase of ≥ 25% from baseline in:  serum M­component and/or (absolute increase ≥ 0.5 g/dL) (for
progressive disease, serum M­component increases of ≥ 1 g/dL are sufficient to define relapse if the starting M­component is ≥ 5 g/dL).  Urine M­
component and/or (absolute increase ≥ 200 mg/24 hours) for recipients without measurable serum and urine M­protein levels: the difference between
involved and uninvolved free light chain levels (absolute increase > 10 mg/dL).  Bone marrow plasma cell percentage (absolute percentage ≥ 10%)
(relapse from CR has a 5% cutoff vs. 10% for other categories of relapse) definite development of new bone lesions or soft tissue plasmacytomas, or
definite increase in the size of any existing  bone lesions or soft tissue plasmacytomas. Development of hypercalcemia (corrected serum calcium >
11.5 mg/dL or 2.65 mmol) that can be attributed solely to the plasma cell proliferative disorder.  PD requires two consecutive assessments made at
any time before classification as disease progression, and/or the institution of any new therapy.

Relapse
from CR
(Rel)
(untreated)

­ requires one or more of the following: reappearance of serum or urine M­protein by immunofixation or electrophoresis development of ≥ 5% plasma
cells in the bone marrow (relapse from CR has a 5% cutoff vs. 10% for other categories of relapse) appearance of any other sign of progression (e.g.,
new plasmacytoma, lytic bone lesion, hypercalcemia).  Rel requires two consecutive assessments made at any time before classification as relapse,
and/or the institution of any new therapy.

Unknown

Not applicable (Amyloidosis with no evidence of myeloma)

Date assessed:317 __ __ __ __ - __ __- __ __

Solid Tumors Questions: 318 - 319

Specify the solid tumor classification318

Specify other solid tumor:319

Severe Aplastic Anemia Questions: 320 - 321

Specify the severe aplastic anemia classification320

Specify other acquired cytopenic syndrome:321

Inherited Abnormalities of Erythrocyte Differentiation or Function Questions: 322 - 324

Specify the inherited abnormalities of erythrocyte differentiation or function classification322

Specify other constitutional anemia:323

Specify other hemoglobinopathy:324

Disorders of the Immune System Questions: 325 - 327

Specify disorder of immune system classification325

Specify other SCID:326

Specify other immunodeficiency:327

Inherited Abnormalities of Platelets Questions: 328 - 329

Specify inherited abnormalities of platelets classification328

Congenital amegakaryocytosis / congenital thrombocytopenia (501)

Glanzmann thrombasthenia (502)

Other inherited platelet abnormality (509)

Specify other inherited platelet abnormality:329

Inherited Disorders of Metabolism Questions: 330 - 331

Specify inherited disorders of metabolism classification330

Specify other inherited metabolic disorder:331

Histiocytic Disorders Questions: 332 - 333

Specify histiocytic disorder classification332

Specify other histiocytic disorder:333

Autoimmune Diseases Questions: 334 - 341

Specify autoimmune disease classification334

Specify other arthritis:335

Specify other juvenile idiopathic arthritis (JIA):336

Specify other connective tissue disease:337

Specify other vasculitis:338

Specify other autoimmune neurological disorder:339

Specify other autoimmune cytopenia:340

Specify other autoimmune bowel disorder:341

Other Disease Questions: 342 - 342

Specify other disease:342

First Name:

Last Name:

E-mail address:

Date: __ __ __ __ - __ __- __ __

OMB No: 0915-0310

Expiration Date: 1/31/2020

Public Burden Statement:  An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control
number.  The OMB control number for this project is 0915-0310.  Public reporting burden for this collection of information is estimated to average 1.0 hours per response, including the
time for reviewing instructions, searching existing data sources, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other
aspect of this collection of information, including suggestions for reducing this burden, to HRSA Reports Clearance Officer, 5600 Fishers Lane, Room 10-29, Rockville, Maryland, 20857.

Labs at diagnosis

Specify cytogenetic abnormalities identified at diagnosis:

Specify cytogenetic abnormalities identified at diagnosis:

Specify molecular markers identified at diagnosis:

Labs between diagnosis and last evaluation:

Specify cytogenetic abnormalities identified between diagnosis and last evaluation:

Specify cytogenetic abnormalities identified between diagnosis and last evaluation:

Specify molecular markers identified between diagnosis and last evaluation:

Labs at last evaluation:

Specify cytogenetic abnormalities identified at last evaluation:

Specify cytogenetic abnormalities identified at last evaluation:

Specify molecular markers identified at last evaluation:

CNS Leukemia

Status at transplantation:

Laboratory studies at diagnosis:

Specify cytogenetic abnormalities identified at diagnosis:

Specify cytogenetic abnormalities identified at diagnosis:

Specify molecular markers identified at diagnosis:

Laboratory studies between diagnosis and last evaluation:

Specify cytogenetic abnormalities identified between diagnosis and last evaluation:

Specify cytogenetic abnormalities identified between diagnosis and last evaluation:

Specify molecular markers identified between diagnosis and last evaluation:

Laboratory studies at last evaluation:

Specify cytogenetic abnormalities identified at last evaluation:

Specify cytogenetic abnormalities identified at last evaluation:

Specify molecular markers identified at last evaluation:

CNS Leukemia

Status at transplantation:

Status at transplantation:

Laboratory studies at diagnosis of MDS:

Specify abnormalities identified at diagnosis:

Monosomy

Trisomy

Translocation

Deletion

Inversion

Other

Laboratory studies at last evaluation prior to the start of the preparative regimen:

Specify cytogenetic abnormalities identified at last evaluation prior to the start of the preparative regimen:

Monosomy

Trisomy

Translocation

Deletion

Inversion

Other

Status at transplantation:

Status at transplantation:

Status at transplantation / infusion:

I.S.S.:

Specify cytogenetic abnormalities identified at any time prior to the start of the preparative regimen:

Trisomy

Translocation

Deletion

Other

Status at transplantation:

Center: CRID: 

Form 2402 R3.0: Disease Classification

CIBMTR Form 2402 revision 3.0 last updated Monday, January 29, 2018
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 6 / 26



Key Fields

Sequence Number:

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number:

CIBMTR Research ID:

Event date: __ __ __ __ - __ __- __ __

Primary Disease for HCT / Cellular Therapy Questions: 1 - 2

Date of diagnosis of primary disease for HCT / cellular therapy:1 __ __ __ __ - __ __- __ __

What was the primary disease for which the HCT / cellular therapy was performed?2

Acute myelogenous leukemia (AML or ANLL) (10)

Acute lymphoblastic leukemia (ALL) (20)

Acute leukemia of ambiguous lineage and other myeloid neoplasms (80)

Chronic myelogenous leukemia (CML) (40)

Myelodysplastic (MDS) / myeloproliferative (MPN) diseases (50) (Please classify all preleukemias) (If recipient has transformed to AML, indicate AML as the primary disease)

Other leukemia (30) (includes CLL)

Hodgkin lymphoma (150)

Non-Hodgkin lymphoma (100)

Multiple myeloma / plasma cell disorder (PCD) (170)

Solid tumors (200)

Severe aplastic anemia (300) (If the recipient developed MDS or AML, indicate MDS or AML as the primary disease)

Inherited abnormalities of erythrocyte differentiation or function (310)

Disorders of the immune system (400)

Inherited abnormalities of platelets (500)

Inherited disorders of metabolism (520)

Histiocytic disorders (570)

Autoimmune diseases (600)

Other disease (900)

Acute Myelogenous Leukemia (AML) Questions: 3 - 89

Specify the AML classification3

Did AML transform from MDS or MPN?4

yes - Also complete MDS Disease Classification questions

no

Is the disease (AML) therapy related?

yes no Unknown

5

Did the recipient have a predisposing condition?

yes no Unknown

6

Specify condition7

Bloom syndrome

Down syndrome

Fanconi anemia

Dyskeratosis congenita

Other condition

Specify other condition:8

Were cytogenetics tested (karyotyping or FISH)? (at diagnosis)

yes no Unknown

9

Were cytogenetics tested via FISH? (at diagnosis)

Yes No

10

Results of tests11

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities12

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

13

Specify other abnormality:14

Were cytogenetics tested via karyotyping? (at diagnosis)

Yes No

15

Results of tests16

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities17

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

18

Specify other abnormality:19

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

20

Were tests for molecular markers performed? (e.g. PCR, NGS) (at diagnosis)

yes no Unknown

21

CEBPA

Positive Negative Not Done

22

Specify CEBPA mutation23

Biallelic (homozygous)

Monoallelic (heterozygous)

Unknown

FLT3 – D835 point mutation

Positive Negative Not Done

24

FLT3 – ITD mutation

Positive Negative Not Done

25

FLT3 - ITD allelic ratio

Known Unknown

26

Specify FLT3 - ITD allelic ratio:27

IDH1

Positive Negative Not Done

28

IDH2

Positive Negative Not Done

29

KIT

Positive Negative Not Done

30

NPM1

Positive Negative Not Done

31

Other Molecular Marker (1) Questions: 32 - 33

Other molecular marker

Positive Negative Not Done

32

Specify other molecular marker:33

Were cytogenetics tested (karyotyping or FISH)? (between diagnosis and last evaluation)

yes no Unknown

34

Were cytogenetics tested via FISH? (between diagnosis and last evaluation)

Yes No

35

Results of tests36

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities37

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

38

Specify other abnormality:39

Were cytogenetics tested via karyotyping? (between diagnosis and last evaluation)

Yes No

40

Results of tests41

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities42

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

43

Specify other abnormality:44

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

45

Were tests for molecular markers performed? (e.g. PCR, NGS) (between diagnosis and last evaluation)

yes no Unknown

46

CEBPA

Positive Negative Not Done

47

Specify CEBPA mutation48

Biallelic (homozygous)

Monoallelic (heterozygous)

Unknown

FLT3 – D835 point mutation

Positive Negative Not Done

49

FLT3 – ITD mutation

Positive Negative Not Done

50

FLT3 - ITD allelic ratio

Known Unknown

51

Specify FLT3 - ITD allelic ratio:52

IDH1

Positive Negative Not Done

53

IDH2

Positive Negative Not Done

54

KIT

Positive Negative Not Done

55

NPM1

Positive Negative Not Done

56

Other Molecular Marker (1) Questions: 57 - 58

Other molecular marker

Positive Negative Not Done

57

Specify other molecular marker:58

Were cytogenetics tested (karyotyping or FISH)? (at last evaluation)

yes no Unknown

59

Were cytogenetics tested via FISH? (at last evaluation)

Yes No

60

Results of tests61

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities62

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

63

Specify other abnormality:64

Were cytogenetics tested via karyotyping? (at last evaluation)

Yes No

65

Results of tests66

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities67

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

68

Specify other abnormality:69

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

70

Were tests for molecular markers performed? (e.g. PCR, NGS) (at last evaluation)

yes no Unknown

71

CEBPA

Positive Negative Not Done

72

Specify CEBPA mutation73

Biallelic (homozygous)

Monoallelic (heterozygous)

Unknown

FLT3 – D835 point mutation

Positive Negative Not Done

74

FLT3 – ITD mutation

Positive Negative Not Done

75

FLT3 - ITD allelic ratio

Known Unknown

76

Specify FLT3 - ITD allelic ratio:77

IDH1

Positive Negative Not Done

78

IDH2

Positive Negative Not Done

79

KIT

Positive Negative Not Done

80

NPM1

Positive Negative Not Done

81

Other Molecular Marker (1) Questions: 82 - 83

Other molecular marker

Positive Negative Not Done

82

Specify other molecular marker:83

Did the recipient have central nervous system leukemia at any time prior to the start of the preparative regimen / infusion?

yes no Unknown

84

What was the disease status (based on hematological test results)?85

Primary induction failure

1st complete remission (no previous bone marrow or extramedullary relapse) (include CRi)

2nd complete remission

≥3rd complete remission

1st relapse

2nd relapse

≥3rd relapse

No treatment

How many cycles of induction therapy were required to achieve 1st complete remission? (includes CRi)

1 2 ≥ 3

86

Was the recipient in remission by flow cytometry?

Yes No Unknown Not applicable

87

Date of most recent relapse:88 __ __ __ __ - __ __- __ __

Date assessed:89 __ __ __ __ - __ __- __ __

Acute Lymphoblastic Leukemia (ALL) Questions: 90 - 151

Specify ALL classification90

Did the recipient have a predisposing condition?

yes no Unknown

91

Specify condition92

Aplastic anemia - Also complete CIBMTR Form 2028 - APL

Bloom syndrome

Down syndrome

Fanconi anemia - Also complete CIBMTR Form 2029 - FAN

Other condition

Specify other condition:93

Were tyrosine kinase inhibitors given for therapy at any time prior to the start of the preparative regimen / infusion? (e.g. imatinib mesylate, dasatinib, etc.)

yes no

94

Were cytogenetics tested (karyotyping or FISH)? (at diagnosis)

yes no Unknown

95

Were cytogenetics tested via FISH? (at diagnosis)

Yes No

96

Results of tests97

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities98

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

99

Specify other abnormality:100

Were cytogenetics tested via karyotyping? (at diagnosis)

Yes No

101

Results of tests102

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities103

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

104

Specify other abnormality:105

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

106

Were tests for molecular markers performed? (e.g. PCR, NGS) (at diagnosis)

yes no Unknown

107

BCR / ABL

Positive Negative Not Done

108

TEL-AML / AML1

Positive Negative Not Done

109

Other Molecular Marker (1) Questions: 110 - 111

Other molecular marker

Positive Negative Not Done

110

Specify other molecular marker:111

Were cytogenetics tested (karyotyping or FISH)? (between diagnosis and last evaluation)

yes no Unknown

112

Were cytogenetics tested via FISH? (between diagnosis and last evaluation)

Yes No

113

Results of tests114

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities115

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

116

Specify other abnormality:117

Were cytogenetics tested via karyotyping? (between diagnosis and last evaluation)

Yes No

118

Results of tests119

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities120

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

121

Specify other abnormality:122

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

123

Were tests for molecular markers performed? (e.g. PCR, NGS) (between diagnosis and last evaluation)

yes no Unknown

124

BCR / ABL

Positive Negative Not Done

125

TEL-AML / AML1

Positive Negative Not Done

126

Other Molecular Marker (1) Questions: 127 - 128

Other molecular marker

Positive Negative Not Done

127

Specify other molecular marker:128

Were cytogenetics tested (karyotyping or FISH)? (at last evaluation)

yes no Unknown

129

Were cytogenetics tested via FISH? (at last evaluation)

Yes No

130

Results of tests131

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities132

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

133

Specify other abnormality:134

Were cytogenetics tested via karyotyping? (at last evaluation)

Yes No

135

Results of tests136

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities137

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

138

Specify other abnormality:139

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

140

Were tests for molecular markers performed? (e.g. PCR, NGS) (at last evaluation)

yes no Unknown

141

BCR / ABL

Positive Negative Not Done

142

TEL-AML / AML1

Positive Negative Not Done

143

Other Molecular Marker (1) Questions: 144 - 145

Other molecular marker

Positive Negative Not Done

144

Specify other molecular marker:145

Did the recipient have central nervous system leukemia at any time prior to the start of the preparative regimen / infusion?

yes no Unknown

146

What was the disease status (based on hematological test results)?147

Primary induction failure

1st complete remission (no previous marrow or extramedullary relapse) (include CRi)

2nd complete remission

≥3rd complete remission

1st relapse

2nd relapse

≥3rd relapse

No treatment

How many cycles of induction therapy were required to achieve 1st complete remission? (include CRi)

1 2 ≥ 3

148

Was the recipient in remission by flow cytometry?

Yes No Unknown Not applicable

149

Date of most recent relapse:150 __ __ __ __ - __ __- __ __

Date assessed:151 __ __ __ __ - __ __- __ __

Acute Leukemias of Ambiguous Lineage and Other Myeloid Neoplasms Questions: 152 - 155

Specify acute leukemias of ambiguous lineage and other myeloid neoplasm classification152

Blastic plasmacytoid dendritic cell neoplasm (296)

Acute undifferentiated leukemia (31)

Mixed phenotype acute leukemia (MPAL) with t(9;22)(q34.1;q11.2); BCR-ABL1 (84)

Mixed phenotype acute leukemia with t(v; 11q23.3); KMT2A rearranged (85)

Mixed phenotype acute leukemia, B/myeloid, NOS (86)

Mixed phenotype acute leukemia, T/myeloid, NOS (87)

Other acute leukemia of ambiguous lineage or myeloid neoplasm (88)

Specify other acute leukemia of ambiguous lineage or myeloid neoplasm:153

What was the disease status (based on hematological test results)?154

Primary induction failure

1st complete remission (no previous marrow or extramedullary relapse)

2nd complete remission

≥3rd complete remission

1st relapse

2nd relapse

≥3rd relapse

No treatment

Date assessed:155 __ __ __ __ - __ __- __ __

Chronic Myelogenous Leukemia (CML) Questions: 156 - 166

Was therapy given prior to this HCT?

yes no

156

Combination chemotherapy

yes no

157

Hydroxyurea (Droxia, Hydrea)

yes no

158

Tyrosine kinase inhibitor (e.g. imatinib mesylate, dasatinib, nilotinib)

yes no

159

Interferon­α (Intron, Roferon) (includes PEG)

yes no

160

Other therapy

yes no

161

Specify other therapy:162

What was the disease status?163

Complete hematologic response (CHR)

Chronic phase

Accelerated phase

Blast phase

Specify level of response164

No cytogenetic response (No CyR)

Minimal cytogenetic response

Minor cytogenetic response

Partial cytogenetic response (PCyR)

Complete cytogenetic response (CCyR)

Major molecular remission (MMR)

Complete molecular remission (CMR)

Number

1st 2nd 3rd or higher

165

Date assessed:166 __ __ __ __ - __ __- __ __

Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases Questions: 167 - 260

What was the MDS / MPN subtype at diagnosis? - If transformed to AML, indicate AML as primary disease; also complete AML Disease Classification
questions

167

Was the disease (MDS/MPN) therapy related?

yes no Unknown

168

Did the recipient have a predisposing condition?

yes no Unknown

169

Specify condition

Aplastic Anemia Bloom syndrome Down syndrome Fanconi anemia Other condition

170

Specify other condition:171

WBC

Known Unknown

172

173 x 109/L (x 103/mm3)

x 106/L

Hemoglobin

Known Unknown

174

175 g/dL g/L mmol/L

Was RBC transfused ≤ 30 days before date of test?

Yes No

176

Platelets

Known Unknown

177

178 x 109/L (x 103/mm3)

x 106/L

Were platelets transfused ≤ 7 days before date of test?

Yes No

179

Neutrophils

Known Unknown

180

181 %

Blasts in bone marrow

Known Unknown

182

183 %

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

184

Results of tests185

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities186

One (1)

Two (2)

Three (3)

Four or more (4 or more)

–5

yes no

187

-7

yes no

188

–13

yes no

189

–20

yes no

190

–Y

yes no

191

+8

yes no

192

+19

yes no

193

t(1;3)

yes no

194

t(2;11)

yes no

195

t(3;3)

yes no

196

t(3;21)

yes no

197

t(6;9)

yes no

198

t(11;16)

yes no

199

del(3q) / 3q–

yes no

200

del(5q) / 5q-

yes no

201

del(7q) / 7q–

yes no

202

del(9q) / 9q–

yes no

203

del(11q) / 11q–

yes no

204

del(12p) / 12p–

yes no

205

del(13q) / 13q-

yes no

206

del(20q) / 20q–

yes no

207

inv(3)

yes no

208

i17q

yes no

209

Other abnormality

yes no

210

Specify other abnormality:211

Did the recipient progress or transform to a different MDS / MPN subtype between diagnosis and the start of the preparative regimen?

yes no

212

Specify the MDS / MPN classification after transformation:213

Specify the date of the most recent transformation:214 __ __ __ __ - __ __- __ __

Date of MDS diagnosis:215 __ __ __ __ - __ __- __ __

WBC

Known Unknown

216

217 x 109/L (x 103/mm3)

x 106/L

Hemoglobin

Known Unknown

218

219 g/dL g/L mmol/L

Was RBC transfused ≤ 30 days before date of test?

Yes No

220

Platelets

Known Unknown

221

222 x 109/L (x 103/mm3)

x 106/L

Were platelets transfused ≤ 7 days before date of test?

Yes No

223

Neutrophils

Known Unknown

224

225 %

Blasts in bone marrow

Known Unknown

226

227 %

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

228

Results of tests229

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities230

One (1)

Two (2)

Three (3)

Four or more (4 or more)

–5

yes no

231

-7

yes no

232

–13

yes no

233

–20

yes no

234

–Y

yes no

235

+8

yes no

236

+19

yes no

237

t(1;3)

yes no

238

t(2;11)

yes no

239

t(3;3)

yes no

240

t(3;21)

yes no

241

t(6;9)

yes no

242

t(11;16)

yes no

243

del(3q) / 3q–

yes no

244

del(5q) / 5q-

yes no

245

del(7q) / 7q–

yes no

246

del(9q) / 9q–

yes no

247

del(11q) / 11q–

yes no

248

del(12p) / 12p–

yes no

249

del(13q) / 13q-

yes no

250

del(20q) / 20q–

yes no

251

inv(3)

yes no

252

i17q

yes no

253

Other abnormality

yes no

254

Specify other abnormality:255

What was the disease status?256

Complete
remission

(CR)

– requires all of the following, maintained for ≥ 4 weeks: * bone marrow evaluation: <  5% myeloblasts with normal maturation of all cell lines *
peripheral blood evaluation: hemoglobin ≥ 11 g/dL untransfused and without erythropoietin support; ANC ≥ 1000/mm3  without myeloid growth factor
support; platelets ≥ 100 x 109/L without thrombopoietic support; 0% blasts

Hematologic

improvement
(HI)

– requires one measurement of the following, maintained for ≥ 8 weeks without ongoing cytotoxic therapy; specify which cell line was measured to
determine HI response: * HI­E – hemoglobin increase of ≥ 1.5 g/dL untransfused; for RBC transfusions performed for Hgb ≤ 9.0, reduction in RBC
units transfused in 8 weeks by ≥ 4 units compared to the pre­treatment transfusion number in 8 weeks * HI­P – for pre­treatment platelet count of > 20
x 109/L, platelet absolute increase of ≥ 30 x 109/L; for pre-treatment platelet count of < 20 x 109/L, platelet absolute increase of ≥ 20 x 109/L and ≥
100% from pre­treatment level  * HI­N – neutrophil count increase of ≥ 100% from pre­treatment level and an absolute increase of ≥ 500/mm3

No response (NR) / stable disease (SD) – does not meet the criteria for at least HI, but no evidence of disease progression

Progression from
hematologic improvement

(Prog from HI)

– requires at least one of the following, in the absence of another explanation (e.g., infection, bleeding, ongoing chemotherapy, etc.): *
≥ 50% reduction from maximum response levels in granulocytes or platelets * reduction in hemoglobin by ≥ 1.5 g/dL *transfusion
dependence

Relapse from complete

remission (Rel from CR)

– requires at least one of the following: * return to pre­treatment bone marrow blast percentage * decrease of ≥ 50% from maximum
response levels in granulocytes or platelets * transfusion dependence, or hemoglobin level ≥ 1.5 g/dL lower than prior to therapy

Not assessed

Specify the cell line examined to determine HI status257

HI-
E

– hemoglobin increase of ≥ 1.5 g/dL untransfused; for RBC transfusions performed for Hgb ≤ 9.0, reduction in RBC units transfused in 8 weeks by ≥ 4
units compared to the pre-treatment transfusion number in 8 weeks

HI-
P

– for pre­treatment platelet count of > 20 x 109/L, platelet absolute increase of ≥ 30 x 109/L; for pre-treatment platelet count of < 20 x 109/L, platelet
absolute increase of ≥ 20 x 109/L and ≥ 100% from pre­treatment level 

HI-N – neutrophil count increase of ≥ 100% from pre­treatment level and an absolute increase of ≥ 500/mm3

Date of progression:258 __ __ __ __ - __ __- __ __

Date of relapse:259 __ __ __ __ - __ __- __ __

Date assessed:260 __ __ __ __ - __ __- __ __

Other Leukemia (OL) Questions: 261 - 267

Specify the other leukemia classification261

Specify other leukemia:262

Was any 17p abnormality detected?

yes no

263

Did a histologic transformation to diffuse large B-cell lymphoma (Richter syndrome) occur at any time after CLL diagnosis?264

yes - Also complete NHL Disease Classification questions

no

What was the disease status? (Atypical CML)265

Primary induction failure

1st complete remission (no previous bone marrow or extramedullary relapse)

2nd complete remission

≥3rd complete remission

1st relapse

2nd relapse

≥3rd relapse

No treatment

What was the disease status? (CLL, PLL, Hairy cell leukemia)266

Complete remission (CR)

Partial remission (PR)

Stable disease (SD)

Progressive disease (Prog)

Untreated

Not assessed

Date assessed:267 __ __ __ __ - __ __- __ __

Hodgkin and Non-Hodgkin Lymphoma Questions: 268 - 285

Specify the lymphoma histology (at infusion)268

Specify other lymphoma histology:269

Assignment of DLBCL (germinal center B-cell type vs. activated B-cell type) subtype was based on270

Immunohistochemistry (e.g. Han's algorithm)

Gene expression profile

Unknown method

Is the lymphoma histology reported at transplant a transformation from CLL?

yes no

271

Was any 17p abnormality detected?

yes no

272

Is the lymphoma histology reported at transplant a transformation from a different lymphoma histology? (Not CLL)

Yes No

273

Specify the original lymphoma histology (prior to transformation)274

Specify other lymphoma histology:275

Date of original lymphoma diagnosis:276 __ __ __ __ - __ __- __ __ (report the date of diagnosis of original lymphoma subtype)

Was a PET (or PET/CT) scan performed? (at last evaluation prior to the start of the preparative regimen / infusion)

yes no

277

Was the PET (or PET/CT) scan positive for lymphoma involvement at any disease site?

yes no

278

Date of PET scan

Known Unknown

279

Date of PET (or PET/CT) scan:280 __ __ __ __ - __ __- __ __

Deauville (five-point) score of the PET (or PET/CT) scan

Known Unknown

281

Scale282

1 - no uptake or residual uptake

2 - slight uptake, but below blood pool (mediastinum)

3 - uptake above mediastinal, but below or equal to uptake in the liver

4 - uptake slightly to moderately higher than liver

5 - markedly increased uptake or any new lesions

What was the disease status?283

Total number of lines of therapy received

1 line 2 lines 3+ lines

284

Date assessed:285 __ __ __ __ - __ __- __ __

Multiple Myeloma / Plasma Cell Disorder (PCD) Questions: 286 - 317

Specify the multiple myeloma/plasma cell disorder (PCD) classification286

Specify other plasma cell disorder:287

Light chain

kappa lambda

288

What was the Durie-Salmon staging? (at diagnosis)289

Stage
I

(All of the following: Hgb > 10g/dL; serum calcium normal or <10.5 mg/dL; bone x-ray normal bone structure (scale 0), or solitary bone plasmacytoma
only; low M-component production rates IgG< 5g/dL, IgA < 3g/dL; urine light chain M-component on electrophoresis <4 g/24h)

Stage II (Fitting neither Stage I or III) 

Stage
III

(One or more of the following: Hgb < 8.5 g/dL; serum calcium > 12 mg/dL; advanced lytic bone lesions (scale 3); high M-component production rates
IgG > 7g/dL, IgA > 5 g/dL; Bence Jones protein > 12g/24h)

Unknown

What was the Durie-Salmon sub classification? (at diagnosis)290

A - relatively normal renal function (serum creatinine < 2.0 mg/dL)

B ­ abnormal renal function (serum creatinine ≥ 2.0 mg/dL)

Serum β2­microglobulin:291 μg/dL mg/L nmol/L

Serum albumin:292 g/dL g/L

Stage293

1 (β2 ­mic < 3.5, S. albumin ≥3.5)

2 (Not fitting stage 1 or 3)

3 (β2­mic ≥ 5.5; S. albumin ­)

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

294

Results of tests295

Abnormalities identified

No evaluable metaphases

No abnormalities

+3

yes no

296

+5

yes no

297

+7

yes no

298

+9

yes no

299

+11

yes no

300

+15

yes no

301

+19

yes no

302

t(4;14)

yes no

303

t(6;14)

yes no

304

t(11;14)

yes no

305

t(14;16)

yes no

306

t(14;20)

yes no

307

del(13q) / 13q-

yes no

308

del (17p) / 17p-

yes no

309

Hyperdiploid (>50)

yes no

310

Hypodiploid (<46)

yes no

311

Any abnormality at 1q

yes no

312

Any abnormality at 1p

yes no

313

Other abnormality

yes no

314

Specify other abnormality:315

What was the disease status?316

Stringent
complete

remission
(sCR)

- CR as defined, plus: normal free light chain ratio, and absence of clonal cells in the bone marrow by immunohistochemistry of immunofluorescence
(confirmation with repeat bone marrow biopsy not needed). (Presence and/or absence of clonal cells is based upon the Κ/λ ratio. An abnormal Κ/λ ratio by
immunohistochemistry and/or immunofluorescence requires a minimum of 100 plasma cells for analysis.  An abnormal ratio reflecting the presence of
an abnormal clone is Κ/λ of > 4:1 or < 1:2.) sCR requires two consecutive assessments made at any time before the institution of any new therapy, and
no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy sCR
requirements. 

Complete
remission

(CR)

- negative immunofixation on serum and urine samples, and disappearance of any soft tissue plasmacytomas, and < 5% plasma cells in the bone
marrow (confirmation with repeat bone marrow biopsy not needed).  CR requires two consecutive assessments made at any time before the institution

of any new therapy, and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not
required to satisfy CR requirements. 

Near
complete
remission
(nCR)

- serum and urine M-protein detectable by immunoelectrophoresis (IFE), but not on electrophoresis (negative SPEP & UPEP); < 5% plasma cells in
bone marrow.  nCR requires two consecutive assessments made at any time before the initiation of any new therapy, and no known evidence of
progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy nCR requirements. 

Very good
partial
remission
(VGPR)

­ serum and urine M­protein detectable by immunofixation but not on electrophoresis, or ≥ 90% reduction in serum M­protein and urine M­protein level <
100 mg/24 hours.  VGPR requires two consecutive assessments made at any time before the institution of any new therapy, and no known evidence of
progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy VGPR requirements.

Partial
remission
(PR)

­ ≥ 50% reduction in serum M­protein, and reduction in 24­hour urinary M­protein by ≥ 90% or to < 200 mg/24 hours.  If the serum and urine M­protein are
unmeasurable (i.e., do not meet any of the following criteria: • serum M­protein ≥ 1 g/dL.  Urine M­protein ≥ 200 mg/24 hours • serum free light chain
assay shows involved level ≥ 10 mg/dL, provided serum free light chain ratio is abnormal), a ≥ 50% decrease in the difference between involved and
uninvolved free light chain levels is required in place of the M-protein criteria.  If serum and urine M-protein are unmeasurable, and serum free light assay
is also unmeasurable, a ≥ 50% reduction in plasma cells is required in place of M­protein, provided the baseline bone marrow plasma cell percentage
was ≥ 30%. In addition to the above listed criteria, a ≥ 50% reduction in the size of soft tissue plasmacytomas is also required, if present at baseline. PR
requires two consecutive assessments made at any time before the institution of any new therapy, and no known evidence of progressive or new bone
lesions if radiographic studies were performed; radiographic studies are not required to satisfy PR requirements. 

Stable
disease
(SD)

- not meeting the criteria for CR, VGPR, PR or PD.  SD requires two consecutive assessments made at any time before the institution of any new therapy,
and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy SD
requirements.

Progressive
disease
(PD)

­ requires any one or more of the following:  Increase of ≥ 25% from baseline in:  serum M­component and/or (absolute increase ≥ 0.5 g/dL) (for
progressive disease, serum M­component increases of ≥ 1 g/dL are sufficient to define relapse if the starting M­component is ≥ 5 g/dL).  Urine M­
component and/or (absolute increase ≥ 200 mg/24 hours) for recipients without measurable serum and urine M­protein levels: the difference between
involved and uninvolved free light chain levels (absolute increase > 10 mg/dL).  Bone marrow plasma cell percentage (absolute percentage ≥ 10%)
(relapse from CR has a 5% cutoff vs. 10% for other categories of relapse) definite development of new bone lesions or soft tissue plasmacytomas, or
definite increase in the size of any existing  bone lesions or soft tissue plasmacytomas. Development of hypercalcemia (corrected serum calcium >
11.5 mg/dL or 2.65 mmol) that can be attributed solely to the plasma cell proliferative disorder.  PD requires two consecutive assessments made at
any time before classification as disease progression, and/or the institution of any new therapy.

Relapse
from CR
(Rel)
(untreated)

­ requires one or more of the following: reappearance of serum or urine M­protein by immunofixation or electrophoresis development of ≥ 5% plasma
cells in the bone marrow (relapse from CR has a 5% cutoff vs. 10% for other categories of relapse) appearance of any other sign of progression (e.g.,
new plasmacytoma, lytic bone lesion, hypercalcemia).  Rel requires two consecutive assessments made at any time before classification as relapse,
and/or the institution of any new therapy.

Unknown

Not applicable (Amyloidosis with no evidence of myeloma)

Date assessed:317 __ __ __ __ - __ __- __ __

Solid Tumors Questions: 318 - 319

Specify the solid tumor classification318

Specify other solid tumor:319

Severe Aplastic Anemia Questions: 320 - 321

Specify the severe aplastic anemia classification320

Specify other acquired cytopenic syndrome:321

Inherited Abnormalities of Erythrocyte Differentiation or Function Questions: 322 - 324

Specify the inherited abnormalities of erythrocyte differentiation or function classification322

Specify other constitutional anemia:323

Specify other hemoglobinopathy:324

Disorders of the Immune System Questions: 325 - 327

Specify disorder of immune system classification325

Specify other SCID:326

Specify other immunodeficiency:327

Inherited Abnormalities of Platelets Questions: 328 - 329

Specify inherited abnormalities of platelets classification328

Congenital amegakaryocytosis / congenital thrombocytopenia (501)

Glanzmann thrombasthenia (502)

Other inherited platelet abnormality (509)

Specify other inherited platelet abnormality:329

Inherited Disorders of Metabolism Questions: 330 - 331

Specify inherited disorders of metabolism classification330

Specify other inherited metabolic disorder:331

Histiocytic Disorders Questions: 332 - 333

Specify histiocytic disorder classification332

Specify other histiocytic disorder:333

Autoimmune Diseases Questions: 334 - 341

Specify autoimmune disease classification334

Specify other arthritis:335

Specify other juvenile idiopathic arthritis (JIA):336

Specify other connective tissue disease:337

Specify other vasculitis:338

Specify other autoimmune neurological disorder:339

Specify other autoimmune cytopenia:340

Specify other autoimmune bowel disorder:341

Other Disease Questions: 342 - 342

Specify other disease:342

First Name:

Last Name:

E-mail address:

Date: __ __ __ __ - __ __- __ __

OMB No: 0915-0310

Expiration Date: 1/31/2020

Public Burden Statement:  An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control
number.  The OMB control number for this project is 0915-0310.  Public reporting burden for this collection of information is estimated to average 1.0 hours per response, including the
time for reviewing instructions, searching existing data sources, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other
aspect of this collection of information, including suggestions for reducing this burden, to HRSA Reports Clearance Officer, 5600 Fishers Lane, Room 10-29, Rockville, Maryland, 20857.

Labs at diagnosis

Specify cytogenetic abnormalities identified at diagnosis:

Specify cytogenetic abnormalities identified at diagnosis:

Specify molecular markers identified at diagnosis:

Labs between diagnosis and last evaluation:

Specify cytogenetic abnormalities identified between diagnosis and last evaluation:

Specify cytogenetic abnormalities identified between diagnosis and last evaluation:

Specify molecular markers identified between diagnosis and last evaluation:

Labs at last evaluation:

Specify cytogenetic abnormalities identified at last evaluation:

Specify cytogenetic abnormalities identified at last evaluation:

Specify molecular markers identified at last evaluation:

CNS Leukemia

Status at transplantation:

Laboratory studies at diagnosis:

Specify cytogenetic abnormalities identified at diagnosis:

Specify cytogenetic abnormalities identified at diagnosis:

Specify molecular markers identified at diagnosis:

Laboratory studies between diagnosis and last evaluation:

Specify cytogenetic abnormalities identified between diagnosis and last evaluation:

Specify cytogenetic abnormalities identified between diagnosis and last evaluation:

Specify molecular markers identified between diagnosis and last evaluation:

Laboratory studies at last evaluation:

Specify cytogenetic abnormalities identified at last evaluation:

Specify cytogenetic abnormalities identified at last evaluation:

Specify molecular markers identified at last evaluation:

CNS Leukemia

Status at transplantation:

Status at transplantation:

Laboratory studies at diagnosis of MDS:

Specify abnormalities identified at diagnosis:

Monosomy

Trisomy

Translocation

Deletion

Inversion

Other

Laboratory studies at last evaluation prior to the start of the preparative regimen:

Specify cytogenetic abnormalities identified at last evaluation prior to the start of the preparative regimen:

Monosomy

Trisomy

Translocation

Deletion

Inversion

Other

Status at transplantation:

Status at transplantation:

Status at transplantation / infusion:

I.S.S.:

Specify cytogenetic abnormalities identified at any time prior to the start of the preparative regimen:

Trisomy

Translocation

Deletion

Other

Status at transplantation:

Center: CRID: 

Form 2402 R3.0: Disease Classification

CIBMTR Form 2402 revision 3.0 last updated Monday, January 29, 2018
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 7 / 26



Key Fields

Sequence Number:

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number:

CIBMTR Research ID:

Event date: __ __ __ __ - __ __- __ __

Primary Disease for HCT / Cellular Therapy Questions: 1 - 2

Date of diagnosis of primary disease for HCT / cellular therapy:1 __ __ __ __ - __ __- __ __

What was the primary disease for which the HCT / cellular therapy was performed?2

Acute myelogenous leukemia (AML or ANLL) (10)

Acute lymphoblastic leukemia (ALL) (20)

Acute leukemia of ambiguous lineage and other myeloid neoplasms (80)

Chronic myelogenous leukemia (CML) (40)

Myelodysplastic (MDS) / myeloproliferative (MPN) diseases (50) (Please classify all preleukemias) (If recipient has transformed to AML, indicate AML as the primary disease)

Other leukemia (30) (includes CLL)

Hodgkin lymphoma (150)

Non-Hodgkin lymphoma (100)

Multiple myeloma / plasma cell disorder (PCD) (170)

Solid tumors (200)

Severe aplastic anemia (300) (If the recipient developed MDS or AML, indicate MDS or AML as the primary disease)

Inherited abnormalities of erythrocyte differentiation or function (310)

Disorders of the immune system (400)

Inherited abnormalities of platelets (500)

Inherited disorders of metabolism (520)

Histiocytic disorders (570)

Autoimmune diseases (600)

Other disease (900)

Acute Myelogenous Leukemia (AML) Questions: 3 - 89

Specify the AML classification3

Did AML transform from MDS or MPN?4

yes - Also complete MDS Disease Classification questions

no

Is the disease (AML) therapy related?

yes no Unknown

5

Did the recipient have a predisposing condition?

yes no Unknown

6

Specify condition7

Bloom syndrome

Down syndrome

Fanconi anemia

Dyskeratosis congenita

Other condition

Specify other condition:8

Were cytogenetics tested (karyotyping or FISH)? (at diagnosis)

yes no Unknown

9

Were cytogenetics tested via FISH? (at diagnosis)

Yes No

10

Results of tests11

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities12

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

13

Specify other abnormality:14

Were cytogenetics tested via karyotyping? (at diagnosis)

Yes No

15

Results of tests16

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities17

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

18

Specify other abnormality:19

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

20

Were tests for molecular markers performed? (e.g. PCR, NGS) (at diagnosis)

yes no Unknown

21

CEBPA

Positive Negative Not Done

22

Specify CEBPA mutation23

Biallelic (homozygous)

Monoallelic (heterozygous)

Unknown

FLT3 – D835 point mutation

Positive Negative Not Done

24

FLT3 – ITD mutation

Positive Negative Not Done

25

FLT3 - ITD allelic ratio

Known Unknown

26

Specify FLT3 - ITD allelic ratio:27

IDH1

Positive Negative Not Done

28

IDH2

Positive Negative Not Done

29

KIT

Positive Negative Not Done

30

NPM1

Positive Negative Not Done

31

Other Molecular Marker (1) Questions: 32 - 33

Other molecular marker

Positive Negative Not Done

32

Specify other molecular marker:33

Were cytogenetics tested (karyotyping or FISH)? (between diagnosis and last evaluation)

yes no Unknown

34

Were cytogenetics tested via FISH? (between diagnosis and last evaluation)

Yes No

35

Results of tests36

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities37

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

38

Specify other abnormality:39

Were cytogenetics tested via karyotyping? (between diagnosis and last evaluation)

Yes No

40

Results of tests41

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities42

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

43

Specify other abnormality:44

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

45

Were tests for molecular markers performed? (e.g. PCR, NGS) (between diagnosis and last evaluation)

yes no Unknown

46

CEBPA

Positive Negative Not Done

47

Specify CEBPA mutation48

Biallelic (homozygous)

Monoallelic (heterozygous)

Unknown

FLT3 – D835 point mutation

Positive Negative Not Done

49

FLT3 – ITD mutation

Positive Negative Not Done

50

FLT3 - ITD allelic ratio

Known Unknown

51

Specify FLT3 - ITD allelic ratio:52

IDH1

Positive Negative Not Done

53

IDH2

Positive Negative Not Done

54

KIT

Positive Negative Not Done

55

NPM1

Positive Negative Not Done

56

Other Molecular Marker (1) Questions: 57 - 58

Other molecular marker

Positive Negative Not Done

57

Specify other molecular marker:58

Were cytogenetics tested (karyotyping or FISH)? (at last evaluation)

yes no Unknown

59

Were cytogenetics tested via FISH? (at last evaluation)

Yes No

60

Results of tests61

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities62

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

63

Specify other abnormality:64

Were cytogenetics tested via karyotyping? (at last evaluation)

Yes No

65

Results of tests66

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities67

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

68

Specify other abnormality:69

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

70

Were tests for molecular markers performed? (e.g. PCR, NGS) (at last evaluation)

yes no Unknown

71

CEBPA

Positive Negative Not Done

72

Specify CEBPA mutation73

Biallelic (homozygous)

Monoallelic (heterozygous)

Unknown

FLT3 – D835 point mutation

Positive Negative Not Done

74

FLT3 – ITD mutation

Positive Negative Not Done

75

FLT3 - ITD allelic ratio

Known Unknown

76

Specify FLT3 - ITD allelic ratio:77

IDH1

Positive Negative Not Done

78

IDH2

Positive Negative Not Done

79

KIT

Positive Negative Not Done

80

NPM1

Positive Negative Not Done

81

Other Molecular Marker (1) Questions: 82 - 83

Other molecular marker

Positive Negative Not Done

82

Specify other molecular marker:83

Did the recipient have central nervous system leukemia at any time prior to the start of the preparative regimen / infusion?

yes no Unknown

84

What was the disease status (based on hematological test results)?85

Primary induction failure

1st complete remission (no previous bone marrow or extramedullary relapse) (include CRi)

2nd complete remission

≥3rd complete remission

1st relapse

2nd relapse

≥3rd relapse

No treatment

How many cycles of induction therapy were required to achieve 1st complete remission? (includes CRi)

1 2 ≥ 3

86

Was the recipient in remission by flow cytometry?

Yes No Unknown Not applicable

87

Date of most recent relapse:88 __ __ __ __ - __ __- __ __

Date assessed:89 __ __ __ __ - __ __- __ __

Acute Lymphoblastic Leukemia (ALL) Questions: 90 - 151

Specify ALL classification90

Did the recipient have a predisposing condition?

yes no Unknown

91

Specify condition92

Aplastic anemia - Also complete CIBMTR Form 2028 - APL

Bloom syndrome

Down syndrome

Fanconi anemia - Also complete CIBMTR Form 2029 - FAN

Other condition

Specify other condition:93

Were tyrosine kinase inhibitors given for therapy at any time prior to the start of the preparative regimen / infusion? (e.g. imatinib mesylate, dasatinib, etc.)

yes no

94

Were cytogenetics tested (karyotyping or FISH)? (at diagnosis)

yes no Unknown

95

Were cytogenetics tested via FISH? (at diagnosis)

Yes No

96

Results of tests97

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities98

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

99

Specify other abnormality:100

Were cytogenetics tested via karyotyping? (at diagnosis)

Yes No

101

Results of tests102

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities103

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

104

Specify other abnormality:105

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

106

Were tests for molecular markers performed? (e.g. PCR, NGS) (at diagnosis)

yes no Unknown

107

BCR / ABL

Positive Negative Not Done

108

TEL-AML / AML1

Positive Negative Not Done

109

Other Molecular Marker (1) Questions: 110 - 111

Other molecular marker

Positive Negative Not Done

110

Specify other molecular marker:111

Were cytogenetics tested (karyotyping or FISH)? (between diagnosis and last evaluation)

yes no Unknown

112

Were cytogenetics tested via FISH? (between diagnosis and last evaluation)

Yes No

113

Results of tests114

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities115

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

116

Specify other abnormality:117

Were cytogenetics tested via karyotyping? (between diagnosis and last evaluation)

Yes No

118

Results of tests119

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities120

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

121

Specify other abnormality:122

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

123

Were tests for molecular markers performed? (e.g. PCR, NGS) (between diagnosis and last evaluation)

yes no Unknown

124

BCR / ABL

Positive Negative Not Done

125

TEL-AML / AML1

Positive Negative Not Done

126

Other Molecular Marker (1) Questions: 127 - 128

Other molecular marker

Positive Negative Not Done

127

Specify other molecular marker:128

Were cytogenetics tested (karyotyping or FISH)? (at last evaluation)

yes no Unknown

129

Were cytogenetics tested via FISH? (at last evaluation)

Yes No

130

Results of tests131

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities132

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

133

Specify other abnormality:134

Were cytogenetics tested via karyotyping? (at last evaluation)

Yes No

135

Results of tests136

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities137

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

138

Specify other abnormality:139

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

140

Were tests for molecular markers performed? (e.g. PCR, NGS) (at last evaluation)

yes no Unknown

141

BCR / ABL

Positive Negative Not Done

142

TEL-AML / AML1

Positive Negative Not Done

143

Other Molecular Marker (1) Questions: 144 - 145

Other molecular marker

Positive Negative Not Done

144

Specify other molecular marker:145

Did the recipient have central nervous system leukemia at any time prior to the start of the preparative regimen / infusion?

yes no Unknown

146

What was the disease status (based on hematological test results)?147

Primary induction failure

1st complete remission (no previous marrow or extramedullary relapse) (include CRi)

2nd complete remission

≥3rd complete remission

1st relapse

2nd relapse

≥3rd relapse

No treatment

How many cycles of induction therapy were required to achieve 1st complete remission? (include CRi)

1 2 ≥ 3

148

Was the recipient in remission by flow cytometry?

Yes No Unknown Not applicable

149

Date of most recent relapse:150 __ __ __ __ - __ __- __ __

Date assessed:151 __ __ __ __ - __ __- __ __

Acute Leukemias of Ambiguous Lineage and Other Myeloid Neoplasms Questions: 152 - 155

Specify acute leukemias of ambiguous lineage and other myeloid neoplasm classification152

Blastic plasmacytoid dendritic cell neoplasm (296)

Acute undifferentiated leukemia (31)

Mixed phenotype acute leukemia (MPAL) with t(9;22)(q34.1;q11.2); BCR-ABL1 (84)

Mixed phenotype acute leukemia with t(v; 11q23.3); KMT2A rearranged (85)

Mixed phenotype acute leukemia, B/myeloid, NOS (86)

Mixed phenotype acute leukemia, T/myeloid, NOS (87)

Other acute leukemia of ambiguous lineage or myeloid neoplasm (88)

Specify other acute leukemia of ambiguous lineage or myeloid neoplasm:153

What was the disease status (based on hematological test results)?154

Primary induction failure

1st complete remission (no previous marrow or extramedullary relapse)

2nd complete remission

≥3rd complete remission

1st relapse

2nd relapse

≥3rd relapse

No treatment

Date assessed:155 __ __ __ __ - __ __- __ __

Chronic Myelogenous Leukemia (CML) Questions: 156 - 166

Was therapy given prior to this HCT?

yes no

156

Combination chemotherapy

yes no

157

Hydroxyurea (Droxia, Hydrea)

yes no

158

Tyrosine kinase inhibitor (e.g. imatinib mesylate, dasatinib, nilotinib)

yes no

159

Interferon­α (Intron, Roferon) (includes PEG)

yes no

160

Other therapy

yes no

161

Specify other therapy:162

What was the disease status?163

Complete hematologic response (CHR)

Chronic phase

Accelerated phase

Blast phase

Specify level of response164

No cytogenetic response (No CyR)

Minimal cytogenetic response

Minor cytogenetic response

Partial cytogenetic response (PCyR)

Complete cytogenetic response (CCyR)

Major molecular remission (MMR)

Complete molecular remission (CMR)

Number

1st 2nd 3rd or higher

165

Date assessed:166 __ __ __ __ - __ __- __ __

Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases Questions: 167 - 260

What was the MDS / MPN subtype at diagnosis? - If transformed to AML, indicate AML as primary disease; also complete AML Disease Classification
questions

167

Was the disease (MDS/MPN) therapy related?

yes no Unknown

168

Did the recipient have a predisposing condition?

yes no Unknown

169

Specify condition

Aplastic Anemia Bloom syndrome Down syndrome Fanconi anemia Other condition

170

Specify other condition:171

WBC

Known Unknown

172

173 x 109/L (x 103/mm3)

x 106/L

Hemoglobin

Known Unknown

174

175 g/dL g/L mmol/L

Was RBC transfused ≤ 30 days before date of test?

Yes No

176

Platelets

Known Unknown

177

178 x 109/L (x 103/mm3)

x 106/L

Were platelets transfused ≤ 7 days before date of test?

Yes No

179

Neutrophils

Known Unknown

180

181 %

Blasts in bone marrow

Known Unknown

182

183 %

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

184

Results of tests185

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities186

One (1)

Two (2)

Three (3)

Four or more (4 or more)

–5

yes no

187

-7

yes no

188

–13

yes no

189

–20

yes no

190

–Y

yes no

191

+8

yes no

192

+19

yes no

193

t(1;3)

yes no

194

t(2;11)

yes no

195

t(3;3)

yes no

196

t(3;21)

yes no

197

t(6;9)

yes no

198

t(11;16)

yes no

199

del(3q) / 3q–

yes no

200

del(5q) / 5q-

yes no

201

del(7q) / 7q–

yes no

202

del(9q) / 9q–

yes no

203

del(11q) / 11q–

yes no

204

del(12p) / 12p–

yes no

205

del(13q) / 13q-

yes no

206

del(20q) / 20q–

yes no

207

inv(3)

yes no

208

i17q

yes no

209

Other abnormality

yes no

210

Specify other abnormality:211

Did the recipient progress or transform to a different MDS / MPN subtype between diagnosis and the start of the preparative regimen?

yes no

212

Specify the MDS / MPN classification after transformation:213

Specify the date of the most recent transformation:214 __ __ __ __ - __ __- __ __

Date of MDS diagnosis:215 __ __ __ __ - __ __- __ __

WBC

Known Unknown

216

217 x 109/L (x 103/mm3)

x 106/L

Hemoglobin

Known Unknown

218

219 g/dL g/L mmol/L

Was RBC transfused ≤ 30 days before date of test?

Yes No

220

Platelets

Known Unknown

221

222 x 109/L (x 103/mm3)

x 106/L

Were platelets transfused ≤ 7 days before date of test?

Yes No

223

Neutrophils

Known Unknown

224

225 %

Blasts in bone marrow

Known Unknown

226

227 %

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

228

Results of tests229

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities230

One (1)

Two (2)

Three (3)

Four or more (4 or more)

–5

yes no

231

-7

yes no

232

–13

yes no

233

–20

yes no

234

–Y

yes no

235

+8

yes no

236

+19

yes no

237

t(1;3)

yes no

238

t(2;11)

yes no

239

t(3;3)

yes no

240

t(3;21)

yes no

241

t(6;9)

yes no

242

t(11;16)

yes no

243

del(3q) / 3q–

yes no

244

del(5q) / 5q-

yes no

245

del(7q) / 7q–

yes no

246

del(9q) / 9q–

yes no

247

del(11q) / 11q–

yes no

248

del(12p) / 12p–

yes no

249

del(13q) / 13q-

yes no

250

del(20q) / 20q–

yes no

251

inv(3)

yes no

252

i17q

yes no

253

Other abnormality

yes no

254

Specify other abnormality:255

What was the disease status?256

Complete

remission
(CR)

– requires all of the following, maintained for ≥ 4 weeks: * bone marrow evaluation: <  5% myeloblasts with normal maturation of all cell lines *
peripheral blood evaluation: hemoglobin ≥ 11 g/dL untransfused and without erythropoietin support; ANC ≥ 1000/mm3  without myeloid growth factor
support; platelets ≥ 100 x 109/L without thrombopoietic support; 0% blasts

Hematologic
improvement

(HI)

– requires one measurement of the following, maintained for ≥ 8 weeks without ongoing cytotoxic therapy; specify which cell line was measured to
determine HI response: * HI­E – hemoglobin increase of ≥ 1.5 g/dL untransfused; for RBC transfusions performed for Hgb ≤ 9.0, reduction in RBC
units transfused in 8 weeks by ≥ 4 units compared to the pre­treatment transfusion number in 8 weeks * HI­P – for pre­treatment platelet count of > 20
x 109/L, platelet absolute increase of ≥ 30 x 109/L; for pre-treatment platelet count of < 20 x 109/L, platelet absolute increase of ≥ 20 x 109/L and ≥
100% from pre­treatment level  * HI­N – neutrophil count increase of ≥ 100% from pre­treatment level and an absolute increase of ≥ 500/mm3

No response (NR) / stable disease (SD) – does not meet the criteria for at least HI, but no evidence of disease progression

Progression from

hematologic improvement
(Prog from HI)

– requires at least one of the following, in the absence of another explanation (e.g., infection, bleeding, ongoing chemotherapy, etc.): *
≥ 50% reduction from maximum response levels in granulocytes or platelets * reduction in hemoglobin by ≥ 1.5 g/dL *transfusion
dependence

Relapse from complete
remission (Rel from CR)

– requires at least one of the following: * return to pre­treatment bone marrow blast percentage * decrease of ≥ 50% from maximum
response levels in granulocytes or platelets * transfusion dependence, or hemoglobin level ≥ 1.5 g/dL lower than prior to therapy

Not assessed

Specify the cell line examined to determine HI status257

HI-

E

– hemoglobin increase of ≥ 1.5 g/dL untransfused; for RBC transfusions performed for Hgb ≤ 9.0, reduction in RBC units transfused in 8 weeks by ≥ 4
units compared to the pre-treatment transfusion number in 8 weeks

HI-

P

– for pre­treatment platelet count of > 20 x 109/L, platelet absolute increase of ≥ 30 x 109/L; for pre-treatment platelet count of < 20 x 109/L, platelet
absolute increase of ≥ 20 x 109/L and ≥ 100% from pre­treatment level 

HI-N – neutrophil count increase of ≥ 100% from pre­treatment level and an absolute increase of ≥ 500/mm3

Date of progression:258 __ __ __ __ - __ __- __ __

Date of relapse:259 __ __ __ __ - __ __- __ __

Date assessed:260 __ __ __ __ - __ __- __ __

Other Leukemia (OL) Questions: 261 - 267

Specify the other leukemia classification261

Specify other leukemia:262

Was any 17p abnormality detected?

yes no

263

Did a histologic transformation to diffuse large B-cell lymphoma (Richter syndrome) occur at any time after CLL diagnosis?264

yes - Also complete NHL Disease Classification questions

no

What was the disease status? (Atypical CML)265

Primary induction failure

1st complete remission (no previous bone marrow or extramedullary relapse)

2nd complete remission

≥3rd complete remission

1st relapse

2nd relapse

≥3rd relapse

No treatment

What was the disease status? (CLL, PLL, Hairy cell leukemia)266

Complete remission (CR)

Partial remission (PR)

Stable disease (SD)

Progressive disease (Prog)

Untreated

Not assessed

Date assessed:267 __ __ __ __ - __ __- __ __

Hodgkin and Non-Hodgkin Lymphoma Questions: 268 - 285

Specify the lymphoma histology (at infusion)268

Specify other lymphoma histology:269

Assignment of DLBCL (germinal center B-cell type vs. activated B-cell type) subtype was based on270

Immunohistochemistry (e.g. Han's algorithm)

Gene expression profile

Unknown method

Is the lymphoma histology reported at transplant a transformation from CLL?

yes no

271

Was any 17p abnormality detected?

yes no

272

Is the lymphoma histology reported at transplant a transformation from a different lymphoma histology? (Not CLL)

Yes No

273

Specify the original lymphoma histology (prior to transformation)274

Specify other lymphoma histology:275

Date of original lymphoma diagnosis:276 __ __ __ __ - __ __- __ __ (report the date of diagnosis of original lymphoma subtype)

Was a PET (or PET/CT) scan performed? (at last evaluation prior to the start of the preparative regimen / infusion)

yes no

277

Was the PET (or PET/CT) scan positive for lymphoma involvement at any disease site?

yes no

278

Date of PET scan

Known Unknown

279

Date of PET (or PET/CT) scan:280 __ __ __ __ - __ __- __ __

Deauville (five-point) score of the PET (or PET/CT) scan

Known Unknown

281

Scale282

1 - no uptake or residual uptake

2 - slight uptake, but below blood pool (mediastinum)

3 - uptake above mediastinal, but below or equal to uptake in the liver

4 - uptake slightly to moderately higher than liver

5 - markedly increased uptake or any new lesions

What was the disease status?283

Total number of lines of therapy received

1 line 2 lines 3+ lines

284

Date assessed:285 __ __ __ __ - __ __- __ __

Multiple Myeloma / Plasma Cell Disorder (PCD) Questions: 286 - 317

Specify the multiple myeloma/plasma cell disorder (PCD) classification286

Specify other plasma cell disorder:287

Light chain

kappa lambda

288

What was the Durie-Salmon staging? (at diagnosis)289

Stage
I

(All of the following: Hgb > 10g/dL; serum calcium normal or <10.5 mg/dL; bone x-ray normal bone structure (scale 0), or solitary bone plasmacytoma
only; low M-component production rates IgG< 5g/dL, IgA < 3g/dL; urine light chain M-component on electrophoresis <4 g/24h)

Stage II (Fitting neither Stage I or III) 

Stage
III

(One or more of the following: Hgb < 8.5 g/dL; serum calcium > 12 mg/dL; advanced lytic bone lesions (scale 3); high M-component production rates
IgG > 7g/dL, IgA > 5 g/dL; Bence Jones protein > 12g/24h)

Unknown

What was the Durie-Salmon sub classification? (at diagnosis)290

A - relatively normal renal function (serum creatinine < 2.0 mg/dL)

B ­ abnormal renal function (serum creatinine ≥ 2.0 mg/dL)

Serum β2­microglobulin:291 μg/dL mg/L nmol/L

Serum albumin:292 g/dL g/L

Stage293

1 (β2 ­mic < 3.5, S. albumin ≥3.5)

2 (Not fitting stage 1 or 3)

3 (β2­mic ≥ 5.5; S. albumin ­)

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

294

Results of tests295

Abnormalities identified

No evaluable metaphases

No abnormalities

+3

yes no

296

+5

yes no

297

+7

yes no

298

+9

yes no

299

+11

yes no

300

+15

yes no

301

+19

yes no

302

t(4;14)

yes no

303

t(6;14)

yes no

304

t(11;14)

yes no

305

t(14;16)

yes no

306

t(14;20)

yes no

307

del(13q) / 13q-

yes no

308

del (17p) / 17p-

yes no

309

Hyperdiploid (>50)

yes no

310

Hypodiploid (<46)

yes no

311

Any abnormality at 1q

yes no

312

Any abnormality at 1p

yes no

313

Other abnormality

yes no

314

Specify other abnormality:315

What was the disease status?316

Stringent

complete
remission

(sCR)

- CR as defined, plus: normal free light chain ratio, and absence of clonal cells in the bone marrow by immunohistochemistry of immunofluorescence

(confirmation with repeat bone marrow biopsy not needed). (Presence and/or absence of clonal cells is based upon the Κ/λ ratio. An abnormal Κ/λ ratio by
immunohistochemistry and/or immunofluorescence requires a minimum of 100 plasma cells for analysis.  An abnormal ratio reflecting the presence of

an abnormal clone is Κ/λ of > 4:1 or < 1:2.) sCR requires two consecutive assessments made at any time before the institution of any new therapy, and
no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy sCR

requirements. 

Complete

remission
(CR)

- negative immunofixation on serum and urine samples, and disappearance of any soft tissue plasmacytomas, and < 5% plasma cells in the bone

marrow (confirmation with repeat bone marrow biopsy not needed).  CR requires two consecutive assessments made at any time before the institution
of any new therapy, and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not

required to satisfy CR requirements. 

Near
complete
remission
(nCR)

- serum and urine M-protein detectable by immunoelectrophoresis (IFE), but not on electrophoresis (negative SPEP & UPEP); < 5% plasma cells in
bone marrow.  nCR requires two consecutive assessments made at any time before the initiation of any new therapy, and no known evidence of
progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy nCR requirements. 

Very good
partial
remission
(VGPR)

­ serum and urine M­protein detectable by immunofixation but not on electrophoresis, or ≥ 90% reduction in serum M­protein and urine M­protein level <
100 mg/24 hours.  VGPR requires two consecutive assessments made at any time before the institution of any new therapy, and no known evidence of
progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy VGPR requirements.

Partial
remission
(PR)

­ ≥ 50% reduction in serum M­protein, and reduction in 24­hour urinary M­protein by ≥ 90% or to < 200 mg/24 hours.  If the serum and urine M­protein are
unmeasurable (i.e., do not meet any of the following criteria: • serum M­protein ≥ 1 g/dL.  Urine M­protein ≥ 200 mg/24 hours • serum free light chain
assay shows involved level ≥ 10 mg/dL, provided serum free light chain ratio is abnormal), a ≥ 50% decrease in the difference between involved and
uninvolved free light chain levels is required in place of the M-protein criteria.  If serum and urine M-protein are unmeasurable, and serum free light assay
is also unmeasurable, a ≥ 50% reduction in plasma cells is required in place of M­protein, provided the baseline bone marrow plasma cell percentage
was ≥ 30%. In addition to the above listed criteria, a ≥ 50% reduction in the size of soft tissue plasmacytomas is also required, if present at baseline. PR
requires two consecutive assessments made at any time before the institution of any new therapy, and no known evidence of progressive or new bone
lesions if radiographic studies were performed; radiographic studies are not required to satisfy PR requirements. 

Stable
disease
(SD)

- not meeting the criteria for CR, VGPR, PR or PD.  SD requires two consecutive assessments made at any time before the institution of any new therapy,
and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy SD
requirements.

Progressive
disease
(PD)

­ requires any one or more of the following:  Increase of ≥ 25% from baseline in:  serum M­component and/or (absolute increase ≥ 0.5 g/dL) (for
progressive disease, serum M­component increases of ≥ 1 g/dL are sufficient to define relapse if the starting M­component is ≥ 5 g/dL).  Urine M­
component and/or (absolute increase ≥ 200 mg/24 hours) for recipients without measurable serum and urine M­protein levels: the difference between
involved and uninvolved free light chain levels (absolute increase > 10 mg/dL).  Bone marrow plasma cell percentage (absolute percentage ≥ 10%)
(relapse from CR has a 5% cutoff vs. 10% for other categories of relapse) definite development of new bone lesions or soft tissue plasmacytomas, or
definite increase in the size of any existing  bone lesions or soft tissue plasmacytomas. Development of hypercalcemia (corrected serum calcium >
11.5 mg/dL or 2.65 mmol) that can be attributed solely to the plasma cell proliferative disorder.  PD requires two consecutive assessments made at
any time before classification as disease progression, and/or the institution of any new therapy.

Relapse
from CR
(Rel)
(untreated)

­ requires one or more of the following: reappearance of serum or urine M­protein by immunofixation or electrophoresis development of ≥ 5% plasma
cells in the bone marrow (relapse from CR has a 5% cutoff vs. 10% for other categories of relapse) appearance of any other sign of progression (e.g.,
new plasmacytoma, lytic bone lesion, hypercalcemia).  Rel requires two consecutive assessments made at any time before classification as relapse,
and/or the institution of any new therapy.

Unknown

Not applicable (Amyloidosis with no evidence of myeloma)

Date assessed:317 __ __ __ __ - __ __- __ __

Solid Tumors Questions: 318 - 319

Specify the solid tumor classification318

Specify other solid tumor:319

Severe Aplastic Anemia Questions: 320 - 321

Specify the severe aplastic anemia classification320

Specify other acquired cytopenic syndrome:321

Inherited Abnormalities of Erythrocyte Differentiation or Function Questions: 322 - 324

Specify the inherited abnormalities of erythrocyte differentiation or function classification322

Specify other constitutional anemia:323

Specify other hemoglobinopathy:324

Disorders of the Immune System Questions: 325 - 327

Specify disorder of immune system classification325

Specify other SCID:326

Specify other immunodeficiency:327

Inherited Abnormalities of Platelets Questions: 328 - 329

Specify inherited abnormalities of platelets classification328

Congenital amegakaryocytosis / congenital thrombocytopenia (501)

Glanzmann thrombasthenia (502)

Other inherited platelet abnormality (509)

Specify other inherited platelet abnormality:329

Inherited Disorders of Metabolism Questions: 330 - 331

Specify inherited disorders of metabolism classification330

Specify other inherited metabolic disorder:331

Histiocytic Disorders Questions: 332 - 333

Specify histiocytic disorder classification332

Specify other histiocytic disorder:333

Autoimmune Diseases Questions: 334 - 341

Specify autoimmune disease classification334

Specify other arthritis:335

Specify other juvenile idiopathic arthritis (JIA):336

Specify other connective tissue disease:337

Specify other vasculitis:338

Specify other autoimmune neurological disorder:339

Specify other autoimmune cytopenia:340

Specify other autoimmune bowel disorder:341

Other Disease Questions: 342 - 342

Specify other disease:342

First Name:

Last Name:

E-mail address:

Date: __ __ __ __ - __ __- __ __

OMB No: 0915-0310

Expiration Date: 1/31/2020

Public Burden Statement:  An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control
number.  The OMB control number for this project is 0915-0310.  Public reporting burden for this collection of information is estimated to average 1.0 hours per response, including the
time for reviewing instructions, searching existing data sources, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other
aspect of this collection of information, including suggestions for reducing this burden, to HRSA Reports Clearance Officer, 5600 Fishers Lane, Room 10-29, Rockville, Maryland, 20857.

Labs at diagnosis

Specify cytogenetic abnormalities identified at diagnosis:

Specify cytogenetic abnormalities identified at diagnosis:

Specify molecular markers identified at diagnosis:

Labs between diagnosis and last evaluation:

Specify cytogenetic abnormalities identified between diagnosis and last evaluation:

Specify cytogenetic abnormalities identified between diagnosis and last evaluation:

Specify molecular markers identified between diagnosis and last evaluation:

Labs at last evaluation:

Specify cytogenetic abnormalities identified at last evaluation:

Specify cytogenetic abnormalities identified at last evaluation:

Specify molecular markers identified at last evaluation:

CNS Leukemia

Status at transplantation:

Laboratory studies at diagnosis:

Specify cytogenetic abnormalities identified at diagnosis:

Specify cytogenetic abnormalities identified at diagnosis:

Specify molecular markers identified at diagnosis:

Laboratory studies between diagnosis and last evaluation:

Specify cytogenetic abnormalities identified between diagnosis and last evaluation:

Specify cytogenetic abnormalities identified between diagnosis and last evaluation:

Specify molecular markers identified between diagnosis and last evaluation:

Laboratory studies at last evaluation:

Specify cytogenetic abnormalities identified at last evaluation:

Specify cytogenetic abnormalities identified at last evaluation:

Specify molecular markers identified at last evaluation:

CNS Leukemia

Status at transplantation:

Status at transplantation:

Laboratory studies at diagnosis of MDS:

Specify abnormalities identified at diagnosis:

Monosomy

Trisomy

Translocation

Deletion

Inversion

Other

Laboratory studies at last evaluation prior to the start of the preparative regimen:

Specify cytogenetic abnormalities identified at last evaluation prior to the start of the preparative regimen:

Monosomy

Trisomy

Translocation

Deletion

Inversion

Other

Status at transplantation:

Status at transplantation:

Status at transplantation / infusion:

I.S.S.:

Specify cytogenetic abnormalities identified at any time prior to the start of the preparative regimen:

Trisomy

Translocation

Deletion

Other

Status at transplantation:

Center: CRID: 

Form 2402 R3.0: Disease Classification

CIBMTR Form 2402 revision 3.0 last updated Monday, January 29, 2018
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 8 / 26



Key Fields

Sequence Number:

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number:

CIBMTR Research ID:

Event date: __ __ __ __ - __ __- __ __

Primary Disease for HCT / Cellular Therapy Questions: 1 - 2

Date of diagnosis of primary disease for HCT / cellular therapy:1 __ __ __ __ - __ __- __ __

What was the primary disease for which the HCT / cellular therapy was performed?2

Acute myelogenous leukemia (AML or ANLL) (10)

Acute lymphoblastic leukemia (ALL) (20)

Acute leukemia of ambiguous lineage and other myeloid neoplasms (80)

Chronic myelogenous leukemia (CML) (40)

Myelodysplastic (MDS) / myeloproliferative (MPN) diseases (50) (Please classify all preleukemias) (If recipient has transformed to AML, indicate AML as the primary disease)

Other leukemia (30) (includes CLL)

Hodgkin lymphoma (150)

Non-Hodgkin lymphoma (100)

Multiple myeloma / plasma cell disorder (PCD) (170)

Solid tumors (200)

Severe aplastic anemia (300) (If the recipient developed MDS or AML, indicate MDS or AML as the primary disease)

Inherited abnormalities of erythrocyte differentiation or function (310)

Disorders of the immune system (400)

Inherited abnormalities of platelets (500)

Inherited disorders of metabolism (520)

Histiocytic disorders (570)

Autoimmune diseases (600)

Other disease (900)

Acute Myelogenous Leukemia (AML) Questions: 3 - 89

Specify the AML classification3

Did AML transform from MDS or MPN?4

yes - Also complete MDS Disease Classification questions

no

Is the disease (AML) therapy related?

yes no Unknown

5

Did the recipient have a predisposing condition?

yes no Unknown

6

Specify condition7

Bloom syndrome

Down syndrome

Fanconi anemia

Dyskeratosis congenita

Other condition

Specify other condition:8

Were cytogenetics tested (karyotyping or FISH)? (at diagnosis)

yes no Unknown

9

Were cytogenetics tested via FISH? (at diagnosis)

Yes No

10

Results of tests11

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities12

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

13

Specify other abnormality:14

Were cytogenetics tested via karyotyping? (at diagnosis)

Yes No

15

Results of tests16

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities17

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

18

Specify other abnormality:19

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

20

Were tests for molecular markers performed? (e.g. PCR, NGS) (at diagnosis)

yes no Unknown

21

CEBPA

Positive Negative Not Done

22

Specify CEBPA mutation23

Biallelic (homozygous)

Monoallelic (heterozygous)

Unknown

FLT3 – D835 point mutation

Positive Negative Not Done

24

FLT3 – ITD mutation

Positive Negative Not Done

25

FLT3 - ITD allelic ratio

Known Unknown

26

Specify FLT3 - ITD allelic ratio:27

IDH1

Positive Negative Not Done

28

IDH2

Positive Negative Not Done

29

KIT

Positive Negative Not Done

30

NPM1

Positive Negative Not Done

31

Other Molecular Marker (1) Questions: 32 - 33

Other molecular marker

Positive Negative Not Done

32

Specify other molecular marker:33

Were cytogenetics tested (karyotyping or FISH)? (between diagnosis and last evaluation)

yes no Unknown

34

Were cytogenetics tested via FISH? (between diagnosis and last evaluation)

Yes No

35

Results of tests36

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities37

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

38

Specify other abnormality:39

Were cytogenetics tested via karyotyping? (between diagnosis and last evaluation)

Yes No

40

Results of tests41

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities42

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

43

Specify other abnormality:44

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

45

Were tests for molecular markers performed? (e.g. PCR, NGS) (between diagnosis and last evaluation)

yes no Unknown

46

CEBPA

Positive Negative Not Done

47

Specify CEBPA mutation48

Biallelic (homozygous)

Monoallelic (heterozygous)

Unknown

FLT3 – D835 point mutation

Positive Negative Not Done

49

FLT3 – ITD mutation

Positive Negative Not Done

50

FLT3 - ITD allelic ratio

Known Unknown

51

Specify FLT3 - ITD allelic ratio:52

IDH1

Positive Negative Not Done

53

IDH2

Positive Negative Not Done

54

KIT

Positive Negative Not Done

55

NPM1

Positive Negative Not Done

56

Other Molecular Marker (1) Questions: 57 - 58

Other molecular marker

Positive Negative Not Done

57

Specify other molecular marker:58

Were cytogenetics tested (karyotyping or FISH)? (at last evaluation)

yes no Unknown

59

Were cytogenetics tested via FISH? (at last evaluation)

Yes No

60

Results of tests61

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities62

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

63

Specify other abnormality:64

Were cytogenetics tested via karyotyping? (at last evaluation)

Yes No

65

Results of tests66

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities67

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

68

Specify other abnormality:69

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

70

Were tests for molecular markers performed? (e.g. PCR, NGS) (at last evaluation)

yes no Unknown

71

CEBPA

Positive Negative Not Done

72

Specify CEBPA mutation73

Biallelic (homozygous)

Monoallelic (heterozygous)

Unknown

FLT3 – D835 point mutation

Positive Negative Not Done

74

FLT3 – ITD mutation

Positive Negative Not Done

75

FLT3 - ITD allelic ratio

Known Unknown

76

Specify FLT3 - ITD allelic ratio:77

IDH1

Positive Negative Not Done

78

IDH2

Positive Negative Not Done

79

KIT

Positive Negative Not Done

80

NPM1

Positive Negative Not Done

81

Other Molecular Marker (1) Questions: 82 - 83

Other molecular marker

Positive Negative Not Done

82

Specify other molecular marker:83

Did the recipient have central nervous system leukemia at any time prior to the start of the preparative regimen / infusion?

yes no Unknown

84

What was the disease status (based on hematological test results)?85

Primary induction failure

1st complete remission (no previous bone marrow or extramedullary relapse) (include CRi)

2nd complete remission

≥3rd complete remission

1st relapse

2nd relapse

≥3rd relapse

No treatment

How many cycles of induction therapy were required to achieve 1st complete remission? (includes CRi)

1 2 ≥ 3

86

Was the recipient in remission by flow cytometry?

Yes No Unknown Not applicable

87

Date of most recent relapse:88 __ __ __ __ - __ __- __ __

Date assessed:89 __ __ __ __ - __ __- __ __

Acute Lymphoblastic Leukemia (ALL) Questions: 90 - 151

Specify ALL classification90

Did the recipient have a predisposing condition?

yes no Unknown

91

Specify condition92

Aplastic anemia - Also complete CIBMTR Form 2028 - APL

Bloom syndrome

Down syndrome

Fanconi anemia - Also complete CIBMTR Form 2029 - FAN

Other condition

Specify other condition:93

Were tyrosine kinase inhibitors given for therapy at any time prior to the start of the preparative regimen / infusion? (e.g. imatinib mesylate, dasatinib, etc.)

yes no

94

Were cytogenetics tested (karyotyping or FISH)? (at diagnosis)

yes no Unknown

95

Were cytogenetics tested via FISH? (at diagnosis)

Yes No

96

Results of tests97

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities98

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

99

Specify other abnormality:100

Were cytogenetics tested via karyotyping? (at diagnosis)

Yes No

101

Results of tests102

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities103

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

104

Specify other abnormality:105

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

106

Were tests for molecular markers performed? (e.g. PCR, NGS) (at diagnosis)

yes no Unknown

107

BCR / ABL

Positive Negative Not Done

108

TEL-AML / AML1

Positive Negative Not Done

109

Other Molecular Marker (1) Questions: 110 - 111

Other molecular marker

Positive Negative Not Done

110

Specify other molecular marker:111

Were cytogenetics tested (karyotyping or FISH)? (between diagnosis and last evaluation)

yes no Unknown

112

Were cytogenetics tested via FISH? (between diagnosis and last evaluation)

Yes No

113

Results of tests114

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities115

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

116

Specify other abnormality:117

Were cytogenetics tested via karyotyping? (between diagnosis and last evaluation)

Yes No

118

Results of tests119

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities120

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

121

Specify other abnormality:122

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

123

Were tests for molecular markers performed? (e.g. PCR, NGS) (between diagnosis and last evaluation)

yes no Unknown

124

BCR / ABL

Positive Negative Not Done

125

TEL-AML / AML1

Positive Negative Not Done

126

Other Molecular Marker (1) Questions: 127 - 128

Other molecular marker

Positive Negative Not Done

127

Specify other molecular marker:128

Were cytogenetics tested (karyotyping or FISH)? (at last evaluation)

yes no Unknown

129

Were cytogenetics tested via FISH? (at last evaluation)

Yes No

130

Results of tests131

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities132

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

133

Specify other abnormality:134

Were cytogenetics tested via karyotyping? (at last evaluation)

Yes No

135

Results of tests136

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities137

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

138

Specify other abnormality:139

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

140

Were tests for molecular markers performed? (e.g. PCR, NGS) (at last evaluation)

yes no Unknown

141

BCR / ABL

Positive Negative Not Done

142

TEL-AML / AML1

Positive Negative Not Done

143

Other Molecular Marker (1) Questions: 144 - 145

Other molecular marker

Positive Negative Not Done

144

Specify other molecular marker:145

Did the recipient have central nervous system leukemia at any time prior to the start of the preparative regimen / infusion?

yes no Unknown

146

What was the disease status (based on hematological test results)?147

Primary induction failure

1st complete remission (no previous marrow or extramedullary relapse) (include CRi)

2nd complete remission

≥3rd complete remission

1st relapse

2nd relapse

≥3rd relapse

No treatment

How many cycles of induction therapy were required to achieve 1st complete remission? (include CRi)

1 2 ≥ 3

148

Was the recipient in remission by flow cytometry?

Yes No Unknown Not applicable

149

Date of most recent relapse:150 __ __ __ __ - __ __- __ __

Date assessed:151 __ __ __ __ - __ __- __ __

Acute Leukemias of Ambiguous Lineage and Other Myeloid Neoplasms Questions: 152 - 155

Specify acute leukemias of ambiguous lineage and other myeloid neoplasm classification152

Blastic plasmacytoid dendritic cell neoplasm (296)

Acute undifferentiated leukemia (31)

Mixed phenotype acute leukemia (MPAL) with t(9;22)(q34.1;q11.2); BCR-ABL1 (84)

Mixed phenotype acute leukemia with t(v; 11q23.3); KMT2A rearranged (85)

Mixed phenotype acute leukemia, B/myeloid, NOS (86)

Mixed phenotype acute leukemia, T/myeloid, NOS (87)

Other acute leukemia of ambiguous lineage or myeloid neoplasm (88)

Specify other acute leukemia of ambiguous lineage or myeloid neoplasm:153

What was the disease status (based on hematological test results)?154

Primary induction failure

1st complete remission (no previous marrow or extramedullary relapse)

2nd complete remission

≥3rd complete remission

1st relapse

2nd relapse

≥3rd relapse

No treatment

Date assessed:155 __ __ __ __ - __ __- __ __

Chronic Myelogenous Leukemia (CML) Questions: 156 - 166

Was therapy given prior to this HCT?

yes no

156

Combination chemotherapy

yes no

157

Hydroxyurea (Droxia, Hydrea)

yes no

158

Tyrosine kinase inhibitor (e.g. imatinib mesylate, dasatinib, nilotinib)

yes no

159

Interferon­α (Intron, Roferon) (includes PEG)

yes no

160

Other therapy

yes no

161

Specify other therapy:162

What was the disease status?163

Complete hematologic response (CHR)

Chronic phase

Accelerated phase

Blast phase

Specify level of response164

No cytogenetic response (No CyR)

Minimal cytogenetic response

Minor cytogenetic response

Partial cytogenetic response (PCyR)

Complete cytogenetic response (CCyR)

Major molecular remission (MMR)

Complete molecular remission (CMR)

Number

1st 2nd 3rd or higher

165

Date assessed:166 __ __ __ __ - __ __- __ __

Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases Questions: 167 - 260

What was the MDS / MPN subtype at diagnosis? - If transformed to AML, indicate AML as primary disease; also complete AML Disease Classification
questions

167

Was the disease (MDS/MPN) therapy related?

yes no Unknown

168

Did the recipient have a predisposing condition?

yes no Unknown

169

Specify condition

Aplastic Anemia Bloom syndrome Down syndrome Fanconi anemia Other condition

170

Specify other condition:171

WBC

Known Unknown

172

173 x 109/L (x 103/mm3)

x 106/L

Hemoglobin

Known Unknown

174

175 g/dL g/L mmol/L

Was RBC transfused ≤ 30 days before date of test?

Yes No

176

Platelets

Known Unknown

177

178 x 109/L (x 103/mm3)

x 106/L

Were platelets transfused ≤ 7 days before date of test?

Yes No

179

Neutrophils

Known Unknown

180

181 %

Blasts in bone marrow

Known Unknown

182

183 %

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

184

Results of tests185

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities186

One (1)

Two (2)

Three (3)

Four or more (4 or more)

–5

yes no

187

-7

yes no

188

–13

yes no

189

–20

yes no

190

–Y

yes no

191

+8

yes no

192

+19

yes no

193

t(1;3)

yes no

194

t(2;11)

yes no

195

t(3;3)

yes no

196

t(3;21)

yes no

197

t(6;9)

yes no

198

t(11;16)

yes no

199

del(3q) / 3q–

yes no

200

del(5q) / 5q-

yes no

201

del(7q) / 7q–

yes no

202

del(9q) / 9q–

yes no

203

del(11q) / 11q–

yes no

204

del(12p) / 12p–

yes no

205

del(13q) / 13q-

yes no

206

del(20q) / 20q–

yes no

207

inv(3)

yes no

208

i17q

yes no

209

Other abnormality

yes no

210

Specify other abnormality:211

Did the recipient progress or transform to a different MDS / MPN subtype between diagnosis and the start of the preparative regimen?

yes no

212

Specify the MDS / MPN classification after transformation:213

Specify the date of the most recent transformation:214 __ __ __ __ - __ __- __ __

Date of MDS diagnosis:215 __ __ __ __ - __ __- __ __

WBC

Known Unknown

216

217 x 109/L (x 103/mm3)

x 106/L

Hemoglobin

Known Unknown

218

219 g/dL g/L mmol/L

Was RBC transfused ≤ 30 days before date of test?

Yes No

220

Platelets

Known Unknown

221

222 x 109/L (x 103/mm3)

x 106/L

Were platelets transfused ≤ 7 days before date of test?

Yes No

223

Neutrophils

Known Unknown

224

225 %

Blasts in bone marrow

Known Unknown

226

227 %

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

228

Results of tests229

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities230

One (1)

Two (2)

Three (3)

Four or more (4 or more)

–5

yes no

231

-7

yes no

232

–13

yes no

233

–20

yes no

234

–Y

yes no

235

+8

yes no

236

+19

yes no

237

t(1;3)

yes no

238

t(2;11)

yes no

239

t(3;3)

yes no

240

t(3;21)

yes no

241

t(6;9)

yes no

242

t(11;16)

yes no

243

del(3q) / 3q–

yes no

244

del(5q) / 5q-

yes no

245

del(7q) / 7q–

yes no

246

del(9q) / 9q–

yes no

247

del(11q) / 11q–

yes no

248

del(12p) / 12p–

yes no

249

del(13q) / 13q-

yes no

250

del(20q) / 20q–

yes no

251

inv(3)

yes no

252

i17q

yes no

253

Other abnormality

yes no

254

Specify other abnormality:255

What was the disease status?256

Complete
remission

(CR)

– requires all of the following, maintained for ≥ 4 weeks: * bone marrow evaluation: <  5% myeloblasts with normal maturation of all cell lines *
peripheral blood evaluation: hemoglobin ≥ 11 g/dL untransfused and without erythropoietin support; ANC ≥ 1000/mm3  without myeloid growth factor
support; platelets ≥ 100 x 109/L without thrombopoietic support; 0% blasts

Hematologic

improvement
(HI)

– requires one measurement of the following, maintained for ≥ 8 weeks without ongoing cytotoxic therapy; specify which cell line was measured to
determine HI response: * HI­E – hemoglobin increase of ≥ 1.5 g/dL untransfused; for RBC transfusions performed for Hgb ≤ 9.0, reduction in RBC
units transfused in 8 weeks by ≥ 4 units compared to the pre­treatment transfusion number in 8 weeks * HI­P – for pre­treatment platelet count of > 20
x 109/L, platelet absolute increase of ≥ 30 x 109/L; for pre-treatment platelet count of < 20 x 109/L, platelet absolute increase of ≥ 20 x 109/L and ≥
100% from pre­treatment level  * HI­N – neutrophil count increase of ≥ 100% from pre­treatment level and an absolute increase of ≥ 500/mm3

No response (NR) / stable disease (SD) – does not meet the criteria for at least HI, but no evidence of disease progression

Progression from
hematologic improvement

(Prog from HI)

– requires at least one of the following, in the absence of another explanation (e.g., infection, bleeding, ongoing chemotherapy, etc.): *
≥ 50% reduction from maximum response levels in granulocytes or platelets * reduction in hemoglobin by ≥ 1.5 g/dL *transfusion
dependence

Relapse from complete

remission (Rel from CR)

– requires at least one of the following: * return to pre­treatment bone marrow blast percentage * decrease of ≥ 50% from maximum
response levels in granulocytes or platelets * transfusion dependence, or hemoglobin level ≥ 1.5 g/dL lower than prior to therapy

Not assessed

Specify the cell line examined to determine HI status257

HI-
E

– hemoglobin increase of ≥ 1.5 g/dL untransfused; for RBC transfusions performed for Hgb ≤ 9.0, reduction in RBC units transfused in 8 weeks by ≥ 4
units compared to the pre-treatment transfusion number in 8 weeks

HI-
P

– for pre­treatment platelet count of > 20 x 109/L, platelet absolute increase of ≥ 30 x 109/L; for pre-treatment platelet count of < 20 x 109/L, platelet
absolute increase of ≥ 20 x 109/L and ≥ 100% from pre­treatment level 

HI-N – neutrophil count increase of ≥ 100% from pre­treatment level and an absolute increase of ≥ 500/mm3

Date of progression:258 __ __ __ __ - __ __- __ __

Date of relapse:259 __ __ __ __ - __ __- __ __

Date assessed:260 __ __ __ __ - __ __- __ __

Other Leukemia (OL) Questions: 261 - 267

Specify the other leukemia classification261

Specify other leukemia:262

Was any 17p abnormality detected?

yes no

263

Did a histologic transformation to diffuse large B-cell lymphoma (Richter syndrome) occur at any time after CLL diagnosis?264

yes - Also complete NHL Disease Classification questions

no

What was the disease status? (Atypical CML)265

Primary induction failure

1st complete remission (no previous bone marrow or extramedullary relapse)

2nd complete remission

≥3rd complete remission

1st relapse

2nd relapse

≥3rd relapse

No treatment

What was the disease status? (CLL, PLL, Hairy cell leukemia)266

Complete remission (CR)

Partial remission (PR)

Stable disease (SD)

Progressive disease (Prog)

Untreated

Not assessed

Date assessed:267 __ __ __ __ - __ __- __ __

Hodgkin and Non-Hodgkin Lymphoma Questions: 268 - 285

Specify the lymphoma histology (at infusion)268

Specify other lymphoma histology:269

Assignment of DLBCL (germinal center B-cell type vs. activated B-cell type) subtype was based on270

Immunohistochemistry (e.g. Han's algorithm)

Gene expression profile

Unknown method

Is the lymphoma histology reported at transplant a transformation from CLL?

yes no

271

Was any 17p abnormality detected?

yes no

272

Is the lymphoma histology reported at transplant a transformation from a different lymphoma histology? (Not CLL)

Yes No

273

Specify the original lymphoma histology (prior to transformation)274

Specify other lymphoma histology:275

Date of original lymphoma diagnosis:276 __ __ __ __ - __ __- __ __ (report the date of diagnosis of original lymphoma subtype)

Was a PET (or PET/CT) scan performed? (at last evaluation prior to the start of the preparative regimen / infusion)

yes no

277

Was the PET (or PET/CT) scan positive for lymphoma involvement at any disease site?

yes no

278

Date of PET scan

Known Unknown

279

Date of PET (or PET/CT) scan:280 __ __ __ __ - __ __- __ __

Deauville (five-point) score of the PET (or PET/CT) scan

Known Unknown

281

Scale282

1 - no uptake or residual uptake

2 - slight uptake, but below blood pool (mediastinum)

3 - uptake above mediastinal, but below or equal to uptake in the liver

4 - uptake slightly to moderately higher than liver

5 - markedly increased uptake or any new lesions

What was the disease status?283

Total number of lines of therapy received

1 line 2 lines 3+ lines

284

Date assessed:285 __ __ __ __ - __ __- __ __

Multiple Myeloma / Plasma Cell Disorder (PCD) Questions: 286 - 317

Specify the multiple myeloma/plasma cell disorder (PCD) classification286

Specify other plasma cell disorder:287

Light chain

kappa lambda

288

What was the Durie-Salmon staging? (at diagnosis)289

Stage
I

(All of the following: Hgb > 10g/dL; serum calcium normal or <10.5 mg/dL; bone x-ray normal bone structure (scale 0), or solitary bone plasmacytoma
only; low M-component production rates IgG< 5g/dL, IgA < 3g/dL; urine light chain M-component on electrophoresis <4 g/24h)

Stage II (Fitting neither Stage I or III) 

Stage
III

(One or more of the following: Hgb < 8.5 g/dL; serum calcium > 12 mg/dL; advanced lytic bone lesions (scale 3); high M-component production rates
IgG > 7g/dL, IgA > 5 g/dL; Bence Jones protein > 12g/24h)

Unknown

What was the Durie-Salmon sub classification? (at diagnosis)290

A - relatively normal renal function (serum creatinine < 2.0 mg/dL)

B ­ abnormal renal function (serum creatinine ≥ 2.0 mg/dL)

Serum β2­microglobulin:291 μg/dL mg/L nmol/L

Serum albumin:292 g/dL g/L

Stage293

1 (β2 ­mic < 3.5, S. albumin ≥3.5)

2 (Not fitting stage 1 or 3)

3 (β2­mic ≥ 5.5; S. albumin ­)

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

294

Results of tests295

Abnormalities identified

No evaluable metaphases

No abnormalities

+3

yes no

296

+5

yes no

297

+7

yes no

298

+9

yes no

299

+11

yes no

300

+15

yes no

301

+19

yes no

302

t(4;14)

yes no

303

t(6;14)

yes no

304

t(11;14)

yes no

305

t(14;16)

yes no

306

t(14;20)

yes no

307

del(13q) / 13q-

yes no

308

del (17p) / 17p-

yes no

309

Hyperdiploid (>50)

yes no

310

Hypodiploid (<46)

yes no

311

Any abnormality at 1q

yes no

312

Any abnormality at 1p

yes no

313

Other abnormality

yes no

314

Specify other abnormality:315

What was the disease status?316

Stringent
complete

remission
(sCR)

- CR as defined, plus: normal free light chain ratio, and absence of clonal cells in the bone marrow by immunohistochemistry of immunofluorescence
(confirmation with repeat bone marrow biopsy not needed). (Presence and/or absence of clonal cells is based upon the Κ/λ ratio. An abnormal Κ/λ ratio by
immunohistochemistry and/or immunofluorescence requires a minimum of 100 plasma cells for analysis.  An abnormal ratio reflecting the presence of
an abnormal clone is Κ/λ of > 4:1 or < 1:2.) sCR requires two consecutive assessments made at any time before the institution of any new therapy, and
no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy sCR
requirements. 

Complete
remission

(CR)

- negative immunofixation on serum and urine samples, and disappearance of any soft tissue plasmacytomas, and < 5% plasma cells in the bone
marrow (confirmation with repeat bone marrow biopsy not needed).  CR requires two consecutive assessments made at any time before the institution

of any new therapy, and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not
required to satisfy CR requirements. 

Near
complete
remission
(nCR)

- serum and urine M-protein detectable by immunoelectrophoresis (IFE), but not on electrophoresis (negative SPEP & UPEP); < 5% plasma cells in
bone marrow.  nCR requires two consecutive assessments made at any time before the initiation of any new therapy, and no known evidence of
progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy nCR requirements. 

Very good
partial
remission
(VGPR)

­ serum and urine M­protein detectable by immunofixation but not on electrophoresis, or ≥ 90% reduction in serum M­protein and urine M­protein level <
100 mg/24 hours.  VGPR requires two consecutive assessments made at any time before the institution of any new therapy, and no known evidence of
progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy VGPR requirements.

Partial
remission
(PR)

­ ≥ 50% reduction in serum M­protein, and reduction in 24­hour urinary M­protein by ≥ 90% or to < 200 mg/24 hours.  If the serum and urine M­protein are
unmeasurable (i.e., do not meet any of the following criteria: • serum M­protein ≥ 1 g/dL.  Urine M­protein ≥ 200 mg/24 hours • serum free light chain
assay shows involved level ≥ 10 mg/dL, provided serum free light chain ratio is abnormal), a ≥ 50% decrease in the difference between involved and
uninvolved free light chain levels is required in place of the M-protein criteria.  If serum and urine M-protein are unmeasurable, and serum free light assay
is also unmeasurable, a ≥ 50% reduction in plasma cells is required in place of M­protein, provided the baseline bone marrow plasma cell percentage
was ≥ 30%. In addition to the above listed criteria, a ≥ 50% reduction in the size of soft tissue plasmacytomas is also required, if present at baseline. PR
requires two consecutive assessments made at any time before the institution of any new therapy, and no known evidence of progressive or new bone
lesions if radiographic studies were performed; radiographic studies are not required to satisfy PR requirements. 

Stable
disease
(SD)

- not meeting the criteria for CR, VGPR, PR or PD.  SD requires two consecutive assessments made at any time before the institution of any new therapy,
and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy SD
requirements.

Progressive
disease
(PD)

­ requires any one or more of the following:  Increase of ≥ 25% from baseline in:  serum M­component and/or (absolute increase ≥ 0.5 g/dL) (for
progressive disease, serum M­component increases of ≥ 1 g/dL are sufficient to define relapse if the starting M­component is ≥ 5 g/dL).  Urine M­
component and/or (absolute increase ≥ 200 mg/24 hours) for recipients without measurable serum and urine M­protein levels: the difference between
involved and uninvolved free light chain levels (absolute increase > 10 mg/dL).  Bone marrow plasma cell percentage (absolute percentage ≥ 10%)
(relapse from CR has a 5% cutoff vs. 10% for other categories of relapse) definite development of new bone lesions or soft tissue plasmacytomas, or
definite increase in the size of any existing  bone lesions or soft tissue plasmacytomas. Development of hypercalcemia (corrected serum calcium >
11.5 mg/dL or 2.65 mmol) that can be attributed solely to the plasma cell proliferative disorder.  PD requires two consecutive assessments made at
any time before classification as disease progression, and/or the institution of any new therapy.

Relapse
from CR
(Rel)
(untreated)

­ requires one or more of the following: reappearance of serum or urine M­protein by immunofixation or electrophoresis development of ≥ 5% plasma
cells in the bone marrow (relapse from CR has a 5% cutoff vs. 10% for other categories of relapse) appearance of any other sign of progression (e.g.,
new plasmacytoma, lytic bone lesion, hypercalcemia).  Rel requires two consecutive assessments made at any time before classification as relapse,
and/or the institution of any new therapy.

Unknown

Not applicable (Amyloidosis with no evidence of myeloma)

Date assessed:317 __ __ __ __ - __ __- __ __

Solid Tumors Questions: 318 - 319

Specify the solid tumor classification318

Specify other solid tumor:319

Severe Aplastic Anemia Questions: 320 - 321

Specify the severe aplastic anemia classification320

Specify other acquired cytopenic syndrome:321

Inherited Abnormalities of Erythrocyte Differentiation or Function Questions: 322 - 324

Specify the inherited abnormalities of erythrocyte differentiation or function classification322

Specify other constitutional anemia:323

Specify other hemoglobinopathy:324

Disorders of the Immune System Questions: 325 - 327

Specify disorder of immune system classification325

Specify other SCID:326

Specify other immunodeficiency:327

Inherited Abnormalities of Platelets Questions: 328 - 329

Specify inherited abnormalities of platelets classification328

Congenital amegakaryocytosis / congenital thrombocytopenia (501)

Glanzmann thrombasthenia (502)

Other inherited platelet abnormality (509)

Specify other inherited platelet abnormality:329

Inherited Disorders of Metabolism Questions: 330 - 331

Specify inherited disorders of metabolism classification330

Specify other inherited metabolic disorder:331

Histiocytic Disorders Questions: 332 - 333

Specify histiocytic disorder classification332

Specify other histiocytic disorder:333

Autoimmune Diseases Questions: 334 - 341

Specify autoimmune disease classification334

Specify other arthritis:335

Specify other juvenile idiopathic arthritis (JIA):336

Specify other connective tissue disease:337

Specify other vasculitis:338

Specify other autoimmune neurological disorder:339

Specify other autoimmune cytopenia:340

Specify other autoimmune bowel disorder:341

Other Disease Questions: 342 - 342

Specify other disease:342

First Name:

Last Name:

E-mail address:

Date: __ __ __ __ - __ __- __ __

OMB No: 0915-0310

Expiration Date: 1/31/2020

Public Burden Statement:  An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control
number.  The OMB control number for this project is 0915-0310.  Public reporting burden for this collection of information is estimated to average 1.0 hours per response, including the
time for reviewing instructions, searching existing data sources, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other
aspect of this collection of information, including suggestions for reducing this burden, to HRSA Reports Clearance Officer, 5600 Fishers Lane, Room 10-29, Rockville, Maryland, 20857.

Labs at diagnosis

Specify cytogenetic abnormalities identified at diagnosis:

Specify cytogenetic abnormalities identified at diagnosis:

Specify molecular markers identified at diagnosis:

Labs between diagnosis and last evaluation:

Specify cytogenetic abnormalities identified between diagnosis and last evaluation:

Specify cytogenetic abnormalities identified between diagnosis and last evaluation:

Specify molecular markers identified between diagnosis and last evaluation:

Labs at last evaluation:

Specify cytogenetic abnormalities identified at last evaluation:

Specify cytogenetic abnormalities identified at last evaluation:

Specify molecular markers identified at last evaluation:

CNS Leukemia

Status at transplantation:

Laboratory studies at diagnosis:

Specify cytogenetic abnormalities identified at diagnosis:

Specify cytogenetic abnormalities identified at diagnosis:

Specify molecular markers identified at diagnosis:

Laboratory studies between diagnosis and last evaluation:

Specify cytogenetic abnormalities identified between diagnosis and last evaluation:

Specify cytogenetic abnormalities identified between diagnosis and last evaluation:

Specify molecular markers identified between diagnosis and last evaluation:

Laboratory studies at last evaluation:

Specify cytogenetic abnormalities identified at last evaluation:

Specify cytogenetic abnormalities identified at last evaluation:

Specify molecular markers identified at last evaluation:

CNS Leukemia

Status at transplantation:

Status at transplantation:

Laboratory studies at diagnosis of MDS:

Specify abnormalities identified at diagnosis:

Monosomy

Trisomy

Translocation

Deletion

Inversion

Other

Laboratory studies at last evaluation prior to the start of the preparative regimen:

Specify cytogenetic abnormalities identified at last evaluation prior to the start of the preparative regimen:

Monosomy

Trisomy

Translocation

Deletion

Inversion

Other

Status at transplantation:

Status at transplantation:

Status at transplantation / infusion:

I.S.S.:

Specify cytogenetic abnormalities identified at any time prior to the start of the preparative regimen:

Trisomy

Translocation

Deletion

Other

Status at transplantation:

Center: CRID: 

Form 2402 R3.0: Disease Classification

CIBMTR Form 2402 revision 3.0 last updated Monday, January 29, 2018
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 9 / 26



Key Fields

Sequence Number:

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number:

CIBMTR Research ID:

Event date: __ __ __ __ - __ __- __ __

Primary Disease for HCT / Cellular Therapy Questions: 1 - 2

Date of diagnosis of primary disease for HCT / cellular therapy:1 __ __ __ __ - __ __- __ __

What was the primary disease for which the HCT / cellular therapy was performed?2

Acute myelogenous leukemia (AML or ANLL) (10)

Acute lymphoblastic leukemia (ALL) (20)

Acute leukemia of ambiguous lineage and other myeloid neoplasms (80)

Chronic myelogenous leukemia (CML) (40)

Myelodysplastic (MDS) / myeloproliferative (MPN) diseases (50) (Please classify all preleukemias) (If recipient has transformed to AML, indicate AML as the primary disease)

Other leukemia (30) (includes CLL)

Hodgkin lymphoma (150)

Non-Hodgkin lymphoma (100)

Multiple myeloma / plasma cell disorder (PCD) (170)

Solid tumors (200)

Severe aplastic anemia (300) (If the recipient developed MDS or AML, indicate MDS or AML as the primary disease)

Inherited abnormalities of erythrocyte differentiation or function (310)

Disorders of the immune system (400)

Inherited abnormalities of platelets (500)

Inherited disorders of metabolism (520)

Histiocytic disorders (570)

Autoimmune diseases (600)

Other disease (900)

Acute Myelogenous Leukemia (AML) Questions: 3 - 89

Specify the AML classification3

Did AML transform from MDS or MPN?4

yes - Also complete MDS Disease Classification questions

no

Is the disease (AML) therapy related?

yes no Unknown

5

Did the recipient have a predisposing condition?

yes no Unknown

6

Specify condition7

Bloom syndrome

Down syndrome

Fanconi anemia

Dyskeratosis congenita

Other condition

Specify other condition:8

Were cytogenetics tested (karyotyping or FISH)? (at diagnosis)

yes no Unknown

9

Were cytogenetics tested via FISH? (at diagnosis)

Yes No

10

Results of tests11

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities12

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

13

Specify other abnormality:14

Were cytogenetics tested via karyotyping? (at diagnosis)

Yes No

15

Results of tests16

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities17

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

18

Specify other abnormality:19

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

20

Were tests for molecular markers performed? (e.g. PCR, NGS) (at diagnosis)

yes no Unknown

21

CEBPA

Positive Negative Not Done

22

Specify CEBPA mutation23

Biallelic (homozygous)

Monoallelic (heterozygous)

Unknown

FLT3 – D835 point mutation

Positive Negative Not Done

24

FLT3 – ITD mutation

Positive Negative Not Done

25

FLT3 - ITD allelic ratio

Known Unknown

26

Specify FLT3 - ITD allelic ratio:27

IDH1

Positive Negative Not Done

28

IDH2

Positive Negative Not Done

29

KIT

Positive Negative Not Done

30

NPM1

Positive Negative Not Done

31

Other Molecular Marker (1) Questions: 32 - 33

Other molecular marker

Positive Negative Not Done

32

Specify other molecular marker:33

Were cytogenetics tested (karyotyping or FISH)? (between diagnosis and last evaluation)

yes no Unknown

34

Were cytogenetics tested via FISH? (between diagnosis and last evaluation)

Yes No

35

Results of tests36

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities37

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

38

Specify other abnormality:39

Were cytogenetics tested via karyotyping? (between diagnosis and last evaluation)

Yes No

40

Results of tests41

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities42

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

43

Specify other abnormality:44

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

45

Were tests for molecular markers performed? (e.g. PCR, NGS) (between diagnosis and last evaluation)

yes no Unknown

46

CEBPA

Positive Negative Not Done

47

Specify CEBPA mutation48

Biallelic (homozygous)

Monoallelic (heterozygous)

Unknown

FLT3 – D835 point mutation

Positive Negative Not Done

49

FLT3 – ITD mutation

Positive Negative Not Done

50

FLT3 - ITD allelic ratio

Known Unknown

51

Specify FLT3 - ITD allelic ratio:52

IDH1

Positive Negative Not Done

53

IDH2

Positive Negative Not Done

54

KIT

Positive Negative Not Done

55

NPM1

Positive Negative Not Done

56

Other Molecular Marker (1) Questions: 57 - 58

Other molecular marker

Positive Negative Not Done

57

Specify other molecular marker:58

Were cytogenetics tested (karyotyping or FISH)? (at last evaluation)

yes no Unknown

59

Were cytogenetics tested via FISH? (at last evaluation)

Yes No

60

Results of tests61

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities62

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

63

Specify other abnormality:64

Were cytogenetics tested via karyotyping? (at last evaluation)

Yes No

65

Results of tests66

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities67

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

68

Specify other abnormality:69

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

70

Were tests for molecular markers performed? (e.g. PCR, NGS) (at last evaluation)

yes no Unknown

71

CEBPA

Positive Negative Not Done

72

Specify CEBPA mutation73

Biallelic (homozygous)

Monoallelic (heterozygous)

Unknown

FLT3 – D835 point mutation

Positive Negative Not Done

74

FLT3 – ITD mutation

Positive Negative Not Done

75

FLT3 - ITD allelic ratio

Known Unknown

76

Specify FLT3 - ITD allelic ratio:77

IDH1

Positive Negative Not Done

78

IDH2

Positive Negative Not Done

79

KIT

Positive Negative Not Done

80

NPM1

Positive Negative Not Done

81

Other Molecular Marker (1) Questions: 82 - 83

Other molecular marker

Positive Negative Not Done

82

Specify other molecular marker:83

Did the recipient have central nervous system leukemia at any time prior to the start of the preparative regimen / infusion?

yes no Unknown

84

What was the disease status (based on hematological test results)?85

Primary induction failure

1st complete remission (no previous bone marrow or extramedullary relapse) (include CRi)

2nd complete remission

≥3rd complete remission

1st relapse

2nd relapse

≥3rd relapse

No treatment

How many cycles of induction therapy were required to achieve 1st complete remission? (includes CRi)

1 2 ≥ 3

86

Was the recipient in remission by flow cytometry?

Yes No Unknown Not applicable

87

Date of most recent relapse:88 __ __ __ __ - __ __- __ __

Date assessed:89 __ __ __ __ - __ __- __ __

Acute Lymphoblastic Leukemia (ALL) Questions: 90 - 151

Specify ALL classification90

Did the recipient have a predisposing condition?

yes no Unknown

91

Specify condition92

Aplastic anemia - Also complete CIBMTR Form 2028 - APL

Bloom syndrome

Down syndrome

Fanconi anemia - Also complete CIBMTR Form 2029 - FAN

Other condition

Specify other condition:93

Were tyrosine kinase inhibitors given for therapy at any time prior to the start of the preparative regimen / infusion? (e.g. imatinib mesylate, dasatinib, etc.)

yes no

94

Were cytogenetics tested (karyotyping or FISH)? (at diagnosis)

yes no Unknown

95

Were cytogenetics tested via FISH? (at diagnosis)

Yes No

96

Results of tests97

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities98

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

99

Specify other abnormality:100

Were cytogenetics tested via karyotyping? (at diagnosis)

Yes No

101

Results of tests102

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities103

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

104

Specify other abnormality:105

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

106

Were tests for molecular markers performed? (e.g. PCR, NGS) (at diagnosis)

yes no Unknown

107

BCR / ABL

Positive Negative Not Done

108

TEL-AML / AML1

Positive Negative Not Done

109

Other Molecular Marker (1) Questions: 110 - 111

Other molecular marker

Positive Negative Not Done

110

Specify other molecular marker:111

Were cytogenetics tested (karyotyping or FISH)? (between diagnosis and last evaluation)

yes no Unknown

112

Were cytogenetics tested via FISH? (between diagnosis and last evaluation)

Yes No

113

Results of tests114

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities115

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

116

Specify other abnormality:117

Were cytogenetics tested via karyotyping? (between diagnosis and last evaluation)

Yes No

118

Results of tests119

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities120

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

121

Specify other abnormality:122

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

123

Were tests for molecular markers performed? (e.g. PCR, NGS) (between diagnosis and last evaluation)

yes no Unknown

124

BCR / ABL

Positive Negative Not Done

125

TEL-AML / AML1

Positive Negative Not Done

126

Other Molecular Marker (1) Questions: 127 - 128

Other molecular marker

Positive Negative Not Done

127

Specify other molecular marker:128

Were cytogenetics tested (karyotyping or FISH)? (at last evaluation)

yes no Unknown

129

Were cytogenetics tested via FISH? (at last evaluation)

Yes No

130

Results of tests131

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities132

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

133

Specify other abnormality:134

Were cytogenetics tested via karyotyping? (at last evaluation)

Yes No

135

Results of tests136

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities137

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

138

Specify other abnormality:139

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

140

Were tests for molecular markers performed? (e.g. PCR, NGS) (at last evaluation)

yes no Unknown

141

BCR / ABL

Positive Negative Not Done

142

TEL-AML / AML1

Positive Negative Not Done

143

Other Molecular Marker (1) Questions: 144 - 145

Other molecular marker

Positive Negative Not Done

144

Specify other molecular marker:145

Did the recipient have central nervous system leukemia at any time prior to the start of the preparative regimen / infusion?

yes no Unknown

146

What was the disease status (based on hematological test results)?147

Primary induction failure

1st complete remission (no previous marrow or extramedullary relapse) (include CRi)

2nd complete remission

≥3rd complete remission

1st relapse

2nd relapse

≥3rd relapse

No treatment

How many cycles of induction therapy were required to achieve 1st complete remission? (include CRi)

1 2 ≥ 3

148

Was the recipient in remission by flow cytometry?

Yes No Unknown Not applicable

149

Date of most recent relapse:150 __ __ __ __ - __ __- __ __

Date assessed:151 __ __ __ __ - __ __- __ __

Acute Leukemias of Ambiguous Lineage and Other Myeloid Neoplasms Questions: 152 - 155

Specify acute leukemias of ambiguous lineage and other myeloid neoplasm classification152

Blastic plasmacytoid dendritic cell neoplasm (296)

Acute undifferentiated leukemia (31)

Mixed phenotype acute leukemia (MPAL) with t(9;22)(q34.1;q11.2); BCR-ABL1 (84)

Mixed phenotype acute leukemia with t(v; 11q23.3); KMT2A rearranged (85)

Mixed phenotype acute leukemia, B/myeloid, NOS (86)

Mixed phenotype acute leukemia, T/myeloid, NOS (87)

Other acute leukemia of ambiguous lineage or myeloid neoplasm (88)

Specify other acute leukemia of ambiguous lineage or myeloid neoplasm:153

What was the disease status (based on hematological test results)?154

Primary induction failure

1st complete remission (no previous marrow or extramedullary relapse)

2nd complete remission

≥3rd complete remission

1st relapse

2nd relapse

≥3rd relapse

No treatment

Date assessed:155 __ __ __ __ - __ __- __ __

Chronic Myelogenous Leukemia (CML) Questions: 156 - 166

Was therapy given prior to this HCT?

yes no

156

Combination chemotherapy

yes no

157

Hydroxyurea (Droxia, Hydrea)

yes no

158

Tyrosine kinase inhibitor (e.g. imatinib mesylate, dasatinib, nilotinib)

yes no

159

Interferon­α (Intron, Roferon) (includes PEG)

yes no

160

Other therapy

yes no

161

Specify other therapy:162

What was the disease status?163

Complete hematologic response (CHR)

Chronic phase

Accelerated phase

Blast phase

Specify level of response164

No cytogenetic response (No CyR)

Minimal cytogenetic response

Minor cytogenetic response

Partial cytogenetic response (PCyR)

Complete cytogenetic response (CCyR)

Major molecular remission (MMR)

Complete molecular remission (CMR)

Number

1st 2nd 3rd or higher

165

Date assessed:166 __ __ __ __ - __ __- __ __

Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases Questions: 167 - 260

What was the MDS / MPN subtype at diagnosis? - If transformed to AML, indicate AML as primary disease; also complete AML Disease Classification
questions

167

Was the disease (MDS/MPN) therapy related?

yes no Unknown

168

Did the recipient have a predisposing condition?

yes no Unknown

169

Specify condition

Aplastic Anemia Bloom syndrome Down syndrome Fanconi anemia Other condition

170

Specify other condition:171

WBC

Known Unknown

172

173 x 109/L (x 103/mm3)

x 106/L

Hemoglobin

Known Unknown

174

175 g/dL g/L mmol/L

Was RBC transfused ≤ 30 days before date of test?

Yes No

176

Platelets

Known Unknown

177

178 x 109/L (x 103/mm3)

x 106/L

Were platelets transfused ≤ 7 days before date of test?

Yes No

179

Neutrophils

Known Unknown

180

181 %

Blasts in bone marrow

Known Unknown

182

183 %

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

184

Results of tests185

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities186

One (1)

Two (2)

Three (3)

Four or more (4 or more)

–5

yes no

187

-7

yes no

188

–13

yes no

189

–20

yes no

190

–Y

yes no

191

+8

yes no

192

+19

yes no

193

t(1;3)

yes no

194

t(2;11)

yes no

195

t(3;3)

yes no

196

t(3;21)

yes no

197

t(6;9)

yes no

198

t(11;16)

yes no

199

del(3q) / 3q–

yes no

200

del(5q) / 5q-

yes no

201

del(7q) / 7q–

yes no

202

del(9q) / 9q–

yes no

203

del(11q) / 11q–

yes no

204

del(12p) / 12p–

yes no

205

del(13q) / 13q-

yes no

206

del(20q) / 20q–

yes no

207

inv(3)

yes no

208

i17q

yes no

209

Other abnormality

yes no

210

Specify other abnormality:211

Did the recipient progress or transform to a different MDS / MPN subtype between diagnosis and the start of the preparative regimen?

yes no

212

Specify the MDS / MPN classification after transformation:213

Specify the date of the most recent transformation:214 __ __ __ __ - __ __- __ __

Date of MDS diagnosis:215 __ __ __ __ - __ __- __ __

WBC

Known Unknown

216

217 x 109/L (x 103/mm3)

x 106/L

Hemoglobin

Known Unknown

218

219 g/dL g/L mmol/L

Was RBC transfused ≤ 30 days before date of test?

Yes No

220

Platelets

Known Unknown

221

222 x 109/L (x 103/mm3)

x 106/L

Were platelets transfused ≤ 7 days before date of test?

Yes No

223

Neutrophils

Known Unknown

224

225 %

Blasts in bone marrow

Known Unknown

226

227 %

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

228

Results of tests229

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities230

One (1)

Two (2)

Three (3)

Four or more (4 or more)

–5

yes no

231

-7

yes no

232

–13

yes no

233

–20

yes no

234

–Y

yes no

235

+8

yes no

236

+19

yes no

237

t(1;3)

yes no

238

t(2;11)

yes no

239

t(3;3)

yes no

240

t(3;21)

yes no

241

t(6;9)

yes no

242

t(11;16)

yes no

243

del(3q) / 3q–

yes no

244

del(5q) / 5q-

yes no

245

del(7q) / 7q–

yes no

246

del(9q) / 9q–

yes no

247

del(11q) / 11q–

yes no

248

del(12p) / 12p–

yes no

249

del(13q) / 13q-

yes no

250

del(20q) / 20q–

yes no

251

inv(3)

yes no

252

i17q

yes no

253

Other abnormality

yes no

254

Specify other abnormality:255

What was the disease status?256

Complete
remission
(CR)

– requires all of the following, maintained for ≥ 4 weeks: * bone marrow evaluation: <  5% myeloblasts with normal maturation of all cell lines *
peripheral blood evaluation: hemoglobin ≥ 11 g/dL untransfused and without erythropoietin support; ANC ≥ 1000/mm3  without myeloid growth factor
support; platelets ≥ 100 x 109/L without thrombopoietic support; 0% blasts

Hematologic
improvement
(HI)

– requires one measurement of the following, maintained for ≥ 8 weeks without ongoing cytotoxic therapy; specify which cell line was measured to
determine HI response: * HI­E – hemoglobin increase of ≥ 1.5 g/dL untransfused; for RBC transfusions performed for Hgb ≤ 9.0, reduction in RBC
units transfused in 8 weeks by ≥ 4 units compared to the pre­treatment transfusion number in 8 weeks * HI­P – for pre­treatment platelet count of > 20
x 109/L, platelet absolute increase of ≥ 30 x 109/L; for pre-treatment platelet count of < 20 x 109/L, platelet absolute increase of ≥ 20 x 109/L and ≥
100% from pre­treatment level  * HI­N – neutrophil count increase of ≥ 100% from pre­treatment level and an absolute increase of ≥ 500/mm3

No response (NR) / stable disease (SD) – does not meet the criteria for at least HI, but no evidence of disease progression

Progression from
hematologic improvement
(Prog from HI)

– requires at least one of the following, in the absence of another explanation (e.g., infection, bleeding, ongoing chemotherapy, etc.): *
≥ 50% reduction from maximum response levels in granulocytes or platelets * reduction in hemoglobin by ≥ 1.5 g/dL *transfusion
dependence

Relapse from complete
remission (Rel from CR)

– requires at least one of the following: * return to pre­treatment bone marrow blast percentage * decrease of ≥ 50% from maximum
response levels in granulocytes or platelets * transfusion dependence, or hemoglobin level ≥ 1.5 g/dL lower than prior to therapy

Not assessed

Specify the cell line examined to determine HI status257

HI-
E

– hemoglobin increase of ≥ 1.5 g/dL untransfused; for RBC transfusions performed for Hgb ≤ 9.0, reduction in RBC units transfused in 8 weeks by ≥ 4
units compared to the pre-treatment transfusion number in 8 weeks

HI-
P

– for pre­treatment platelet count of > 20 x 109/L, platelet absolute increase of ≥ 30 x 109/L; for pre-treatment platelet count of < 20 x 109/L, platelet
absolute increase of ≥ 20 x 109/L and ≥ 100% from pre­treatment level 

HI-N – neutrophil count increase of ≥ 100% from pre­treatment level and an absolute increase of ≥ 500/mm3

Date of progression:258 __ __ __ __ - __ __- __ __

Date of relapse:259 __ __ __ __ - __ __- __ __

Date assessed:260 __ __ __ __ - __ __- __ __

Other Leukemia (OL) Questions: 261 - 267

Specify the other leukemia classification261

Specify other leukemia:262

Was any 17p abnormality detected?

yes no

263

Did a histologic transformation to diffuse large B-cell lymphoma (Richter syndrome) occur at any time after CLL diagnosis?264

yes - Also complete NHL Disease Classification questions

no

What was the disease status? (Atypical CML)265

Primary induction failure

1st complete remission (no previous bone marrow or extramedullary relapse)

2nd complete remission

≥3rd complete remission

1st relapse

2nd relapse

≥3rd relapse

No treatment

What was the disease status? (CLL, PLL, Hairy cell leukemia)266

Complete remission (CR)

Partial remission (PR)

Stable disease (SD)

Progressive disease (Prog)

Untreated

Not assessed

Date assessed:267 __ __ __ __ - __ __- __ __

Hodgkin and Non-Hodgkin Lymphoma Questions: 268 - 285

Specify the lymphoma histology (at infusion)268

Specify other lymphoma histology:269

Assignment of DLBCL (germinal center B-cell type vs. activated B-cell type) subtype was based on270

Immunohistochemistry (e.g. Han's algorithm)

Gene expression profile

Unknown method

Is the lymphoma histology reported at transplant a transformation from CLL?

yes no

271

Was any 17p abnormality detected?

yes no

272

Is the lymphoma histology reported at transplant a transformation from a different lymphoma histology? (Not CLL)

Yes No

273

Specify the original lymphoma histology (prior to transformation)274

Specify other lymphoma histology:275

Date of original lymphoma diagnosis:276 __ __ __ __ - __ __- __ __ (report the date of diagnosis of original lymphoma subtype)

Was a PET (or PET/CT) scan performed? (at last evaluation prior to the start of the preparative regimen / infusion)

yes no

277

Was the PET (or PET/CT) scan positive for lymphoma involvement at any disease site?

yes no

278

Date of PET scan

Known Unknown

279

Date of PET (or PET/CT) scan:280 __ __ __ __ - __ __- __ __

Deauville (five-point) score of the PET (or PET/CT) scan

Known Unknown

281

Scale282

1 - no uptake or residual uptake

2 - slight uptake, but below blood pool (mediastinum)

3 - uptake above mediastinal, but below or equal to uptake in the liver

4 - uptake slightly to moderately higher than liver

5 - markedly increased uptake or any new lesions

What was the disease status?283

Total number of lines of therapy received

1 line 2 lines 3+ lines

284

Date assessed:285 __ __ __ __ - __ __- __ __

Multiple Myeloma / Plasma Cell Disorder (PCD) Questions: 286 - 317

Specify the multiple myeloma/plasma cell disorder (PCD) classification286

Specify other plasma cell disorder:287

Light chain

kappa lambda

288

What was the Durie-Salmon staging? (at diagnosis)289

Stage
I

(All of the following: Hgb > 10g/dL; serum calcium normal or <10.5 mg/dL; bone x-ray normal bone structure (scale 0), or solitary bone plasmacytoma
only; low M-component production rates IgG< 5g/dL, IgA < 3g/dL; urine light chain M-component on electrophoresis <4 g/24h)

Stage II (Fitting neither Stage I or III) 

Stage
III

(One or more of the following: Hgb < 8.5 g/dL; serum calcium > 12 mg/dL; advanced lytic bone lesions (scale 3); high M-component production rates
IgG > 7g/dL, IgA > 5 g/dL; Bence Jones protein > 12g/24h)

Unknown

What was the Durie-Salmon sub classification? (at diagnosis)290

A - relatively normal renal function (serum creatinine < 2.0 mg/dL)

B ­ abnormal renal function (serum creatinine ≥ 2.0 mg/dL)

Serum β2­microglobulin:291 μg/dL mg/L nmol/L

Serum albumin:292 g/dL g/L

Stage293

1 (β2 ­mic < 3.5, S. albumin ≥3.5)

2 (Not fitting stage 1 or 3)

3 (β2­mic ≥ 5.5; S. albumin ­)

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

294

Results of tests295

Abnormalities identified

No evaluable metaphases

No abnormalities

+3

yes no

296

+5

yes no

297

+7

yes no

298

+9

yes no

299

+11

yes no

300

+15

yes no

301

+19

yes no

302

t(4;14)

yes no

303

t(6;14)

yes no

304

t(11;14)

yes no

305

t(14;16)

yes no

306

t(14;20)

yes no

307

del(13q) / 13q-

yes no

308

del (17p) / 17p-

yes no

309

Hyperdiploid (>50)

yes no

310

Hypodiploid (<46)

yes no

311

Any abnormality at 1q

yes no

312

Any abnormality at 1p

yes no

313

Other abnormality

yes no

314

Specify other abnormality:315

What was the disease status?316

Stringent

complete
remission

(sCR)

- CR as defined, plus: normal free light chain ratio, and absence of clonal cells in the bone marrow by immunohistochemistry of immunofluorescence

(confirmation with repeat bone marrow biopsy not needed). (Presence and/or absence of clonal cells is based upon the Κ/λ ratio. An abnormal Κ/λ ratio by
immunohistochemistry and/or immunofluorescence requires a minimum of 100 plasma cells for analysis.  An abnormal ratio reflecting the presence of

an abnormal clone is Κ/λ of > 4:1 or < 1:2.) sCR requires two consecutive assessments made at any time before the institution of any new therapy, and
no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy sCR

requirements. 

Complete

remission
(CR)

- negative immunofixation on serum and urine samples, and disappearance of any soft tissue plasmacytomas, and < 5% plasma cells in the bone

marrow (confirmation with repeat bone marrow biopsy not needed).  CR requires two consecutive assessments made at any time before the institution
of any new therapy, and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not

required to satisfy CR requirements. 

Near
complete
remission
(nCR)

- serum and urine M-protein detectable by immunoelectrophoresis (IFE), but not on electrophoresis (negative SPEP & UPEP); < 5% plasma cells in
bone marrow.  nCR requires two consecutive assessments made at any time before the initiation of any new therapy, and no known evidence of
progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy nCR requirements. 

Very good
partial
remission
(VGPR)

­ serum and urine M­protein detectable by immunofixation but not on electrophoresis, or ≥ 90% reduction in serum M­protein and urine M­protein level <
100 mg/24 hours.  VGPR requires two consecutive assessments made at any time before the institution of any new therapy, and no known evidence of
progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy VGPR requirements.

Partial
remission
(PR)

­ ≥ 50% reduction in serum M­protein, and reduction in 24­hour urinary M­protein by ≥ 90% or to < 200 mg/24 hours.  If the serum and urine M­protein are
unmeasurable (i.e., do not meet any of the following criteria: • serum M­protein ≥ 1 g/dL.  Urine M­protein ≥ 200 mg/24 hours • serum free light chain
assay shows involved level ≥ 10 mg/dL, provided serum free light chain ratio is abnormal), a ≥ 50% decrease in the difference between involved and
uninvolved free light chain levels is required in place of the M-protein criteria.  If serum and urine M-protein are unmeasurable, and serum free light assay
is also unmeasurable, a ≥ 50% reduction in plasma cells is required in place of M­protein, provided the baseline bone marrow plasma cell percentage
was ≥ 30%. In addition to the above listed criteria, a ≥ 50% reduction in the size of soft tissue plasmacytomas is also required, if present at baseline. PR
requires two consecutive assessments made at any time before the institution of any new therapy, and no known evidence of progressive or new bone
lesions if radiographic studies were performed; radiographic studies are not required to satisfy PR requirements. 

Stable
disease
(SD)

- not meeting the criteria for CR, VGPR, PR or PD.  SD requires two consecutive assessments made at any time before the institution of any new therapy,
and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy SD
requirements.

Progressive
disease
(PD)

­ requires any one or more of the following:  Increase of ≥ 25% from baseline in:  serum M­component and/or (absolute increase ≥ 0.5 g/dL) (for
progressive disease, serum M­component increases of ≥ 1 g/dL are sufficient to define relapse if the starting M­component is ≥ 5 g/dL).  Urine M­
component and/or (absolute increase ≥ 200 mg/24 hours) for recipients without measurable serum and urine M­protein levels: the difference between
involved and uninvolved free light chain levels (absolute increase > 10 mg/dL).  Bone marrow plasma cell percentage (absolute percentage ≥ 10%)
(relapse from CR has a 5% cutoff vs. 10% for other categories of relapse) definite development of new bone lesions or soft tissue plasmacytomas, or
definite increase in the size of any existing  bone lesions or soft tissue plasmacytomas. Development of hypercalcemia (corrected serum calcium >
11.5 mg/dL or 2.65 mmol) that can be attributed solely to the plasma cell proliferative disorder.  PD requires two consecutive assessments made at
any time before classification as disease progression, and/or the institution of any new therapy.

Relapse
from CR
(Rel)
(untreated)

­ requires one or more of the following: reappearance of serum or urine M­protein by immunofixation or electrophoresis development of ≥ 5% plasma
cells in the bone marrow (relapse from CR has a 5% cutoff vs. 10% for other categories of relapse) appearance of any other sign of progression (e.g.,
new plasmacytoma, lytic bone lesion, hypercalcemia).  Rel requires two consecutive assessments made at any time before classification as relapse,
and/or the institution of any new therapy.

Unknown

Not applicable (Amyloidosis with no evidence of myeloma)

Date assessed:317 __ __ __ __ - __ __- __ __

Solid Tumors Questions: 318 - 319

Specify the solid tumor classification318

Specify other solid tumor:319

Severe Aplastic Anemia Questions: 320 - 321

Specify the severe aplastic anemia classification320

Specify other acquired cytopenic syndrome:321

Inherited Abnormalities of Erythrocyte Differentiation or Function Questions: 322 - 324

Specify the inherited abnormalities of erythrocyte differentiation or function classification322

Specify other constitutional anemia:323

Specify other hemoglobinopathy:324

Disorders of the Immune System Questions: 325 - 327

Specify disorder of immune system classification325

Specify other SCID:326

Specify other immunodeficiency:327

Inherited Abnormalities of Platelets Questions: 328 - 329

Specify inherited abnormalities of platelets classification328

Congenital amegakaryocytosis / congenital thrombocytopenia (501)

Glanzmann thrombasthenia (502)

Other inherited platelet abnormality (509)

Specify other inherited platelet abnormality:329

Inherited Disorders of Metabolism Questions: 330 - 331

Specify inherited disorders of metabolism classification330

Specify other inherited metabolic disorder:331

Histiocytic Disorders Questions: 332 - 333

Specify histiocytic disorder classification332

Specify other histiocytic disorder:333

Autoimmune Diseases Questions: 334 - 341

Specify autoimmune disease classification334

Specify other arthritis:335

Specify other juvenile idiopathic arthritis (JIA):336

Specify other connective tissue disease:337

Specify other vasculitis:338

Specify other autoimmune neurological disorder:339

Specify other autoimmune cytopenia:340

Specify other autoimmune bowel disorder:341

Other Disease Questions: 342 - 342

Specify other disease:342

First Name:

Last Name:

E-mail address:

Date: __ __ __ __ - __ __- __ __

OMB No: 0915-0310

Expiration Date: 1/31/2020

Public Burden Statement:  An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control
number.  The OMB control number for this project is 0915-0310.  Public reporting burden for this collection of information is estimated to average 1.0 hours per response, including the
time for reviewing instructions, searching existing data sources, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other
aspect of this collection of information, including suggestions for reducing this burden, to HRSA Reports Clearance Officer, 5600 Fishers Lane, Room 10-29, Rockville, Maryland, 20857.

Labs at diagnosis

Specify cytogenetic abnormalities identified at diagnosis:

Specify cytogenetic abnormalities identified at diagnosis:

Specify molecular markers identified at diagnosis:

Labs between diagnosis and last evaluation:

Specify cytogenetic abnormalities identified between diagnosis and last evaluation:

Specify cytogenetic abnormalities identified between diagnosis and last evaluation:

Specify molecular markers identified between diagnosis and last evaluation:

Labs at last evaluation:

Specify cytogenetic abnormalities identified at last evaluation:

Specify cytogenetic abnormalities identified at last evaluation:

Specify molecular markers identified at last evaluation:

CNS Leukemia

Status at transplantation:

Laboratory studies at diagnosis:

Specify cytogenetic abnormalities identified at diagnosis:

Specify cytogenetic abnormalities identified at diagnosis:

Specify molecular markers identified at diagnosis:

Laboratory studies between diagnosis and last evaluation:

Specify cytogenetic abnormalities identified between diagnosis and last evaluation:

Specify cytogenetic abnormalities identified between diagnosis and last evaluation:

Specify molecular markers identified between diagnosis and last evaluation:

Laboratory studies at last evaluation:

Specify cytogenetic abnormalities identified at last evaluation:

Specify cytogenetic abnormalities identified at last evaluation:

Specify molecular markers identified at last evaluation:

CNS Leukemia

Status at transplantation:

Status at transplantation:

Laboratory studies at diagnosis of MDS:

Specify abnormalities identified at diagnosis:

Monosomy

Trisomy

Translocation

Deletion

Inversion

Other

Laboratory studies at last evaluation prior to the start of the preparative regimen:

Specify cytogenetic abnormalities identified at last evaluation prior to the start of the preparative regimen:

Monosomy

Trisomy

Translocation

Deletion

Inversion

Other

Status at transplantation:

Status at transplantation:

Status at transplantation / infusion:

I.S.S.:

Specify cytogenetic abnormalities identified at any time prior to the start of the preparative regimen:

Trisomy

Translocation

Deletion

Other

Status at transplantation:

Center: CRID: 

Form 2402 R3.0: Disease Classification

CIBMTR Form 2402 revision 3.0 last updated Monday, January 29, 2018
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 10 / 26



Key Fields

Sequence Number:

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number:

CIBMTR Research ID:

Event date: __ __ __ __ - __ __- __ __

Primary Disease for HCT / Cellular Therapy Questions: 1 - 2

Date of diagnosis of primary disease for HCT / cellular therapy:1 __ __ __ __ - __ __- __ __

What was the primary disease for which the HCT / cellular therapy was performed?2

Acute myelogenous leukemia (AML or ANLL) (10)

Acute lymphoblastic leukemia (ALL) (20)

Acute leukemia of ambiguous lineage and other myeloid neoplasms (80)

Chronic myelogenous leukemia (CML) (40)

Myelodysplastic (MDS) / myeloproliferative (MPN) diseases (50) (Please classify all preleukemias) (If recipient has transformed to AML, indicate AML as the primary disease)

Other leukemia (30) (includes CLL)

Hodgkin lymphoma (150)

Non-Hodgkin lymphoma (100)

Multiple myeloma / plasma cell disorder (PCD) (170)

Solid tumors (200)

Severe aplastic anemia (300) (If the recipient developed MDS or AML, indicate MDS or AML as the primary disease)

Inherited abnormalities of erythrocyte differentiation or function (310)

Disorders of the immune system (400)

Inherited abnormalities of platelets (500)

Inherited disorders of metabolism (520)

Histiocytic disorders (570)

Autoimmune diseases (600)

Other disease (900)

Acute Myelogenous Leukemia (AML) Questions: 3 - 89

Specify the AML classification3

Did AML transform from MDS or MPN?4

yes - Also complete MDS Disease Classification questions

no

Is the disease (AML) therapy related?

yes no Unknown

5

Did the recipient have a predisposing condition?

yes no Unknown

6

Specify condition7

Bloom syndrome

Down syndrome

Fanconi anemia

Dyskeratosis congenita

Other condition

Specify other condition:8

Were cytogenetics tested (karyotyping or FISH)? (at diagnosis)

yes no Unknown

9

Were cytogenetics tested via FISH? (at diagnosis)

Yes No

10

Results of tests11

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities12

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

13

Specify other abnormality:14

Were cytogenetics tested via karyotyping? (at diagnosis)

Yes No

15

Results of tests16

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities17

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

18

Specify other abnormality:19

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

20

Were tests for molecular markers performed? (e.g. PCR, NGS) (at diagnosis)

yes no Unknown

21

CEBPA

Positive Negative Not Done

22

Specify CEBPA mutation23

Biallelic (homozygous)

Monoallelic (heterozygous)

Unknown

FLT3 – D835 point mutation

Positive Negative Not Done

24

FLT3 – ITD mutation

Positive Negative Not Done

25

FLT3 - ITD allelic ratio

Known Unknown

26

Specify FLT3 - ITD allelic ratio:27

IDH1

Positive Negative Not Done

28

IDH2

Positive Negative Not Done

29

KIT

Positive Negative Not Done

30

NPM1

Positive Negative Not Done

31

Other Molecular Marker (1) Questions: 32 - 33

Other molecular marker

Positive Negative Not Done

32

Specify other molecular marker:33

Were cytogenetics tested (karyotyping or FISH)? (between diagnosis and last evaluation)

yes no Unknown

34

Were cytogenetics tested via FISH? (between diagnosis and last evaluation)

Yes No

35

Results of tests36

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities37

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

38

Specify other abnormality:39

Were cytogenetics tested via karyotyping? (between diagnosis and last evaluation)

Yes No

40

Results of tests41

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities42

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

43

Specify other abnormality:44

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

45

Were tests for molecular markers performed? (e.g. PCR, NGS) (between diagnosis and last evaluation)

yes no Unknown

46

CEBPA

Positive Negative Not Done

47

Specify CEBPA mutation48

Biallelic (homozygous)

Monoallelic (heterozygous)

Unknown

FLT3 – D835 point mutation

Positive Negative Not Done

49

FLT3 – ITD mutation

Positive Negative Not Done

50

FLT3 - ITD allelic ratio

Known Unknown

51

Specify FLT3 - ITD allelic ratio:52

IDH1

Positive Negative Not Done

53

IDH2

Positive Negative Not Done

54

KIT

Positive Negative Not Done

55

NPM1

Positive Negative Not Done

56

Other Molecular Marker (1) Questions: 57 - 58

Other molecular marker

Positive Negative Not Done

57

Specify other molecular marker:58

Were cytogenetics tested (karyotyping or FISH)? (at last evaluation)

yes no Unknown

59

Were cytogenetics tested via FISH? (at last evaluation)

Yes No

60

Results of tests61

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities62

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

63

Specify other abnormality:64

Were cytogenetics tested via karyotyping? (at last evaluation)

Yes No

65

Results of tests66

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities67

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

68

Specify other abnormality:69

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

70

Were tests for molecular markers performed? (e.g. PCR, NGS) (at last evaluation)

yes no Unknown

71

CEBPA

Positive Negative Not Done

72

Specify CEBPA mutation73

Biallelic (homozygous)

Monoallelic (heterozygous)

Unknown

FLT3 – D835 point mutation

Positive Negative Not Done

74

FLT3 – ITD mutation

Positive Negative Not Done

75

FLT3 - ITD allelic ratio

Known Unknown

76

Specify FLT3 - ITD allelic ratio:77

IDH1

Positive Negative Not Done

78

IDH2

Positive Negative Not Done

79

KIT

Positive Negative Not Done

80

NPM1

Positive Negative Not Done

81

Other Molecular Marker (1) Questions: 82 - 83

Other molecular marker

Positive Negative Not Done

82

Specify other molecular marker:83

Did the recipient have central nervous system leukemia at any time prior to the start of the preparative regimen / infusion?

yes no Unknown

84

What was the disease status (based on hematological test results)?85

Primary induction failure

1st complete remission (no previous bone marrow or extramedullary relapse) (include CRi)

2nd complete remission

≥3rd complete remission

1st relapse

2nd relapse

≥3rd relapse

No treatment

How many cycles of induction therapy were required to achieve 1st complete remission? (includes CRi)

1 2 ≥ 3

86

Was the recipient in remission by flow cytometry?

Yes No Unknown Not applicable

87

Date of most recent relapse:88 __ __ __ __ - __ __- __ __

Date assessed:89 __ __ __ __ - __ __- __ __

Acute Lymphoblastic Leukemia (ALL) Questions: 90 - 151

Specify ALL classification90

Did the recipient have a predisposing condition?

yes no Unknown

91

Specify condition92

Aplastic anemia - Also complete CIBMTR Form 2028 - APL

Bloom syndrome

Down syndrome

Fanconi anemia - Also complete CIBMTR Form 2029 - FAN

Other condition

Specify other condition:93

Were tyrosine kinase inhibitors given for therapy at any time prior to the start of the preparative regimen / infusion? (e.g. imatinib mesylate, dasatinib, etc.)

yes no

94

Were cytogenetics tested (karyotyping or FISH)? (at diagnosis)

yes no Unknown

95

Were cytogenetics tested via FISH? (at diagnosis)

Yes No

96

Results of tests97

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities98

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

99

Specify other abnormality:100

Were cytogenetics tested via karyotyping? (at diagnosis)

Yes No

101

Results of tests102

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities103

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

104

Specify other abnormality:105

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

106

Were tests for molecular markers performed? (e.g. PCR, NGS) (at diagnosis)

yes no Unknown

107

BCR / ABL

Positive Negative Not Done

108

TEL-AML / AML1

Positive Negative Not Done

109

Other Molecular Marker (1) Questions: 110 - 111

Other molecular marker

Positive Negative Not Done

110

Specify other molecular marker:111

Were cytogenetics tested (karyotyping or FISH)? (between diagnosis and last evaluation)

yes no Unknown

112

Were cytogenetics tested via FISH? (between diagnosis and last evaluation)

Yes No

113

Results of tests114

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities115

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

116

Specify other abnormality:117

Were cytogenetics tested via karyotyping? (between diagnosis and last evaluation)

Yes No

118

Results of tests119

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities120

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

121

Specify other abnormality:122

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

123

Were tests for molecular markers performed? (e.g. PCR, NGS) (between diagnosis and last evaluation)

yes no Unknown

124

BCR / ABL

Positive Negative Not Done

125

TEL-AML / AML1

Positive Negative Not Done

126

Other Molecular Marker (1) Questions: 127 - 128

Other molecular marker

Positive Negative Not Done

127

Specify other molecular marker:128

Were cytogenetics tested (karyotyping or FISH)? (at last evaluation)

yes no Unknown

129

Were cytogenetics tested via FISH? (at last evaluation)

Yes No

130

Results of tests131

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities132

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

133

Specify other abnormality:134

Were cytogenetics tested via karyotyping? (at last evaluation)

Yes No

135

Results of tests136

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities137

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

138

Specify other abnormality:139

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

140

Were tests for molecular markers performed? (e.g. PCR, NGS) (at last evaluation)

yes no Unknown

141

BCR / ABL

Positive Negative Not Done

142

TEL-AML / AML1

Positive Negative Not Done

143

Other Molecular Marker (1) Questions: 144 - 145

Other molecular marker

Positive Negative Not Done

144

Specify other molecular marker:145

Did the recipient have central nervous system leukemia at any time prior to the start of the preparative regimen / infusion?

yes no Unknown

146

What was the disease status (based on hematological test results)?147

Primary induction failure

1st complete remission (no previous marrow or extramedullary relapse) (include CRi)

2nd complete remission

≥3rd complete remission

1st relapse

2nd relapse

≥3rd relapse

No treatment

How many cycles of induction therapy were required to achieve 1st complete remission? (include CRi)

1 2 ≥ 3

148

Was the recipient in remission by flow cytometry?

Yes No Unknown Not applicable

149

Date of most recent relapse:150 __ __ __ __ - __ __- __ __

Date assessed:151 __ __ __ __ - __ __- __ __

Acute Leukemias of Ambiguous Lineage and Other Myeloid Neoplasms Questions: 152 - 155

Specify acute leukemias of ambiguous lineage and other myeloid neoplasm classification152

Blastic plasmacytoid dendritic cell neoplasm (296)

Acute undifferentiated leukemia (31)

Mixed phenotype acute leukemia (MPAL) with t(9;22)(q34.1;q11.2); BCR-ABL1 (84)

Mixed phenotype acute leukemia with t(v; 11q23.3); KMT2A rearranged (85)

Mixed phenotype acute leukemia, B/myeloid, NOS (86)

Mixed phenotype acute leukemia, T/myeloid, NOS (87)

Other acute leukemia of ambiguous lineage or myeloid neoplasm (88)

Specify other acute leukemia of ambiguous lineage or myeloid neoplasm:153

What was the disease status (based on hematological test results)?154

Primary induction failure

1st complete remission (no previous marrow or extramedullary relapse)

2nd complete remission

≥3rd complete remission

1st relapse

2nd relapse

≥3rd relapse

No treatment

Date assessed:155 __ __ __ __ - __ __- __ __

Chronic Myelogenous Leukemia (CML) Questions: 156 - 166

Was therapy given prior to this HCT?

yes no

156

Combination chemotherapy

yes no

157

Hydroxyurea (Droxia, Hydrea)

yes no

158

Tyrosine kinase inhibitor (e.g. imatinib mesylate, dasatinib, nilotinib)

yes no

159

Interferon­α (Intron, Roferon) (includes PEG)

yes no

160

Other therapy

yes no

161

Specify other therapy:162

What was the disease status?163

Complete hematologic response (CHR)

Chronic phase

Accelerated phase

Blast phase

Specify level of response164

No cytogenetic response (No CyR)

Minimal cytogenetic response

Minor cytogenetic response

Partial cytogenetic response (PCyR)

Complete cytogenetic response (CCyR)

Major molecular remission (MMR)

Complete molecular remission (CMR)

Number

1st 2nd 3rd or higher

165

Date assessed:166 __ __ __ __ - __ __- __ __

Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases Questions: 167 - 260

What was the MDS / MPN subtype at diagnosis? - If transformed to AML, indicate AML as primary disease; also complete AML Disease Classification
questions

167

Was the disease (MDS/MPN) therapy related?

yes no Unknown

168

Did the recipient have a predisposing condition?

yes no Unknown

169

Specify condition

Aplastic Anemia Bloom syndrome Down syndrome Fanconi anemia Other condition

170

Specify other condition:171

WBC

Known Unknown

172

173 x 109/L (x 103/mm3)

x 106/L

Hemoglobin

Known Unknown

174

175 g/dL g/L mmol/L

Was RBC transfused ≤ 30 days before date of test?

Yes No

176

Platelets

Known Unknown

177

178 x 109/L (x 103/mm3)

x 106/L

Were platelets transfused ≤ 7 days before date of test?

Yes No

179

Neutrophils

Known Unknown

180

181 %

Blasts in bone marrow

Known Unknown

182

183 %

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

184

Results of tests185

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities186

One (1)

Two (2)

Three (3)

Four or more (4 or more)

–5

yes no

187

-7

yes no

188

–13

yes no

189

–20

yes no

190

–Y

yes no

191

+8

yes no

192

+19

yes no

193

t(1;3)

yes no

194

t(2;11)

yes no

195

t(3;3)

yes no

196

t(3;21)

yes no

197

t(6;9)

yes no

198

t(11;16)

yes no

199

del(3q) / 3q–

yes no

200

del(5q) / 5q-

yes no

201

del(7q) / 7q–

yes no

202

del(9q) / 9q–

yes no

203

del(11q) / 11q–

yes no

204

del(12p) / 12p–

yes no

205

del(13q) / 13q-

yes no

206

del(20q) / 20q–

yes no

207

inv(3)

yes no

208

i17q

yes no

209

Other abnormality

yes no

210

Specify other abnormality:211

Did the recipient progress or transform to a different MDS / MPN subtype between diagnosis and the start of the preparative regimen?

yes no

212

Specify the MDS / MPN classification after transformation:213

Specify the date of the most recent transformation:214 __ __ __ __ - __ __- __ __

Date of MDS diagnosis:215 __ __ __ __ - __ __- __ __

WBC

Known Unknown

216

217 x 109/L (x 103/mm3)

x 106/L

Hemoglobin

Known Unknown

218

219 g/dL g/L mmol/L

Was RBC transfused ≤ 30 days before date of test?

Yes No

220

Platelets

Known Unknown

221

222 x 109/L (x 103/mm3)

x 106/L

Were platelets transfused ≤ 7 days before date of test?

Yes No

223

Neutrophils

Known Unknown

224

225 %

Blasts in bone marrow

Known Unknown

226

227 %

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

228

Results of tests229

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities230

One (1)

Two (2)

Three (3)

Four or more (4 or more)

–5

yes no

231

-7

yes no

232

–13

yes no

233

–20

yes no

234

–Y

yes no

235

+8

yes no

236

+19

yes no

237

t(1;3)

yes no

238

t(2;11)

yes no

239

t(3;3)

yes no

240

t(3;21)

yes no

241

t(6;9)

yes no

242

t(11;16)

yes no

243

del(3q) / 3q–

yes no

244

del(5q) / 5q-

yes no

245

del(7q) / 7q–

yes no

246

del(9q) / 9q–

yes no

247

del(11q) / 11q–

yes no

248

del(12p) / 12p–

yes no

249

del(13q) / 13q-

yes no

250

del(20q) / 20q–

yes no

251

inv(3)

yes no

252

i17q

yes no

253

Other abnormality

yes no

254

Specify other abnormality:255

What was the disease status?256

Complete
remission
(CR)

– requires all of the following, maintained for ≥ 4 weeks: * bone marrow evaluation: <  5% myeloblasts with normal maturation of all cell lines *
peripheral blood evaluation: hemoglobin ≥ 11 g/dL untransfused and without erythropoietin support; ANC ≥ 1000/mm3  without myeloid growth factor
support; platelets ≥ 100 x 109/L without thrombopoietic support; 0% blasts

Hematologic
improvement
(HI)

– requires one measurement of the following, maintained for ≥ 8 weeks without ongoing cytotoxic therapy; specify which cell line was measured to
determine HI response: * HI­E – hemoglobin increase of ≥ 1.5 g/dL untransfused; for RBC transfusions performed for Hgb ≤ 9.0, reduction in RBC
units transfused in 8 weeks by ≥ 4 units compared to the pre­treatment transfusion number in 8 weeks * HI­P – for pre­treatment platelet count of > 20
x 109/L, platelet absolute increase of ≥ 30 x 109/L; for pre-treatment platelet count of < 20 x 109/L, platelet absolute increase of ≥ 20 x 109/L and ≥
100% from pre­treatment level  * HI­N – neutrophil count increase of ≥ 100% from pre­treatment level and an absolute increase of ≥ 500/mm3

No response (NR) / stable disease (SD) – does not meet the criteria for at least HI, but no evidence of disease progression

Progression from
hematologic improvement
(Prog from HI)

– requires at least one of the following, in the absence of another explanation (e.g., infection, bleeding, ongoing chemotherapy, etc.): *
≥ 50% reduction from maximum response levels in granulocytes or platelets * reduction in hemoglobin by ≥ 1.5 g/dL *transfusion
dependence

Relapse from complete
remission (Rel from CR)

– requires at least one of the following: * return to pre­treatment bone marrow blast percentage * decrease of ≥ 50% from maximum
response levels in granulocytes or platelets * transfusion dependence, or hemoglobin level ≥ 1.5 g/dL lower than prior to therapy

Not assessed

Specify the cell line examined to determine HI status257

HI-
E

– hemoglobin increase of ≥ 1.5 g/dL untransfused; for RBC transfusions performed for Hgb ≤ 9.0, reduction in RBC units transfused in 8 weeks by ≥ 4
units compared to the pre-treatment transfusion number in 8 weeks

HI-
P

– for pre­treatment platelet count of > 20 x 109/L, platelet absolute increase of ≥ 30 x 109/L; for pre-treatment platelet count of < 20 x 109/L, platelet
absolute increase of ≥ 20 x 109/L and ≥ 100% from pre­treatment level 

HI-N – neutrophil count increase of ≥ 100% from pre­treatment level and an absolute increase of ≥ 500/mm3

Date of progression:258 __ __ __ __ - __ __- __ __

Date of relapse:259 __ __ __ __ - __ __- __ __

Date assessed:260 __ __ __ __ - __ __- __ __

Other Leukemia (OL) Questions: 261 - 267

Specify the other leukemia classification261

Specify other leukemia:262

Was any 17p abnormality detected?

yes no

263

Did a histologic transformation to diffuse large B-cell lymphoma (Richter syndrome) occur at any time after CLL diagnosis?264

yes - Also complete NHL Disease Classification questions

no

What was the disease status? (Atypical CML)265

Primary induction failure

1st complete remission (no previous bone marrow or extramedullary relapse)

2nd complete remission

≥3rd complete remission

1st relapse

2nd relapse

≥3rd relapse

No treatment

What was the disease status? (CLL, PLL, Hairy cell leukemia)266

Complete remission (CR)

Partial remission (PR)

Stable disease (SD)

Progressive disease (Prog)

Untreated

Not assessed

Date assessed:267 __ __ __ __ - __ __- __ __

Hodgkin and Non-Hodgkin Lymphoma Questions: 268 - 285

Specify the lymphoma histology (at infusion)268

Specify other lymphoma histology:269

Assignment of DLBCL (germinal center B-cell type vs. activated B-cell type) subtype was based on270

Immunohistochemistry (e.g. Han's algorithm)

Gene expression profile

Unknown method

Is the lymphoma histology reported at transplant a transformation from CLL?

yes no

271

Was any 17p abnormality detected?

yes no

272

Is the lymphoma histology reported at transplant a transformation from a different lymphoma histology? (Not CLL)

Yes No

273

Specify the original lymphoma histology (prior to transformation)274

Specify other lymphoma histology:275

Date of original lymphoma diagnosis:276 __ __ __ __ - __ __- __ __ (report the date of diagnosis of original lymphoma subtype)

Was a PET (or PET/CT) scan performed? (at last evaluation prior to the start of the preparative regimen / infusion)

yes no

277

Was the PET (or PET/CT) scan positive for lymphoma involvement at any disease site?

yes no

278

Date of PET scan

Known Unknown

279

Date of PET (or PET/CT) scan:280 __ __ __ __ - __ __- __ __

Deauville (five-point) score of the PET (or PET/CT) scan

Known Unknown

281

Scale282

1 - no uptake or residual uptake

2 - slight uptake, but below blood pool (mediastinum)

3 - uptake above mediastinal, but below or equal to uptake in the liver

4 - uptake slightly to moderately higher than liver

5 - markedly increased uptake or any new lesions

What was the disease status?283

Total number of lines of therapy received

1 line 2 lines 3+ lines

284

Date assessed:285 __ __ __ __ - __ __- __ __

Multiple Myeloma / Plasma Cell Disorder (PCD) Questions: 286 - 317

Specify the multiple myeloma/plasma cell disorder (PCD) classification286

Specify other plasma cell disorder:287

Light chain

kappa lambda

288

What was the Durie-Salmon staging? (at diagnosis)289

Stage
I

(All of the following: Hgb > 10g/dL; serum calcium normal or <10.5 mg/dL; bone x-ray normal bone structure (scale 0), or solitary bone plasmacytoma
only; low M-component production rates IgG< 5g/dL, IgA < 3g/dL; urine light chain M-component on electrophoresis <4 g/24h)

Stage II (Fitting neither Stage I or III) 

Stage
III

(One or more of the following: Hgb < 8.5 g/dL; serum calcium > 12 mg/dL; advanced lytic bone lesions (scale 3); high M-component production rates
IgG > 7g/dL, IgA > 5 g/dL; Bence Jones protein > 12g/24h)

Unknown

What was the Durie-Salmon sub classification? (at diagnosis)290

A - relatively normal renal function (serum creatinine < 2.0 mg/dL)

B ­ abnormal renal function (serum creatinine ≥ 2.0 mg/dL)

Serum β2­microglobulin:291 μg/dL mg/L nmol/L

Serum albumin:292 g/dL g/L

Stage293

1 (β2 ­mic < 3.5, S. albumin ≥3.5)

2 (Not fitting stage 1 or 3)

3 (β2­mic ≥ 5.5; S. albumin ­)

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

294

Results of tests295

Abnormalities identified

No evaluable metaphases

No abnormalities

+3

yes no

296

+5

yes no

297

+7

yes no

298

+9

yes no

299

+11

yes no

300

+15

yes no

301

+19

yes no

302

t(4;14)

yes no

303

t(6;14)

yes no

304

t(11;14)

yes no

305

t(14;16)

yes no

306

t(14;20)

yes no

307

del(13q) / 13q-

yes no

308

del (17p) / 17p-

yes no

309

Hyperdiploid (>50)

yes no

310

Hypodiploid (<46)

yes no

311

Any abnormality at 1q

yes no

312

Any abnormality at 1p

yes no

313

Other abnormality

yes no

314

Specify other abnormality:315

What was the disease status?316

Stringent
complete

remission
(sCR)

- CR as defined, plus: normal free light chain ratio, and absence of clonal cells in the bone marrow by immunohistochemistry of immunofluorescence
(confirmation with repeat bone marrow biopsy not needed). (Presence and/or absence of clonal cells is based upon the Κ/λ ratio. An abnormal Κ/λ ratio by
immunohistochemistry and/or immunofluorescence requires a minimum of 100 plasma cells for analysis.  An abnormal ratio reflecting the presence of
an abnormal clone is Κ/λ of > 4:1 or < 1:2.) sCR requires two consecutive assessments made at any time before the institution of any new therapy, and
no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy sCR
requirements. 

Complete
remission

(CR)

- negative immunofixation on serum and urine samples, and disappearance of any soft tissue plasmacytomas, and < 5% plasma cells in the bone
marrow (confirmation with repeat bone marrow biopsy not needed).  CR requires two consecutive assessments made at any time before the institution

of any new therapy, and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not
required to satisfy CR requirements. 

Near
complete
remission
(nCR)

- serum and urine M-protein detectable by immunoelectrophoresis (IFE), but not on electrophoresis (negative SPEP & UPEP); < 5% plasma cells in
bone marrow.  nCR requires two consecutive assessments made at any time before the initiation of any new therapy, and no known evidence of
progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy nCR requirements. 

Very good
partial
remission
(VGPR)

­ serum and urine M­protein detectable by immunofixation but not on electrophoresis, or ≥ 90% reduction in serum M­protein and urine M­protein level <
100 mg/24 hours.  VGPR requires two consecutive assessments made at any time before the institution of any new therapy, and no known evidence of
progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy VGPR requirements.

Partial
remission
(PR)

­ ≥ 50% reduction in serum M­protein, and reduction in 24­hour urinary M­protein by ≥ 90% or to < 200 mg/24 hours.  If the serum and urine M­protein are
unmeasurable (i.e., do not meet any of the following criteria: • serum M­protein ≥ 1 g/dL.  Urine M­protein ≥ 200 mg/24 hours • serum free light chain
assay shows involved level ≥ 10 mg/dL, provided serum free light chain ratio is abnormal), a ≥ 50% decrease in the difference between involved and
uninvolved free light chain levels is required in place of the M-protein criteria.  If serum and urine M-protein are unmeasurable, and serum free light assay
is also unmeasurable, a ≥ 50% reduction in plasma cells is required in place of M­protein, provided the baseline bone marrow plasma cell percentage
was ≥ 30%. In addition to the above listed criteria, a ≥ 50% reduction in the size of soft tissue plasmacytomas is also required, if present at baseline. PR
requires two consecutive assessments made at any time before the institution of any new therapy, and no known evidence of progressive or new bone
lesions if radiographic studies were performed; radiographic studies are not required to satisfy PR requirements. 

Stable
disease
(SD)

- not meeting the criteria for CR, VGPR, PR or PD.  SD requires two consecutive assessments made at any time before the institution of any new therapy,
and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy SD
requirements.

Progressive
disease
(PD)

­ requires any one or more of the following:  Increase of ≥ 25% from baseline in:  serum M­component and/or (absolute increase ≥ 0.5 g/dL) (for
progressive disease, serum M­component increases of ≥ 1 g/dL are sufficient to define relapse if the starting M­component is ≥ 5 g/dL).  Urine M­
component and/or (absolute increase ≥ 200 mg/24 hours) for recipients without measurable serum and urine M­protein levels: the difference between
involved and uninvolved free light chain levels (absolute increase > 10 mg/dL).  Bone marrow plasma cell percentage (absolute percentage ≥ 10%)
(relapse from CR has a 5% cutoff vs. 10% for other categories of relapse) definite development of new bone lesions or soft tissue plasmacytomas, or
definite increase in the size of any existing  bone lesions or soft tissue plasmacytomas. Development of hypercalcemia (corrected serum calcium >
11.5 mg/dL or 2.65 mmol) that can be attributed solely to the plasma cell proliferative disorder.  PD requires two consecutive assessments made at
any time before classification as disease progression, and/or the institution of any new therapy.

Relapse
from CR
(Rel)
(untreated)

­ requires one or more of the following: reappearance of serum or urine M­protein by immunofixation or electrophoresis development of ≥ 5% plasma
cells in the bone marrow (relapse from CR has a 5% cutoff vs. 10% for other categories of relapse) appearance of any other sign of progression (e.g.,
new plasmacytoma, lytic bone lesion, hypercalcemia).  Rel requires two consecutive assessments made at any time before classification as relapse,
and/or the institution of any new therapy.

Unknown

Not applicable (Amyloidosis with no evidence of myeloma)

Date assessed:317 __ __ __ __ - __ __- __ __

Solid Tumors Questions: 318 - 319

Specify the solid tumor classification318

Specify other solid tumor:319

Severe Aplastic Anemia Questions: 320 - 321

Specify the severe aplastic anemia classification320

Specify other acquired cytopenic syndrome:321

Inherited Abnormalities of Erythrocyte Differentiation or Function Questions: 322 - 324

Specify the inherited abnormalities of erythrocyte differentiation or function classification322

Specify other constitutional anemia:323

Specify other hemoglobinopathy:324

Disorders of the Immune System Questions: 325 - 327

Specify disorder of immune system classification325

Specify other SCID:326

Specify other immunodeficiency:327

Inherited Abnormalities of Platelets Questions: 328 - 329

Specify inherited abnormalities of platelets classification328

Congenital amegakaryocytosis / congenital thrombocytopenia (501)

Glanzmann thrombasthenia (502)

Other inherited platelet abnormality (509)

Specify other inherited platelet abnormality:329

Inherited Disorders of Metabolism Questions: 330 - 331

Specify inherited disorders of metabolism classification330

Specify other inherited metabolic disorder:331

Histiocytic Disorders Questions: 332 - 333

Specify histiocytic disorder classification332

Specify other histiocytic disorder:333

Autoimmune Diseases Questions: 334 - 341

Specify autoimmune disease classification334

Specify other arthritis:335

Specify other juvenile idiopathic arthritis (JIA):336

Specify other connective tissue disease:337

Specify other vasculitis:338

Specify other autoimmune neurological disorder:339

Specify other autoimmune cytopenia:340

Specify other autoimmune bowel disorder:341

Other Disease Questions: 342 - 342

Specify other disease:342

First Name:

Last Name:

E-mail address:

Date: __ __ __ __ - __ __- __ __

OMB No: 0915-0310

Expiration Date: 1/31/2020

Public Burden Statement:  An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control
number.  The OMB control number for this project is 0915-0310.  Public reporting burden for this collection of information is estimated to average 1.0 hours per response, including the
time for reviewing instructions, searching existing data sources, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other
aspect of this collection of information, including suggestions for reducing this burden, to HRSA Reports Clearance Officer, 5600 Fishers Lane, Room 10-29, Rockville, Maryland, 20857.

Labs at diagnosis

Specify cytogenetic abnormalities identified at diagnosis:

Specify cytogenetic abnormalities identified at diagnosis:

Specify molecular markers identified at diagnosis:

Labs between diagnosis and last evaluation:

Specify cytogenetic abnormalities identified between diagnosis and last evaluation:

Specify cytogenetic abnormalities identified between diagnosis and last evaluation:

Specify molecular markers identified between diagnosis and last evaluation:

Labs at last evaluation:

Specify cytogenetic abnormalities identified at last evaluation:

Specify cytogenetic abnormalities identified at last evaluation:

Specify molecular markers identified at last evaluation:

CNS Leukemia

Status at transplantation:

Laboratory studies at diagnosis:

Specify cytogenetic abnormalities identified at diagnosis:

Specify cytogenetic abnormalities identified at diagnosis:

Specify molecular markers identified at diagnosis:

Laboratory studies between diagnosis and last evaluation:

Specify cytogenetic abnormalities identified between diagnosis and last evaluation:

Specify cytogenetic abnormalities identified between diagnosis and last evaluation:

Specify molecular markers identified between diagnosis and last evaluation:

Laboratory studies at last evaluation:

Specify cytogenetic abnormalities identified at last evaluation:

Specify cytogenetic abnormalities identified at last evaluation:

Specify molecular markers identified at last evaluation:

CNS Leukemia

Status at transplantation:

Status at transplantation:

Laboratory studies at diagnosis of MDS:

Specify abnormalities identified at diagnosis:

Monosomy

Trisomy

Translocation

Deletion

Inversion

Other

Laboratory studies at last evaluation prior to the start of the preparative regimen:

Specify cytogenetic abnormalities identified at last evaluation prior to the start of the preparative regimen:

Monosomy

Trisomy

Translocation

Deletion

Inversion

Other

Status at transplantation:

Status at transplantation:

Status at transplantation / infusion:

I.S.S.:

Specify cytogenetic abnormalities identified at any time prior to the start of the preparative regimen:

Trisomy

Translocation

Deletion

Other

Status at transplantation:

Center: CRID: 

Form 2402 R3.0: Disease Classification

CIBMTR Form 2402 revision 3.0 last updated Monday, January 29, 2018
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 11 / 26



Key Fields

Sequence Number:

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number:

CIBMTR Research ID:

Event date: __ __ __ __ - __ __- __ __

Primary Disease for HCT / Cellular Therapy Questions: 1 - 2

Date of diagnosis of primary disease for HCT / cellular therapy:1 __ __ __ __ - __ __- __ __

What was the primary disease for which the HCT / cellular therapy was performed?2

Acute myelogenous leukemia (AML or ANLL) (10)

Acute lymphoblastic leukemia (ALL) (20)

Acute leukemia of ambiguous lineage and other myeloid neoplasms (80)

Chronic myelogenous leukemia (CML) (40)

Myelodysplastic (MDS) / myeloproliferative (MPN) diseases (50) (Please classify all preleukemias) (If recipient has transformed to AML, indicate AML as the primary disease)

Other leukemia (30) (includes CLL)

Hodgkin lymphoma (150)

Non-Hodgkin lymphoma (100)

Multiple myeloma / plasma cell disorder (PCD) (170)

Solid tumors (200)

Severe aplastic anemia (300) (If the recipient developed MDS or AML, indicate MDS or AML as the primary disease)

Inherited abnormalities of erythrocyte differentiation or function (310)

Disorders of the immune system (400)

Inherited abnormalities of platelets (500)

Inherited disorders of metabolism (520)

Histiocytic disorders (570)

Autoimmune diseases (600)

Other disease (900)

Acute Myelogenous Leukemia (AML) Questions: 3 - 89

Specify the AML classification3

Did AML transform from MDS or MPN?4

yes - Also complete MDS Disease Classification questions

no

Is the disease (AML) therapy related?

yes no Unknown

5

Did the recipient have a predisposing condition?

yes no Unknown

6

Specify condition7

Bloom syndrome

Down syndrome

Fanconi anemia

Dyskeratosis congenita

Other condition

Specify other condition:8

Were cytogenetics tested (karyotyping or FISH)? (at diagnosis)

yes no Unknown

9

Were cytogenetics tested via FISH? (at diagnosis)

Yes No

10

Results of tests11

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities12

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

13

Specify other abnormality:14

Were cytogenetics tested via karyotyping? (at diagnosis)

Yes No

15

Results of tests16

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities17

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

18

Specify other abnormality:19

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

20

Were tests for molecular markers performed? (e.g. PCR, NGS) (at diagnosis)

yes no Unknown

21

CEBPA

Positive Negative Not Done

22

Specify CEBPA mutation23

Biallelic (homozygous)

Monoallelic (heterozygous)

Unknown

FLT3 – D835 point mutation

Positive Negative Not Done

24

FLT3 – ITD mutation

Positive Negative Not Done

25

FLT3 - ITD allelic ratio

Known Unknown

26

Specify FLT3 - ITD allelic ratio:27

IDH1

Positive Negative Not Done

28

IDH2

Positive Negative Not Done

29

KIT

Positive Negative Not Done

30

NPM1

Positive Negative Not Done

31

Other Molecular Marker (1) Questions: 32 - 33

Other molecular marker

Positive Negative Not Done

32

Specify other molecular marker:33

Were cytogenetics tested (karyotyping or FISH)? (between diagnosis and last evaluation)

yes no Unknown

34

Were cytogenetics tested via FISH? (between diagnosis and last evaluation)

Yes No

35

Results of tests36

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities37

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

38

Specify other abnormality:39

Were cytogenetics tested via karyotyping? (between diagnosis and last evaluation)

Yes No

40

Results of tests41

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities42

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

43

Specify other abnormality:44

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

45

Were tests for molecular markers performed? (e.g. PCR, NGS) (between diagnosis and last evaluation)

yes no Unknown

46

CEBPA

Positive Negative Not Done

47

Specify CEBPA mutation48

Biallelic (homozygous)

Monoallelic (heterozygous)

Unknown

FLT3 – D835 point mutation

Positive Negative Not Done

49

FLT3 – ITD mutation

Positive Negative Not Done

50

FLT3 - ITD allelic ratio

Known Unknown

51

Specify FLT3 - ITD allelic ratio:52

IDH1

Positive Negative Not Done

53

IDH2

Positive Negative Not Done

54

KIT

Positive Negative Not Done

55

NPM1

Positive Negative Not Done

56

Other Molecular Marker (1) Questions: 57 - 58

Other molecular marker

Positive Negative Not Done

57

Specify other molecular marker:58

Were cytogenetics tested (karyotyping or FISH)? (at last evaluation)

yes no Unknown

59

Were cytogenetics tested via FISH? (at last evaluation)

Yes No

60

Results of tests61

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities62

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

63

Specify other abnormality:64

Were cytogenetics tested via karyotyping? (at last evaluation)

Yes No

65

Results of tests66

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities67

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

68

Specify other abnormality:69

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

70

Were tests for molecular markers performed? (e.g. PCR, NGS) (at last evaluation)

yes no Unknown

71

CEBPA

Positive Negative Not Done

72

Specify CEBPA mutation73

Biallelic (homozygous)

Monoallelic (heterozygous)

Unknown

FLT3 – D835 point mutation

Positive Negative Not Done

74

FLT3 – ITD mutation

Positive Negative Not Done

75

FLT3 - ITD allelic ratio

Known Unknown

76

Specify FLT3 - ITD allelic ratio:77

IDH1

Positive Negative Not Done

78

IDH2

Positive Negative Not Done

79

KIT

Positive Negative Not Done

80

NPM1

Positive Negative Not Done

81

Other Molecular Marker (1) Questions: 82 - 83

Other molecular marker

Positive Negative Not Done

82

Specify other molecular marker:83

Did the recipient have central nervous system leukemia at any time prior to the start of the preparative regimen / infusion?

yes no Unknown

84

What was the disease status (based on hematological test results)?85

Primary induction failure

1st complete remission (no previous bone marrow or extramedullary relapse) (include CRi)

2nd complete remission

≥3rd complete remission

1st relapse

2nd relapse

≥3rd relapse

No treatment

How many cycles of induction therapy were required to achieve 1st complete remission? (includes CRi)

1 2 ≥ 3

86

Was the recipient in remission by flow cytometry?

Yes No Unknown Not applicable

87

Date of most recent relapse:88 __ __ __ __ - __ __- __ __

Date assessed:89 __ __ __ __ - __ __- __ __

Acute Lymphoblastic Leukemia (ALL) Questions: 90 - 151

Specify ALL classification90

Did the recipient have a predisposing condition?

yes no Unknown

91

Specify condition92

Aplastic anemia - Also complete CIBMTR Form 2028 - APL

Bloom syndrome

Down syndrome

Fanconi anemia - Also complete CIBMTR Form 2029 - FAN

Other condition

Specify other condition:93

Were tyrosine kinase inhibitors given for therapy at any time prior to the start of the preparative regimen / infusion? (e.g. imatinib mesylate, dasatinib, etc.)

yes no

94

Were cytogenetics tested (karyotyping or FISH)? (at diagnosis)

yes no Unknown

95

Were cytogenetics tested via FISH? (at diagnosis)

Yes No

96

Results of tests97

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities98

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

99

Specify other abnormality:100

Were cytogenetics tested via karyotyping? (at diagnosis)

Yes No

101

Results of tests102

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities103

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

104

Specify other abnormality:105

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

106

Were tests for molecular markers performed? (e.g. PCR, NGS) (at diagnosis)

yes no Unknown

107

BCR / ABL

Positive Negative Not Done

108

TEL-AML / AML1

Positive Negative Not Done

109

Other Molecular Marker (1) Questions: 110 - 111

Other molecular marker

Positive Negative Not Done

110

Specify other molecular marker:111

Were cytogenetics tested (karyotyping or FISH)? (between diagnosis and last evaluation)

yes no Unknown

112

Were cytogenetics tested via FISH? (between diagnosis and last evaluation)

Yes No

113

Results of tests114

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities115

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

116

Specify other abnormality:117

Were cytogenetics tested via karyotyping? (between diagnosis and last evaluation)

Yes No

118

Results of tests119

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities120

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

121

Specify other abnormality:122

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

123

Were tests for molecular markers performed? (e.g. PCR, NGS) (between diagnosis and last evaluation)

yes no Unknown

124

BCR / ABL

Positive Negative Not Done

125

TEL-AML / AML1

Positive Negative Not Done

126

Other Molecular Marker (1) Questions: 127 - 128

Other molecular marker

Positive Negative Not Done

127

Specify other molecular marker:128

Were cytogenetics tested (karyotyping or FISH)? (at last evaluation)

yes no Unknown

129

Were cytogenetics tested via FISH? (at last evaluation)

Yes No

130

Results of tests131

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities132

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

133

Specify other abnormality:134

Were cytogenetics tested via karyotyping? (at last evaluation)

Yes No

135

Results of tests136

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities137

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

138

Specify other abnormality:139

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

140

Were tests for molecular markers performed? (e.g. PCR, NGS) (at last evaluation)

yes no Unknown

141

BCR / ABL

Positive Negative Not Done

142

TEL-AML / AML1

Positive Negative Not Done

143

Other Molecular Marker (1) Questions: 144 - 145

Other molecular marker

Positive Negative Not Done

144

Specify other molecular marker:145

Did the recipient have central nervous system leukemia at any time prior to the start of the preparative regimen / infusion?

yes no Unknown

146

What was the disease status (based on hematological test results)?147

Primary induction failure

1st complete remission (no previous marrow or extramedullary relapse) (include CRi)

2nd complete remission

≥3rd complete remission

1st relapse

2nd relapse

≥3rd relapse

No treatment

How many cycles of induction therapy were required to achieve 1st complete remission? (include CRi)

1 2 ≥ 3

148

Was the recipient in remission by flow cytometry?

Yes No Unknown Not applicable

149

Date of most recent relapse:150 __ __ __ __ - __ __- __ __

Date assessed:151 __ __ __ __ - __ __- __ __

Acute Leukemias of Ambiguous Lineage and Other Myeloid Neoplasms Questions: 152 - 155

Specify acute leukemias of ambiguous lineage and other myeloid neoplasm classification152

Blastic plasmacytoid dendritic cell neoplasm (296)

Acute undifferentiated leukemia (31)

Mixed phenotype acute leukemia (MPAL) with t(9;22)(q34.1;q11.2); BCR-ABL1 (84)

Mixed phenotype acute leukemia with t(v; 11q23.3); KMT2A rearranged (85)

Mixed phenotype acute leukemia, B/myeloid, NOS (86)

Mixed phenotype acute leukemia, T/myeloid, NOS (87)

Other acute leukemia of ambiguous lineage or myeloid neoplasm (88)

Specify other acute leukemia of ambiguous lineage or myeloid neoplasm:153

What was the disease status (based on hematological test results)?154

Primary induction failure

1st complete remission (no previous marrow or extramedullary relapse)

2nd complete remission

≥3rd complete remission

1st relapse

2nd relapse

≥3rd relapse

No treatment

Date assessed:155 __ __ __ __ - __ __- __ __

Chronic Myelogenous Leukemia (CML) Questions: 156 - 166

Was therapy given prior to this HCT?

yes no

156

Combination chemotherapy

yes no

157

Hydroxyurea (Droxia, Hydrea)

yes no

158

Tyrosine kinase inhibitor (e.g. imatinib mesylate, dasatinib, nilotinib)

yes no

159

Interferon­α (Intron, Roferon) (includes PEG)

yes no

160

Other therapy

yes no

161

Specify other therapy:162

What was the disease status?163

Complete hematologic response (CHR)

Chronic phase

Accelerated phase

Blast phase

Specify level of response164

No cytogenetic response (No CyR)

Minimal cytogenetic response

Minor cytogenetic response

Partial cytogenetic response (PCyR)

Complete cytogenetic response (CCyR)

Major molecular remission (MMR)

Complete molecular remission (CMR)

Number

1st 2nd 3rd or higher

165

Date assessed:166 __ __ __ __ - __ __- __ __

Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases Questions: 167 - 260

What was the MDS / MPN subtype at diagnosis? - If transformed to AML, indicate AML as primary disease; also complete AML Disease Classification
questions

167

Was the disease (MDS/MPN) therapy related?

yes no Unknown

168

Did the recipient have a predisposing condition?

yes no Unknown

169

Specify condition

Aplastic Anemia Bloom syndrome Down syndrome Fanconi anemia Other condition

170

Specify other condition:171

WBC

Known Unknown

172

173 x 109/L (x 103/mm3)

x 106/L

Hemoglobin

Known Unknown

174

175 g/dL g/L mmol/L

Was RBC transfused ≤ 30 days before date of test?

Yes No

176

Platelets

Known Unknown

177

178 x 109/L (x 103/mm3)

x 106/L

Were platelets transfused ≤ 7 days before date of test?

Yes No

179

Neutrophils

Known Unknown

180

181 %

Blasts in bone marrow

Known Unknown

182

183 %

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

184

Results of tests185

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities186

One (1)

Two (2)

Three (3)

Four or more (4 or more)

–5

yes no

187

-7

yes no

188

–13

yes no

189

–20

yes no

190

–Y

yes no

191

+8

yes no

192

+19

yes no

193

t(1;3)

yes no

194

t(2;11)

yes no

195

t(3;3)

yes no

196

t(3;21)

yes no

197

t(6;9)

yes no

198

t(11;16)

yes no

199

del(3q) / 3q–

yes no

200

del(5q) / 5q-

yes no

201

del(7q) / 7q–

yes no

202

del(9q) / 9q–

yes no

203

del(11q) / 11q–

yes no

204

del(12p) / 12p–

yes no

205

del(13q) / 13q-

yes no

206

del(20q) / 20q–

yes no

207

inv(3)

yes no

208

i17q

yes no

209

Other abnormality

yes no

210

Specify other abnormality:211

Did the recipient progress or transform to a different MDS / MPN subtype between diagnosis and the start of the preparative regimen?

yes no

212

Specify the MDS / MPN classification after transformation:213

Specify the date of the most recent transformation:214 __ __ __ __ - __ __- __ __

Date of MDS diagnosis:215 __ __ __ __ - __ __- __ __

WBC

Known Unknown

216

217 x 109/L (x 103/mm3)

x 106/L

Hemoglobin

Known Unknown

218

219 g/dL g/L mmol/L

Was RBC transfused ≤ 30 days before date of test?

Yes No

220

Platelets

Known Unknown

221

222 x 109/L (x 103/mm3)

x 106/L

Were platelets transfused ≤ 7 days before date of test?

Yes No

223

Neutrophils

Known Unknown

224

225 %

Blasts in bone marrow

Known Unknown

226

227 %

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

228

Results of tests229

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities230

One (1)

Two (2)

Three (3)

Four or more (4 or more)

–5

yes no

231

-7

yes no

232

–13

yes no

233

–20

yes no

234

–Y

yes no

235

+8

yes no

236

+19

yes no

237

t(1;3)

yes no

238

t(2;11)

yes no

239

t(3;3)

yes no

240

t(3;21)

yes no

241

t(6;9)

yes no

242

t(11;16)

yes no

243

del(3q) / 3q–

yes no

244

del(5q) / 5q-

yes no

245

del(7q) / 7q–

yes no

246

del(9q) / 9q–

yes no

247

del(11q) / 11q–

yes no

248

del(12p) / 12p–

yes no

249

del(13q) / 13q-

yes no

250

del(20q) / 20q–

yes no

251

inv(3)

yes no

252

i17q

yes no

253

Other abnormality

yes no

254

Specify other abnormality:255

What was the disease status?256

Complete
remission
(CR)

– requires all of the following, maintained for ≥ 4 weeks: * bone marrow evaluation: <  5% myeloblasts with normal maturation of all cell lines *
peripheral blood evaluation: hemoglobin ≥ 11 g/dL untransfused and without erythropoietin support; ANC ≥ 1000/mm3  without myeloid growth factor
support; platelets ≥ 100 x 109/L without thrombopoietic support; 0% blasts

Hematologic
improvement
(HI)

– requires one measurement of the following, maintained for ≥ 8 weeks without ongoing cytotoxic therapy; specify which cell line was measured to
determine HI response: * HI­E – hemoglobin increase of ≥ 1.5 g/dL untransfused; for RBC transfusions performed for Hgb ≤ 9.0, reduction in RBC
units transfused in 8 weeks by ≥ 4 units compared to the pre­treatment transfusion number in 8 weeks * HI­P – for pre­treatment platelet count of > 20
x 109/L, platelet absolute increase of ≥ 30 x 109/L; for pre-treatment platelet count of < 20 x 109/L, platelet absolute increase of ≥ 20 x 109/L and ≥
100% from pre­treatment level  * HI­N – neutrophil count increase of ≥ 100% from pre­treatment level and an absolute increase of ≥ 500/mm3

No response (NR) / stable disease (SD) – does not meet the criteria for at least HI, but no evidence of disease progression

Progression from
hematologic improvement
(Prog from HI)

– requires at least one of the following, in the absence of another explanation (e.g., infection, bleeding, ongoing chemotherapy, etc.): *
≥ 50% reduction from maximum response levels in granulocytes or platelets * reduction in hemoglobin by ≥ 1.5 g/dL *transfusion
dependence

Relapse from complete
remission (Rel from CR)

– requires at least one of the following: * return to pre­treatment bone marrow blast percentage * decrease of ≥ 50% from maximum
response levels in granulocytes or platelets * transfusion dependence, or hemoglobin level ≥ 1.5 g/dL lower than prior to therapy

Not assessed

Specify the cell line examined to determine HI status257

HI-
E

– hemoglobin increase of ≥ 1.5 g/dL untransfused; for RBC transfusions performed for Hgb ≤ 9.0, reduction in RBC units transfused in 8 weeks by ≥ 4
units compared to the pre-treatment transfusion number in 8 weeks

HI-
P

– for pre­treatment platelet count of > 20 x 109/L, platelet absolute increase of ≥ 30 x 109/L; for pre-treatment platelet count of < 20 x 109/L, platelet
absolute increase of ≥ 20 x 109/L and ≥ 100% from pre­treatment level 

HI-N – neutrophil count increase of ≥ 100% from pre­treatment level and an absolute increase of ≥ 500/mm3

Date of progression:258 __ __ __ __ - __ __- __ __

Date of relapse:259 __ __ __ __ - __ __- __ __

Date assessed:260 __ __ __ __ - __ __- __ __

Other Leukemia (OL) Questions: 261 - 267

Specify the other leukemia classification261

Specify other leukemia:262

Was any 17p abnormality detected?

yes no

263

Did a histologic transformation to diffuse large B-cell lymphoma (Richter syndrome) occur at any time after CLL diagnosis?264

yes - Also complete NHL Disease Classification questions

no

What was the disease status? (Atypical CML)265

Primary induction failure

1st complete remission (no previous bone marrow or extramedullary relapse)

2nd complete remission

≥3rd complete remission

1st relapse

2nd relapse

≥3rd relapse

No treatment

What was the disease status? (CLL, PLL, Hairy cell leukemia)266

Complete remission (CR)

Partial remission (PR)

Stable disease (SD)

Progressive disease (Prog)

Untreated

Not assessed

Date assessed:267 __ __ __ __ - __ __- __ __

Hodgkin and Non-Hodgkin Lymphoma Questions: 268 - 285

Specify the lymphoma histology (at infusion)268

Specify other lymphoma histology:269

Assignment of DLBCL (germinal center B-cell type vs. activated B-cell type) subtype was based on270

Immunohistochemistry (e.g. Han's algorithm)

Gene expression profile

Unknown method

Is the lymphoma histology reported at transplant a transformation from CLL?

yes no

271

Was any 17p abnormality detected?

yes no

272

Is the lymphoma histology reported at transplant a transformation from a different lymphoma histology? (Not CLL)

Yes No

273

Specify the original lymphoma histology (prior to transformation)274

Specify other lymphoma histology:275

Date of original lymphoma diagnosis:276 __ __ __ __ - __ __- __ __ (report the date of diagnosis of original lymphoma subtype)

Was a PET (or PET/CT) scan performed? (at last evaluation prior to the start of the preparative regimen / infusion)

yes no

277

Was the PET (or PET/CT) scan positive for lymphoma involvement at any disease site?

yes no

278

Date of PET scan

Known Unknown

279

Date of PET (or PET/CT) scan:280 __ __ __ __ - __ __- __ __

Deauville (five-point) score of the PET (or PET/CT) scan

Known Unknown

281

Scale282

1 - no uptake or residual uptake

2 - slight uptake, but below blood pool (mediastinum)

3 - uptake above mediastinal, but below or equal to uptake in the liver

4 - uptake slightly to moderately higher than liver

5 - markedly increased uptake or any new lesions

What was the disease status?283

Total number of lines of therapy received

1 line 2 lines 3+ lines

284

Date assessed:285 __ __ __ __ - __ __- __ __

Multiple Myeloma / Plasma Cell Disorder (PCD) Questions: 286 - 317

Specify the multiple myeloma/plasma cell disorder (PCD) classification286

Specify other plasma cell disorder:287

Light chain

kappa lambda

288

What was the Durie-Salmon staging? (at diagnosis)289

Stage
I

(All of the following: Hgb > 10g/dL; serum calcium normal or <10.5 mg/dL; bone x-ray normal bone structure (scale 0), or solitary bone plasmacytoma
only; low M-component production rates IgG< 5g/dL, IgA < 3g/dL; urine light chain M-component on electrophoresis <4 g/24h)

Stage II (Fitting neither Stage I or III) 

Stage
III

(One or more of the following: Hgb < 8.5 g/dL; serum calcium > 12 mg/dL; advanced lytic bone lesions (scale 3); high M-component production rates
IgG > 7g/dL, IgA > 5 g/dL; Bence Jones protein > 12g/24h)

Unknown

What was the Durie-Salmon sub classification? (at diagnosis)290

A - relatively normal renal function (serum creatinine < 2.0 mg/dL)

B ­ abnormal renal function (serum creatinine ≥ 2.0 mg/dL)

Serum β2­microglobulin:291 μg/dL mg/L nmol/L

Serum albumin:292 g/dL g/L

Stage293

1 (β2 ­mic < 3.5, S. albumin ≥3.5)

2 (Not fitting stage 1 or 3)

3 (β2­mic ≥ 5.5; S. albumin ­)

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

294

Results of tests295

Abnormalities identified

No evaluable metaphases

No abnormalities

+3

yes no

296

+5

yes no

297

+7

yes no

298

+9

yes no

299

+11

yes no

300

+15

yes no

301

+19

yes no

302

t(4;14)

yes no

303

t(6;14)

yes no

304

t(11;14)

yes no

305

t(14;16)

yes no

306

t(14;20)

yes no

307

del(13q) / 13q-

yes no

308

del (17p) / 17p-

yes no

309

Hyperdiploid (>50)

yes no

310

Hypodiploid (<46)

yes no

311

Any abnormality at 1q

yes no

312

Any abnormality at 1p

yes no

313

Other abnormality

yes no

314

Specify other abnormality:315

What was the disease status?316

Stringent

complete
remission

(sCR)

- CR as defined, plus: normal free light chain ratio, and absence of clonal cells in the bone marrow by immunohistochemistry of immunofluorescence

(confirmation with repeat bone marrow biopsy not needed). (Presence and/or absence of clonal cells is based upon the Κ/λ ratio. An abnormal Κ/λ ratio by
immunohistochemistry and/or immunofluorescence requires a minimum of 100 plasma cells for analysis.  An abnormal ratio reflecting the presence of

an abnormal clone is Κ/λ of > 4:1 or < 1:2.) sCR requires two consecutive assessments made at any time before the institution of any new therapy, and
no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy sCR

requirements. 

Complete

remission
(CR)

- negative immunofixation on serum and urine samples, and disappearance of any soft tissue plasmacytomas, and < 5% plasma cells in the bone

marrow (confirmation with repeat bone marrow biopsy not needed).  CR requires two consecutive assessments made at any time before the institution
of any new therapy, and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not

required to satisfy CR requirements. 

Near

complete
remission

(nCR)

- serum and urine M-protein detectable by immunoelectrophoresis (IFE), but not on electrophoresis (negative SPEP & UPEP); < 5% plasma cells in

bone marrow.  nCR requires two consecutive assessments made at any time before the initiation of any new therapy, and no known evidence of
progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy nCR requirements. 

Very good

partial
remission

(VGPR)

­ serum and urine M­protein detectable by immunofixation but not on electrophoresis, or ≥ 90% reduction in serum M­protein and urine M­protein level <
100 mg/24 hours.  VGPR requires two consecutive assessments made at any time before the institution of any new therapy, and no known evidence of
progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy VGPR requirements.

Partial

remission
(PR)

­ ≥ 50% reduction in serum M­protein, and reduction in 24­hour urinary M­protein by ≥ 90% or to < 200 mg/24 hours.  If the serum and urine M­protein are
unmeasurable (i.e., do not meet any of the following criteria: • serum M­protein ≥ 1 g/dL.  Urine M­protein ≥ 200 mg/24 hours • serum free light chain
assay shows involved level ≥ 10 mg/dL, provided serum free light chain ratio is abnormal), a ≥ 50% decrease in the difference between involved and
uninvolved free light chain levels is required in place of the M-protein criteria.  If serum and urine M-protein are unmeasurable, and serum free light assay
is also unmeasurable, a ≥ 50% reduction in plasma cells is required in place of M­protein, provided the baseline bone marrow plasma cell percentage
was ≥ 30%. In addition to the above listed criteria, a ≥ 50% reduction in the size of soft tissue plasmacytomas is also required, if present at baseline. PR
requires two consecutive assessments made at any time before the institution of any new therapy, and no known evidence of progressive or new bone

lesions if radiographic studies were performed; radiographic studies are not required to satisfy PR requirements. 

Stable

disease
(SD)

- not meeting the criteria for CR, VGPR, PR or PD.  SD requires two consecutive assessments made at any time before the institution of any new therapy,

and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy SD
requirements.

Progressive
disease

(PD)

­ requires any one or more of the following:  Increase of ≥ 25% from baseline in:  serum M­component and/or (absolute increase ≥ 0.5 g/dL) (for
progressive disease, serum M­component increases of ≥ 1 g/dL are sufficient to define relapse if the starting M­component is ≥ 5 g/dL).  Urine M­
component and/or (absolute increase ≥ 200 mg/24 hours) for recipients without measurable serum and urine M­protein levels: the difference between
involved and uninvolved free light chain levels (absolute increase > 10 mg/dL).  Bone marrow plasma cell percentage (absolute percentage ≥ 10%)
(relapse from CR has a 5% cutoff vs. 10% for other categories of relapse) definite development of new bone lesions or soft tissue plasmacytomas, or
definite increase in the size of any existing  bone lesions or soft tissue plasmacytomas. Development of hypercalcemia (corrected serum calcium >

11.5 mg/dL or 2.65 mmol) that can be attributed solely to the plasma cell proliferative disorder.  PD requires two consecutive assessments made at
any time before classification as disease progression, and/or the institution of any new therapy.

Relapse
from CR

(Rel)
(untreated)

­ requires one or more of the following: reappearance of serum or urine M­protein by immunofixation or electrophoresis development of ≥ 5% plasma
cells in the bone marrow (relapse from CR has a 5% cutoff vs. 10% for other categories of relapse) appearance of any other sign of progression (e.g.,

new plasmacytoma, lytic bone lesion, hypercalcemia).  Rel requires two consecutive assessments made at any time before classification as relapse,
and/or the institution of any new therapy.

Unknown

Not applicable (Amyloidosis with no evidence of myeloma)

Date assessed:317 __ __ __ __ - __ __- __ __

Solid Tumors Questions: 318 - 319

Specify the solid tumor classification318

Specify other solid tumor:319

Severe Aplastic Anemia Questions: 320 - 321

Specify the severe aplastic anemia classification320

Specify other acquired cytopenic syndrome:321

Inherited Abnormalities of Erythrocyte Differentiation or Function Questions: 322 - 324

Specify the inherited abnormalities of erythrocyte differentiation or function classification322

Specify other constitutional anemia:323

Specify other hemoglobinopathy:324

Disorders of the Immune System Questions: 325 - 327

Specify disorder of immune system classification325

Specify other SCID:326

Specify other immunodeficiency:327

Inherited Abnormalities of Platelets Questions: 328 - 329

Specify inherited abnormalities of platelets classification328

Congenital amegakaryocytosis / congenital thrombocytopenia (501)

Glanzmann thrombasthenia (502)

Other inherited platelet abnormality (509)

Specify other inherited platelet abnormality:329

Inherited Disorders of Metabolism Questions: 330 - 331

Specify inherited disorders of metabolism classification330

Specify other inherited metabolic disorder:331

Histiocytic Disorders Questions: 332 - 333

Specify histiocytic disorder classification332

Specify other histiocytic disorder:333

Autoimmune Diseases Questions: 334 - 341

Specify autoimmune disease classification334

Specify other arthritis:335

Specify other juvenile idiopathic arthritis (JIA):336

Specify other connective tissue disease:337

Specify other vasculitis:338

Specify other autoimmune neurological disorder:339

Specify other autoimmune cytopenia:340

Specify other autoimmune bowel disorder:341

Other Disease Questions: 342 - 342

Specify other disease:342

First Name:

Last Name:

E-mail address:

Date: __ __ __ __ - __ __- __ __

OMB No: 0915-0310

Expiration Date: 1/31/2020

Public Burden Statement:  An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control
number.  The OMB control number for this project is 0915-0310.  Public reporting burden for this collection of information is estimated to average 1.0 hours per response, including the
time for reviewing instructions, searching existing data sources, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other
aspect of this collection of information, including suggestions for reducing this burden, to HRSA Reports Clearance Officer, 5600 Fishers Lane, Room 10-29, Rockville, Maryland, 20857.

Labs at diagnosis

Specify cytogenetic abnormalities identified at diagnosis:

Specify cytogenetic abnormalities identified at diagnosis:

Specify molecular markers identified at diagnosis:

Labs between diagnosis and last evaluation:

Specify cytogenetic abnormalities identified between diagnosis and last evaluation:

Specify cytogenetic abnormalities identified between diagnosis and last evaluation:

Specify molecular markers identified between diagnosis and last evaluation:

Labs at last evaluation:

Specify cytogenetic abnormalities identified at last evaluation:

Specify cytogenetic abnormalities identified at last evaluation:

Specify molecular markers identified at last evaluation:

CNS Leukemia

Status at transplantation:

Laboratory studies at diagnosis:

Specify cytogenetic abnormalities identified at diagnosis:

Specify cytogenetic abnormalities identified at diagnosis:

Specify molecular markers identified at diagnosis:

Laboratory studies between diagnosis and last evaluation:

Specify cytogenetic abnormalities identified between diagnosis and last evaluation:

Specify cytogenetic abnormalities identified between diagnosis and last evaluation:

Specify molecular markers identified between diagnosis and last evaluation:

Laboratory studies at last evaluation:

Specify cytogenetic abnormalities identified at last evaluation:

Specify cytogenetic abnormalities identified at last evaluation:

Specify molecular markers identified at last evaluation:

CNS Leukemia

Status at transplantation:

Status at transplantation:

Laboratory studies at diagnosis of MDS:

Specify abnormalities identified at diagnosis:

Monosomy

Trisomy

Translocation

Deletion

Inversion

Other

Laboratory studies at last evaluation prior to the start of the preparative regimen:

Specify cytogenetic abnormalities identified at last evaluation prior to the start of the preparative regimen:

Monosomy

Trisomy

Translocation

Deletion

Inversion

Other

Status at transplantation:

Status at transplantation:

Status at transplantation / infusion:

I.S.S.:

Specify cytogenetic abnormalities identified at any time prior to the start of the preparative regimen:

Trisomy

Translocation

Deletion

Other

Status at transplantation:

Center: CRID: 

Form 2402 R3.0: Disease Classification

CIBMTR Form 2402 revision 3.0 last updated Monday, January 29, 2018
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 12 / 26



Key Fields

Sequence Number:

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number:

CIBMTR Research ID:

Event date: __ __ __ __ - __ __- __ __

Primary Disease for HCT / Cellular Therapy Questions: 1 - 2

Date of diagnosis of primary disease for HCT / cellular therapy:1 __ __ __ __ - __ __- __ __

What was the primary disease for which the HCT / cellular therapy was performed?2

Acute myelogenous leukemia (AML or ANLL) (10)

Acute lymphoblastic leukemia (ALL) (20)

Acute leukemia of ambiguous lineage and other myeloid neoplasms (80)

Chronic myelogenous leukemia (CML) (40)

Myelodysplastic (MDS) / myeloproliferative (MPN) diseases (50) (Please classify all preleukemias) (If recipient has transformed to AML, indicate AML as the primary disease)

Other leukemia (30) (includes CLL)

Hodgkin lymphoma (150)

Non-Hodgkin lymphoma (100)

Multiple myeloma / plasma cell disorder (PCD) (170)

Solid tumors (200)

Severe aplastic anemia (300) (If the recipient developed MDS or AML, indicate MDS or AML as the primary disease)

Inherited abnormalities of erythrocyte differentiation or function (310)

Disorders of the immune system (400)

Inherited abnormalities of platelets (500)

Inherited disorders of metabolism (520)

Histiocytic disorders (570)

Autoimmune diseases (600)

Other disease (900)

Acute Myelogenous Leukemia (AML) Questions: 3 - 89

Specify the AML classification3

Did AML transform from MDS or MPN?4

yes - Also complete MDS Disease Classification questions

no

Is the disease (AML) therapy related?

yes no Unknown

5

Did the recipient have a predisposing condition?

yes no Unknown

6

Specify condition7

Bloom syndrome

Down syndrome

Fanconi anemia

Dyskeratosis congenita

Other condition

Specify other condition:8

Were cytogenetics tested (karyotyping or FISH)? (at diagnosis)

yes no Unknown

9

Were cytogenetics tested via FISH? (at diagnosis)

Yes No

10

Results of tests11

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities12

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

13

Specify other abnormality:14

Were cytogenetics tested via karyotyping? (at diagnosis)

Yes No

15

Results of tests16

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities17

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

18

Specify other abnormality:19

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

20

Were tests for molecular markers performed? (e.g. PCR, NGS) (at diagnosis)

yes no Unknown

21

CEBPA

Positive Negative Not Done

22

Specify CEBPA mutation23

Biallelic (homozygous)

Monoallelic (heterozygous)

Unknown

FLT3 – D835 point mutation

Positive Negative Not Done

24

FLT3 – ITD mutation

Positive Negative Not Done

25

FLT3 - ITD allelic ratio

Known Unknown

26

Specify FLT3 - ITD allelic ratio:27

IDH1

Positive Negative Not Done

28

IDH2

Positive Negative Not Done

29

KIT

Positive Negative Not Done

30

NPM1

Positive Negative Not Done

31

Other Molecular Marker (1) Questions: 32 - 33

Other molecular marker

Positive Negative Not Done

32

Specify other molecular marker:33

Were cytogenetics tested (karyotyping or FISH)? (between diagnosis and last evaluation)

yes no Unknown

34

Were cytogenetics tested via FISH? (between diagnosis and last evaluation)

Yes No

35

Results of tests36

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities37

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

38

Specify other abnormality:39

Were cytogenetics tested via karyotyping? (between diagnosis and last evaluation)

Yes No

40

Results of tests41

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities42

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

43

Specify other abnormality:44

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

45

Were tests for molecular markers performed? (e.g. PCR, NGS) (between diagnosis and last evaluation)

yes no Unknown

46

CEBPA

Positive Negative Not Done

47

Specify CEBPA mutation48

Biallelic (homozygous)

Monoallelic (heterozygous)

Unknown

FLT3 – D835 point mutation

Positive Negative Not Done

49

FLT3 – ITD mutation

Positive Negative Not Done

50

FLT3 - ITD allelic ratio

Known Unknown

51

Specify FLT3 - ITD allelic ratio:52

IDH1

Positive Negative Not Done

53

IDH2

Positive Negative Not Done

54

KIT

Positive Negative Not Done

55

NPM1

Positive Negative Not Done

56

Other Molecular Marker (1) Questions: 57 - 58

Other molecular marker

Positive Negative Not Done

57

Specify other molecular marker:58

Were cytogenetics tested (karyotyping or FISH)? (at last evaluation)

yes no Unknown

59

Were cytogenetics tested via FISH? (at last evaluation)

Yes No

60

Results of tests61

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities62

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

63

Specify other abnormality:64

Were cytogenetics tested via karyotyping? (at last evaluation)

Yes No

65

Results of tests66

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities67

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

68

Specify other abnormality:69

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

70

Were tests for molecular markers performed? (e.g. PCR, NGS) (at last evaluation)

yes no Unknown

71

CEBPA

Positive Negative Not Done

72

Specify CEBPA mutation73

Biallelic (homozygous)

Monoallelic (heterozygous)

Unknown

FLT3 – D835 point mutation

Positive Negative Not Done

74

FLT3 – ITD mutation

Positive Negative Not Done

75

FLT3 - ITD allelic ratio

Known Unknown

76

Specify FLT3 - ITD allelic ratio:77

IDH1

Positive Negative Not Done

78

IDH2

Positive Negative Not Done

79

KIT

Positive Negative Not Done

80

NPM1

Positive Negative Not Done

81

Other Molecular Marker (1) Questions: 82 - 83

Other molecular marker

Positive Negative Not Done

82

Specify other molecular marker:83

Did the recipient have central nervous system leukemia at any time prior to the start of the preparative regimen / infusion?

yes no Unknown

84

What was the disease status (based on hematological test results)?85

Primary induction failure

1st complete remission (no previous bone marrow or extramedullary relapse) (include CRi)

2nd complete remission

≥3rd complete remission

1st relapse

2nd relapse

≥3rd relapse

No treatment

How many cycles of induction therapy were required to achieve 1st complete remission? (includes CRi)

1 2 ≥ 3

86

Was the recipient in remission by flow cytometry?

Yes No Unknown Not applicable

87

Date of most recent relapse:88 __ __ __ __ - __ __- __ __

Date assessed:89 __ __ __ __ - __ __- __ __

Acute Lymphoblastic Leukemia (ALL) Questions: 90 - 151

Specify ALL classification90

Did the recipient have a predisposing condition?

yes no Unknown

91

Specify condition92

Aplastic anemia - Also complete CIBMTR Form 2028 - APL

Bloom syndrome

Down syndrome

Fanconi anemia - Also complete CIBMTR Form 2029 - FAN

Other condition

Specify other condition:93

Were tyrosine kinase inhibitors given for therapy at any time prior to the start of the preparative regimen / infusion? (e.g. imatinib mesylate, dasatinib, etc.)

yes no

94

Were cytogenetics tested (karyotyping or FISH)? (at diagnosis)

yes no Unknown

95

Were cytogenetics tested via FISH? (at diagnosis)

Yes No

96

Results of tests97

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities98

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

99

Specify other abnormality:100

Were cytogenetics tested via karyotyping? (at diagnosis)

Yes No

101

Results of tests102

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities103

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

104

Specify other abnormality:105

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

106

Were tests for molecular markers performed? (e.g. PCR, NGS) (at diagnosis)

yes no Unknown

107

BCR / ABL

Positive Negative Not Done

108

TEL-AML / AML1

Positive Negative Not Done

109

Other Molecular Marker (1) Questions: 110 - 111

Other molecular marker

Positive Negative Not Done

110

Specify other molecular marker:111

Were cytogenetics tested (karyotyping or FISH)? (between diagnosis and last evaluation)

yes no Unknown

112

Were cytogenetics tested via FISH? (between diagnosis and last evaluation)

Yes No

113

Results of tests114

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities115

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

116

Specify other abnormality:117

Were cytogenetics tested via karyotyping? (between diagnosis and last evaluation)

Yes No

118

Results of tests119

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities120

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

121

Specify other abnormality:122

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

123

Were tests for molecular markers performed? (e.g. PCR, NGS) (between diagnosis and last evaluation)

yes no Unknown

124

BCR / ABL

Positive Negative Not Done

125

TEL-AML / AML1

Positive Negative Not Done

126

Other Molecular Marker (1) Questions: 127 - 128

Other molecular marker

Positive Negative Not Done

127

Specify other molecular marker:128

Were cytogenetics tested (karyotyping or FISH)? (at last evaluation)

yes no Unknown

129

Were cytogenetics tested via FISH? (at last evaluation)

Yes No

130

Results of tests131

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities132

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

133

Specify other abnormality:134

Were cytogenetics tested via karyotyping? (at last evaluation)

Yes No

135

Results of tests136

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities137

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

138

Specify other abnormality:139

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

140

Were tests for molecular markers performed? (e.g. PCR, NGS) (at last evaluation)

yes no Unknown

141

BCR / ABL

Positive Negative Not Done

142

TEL-AML / AML1

Positive Negative Not Done

143

Other Molecular Marker (1) Questions: 144 - 145

Other molecular marker

Positive Negative Not Done

144

Specify other molecular marker:145

Did the recipient have central nervous system leukemia at any time prior to the start of the preparative regimen / infusion?

yes no Unknown

146

What was the disease status (based on hematological test results)?147

Primary induction failure

1st complete remission (no previous marrow or extramedullary relapse) (include CRi)

2nd complete remission

≥3rd complete remission

1st relapse

2nd relapse

≥3rd relapse

No treatment

How many cycles of induction therapy were required to achieve 1st complete remission? (include CRi)

1 2 ≥ 3

148

Was the recipient in remission by flow cytometry?

Yes No Unknown Not applicable

149

Date of most recent relapse:150 __ __ __ __ - __ __- __ __

Date assessed:151 __ __ __ __ - __ __- __ __

Acute Leukemias of Ambiguous Lineage and Other Myeloid Neoplasms Questions: 152 - 155

Specify acute leukemias of ambiguous lineage and other myeloid neoplasm classification152

Blastic plasmacytoid dendritic cell neoplasm (296)

Acute undifferentiated leukemia (31)

Mixed phenotype acute leukemia (MPAL) with t(9;22)(q34.1;q11.2); BCR-ABL1 (84)

Mixed phenotype acute leukemia with t(v; 11q23.3); KMT2A rearranged (85)

Mixed phenotype acute leukemia, B/myeloid, NOS (86)

Mixed phenotype acute leukemia, T/myeloid, NOS (87)

Other acute leukemia of ambiguous lineage or myeloid neoplasm (88)

Specify other acute leukemia of ambiguous lineage or myeloid neoplasm:153

What was the disease status (based on hematological test results)?154

Primary induction failure

1st complete remission (no previous marrow or extramedullary relapse)

2nd complete remission

≥3rd complete remission

1st relapse

2nd relapse

≥3rd relapse

No treatment

Date assessed:155 __ __ __ __ - __ __- __ __

Chronic Myelogenous Leukemia (CML) Questions: 156 - 166

Was therapy given prior to this HCT?

yes no

156

Combination chemotherapy

yes no

157

Hydroxyurea (Droxia, Hydrea)

yes no

158

Tyrosine kinase inhibitor (e.g. imatinib mesylate, dasatinib, nilotinib)

yes no

159

Interferon­α (Intron, Roferon) (includes PEG)

yes no

160

Other therapy

yes no

161

Specify other therapy:162

What was the disease status?163

Complete hematologic response (CHR)

Chronic phase

Accelerated phase

Blast phase

Specify level of response164

No cytogenetic response (No CyR)

Minimal cytogenetic response

Minor cytogenetic response

Partial cytogenetic response (PCyR)

Complete cytogenetic response (CCyR)

Major molecular remission (MMR)

Complete molecular remission (CMR)

Number

1st 2nd 3rd or higher

165

Date assessed:166 __ __ __ __ - __ __- __ __

Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases Questions: 167 - 260

What was the MDS / MPN subtype at diagnosis? - If transformed to AML, indicate AML as primary disease; also complete AML Disease Classification
questions

167

Was the disease (MDS/MPN) therapy related?

yes no Unknown

168

Did the recipient have a predisposing condition?

yes no Unknown

169

Specify condition

Aplastic Anemia Bloom syndrome Down syndrome Fanconi anemia Other condition

170

Specify other condition:171

WBC

Known Unknown

172

173 x 109/L (x 103/mm3)

x 106/L

Hemoglobin

Known Unknown

174

175 g/dL g/L mmol/L

Was RBC transfused ≤ 30 days before date of test?

Yes No

176

Platelets

Known Unknown

177

178 x 109/L (x 103/mm3)

x 106/L

Were platelets transfused ≤ 7 days before date of test?

Yes No

179

Neutrophils

Known Unknown

180

181 %

Blasts in bone marrow

Known Unknown

182

183 %

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

184

Results of tests185

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities186

One (1)

Two (2)

Three (3)

Four or more (4 or more)

–5

yes no

187

-7

yes no

188

–13

yes no

189

–20

yes no

190

–Y

yes no

191

+8

yes no

192

+19

yes no

193

t(1;3)

yes no

194

t(2;11)

yes no

195

t(3;3)

yes no

196

t(3;21)

yes no

197

t(6;9)

yes no

198

t(11;16)

yes no

199

del(3q) / 3q–

yes no

200

del(5q) / 5q-

yes no

201

del(7q) / 7q–

yes no

202

del(9q) / 9q–

yes no

203

del(11q) / 11q–

yes no

204

del(12p) / 12p–

yes no

205

del(13q) / 13q-

yes no

206

del(20q) / 20q–

yes no

207

inv(3)

yes no

208

i17q

yes no

209

Other abnormality

yes no

210

Specify other abnormality:211

Did the recipient progress or transform to a different MDS / MPN subtype between diagnosis and the start of the preparative regimen?

yes no

212

Specify the MDS / MPN classification after transformation:213

Specify the date of the most recent transformation:214 __ __ __ __ - __ __- __ __

Date of MDS diagnosis:215 __ __ __ __ - __ __- __ __

WBC

Known Unknown

216

217 x 109/L (x 103/mm3)

x 106/L

Hemoglobin

Known Unknown

218

219 g/dL g/L mmol/L

Was RBC transfused ≤ 30 days before date of test?

Yes No

220

Platelets

Known Unknown

221

222 x 109/L (x 103/mm3)

x 106/L

Were platelets transfused ≤ 7 days before date of test?

Yes No

223

Neutrophils

Known Unknown

224

225 %

Blasts in bone marrow

Known Unknown

226

227 %

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

228

Results of tests229

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities230

One (1)

Two (2)

Three (3)

Four or more (4 or more)

–5

yes no

231

-7

yes no

232

–13

yes no

233

–20

yes no

234

–Y

yes no

235

+8

yes no

236

+19

yes no

237

t(1;3)

yes no

238

t(2;11)

yes no

239

t(3;3)

yes no

240

t(3;21)

yes no

241

t(6;9)

yes no

242

t(11;16)

yes no

243

del(3q) / 3q–

yes no

244

del(5q) / 5q-

yes no

245

del(7q) / 7q–

yes no

246

del(9q) / 9q–

yes no

247

del(11q) / 11q–

yes no

248

del(12p) / 12p–

yes no

249

del(13q) / 13q-

yes no

250

del(20q) / 20q–

yes no

251

inv(3)

yes no

252

i17q

yes no

253

Other abnormality

yes no

254

Specify other abnormality:255

What was the disease status?256

Complete
remission
(CR)

– requires all of the following, maintained for ≥ 4 weeks: * bone marrow evaluation: <  5% myeloblasts with normal maturation of all cell lines *
peripheral blood evaluation: hemoglobin ≥ 11 g/dL untransfused and without erythropoietin support; ANC ≥ 1000/mm3  without myeloid growth factor
support; platelets ≥ 100 x 109/L without thrombopoietic support; 0% blasts

Hematologic
improvement
(HI)

– requires one measurement of the following, maintained for ≥ 8 weeks without ongoing cytotoxic therapy; specify which cell line was measured to
determine HI response: * HI­E – hemoglobin increase of ≥ 1.5 g/dL untransfused; for RBC transfusions performed for Hgb ≤ 9.0, reduction in RBC
units transfused in 8 weeks by ≥ 4 units compared to the pre­treatment transfusion number in 8 weeks * HI­P – for pre­treatment platelet count of > 20
x 109/L, platelet absolute increase of ≥ 30 x 109/L; for pre-treatment platelet count of < 20 x 109/L, platelet absolute increase of ≥ 20 x 109/L and ≥
100% from pre­treatment level  * HI­N – neutrophil count increase of ≥ 100% from pre­treatment level and an absolute increase of ≥ 500/mm3

No response (NR) / stable disease (SD) – does not meet the criteria for at least HI, but no evidence of disease progression

Progression from
hematologic improvement
(Prog from HI)

– requires at least one of the following, in the absence of another explanation (e.g., infection, bleeding, ongoing chemotherapy, etc.): *
≥ 50% reduction from maximum response levels in granulocytes or platelets * reduction in hemoglobin by ≥ 1.5 g/dL *transfusion
dependence

Relapse from complete
remission (Rel from CR)

– requires at least one of the following: * return to pre­treatment bone marrow blast percentage * decrease of ≥ 50% from maximum
response levels in granulocytes or platelets * transfusion dependence, or hemoglobin level ≥ 1.5 g/dL lower than prior to therapy

Not assessed

Specify the cell line examined to determine HI status257

HI-
E

– hemoglobin increase of ≥ 1.5 g/dL untransfused; for RBC transfusions performed for Hgb ≤ 9.0, reduction in RBC units transfused in 8 weeks by ≥ 4
units compared to the pre-treatment transfusion number in 8 weeks

HI-
P

– for pre­treatment platelet count of > 20 x 109/L, platelet absolute increase of ≥ 30 x 109/L; for pre-treatment platelet count of < 20 x 109/L, platelet
absolute increase of ≥ 20 x 109/L and ≥ 100% from pre­treatment level 

HI-N – neutrophil count increase of ≥ 100% from pre­treatment level and an absolute increase of ≥ 500/mm3

Date of progression:258 __ __ __ __ - __ __- __ __

Date of relapse:259 __ __ __ __ - __ __- __ __

Date assessed:260 __ __ __ __ - __ __- __ __

Other Leukemia (OL) Questions: 261 - 267

Specify the other leukemia classification261

Specify other leukemia:262

Was any 17p abnormality detected?

yes no

263

Did a histologic transformation to diffuse large B-cell lymphoma (Richter syndrome) occur at any time after CLL diagnosis?264

yes - Also complete NHL Disease Classification questions

no

What was the disease status? (Atypical CML)265

Primary induction failure

1st complete remission (no previous bone marrow or extramedullary relapse)

2nd complete remission

≥3rd complete remission

1st relapse

2nd relapse

≥3rd relapse

No treatment

What was the disease status? (CLL, PLL, Hairy cell leukemia)266

Complete remission (CR)

Partial remission (PR)

Stable disease (SD)

Progressive disease (Prog)

Untreated

Not assessed

Date assessed:267 __ __ __ __ - __ __- __ __

Hodgkin and Non-Hodgkin Lymphoma Questions: 268 - 285

Specify the lymphoma histology (at infusion)268

Specify other lymphoma histology:269

Assignment of DLBCL (germinal center B-cell type vs. activated B-cell type) subtype was based on270

Immunohistochemistry (e.g. Han's algorithm)

Gene expression profile

Unknown method

Is the lymphoma histology reported at transplant a transformation from CLL?

yes no

271

Was any 17p abnormality detected?

yes no

272

Is the lymphoma histology reported at transplant a transformation from a different lymphoma histology? (Not CLL)

Yes No

273

Specify the original lymphoma histology (prior to transformation)274

Specify other lymphoma histology:275

Date of original lymphoma diagnosis:276 __ __ __ __ - __ __- __ __ (report the date of diagnosis of original lymphoma subtype)

Was a PET (or PET/CT) scan performed? (at last evaluation prior to the start of the preparative regimen / infusion)

yes no

277

Was the PET (or PET/CT) scan positive for lymphoma involvement at any disease site?

yes no

278

Date of PET scan

Known Unknown

279

Date of PET (or PET/CT) scan:280 __ __ __ __ - __ __- __ __

Deauville (five-point) score of the PET (or PET/CT) scan

Known Unknown

281

Scale282

1 - no uptake or residual uptake

2 - slight uptake, but below blood pool (mediastinum)

3 - uptake above mediastinal, but below or equal to uptake in the liver

4 - uptake slightly to moderately higher than liver

5 - markedly increased uptake or any new lesions

What was the disease status?283

Total number of lines of therapy received

1 line 2 lines 3+ lines

284

Date assessed:285 __ __ __ __ - __ __- __ __

Multiple Myeloma / Plasma Cell Disorder (PCD) Questions: 286 - 317

Specify the multiple myeloma/plasma cell disorder (PCD) classification286

Specify other plasma cell disorder:287

Light chain

kappa lambda

288

What was the Durie-Salmon staging? (at diagnosis)289

Stage
I

(All of the following: Hgb > 10g/dL; serum calcium normal or <10.5 mg/dL; bone x-ray normal bone structure (scale 0), or solitary bone plasmacytoma
only; low M-component production rates IgG< 5g/dL, IgA < 3g/dL; urine light chain M-component on electrophoresis <4 g/24h)

Stage II (Fitting neither Stage I or III) 

Stage
III

(One or more of the following: Hgb < 8.5 g/dL; serum calcium > 12 mg/dL; advanced lytic bone lesions (scale 3); high M-component production rates
IgG > 7g/dL, IgA > 5 g/dL; Bence Jones protein > 12g/24h)

Unknown

What was the Durie-Salmon sub classification? (at diagnosis)290

A - relatively normal renal function (serum creatinine < 2.0 mg/dL)

B ­ abnormal renal function (serum creatinine ≥ 2.0 mg/dL)

Serum β2­microglobulin:291 μg/dL mg/L nmol/L

Serum albumin:292 g/dL g/L

Stage293

1 (β2 ­mic < 3.5, S. albumin ≥3.5)

2 (Not fitting stage 1 or 3)

3 (β2­mic ≥ 5.5; S. albumin ­)

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

294

Results of tests295

Abnormalities identified

No evaluable metaphases

No abnormalities

+3

yes no

296

+5

yes no

297

+7

yes no

298

+9

yes no

299

+11

yes no

300

+15

yes no

301

+19

yes no

302

t(4;14)

yes no

303

t(6;14)

yes no

304

t(11;14)

yes no

305

t(14;16)

yes no

306

t(14;20)

yes no

307

del(13q) / 13q-

yes no

308

del (17p) / 17p-

yes no

309

Hyperdiploid (>50)

yes no

310

Hypodiploid (<46)

yes no

311

Any abnormality at 1q

yes no

312

Any abnormality at 1p

yes no

313

Other abnormality

yes no

314

Specify other abnormality:315

What was the disease status?316

Stringent
complete
remission
(sCR)

- CR as defined, plus: normal free light chain ratio, and absence of clonal cells in the bone marrow by immunohistochemistry of immunofluorescence
(confirmation with repeat bone marrow biopsy not needed). (Presence and/or absence of clonal cells is based upon the Κ/λ ratio. An abnormal Κ/λ ratio by
immunohistochemistry and/or immunofluorescence requires a minimum of 100 plasma cells for analysis.  An abnormal ratio reflecting the presence of
an abnormal clone is Κ/λ of > 4:1 or < 1:2.) sCR requires two consecutive assessments made at any time before the institution of any new therapy, and
no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy sCR
requirements. 

Complete
remission
(CR)

- negative immunofixation on serum and urine samples, and disappearance of any soft tissue plasmacytomas, and < 5% plasma cells in the bone
marrow (confirmation with repeat bone marrow biopsy not needed).  CR requires two consecutive assessments made at any time before the institution
of any new therapy, and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not
required to satisfy CR requirements. 

Near
complete
remission
(nCR)

- serum and urine M-protein detectable by immunoelectrophoresis (IFE), but not on electrophoresis (negative SPEP & UPEP); < 5% plasma cells in
bone marrow.  nCR requires two consecutive assessments made at any time before the initiation of any new therapy, and no known evidence of
progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy nCR requirements. 

Very good
partial
remission
(VGPR)

­ serum and urine M­protein detectable by immunofixation but not on electrophoresis, or ≥ 90% reduction in serum M­protein and urine M­protein level <
100 mg/24 hours.  VGPR requires two consecutive assessments made at any time before the institution of any new therapy, and no known evidence of
progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy VGPR requirements.

Partial
remission
(PR)

­ ≥ 50% reduction in serum M­protein, and reduction in 24­hour urinary M­protein by ≥ 90% or to < 200 mg/24 hours.  If the serum and urine M­protein are
unmeasurable (i.e., do not meet any of the following criteria: • serum M­protein ≥ 1 g/dL.  Urine M­protein ≥ 200 mg/24 hours • serum free light chain
assay shows involved level ≥ 10 mg/dL, provided serum free light chain ratio is abnormal), a ≥ 50% decrease in the difference between involved and
uninvolved free light chain levels is required in place of the M-protein criteria.  If serum and urine M-protein are unmeasurable, and serum free light assay
is also unmeasurable, a ≥ 50% reduction in plasma cells is required in place of M­protein, provided the baseline bone marrow plasma cell percentage
was ≥ 30%. In addition to the above listed criteria, a ≥ 50% reduction in the size of soft tissue plasmacytomas is also required, if present at baseline. PR
requires two consecutive assessments made at any time before the institution of any new therapy, and no known evidence of progressive or new bone
lesions if radiographic studies were performed; radiographic studies are not required to satisfy PR requirements. 

Stable
disease
(SD)

- not meeting the criteria for CR, VGPR, PR or PD.  SD requires two consecutive assessments made at any time before the institution of any new therapy,
and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy SD
requirements.

Progressive
disease
(PD)

­ requires any one or more of the following:  Increase of ≥ 25% from baseline in:  serum M­component and/or (absolute increase ≥ 0.5 g/dL) (for
progressive disease, serum M­component increases of ≥ 1 g/dL are sufficient to define relapse if the starting M­component is ≥ 5 g/dL).  Urine M­
component and/or (absolute increase ≥ 200 mg/24 hours) for recipients without measurable serum and urine M­protein levels: the difference between
involved and uninvolved free light chain levels (absolute increase > 10 mg/dL).  Bone marrow plasma cell percentage (absolute percentage ≥ 10%)
(relapse from CR has a 5% cutoff vs. 10% for other categories of relapse) definite development of new bone lesions or soft tissue plasmacytomas, or
definite increase in the size of any existing  bone lesions or soft tissue plasmacytomas. Development of hypercalcemia (corrected serum calcium >
11.5 mg/dL or 2.65 mmol) that can be attributed solely to the plasma cell proliferative disorder.  PD requires two consecutive assessments made at
any time before classification as disease progression, and/or the institution of any new therapy.

Relapse
from CR
(Rel)
(untreated)

­ requires one or more of the following: reappearance of serum or urine M­protein by immunofixation or electrophoresis development of ≥ 5% plasma
cells in the bone marrow (relapse from CR has a 5% cutoff vs. 10% for other categories of relapse) appearance of any other sign of progression (e.g.,
new plasmacytoma, lytic bone lesion, hypercalcemia).  Rel requires two consecutive assessments made at any time before classification as relapse,
and/or the institution of any new therapy.

Unknown

Not applicable (Amyloidosis with no evidence of myeloma)

Date assessed:317 __ __ __ __ - __ __- __ __

Solid Tumors Questions: 318 - 319

Specify the solid tumor classification318

Specify other solid tumor:319

Severe Aplastic Anemia Questions: 320 - 321

Specify the severe aplastic anemia classification320

Specify other acquired cytopenic syndrome:321

Inherited Abnormalities of Erythrocyte Differentiation or Function Questions: 322 - 324

Specify the inherited abnormalities of erythrocyte differentiation or function classification322

Specify other constitutional anemia:323

Specify other hemoglobinopathy:324

Disorders of the Immune System Questions: 325 - 327

Specify disorder of immune system classification325

Specify other SCID:326

Specify other immunodeficiency:327

Inherited Abnormalities of Platelets Questions: 328 - 329

Specify inherited abnormalities of platelets classification328

Congenital amegakaryocytosis / congenital thrombocytopenia (501)

Glanzmann thrombasthenia (502)

Other inherited platelet abnormality (509)

Specify other inherited platelet abnormality:329

Inherited Disorders of Metabolism Questions: 330 - 331

Specify inherited disorders of metabolism classification330

Specify other inherited metabolic disorder:331

Histiocytic Disorders Questions: 332 - 333

Specify histiocytic disorder classification332

Specify other histiocytic disorder:333

Autoimmune Diseases Questions: 334 - 341

Specify autoimmune disease classification334

Specify other arthritis:335

Specify other juvenile idiopathic arthritis (JIA):336

Specify other connective tissue disease:337

Specify other vasculitis:338

Specify other autoimmune neurological disorder:339

Specify other autoimmune cytopenia:340

Specify other autoimmune bowel disorder:341

Other Disease Questions: 342 - 342

Specify other disease:342

First Name:

Last Name:

E-mail address:

Date: __ __ __ __ - __ __- __ __

OMB No: 0915-0310

Expiration Date: 1/31/2020

Public Burden Statement:  An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control

number.  The OMB control number for this project is 0915-0310.  Public reporting burden for this collection of information is estimated to average 1.0 hours per response, including the
time for reviewing instructions, searching existing data sources, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other

aspect of this collection of information, including suggestions for reducing this burden, to HRSA Reports Clearance Officer, 5600 Fishers Lane, Room 10-29, Rockville, Maryland, 20857.

Labs at diagnosis

Specify cytogenetic abnormalities identified at diagnosis:

Specify cytogenetic abnormalities identified at diagnosis:

Specify molecular markers identified at diagnosis:

Labs between diagnosis and last evaluation:

Specify cytogenetic abnormalities identified between diagnosis and last evaluation:

Specify cytogenetic abnormalities identified between diagnosis and last evaluation:

Specify molecular markers identified between diagnosis and last evaluation:

Labs at last evaluation:

Specify cytogenetic abnormalities identified at last evaluation:

Specify cytogenetic abnormalities identified at last evaluation:

Specify molecular markers identified at last evaluation:

CNS Leukemia

Status at transplantation:

Laboratory studies at diagnosis:

Specify cytogenetic abnormalities identified at diagnosis:

Specify cytogenetic abnormalities identified at diagnosis:

Specify molecular markers identified at diagnosis:

Laboratory studies between diagnosis and last evaluation:

Specify cytogenetic abnormalities identified between diagnosis and last evaluation:

Specify cytogenetic abnormalities identified between diagnosis and last evaluation:

Specify molecular markers identified between diagnosis and last evaluation:

Laboratory studies at last evaluation:

Specify cytogenetic abnormalities identified at last evaluation:

Specify cytogenetic abnormalities identified at last evaluation:

Specify molecular markers identified at last evaluation:

CNS Leukemia

Status at transplantation:

Status at transplantation:

Laboratory studies at diagnosis of MDS:

Specify abnormalities identified at diagnosis:

Monosomy

Trisomy

Translocation

Deletion

Inversion

Other

Laboratory studies at last evaluation prior to the start of the preparative regimen:

Specify cytogenetic abnormalities identified at last evaluation prior to the start of the preparative regimen:

Monosomy

Trisomy

Translocation

Deletion

Inversion

Other

Status at transplantation:

Status at transplantation:

Status at transplantation / infusion:

I.S.S.:

Specify cytogenetic abnormalities identified at any time prior to the start of the preparative regimen:

Trisomy

Translocation

Deletion

Other

Status at transplantation:

Center: CRID: 

Form 2402 R3.0: Disease Classification

CIBMTR Form 2402 revision 3.0 last updated Monday, January 29, 2018
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 13 / 26



Key Fields

Sequence Number:

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number:

CIBMTR Research ID:

Event date: __ __ __ __ - __ __- __ __

Primary Disease for HCT / Cellular Therapy Questions: 1 - 2

Date of diagnosis of primary disease for HCT / cellular therapy:1 __ __ __ __ - __ __- __ __

What was the primary disease for which the HCT / cellular therapy was performed?2

Acute myelogenous leukemia (AML or ANLL) (10)

Acute lymphoblastic leukemia (ALL) (20)

Acute leukemia of ambiguous lineage and other myeloid neoplasms (80)

Chronic myelogenous leukemia (CML) (40)

Myelodysplastic (MDS) / myeloproliferative (MPN) diseases (50) (Please classify all preleukemias) (If recipient has transformed to AML, indicate AML as the primary disease)

Other leukemia (30) (includes CLL)

Hodgkin lymphoma (150)

Non-Hodgkin lymphoma (100)

Multiple myeloma / plasma cell disorder (PCD) (170)

Solid tumors (200)

Severe aplastic anemia (300) (If the recipient developed MDS or AML, indicate MDS or AML as the primary disease)

Inherited abnormalities of erythrocyte differentiation or function (310)

Disorders of the immune system (400)

Inherited abnormalities of platelets (500)

Inherited disorders of metabolism (520)

Histiocytic disorders (570)

Autoimmune diseases (600)

Other disease (900)

Acute Myelogenous Leukemia (AML) Questions: 3 - 89

Specify the AML classification3

Did AML transform from MDS or MPN?4

yes - Also complete MDS Disease Classification questions

no

Is the disease (AML) therapy related?

yes no Unknown

5

Did the recipient have a predisposing condition?

yes no Unknown

6

Specify condition7

Bloom syndrome

Down syndrome

Fanconi anemia

Dyskeratosis congenita

Other condition

Specify other condition:8

Were cytogenetics tested (karyotyping or FISH)? (at diagnosis)

yes no Unknown

9

Were cytogenetics tested via FISH? (at diagnosis)

Yes No

10

Results of tests11

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities12

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

13

Specify other abnormality:14

Were cytogenetics tested via karyotyping? (at diagnosis)

Yes No

15

Results of tests16

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities17

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

18

Specify other abnormality:19

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

20

Were tests for molecular markers performed? (e.g. PCR, NGS) (at diagnosis)

yes no Unknown

21

CEBPA

Positive Negative Not Done

22

Specify CEBPA mutation23

Biallelic (homozygous)

Monoallelic (heterozygous)

Unknown

FLT3 – D835 point mutation

Positive Negative Not Done

24

FLT3 – ITD mutation

Positive Negative Not Done

25

FLT3 - ITD allelic ratio

Known Unknown

26

Specify FLT3 - ITD allelic ratio:27

IDH1

Positive Negative Not Done

28

IDH2

Positive Negative Not Done

29

KIT

Positive Negative Not Done

30

NPM1

Positive Negative Not Done

31

Other Molecular Marker (1) Questions: 32 - 33

Other molecular marker

Positive Negative Not Done

32

Specify other molecular marker:33

Were cytogenetics tested (karyotyping or FISH)? (between diagnosis and last evaluation)

yes no Unknown

34

Were cytogenetics tested via FISH? (between diagnosis and last evaluation)

Yes No

35

Results of tests36

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities37

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

38

Specify other abnormality:39

Were cytogenetics tested via karyotyping? (between diagnosis and last evaluation)

Yes No

40

Results of tests41

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities42

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

43

Specify other abnormality:44

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

45

Were tests for molecular markers performed? (e.g. PCR, NGS) (between diagnosis and last evaluation)

yes no Unknown

46

CEBPA

Positive Negative Not Done

47

Specify CEBPA mutation48

Biallelic (homozygous)

Monoallelic (heterozygous)

Unknown

FLT3 – D835 point mutation

Positive Negative Not Done

49

FLT3 – ITD mutation

Positive Negative Not Done

50

FLT3 - ITD allelic ratio

Known Unknown

51

Specify FLT3 - ITD allelic ratio:52

IDH1

Positive Negative Not Done

53

IDH2

Positive Negative Not Done

54

KIT

Positive Negative Not Done

55

NPM1

Positive Negative Not Done

56

Other Molecular Marker (1) Questions: 57 - 58

Other molecular marker

Positive Negative Not Done

57

Specify other molecular marker:58

Were cytogenetics tested (karyotyping or FISH)? (at last evaluation)

yes no Unknown

59

Were cytogenetics tested via FISH? (at last evaluation)

Yes No

60

Results of tests61

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities62

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

63

Specify other abnormality:64

Were cytogenetics tested via karyotyping? (at last evaluation)

Yes No

65

Results of tests66

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities67

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

68

Specify other abnormality:69

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

70

Were tests for molecular markers performed? (e.g. PCR, NGS) (at last evaluation)

yes no Unknown

71

CEBPA

Positive Negative Not Done

72

Specify CEBPA mutation73

Biallelic (homozygous)

Monoallelic (heterozygous)

Unknown

FLT3 – D835 point mutation

Positive Negative Not Done

74

FLT3 – ITD mutation

Positive Negative Not Done

75

FLT3 - ITD allelic ratio

Known Unknown

76

Specify FLT3 - ITD allelic ratio:77

IDH1

Positive Negative Not Done

78

IDH2

Positive Negative Not Done

79

KIT

Positive Negative Not Done

80

NPM1

Positive Negative Not Done

81

Other Molecular Marker (1) Questions: 82 - 83

Other molecular marker

Positive Negative Not Done

82

Specify other molecular marker:83

Did the recipient have central nervous system leukemia at any time prior to the start of the preparative regimen / infusion?

yes no Unknown

84

What was the disease status (based on hematological test results)?85

Primary induction failure

1st complete remission (no previous bone marrow or extramedullary relapse) (include CRi)

2nd complete remission

≥3rd complete remission

1st relapse

2nd relapse

≥3rd relapse

No treatment

How many cycles of induction therapy were required to achieve 1st complete remission? (includes CRi)

1 2 ≥ 3

86

Was the recipient in remission by flow cytometry?

Yes No Unknown Not applicable

87

Date of most recent relapse:88 __ __ __ __ - __ __- __ __

Date assessed:89 __ __ __ __ - __ __- __ __

Acute Lymphoblastic Leukemia (ALL) Questions: 90 - 151

Specify ALL classification90

Did the recipient have a predisposing condition?

yes no Unknown

91

Specify condition92

Aplastic anemia - Also complete CIBMTR Form 2028 - APL

Bloom syndrome

Down syndrome

Fanconi anemia - Also complete CIBMTR Form 2029 - FAN

Other condition

Specify other condition:93

Were tyrosine kinase inhibitors given for therapy at any time prior to the start of the preparative regimen / infusion? (e.g. imatinib mesylate, dasatinib, etc.)

yes no

94

Were cytogenetics tested (karyotyping or FISH)? (at diagnosis)

yes no Unknown

95

Were cytogenetics tested via FISH? (at diagnosis)

Yes No

96

Results of tests97

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities98

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

99

Specify other abnormality:100

Were cytogenetics tested via karyotyping? (at diagnosis)

Yes No

101

Results of tests102

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities103

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

104

Specify other abnormality:105

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

106

Were tests for molecular markers performed? (e.g. PCR, NGS) (at diagnosis)

yes no Unknown

107

BCR / ABL

Positive Negative Not Done

108

TEL-AML / AML1

Positive Negative Not Done

109

Other Molecular Marker (1) Questions: 110 - 111

Other molecular marker

Positive Negative Not Done

110

Specify other molecular marker:111

Were cytogenetics tested (karyotyping or FISH)? (between diagnosis and last evaluation)

yes no Unknown

112

Were cytogenetics tested via FISH? (between diagnosis and last evaluation)

Yes No

113

Results of tests114

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities115

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

116

Specify other abnormality:117

Were cytogenetics tested via karyotyping? (between diagnosis and last evaluation)

Yes No

118

Results of tests119

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities120

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

121

Specify other abnormality:122

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

123

Were tests for molecular markers performed? (e.g. PCR, NGS) (between diagnosis and last evaluation)

yes no Unknown

124

BCR / ABL

Positive Negative Not Done

125

TEL-AML / AML1

Positive Negative Not Done

126

Other Molecular Marker (1) Questions: 127 - 128

Other molecular marker

Positive Negative Not Done

127

Specify other molecular marker:128

Were cytogenetics tested (karyotyping or FISH)? (at last evaluation)

yes no Unknown

129

Were cytogenetics tested via FISH? (at last evaluation)

Yes No

130

Results of tests131

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities132

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

133

Specify other abnormality:134

Were cytogenetics tested via karyotyping? (at last evaluation)

Yes No

135

Results of tests136

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities137

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

138

Specify other abnormality:139

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

140

Were tests for molecular markers performed? (e.g. PCR, NGS) (at last evaluation)

yes no Unknown

141

BCR / ABL

Positive Negative Not Done

142

TEL-AML / AML1

Positive Negative Not Done

143

Other Molecular Marker (1) Questions: 144 - 145

Other molecular marker

Positive Negative Not Done

144

Specify other molecular marker:145

Did the recipient have central nervous system leukemia at any time prior to the start of the preparative regimen / infusion?

yes no Unknown

146

What was the disease status (based on hematological test results)?147

Primary induction failure

1st complete remission (no previous marrow or extramedullary relapse) (include CRi)

2nd complete remission

≥3rd complete remission

1st relapse

2nd relapse

≥3rd relapse

No treatment

How many cycles of induction therapy were required to achieve 1st complete remission? (include CRi)

1 2 ≥ 3

148

Was the recipient in remission by flow cytometry?

Yes No Unknown Not applicable

149

Date of most recent relapse:150 __ __ __ __ - __ __- __ __

Date assessed:151 __ __ __ __ - __ __- __ __

Acute Leukemias of Ambiguous Lineage and Other Myeloid Neoplasms Questions: 152 - 155

Specify acute leukemias of ambiguous lineage and other myeloid neoplasm classification152

Blastic plasmacytoid dendritic cell neoplasm (296)

Acute undifferentiated leukemia (31)

Mixed phenotype acute leukemia (MPAL) with t(9;22)(q34.1;q11.2); BCR-ABL1 (84)

Mixed phenotype acute leukemia with t(v; 11q23.3); KMT2A rearranged (85)

Mixed phenotype acute leukemia, B/myeloid, NOS (86)

Mixed phenotype acute leukemia, T/myeloid, NOS (87)

Other acute leukemia of ambiguous lineage or myeloid neoplasm (88)

Specify other acute leukemia of ambiguous lineage or myeloid neoplasm:153

What was the disease status (based on hematological test results)?154

Primary induction failure

1st complete remission (no previous marrow or extramedullary relapse)

2nd complete remission

≥3rd complete remission

1st relapse

2nd relapse

≥3rd relapse

No treatment

Date assessed:155 __ __ __ __ - __ __- __ __

Chronic Myelogenous Leukemia (CML) Questions: 156 - 166

Was therapy given prior to this HCT?

yes no

156

Combination chemotherapy

yes no

157

Hydroxyurea (Droxia, Hydrea)

yes no

158

Tyrosine kinase inhibitor (e.g. imatinib mesylate, dasatinib, nilotinib)

yes no

159

Interferon­α (Intron, Roferon) (includes PEG)

yes no

160

Other therapy

yes no

161

Specify other therapy:162

What was the disease status?163

Complete hematologic response (CHR)

Chronic phase

Accelerated phase

Blast phase

Specify level of response164

No cytogenetic response (No CyR)

Minimal cytogenetic response

Minor cytogenetic response

Partial cytogenetic response (PCyR)

Complete cytogenetic response (CCyR)

Major molecular remission (MMR)

Complete molecular remission (CMR)

Number

1st 2nd 3rd or higher

165

Date assessed:166 __ __ __ __ - __ __- __ __

Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases Questions: 167 - 260

What was the MDS / MPN subtype at diagnosis? - If transformed to AML, indicate AML as primary disease; also complete AML Disease Classification
questions

167

Was the disease (MDS/MPN) therapy related?

yes no Unknown

168

Did the recipient have a predisposing condition?

yes no Unknown

169

Specify condition

Aplastic Anemia Bloom syndrome Down syndrome Fanconi anemia Other condition

170

Specify other condition:171

WBC

Known Unknown

172

173 x 109/L (x 103/mm3)

x 106/L

Hemoglobin

Known Unknown

174

175 g/dL g/L mmol/L

Was RBC transfused ≤ 30 days before date of test?

Yes No

176

Platelets

Known Unknown

177

178 x 109/L (x 103/mm3)

x 106/L

Were platelets transfused ≤ 7 days before date of test?

Yes No

179

Neutrophils

Known Unknown

180

181 %

Blasts in bone marrow

Known Unknown

182

183 %

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

184

Results of tests185

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities186

One (1)

Two (2)

Three (3)

Four or more (4 or more)

–5

yes no

187

-7

yes no

188

–13

yes no

189

–20

yes no

190

–Y

yes no

191

+8

yes no

192

+19

yes no

193

t(1;3)

yes no

194

t(2;11)

yes no

195

t(3;3)

yes no

196

t(3;21)

yes no

197

t(6;9)

yes no

198

t(11;16)

yes no

199

del(3q) / 3q–

yes no

200

del(5q) / 5q-

yes no

201

del(7q) / 7q–

yes no

202

del(9q) / 9q–

yes no

203

del(11q) / 11q–

yes no

204

del(12p) / 12p–

yes no

205

del(13q) / 13q-

yes no

206

del(20q) / 20q–

yes no

207

inv(3)

yes no

208

i17q

yes no

209

Other abnormality

yes no

210

Specify other abnormality:211

Did the recipient progress or transform to a different MDS / MPN subtype between diagnosis and the start of the preparative regimen?

yes no

212

Specify the MDS / MPN classification after transformation:213

Specify the date of the most recent transformation:214 __ __ __ __ - __ __- __ __

Date of MDS diagnosis:215 __ __ __ __ - __ __- __ __

WBC

Known Unknown

216

217 x 109/L (x 103/mm3)

x 106/L

Hemoglobin

Known Unknown

218

219 g/dL g/L mmol/L

Was RBC transfused ≤ 30 days before date of test?

Yes No

220

Platelets

Known Unknown

221

222 x 109/L (x 103/mm3)

x 106/L

Were platelets transfused ≤ 7 days before date of test?

Yes No

223

Neutrophils

Known Unknown

224

225 %

Blasts in bone marrow

Known Unknown

226

227 %

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

228

Results of tests229

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities230

One (1)

Two (2)

Three (3)

Four or more (4 or more)

–5

yes no

231

-7

yes no

232

–13

yes no

233

–20

yes no

234

–Y

yes no

235

+8

yes no

236

+19

yes no

237

t(1;3)

yes no

238

t(2;11)

yes no

239

t(3;3)

yes no

240

t(3;21)

yes no

241

t(6;9)

yes no

242

t(11;16)

yes no

243

del(3q) / 3q–

yes no

244

del(5q) / 5q-

yes no

245

del(7q) / 7q–

yes no

246

del(9q) / 9q–

yes no

247

del(11q) / 11q–

yes no

248

del(12p) / 12p–

yes no

249

del(13q) / 13q-

yes no

250

del(20q) / 20q–

yes no

251

inv(3)

yes no

252

i17q

yes no

253

Other abnormality

yes no

254

Specify other abnormality:255

What was the disease status?256

Complete
remission
(CR)

– requires all of the following, maintained for ≥ 4 weeks: * bone marrow evaluation: <  5% myeloblasts with normal maturation of all cell lines *
peripheral blood evaluation: hemoglobin ≥ 11 g/dL untransfused and without erythropoietin support; ANC ≥ 1000/mm3  without myeloid growth factor
support; platelets ≥ 100 x 109/L without thrombopoietic support; 0% blasts

Hematologic
improvement
(HI)

– requires one measurement of the following, maintained for ≥ 8 weeks without ongoing cytotoxic therapy; specify which cell line was measured to
determine HI response: * HI­E – hemoglobin increase of ≥ 1.5 g/dL untransfused; for RBC transfusions performed for Hgb ≤ 9.0, reduction in RBC
units transfused in 8 weeks by ≥ 4 units compared to the pre­treatment transfusion number in 8 weeks * HI­P – for pre­treatment platelet count of > 20
x 109/L, platelet absolute increase of ≥ 30 x 109/L; for pre-treatment platelet count of < 20 x 109/L, platelet absolute increase of ≥ 20 x 109/L and ≥
100% from pre­treatment level  * HI­N – neutrophil count increase of ≥ 100% from pre­treatment level and an absolute increase of ≥ 500/mm3

No response (NR) / stable disease (SD) – does not meet the criteria for at least HI, but no evidence of disease progression

Progression from
hematologic improvement
(Prog from HI)

– requires at least one of the following, in the absence of another explanation (e.g., infection, bleeding, ongoing chemotherapy, etc.): *
≥ 50% reduction from maximum response levels in granulocytes or platelets * reduction in hemoglobin by ≥ 1.5 g/dL *transfusion
dependence

Relapse from complete
remission (Rel from CR)

– requires at least one of the following: * return to pre­treatment bone marrow blast percentage * decrease of ≥ 50% from maximum
response levels in granulocytes or platelets * transfusion dependence, or hemoglobin level ≥ 1.5 g/dL lower than prior to therapy

Not assessed

Specify the cell line examined to determine HI status257

HI-
E

– hemoglobin increase of ≥ 1.5 g/dL untransfused; for RBC transfusions performed for Hgb ≤ 9.0, reduction in RBC units transfused in 8 weeks by ≥ 4
units compared to the pre-treatment transfusion number in 8 weeks

HI-
P

– for pre­treatment platelet count of > 20 x 109/L, platelet absolute increase of ≥ 30 x 109/L; for pre-treatment platelet count of < 20 x 109/L, platelet
absolute increase of ≥ 20 x 109/L and ≥ 100% from pre­treatment level 

HI-N – neutrophil count increase of ≥ 100% from pre­treatment level and an absolute increase of ≥ 500/mm3

Date of progression:258 __ __ __ __ - __ __- __ __

Date of relapse:259 __ __ __ __ - __ __- __ __

Date assessed:260 __ __ __ __ - __ __- __ __

Other Leukemia (OL) Questions: 261 - 267

Specify the other leukemia classification261

Specify other leukemia:262

Was any 17p abnormality detected?

yes no

263

Did a histologic transformation to diffuse large B-cell lymphoma (Richter syndrome) occur at any time after CLL diagnosis?264

yes - Also complete NHL Disease Classification questions

no

What was the disease status? (Atypical CML)265

Primary induction failure

1st complete remission (no previous bone marrow or extramedullary relapse)

2nd complete remission

≥3rd complete remission

1st relapse

2nd relapse

≥3rd relapse

No treatment

What was the disease status? (CLL, PLL, Hairy cell leukemia)266

Complete remission (CR)

Partial remission (PR)

Stable disease (SD)

Progressive disease (Prog)

Untreated

Not assessed

Date assessed:267 __ __ __ __ - __ __- __ __

Hodgkin and Non-Hodgkin Lymphoma Questions: 268 - 285

Specify the lymphoma histology (at infusion)268

Specify other lymphoma histology:269

Assignment of DLBCL (germinal center B-cell type vs. activated B-cell type) subtype was based on270

Immunohistochemistry (e.g. Han's algorithm)

Gene expression profile

Unknown method

Is the lymphoma histology reported at transplant a transformation from CLL?

yes no

271

Was any 17p abnormality detected?

yes no

272

Is the lymphoma histology reported at transplant a transformation from a different lymphoma histology? (Not CLL)

Yes No

273

Specify the original lymphoma histology (prior to transformation)274

Specify other lymphoma histology:275

Date of original lymphoma diagnosis:276 __ __ __ __ - __ __- __ __ (report the date of diagnosis of original lymphoma subtype)

Was a PET (or PET/CT) scan performed? (at last evaluation prior to the start of the preparative regimen / infusion)

yes no

277

Was the PET (or PET/CT) scan positive for lymphoma involvement at any disease site?

yes no

278

Date of PET scan

Known Unknown

279

Date of PET (or PET/CT) scan:280 __ __ __ __ - __ __- __ __

Deauville (five-point) score of the PET (or PET/CT) scan

Known Unknown

281

Scale282

1 - no uptake or residual uptake

2 - slight uptake, but below blood pool (mediastinum)

3 - uptake above mediastinal, but below or equal to uptake in the liver

4 - uptake slightly to moderately higher than liver

5 - markedly increased uptake or any new lesions

What was the disease status?283

Total number of lines of therapy received

1 line 2 lines 3+ lines

284

Date assessed:285 __ __ __ __ - __ __- __ __

Multiple Myeloma / Plasma Cell Disorder (PCD) Questions: 286 - 317

Specify the multiple myeloma/plasma cell disorder (PCD) classification286

Specify other plasma cell disorder:287

Light chain

kappa lambda

288

What was the Durie-Salmon staging? (at diagnosis)289

Stage
I

(All of the following: Hgb > 10g/dL; serum calcium normal or <10.5 mg/dL; bone x-ray normal bone structure (scale 0), or solitary bone plasmacytoma
only; low M-component production rates IgG< 5g/dL, IgA < 3g/dL; urine light chain M-component on electrophoresis <4 g/24h)

Stage II (Fitting neither Stage I or III) 

Stage
III

(One or more of the following: Hgb < 8.5 g/dL; serum calcium > 12 mg/dL; advanced lytic bone lesions (scale 3); high M-component production rates
IgG > 7g/dL, IgA > 5 g/dL; Bence Jones protein > 12g/24h)

Unknown

What was the Durie-Salmon sub classification? (at diagnosis)290

A - relatively normal renal function (serum creatinine < 2.0 mg/dL)

B ­ abnormal renal function (serum creatinine ≥ 2.0 mg/dL)

Serum β2­microglobulin:291 μg/dL mg/L nmol/L

Serum albumin:292 g/dL g/L

Stage293

1 (β2 ­mic < 3.5, S. albumin ≥3.5)

2 (Not fitting stage 1 or 3)

3 (β2­mic ≥ 5.5; S. albumin ­)

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

294

Results of tests295

Abnormalities identified

No evaluable metaphases

No abnormalities

+3

yes no

296

+5

yes no

297

+7

yes no

298

+9

yes no

299

+11

yes no

300

+15

yes no

301

+19

yes no

302

t(4;14)

yes no

303

t(6;14)

yes no

304

t(11;14)

yes no

305

t(14;16)

yes no

306

t(14;20)

yes no

307

del(13q) / 13q-

yes no

308

del (17p) / 17p-

yes no

309

Hyperdiploid (>50)

yes no

310

Hypodiploid (<46)

yes no

311

Any abnormality at 1q

yes no

312

Any abnormality at 1p

yes no

313

Other abnormality

yes no

314

Specify other abnormality:315

What was the disease status?316

Stringent
complete
remission
(sCR)

- CR as defined, plus: normal free light chain ratio, and absence of clonal cells in the bone marrow by immunohistochemistry of immunofluorescence
(confirmation with repeat bone marrow biopsy not needed). (Presence and/or absence of clonal cells is based upon the Κ/λ ratio. An abnormal Κ/λ ratio by
immunohistochemistry and/or immunofluorescence requires a minimum of 100 plasma cells for analysis.  An abnormal ratio reflecting the presence of
an abnormal clone is Κ/λ of > 4:1 or < 1:2.) sCR requires two consecutive assessments made at any time before the institution of any new therapy, and
no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy sCR
requirements. 

Complete
remission
(CR)

- negative immunofixation on serum and urine samples, and disappearance of any soft tissue plasmacytomas, and < 5% plasma cells in the bone
marrow (confirmation with repeat bone marrow biopsy not needed).  CR requires two consecutive assessments made at any time before the institution
of any new therapy, and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not
required to satisfy CR requirements. 

Near
complete
remission
(nCR)

- serum and urine M-protein detectable by immunoelectrophoresis (IFE), but not on electrophoresis (negative SPEP & UPEP); < 5% plasma cells in
bone marrow.  nCR requires two consecutive assessments made at any time before the initiation of any new therapy, and no known evidence of
progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy nCR requirements. 

Very good
partial
remission
(VGPR)

­ serum and urine M­protein detectable by immunofixation but not on electrophoresis, or ≥ 90% reduction in serum M­protein and urine M­protein level <
100 mg/24 hours.  VGPR requires two consecutive assessments made at any time before the institution of any new therapy, and no known evidence of
progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy VGPR requirements.

Partial
remission
(PR)

­ ≥ 50% reduction in serum M­protein, and reduction in 24­hour urinary M­protein by ≥ 90% or to < 200 mg/24 hours.  If the serum and urine M­protein are
unmeasurable (i.e., do not meet any of the following criteria: • serum M­protein ≥ 1 g/dL.  Urine M­protein ≥ 200 mg/24 hours • serum free light chain
assay shows involved level ≥ 10 mg/dL, provided serum free light chain ratio is abnormal), a ≥ 50% decrease in the difference between involved and
uninvolved free light chain levels is required in place of the M-protein criteria.  If serum and urine M-protein are unmeasurable, and serum free light assay
is also unmeasurable, a ≥ 50% reduction in plasma cells is required in place of M­protein, provided the baseline bone marrow plasma cell percentage
was ≥ 30%. In addition to the above listed criteria, a ≥ 50% reduction in the size of soft tissue plasmacytomas is also required, if present at baseline. PR
requires two consecutive assessments made at any time before the institution of any new therapy, and no known evidence of progressive or new bone
lesions if radiographic studies were performed; radiographic studies are not required to satisfy PR requirements. 

Stable
disease
(SD)

- not meeting the criteria for CR, VGPR, PR or PD.  SD requires two consecutive assessments made at any time before the institution of any new therapy,
and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy SD
requirements.

Progressive
disease
(PD)

­ requires any one or more of the following:  Increase of ≥ 25% from baseline in:  serum M­component and/or (absolute increase ≥ 0.5 g/dL) (for
progressive disease, serum M­component increases of ≥ 1 g/dL are sufficient to define relapse if the starting M­component is ≥ 5 g/dL).  Urine M­
component and/or (absolute increase ≥ 200 mg/24 hours) for recipients without measurable serum and urine M­protein levels: the difference between
involved and uninvolved free light chain levels (absolute increase > 10 mg/dL).  Bone marrow plasma cell percentage (absolute percentage ≥ 10%)
(relapse from CR has a 5% cutoff vs. 10% for other categories of relapse) definite development of new bone lesions or soft tissue plasmacytomas, or
definite increase in the size of any existing  bone lesions or soft tissue plasmacytomas. Development of hypercalcemia (corrected serum calcium >
11.5 mg/dL or 2.65 mmol) that can be attributed solely to the plasma cell proliferative disorder.  PD requires two consecutive assessments made at
any time before classification as disease progression, and/or the institution of any new therapy.

Relapse
from CR
(Rel)
(untreated)

­ requires one or more of the following: reappearance of serum or urine M­protein by immunofixation or electrophoresis development of ≥ 5% plasma
cells in the bone marrow (relapse from CR has a 5% cutoff vs. 10% for other categories of relapse) appearance of any other sign of progression (e.g.,
new plasmacytoma, lytic bone lesion, hypercalcemia).  Rel requires two consecutive assessments made at any time before classification as relapse,
and/or the institution of any new therapy.

Unknown

Not applicable (Amyloidosis with no evidence of myeloma)

Date assessed:317 __ __ __ __ - __ __- __ __

Solid Tumors Questions: 318 - 319

Specify the solid tumor classification318

Specify other solid tumor:319

Severe Aplastic Anemia Questions: 320 - 321

Specify the severe aplastic anemia classification320

Specify other acquired cytopenic syndrome:321

Inherited Abnormalities of Erythrocyte Differentiation or Function Questions: 322 - 324

Specify the inherited abnormalities of erythrocyte differentiation or function classification322

Specify other constitutional anemia:323

Specify other hemoglobinopathy:324

Disorders of the Immune System Questions: 325 - 327

Specify disorder of immune system classification325

Specify other SCID:326

Specify other immunodeficiency:327

Inherited Abnormalities of Platelets Questions: 328 - 329

Specify inherited abnormalities of platelets classification328

Congenital amegakaryocytosis / congenital thrombocytopenia (501)

Glanzmann thrombasthenia (502)

Other inherited platelet abnormality (509)

Specify other inherited platelet abnormality:329

Inherited Disorders of Metabolism Questions: 330 - 331

Specify inherited disorders of metabolism classification330

Specify other inherited metabolic disorder:331

Histiocytic Disorders Questions: 332 - 333

Specify histiocytic disorder classification332

Specify other histiocytic disorder:333

Autoimmune Diseases Questions: 334 - 341

Specify autoimmune disease classification334

Specify other arthritis:335

Specify other juvenile idiopathic arthritis (JIA):336

Specify other connective tissue disease:337

Specify other vasculitis:338

Specify other autoimmune neurological disorder:339

Specify other autoimmune cytopenia:340

Specify other autoimmune bowel disorder:341

Other Disease Questions: 342 - 342

Specify other disease:342

First Name:

Last Name:

E-mail address:

Date: __ __ __ __ - __ __- __ __

OMB No: 0915-0310

Expiration Date: 1/31/2020

Public Burden Statement:  An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control
number.  The OMB control number for this project is 0915-0310.  Public reporting burden for this collection of information is estimated to average 1.0 hours per response, including the
time for reviewing instructions, searching existing data sources, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other
aspect of this collection of information, including suggestions for reducing this burden, to HRSA Reports Clearance Officer, 5600 Fishers Lane, Room 10-29, Rockville, Maryland, 20857.

Labs at diagnosis

Specify cytogenetic abnormalities identified at diagnosis:

Specify cytogenetic abnormalities identified at diagnosis:

Specify molecular markers identified at diagnosis:

Labs between diagnosis and last evaluation:

Specify cytogenetic abnormalities identified between diagnosis and last evaluation:

Specify cytogenetic abnormalities identified between diagnosis and last evaluation:

Specify molecular markers identified between diagnosis and last evaluation:

Labs at last evaluation:

Specify cytogenetic abnormalities identified at last evaluation:

Specify cytogenetic abnormalities identified at last evaluation:

Specify molecular markers identified at last evaluation:

CNS Leukemia

Status at transplantation:

Laboratory studies at diagnosis:

Specify cytogenetic abnormalities identified at diagnosis:

Specify cytogenetic abnormalities identified at diagnosis:

Specify molecular markers identified at diagnosis:

Laboratory studies between diagnosis and last evaluation:

Specify cytogenetic abnormalities identified between diagnosis and last evaluation:

Specify cytogenetic abnormalities identified between diagnosis and last evaluation:

Specify molecular markers identified between diagnosis and last evaluation:

Laboratory studies at last evaluation:

Specify cytogenetic abnormalities identified at last evaluation:

Specify cytogenetic abnormalities identified at last evaluation:

Specify molecular markers identified at last evaluation:

CNS Leukemia

Status at transplantation:

Status at transplantation:

Laboratory studies at diagnosis of MDS:

Specify abnormalities identified at diagnosis:

Monosomy

Trisomy

Translocation

Deletion

Inversion

Other

Laboratory studies at last evaluation prior to the start of the preparative regimen:

Specify cytogenetic abnormalities identified at last evaluation prior to the start of the preparative regimen:

Monosomy

Trisomy

Translocation

Deletion

Inversion

Other

Status at transplantation:

Status at transplantation:

Status at transplantation / infusion:

I.S.S.:

Specify cytogenetic abnormalities identified at any time prior to the start of the preparative regimen:

Trisomy

Translocation

Deletion

Other

Status at transplantation:

Center: CRID: 

Form 2402 R3.0: Disease Classification

CIBMTR Form 2402 revision 3.0 last updated Monday, January 29, 2018
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 14 / 26



Key Fields

Sequence Number:

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number:

CIBMTR Research ID:

Event date: __ __ __ __ - __ __- __ __

Primary Disease for HCT / Cellular Therapy Questions: 1 - 2

Date of diagnosis of primary disease for HCT / cellular therapy:1 __ __ __ __ - __ __- __ __

What was the primary disease for which the HCT / cellular therapy was performed?2

Acute myelogenous leukemia (AML or ANLL) (10)

Acute lymphoblastic leukemia (ALL) (20)

Acute leukemia of ambiguous lineage and other myeloid neoplasms (80)

Chronic myelogenous leukemia (CML) (40)

Myelodysplastic (MDS) / myeloproliferative (MPN) diseases (50) (Please classify all preleukemias) (If recipient has transformed to AML, indicate AML as the primary disease)

Other leukemia (30) (includes CLL)

Hodgkin lymphoma (150)

Non-Hodgkin lymphoma (100)

Multiple myeloma / plasma cell disorder (PCD) (170)

Solid tumors (200)

Severe aplastic anemia (300) (If the recipient developed MDS or AML, indicate MDS or AML as the primary disease)

Inherited abnormalities of erythrocyte differentiation or function (310)

Disorders of the immune system (400)

Inherited abnormalities of platelets (500)

Inherited disorders of metabolism (520)

Histiocytic disorders (570)

Autoimmune diseases (600)

Other disease (900)

Acute Myelogenous Leukemia (AML) Questions: 3 - 89

Specify the AML classification3

Did AML transform from MDS or MPN?4

yes - Also complete MDS Disease Classification questions

no

Is the disease (AML) therapy related?

yes no Unknown

5

Did the recipient have a predisposing condition?

yes no Unknown

6

Specify condition7

Bloom syndrome

Down syndrome

Fanconi anemia

Dyskeratosis congenita

Other condition

Specify other condition:8

Were cytogenetics tested (karyotyping or FISH)? (at diagnosis)

yes no Unknown

9

Were cytogenetics tested via FISH? (at diagnosis)

Yes No

10

Results of tests11

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities12

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

13

Specify other abnormality:14

Were cytogenetics tested via karyotyping? (at diagnosis)

Yes No

15

Results of tests16

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities17

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

18

Specify other abnormality:19

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

20

Were tests for molecular markers performed? (e.g. PCR, NGS) (at diagnosis)

yes no Unknown

21

CEBPA

Positive Negative Not Done

22

Specify CEBPA mutation23

Biallelic (homozygous)

Monoallelic (heterozygous)

Unknown

FLT3 – D835 point mutation

Positive Negative Not Done

24

FLT3 – ITD mutation

Positive Negative Not Done

25

FLT3 - ITD allelic ratio

Known Unknown

26

Specify FLT3 - ITD allelic ratio:27

IDH1

Positive Negative Not Done

28

IDH2

Positive Negative Not Done

29

KIT

Positive Negative Not Done

30

NPM1

Positive Negative Not Done

31

Other Molecular Marker (1) Questions: 32 - 33

Other molecular marker

Positive Negative Not Done

32

Specify other molecular marker:33

Were cytogenetics tested (karyotyping or FISH)? (between diagnosis and last evaluation)

yes no Unknown

34

Were cytogenetics tested via FISH? (between diagnosis and last evaluation)

Yes No

35

Results of tests36

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities37

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

38

Specify other abnormality:39

Were cytogenetics tested via karyotyping? (between diagnosis and last evaluation)

Yes No

40

Results of tests41

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities42

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

43

Specify other abnormality:44

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

45

Were tests for molecular markers performed? (e.g. PCR, NGS) (between diagnosis and last evaluation)

yes no Unknown

46

CEBPA

Positive Negative Not Done

47

Specify CEBPA mutation48

Biallelic (homozygous)

Monoallelic (heterozygous)

Unknown

FLT3 – D835 point mutation

Positive Negative Not Done

49

FLT3 – ITD mutation

Positive Negative Not Done

50

FLT3 - ITD allelic ratio

Known Unknown

51

Specify FLT3 - ITD allelic ratio:52

IDH1

Positive Negative Not Done

53

IDH2

Positive Negative Not Done

54

KIT

Positive Negative Not Done

55

NPM1

Positive Negative Not Done

56

Other Molecular Marker (1) Questions: 57 - 58

Other molecular marker

Positive Negative Not Done

57

Specify other molecular marker:58

Were cytogenetics tested (karyotyping or FISH)? (at last evaluation)

yes no Unknown

59

Were cytogenetics tested via FISH? (at last evaluation)

Yes No

60

Results of tests61

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities62

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

63

Specify other abnormality:64

Were cytogenetics tested via karyotyping? (at last evaluation)

Yes No

65

Results of tests66

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities67

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

68

Specify other abnormality:69

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

70

Were tests for molecular markers performed? (e.g. PCR, NGS) (at last evaluation)

yes no Unknown

71

CEBPA

Positive Negative Not Done

72

Specify CEBPA mutation73

Biallelic (homozygous)

Monoallelic (heterozygous)

Unknown

FLT3 – D835 point mutation

Positive Negative Not Done

74

FLT3 – ITD mutation

Positive Negative Not Done

75

FLT3 - ITD allelic ratio

Known Unknown

76

Specify FLT3 - ITD allelic ratio:77

IDH1

Positive Negative Not Done

78

IDH2

Positive Negative Not Done

79

KIT

Positive Negative Not Done

80

NPM1

Positive Negative Not Done

81

Other Molecular Marker (1) Questions: 82 - 83

Other molecular marker

Positive Negative Not Done

82

Specify other molecular marker:83

Did the recipient have central nervous system leukemia at any time prior to the start of the preparative regimen / infusion?

yes no Unknown

84

What was the disease status (based on hematological test results)?85

Primary induction failure

1st complete remission (no previous bone marrow or extramedullary relapse) (include CRi)

2nd complete remission

≥3rd complete remission

1st relapse

2nd relapse

≥3rd relapse

No treatment

How many cycles of induction therapy were required to achieve 1st complete remission? (includes CRi)

1 2 ≥ 3

86

Was the recipient in remission by flow cytometry?

Yes No Unknown Not applicable

87

Date of most recent relapse:88 __ __ __ __ - __ __- __ __

Date assessed:89 __ __ __ __ - __ __- __ __

Acute Lymphoblastic Leukemia (ALL) Questions: 90 - 151

Specify ALL classification90

Did the recipient have a predisposing condition?

yes no Unknown

91

Specify condition92

Aplastic anemia - Also complete CIBMTR Form 2028 - APL

Bloom syndrome

Down syndrome

Fanconi anemia - Also complete CIBMTR Form 2029 - FAN

Other condition

Specify other condition:93

Were tyrosine kinase inhibitors given for therapy at any time prior to the start of the preparative regimen / infusion? (e.g. imatinib mesylate, dasatinib, etc.)

yes no

94

Were cytogenetics tested (karyotyping or FISH)? (at diagnosis)

yes no Unknown

95

Were cytogenetics tested via FISH? (at diagnosis)

Yes No

96

Results of tests97

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities98

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

99

Specify other abnormality:100

Were cytogenetics tested via karyotyping? (at diagnosis)

Yes No

101

Results of tests102

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities103

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

104

Specify other abnormality:105

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

106

Were tests for molecular markers performed? (e.g. PCR, NGS) (at diagnosis)

yes no Unknown

107

BCR / ABL

Positive Negative Not Done

108

TEL-AML / AML1

Positive Negative Not Done

109

Other Molecular Marker (1) Questions: 110 - 111

Other molecular marker

Positive Negative Not Done

110

Specify other molecular marker:111

Were cytogenetics tested (karyotyping or FISH)? (between diagnosis and last evaluation)

yes no Unknown

112

Were cytogenetics tested via FISH? (between diagnosis and last evaluation)

Yes No

113

Results of tests114

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities115

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

116

Specify other abnormality:117

Were cytogenetics tested via karyotyping? (between diagnosis and last evaluation)

Yes No

118

Results of tests119

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities120

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

121

Specify other abnormality:122

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

123

Were tests for molecular markers performed? (e.g. PCR, NGS) (between diagnosis and last evaluation)

yes no Unknown

124

BCR / ABL

Positive Negative Not Done

125

TEL-AML / AML1

Positive Negative Not Done

126

Other Molecular Marker (1) Questions: 127 - 128

Other molecular marker

Positive Negative Not Done

127

Specify other molecular marker:128

Were cytogenetics tested (karyotyping or FISH)? (at last evaluation)

yes no Unknown

129

Were cytogenetics tested via FISH? (at last evaluation)

Yes No

130

Results of tests131

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities132

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

133

Specify other abnormality:134

Were cytogenetics tested via karyotyping? (at last evaluation)

Yes No

135

Results of tests136

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities137

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

138

Specify other abnormality:139

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

140

Were tests for molecular markers performed? (e.g. PCR, NGS) (at last evaluation)

yes no Unknown

141

BCR / ABL

Positive Negative Not Done

142

TEL-AML / AML1

Positive Negative Not Done

143

Other Molecular Marker (1) Questions: 144 - 145

Other molecular marker

Positive Negative Not Done

144

Specify other molecular marker:145

Did the recipient have central nervous system leukemia at any time prior to the start of the preparative regimen / infusion?

yes no Unknown

146

What was the disease status (based on hematological test results)?147

Primary induction failure

1st complete remission (no previous marrow or extramedullary relapse) (include CRi)

2nd complete remission

≥3rd complete remission

1st relapse

2nd relapse

≥3rd relapse

No treatment

How many cycles of induction therapy were required to achieve 1st complete remission? (include CRi)

1 2 ≥ 3

148

Was the recipient in remission by flow cytometry?

Yes No Unknown Not applicable

149

Date of most recent relapse:150 __ __ __ __ - __ __- __ __

Date assessed:151 __ __ __ __ - __ __- __ __

Acute Leukemias of Ambiguous Lineage and Other Myeloid Neoplasms Questions: 152 - 155

Specify acute leukemias of ambiguous lineage and other myeloid neoplasm classification152

Blastic plasmacytoid dendritic cell neoplasm (296)

Acute undifferentiated leukemia (31)

Mixed phenotype acute leukemia (MPAL) with t(9;22)(q34.1;q11.2); BCR-ABL1 (84)

Mixed phenotype acute leukemia with t(v; 11q23.3); KMT2A rearranged (85)

Mixed phenotype acute leukemia, B/myeloid, NOS (86)

Mixed phenotype acute leukemia, T/myeloid, NOS (87)

Other acute leukemia of ambiguous lineage or myeloid neoplasm (88)

Specify other acute leukemia of ambiguous lineage or myeloid neoplasm:153

What was the disease status (based on hematological test results)?154

Primary induction failure

1st complete remission (no previous marrow or extramedullary relapse)

2nd complete remission

≥3rd complete remission

1st relapse

2nd relapse

≥3rd relapse

No treatment

Date assessed:155 __ __ __ __ - __ __- __ __

Chronic Myelogenous Leukemia (CML) Questions: 156 - 166

Was therapy given prior to this HCT?

yes no

156

Combination chemotherapy

yes no

157

Hydroxyurea (Droxia, Hydrea)

yes no

158

Tyrosine kinase inhibitor (e.g. imatinib mesylate, dasatinib, nilotinib)

yes no

159

Interferon­α (Intron, Roferon) (includes PEG)

yes no

160

Other therapy

yes no

161

Specify other therapy:162

What was the disease status?163

Complete hematologic response (CHR)

Chronic phase

Accelerated phase

Blast phase

Specify level of response164

No cytogenetic response (No CyR)

Minimal cytogenetic response

Minor cytogenetic response

Partial cytogenetic response (PCyR)

Complete cytogenetic response (CCyR)

Major molecular remission (MMR)

Complete molecular remission (CMR)

Number

1st 2nd 3rd or higher

165

Date assessed:166 __ __ __ __ - __ __- __ __

Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases Questions: 167 - 260

What was the MDS / MPN subtype at diagnosis? - If transformed to AML, indicate AML as primary disease; also complete AML Disease Classification
questions

167

Was the disease (MDS/MPN) therapy related?

yes no Unknown

168

Did the recipient have a predisposing condition?

yes no Unknown

169

Specify condition

Aplastic Anemia Bloom syndrome Down syndrome Fanconi anemia Other condition

170

Specify other condition:171

WBC

Known Unknown

172

173 x 109/L (x 103/mm3)

x 106/L

Hemoglobin

Known Unknown

174

175 g/dL g/L mmol/L

Was RBC transfused ≤ 30 days before date of test?

Yes No

176

Platelets

Known Unknown

177

178 x 109/L (x 103/mm3)

x 106/L

Were platelets transfused ≤ 7 days before date of test?

Yes No

179

Neutrophils

Known Unknown

180

181 %

Blasts in bone marrow

Known Unknown

182

183 %

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

184

Results of tests185

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities186

One (1)

Two (2)

Three (3)

Four or more (4 or more)

–5

yes no

187

-7

yes no

188

–13

yes no

189

–20

yes no

190

–Y

yes no

191

+8

yes no

192

+19

yes no

193

t(1;3)

yes no

194

t(2;11)

yes no

195

t(3;3)

yes no

196

t(3;21)

yes no

197

t(6;9)

yes no

198

t(11;16)

yes no

199

del(3q) / 3q–

yes no

200

del(5q) / 5q-

yes no

201

del(7q) / 7q–

yes no

202

del(9q) / 9q–

yes no

203

del(11q) / 11q–

yes no

204

del(12p) / 12p–

yes no

205

del(13q) / 13q-

yes no

206

del(20q) / 20q–

yes no

207

inv(3)

yes no

208

i17q

yes no

209

Other abnormality

yes no

210

Specify other abnormality:211

Did the recipient progress or transform to a different MDS / MPN subtype between diagnosis and the start of the preparative regimen?

yes no

212

Specify the MDS / MPN classification after transformation:213

Specify the date of the most recent transformation:214 __ __ __ __ - __ __- __ __

Date of MDS diagnosis:215 __ __ __ __ - __ __- __ __

WBC

Known Unknown

216

217 x 109/L (x 103/mm3)

x 106/L

Hemoglobin

Known Unknown

218

219 g/dL g/L mmol/L

Was RBC transfused ≤ 30 days before date of test?

Yes No

220

Platelets

Known Unknown

221

222 x 109/L (x 103/mm3)

x 106/L

Were platelets transfused ≤ 7 days before date of test?

Yes No

223

Neutrophils

Known Unknown

224

225 %

Blasts in bone marrow

Known Unknown

226

227 %

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

228

Results of tests229

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities230

One (1)

Two (2)

Three (3)

Four or more (4 or more)

–5

yes no

231

-7

yes no

232

–13

yes no

233

–20

yes no

234

–Y

yes no

235

+8

yes no

236

+19

yes no

237

t(1;3)

yes no

238

t(2;11)

yes no

239

t(3;3)

yes no

240

t(3;21)

yes no

241

t(6;9)

yes no

242

t(11;16)

yes no

243

del(3q) / 3q–

yes no

244

del(5q) / 5q-

yes no

245

del(7q) / 7q–

yes no

246

del(9q) / 9q–

yes no

247

del(11q) / 11q–

yes no

248

del(12p) / 12p–

yes no

249

del(13q) / 13q-

yes no

250

del(20q) / 20q–

yes no

251

inv(3)

yes no

252

i17q

yes no

253

Other abnormality

yes no

254

Specify other abnormality:255

What was the disease status?256

Complete
remission
(CR)

– requires all of the following, maintained for ≥ 4 weeks: * bone marrow evaluation: <  5% myeloblasts with normal maturation of all cell lines *
peripheral blood evaluation: hemoglobin ≥ 11 g/dL untransfused and without erythropoietin support; ANC ≥ 1000/mm3  without myeloid growth factor
support; platelets ≥ 100 x 109/L without thrombopoietic support; 0% blasts

Hematologic
improvement
(HI)

– requires one measurement of the following, maintained for ≥ 8 weeks without ongoing cytotoxic therapy; specify which cell line was measured to
determine HI response: * HI­E – hemoglobin increase of ≥ 1.5 g/dL untransfused; for RBC transfusions performed for Hgb ≤ 9.0, reduction in RBC
units transfused in 8 weeks by ≥ 4 units compared to the pre­treatment transfusion number in 8 weeks * HI­P – for pre­treatment platelet count of > 20
x 109/L, platelet absolute increase of ≥ 30 x 109/L; for pre-treatment platelet count of < 20 x 109/L, platelet absolute increase of ≥ 20 x 109/L and ≥
100% from pre­treatment level  * HI­N – neutrophil count increase of ≥ 100% from pre­treatment level and an absolute increase of ≥ 500/mm3

No response (NR) / stable disease (SD) – does not meet the criteria for at least HI, but no evidence of disease progression

Progression from
hematologic improvement
(Prog from HI)

– requires at least one of the following, in the absence of another explanation (e.g., infection, bleeding, ongoing chemotherapy, etc.): *
≥ 50% reduction from maximum response levels in granulocytes or platelets * reduction in hemoglobin by ≥ 1.5 g/dL *transfusion
dependence

Relapse from complete
remission (Rel from CR)

– requires at least one of the following: * return to pre­treatment bone marrow blast percentage * decrease of ≥ 50% from maximum
response levels in granulocytes or platelets * transfusion dependence, or hemoglobin level ≥ 1.5 g/dL lower than prior to therapy

Not assessed

Specify the cell line examined to determine HI status257

HI-
E

– hemoglobin increase of ≥ 1.5 g/dL untransfused; for RBC transfusions performed for Hgb ≤ 9.0, reduction in RBC units transfused in 8 weeks by ≥ 4
units compared to the pre-treatment transfusion number in 8 weeks

HI-
P

– for pre­treatment platelet count of > 20 x 109/L, platelet absolute increase of ≥ 30 x 109/L; for pre-treatment platelet count of < 20 x 109/L, platelet
absolute increase of ≥ 20 x 109/L and ≥ 100% from pre­treatment level 

HI-N – neutrophil count increase of ≥ 100% from pre­treatment level and an absolute increase of ≥ 500/mm3

Date of progression:258 __ __ __ __ - __ __- __ __

Date of relapse:259 __ __ __ __ - __ __- __ __

Date assessed:260 __ __ __ __ - __ __- __ __

Other Leukemia (OL) Questions: 261 - 267

Specify the other leukemia classification261

Specify other leukemia:262

Was any 17p abnormality detected?

yes no

263

Did a histologic transformation to diffuse large B-cell lymphoma (Richter syndrome) occur at any time after CLL diagnosis?264

yes - Also complete NHL Disease Classification questions

no

What was the disease status? (Atypical CML)265

Primary induction failure

1st complete remission (no previous bone marrow or extramedullary relapse)

2nd complete remission

≥3rd complete remission

1st relapse

2nd relapse

≥3rd relapse

No treatment

What was the disease status? (CLL, PLL, Hairy cell leukemia)266

Complete remission (CR)

Partial remission (PR)

Stable disease (SD)

Progressive disease (Prog)

Untreated

Not assessed

Date assessed:267 __ __ __ __ - __ __- __ __

Hodgkin and Non-Hodgkin Lymphoma Questions: 268 - 285

Specify the lymphoma histology (at infusion)268

Specify other lymphoma histology:269

Assignment of DLBCL (germinal center B-cell type vs. activated B-cell type) subtype was based on270

Immunohistochemistry (e.g. Han's algorithm)

Gene expression profile

Unknown method

Is the lymphoma histology reported at transplant a transformation from CLL?

yes no

271

Was any 17p abnormality detected?

yes no

272

Is the lymphoma histology reported at transplant a transformation from a different lymphoma histology? (Not CLL)

Yes No

273

Specify the original lymphoma histology (prior to transformation)274

Specify other lymphoma histology:275

Date of original lymphoma diagnosis:276 __ __ __ __ - __ __- __ __ (report the date of diagnosis of original lymphoma subtype)

Was a PET (or PET/CT) scan performed? (at last evaluation prior to the start of the preparative regimen / infusion)

yes no

277

Was the PET (or PET/CT) scan positive for lymphoma involvement at any disease site?

yes no

278

Date of PET scan

Known Unknown

279

Date of PET (or PET/CT) scan:280 __ __ __ __ - __ __- __ __

Deauville (five-point) score of the PET (or PET/CT) scan

Known Unknown

281

Scale282

1 - no uptake or residual uptake

2 - slight uptake, but below blood pool (mediastinum)

3 - uptake above mediastinal, but below or equal to uptake in the liver

4 - uptake slightly to moderately higher than liver

5 - markedly increased uptake or any new lesions

What was the disease status?283

Total number of lines of therapy received

1 line 2 lines 3+ lines

284

Date assessed:285 __ __ __ __ - __ __- __ __

Multiple Myeloma / Plasma Cell Disorder (PCD) Questions: 286 - 317

Specify the multiple myeloma/plasma cell disorder (PCD) classification286

Specify other plasma cell disorder:287

Light chain

kappa lambda

288

What was the Durie-Salmon staging? (at diagnosis)289

Stage
I

(All of the following: Hgb > 10g/dL; serum calcium normal or <10.5 mg/dL; bone x-ray normal bone structure (scale 0), or solitary bone plasmacytoma
only; low M-component production rates IgG< 5g/dL, IgA < 3g/dL; urine light chain M-component on electrophoresis <4 g/24h)

Stage II (Fitting neither Stage I or III) 

Stage
III

(One or more of the following: Hgb < 8.5 g/dL; serum calcium > 12 mg/dL; advanced lytic bone lesions (scale 3); high M-component production rates
IgG > 7g/dL, IgA > 5 g/dL; Bence Jones protein > 12g/24h)

Unknown

What was the Durie-Salmon sub classification? (at diagnosis)290

A - relatively normal renal function (serum creatinine < 2.0 mg/dL)

B ­ abnormal renal function (serum creatinine ≥ 2.0 mg/dL)

Serum β2­microglobulin:291 μg/dL mg/L nmol/L

Serum albumin:292 g/dL g/L

Stage293

1 (β2 ­mic < 3.5, S. albumin ≥3.5)

2 (Not fitting stage 1 or 3)

3 (β2­mic ≥ 5.5; S. albumin ­)

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

294

Results of tests295

Abnormalities identified

No evaluable metaphases

No abnormalities

+3

yes no

296

+5

yes no

297

+7

yes no

298

+9

yes no

299

+11

yes no

300

+15

yes no

301

+19

yes no

302

t(4;14)

yes no

303

t(6;14)

yes no

304

t(11;14)

yes no

305

t(14;16)

yes no

306

t(14;20)

yes no

307

del(13q) / 13q-

yes no

308

del (17p) / 17p-

yes no

309

Hyperdiploid (>50)

yes no

310

Hypodiploid (<46)

yes no

311

Any abnormality at 1q

yes no

312

Any abnormality at 1p

yes no

313

Other abnormality

yes no

314

Specify other abnormality:315

What was the disease status?316

Stringent
complete
remission
(sCR)

- CR as defined, plus: normal free light chain ratio, and absence of clonal cells in the bone marrow by immunohistochemistry of immunofluorescence
(confirmation with repeat bone marrow biopsy not needed). (Presence and/or absence of clonal cells is based upon the Κ/λ ratio. An abnormal Κ/λ ratio by
immunohistochemistry and/or immunofluorescence requires a minimum of 100 plasma cells for analysis.  An abnormal ratio reflecting the presence of
an abnormal clone is Κ/λ of > 4:1 or < 1:2.) sCR requires two consecutive assessments made at any time before the institution of any new therapy, and
no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy sCR
requirements. 

Complete
remission
(CR)

- negative immunofixation on serum and urine samples, and disappearance of any soft tissue plasmacytomas, and < 5% plasma cells in the bone
marrow (confirmation with repeat bone marrow biopsy not needed).  CR requires two consecutive assessments made at any time before the institution
of any new therapy, and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not
required to satisfy CR requirements. 

Near
complete
remission
(nCR)

- serum and urine M-protein detectable by immunoelectrophoresis (IFE), but not on electrophoresis (negative SPEP & UPEP); < 5% plasma cells in
bone marrow.  nCR requires two consecutive assessments made at any time before the initiation of any new therapy, and no known evidence of
progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy nCR requirements. 

Very good
partial
remission
(VGPR)

­ serum and urine M­protein detectable by immunofixation but not on electrophoresis, or ≥ 90% reduction in serum M­protein and urine M­protein level <
100 mg/24 hours.  VGPR requires two consecutive assessments made at any time before the institution of any new therapy, and no known evidence of
progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy VGPR requirements.

Partial
remission
(PR)

­ ≥ 50% reduction in serum M­protein, and reduction in 24­hour urinary M­protein by ≥ 90% or to < 200 mg/24 hours.  If the serum and urine M­protein are
unmeasurable (i.e., do not meet any of the following criteria: • serum M­protein ≥ 1 g/dL.  Urine M­protein ≥ 200 mg/24 hours • serum free light chain
assay shows involved level ≥ 10 mg/dL, provided serum free light chain ratio is abnormal), a ≥ 50% decrease in the difference between involved and
uninvolved free light chain levels is required in place of the M-protein criteria.  If serum and urine M-protein are unmeasurable, and serum free light assay
is also unmeasurable, a ≥ 50% reduction in plasma cells is required in place of M­protein, provided the baseline bone marrow plasma cell percentage
was ≥ 30%. In addition to the above listed criteria, a ≥ 50% reduction in the size of soft tissue plasmacytomas is also required, if present at baseline. PR
requires two consecutive assessments made at any time before the institution of any new therapy, and no known evidence of progressive or new bone
lesions if radiographic studies were performed; radiographic studies are not required to satisfy PR requirements. 

Stable
disease
(SD)

- not meeting the criteria for CR, VGPR, PR or PD.  SD requires two consecutive assessments made at any time before the institution of any new therapy,
and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy SD
requirements.

Progressive
disease
(PD)

­ requires any one or more of the following:  Increase of ≥ 25% from baseline in:  serum M­component and/or (absolute increase ≥ 0.5 g/dL) (for
progressive disease, serum M­component increases of ≥ 1 g/dL are sufficient to define relapse if the starting M­component is ≥ 5 g/dL).  Urine M­
component and/or (absolute increase ≥ 200 mg/24 hours) for recipients without measurable serum and urine M­protein levels: the difference between
involved and uninvolved free light chain levels (absolute increase > 10 mg/dL).  Bone marrow plasma cell percentage (absolute percentage ≥ 10%)
(relapse from CR has a 5% cutoff vs. 10% for other categories of relapse) definite development of new bone lesions or soft tissue plasmacytomas, or
definite increase in the size of any existing  bone lesions or soft tissue plasmacytomas. Development of hypercalcemia (corrected serum calcium >
11.5 mg/dL or 2.65 mmol) that can be attributed solely to the plasma cell proliferative disorder.  PD requires two consecutive assessments made at
any time before classification as disease progression, and/or the institution of any new therapy.

Relapse
from CR
(Rel)
(untreated)

­ requires one or more of the following: reappearance of serum or urine M­protein by immunofixation or electrophoresis development of ≥ 5% plasma
cells in the bone marrow (relapse from CR has a 5% cutoff vs. 10% for other categories of relapse) appearance of any other sign of progression (e.g.,
new plasmacytoma, lytic bone lesion, hypercalcemia).  Rel requires two consecutive assessments made at any time before classification as relapse,
and/or the institution of any new therapy.

Unknown

Not applicable (Amyloidosis with no evidence of myeloma)

Date assessed:317 __ __ __ __ - __ __- __ __

Solid Tumors Questions: 318 - 319

Specify the solid tumor classification318

Specify other solid tumor:319

Severe Aplastic Anemia Questions: 320 - 321

Specify the severe aplastic anemia classification320

Specify other acquired cytopenic syndrome:321

Inherited Abnormalities of Erythrocyte Differentiation or Function Questions: 322 - 324

Specify the inherited abnormalities of erythrocyte differentiation or function classification322

Specify other constitutional anemia:323

Specify other hemoglobinopathy:324

Disorders of the Immune System Questions: 325 - 327

Specify disorder of immune system classification325

Specify other SCID:326

Specify other immunodeficiency:327

Inherited Abnormalities of Platelets Questions: 328 - 329

Specify inherited abnormalities of platelets classification328

Congenital amegakaryocytosis / congenital thrombocytopenia (501)

Glanzmann thrombasthenia (502)

Other inherited platelet abnormality (509)

Specify other inherited platelet abnormality:329

Inherited Disorders of Metabolism Questions: 330 - 331

Specify inherited disorders of metabolism classification330

Specify other inherited metabolic disorder:331

Histiocytic Disorders Questions: 332 - 333

Specify histiocytic disorder classification332

Specify other histiocytic disorder:333

Autoimmune Diseases Questions: 334 - 341

Specify autoimmune disease classification334

Specify other arthritis:335

Specify other juvenile idiopathic arthritis (JIA):336

Specify other connective tissue disease:337

Specify other vasculitis:338

Specify other autoimmune neurological disorder:339

Specify other autoimmune cytopenia:340

Specify other autoimmune bowel disorder:341

Other Disease Questions: 342 - 342

Specify other disease:342

First Name:

Last Name:

E-mail address:

Date: __ __ __ __ - __ __- __ __

OMB No: 0915-0310

Expiration Date: 1/31/2020

Public Burden Statement:  An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control
number.  The OMB control number for this project is 0915-0310.  Public reporting burden for this collection of information is estimated to average 1.0 hours per response, including the

time for reviewing instructions, searching existing data sources, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other
aspect of this collection of information, including suggestions for reducing this burden, to HRSA Reports Clearance Officer, 5600 Fishers Lane, Room 10-29, Rockville, Maryland, 20857.

Labs at diagnosis

Specify cytogenetic abnormalities identified at diagnosis:

Specify cytogenetic abnormalities identified at diagnosis:

Specify molecular markers identified at diagnosis:

Labs between diagnosis and last evaluation:

Specify cytogenetic abnormalities identified between diagnosis and last evaluation:

Specify cytogenetic abnormalities identified between diagnosis and last evaluation:

Specify molecular markers identified between diagnosis and last evaluation:

Labs at last evaluation:

Specify cytogenetic abnormalities identified at last evaluation:

Specify cytogenetic abnormalities identified at last evaluation:

Specify molecular markers identified at last evaluation:

CNS Leukemia

Status at transplantation:

Laboratory studies at diagnosis:

Specify cytogenetic abnormalities identified at diagnosis:

Specify cytogenetic abnormalities identified at diagnosis:

Specify molecular markers identified at diagnosis:

Laboratory studies between diagnosis and last evaluation:

Specify cytogenetic abnormalities identified between diagnosis and last evaluation:

Specify cytogenetic abnormalities identified between diagnosis and last evaluation:

Specify molecular markers identified between diagnosis and last evaluation:

Laboratory studies at last evaluation:

Specify cytogenetic abnormalities identified at last evaluation:

Specify cytogenetic abnormalities identified at last evaluation:

Specify molecular markers identified at last evaluation:

CNS Leukemia

Status at transplantation:

Status at transplantation:

Laboratory studies at diagnosis of MDS:

Specify abnormalities identified at diagnosis:

Monosomy

Trisomy

Translocation

Deletion

Inversion

Other

Laboratory studies at last evaluation prior to the start of the preparative regimen:

Specify cytogenetic abnormalities identified at last evaluation prior to the start of the preparative regimen:

Monosomy

Trisomy

Translocation

Deletion

Inversion

Other

Status at transplantation:

Status at transplantation:

Status at transplantation / infusion:

I.S.S.:

Specify cytogenetic abnormalities identified at any time prior to the start of the preparative regimen:

Trisomy

Translocation

Deletion

Other

Status at transplantation:

Center: CRID: 

Form 2402 R3.0: Disease Classification

CIBMTR Form 2402 revision 3.0 last updated Monday, January 29, 2018
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 15 / 26



Key Fields

Sequence Number:

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number:

CIBMTR Research ID:

Event date: __ __ __ __ - __ __- __ __

Primary Disease for HCT / Cellular Therapy Questions: 1 - 2

Date of diagnosis of primary disease for HCT / cellular therapy:1 __ __ __ __ - __ __- __ __

What was the primary disease for which the HCT / cellular therapy was performed?2

Acute myelogenous leukemia (AML or ANLL) (10)

Acute lymphoblastic leukemia (ALL) (20)

Acute leukemia of ambiguous lineage and other myeloid neoplasms (80)

Chronic myelogenous leukemia (CML) (40)

Myelodysplastic (MDS) / myeloproliferative (MPN) diseases (50) (Please classify all preleukemias) (If recipient has transformed to AML, indicate AML as the primary disease)

Other leukemia (30) (includes CLL)

Hodgkin lymphoma (150)

Non-Hodgkin lymphoma (100)

Multiple myeloma / plasma cell disorder (PCD) (170)

Solid tumors (200)

Severe aplastic anemia (300) (If the recipient developed MDS or AML, indicate MDS or AML as the primary disease)

Inherited abnormalities of erythrocyte differentiation or function (310)

Disorders of the immune system (400)

Inherited abnormalities of platelets (500)

Inherited disorders of metabolism (520)

Histiocytic disorders (570)

Autoimmune diseases (600)

Other disease (900)

Acute Myelogenous Leukemia (AML) Questions: 3 - 89

Specify the AML classification3

Did AML transform from MDS or MPN?4

yes - Also complete MDS Disease Classification questions

no

Is the disease (AML) therapy related?

yes no Unknown

5

Did the recipient have a predisposing condition?

yes no Unknown

6

Specify condition7

Bloom syndrome

Down syndrome

Fanconi anemia

Dyskeratosis congenita

Other condition

Specify other condition:8

Were cytogenetics tested (karyotyping or FISH)? (at diagnosis)

yes no Unknown

9

Were cytogenetics tested via FISH? (at diagnosis)

Yes No

10

Results of tests11

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities12

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

13

Specify other abnormality:14

Were cytogenetics tested via karyotyping? (at diagnosis)

Yes No

15

Results of tests16

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities17

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

18

Specify other abnormality:19

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

20

Were tests for molecular markers performed? (e.g. PCR, NGS) (at diagnosis)

yes no Unknown

21

CEBPA

Positive Negative Not Done

22

Specify CEBPA mutation23

Biallelic (homozygous)

Monoallelic (heterozygous)

Unknown

FLT3 – D835 point mutation

Positive Negative Not Done

24

FLT3 – ITD mutation

Positive Negative Not Done

25

FLT3 - ITD allelic ratio

Known Unknown

26

Specify FLT3 - ITD allelic ratio:27

IDH1

Positive Negative Not Done

28

IDH2

Positive Negative Not Done

29

KIT

Positive Negative Not Done

30

NPM1

Positive Negative Not Done

31

Other Molecular Marker (1) Questions: 32 - 33

Other molecular marker

Positive Negative Not Done

32

Specify other molecular marker:33

Were cytogenetics tested (karyotyping or FISH)? (between diagnosis and last evaluation)

yes no Unknown

34

Were cytogenetics tested via FISH? (between diagnosis and last evaluation)

Yes No

35

Results of tests36

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities37

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

38

Specify other abnormality:39

Were cytogenetics tested via karyotyping? (between diagnosis and last evaluation)

Yes No

40

Results of tests41

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities42

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

43

Specify other abnormality:44

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

45

Were tests for molecular markers performed? (e.g. PCR, NGS) (between diagnosis and last evaluation)

yes no Unknown

46

CEBPA

Positive Negative Not Done

47

Specify CEBPA mutation48

Biallelic (homozygous)

Monoallelic (heterozygous)

Unknown

FLT3 – D835 point mutation

Positive Negative Not Done

49

FLT3 – ITD mutation

Positive Negative Not Done

50

FLT3 - ITD allelic ratio

Known Unknown

51

Specify FLT3 - ITD allelic ratio:52

IDH1

Positive Negative Not Done

53

IDH2

Positive Negative Not Done

54

KIT

Positive Negative Not Done

55

NPM1

Positive Negative Not Done

56

Other Molecular Marker (1) Questions: 57 - 58

Other molecular marker

Positive Negative Not Done

57

Specify other molecular marker:58

Were cytogenetics tested (karyotyping or FISH)? (at last evaluation)

yes no Unknown

59

Were cytogenetics tested via FISH? (at last evaluation)

Yes No

60

Results of tests61

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities62

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

63

Specify other abnormality:64

Were cytogenetics tested via karyotyping? (at last evaluation)

Yes No

65

Results of tests66

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities67

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

68

Specify other abnormality:69

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

70

Were tests for molecular markers performed? (e.g. PCR, NGS) (at last evaluation)

yes no Unknown

71

CEBPA

Positive Negative Not Done

72

Specify CEBPA mutation73

Biallelic (homozygous)

Monoallelic (heterozygous)

Unknown

FLT3 – D835 point mutation

Positive Negative Not Done

74

FLT3 – ITD mutation

Positive Negative Not Done

75

FLT3 - ITD allelic ratio

Known Unknown

76

Specify FLT3 - ITD allelic ratio:77

IDH1

Positive Negative Not Done

78

IDH2

Positive Negative Not Done

79

KIT

Positive Negative Not Done

80

NPM1

Positive Negative Not Done

81

Other Molecular Marker (1) Questions: 82 - 83

Other molecular marker

Positive Negative Not Done

82

Specify other molecular marker:83

Did the recipient have central nervous system leukemia at any time prior to the start of the preparative regimen / infusion?

yes no Unknown

84

What was the disease status (based on hematological test results)?85

Primary induction failure

1st complete remission (no previous bone marrow or extramedullary relapse) (include CRi)

2nd complete remission

≥3rd complete remission

1st relapse

2nd relapse

≥3rd relapse

No treatment

How many cycles of induction therapy were required to achieve 1st complete remission? (includes CRi)

1 2 ≥ 3

86

Was the recipient in remission by flow cytometry?

Yes No Unknown Not applicable

87

Date of most recent relapse:88 __ __ __ __ - __ __- __ __

Date assessed:89 __ __ __ __ - __ __- __ __

Acute Lymphoblastic Leukemia (ALL) Questions: 90 - 151

Specify ALL classification90

Did the recipient have a predisposing condition?

yes no Unknown

91

Specify condition92

Aplastic anemia - Also complete CIBMTR Form 2028 - APL

Bloom syndrome

Down syndrome

Fanconi anemia - Also complete CIBMTR Form 2029 - FAN

Other condition

Specify other condition:93

Were tyrosine kinase inhibitors given for therapy at any time prior to the start of the preparative regimen / infusion? (e.g. imatinib mesylate, dasatinib, etc.)

yes no

94

Were cytogenetics tested (karyotyping or FISH)? (at diagnosis)

yes no Unknown

95

Were cytogenetics tested via FISH? (at diagnosis)

Yes No

96

Results of tests97

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities98

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

99

Specify other abnormality:100

Were cytogenetics tested via karyotyping? (at diagnosis)

Yes No

101

Results of tests102

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities103

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

104

Specify other abnormality:105

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

106

Were tests for molecular markers performed? (e.g. PCR, NGS) (at diagnosis)

yes no Unknown

107

BCR / ABL

Positive Negative Not Done

108

TEL-AML / AML1

Positive Negative Not Done

109

Other Molecular Marker (1) Questions: 110 - 111

Other molecular marker

Positive Negative Not Done

110

Specify other molecular marker:111

Were cytogenetics tested (karyotyping or FISH)? (between diagnosis and last evaluation)

yes no Unknown

112

Were cytogenetics tested via FISH? (between diagnosis and last evaluation)

Yes No

113

Results of tests114

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities115

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

116

Specify other abnormality:117

Were cytogenetics tested via karyotyping? (between diagnosis and last evaluation)

Yes No

118

Results of tests119

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities120

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

121

Specify other abnormality:122

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

123

Were tests for molecular markers performed? (e.g. PCR, NGS) (between diagnosis and last evaluation)

yes no Unknown

124

BCR / ABL

Positive Negative Not Done

125

TEL-AML / AML1

Positive Negative Not Done

126

Other Molecular Marker (1) Questions: 127 - 128

Other molecular marker

Positive Negative Not Done

127

Specify other molecular marker:128

Were cytogenetics tested (karyotyping or FISH)? (at last evaluation)

yes no Unknown

129

Were cytogenetics tested via FISH? (at last evaluation)

Yes No

130

Results of tests131

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities132

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

133

Specify other abnormality:134

Were cytogenetics tested via karyotyping? (at last evaluation)

Yes No

135

Results of tests136

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities137

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

138

Specify other abnormality:139

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

140

Were tests for molecular markers performed? (e.g. PCR, NGS) (at last evaluation)

yes no Unknown

141

BCR / ABL

Positive Negative Not Done

142

TEL-AML / AML1

Positive Negative Not Done

143

Other Molecular Marker (1) Questions: 144 - 145

Other molecular marker

Positive Negative Not Done

144

Specify other molecular marker:145

Did the recipient have central nervous system leukemia at any time prior to the start of the preparative regimen / infusion?

yes no Unknown

146

What was the disease status (based on hematological test results)?147

Primary induction failure

1st complete remission (no previous marrow or extramedullary relapse) (include CRi)

2nd complete remission

≥3rd complete remission

1st relapse

2nd relapse

≥3rd relapse

No treatment

How many cycles of induction therapy were required to achieve 1st complete remission? (include CRi)

1 2 ≥ 3

148

Was the recipient in remission by flow cytometry?

Yes No Unknown Not applicable

149

Date of most recent relapse:150 __ __ __ __ - __ __- __ __

Date assessed:151 __ __ __ __ - __ __- __ __

Acute Leukemias of Ambiguous Lineage and Other Myeloid Neoplasms Questions: 152 - 155

Specify acute leukemias of ambiguous lineage and other myeloid neoplasm classification152

Blastic plasmacytoid dendritic cell neoplasm (296)

Acute undifferentiated leukemia (31)

Mixed phenotype acute leukemia (MPAL) with t(9;22)(q34.1;q11.2); BCR-ABL1 (84)

Mixed phenotype acute leukemia with t(v; 11q23.3); KMT2A rearranged (85)

Mixed phenotype acute leukemia, B/myeloid, NOS (86)

Mixed phenotype acute leukemia, T/myeloid, NOS (87)

Other acute leukemia of ambiguous lineage or myeloid neoplasm (88)

Specify other acute leukemia of ambiguous lineage or myeloid neoplasm:153

What was the disease status (based on hematological test results)?154

Primary induction failure

1st complete remission (no previous marrow or extramedullary relapse)

2nd complete remission

≥3rd complete remission

1st relapse

2nd relapse

≥3rd relapse

No treatment

Date assessed:155 __ __ __ __ - __ __- __ __

Chronic Myelogenous Leukemia (CML) Questions: 156 - 166

Was therapy given prior to this HCT?

yes no

156

Combination chemotherapy

yes no

157

Hydroxyurea (Droxia, Hydrea)

yes no

158

Tyrosine kinase inhibitor (e.g. imatinib mesylate, dasatinib, nilotinib)

yes no

159

Interferon­α (Intron, Roferon) (includes PEG)

yes no

160

Other therapy

yes no

161

Specify other therapy:162

What was the disease status?163

Complete hematologic response (CHR)

Chronic phase

Accelerated phase

Blast phase

Specify level of response164

No cytogenetic response (No CyR)

Minimal cytogenetic response

Minor cytogenetic response

Partial cytogenetic response (PCyR)

Complete cytogenetic response (CCyR)

Major molecular remission (MMR)

Complete molecular remission (CMR)

Number

1st 2nd 3rd or higher

165

Date assessed:166 __ __ __ __ - __ __- __ __

Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases Questions: 167 - 260

What was the MDS / MPN subtype at diagnosis? - If transformed to AML, indicate AML as primary disease; also complete AML Disease Classification
questions

167

Was the disease (MDS/MPN) therapy related?

yes no Unknown

168

Did the recipient have a predisposing condition?

yes no Unknown

169

Specify condition

Aplastic Anemia Bloom syndrome Down syndrome Fanconi anemia Other condition

170

Specify other condition:171

WBC

Known Unknown

172

173 x 109/L (x 103/mm3)

x 106/L

Hemoglobin

Known Unknown

174

175 g/dL g/L mmol/L

Was RBC transfused ≤ 30 days before date of test?

Yes No

176

Platelets

Known Unknown

177

178 x 109/L (x 103/mm3)

x 106/L

Were platelets transfused ≤ 7 days before date of test?

Yes No

179

Neutrophils

Known Unknown

180

181 %

Blasts in bone marrow

Known Unknown

182

183 %

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

184

Results of tests185

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities186

One (1)

Two (2)

Three (3)

Four or more (4 or more)

–5

yes no

187

-7

yes no

188

–13

yes no

189

–20

yes no

190

–Y

yes no

191

+8

yes no

192

+19

yes no

193

t(1;3)

yes no

194

t(2;11)

yes no

195

t(3;3)

yes no

196

t(3;21)

yes no

197

t(6;9)

yes no

198

t(11;16)

yes no

199

del(3q) / 3q–

yes no

200

del(5q) / 5q-

yes no

201

del(7q) / 7q–

yes no

202

del(9q) / 9q–

yes no

203

del(11q) / 11q–

yes no

204

del(12p) / 12p–

yes no

205

del(13q) / 13q-

yes no

206

del(20q) / 20q–

yes no

207

inv(3)

yes no

208

i17q

yes no

209

Other abnormality

yes no

210

Specify other abnormality:211

Did the recipient progress or transform to a different MDS / MPN subtype between diagnosis and the start of the preparative regimen?

yes no

212

Specify the MDS / MPN classification after transformation:213

Specify the date of the most recent transformation:214 __ __ __ __ - __ __- __ __

Date of MDS diagnosis:215 __ __ __ __ - __ __- __ __

WBC

Known Unknown

216

217 x 109/L (x 103/mm3)

x 106/L

Hemoglobin

Known Unknown

218

219 g/dL g/L mmol/L

Was RBC transfused ≤ 30 days before date of test?

Yes No

220

Platelets

Known Unknown

221

222 x 109/L (x 103/mm3)

x 106/L

Were platelets transfused ≤ 7 days before date of test?

Yes No

223

Neutrophils

Known Unknown

224

225 %

Blasts in bone marrow

Known Unknown

226

227 %

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

228

Results of tests229

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities230

One (1)

Two (2)

Three (3)

Four or more (4 or more)

–5

yes no

231

-7

yes no

232

–13

yes no

233

–20

yes no

234

–Y

yes no

235

+8

yes no

236

+19

yes no

237

t(1;3)

yes no

238

t(2;11)

yes no

239

t(3;3)

yes no

240

t(3;21)

yes no

241

t(6;9)

yes no

242

t(11;16)

yes no

243

del(3q) / 3q–

yes no

244

del(5q) / 5q-

yes no

245

del(7q) / 7q–

yes no

246

del(9q) / 9q–

yes no

247

del(11q) / 11q–

yes no

248

del(12p) / 12p–

yes no

249

del(13q) / 13q-

yes no

250

del(20q) / 20q–

yes no

251

inv(3)

yes no

252

i17q

yes no

253

Other abnormality

yes no

254

Specify other abnormality:255

What was the disease status?256

Complete
remission
(CR)

– requires all of the following, maintained for ≥ 4 weeks: * bone marrow evaluation: <  5% myeloblasts with normal maturation of all cell lines *
peripheral blood evaluation: hemoglobin ≥ 11 g/dL untransfused and without erythropoietin support; ANC ≥ 1000/mm3  without myeloid growth factor
support; platelets ≥ 100 x 109/L without thrombopoietic support; 0% blasts

Hematologic
improvement
(HI)

– requires one measurement of the following, maintained for ≥ 8 weeks without ongoing cytotoxic therapy; specify which cell line was measured to
determine HI response: * HI­E – hemoglobin increase of ≥ 1.5 g/dL untransfused; for RBC transfusions performed for Hgb ≤ 9.0, reduction in RBC
units transfused in 8 weeks by ≥ 4 units compared to the pre­treatment transfusion number in 8 weeks * HI­P – for pre­treatment platelet count of > 20
x 109/L, platelet absolute increase of ≥ 30 x 109/L; for pre-treatment platelet count of < 20 x 109/L, platelet absolute increase of ≥ 20 x 109/L and ≥
100% from pre­treatment level  * HI­N – neutrophil count increase of ≥ 100% from pre­treatment level and an absolute increase of ≥ 500/mm3

No response (NR) / stable disease (SD) – does not meet the criteria for at least HI, but no evidence of disease progression

Progression from
hematologic improvement
(Prog from HI)

– requires at least one of the following, in the absence of another explanation (e.g., infection, bleeding, ongoing chemotherapy, etc.): *
≥ 50% reduction from maximum response levels in granulocytes or platelets * reduction in hemoglobin by ≥ 1.5 g/dL *transfusion
dependence

Relapse from complete
remission (Rel from CR)

– requires at least one of the following: * return to pre­treatment bone marrow blast percentage * decrease of ≥ 50% from maximum
response levels in granulocytes or platelets * transfusion dependence, or hemoglobin level ≥ 1.5 g/dL lower than prior to therapy

Not assessed

Specify the cell line examined to determine HI status257

HI-
E

– hemoglobin increase of ≥ 1.5 g/dL untransfused; for RBC transfusions performed for Hgb ≤ 9.0, reduction in RBC units transfused in 8 weeks by ≥ 4
units compared to the pre-treatment transfusion number in 8 weeks

HI-
P

– for pre­treatment platelet count of > 20 x 109/L, platelet absolute increase of ≥ 30 x 109/L; for pre-treatment platelet count of < 20 x 109/L, platelet
absolute increase of ≥ 20 x 109/L and ≥ 100% from pre­treatment level 

HI-N – neutrophil count increase of ≥ 100% from pre­treatment level and an absolute increase of ≥ 500/mm3

Date of progression:258 __ __ __ __ - __ __- __ __

Date of relapse:259 __ __ __ __ - __ __- __ __

Date assessed:260 __ __ __ __ - __ __- __ __

Other Leukemia (OL) Questions: 261 - 267

Specify the other leukemia classification261

Specify other leukemia:262

Was any 17p abnormality detected?

yes no

263

Did a histologic transformation to diffuse large B-cell lymphoma (Richter syndrome) occur at any time after CLL diagnosis?264

yes - Also complete NHL Disease Classification questions

no

What was the disease status? (Atypical CML)265

Primary induction failure

1st complete remission (no previous bone marrow or extramedullary relapse)

2nd complete remission

≥3rd complete remission

1st relapse

2nd relapse

≥3rd relapse

No treatment

What was the disease status? (CLL, PLL, Hairy cell leukemia)266

Complete remission (CR)

Partial remission (PR)

Stable disease (SD)

Progressive disease (Prog)

Untreated

Not assessed

Date assessed:267 __ __ __ __ - __ __- __ __

Hodgkin and Non-Hodgkin Lymphoma Questions: 268 - 285

Specify the lymphoma histology (at infusion)268

Specify other lymphoma histology:269

Assignment of DLBCL (germinal center B-cell type vs. activated B-cell type) subtype was based on270

Immunohistochemistry (e.g. Han's algorithm)

Gene expression profile

Unknown method

Is the lymphoma histology reported at transplant a transformation from CLL?

yes no

271

Was any 17p abnormality detected?

yes no

272

Is the lymphoma histology reported at transplant a transformation from a different lymphoma histology? (Not CLL)

Yes No

273

Specify the original lymphoma histology (prior to transformation)274

Specify other lymphoma histology:275

Date of original lymphoma diagnosis:276 __ __ __ __ - __ __- __ __ (report the date of diagnosis of original lymphoma subtype)

Was a PET (or PET/CT) scan performed? (at last evaluation prior to the start of the preparative regimen / infusion)

yes no

277

Was the PET (or PET/CT) scan positive for lymphoma involvement at any disease site?

yes no

278

Date of PET scan

Known Unknown

279

Date of PET (or PET/CT) scan:280 __ __ __ __ - __ __- __ __

Deauville (five-point) score of the PET (or PET/CT) scan

Known Unknown

281

Scale282

1 - no uptake or residual uptake

2 - slight uptake, but below blood pool (mediastinum)

3 - uptake above mediastinal, but below or equal to uptake in the liver

4 - uptake slightly to moderately higher than liver

5 - markedly increased uptake or any new lesions

What was the disease status?283

Total number of lines of therapy received

1 line 2 lines 3+ lines

284

Date assessed:285 __ __ __ __ - __ __- __ __

Multiple Myeloma / Plasma Cell Disorder (PCD) Questions: 286 - 317

Specify the multiple myeloma/plasma cell disorder (PCD) classification286

Specify other plasma cell disorder:287

Light chain

kappa lambda

288

What was the Durie-Salmon staging? (at diagnosis)289

Stage
I

(All of the following: Hgb > 10g/dL; serum calcium normal or <10.5 mg/dL; bone x-ray normal bone structure (scale 0), or solitary bone plasmacytoma
only; low M-component production rates IgG< 5g/dL, IgA < 3g/dL; urine light chain M-component on electrophoresis <4 g/24h)

Stage II (Fitting neither Stage I or III) 

Stage
III

(One or more of the following: Hgb < 8.5 g/dL; serum calcium > 12 mg/dL; advanced lytic bone lesions (scale 3); high M-component production rates
IgG > 7g/dL, IgA > 5 g/dL; Bence Jones protein > 12g/24h)

Unknown

What was the Durie-Salmon sub classification? (at diagnosis)290

A - relatively normal renal function (serum creatinine < 2.0 mg/dL)

B ­ abnormal renal function (serum creatinine ≥ 2.0 mg/dL)

Serum β2­microglobulin:291 μg/dL mg/L nmol/L

Serum albumin:292 g/dL g/L

Stage293

1 (β2 ­mic < 3.5, S. albumin ≥3.5)

2 (Not fitting stage 1 or 3)

3 (β2­mic ≥ 5.5; S. albumin ­)

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

294

Results of tests295

Abnormalities identified

No evaluable metaphases

No abnormalities

+3

yes no

296

+5

yes no

297

+7

yes no

298

+9

yes no

299

+11

yes no

300

+15

yes no

301

+19

yes no

302

t(4;14)

yes no

303

t(6;14)

yes no

304

t(11;14)

yes no

305

t(14;16)

yes no

306

t(14;20)

yes no

307

del(13q) / 13q-

yes no

308

del (17p) / 17p-

yes no

309

Hyperdiploid (>50)

yes no

310

Hypodiploid (<46)

yes no

311

Any abnormality at 1q

yes no

312

Any abnormality at 1p

yes no

313

Other abnormality

yes no

314

Specify other abnormality:315

What was the disease status?316

Stringent
complete
remission
(sCR)

- CR as defined, plus: normal free light chain ratio, and absence of clonal cells in the bone marrow by immunohistochemistry of immunofluorescence
(confirmation with repeat bone marrow biopsy not needed). (Presence and/or absence of clonal cells is based upon the Κ/λ ratio. An abnormal Κ/λ ratio by
immunohistochemistry and/or immunofluorescence requires a minimum of 100 plasma cells for analysis.  An abnormal ratio reflecting the presence of
an abnormal clone is Κ/λ of > 4:1 or < 1:2.) sCR requires two consecutive assessments made at any time before the institution of any new therapy, and
no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy sCR
requirements. 

Complete
remission
(CR)

- negative immunofixation on serum and urine samples, and disappearance of any soft tissue plasmacytomas, and < 5% plasma cells in the bone
marrow (confirmation with repeat bone marrow biopsy not needed).  CR requires two consecutive assessments made at any time before the institution
of any new therapy, and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not
required to satisfy CR requirements. 

Near
complete
remission
(nCR)

- serum and urine M-protein detectable by immunoelectrophoresis (IFE), but not on electrophoresis (negative SPEP & UPEP); < 5% plasma cells in
bone marrow.  nCR requires two consecutive assessments made at any time before the initiation of any new therapy, and no known evidence of
progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy nCR requirements. 

Very good
partial
remission
(VGPR)

­ serum and urine M­protein detectable by immunofixation but not on electrophoresis, or ≥ 90% reduction in serum M­protein and urine M­protein level <
100 mg/24 hours.  VGPR requires two consecutive assessments made at any time before the institution of any new therapy, and no known evidence of
progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy VGPR requirements.

Partial
remission
(PR)

­ ≥ 50% reduction in serum M­protein, and reduction in 24­hour urinary M­protein by ≥ 90% or to < 200 mg/24 hours.  If the serum and urine M­protein are
unmeasurable (i.e., do not meet any of the following criteria: • serum M­protein ≥ 1 g/dL.  Urine M­protein ≥ 200 mg/24 hours • serum free light chain
assay shows involved level ≥ 10 mg/dL, provided serum free light chain ratio is abnormal), a ≥ 50% decrease in the difference between involved and
uninvolved free light chain levels is required in place of the M-protein criteria.  If serum and urine M-protein are unmeasurable, and serum free light assay
is also unmeasurable, a ≥ 50% reduction in plasma cells is required in place of M­protein, provided the baseline bone marrow plasma cell percentage
was ≥ 30%. In addition to the above listed criteria, a ≥ 50% reduction in the size of soft tissue plasmacytomas is also required, if present at baseline. PR
requires two consecutive assessments made at any time before the institution of any new therapy, and no known evidence of progressive or new bone
lesions if radiographic studies were performed; radiographic studies are not required to satisfy PR requirements. 

Stable
disease
(SD)

- not meeting the criteria for CR, VGPR, PR or PD.  SD requires two consecutive assessments made at any time before the institution of any new therapy,
and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy SD
requirements.

Progressive
disease
(PD)

­ requires any one or more of the following:  Increase of ≥ 25% from baseline in:  serum M­component and/or (absolute increase ≥ 0.5 g/dL) (for
progressive disease, serum M­component increases of ≥ 1 g/dL are sufficient to define relapse if the starting M­component is ≥ 5 g/dL).  Urine M­
component and/or (absolute increase ≥ 200 mg/24 hours) for recipients without measurable serum and urine M­protein levels: the difference between
involved and uninvolved free light chain levels (absolute increase > 10 mg/dL).  Bone marrow plasma cell percentage (absolute percentage ≥ 10%)
(relapse from CR has a 5% cutoff vs. 10% for other categories of relapse) definite development of new bone lesions or soft tissue plasmacytomas, or
definite increase in the size of any existing  bone lesions or soft tissue plasmacytomas. Development of hypercalcemia (corrected serum calcium >
11.5 mg/dL or 2.65 mmol) that can be attributed solely to the plasma cell proliferative disorder.  PD requires two consecutive assessments made at
any time before classification as disease progression, and/or the institution of any new therapy.

Relapse
from CR
(Rel)
(untreated)

­ requires one or more of the following: reappearance of serum or urine M­protein by immunofixation or electrophoresis development of ≥ 5% plasma
cells in the bone marrow (relapse from CR has a 5% cutoff vs. 10% for other categories of relapse) appearance of any other sign of progression (e.g.,
new plasmacytoma, lytic bone lesion, hypercalcemia).  Rel requires two consecutive assessments made at any time before classification as relapse,
and/or the institution of any new therapy.

Unknown

Not applicable (Amyloidosis with no evidence of myeloma)

Date assessed:317 __ __ __ __ - __ __- __ __

Solid Tumors Questions: 318 - 319

Specify the solid tumor classification318

Specify other solid tumor:319

Severe Aplastic Anemia Questions: 320 - 321

Specify the severe aplastic anemia classification320

Specify other acquired cytopenic syndrome:321

Inherited Abnormalities of Erythrocyte Differentiation or Function Questions: 322 - 324

Specify the inherited abnormalities of erythrocyte differentiation or function classification322

Specify other constitutional anemia:323

Specify other hemoglobinopathy:324

Disorders of the Immune System Questions: 325 - 327

Specify disorder of immune system classification325

Specify other SCID:326

Specify other immunodeficiency:327

Inherited Abnormalities of Platelets Questions: 328 - 329

Specify inherited abnormalities of platelets classification328

Congenital amegakaryocytosis / congenital thrombocytopenia (501)

Glanzmann thrombasthenia (502)

Other inherited platelet abnormality (509)

Specify other inherited platelet abnormality:329

Inherited Disorders of Metabolism Questions: 330 - 331

Specify inherited disorders of metabolism classification330

Specify other inherited metabolic disorder:331

Histiocytic Disorders Questions: 332 - 333

Specify histiocytic disorder classification332

Specify other histiocytic disorder:333

Autoimmune Diseases Questions: 334 - 341

Specify autoimmune disease classification334

Specify other arthritis:335

Specify other juvenile idiopathic arthritis (JIA):336

Specify other connective tissue disease:337

Specify other vasculitis:338

Specify other autoimmune neurological disorder:339

Specify other autoimmune cytopenia:340

Specify other autoimmune bowel disorder:341

Other Disease Questions: 342 - 342

Specify other disease:342

First Name:

Last Name:

E-mail address:

Date: __ __ __ __ - __ __- __ __

OMB No: 0915-0310

Expiration Date: 1/31/2020

Public Burden Statement:  An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control
number.  The OMB control number for this project is 0915-0310.  Public reporting burden for this collection of information is estimated to average 1.0 hours per response, including the

time for reviewing instructions, searching existing data sources, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other
aspect of this collection of information, including suggestions for reducing this burden, to HRSA Reports Clearance Officer, 5600 Fishers Lane, Room 10-29, Rockville, Maryland, 20857.

Labs at diagnosis

Specify cytogenetic abnormalities identified at diagnosis:

Specify cytogenetic abnormalities identified at diagnosis:

Specify molecular markers identified at diagnosis:

Labs between diagnosis and last evaluation:

Specify cytogenetic abnormalities identified between diagnosis and last evaluation:

Specify cytogenetic abnormalities identified between diagnosis and last evaluation:

Specify molecular markers identified between diagnosis and last evaluation:

Labs at last evaluation:

Specify cytogenetic abnormalities identified at last evaluation:

Specify cytogenetic abnormalities identified at last evaluation:

Specify molecular markers identified at last evaluation:

CNS Leukemia

Status at transplantation:

Laboratory studies at diagnosis:

Specify cytogenetic abnormalities identified at diagnosis:

Specify cytogenetic abnormalities identified at diagnosis:

Specify molecular markers identified at diagnosis:

Laboratory studies between diagnosis and last evaluation:

Specify cytogenetic abnormalities identified between diagnosis and last evaluation:

Specify cytogenetic abnormalities identified between diagnosis and last evaluation:

Specify molecular markers identified between diagnosis and last evaluation:

Laboratory studies at last evaluation:

Specify cytogenetic abnormalities identified at last evaluation:

Specify cytogenetic abnormalities identified at last evaluation:

Specify molecular markers identified at last evaluation:

CNS Leukemia

Status at transplantation:

Status at transplantation:

Laboratory studies at diagnosis of MDS:

Specify abnormalities identified at diagnosis:

Monosomy

Trisomy

Translocation

Deletion

Inversion

Other

Laboratory studies at last evaluation prior to the start of the preparative regimen:

Specify cytogenetic abnormalities identified at last evaluation prior to the start of the preparative regimen:

Monosomy

Trisomy

Translocation

Deletion

Inversion

Other

Status at transplantation:

Status at transplantation:

Status at transplantation / infusion:

I.S.S.:

Specify cytogenetic abnormalities identified at any time prior to the start of the preparative regimen:

Trisomy

Translocation

Deletion

Other

Status at transplantation:

Center: CRID: 

Form 2402 R3.0: Disease Classification

CIBMTR Form 2402 revision 3.0 last updated Monday, January 29, 2018
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 16 / 26



Key Fields

Sequence Number:

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number:

CIBMTR Research ID:

Event date: __ __ __ __ - __ __- __ __

Primary Disease for HCT / Cellular Therapy Questions: 1 - 2

Date of diagnosis of primary disease for HCT / cellular therapy:1 __ __ __ __ - __ __- __ __

What was the primary disease for which the HCT / cellular therapy was performed?2

Acute myelogenous leukemia (AML or ANLL) (10)

Acute lymphoblastic leukemia (ALL) (20)

Acute leukemia of ambiguous lineage and other myeloid neoplasms (80)

Chronic myelogenous leukemia (CML) (40)

Myelodysplastic (MDS) / myeloproliferative (MPN) diseases (50) (Please classify all preleukemias) (If recipient has transformed to AML, indicate AML as the primary disease)

Other leukemia (30) (includes CLL)

Hodgkin lymphoma (150)

Non-Hodgkin lymphoma (100)

Multiple myeloma / plasma cell disorder (PCD) (170)

Solid tumors (200)

Severe aplastic anemia (300) (If the recipient developed MDS or AML, indicate MDS or AML as the primary disease)

Inherited abnormalities of erythrocyte differentiation or function (310)

Disorders of the immune system (400)

Inherited abnormalities of platelets (500)

Inherited disorders of metabolism (520)

Histiocytic disorders (570)

Autoimmune diseases (600)

Other disease (900)

Acute Myelogenous Leukemia (AML) Questions: 3 - 89

Specify the AML classification3

Did AML transform from MDS or MPN?4

yes - Also complete MDS Disease Classification questions

no

Is the disease (AML) therapy related?

yes no Unknown

5

Did the recipient have a predisposing condition?

yes no Unknown

6

Specify condition7

Bloom syndrome

Down syndrome

Fanconi anemia

Dyskeratosis congenita

Other condition

Specify other condition:8

Were cytogenetics tested (karyotyping or FISH)? (at diagnosis)

yes no Unknown

9

Were cytogenetics tested via FISH? (at diagnosis)

Yes No

10

Results of tests11

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities12

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

13

Specify other abnormality:14

Were cytogenetics tested via karyotyping? (at diagnosis)

Yes No

15

Results of tests16

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities17

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

18

Specify other abnormality:19

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

20

Were tests for molecular markers performed? (e.g. PCR, NGS) (at diagnosis)

yes no Unknown

21

CEBPA

Positive Negative Not Done

22

Specify CEBPA mutation23

Biallelic (homozygous)

Monoallelic (heterozygous)

Unknown

FLT3 – D835 point mutation

Positive Negative Not Done

24

FLT3 – ITD mutation

Positive Negative Not Done

25

FLT3 - ITD allelic ratio

Known Unknown

26

Specify FLT3 - ITD allelic ratio:27

IDH1

Positive Negative Not Done

28

IDH2

Positive Negative Not Done

29

KIT

Positive Negative Not Done

30

NPM1

Positive Negative Not Done

31

Other Molecular Marker (1) Questions: 32 - 33

Other molecular marker

Positive Negative Not Done

32

Specify other molecular marker:33

Were cytogenetics tested (karyotyping or FISH)? (between diagnosis and last evaluation)

yes no Unknown

34

Were cytogenetics tested via FISH? (between diagnosis and last evaluation)

Yes No

35

Results of tests36

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities37

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

38

Specify other abnormality:39

Were cytogenetics tested via karyotyping? (between diagnosis and last evaluation)

Yes No

40

Results of tests41

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities42

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

43

Specify other abnormality:44

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

45

Were tests for molecular markers performed? (e.g. PCR, NGS) (between diagnosis and last evaluation)

yes no Unknown

46

CEBPA

Positive Negative Not Done

47

Specify CEBPA mutation48

Biallelic (homozygous)

Monoallelic (heterozygous)

Unknown

FLT3 – D835 point mutation

Positive Negative Not Done

49

FLT3 – ITD mutation

Positive Negative Not Done

50

FLT3 - ITD allelic ratio

Known Unknown

51

Specify FLT3 - ITD allelic ratio:52

IDH1

Positive Negative Not Done

53

IDH2

Positive Negative Not Done

54

KIT

Positive Negative Not Done

55

NPM1

Positive Negative Not Done

56

Other Molecular Marker (1) Questions: 57 - 58

Other molecular marker

Positive Negative Not Done

57

Specify other molecular marker:58

Were cytogenetics tested (karyotyping or FISH)? (at last evaluation)

yes no Unknown

59

Were cytogenetics tested via FISH? (at last evaluation)

Yes No

60

Results of tests61

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities62

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

63

Specify other abnormality:64

Were cytogenetics tested via karyotyping? (at last evaluation)

Yes No

65

Results of tests66

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities67

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

68

Specify other abnormality:69

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

70

Were tests for molecular markers performed? (e.g. PCR, NGS) (at last evaluation)

yes no Unknown

71

CEBPA

Positive Negative Not Done

72

Specify CEBPA mutation73

Biallelic (homozygous)

Monoallelic (heterozygous)

Unknown

FLT3 – D835 point mutation

Positive Negative Not Done

74

FLT3 – ITD mutation

Positive Negative Not Done

75

FLT3 - ITD allelic ratio

Known Unknown

76

Specify FLT3 - ITD allelic ratio:77

IDH1

Positive Negative Not Done

78

IDH2

Positive Negative Not Done

79

KIT

Positive Negative Not Done

80

NPM1

Positive Negative Not Done

81

Other Molecular Marker (1) Questions: 82 - 83

Other molecular marker

Positive Negative Not Done

82

Specify other molecular marker:83

Did the recipient have central nervous system leukemia at any time prior to the start of the preparative regimen / infusion?

yes no Unknown

84

What was the disease status (based on hematological test results)?85

Primary induction failure

1st complete remission (no previous bone marrow or extramedullary relapse) (include CRi)

2nd complete remission

≥3rd complete remission

1st relapse

2nd relapse

≥3rd relapse

No treatment

How many cycles of induction therapy were required to achieve 1st complete remission? (includes CRi)

1 2 ≥ 3

86

Was the recipient in remission by flow cytometry?

Yes No Unknown Not applicable

87

Date of most recent relapse:88 __ __ __ __ - __ __- __ __

Date assessed:89 __ __ __ __ - __ __- __ __

Acute Lymphoblastic Leukemia (ALL) Questions: 90 - 151

Specify ALL classification90

Did the recipient have a predisposing condition?

yes no Unknown

91

Specify condition92

Aplastic anemia - Also complete CIBMTR Form 2028 - APL

Bloom syndrome

Down syndrome

Fanconi anemia - Also complete CIBMTR Form 2029 - FAN

Other condition

Specify other condition:93

Were tyrosine kinase inhibitors given for therapy at any time prior to the start of the preparative regimen / infusion? (e.g. imatinib mesylate, dasatinib, etc.)

yes no

94

Were cytogenetics tested (karyotyping or FISH)? (at diagnosis)

yes no Unknown

95

Were cytogenetics tested via FISH? (at diagnosis)

Yes No

96

Results of tests97

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities98

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

99

Specify other abnormality:100

Were cytogenetics tested via karyotyping? (at diagnosis)

Yes No

101

Results of tests102

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities103

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

104

Specify other abnormality:105

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

106

Were tests for molecular markers performed? (e.g. PCR, NGS) (at diagnosis)

yes no Unknown

107

BCR / ABL

Positive Negative Not Done

108

TEL-AML / AML1

Positive Negative Not Done

109

Other Molecular Marker (1) Questions: 110 - 111

Other molecular marker

Positive Negative Not Done

110

Specify other molecular marker:111

Were cytogenetics tested (karyotyping or FISH)? (between diagnosis and last evaluation)

yes no Unknown

112

Were cytogenetics tested via FISH? (between diagnosis and last evaluation)

Yes No

113

Results of tests114

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities115

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

116

Specify other abnormality:117

Were cytogenetics tested via karyotyping? (between diagnosis and last evaluation)

Yes No

118

Results of tests119

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities120

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

121

Specify other abnormality:122

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

123

Were tests for molecular markers performed? (e.g. PCR, NGS) (between diagnosis and last evaluation)

yes no Unknown

124

BCR / ABL

Positive Negative Not Done

125

TEL-AML / AML1

Positive Negative Not Done

126

Other Molecular Marker (1) Questions: 127 - 128

Other molecular marker

Positive Negative Not Done

127

Specify other molecular marker:128

Were cytogenetics tested (karyotyping or FISH)? (at last evaluation)

yes no Unknown

129

Were cytogenetics tested via FISH? (at last evaluation)

Yes No

130

Results of tests131

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities132

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

133

Specify other abnormality:134

Were cytogenetics tested via karyotyping? (at last evaluation)

Yes No

135

Results of tests136

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities137

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

138

Specify other abnormality:139

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

140

Were tests for molecular markers performed? (e.g. PCR, NGS) (at last evaluation)

yes no Unknown

141

BCR / ABL

Positive Negative Not Done

142

TEL-AML / AML1

Positive Negative Not Done

143

Other Molecular Marker (1) Questions: 144 - 145

Other molecular marker

Positive Negative Not Done

144

Specify other molecular marker:145

Did the recipient have central nervous system leukemia at any time prior to the start of the preparative regimen / infusion?

yes no Unknown

146

What was the disease status (based on hematological test results)?147

Primary induction failure

1st complete remission (no previous marrow or extramedullary relapse) (include CRi)

2nd complete remission

≥3rd complete remission

1st relapse

2nd relapse

≥3rd relapse

No treatment

How many cycles of induction therapy were required to achieve 1st complete remission? (include CRi)

1 2 ≥ 3

148

Was the recipient in remission by flow cytometry?

Yes No Unknown Not applicable

149

Date of most recent relapse:150 __ __ __ __ - __ __- __ __

Date assessed:151 __ __ __ __ - __ __- __ __

Acute Leukemias of Ambiguous Lineage and Other Myeloid Neoplasms Questions: 152 - 155

Specify acute leukemias of ambiguous lineage and other myeloid neoplasm classification152

Blastic plasmacytoid dendritic cell neoplasm (296)

Acute undifferentiated leukemia (31)

Mixed phenotype acute leukemia (MPAL) with t(9;22)(q34.1;q11.2); BCR-ABL1 (84)

Mixed phenotype acute leukemia with t(v; 11q23.3); KMT2A rearranged (85)

Mixed phenotype acute leukemia, B/myeloid, NOS (86)

Mixed phenotype acute leukemia, T/myeloid, NOS (87)

Other acute leukemia of ambiguous lineage or myeloid neoplasm (88)

Specify other acute leukemia of ambiguous lineage or myeloid neoplasm:153

What was the disease status (based on hematological test results)?154

Primary induction failure

1st complete remission (no previous marrow or extramedullary relapse)

2nd complete remission

≥3rd complete remission

1st relapse

2nd relapse

≥3rd relapse

No treatment

Date assessed:155 __ __ __ __ - __ __- __ __

Chronic Myelogenous Leukemia (CML) Questions: 156 - 166

Was therapy given prior to this HCT?

yes no

156

Combination chemotherapy

yes no

157

Hydroxyurea (Droxia, Hydrea)

yes no

158

Tyrosine kinase inhibitor (e.g. imatinib mesylate, dasatinib, nilotinib)

yes no

159

Interferon­α (Intron, Roferon) (includes PEG)

yes no

160

Other therapy

yes no

161

Specify other therapy:162

What was the disease status?163

Complete hematologic response (CHR)

Chronic phase

Accelerated phase

Blast phase

Specify level of response164

No cytogenetic response (No CyR)

Minimal cytogenetic response

Minor cytogenetic response

Partial cytogenetic response (PCyR)

Complete cytogenetic response (CCyR)

Major molecular remission (MMR)

Complete molecular remission (CMR)

Number

1st 2nd 3rd or higher

165

Date assessed:166 __ __ __ __ - __ __- __ __

Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases Questions: 167 - 260

What was the MDS / MPN subtype at diagnosis? - If transformed to AML, indicate AML as primary disease; also complete AML Disease Classification
questions

167

Was the disease (MDS/MPN) therapy related?

yes no Unknown

168

Did the recipient have a predisposing condition?

yes no Unknown

169

Specify condition

Aplastic Anemia Bloom syndrome Down syndrome Fanconi anemia Other condition

170

Specify other condition:171

WBC

Known Unknown

172

173 x 109/L (x 103/mm3)

x 106/L

Hemoglobin

Known Unknown

174

175 g/dL g/L mmol/L

Was RBC transfused ≤ 30 days before date of test?

Yes No

176

Platelets

Known Unknown

177

178 x 109/L (x 103/mm3)

x 106/L

Were platelets transfused ≤ 7 days before date of test?

Yes No

179

Neutrophils

Known Unknown

180

181 %

Blasts in bone marrow

Known Unknown

182

183 %

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

184

Results of tests185

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities186

One (1)

Two (2)

Three (3)

Four or more (4 or more)

–5

yes no

187

-7

yes no

188

–13

yes no

189

–20

yes no

190

–Y

yes no

191

+8

yes no

192

+19

yes no

193

t(1;3)

yes no

194

t(2;11)

yes no

195

t(3;3)

yes no

196

t(3;21)

yes no

197

t(6;9)

yes no

198

t(11;16)

yes no

199

del(3q) / 3q–

yes no

200

del(5q) / 5q-

yes no

201

del(7q) / 7q–

yes no

202

del(9q) / 9q–

yes no

203

del(11q) / 11q–

yes no

204

del(12p) / 12p–

yes no

205

del(13q) / 13q-

yes no

206

del(20q) / 20q–

yes no

207

inv(3)

yes no

208

i17q

yes no

209

Other abnormality

yes no

210

Specify other abnormality:211

Did the recipient progress or transform to a different MDS / MPN subtype between diagnosis and the start of the preparative regimen?

yes no

212

Specify the MDS / MPN classification after transformation:213

Specify the date of the most recent transformation:214 __ __ __ __ - __ __- __ __

Date of MDS diagnosis:215 __ __ __ __ - __ __- __ __

WBC

Known Unknown

216

217 x 109/L (x 103/mm3)

x 106/L

Hemoglobin

Known Unknown

218

219 g/dL g/L mmol/L

Was RBC transfused ≤ 30 days before date of test?

Yes No

220

Platelets

Known Unknown

221

222 x 109/L (x 103/mm3)

x 106/L

Were platelets transfused ≤ 7 days before date of test?

Yes No

223

Neutrophils

Known Unknown

224

225 %

Blasts in bone marrow

Known Unknown

226

227 %

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

228

Results of tests229

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities230

One (1)

Two (2)

Three (3)

Four or more (4 or more)

–5

yes no

231

-7

yes no

232

–13

yes no

233

–20

yes no

234

–Y

yes no

235

+8

yes no

236

+19

yes no

237

t(1;3)

yes no

238

t(2;11)

yes no

239

t(3;3)

yes no

240

t(3;21)

yes no

241

t(6;9)

yes no

242

t(11;16)

yes no

243

del(3q) / 3q–

yes no

244

del(5q) / 5q-

yes no

245

del(7q) / 7q–

yes no

246

del(9q) / 9q–

yes no

247

del(11q) / 11q–

yes no

248

del(12p) / 12p–

yes no

249

del(13q) / 13q-

yes no

250

del(20q) / 20q–

yes no

251

inv(3)

yes no

252

i17q

yes no

253

Other abnormality

yes no

254

Specify other abnormality:255

What was the disease status?256

Complete
remission
(CR)

– requires all of the following, maintained for ≥ 4 weeks: * bone marrow evaluation: <  5% myeloblasts with normal maturation of all cell lines *
peripheral blood evaluation: hemoglobin ≥ 11 g/dL untransfused and without erythropoietin support; ANC ≥ 1000/mm3  without myeloid growth factor
support; platelets ≥ 100 x 109/L without thrombopoietic support; 0% blasts

Hematologic
improvement
(HI)

– requires one measurement of the following, maintained for ≥ 8 weeks without ongoing cytotoxic therapy; specify which cell line was measured to
determine HI response: * HI­E – hemoglobin increase of ≥ 1.5 g/dL untransfused; for RBC transfusions performed for Hgb ≤ 9.0, reduction in RBC
units transfused in 8 weeks by ≥ 4 units compared to the pre­treatment transfusion number in 8 weeks * HI­P – for pre­treatment platelet count of > 20
x 109/L, platelet absolute increase of ≥ 30 x 109/L; for pre-treatment platelet count of < 20 x 109/L, platelet absolute increase of ≥ 20 x 109/L and ≥
100% from pre­treatment level  * HI­N – neutrophil count increase of ≥ 100% from pre­treatment level and an absolute increase of ≥ 500/mm3

No response (NR) / stable disease (SD) – does not meet the criteria for at least HI, but no evidence of disease progression

Progression from
hematologic improvement
(Prog from HI)

– requires at least one of the following, in the absence of another explanation (e.g., infection, bleeding, ongoing chemotherapy, etc.): *
≥ 50% reduction from maximum response levels in granulocytes or platelets * reduction in hemoglobin by ≥ 1.5 g/dL *transfusion
dependence

Relapse from complete
remission (Rel from CR)

– requires at least one of the following: * return to pre­treatment bone marrow blast percentage * decrease of ≥ 50% from maximum
response levels in granulocytes or platelets * transfusion dependence, or hemoglobin level ≥ 1.5 g/dL lower than prior to therapy

Not assessed

Specify the cell line examined to determine HI status257

HI-
E

– hemoglobin increase of ≥ 1.5 g/dL untransfused; for RBC transfusions performed for Hgb ≤ 9.0, reduction in RBC units transfused in 8 weeks by ≥ 4
units compared to the pre-treatment transfusion number in 8 weeks

HI-
P

– for pre­treatment platelet count of > 20 x 109/L, platelet absolute increase of ≥ 30 x 109/L; for pre-treatment platelet count of < 20 x 109/L, platelet
absolute increase of ≥ 20 x 109/L and ≥ 100% from pre­treatment level 

HI-N – neutrophil count increase of ≥ 100% from pre­treatment level and an absolute increase of ≥ 500/mm3

Date of progression:258 __ __ __ __ - __ __- __ __

Date of relapse:259 __ __ __ __ - __ __- __ __

Date assessed:260 __ __ __ __ - __ __- __ __

Other Leukemia (OL) Questions: 261 - 267

Specify the other leukemia classification261

Specify other leukemia:262

Was any 17p abnormality detected?

yes no

263

Did a histologic transformation to diffuse large B-cell lymphoma (Richter syndrome) occur at any time after CLL diagnosis?264

yes - Also complete NHL Disease Classification questions

no

What was the disease status? (Atypical CML)265

Primary induction failure

1st complete remission (no previous bone marrow or extramedullary relapse)

2nd complete remission

≥3rd complete remission

1st relapse

2nd relapse

≥3rd relapse

No treatment

What was the disease status? (CLL, PLL, Hairy cell leukemia)266

Complete remission (CR)

Partial remission (PR)

Stable disease (SD)

Progressive disease (Prog)

Untreated

Not assessed

Date assessed:267 __ __ __ __ - __ __- __ __

Hodgkin and Non-Hodgkin Lymphoma Questions: 268 - 285

Specify the lymphoma histology (at infusion)268

Specify other lymphoma histology:269

Assignment of DLBCL (germinal center B-cell type vs. activated B-cell type) subtype was based on270

Immunohistochemistry (e.g. Han's algorithm)

Gene expression profile

Unknown method

Is the lymphoma histology reported at transplant a transformation from CLL?

yes no

271

Was any 17p abnormality detected?

yes no

272

Is the lymphoma histology reported at transplant a transformation from a different lymphoma histology? (Not CLL)

Yes No

273

Specify the original lymphoma histology (prior to transformation)274

Specify other lymphoma histology:275

Date of original lymphoma diagnosis:276 __ __ __ __ - __ __- __ __ (report the date of diagnosis of original lymphoma subtype)

Was a PET (or PET/CT) scan performed? (at last evaluation prior to the start of the preparative regimen / infusion)

yes no

277

Was the PET (or PET/CT) scan positive for lymphoma involvement at any disease site?

yes no

278

Date of PET scan

Known Unknown

279

Date of PET (or PET/CT) scan:280 __ __ __ __ - __ __- __ __

Deauville (five-point) score of the PET (or PET/CT) scan

Known Unknown

281

Scale282

1 - no uptake or residual uptake

2 - slight uptake, but below blood pool (mediastinum)

3 - uptake above mediastinal, but below or equal to uptake in the liver

4 - uptake slightly to moderately higher than liver

5 - markedly increased uptake or any new lesions

What was the disease status?283

Total number of lines of therapy received

1 line 2 lines 3+ lines

284

Date assessed:285 __ __ __ __ - __ __- __ __

Multiple Myeloma / Plasma Cell Disorder (PCD) Questions: 286 - 317

Specify the multiple myeloma/plasma cell disorder (PCD) classification286

Specify other plasma cell disorder:287

Light chain

kappa lambda

288

What was the Durie-Salmon staging? (at diagnosis)289

Stage
I

(All of the following: Hgb > 10g/dL; serum calcium normal or <10.5 mg/dL; bone x-ray normal bone structure (scale 0), or solitary bone plasmacytoma
only; low M-component production rates IgG< 5g/dL, IgA < 3g/dL; urine light chain M-component on electrophoresis <4 g/24h)

Stage II (Fitting neither Stage I or III) 

Stage
III

(One or more of the following: Hgb < 8.5 g/dL; serum calcium > 12 mg/dL; advanced lytic bone lesions (scale 3); high M-component production rates
IgG > 7g/dL, IgA > 5 g/dL; Bence Jones protein > 12g/24h)

Unknown

What was the Durie-Salmon sub classification? (at diagnosis)290

A - relatively normal renal function (serum creatinine < 2.0 mg/dL)

B ­ abnormal renal function (serum creatinine ≥ 2.0 mg/dL)

Serum β2­microglobulin:291 μg/dL mg/L nmol/L

Serum albumin:292 g/dL g/L

Stage293

1 (β2 ­mic < 3.5, S. albumin ≥3.5)

2 (Not fitting stage 1 or 3)

3 (β2­mic ≥ 5.5; S. albumin ­)

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

294

Results of tests295

Abnormalities identified

No evaluable metaphases

No abnormalities

+3

yes no

296

+5

yes no

297

+7

yes no

298

+9

yes no

299

+11

yes no

300

+15

yes no

301

+19

yes no

302

t(4;14)

yes no

303

t(6;14)

yes no

304

t(11;14)

yes no

305

t(14;16)

yes no

306

t(14;20)

yes no

307

del(13q) / 13q-

yes no

308

del (17p) / 17p-

yes no

309

Hyperdiploid (>50)

yes no

310

Hypodiploid (<46)

yes no

311

Any abnormality at 1q

yes no

312

Any abnormality at 1p

yes no

313

Other abnormality

yes no

314

Specify other abnormality:315

What was the disease status?316

Stringent
complete
remission
(sCR)

- CR as defined, plus: normal free light chain ratio, and absence of clonal cells in the bone marrow by immunohistochemistry of immunofluorescence
(confirmation with repeat bone marrow biopsy not needed). (Presence and/or absence of clonal cells is based upon the Κ/λ ratio. An abnormal Κ/λ ratio by
immunohistochemistry and/or immunofluorescence requires a minimum of 100 plasma cells for analysis.  An abnormal ratio reflecting the presence of
an abnormal clone is Κ/λ of > 4:1 or < 1:2.) sCR requires two consecutive assessments made at any time before the institution of any new therapy, and
no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy sCR
requirements. 

Complete
remission
(CR)

- negative immunofixation on serum and urine samples, and disappearance of any soft tissue plasmacytomas, and < 5% plasma cells in the bone
marrow (confirmation with repeat bone marrow biopsy not needed).  CR requires two consecutive assessments made at any time before the institution
of any new therapy, and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not
required to satisfy CR requirements. 

Near
complete
remission
(nCR)

- serum and urine M-protein detectable by immunoelectrophoresis (IFE), but not on electrophoresis (negative SPEP & UPEP); < 5% plasma cells in
bone marrow.  nCR requires two consecutive assessments made at any time before the initiation of any new therapy, and no known evidence of
progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy nCR requirements. 

Very good
partial
remission
(VGPR)

­ serum and urine M­protein detectable by immunofixation but not on electrophoresis, or ≥ 90% reduction in serum M­protein and urine M­protein level <
100 mg/24 hours.  VGPR requires two consecutive assessments made at any time before the institution of any new therapy, and no known evidence of
progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy VGPR requirements.

Partial
remission
(PR)

­ ≥ 50% reduction in serum M­protein, and reduction in 24­hour urinary M­protein by ≥ 90% or to < 200 mg/24 hours.  If the serum and urine M­protein are
unmeasurable (i.e., do not meet any of the following criteria: • serum M­protein ≥ 1 g/dL.  Urine M­protein ≥ 200 mg/24 hours • serum free light chain
assay shows involved level ≥ 10 mg/dL, provided serum free light chain ratio is abnormal), a ≥ 50% decrease in the difference between involved and
uninvolved free light chain levels is required in place of the M-protein criteria.  If serum and urine M-protein are unmeasurable, and serum free light assay
is also unmeasurable, a ≥ 50% reduction in plasma cells is required in place of M­protein, provided the baseline bone marrow plasma cell percentage
was ≥ 30%. In addition to the above listed criteria, a ≥ 50% reduction in the size of soft tissue plasmacytomas is also required, if present at baseline. PR
requires two consecutive assessments made at any time before the institution of any new therapy, and no known evidence of progressive or new bone
lesions if radiographic studies were performed; radiographic studies are not required to satisfy PR requirements. 

Stable
disease
(SD)

- not meeting the criteria for CR, VGPR, PR or PD.  SD requires two consecutive assessments made at any time before the institution of any new therapy,
and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy SD
requirements.

Progressive
disease
(PD)

­ requires any one or more of the following:  Increase of ≥ 25% from baseline in:  serum M­component and/or (absolute increase ≥ 0.5 g/dL) (for
progressive disease, serum M­component increases of ≥ 1 g/dL are sufficient to define relapse if the starting M­component is ≥ 5 g/dL).  Urine M­
component and/or (absolute increase ≥ 200 mg/24 hours) for recipients without measurable serum and urine M­protein levels: the difference between
involved and uninvolved free light chain levels (absolute increase > 10 mg/dL).  Bone marrow plasma cell percentage (absolute percentage ≥ 10%)
(relapse from CR has a 5% cutoff vs. 10% for other categories of relapse) definite development of new bone lesions or soft tissue plasmacytomas, or
definite increase in the size of any existing  bone lesions or soft tissue plasmacytomas. Development of hypercalcemia (corrected serum calcium >
11.5 mg/dL or 2.65 mmol) that can be attributed solely to the plasma cell proliferative disorder.  PD requires two consecutive assessments made at
any time before classification as disease progression, and/or the institution of any new therapy.

Relapse
from CR
(Rel)
(untreated)

­ requires one or more of the following: reappearance of serum or urine M­protein by immunofixation or electrophoresis development of ≥ 5% plasma
cells in the bone marrow (relapse from CR has a 5% cutoff vs. 10% for other categories of relapse) appearance of any other sign of progression (e.g.,
new plasmacytoma, lytic bone lesion, hypercalcemia).  Rel requires two consecutive assessments made at any time before classification as relapse,
and/or the institution of any new therapy.

Unknown

Not applicable (Amyloidosis with no evidence of myeloma)

Date assessed:317 __ __ __ __ - __ __- __ __

Solid Tumors Questions: 318 - 319

Specify the solid tumor classification318

Specify other solid tumor:319

Severe Aplastic Anemia Questions: 320 - 321

Specify the severe aplastic anemia classification320

Specify other acquired cytopenic syndrome:321

Inherited Abnormalities of Erythrocyte Differentiation or Function Questions: 322 - 324

Specify the inherited abnormalities of erythrocyte differentiation or function classification322

Specify other constitutional anemia:323

Specify other hemoglobinopathy:324

Disorders of the Immune System Questions: 325 - 327

Specify disorder of immune system classification325

Specify other SCID:326

Specify other immunodeficiency:327

Inherited Abnormalities of Platelets Questions: 328 - 329

Specify inherited abnormalities of platelets classification328

Congenital amegakaryocytosis / congenital thrombocytopenia (501)

Glanzmann thrombasthenia (502)

Other inherited platelet abnormality (509)

Specify other inherited platelet abnormality:329

Inherited Disorders of Metabolism Questions: 330 - 331

Specify inherited disorders of metabolism classification330

Specify other inherited metabolic disorder:331

Histiocytic Disorders Questions: 332 - 333

Specify histiocytic disorder classification332

Specify other histiocytic disorder:333

Autoimmune Diseases Questions: 334 - 341

Specify autoimmune disease classification334

Specify other arthritis:335

Specify other juvenile idiopathic arthritis (JIA):336

Specify other connective tissue disease:337

Specify other vasculitis:338

Specify other autoimmune neurological disorder:339

Specify other autoimmune cytopenia:340

Specify other autoimmune bowel disorder:341

Other Disease Questions: 342 - 342

Specify other disease:342

First Name:

Last Name:

E-mail address:

Date: __ __ __ __ - __ __- __ __

OMB No: 0915-0310

Expiration Date: 1/31/2020

Public Burden Statement:  An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control
number.  The OMB control number for this project is 0915-0310.  Public reporting burden for this collection of information is estimated to average 1.0 hours per response, including the
time for reviewing instructions, searching existing data sources, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other
aspect of this collection of information, including suggestions for reducing this burden, to HRSA Reports Clearance Officer, 5600 Fishers Lane, Room 10-29, Rockville, Maryland, 20857.

Labs at diagnosis

Specify cytogenetic abnormalities identified at diagnosis:

Specify cytogenetic abnormalities identified at diagnosis:

Specify molecular markers identified at diagnosis:

Labs between diagnosis and last evaluation:

Specify cytogenetic abnormalities identified between diagnosis and last evaluation:

Specify cytogenetic abnormalities identified between diagnosis and last evaluation:

Specify molecular markers identified between diagnosis and last evaluation:

Labs at last evaluation:

Specify cytogenetic abnormalities identified at last evaluation:

Specify cytogenetic abnormalities identified at last evaluation:

Specify molecular markers identified at last evaluation:

CNS Leukemia

Status at transplantation:

Laboratory studies at diagnosis:

Specify cytogenetic abnormalities identified at diagnosis:

Specify cytogenetic abnormalities identified at diagnosis:

Specify molecular markers identified at diagnosis:

Laboratory studies between diagnosis and last evaluation:

Specify cytogenetic abnormalities identified between diagnosis and last evaluation:

Specify cytogenetic abnormalities identified between diagnosis and last evaluation:

Specify molecular markers identified between diagnosis and last evaluation:

Laboratory studies at last evaluation:

Specify cytogenetic abnormalities identified at last evaluation:

Specify cytogenetic abnormalities identified at last evaluation:

Specify molecular markers identified at last evaluation:

CNS Leukemia

Status at transplantation:

Status at transplantation:

Laboratory studies at diagnosis of MDS:

Specify abnormalities identified at diagnosis:

Monosomy

Trisomy

Translocation

Deletion

Inversion

Other

Laboratory studies at last evaluation prior to the start of the preparative regimen:

Specify cytogenetic abnormalities identified at last evaluation prior to the start of the preparative regimen:

Monosomy

Trisomy

Translocation

Deletion

Inversion

Other

Status at transplantation:

Status at transplantation:

Status at transplantation / infusion:

I.S.S.:

Specify cytogenetic abnormalities identified at any time prior to the start of the preparative regimen:

Trisomy

Translocation

Deletion

Other

Status at transplantation:

Center: CRID: 

Form 2402 R3.0: Disease Classification

CIBMTR Form 2402 revision 3.0 last updated Monday, January 29, 2018
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 17 / 26



Key Fields

Sequence Number:

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number:

CIBMTR Research ID:

Event date: __ __ __ __ - __ __- __ __

Primary Disease for HCT / Cellular Therapy Questions: 1 - 2

Date of diagnosis of primary disease for HCT / cellular therapy:1 __ __ __ __ - __ __- __ __

What was the primary disease for which the HCT / cellular therapy was performed?2

Acute myelogenous leukemia (AML or ANLL) (10)

Acute lymphoblastic leukemia (ALL) (20)

Acute leukemia of ambiguous lineage and other myeloid neoplasms (80)

Chronic myelogenous leukemia (CML) (40)

Myelodysplastic (MDS) / myeloproliferative (MPN) diseases (50) (Please classify all preleukemias) (If recipient has transformed to AML, indicate AML as the primary disease)

Other leukemia (30) (includes CLL)

Hodgkin lymphoma (150)

Non-Hodgkin lymphoma (100)

Multiple myeloma / plasma cell disorder (PCD) (170)

Solid tumors (200)

Severe aplastic anemia (300) (If the recipient developed MDS or AML, indicate MDS or AML as the primary disease)

Inherited abnormalities of erythrocyte differentiation or function (310)

Disorders of the immune system (400)

Inherited abnormalities of platelets (500)

Inherited disorders of metabolism (520)

Histiocytic disorders (570)

Autoimmune diseases (600)

Other disease (900)

Acute Myelogenous Leukemia (AML) Questions: 3 - 89

Specify the AML classification3

Did AML transform from MDS or MPN?4

yes - Also complete MDS Disease Classification questions

no

Is the disease (AML) therapy related?

yes no Unknown

5

Did the recipient have a predisposing condition?

yes no Unknown

6

Specify condition7

Bloom syndrome

Down syndrome

Fanconi anemia

Dyskeratosis congenita

Other condition

Specify other condition:8

Were cytogenetics tested (karyotyping or FISH)? (at diagnosis)

yes no Unknown

9

Were cytogenetics tested via FISH? (at diagnosis)

Yes No

10

Results of tests11

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities12

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

13

Specify other abnormality:14

Were cytogenetics tested via karyotyping? (at diagnosis)

Yes No

15

Results of tests16

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities17

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

18

Specify other abnormality:19

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

20

Were tests for molecular markers performed? (e.g. PCR, NGS) (at diagnosis)

yes no Unknown

21

CEBPA

Positive Negative Not Done

22

Specify CEBPA mutation23

Biallelic (homozygous)

Monoallelic (heterozygous)

Unknown

FLT3 – D835 point mutation

Positive Negative Not Done

24

FLT3 – ITD mutation

Positive Negative Not Done

25

FLT3 - ITD allelic ratio

Known Unknown

26

Specify FLT3 - ITD allelic ratio:27

IDH1

Positive Negative Not Done

28

IDH2

Positive Negative Not Done

29

KIT

Positive Negative Not Done

30

NPM1

Positive Negative Not Done

31

Other Molecular Marker (1) Questions: 32 - 33

Other molecular marker

Positive Negative Not Done

32

Specify other molecular marker:33

Were cytogenetics tested (karyotyping or FISH)? (between diagnosis and last evaluation)

yes no Unknown

34

Were cytogenetics tested via FISH? (between diagnosis and last evaluation)

Yes No

35

Results of tests36

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities37

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

38

Specify other abnormality:39

Were cytogenetics tested via karyotyping? (between diagnosis and last evaluation)

Yes No

40

Results of tests41

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities42

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

43

Specify other abnormality:44

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

45

Were tests for molecular markers performed? (e.g. PCR, NGS) (between diagnosis and last evaluation)

yes no Unknown

46

CEBPA

Positive Negative Not Done

47

Specify CEBPA mutation48

Biallelic (homozygous)

Monoallelic (heterozygous)

Unknown

FLT3 – D835 point mutation

Positive Negative Not Done

49

FLT3 – ITD mutation

Positive Negative Not Done

50

FLT3 - ITD allelic ratio

Known Unknown

51

Specify FLT3 - ITD allelic ratio:52

IDH1

Positive Negative Not Done

53

IDH2

Positive Negative Not Done

54

KIT

Positive Negative Not Done

55

NPM1

Positive Negative Not Done

56

Other Molecular Marker (1) Questions: 57 - 58

Other molecular marker

Positive Negative Not Done

57

Specify other molecular marker:58

Were cytogenetics tested (karyotyping or FISH)? (at last evaluation)

yes no Unknown

59

Were cytogenetics tested via FISH? (at last evaluation)

Yes No

60

Results of tests61

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities62

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

63

Specify other abnormality:64

Were cytogenetics tested via karyotyping? (at last evaluation)

Yes No

65

Results of tests66

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities67

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

68

Specify other abnormality:69

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

70

Were tests for molecular markers performed? (e.g. PCR, NGS) (at last evaluation)

yes no Unknown

71

CEBPA

Positive Negative Not Done

72

Specify CEBPA mutation73

Biallelic (homozygous)

Monoallelic (heterozygous)

Unknown

FLT3 – D835 point mutation

Positive Negative Not Done

74

FLT3 – ITD mutation

Positive Negative Not Done

75

FLT3 - ITD allelic ratio

Known Unknown

76

Specify FLT3 - ITD allelic ratio:77

IDH1

Positive Negative Not Done

78

IDH2

Positive Negative Not Done

79

KIT

Positive Negative Not Done

80

NPM1

Positive Negative Not Done

81

Other Molecular Marker (1) Questions: 82 - 83

Other molecular marker

Positive Negative Not Done

82

Specify other molecular marker:83

Did the recipient have central nervous system leukemia at any time prior to the start of the preparative regimen / infusion?

yes no Unknown

84

What was the disease status (based on hematological test results)?85

Primary induction failure

1st complete remission (no previous bone marrow or extramedullary relapse) (include CRi)

2nd complete remission

≥3rd complete remission

1st relapse

2nd relapse

≥3rd relapse

No treatment

How many cycles of induction therapy were required to achieve 1st complete remission? (includes CRi)

1 2 ≥ 3

86

Was the recipient in remission by flow cytometry?

Yes No Unknown Not applicable

87

Date of most recent relapse:88 __ __ __ __ - __ __- __ __

Date assessed:89 __ __ __ __ - __ __- __ __

Acute Lymphoblastic Leukemia (ALL) Questions: 90 - 151

Specify ALL classification90

Did the recipient have a predisposing condition?

yes no Unknown

91

Specify condition92

Aplastic anemia - Also complete CIBMTR Form 2028 - APL

Bloom syndrome

Down syndrome

Fanconi anemia - Also complete CIBMTR Form 2029 - FAN

Other condition

Specify other condition:93

Were tyrosine kinase inhibitors given for therapy at any time prior to the start of the preparative regimen / infusion? (e.g. imatinib mesylate, dasatinib, etc.)

yes no

94

Were cytogenetics tested (karyotyping or FISH)? (at diagnosis)

yes no Unknown

95

Were cytogenetics tested via FISH? (at diagnosis)

Yes No

96

Results of tests97

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities98

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

99

Specify other abnormality:100

Were cytogenetics tested via karyotyping? (at diagnosis)

Yes No

101

Results of tests102

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities103

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

104

Specify other abnormality:105

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

106

Were tests for molecular markers performed? (e.g. PCR, NGS) (at diagnosis)

yes no Unknown

107

BCR / ABL

Positive Negative Not Done

108

TEL-AML / AML1

Positive Negative Not Done

109

Other Molecular Marker (1) Questions: 110 - 111

Other molecular marker

Positive Negative Not Done

110

Specify other molecular marker:111

Were cytogenetics tested (karyotyping or FISH)? (between diagnosis and last evaluation)

yes no Unknown

112

Were cytogenetics tested via FISH? (between diagnosis and last evaluation)

Yes No

113

Results of tests114

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities115

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

116

Specify other abnormality:117

Were cytogenetics tested via karyotyping? (between diagnosis and last evaluation)

Yes No

118

Results of tests119

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities120

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

121

Specify other abnormality:122

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

123

Were tests for molecular markers performed? (e.g. PCR, NGS) (between diagnosis and last evaluation)

yes no Unknown

124

BCR / ABL

Positive Negative Not Done

125

TEL-AML / AML1

Positive Negative Not Done

126

Other Molecular Marker (1) Questions: 127 - 128

Other molecular marker

Positive Negative Not Done

127

Specify other molecular marker:128

Were cytogenetics tested (karyotyping or FISH)? (at last evaluation)

yes no Unknown

129

Were cytogenetics tested via FISH? (at last evaluation)

Yes No

130

Results of tests131

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities132

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

133

Specify other abnormality:134

Were cytogenetics tested via karyotyping? (at last evaluation)

Yes No

135

Results of tests136

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities137

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

138

Specify other abnormality:139

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

140

Were tests for molecular markers performed? (e.g. PCR, NGS) (at last evaluation)

yes no Unknown

141

BCR / ABL

Positive Negative Not Done

142

TEL-AML / AML1

Positive Negative Not Done

143

Other Molecular Marker (1) Questions: 144 - 145

Other molecular marker

Positive Negative Not Done

144

Specify other molecular marker:145

Did the recipient have central nervous system leukemia at any time prior to the start of the preparative regimen / infusion?

yes no Unknown

146

What was the disease status (based on hematological test results)?147

Primary induction failure

1st complete remission (no previous marrow or extramedullary relapse) (include CRi)

2nd complete remission

≥3rd complete remission

1st relapse

2nd relapse

≥3rd relapse

No treatment

How many cycles of induction therapy were required to achieve 1st complete remission? (include CRi)

1 2 ≥ 3

148

Was the recipient in remission by flow cytometry?

Yes No Unknown Not applicable

149

Date of most recent relapse:150 __ __ __ __ - __ __- __ __

Date assessed:151 __ __ __ __ - __ __- __ __

Acute Leukemias of Ambiguous Lineage and Other Myeloid Neoplasms Questions: 152 - 155

Specify acute leukemias of ambiguous lineage and other myeloid neoplasm classification152

Blastic plasmacytoid dendritic cell neoplasm (296)

Acute undifferentiated leukemia (31)

Mixed phenotype acute leukemia (MPAL) with t(9;22)(q34.1;q11.2); BCR-ABL1 (84)

Mixed phenotype acute leukemia with t(v; 11q23.3); KMT2A rearranged (85)

Mixed phenotype acute leukemia, B/myeloid, NOS (86)

Mixed phenotype acute leukemia, T/myeloid, NOS (87)

Other acute leukemia of ambiguous lineage or myeloid neoplasm (88)

Specify other acute leukemia of ambiguous lineage or myeloid neoplasm:153

What was the disease status (based on hematological test results)?154

Primary induction failure

1st complete remission (no previous marrow or extramedullary relapse)

2nd complete remission

≥3rd complete remission

1st relapse

2nd relapse

≥3rd relapse

No treatment

Date assessed:155 __ __ __ __ - __ __- __ __

Chronic Myelogenous Leukemia (CML) Questions: 156 - 166

Was therapy given prior to this HCT?

yes no

156

Combination chemotherapy

yes no

157

Hydroxyurea (Droxia, Hydrea)

yes no

158

Tyrosine kinase inhibitor (e.g. imatinib mesylate, dasatinib, nilotinib)

yes no

159

Interferon­α (Intron, Roferon) (includes PEG)

yes no

160

Other therapy

yes no

161

Specify other therapy:162

What was the disease status?163

Complete hematologic response (CHR)

Chronic phase

Accelerated phase

Blast phase

Specify level of response164

No cytogenetic response (No CyR)

Minimal cytogenetic response

Minor cytogenetic response

Partial cytogenetic response (PCyR)

Complete cytogenetic response (CCyR)

Major molecular remission (MMR)

Complete molecular remission (CMR)

Number

1st 2nd 3rd or higher

165

Date assessed:166 __ __ __ __ - __ __- __ __

Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases Questions: 167 - 260

What was the MDS / MPN subtype at diagnosis? - If transformed to AML, indicate AML as primary disease; also complete AML Disease Classification
questions

167

Was the disease (MDS/MPN) therapy related?

yes no Unknown

168

Did the recipient have a predisposing condition?

yes no Unknown

169

Specify condition

Aplastic Anemia Bloom syndrome Down syndrome Fanconi anemia Other condition

170

Specify other condition:171

WBC

Known Unknown

172

173 x 109/L (x 103/mm3)

x 106/L

Hemoglobin

Known Unknown

174

175 g/dL g/L mmol/L

Was RBC transfused ≤ 30 days before date of test?

Yes No

176

Platelets

Known Unknown

177

178 x 109/L (x 103/mm3)

x 106/L

Were platelets transfused ≤ 7 days before date of test?

Yes No

179

Neutrophils

Known Unknown

180

181 %

Blasts in bone marrow

Known Unknown

182

183 %

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

184

Results of tests185

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities186

One (1)

Two (2)

Three (3)

Four or more (4 or more)

–5

yes no

187

-7

yes no

188

–13

yes no

189

–20

yes no

190

–Y

yes no

191

+8

yes no

192

+19

yes no

193

t(1;3)

yes no

194

t(2;11)

yes no

195

t(3;3)

yes no

196

t(3;21)

yes no

197

t(6;9)

yes no

198

t(11;16)

yes no

199

del(3q) / 3q–

yes no

200

del(5q) / 5q-

yes no

201

del(7q) / 7q–

yes no

202

del(9q) / 9q–

yes no

203

del(11q) / 11q–

yes no

204

del(12p) / 12p–

yes no

205

del(13q) / 13q-

yes no

206

del(20q) / 20q–

yes no

207

inv(3)

yes no

208

i17q

yes no

209

Other abnormality

yes no

210

Specify other abnormality:211

Did the recipient progress or transform to a different MDS / MPN subtype between diagnosis and the start of the preparative regimen?

yes no

212

Specify the MDS / MPN classification after transformation:213

Specify the date of the most recent transformation:214 __ __ __ __ - __ __- __ __

Date of MDS diagnosis:215 __ __ __ __ - __ __- __ __

WBC

Known Unknown

216

217 x 109/L (x 103/mm3)

x 106/L

Hemoglobin

Known Unknown

218

219 g/dL g/L mmol/L

Was RBC transfused ≤ 30 days before date of test?

Yes No

220

Platelets

Known Unknown

221

222 x 109/L (x 103/mm3)

x 106/L

Were platelets transfused ≤ 7 days before date of test?

Yes No

223

Neutrophils

Known Unknown

224

225 %

Blasts in bone marrow

Known Unknown

226

227 %

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

228

Results of tests229

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities230

One (1)

Two (2)

Three (3)

Four or more (4 or more)

–5

yes no

231

-7

yes no

232

–13

yes no

233

–20

yes no

234

–Y

yes no

235

+8

yes no

236

+19

yes no

237

t(1;3)

yes no

238

t(2;11)

yes no

239

t(3;3)

yes no

240

t(3;21)

yes no

241

t(6;9)

yes no

242

t(11;16)

yes no

243

del(3q) / 3q–

yes no

244

del(5q) / 5q-

yes no

245

del(7q) / 7q–

yes no

246

del(9q) / 9q–

yes no

247

del(11q) / 11q–

yes no

248

del(12p) / 12p–

yes no

249

del(13q) / 13q-

yes no

250

del(20q) / 20q–

yes no

251

inv(3)

yes no

252

i17q

yes no

253

Other abnormality

yes no

254

Specify other abnormality:255

What was the disease status?256

Complete
remission
(CR)

– requires all of the following, maintained for ≥ 4 weeks: * bone marrow evaluation: <  5% myeloblasts with normal maturation of all cell lines *
peripheral blood evaluation: hemoglobin ≥ 11 g/dL untransfused and without erythropoietin support; ANC ≥ 1000/mm3  without myeloid growth factor
support; platelets ≥ 100 x 109/L without thrombopoietic support; 0% blasts

Hematologic
improvement
(HI)

– requires one measurement of the following, maintained for ≥ 8 weeks without ongoing cytotoxic therapy; specify which cell line was measured to
determine HI response: * HI­E – hemoglobin increase of ≥ 1.5 g/dL untransfused; for RBC transfusions performed for Hgb ≤ 9.0, reduction in RBC
units transfused in 8 weeks by ≥ 4 units compared to the pre­treatment transfusion number in 8 weeks * HI­P – for pre­treatment platelet count of > 20
x 109/L, platelet absolute increase of ≥ 30 x 109/L; for pre-treatment platelet count of < 20 x 109/L, platelet absolute increase of ≥ 20 x 109/L and ≥
100% from pre­treatment level  * HI­N – neutrophil count increase of ≥ 100% from pre­treatment level and an absolute increase of ≥ 500/mm3

No response (NR) / stable disease (SD) – does not meet the criteria for at least HI, but no evidence of disease progression

Progression from
hematologic improvement
(Prog from HI)

– requires at least one of the following, in the absence of another explanation (e.g., infection, bleeding, ongoing chemotherapy, etc.): *
≥ 50% reduction from maximum response levels in granulocytes or platelets * reduction in hemoglobin by ≥ 1.5 g/dL *transfusion
dependence

Relapse from complete
remission (Rel from CR)

– requires at least one of the following: * return to pre­treatment bone marrow blast percentage * decrease of ≥ 50% from maximum
response levels in granulocytes or platelets * transfusion dependence, or hemoglobin level ≥ 1.5 g/dL lower than prior to therapy

Not assessed

Specify the cell line examined to determine HI status257

HI-
E

– hemoglobin increase of ≥ 1.5 g/dL untransfused; for RBC transfusions performed for Hgb ≤ 9.0, reduction in RBC units transfused in 8 weeks by ≥ 4
units compared to the pre-treatment transfusion number in 8 weeks

HI-
P

– for pre­treatment platelet count of > 20 x 109/L, platelet absolute increase of ≥ 30 x 109/L; for pre-treatment platelet count of < 20 x 109/L, platelet
absolute increase of ≥ 20 x 109/L and ≥ 100% from pre­treatment level 

HI-N – neutrophil count increase of ≥ 100% from pre­treatment level and an absolute increase of ≥ 500/mm3

Date of progression:258 __ __ __ __ - __ __- __ __

Date of relapse:259 __ __ __ __ - __ __- __ __

Date assessed:260 __ __ __ __ - __ __- __ __

Other Leukemia (OL) Questions: 261 - 267

Specify the other leukemia classification261

Specify other leukemia:262

Was any 17p abnormality detected?

yes no

263

Did a histologic transformation to diffuse large B-cell lymphoma (Richter syndrome) occur at any time after CLL diagnosis?264

yes - Also complete NHL Disease Classification questions

no

What was the disease status? (Atypical CML)265

Primary induction failure

1st complete remission (no previous bone marrow or extramedullary relapse)

2nd complete remission

≥3rd complete remission

1st relapse

2nd relapse

≥3rd relapse

No treatment

What was the disease status? (CLL, PLL, Hairy cell leukemia)266

Complete remission (CR)

Partial remission (PR)

Stable disease (SD)

Progressive disease (Prog)

Untreated

Not assessed

Date assessed:267 __ __ __ __ - __ __- __ __

Hodgkin and Non-Hodgkin Lymphoma Questions: 268 - 285

Specify the lymphoma histology (at infusion)268

Specify other lymphoma histology:269

Assignment of DLBCL (germinal center B-cell type vs. activated B-cell type) subtype was based on270

Immunohistochemistry (e.g. Han's algorithm)

Gene expression profile

Unknown method

Is the lymphoma histology reported at transplant a transformation from CLL?

yes no

271

Was any 17p abnormality detected?

yes no

272

Is the lymphoma histology reported at transplant a transformation from a different lymphoma histology? (Not CLL)

Yes No

273

Specify the original lymphoma histology (prior to transformation)274

Specify other lymphoma histology:275

Date of original lymphoma diagnosis:276 __ __ __ __ - __ __- __ __ (report the date of diagnosis of original lymphoma subtype)

Was a PET (or PET/CT) scan performed? (at last evaluation prior to the start of the preparative regimen / infusion)

yes no

277

Was the PET (or PET/CT) scan positive for lymphoma involvement at any disease site?

yes no

278

Date of PET scan

Known Unknown

279

Date of PET (or PET/CT) scan:280 __ __ __ __ - __ __- __ __

Deauville (five-point) score of the PET (or PET/CT) scan

Known Unknown

281

Scale282

1 - no uptake or residual uptake

2 - slight uptake, but below blood pool (mediastinum)

3 - uptake above mediastinal, but below or equal to uptake in the liver

4 - uptake slightly to moderately higher than liver

5 - markedly increased uptake or any new lesions

What was the disease status?283

Total number of lines of therapy received

1 line 2 lines 3+ lines

284

Date assessed:285 __ __ __ __ - __ __- __ __

Multiple Myeloma / Plasma Cell Disorder (PCD) Questions: 286 - 317

Specify the multiple myeloma/plasma cell disorder (PCD) classification286

Specify other plasma cell disorder:287

Light chain

kappa lambda

288

What was the Durie-Salmon staging? (at diagnosis)289

Stage
I

(All of the following: Hgb > 10g/dL; serum calcium normal or <10.5 mg/dL; bone x-ray normal bone structure (scale 0), or solitary bone plasmacytoma
only; low M-component production rates IgG< 5g/dL, IgA < 3g/dL; urine light chain M-component on electrophoresis <4 g/24h)

Stage II (Fitting neither Stage I or III) 

Stage
III

(One or more of the following: Hgb < 8.5 g/dL; serum calcium > 12 mg/dL; advanced lytic bone lesions (scale 3); high M-component production rates
IgG > 7g/dL, IgA > 5 g/dL; Bence Jones protein > 12g/24h)

Unknown

What was the Durie-Salmon sub classification? (at diagnosis)290

A - relatively normal renal function (serum creatinine < 2.0 mg/dL)

B ­ abnormal renal function (serum creatinine ≥ 2.0 mg/dL)

Serum β2­microglobulin:291 μg/dL mg/L nmol/L

Serum albumin:292 g/dL g/L

Stage293

1 (β2 ­mic < 3.5, S. albumin ≥3.5)

2 (Not fitting stage 1 or 3)

3 (β2­mic ≥ 5.5; S. albumin ­)

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

294

Results of tests295

Abnormalities identified

No evaluable metaphases

No abnormalities

+3

yes no

296

+5

yes no

297

+7

yes no

298

+9

yes no

299

+11

yes no

300

+15

yes no

301

+19

yes no

302

t(4;14)

yes no

303

t(6;14)

yes no

304

t(11;14)

yes no

305

t(14;16)

yes no

306

t(14;20)

yes no

307

del(13q) / 13q-

yes no

308

del (17p) / 17p-

yes no

309

Hyperdiploid (>50)

yes no

310

Hypodiploid (<46)

yes no

311

Any abnormality at 1q

yes no

312

Any abnormality at 1p

yes no

313

Other abnormality

yes no

314

Specify other abnormality:315

What was the disease status?316

Stringent
complete
remission
(sCR)

- CR as defined, plus: normal free light chain ratio, and absence of clonal cells in the bone marrow by immunohistochemistry of immunofluorescence
(confirmation with repeat bone marrow biopsy not needed). (Presence and/or absence of clonal cells is based upon the Κ/λ ratio. An abnormal Κ/λ ratio by
immunohistochemistry and/or immunofluorescence requires a minimum of 100 plasma cells for analysis.  An abnormal ratio reflecting the presence of
an abnormal clone is Κ/λ of > 4:1 or < 1:2.) sCR requires two consecutive assessments made at any time before the institution of any new therapy, and
no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy sCR
requirements. 

Complete
remission
(CR)

- negative immunofixation on serum and urine samples, and disappearance of any soft tissue plasmacytomas, and < 5% plasma cells in the bone
marrow (confirmation with repeat bone marrow biopsy not needed).  CR requires two consecutive assessments made at any time before the institution
of any new therapy, and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not
required to satisfy CR requirements. 

Near
complete
remission
(nCR)

- serum and urine M-protein detectable by immunoelectrophoresis (IFE), but not on electrophoresis (negative SPEP & UPEP); < 5% plasma cells in
bone marrow.  nCR requires two consecutive assessments made at any time before the initiation of any new therapy, and no known evidence of
progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy nCR requirements. 

Very good
partial
remission
(VGPR)

­ serum and urine M­protein detectable by immunofixation but not on electrophoresis, or ≥ 90% reduction in serum M­protein and urine M­protein level <
100 mg/24 hours.  VGPR requires two consecutive assessments made at any time before the institution of any new therapy, and no known evidence of
progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy VGPR requirements.

Partial
remission
(PR)

­ ≥ 50% reduction in serum M­protein, and reduction in 24­hour urinary M­protein by ≥ 90% or to < 200 mg/24 hours.  If the serum and urine M­protein are
unmeasurable (i.e., do not meet any of the following criteria: • serum M­protein ≥ 1 g/dL.  Urine M­protein ≥ 200 mg/24 hours • serum free light chain
assay shows involved level ≥ 10 mg/dL, provided serum free light chain ratio is abnormal), a ≥ 50% decrease in the difference between involved and
uninvolved free light chain levels is required in place of the M-protein criteria.  If serum and urine M-protein are unmeasurable, and serum free light assay
is also unmeasurable, a ≥ 50% reduction in plasma cells is required in place of M­protein, provided the baseline bone marrow plasma cell percentage
was ≥ 30%. In addition to the above listed criteria, a ≥ 50% reduction in the size of soft tissue plasmacytomas is also required, if present at baseline. PR
requires two consecutive assessments made at any time before the institution of any new therapy, and no known evidence of progressive or new bone
lesions if radiographic studies were performed; radiographic studies are not required to satisfy PR requirements. 

Stable
disease
(SD)

- not meeting the criteria for CR, VGPR, PR or PD.  SD requires two consecutive assessments made at any time before the institution of any new therapy,
and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy SD
requirements.

Progressive
disease
(PD)

­ requires any one or more of the following:  Increase of ≥ 25% from baseline in:  serum M­component and/or (absolute increase ≥ 0.5 g/dL) (for
progressive disease, serum M­component increases of ≥ 1 g/dL are sufficient to define relapse if the starting M­component is ≥ 5 g/dL).  Urine M­
component and/or (absolute increase ≥ 200 mg/24 hours) for recipients without measurable serum and urine M­protein levels: the difference between
involved and uninvolved free light chain levels (absolute increase > 10 mg/dL).  Bone marrow plasma cell percentage (absolute percentage ≥ 10%)
(relapse from CR has a 5% cutoff vs. 10% for other categories of relapse) definite development of new bone lesions or soft tissue plasmacytomas, or
definite increase in the size of any existing  bone lesions or soft tissue plasmacytomas. Development of hypercalcemia (corrected serum calcium >
11.5 mg/dL or 2.65 mmol) that can be attributed solely to the plasma cell proliferative disorder.  PD requires two consecutive assessments made at
any time before classification as disease progression, and/or the institution of any new therapy.

Relapse
from CR
(Rel)
(untreated)

­ requires one or more of the following: reappearance of serum or urine M­protein by immunofixation or electrophoresis development of ≥ 5% plasma
cells in the bone marrow (relapse from CR has a 5% cutoff vs. 10% for other categories of relapse) appearance of any other sign of progression (e.g.,
new plasmacytoma, lytic bone lesion, hypercalcemia).  Rel requires two consecutive assessments made at any time before classification as relapse,
and/or the institution of any new therapy.

Unknown

Not applicable (Amyloidosis with no evidence of myeloma)

Date assessed:317 __ __ __ __ - __ __- __ __

Solid Tumors Questions: 318 - 319

Specify the solid tumor classification318

Specify other solid tumor:319

Severe Aplastic Anemia Questions: 320 - 321

Specify the severe aplastic anemia classification320

Specify other acquired cytopenic syndrome:321

Inherited Abnormalities of Erythrocyte Differentiation or Function Questions: 322 - 324

Specify the inherited abnormalities of erythrocyte differentiation or function classification322

Specify other constitutional anemia:323

Specify other hemoglobinopathy:324

Disorders of the Immune System Questions: 325 - 327

Specify disorder of immune system classification325

Specify other SCID:326

Specify other immunodeficiency:327

Inherited Abnormalities of Platelets Questions: 328 - 329

Specify inherited abnormalities of platelets classification328

Congenital amegakaryocytosis / congenital thrombocytopenia (501)

Glanzmann thrombasthenia (502)

Other inherited platelet abnormality (509)

Specify other inherited platelet abnormality:329

Inherited Disorders of Metabolism Questions: 330 - 331

Specify inherited disorders of metabolism classification330

Specify other inherited metabolic disorder:331

Histiocytic Disorders Questions: 332 - 333

Specify histiocytic disorder classification332

Specify other histiocytic disorder:333

Autoimmune Diseases Questions: 334 - 341

Specify autoimmune disease classification334

Specify other arthritis:335

Specify other juvenile idiopathic arthritis (JIA):336

Specify other connective tissue disease:337

Specify other vasculitis:338

Specify other autoimmune neurological disorder:339

Specify other autoimmune cytopenia:340

Specify other autoimmune bowel disorder:341

Other Disease Questions: 342 - 342

Specify other disease:342

First Name:

Last Name:

E-mail address:

Date: __ __ __ __ - __ __- __ __

OMB No: 0915-0310

Expiration Date: 1/31/2020

Public Burden Statement:  An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control

number.  The OMB control number for this project is 0915-0310.  Public reporting burden for this collection of information is estimated to average 1.0 hours per response, including the
time for reviewing instructions, searching existing data sources, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other

aspect of this collection of information, including suggestions for reducing this burden, to HRSA Reports Clearance Officer, 5600 Fishers Lane, Room 10-29, Rockville, Maryland, 20857.

Labs at diagnosis

Specify cytogenetic abnormalities identified at diagnosis:

Specify cytogenetic abnormalities identified at diagnosis:

Specify molecular markers identified at diagnosis:

Labs between diagnosis and last evaluation:

Specify cytogenetic abnormalities identified between diagnosis and last evaluation:

Specify cytogenetic abnormalities identified between diagnosis and last evaluation:

Specify molecular markers identified between diagnosis and last evaluation:

Labs at last evaluation:

Specify cytogenetic abnormalities identified at last evaluation:

Specify cytogenetic abnormalities identified at last evaluation:

Specify molecular markers identified at last evaluation:

CNS Leukemia

Status at transplantation:

Laboratory studies at diagnosis:

Specify cytogenetic abnormalities identified at diagnosis:

Specify cytogenetic abnormalities identified at diagnosis:

Specify molecular markers identified at diagnosis:

Laboratory studies between diagnosis and last evaluation:

Specify cytogenetic abnormalities identified between diagnosis and last evaluation:

Specify cytogenetic abnormalities identified between diagnosis and last evaluation:

Specify molecular markers identified between diagnosis and last evaluation:

Laboratory studies at last evaluation:

Specify cytogenetic abnormalities identified at last evaluation:

Specify cytogenetic abnormalities identified at last evaluation:

Specify molecular markers identified at last evaluation:

CNS Leukemia

Status at transplantation:

Status at transplantation:

Laboratory studies at diagnosis of MDS:

Specify abnormalities identified at diagnosis:

Monosomy

Trisomy

Translocation

Deletion

Inversion

Other

Laboratory studies at last evaluation prior to the start of the preparative regimen:

Specify cytogenetic abnormalities identified at last evaluation prior to the start of the preparative regimen:

Monosomy

Trisomy

Translocation

Deletion

Inversion

Other

Status at transplantation:

Status at transplantation:

Status at transplantation / infusion:

I.S.S.:

Specify cytogenetic abnormalities identified at any time prior to the start of the preparative regimen:

Trisomy

Translocation

Deletion

Other

Status at transplantation:

Center: CRID: 

Form 2402 R3.0: Disease Classification

CIBMTR Form 2402 revision 3.0 last updated Monday, January 29, 2018
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 18 / 26



Key Fields

Sequence Number:

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number:

CIBMTR Research ID:

Event date: __ __ __ __ - __ __- __ __

Primary Disease for HCT / Cellular Therapy Questions: 1 - 2

Date of diagnosis of primary disease for HCT / cellular therapy:1 __ __ __ __ - __ __- __ __

What was the primary disease for which the HCT / cellular therapy was performed?2

Acute myelogenous leukemia (AML or ANLL) (10)

Acute lymphoblastic leukemia (ALL) (20)

Acute leukemia of ambiguous lineage and other myeloid neoplasms (80)

Chronic myelogenous leukemia (CML) (40)

Myelodysplastic (MDS) / myeloproliferative (MPN) diseases (50) (Please classify all preleukemias) (If recipient has transformed to AML, indicate AML as the primary disease)

Other leukemia (30) (includes CLL)

Hodgkin lymphoma (150)

Non-Hodgkin lymphoma (100)

Multiple myeloma / plasma cell disorder (PCD) (170)

Solid tumors (200)

Severe aplastic anemia (300) (If the recipient developed MDS or AML, indicate MDS or AML as the primary disease)

Inherited abnormalities of erythrocyte differentiation or function (310)

Disorders of the immune system (400)

Inherited abnormalities of platelets (500)

Inherited disorders of metabolism (520)

Histiocytic disorders (570)

Autoimmune diseases (600)

Other disease (900)

Acute Myelogenous Leukemia (AML) Questions: 3 - 89

Specify the AML classification3

Did AML transform from MDS or MPN?4

yes - Also complete MDS Disease Classification questions

no

Is the disease (AML) therapy related?

yes no Unknown

5

Did the recipient have a predisposing condition?

yes no Unknown

6

Specify condition7

Bloom syndrome

Down syndrome

Fanconi anemia

Dyskeratosis congenita

Other condition

Specify other condition:8

Were cytogenetics tested (karyotyping or FISH)? (at diagnosis)

yes no Unknown

9

Were cytogenetics tested via FISH? (at diagnosis)

Yes No

10

Results of tests11

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities12

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

13

Specify other abnormality:14

Were cytogenetics tested via karyotyping? (at diagnosis)

Yes No

15

Results of tests16

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities17

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

18

Specify other abnormality:19

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

20

Were tests for molecular markers performed? (e.g. PCR, NGS) (at diagnosis)

yes no Unknown

21

CEBPA

Positive Negative Not Done

22

Specify CEBPA mutation23

Biallelic (homozygous)

Monoallelic (heterozygous)

Unknown

FLT3 – D835 point mutation

Positive Negative Not Done

24

FLT3 – ITD mutation

Positive Negative Not Done

25

FLT3 - ITD allelic ratio

Known Unknown

26

Specify FLT3 - ITD allelic ratio:27

IDH1

Positive Negative Not Done

28

IDH2

Positive Negative Not Done

29

KIT

Positive Negative Not Done

30

NPM1

Positive Negative Not Done

31

Other Molecular Marker (1) Questions: 32 - 33

Other molecular marker

Positive Negative Not Done

32

Specify other molecular marker:33

Were cytogenetics tested (karyotyping or FISH)? (between diagnosis and last evaluation)

yes no Unknown

34

Were cytogenetics tested via FISH? (between diagnosis and last evaluation)

Yes No

35

Results of tests36

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities37

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

38

Specify other abnormality:39

Were cytogenetics tested via karyotyping? (between diagnosis and last evaluation)

Yes No

40

Results of tests41

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities42

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

43

Specify other abnormality:44

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

45

Were tests for molecular markers performed? (e.g. PCR, NGS) (between diagnosis and last evaluation)

yes no Unknown

46

CEBPA

Positive Negative Not Done

47

Specify CEBPA mutation48

Biallelic (homozygous)

Monoallelic (heterozygous)

Unknown

FLT3 – D835 point mutation

Positive Negative Not Done

49

FLT3 – ITD mutation

Positive Negative Not Done

50

FLT3 - ITD allelic ratio

Known Unknown

51

Specify FLT3 - ITD allelic ratio:52

IDH1

Positive Negative Not Done

53

IDH2

Positive Negative Not Done

54

KIT

Positive Negative Not Done

55

NPM1

Positive Negative Not Done

56

Other Molecular Marker (1) Questions: 57 - 58

Other molecular marker

Positive Negative Not Done

57

Specify other molecular marker:58

Were cytogenetics tested (karyotyping or FISH)? (at last evaluation)

yes no Unknown

59

Were cytogenetics tested via FISH? (at last evaluation)

Yes No

60

Results of tests61

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities62

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

63

Specify other abnormality:64

Were cytogenetics tested via karyotyping? (at last evaluation)

Yes No

65

Results of tests66

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities67

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

68

Specify other abnormality:69

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

70

Were tests for molecular markers performed? (e.g. PCR, NGS) (at last evaluation)

yes no Unknown

71

CEBPA

Positive Negative Not Done

72

Specify CEBPA mutation73

Biallelic (homozygous)

Monoallelic (heterozygous)

Unknown

FLT3 – D835 point mutation

Positive Negative Not Done

74

FLT3 – ITD mutation

Positive Negative Not Done

75

FLT3 - ITD allelic ratio

Known Unknown

76

Specify FLT3 - ITD allelic ratio:77

IDH1

Positive Negative Not Done

78

IDH2

Positive Negative Not Done

79

KIT

Positive Negative Not Done

80

NPM1

Positive Negative Not Done

81

Other Molecular Marker (1) Questions: 82 - 83

Other molecular marker

Positive Negative Not Done

82

Specify other molecular marker:83

Did the recipient have central nervous system leukemia at any time prior to the start of the preparative regimen / infusion?

yes no Unknown

84

What was the disease status (based on hematological test results)?85

Primary induction failure

1st complete remission (no previous bone marrow or extramedullary relapse) (include CRi)

2nd complete remission

≥3rd complete remission

1st relapse

2nd relapse

≥3rd relapse

No treatment

How many cycles of induction therapy were required to achieve 1st complete remission? (includes CRi)

1 2 ≥ 3

86

Was the recipient in remission by flow cytometry?

Yes No Unknown Not applicable

87

Date of most recent relapse:88 __ __ __ __ - __ __- __ __

Date assessed:89 __ __ __ __ - __ __- __ __

Acute Lymphoblastic Leukemia (ALL) Questions: 90 - 151

Specify ALL classification90

Did the recipient have a predisposing condition?

yes no Unknown

91

Specify condition92

Aplastic anemia - Also complete CIBMTR Form 2028 - APL

Bloom syndrome

Down syndrome

Fanconi anemia - Also complete CIBMTR Form 2029 - FAN

Other condition

Specify other condition:93

Were tyrosine kinase inhibitors given for therapy at any time prior to the start of the preparative regimen / infusion? (e.g. imatinib mesylate, dasatinib, etc.)

yes no

94

Were cytogenetics tested (karyotyping or FISH)? (at diagnosis)

yes no Unknown

95

Were cytogenetics tested via FISH? (at diagnosis)

Yes No

96

Results of tests97

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities98

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

99

Specify other abnormality:100

Were cytogenetics tested via karyotyping? (at diagnosis)

Yes No

101

Results of tests102

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities103

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

104

Specify other abnormality:105

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

106

Were tests for molecular markers performed? (e.g. PCR, NGS) (at diagnosis)

yes no Unknown

107

BCR / ABL

Positive Negative Not Done

108

TEL-AML / AML1

Positive Negative Not Done

109

Other Molecular Marker (1) Questions: 110 - 111

Other molecular marker

Positive Negative Not Done

110

Specify other molecular marker:111

Were cytogenetics tested (karyotyping or FISH)? (between diagnosis and last evaluation)

yes no Unknown

112

Were cytogenetics tested via FISH? (between diagnosis and last evaluation)

Yes No

113

Results of tests114

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities115

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

116

Specify other abnormality:117

Were cytogenetics tested via karyotyping? (between diagnosis and last evaluation)

Yes No

118

Results of tests119

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities120

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

121

Specify other abnormality:122

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

123

Were tests for molecular markers performed? (e.g. PCR, NGS) (between diagnosis and last evaluation)

yes no Unknown

124

BCR / ABL

Positive Negative Not Done

125

TEL-AML / AML1

Positive Negative Not Done

126

Other Molecular Marker (1) Questions: 127 - 128

Other molecular marker

Positive Negative Not Done

127

Specify other molecular marker:128

Were cytogenetics tested (karyotyping or FISH)? (at last evaluation)

yes no Unknown

129

Were cytogenetics tested via FISH? (at last evaluation)

Yes No

130

Results of tests131

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities132

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

133

Specify other abnormality:134

Were cytogenetics tested via karyotyping? (at last evaluation)

Yes No

135

Results of tests136

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities137

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

138

Specify other abnormality:139

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

140

Were tests for molecular markers performed? (e.g. PCR, NGS) (at last evaluation)

yes no Unknown

141

BCR / ABL

Positive Negative Not Done

142

TEL-AML / AML1

Positive Negative Not Done

143

Other Molecular Marker (1) Questions: 144 - 145

Other molecular marker

Positive Negative Not Done

144

Specify other molecular marker:145

Did the recipient have central nervous system leukemia at any time prior to the start of the preparative regimen / infusion?

yes no Unknown

146

What was the disease status (based on hematological test results)?147

Primary induction failure

1st complete remission (no previous marrow or extramedullary relapse) (include CRi)

2nd complete remission

≥3rd complete remission

1st relapse

2nd relapse

≥3rd relapse

No treatment

How many cycles of induction therapy were required to achieve 1st complete remission? (include CRi)

1 2 ≥ 3

148

Was the recipient in remission by flow cytometry?

Yes No Unknown Not applicable

149

Date of most recent relapse:150 __ __ __ __ - __ __- __ __

Date assessed:151 __ __ __ __ - __ __- __ __

Acute Leukemias of Ambiguous Lineage and Other Myeloid Neoplasms Questions: 152 - 155

Specify acute leukemias of ambiguous lineage and other myeloid neoplasm classification152

Blastic plasmacytoid dendritic cell neoplasm (296)

Acute undifferentiated leukemia (31)

Mixed phenotype acute leukemia (MPAL) with t(9;22)(q34.1;q11.2); BCR-ABL1 (84)

Mixed phenotype acute leukemia with t(v; 11q23.3); KMT2A rearranged (85)

Mixed phenotype acute leukemia, B/myeloid, NOS (86)

Mixed phenotype acute leukemia, T/myeloid, NOS (87)

Other acute leukemia of ambiguous lineage or myeloid neoplasm (88)

Specify other acute leukemia of ambiguous lineage or myeloid neoplasm:153

What was the disease status (based on hematological test results)?154

Primary induction failure

1st complete remission (no previous marrow or extramedullary relapse)

2nd complete remission

≥3rd complete remission

1st relapse

2nd relapse

≥3rd relapse

No treatment

Date assessed:155 __ __ __ __ - __ __- __ __

Chronic Myelogenous Leukemia (CML) Questions: 156 - 166

Was therapy given prior to this HCT?

yes no

156

Combination chemotherapy

yes no

157

Hydroxyurea (Droxia, Hydrea)

yes no

158

Tyrosine kinase inhibitor (e.g. imatinib mesylate, dasatinib, nilotinib)

yes no

159

Interferon­α (Intron, Roferon) (includes PEG)

yes no

160

Other therapy

yes no

161

Specify other therapy:162

What was the disease status?163

Complete hematologic response (CHR)

Chronic phase

Accelerated phase

Blast phase

Specify level of response164

No cytogenetic response (No CyR)

Minimal cytogenetic response

Minor cytogenetic response

Partial cytogenetic response (PCyR)

Complete cytogenetic response (CCyR)

Major molecular remission (MMR)

Complete molecular remission (CMR)

Number

1st 2nd 3rd or higher

165

Date assessed:166 __ __ __ __ - __ __- __ __

Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases Questions: 167 - 260

What was the MDS / MPN subtype at diagnosis? - If transformed to AML, indicate AML as primary disease; also complete AML Disease Classification
questions

167

Was the disease (MDS/MPN) therapy related?

yes no Unknown

168

Did the recipient have a predisposing condition?

yes no Unknown

169

Specify condition

Aplastic Anemia Bloom syndrome Down syndrome Fanconi anemia Other condition

170

Specify other condition:171

WBC

Known Unknown

172

173 x 109/L (x 103/mm3)

x 106/L

Hemoglobin

Known Unknown

174

175 g/dL g/L mmol/L

Was RBC transfused ≤ 30 days before date of test?

Yes No

176

Platelets

Known Unknown

177

178 x 109/L (x 103/mm3)

x 106/L

Were platelets transfused ≤ 7 days before date of test?

Yes No

179

Neutrophils

Known Unknown

180

181 %

Blasts in bone marrow

Known Unknown

182

183 %

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

184

Results of tests185

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities186

One (1)

Two (2)

Three (3)

Four or more (4 or more)

–5

yes no

187

-7

yes no

188

–13

yes no

189

–20

yes no

190

–Y

yes no

191

+8

yes no

192

+19

yes no

193

t(1;3)

yes no

194

t(2;11)

yes no

195

t(3;3)

yes no

196

t(3;21)

yes no

197

t(6;9)

yes no

198

t(11;16)

yes no

199

del(3q) / 3q–

yes no

200

del(5q) / 5q-

yes no

201

del(7q) / 7q–

yes no

202

del(9q) / 9q–

yes no

203

del(11q) / 11q–

yes no

204

del(12p) / 12p–

yes no

205

del(13q) / 13q-

yes no

206

del(20q) / 20q–

yes no

207

inv(3)

yes no

208

i17q

yes no

209

Other abnormality

yes no

210

Specify other abnormality:211

Did the recipient progress or transform to a different MDS / MPN subtype between diagnosis and the start of the preparative regimen?

yes no

212

Specify the MDS / MPN classification after transformation:213

Specify the date of the most recent transformation:214 __ __ __ __ - __ __- __ __

Date of MDS diagnosis:215 __ __ __ __ - __ __- __ __

WBC

Known Unknown

216

217 x 109/L (x 103/mm3)

x 106/L

Hemoglobin

Known Unknown

218

219 g/dL g/L mmol/L

Was RBC transfused ≤ 30 days before date of test?

Yes No

220

Platelets

Known Unknown

221

222 x 109/L (x 103/mm3)

x 106/L

Were platelets transfused ≤ 7 days before date of test?

Yes No

223

Neutrophils

Known Unknown

224

225 %

Blasts in bone marrow

Known Unknown

226

227 %

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

228

Results of tests229

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities230

One (1)

Two (2)

Three (3)

Four or more (4 or more)

–5

yes no

231

-7

yes no

232

–13

yes no

233

–20

yes no

234

–Y

yes no

235

+8

yes no

236

+19

yes no

237

t(1;3)

yes no

238

t(2;11)

yes no

239

t(3;3)

yes no

240

t(3;21)

yes no

241

t(6;9)

yes no

242

t(11;16)

yes no

243

del(3q) / 3q–

yes no

244

del(5q) / 5q-

yes no

245

del(7q) / 7q–

yes no

246

del(9q) / 9q–

yes no

247

del(11q) / 11q–

yes no

248

del(12p) / 12p–

yes no

249

del(13q) / 13q-

yes no

250

del(20q) / 20q–

yes no

251

inv(3)

yes no

252

i17q

yes no

253

Other abnormality

yes no

254

Specify other abnormality:255

What was the disease status?256

Complete
remission
(CR)

– requires all of the following, maintained for ≥ 4 weeks: * bone marrow evaluation: <  5% myeloblasts with normal maturation of all cell lines *
peripheral blood evaluation: hemoglobin ≥ 11 g/dL untransfused and without erythropoietin support; ANC ≥ 1000/mm3  without myeloid growth factor
support; platelets ≥ 100 x 109/L without thrombopoietic support; 0% blasts

Hematologic
improvement
(HI)

– requires one measurement of the following, maintained for ≥ 8 weeks without ongoing cytotoxic therapy; specify which cell line was measured to
determine HI response: * HI­E – hemoglobin increase of ≥ 1.5 g/dL untransfused; for RBC transfusions performed for Hgb ≤ 9.0, reduction in RBC
units transfused in 8 weeks by ≥ 4 units compared to the pre­treatment transfusion number in 8 weeks * HI­P – for pre­treatment platelet count of > 20
x 109/L, platelet absolute increase of ≥ 30 x 109/L; for pre-treatment platelet count of < 20 x 109/L, platelet absolute increase of ≥ 20 x 109/L and ≥
100% from pre­treatment level  * HI­N – neutrophil count increase of ≥ 100% from pre­treatment level and an absolute increase of ≥ 500/mm3

No response (NR) / stable disease (SD) – does not meet the criteria for at least HI, but no evidence of disease progression

Progression from
hematologic improvement
(Prog from HI)

– requires at least one of the following, in the absence of another explanation (e.g., infection, bleeding, ongoing chemotherapy, etc.): *
≥ 50% reduction from maximum response levels in granulocytes or platelets * reduction in hemoglobin by ≥ 1.5 g/dL *transfusion
dependence

Relapse from complete
remission (Rel from CR)

– requires at least one of the following: * return to pre­treatment bone marrow blast percentage * decrease of ≥ 50% from maximum
response levels in granulocytes or platelets * transfusion dependence, or hemoglobin level ≥ 1.5 g/dL lower than prior to therapy

Not assessed

Specify the cell line examined to determine HI status257

HI-
E

– hemoglobin increase of ≥ 1.5 g/dL untransfused; for RBC transfusions performed for Hgb ≤ 9.0, reduction in RBC units transfused in 8 weeks by ≥ 4
units compared to the pre-treatment transfusion number in 8 weeks

HI-
P

– for pre­treatment platelet count of > 20 x 109/L, platelet absolute increase of ≥ 30 x 109/L; for pre-treatment platelet count of < 20 x 109/L, platelet
absolute increase of ≥ 20 x 109/L and ≥ 100% from pre­treatment level 

HI-N – neutrophil count increase of ≥ 100% from pre­treatment level and an absolute increase of ≥ 500/mm3

Date of progression:258 __ __ __ __ - __ __- __ __

Date of relapse:259 __ __ __ __ - __ __- __ __

Date assessed:260 __ __ __ __ - __ __- __ __

Other Leukemia (OL) Questions: 261 - 267

Specify the other leukemia classification261

Specify other leukemia:262

Was any 17p abnormality detected?

yes no

263

Did a histologic transformation to diffuse large B-cell lymphoma (Richter syndrome) occur at any time after CLL diagnosis?264

yes - Also complete NHL Disease Classification questions

no

What was the disease status? (Atypical CML)265

Primary induction failure

1st complete remission (no previous bone marrow or extramedullary relapse)

2nd complete remission

≥3rd complete remission

1st relapse

2nd relapse

≥3rd relapse

No treatment

What was the disease status? (CLL, PLL, Hairy cell leukemia)266

Complete remission (CR)

Partial remission (PR)

Stable disease (SD)

Progressive disease (Prog)

Untreated

Not assessed

Date assessed:267 __ __ __ __ - __ __- __ __

Hodgkin and Non-Hodgkin Lymphoma Questions: 268 - 285

Specify the lymphoma histology (at infusion)268

Specify other lymphoma histology:269

Assignment of DLBCL (germinal center B-cell type vs. activated B-cell type) subtype was based on270

Immunohistochemistry (e.g. Han's algorithm)

Gene expression profile

Unknown method

Is the lymphoma histology reported at transplant a transformation from CLL?

yes no

271

Was any 17p abnormality detected?

yes no

272

Is the lymphoma histology reported at transplant a transformation from a different lymphoma histology? (Not CLL)

Yes No

273

Specify the original lymphoma histology (prior to transformation)274

Specify other lymphoma histology:275

Date of original lymphoma diagnosis:276 __ __ __ __ - __ __- __ __ (report the date of diagnosis of original lymphoma subtype)

Was a PET (or PET/CT) scan performed? (at last evaluation prior to the start of the preparative regimen / infusion)

yes no

277

Was the PET (or PET/CT) scan positive for lymphoma involvement at any disease site?

yes no

278

Date of PET scan

Known Unknown

279

Date of PET (or PET/CT) scan:280 __ __ __ __ - __ __- __ __

Deauville (five-point) score of the PET (or PET/CT) scan

Known Unknown

281

Scale282

1 - no uptake or residual uptake

2 - slight uptake, but below blood pool (mediastinum)

3 - uptake above mediastinal, but below or equal to uptake in the liver

4 - uptake slightly to moderately higher than liver

5 - markedly increased uptake or any new lesions

What was the disease status?283

Total number of lines of therapy received

1 line 2 lines 3+ lines

284

Date assessed:285 __ __ __ __ - __ __- __ __

Multiple Myeloma / Plasma Cell Disorder (PCD) Questions: 286 - 317

Specify the multiple myeloma/plasma cell disorder (PCD) classification286

Specify other plasma cell disorder:287

Light chain

kappa lambda

288

What was the Durie-Salmon staging? (at diagnosis)289

Stage
I

(All of the following: Hgb > 10g/dL; serum calcium normal or <10.5 mg/dL; bone x-ray normal bone structure (scale 0), or solitary bone plasmacytoma
only; low M-component production rates IgG< 5g/dL, IgA < 3g/dL; urine light chain M-component on electrophoresis <4 g/24h)

Stage II (Fitting neither Stage I or III) 

Stage
III

(One or more of the following: Hgb < 8.5 g/dL; serum calcium > 12 mg/dL; advanced lytic bone lesions (scale 3); high M-component production rates
IgG > 7g/dL, IgA > 5 g/dL; Bence Jones protein > 12g/24h)

Unknown

What was the Durie-Salmon sub classification? (at diagnosis)290

A - relatively normal renal function (serum creatinine < 2.0 mg/dL)

B ­ abnormal renal function (serum creatinine ≥ 2.0 mg/dL)

Serum β2­microglobulin:291 μg/dL mg/L nmol/L

Serum albumin:292 g/dL g/L

Stage293

1 (β2 ­mic < 3.5, S. albumin ≥3.5)

2 (Not fitting stage 1 or 3)

3 (β2­mic ≥ 5.5; S. albumin ­)

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

294

Results of tests295

Abnormalities identified

No evaluable metaphases

No abnormalities

+3

yes no

296

+5

yes no

297

+7

yes no

298

+9

yes no

299

+11

yes no

300

+15

yes no

301

+19

yes no

302

t(4;14)

yes no

303

t(6;14)

yes no

304

t(11;14)

yes no

305

t(14;16)

yes no

306

t(14;20)

yes no

307

del(13q) / 13q-

yes no

308

del (17p) / 17p-

yes no

309

Hyperdiploid (>50)

yes no

310

Hypodiploid (<46)

yes no

311

Any abnormality at 1q

yes no

312

Any abnormality at 1p

yes no

313

Other abnormality

yes no

314

Specify other abnormality:315

What was the disease status?316

Stringent
complete
remission
(sCR)

- CR as defined, plus: normal free light chain ratio, and absence of clonal cells in the bone marrow by immunohistochemistry of immunofluorescence
(confirmation with repeat bone marrow biopsy not needed). (Presence and/or absence of clonal cells is based upon the Κ/λ ratio. An abnormal Κ/λ ratio by
immunohistochemistry and/or immunofluorescence requires a minimum of 100 plasma cells for analysis.  An abnormal ratio reflecting the presence of
an abnormal clone is Κ/λ of > 4:1 or < 1:2.) sCR requires two consecutive assessments made at any time before the institution of any new therapy, and
no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy sCR
requirements. 

Complete
remission
(CR)

- negative immunofixation on serum and urine samples, and disappearance of any soft tissue plasmacytomas, and < 5% plasma cells in the bone
marrow (confirmation with repeat bone marrow biopsy not needed).  CR requires two consecutive assessments made at any time before the institution
of any new therapy, and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not
required to satisfy CR requirements. 

Near
complete
remission
(nCR)

- serum and urine M-protein detectable by immunoelectrophoresis (IFE), but not on electrophoresis (negative SPEP & UPEP); < 5% plasma cells in
bone marrow.  nCR requires two consecutive assessments made at any time before the initiation of any new therapy, and no known evidence of
progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy nCR requirements. 

Very good
partial
remission
(VGPR)

­ serum and urine M­protein detectable by immunofixation but not on electrophoresis, or ≥ 90% reduction in serum M­protein and urine M­protein level <
100 mg/24 hours.  VGPR requires two consecutive assessments made at any time before the institution of any new therapy, and no known evidence of
progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy VGPR requirements.

Partial
remission
(PR)

­ ≥ 50% reduction in serum M­protein, and reduction in 24­hour urinary M­protein by ≥ 90% or to < 200 mg/24 hours.  If the serum and urine M­protein are
unmeasurable (i.e., do not meet any of the following criteria: • serum M­protein ≥ 1 g/dL.  Urine M­protein ≥ 200 mg/24 hours • serum free light chain
assay shows involved level ≥ 10 mg/dL, provided serum free light chain ratio is abnormal), a ≥ 50% decrease in the difference between involved and
uninvolved free light chain levels is required in place of the M-protein criteria.  If serum and urine M-protein are unmeasurable, and serum free light assay
is also unmeasurable, a ≥ 50% reduction in plasma cells is required in place of M­protein, provided the baseline bone marrow plasma cell percentage
was ≥ 30%. In addition to the above listed criteria, a ≥ 50% reduction in the size of soft tissue plasmacytomas is also required, if present at baseline. PR
requires two consecutive assessments made at any time before the institution of any new therapy, and no known evidence of progressive or new bone
lesions if radiographic studies were performed; radiographic studies are not required to satisfy PR requirements. 

Stable
disease
(SD)

- not meeting the criteria for CR, VGPR, PR or PD.  SD requires two consecutive assessments made at any time before the institution of any new therapy,
and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy SD
requirements.

Progressive
disease
(PD)

­ requires any one or more of the following:  Increase of ≥ 25% from baseline in:  serum M­component and/or (absolute increase ≥ 0.5 g/dL) (for
progressive disease, serum M­component increases of ≥ 1 g/dL are sufficient to define relapse if the starting M­component is ≥ 5 g/dL).  Urine M­
component and/or (absolute increase ≥ 200 mg/24 hours) for recipients without measurable serum and urine M­protein levels: the difference between
involved and uninvolved free light chain levels (absolute increase > 10 mg/dL).  Bone marrow plasma cell percentage (absolute percentage ≥ 10%)
(relapse from CR has a 5% cutoff vs. 10% for other categories of relapse) definite development of new bone lesions or soft tissue plasmacytomas, or
definite increase in the size of any existing  bone lesions or soft tissue plasmacytomas. Development of hypercalcemia (corrected serum calcium >
11.5 mg/dL or 2.65 mmol) that can be attributed solely to the plasma cell proliferative disorder.  PD requires two consecutive assessments made at
any time before classification as disease progression, and/or the institution of any new therapy.

Relapse
from CR
(Rel)
(untreated)

­ requires one or more of the following: reappearance of serum or urine M­protein by immunofixation or electrophoresis development of ≥ 5% plasma
cells in the bone marrow (relapse from CR has a 5% cutoff vs. 10% for other categories of relapse) appearance of any other sign of progression (e.g.,
new plasmacytoma, lytic bone lesion, hypercalcemia).  Rel requires two consecutive assessments made at any time before classification as relapse,
and/or the institution of any new therapy.

Unknown

Not applicable (Amyloidosis with no evidence of myeloma)

Date assessed:317 __ __ __ __ - __ __- __ __

Solid Tumors Questions: 318 - 319

Specify the solid tumor classification318

Specify other solid tumor:319

Severe Aplastic Anemia Questions: 320 - 321

Specify the severe aplastic anemia classification320

Specify other acquired cytopenic syndrome:321

Inherited Abnormalities of Erythrocyte Differentiation or Function Questions: 322 - 324

Specify the inherited abnormalities of erythrocyte differentiation or function classification322

Specify other constitutional anemia:323

Specify other hemoglobinopathy:324

Disorders of the Immune System Questions: 325 - 327

Specify disorder of immune system classification325

Specify other SCID:326

Specify other immunodeficiency:327

Inherited Abnormalities of Platelets Questions: 328 - 329

Specify inherited abnormalities of platelets classification328

Congenital amegakaryocytosis / congenital thrombocytopenia (501)

Glanzmann thrombasthenia (502)

Other inherited platelet abnormality (509)

Specify other inherited platelet abnormality:329

Inherited Disorders of Metabolism Questions: 330 - 331

Specify inherited disorders of metabolism classification330

Specify other inherited metabolic disorder:331

Histiocytic Disorders Questions: 332 - 333

Specify histiocytic disorder classification332

Specify other histiocytic disorder:333

Autoimmune Diseases Questions: 334 - 341

Specify autoimmune disease classification334

Specify other arthritis:335

Specify other juvenile idiopathic arthritis (JIA):336

Specify other connective tissue disease:337

Specify other vasculitis:338

Specify other autoimmune neurological disorder:339

Specify other autoimmune cytopenia:340

Specify other autoimmune bowel disorder:341

Other Disease Questions: 342 - 342

Specify other disease:342

First Name:

Last Name:

E-mail address:

Date: __ __ __ __ - __ __- __ __

OMB No: 0915-0310

Expiration Date: 1/31/2020

Public Burden Statement:  An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control
number.  The OMB control number for this project is 0915-0310.  Public reporting burden for this collection of information is estimated to average 1.0 hours per response, including the

time for reviewing instructions, searching existing data sources, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other
aspect of this collection of information, including suggestions for reducing this burden, to HRSA Reports Clearance Officer, 5600 Fishers Lane, Room 10-29, Rockville, Maryland, 20857.

Labs at diagnosis

Specify cytogenetic abnormalities identified at diagnosis:

Specify cytogenetic abnormalities identified at diagnosis:

Specify molecular markers identified at diagnosis:

Labs between diagnosis and last evaluation:

Specify cytogenetic abnormalities identified between diagnosis and last evaluation:

Specify cytogenetic abnormalities identified between diagnosis and last evaluation:

Specify molecular markers identified between diagnosis and last evaluation:

Labs at last evaluation:

Specify cytogenetic abnormalities identified at last evaluation:

Specify cytogenetic abnormalities identified at last evaluation:

Specify molecular markers identified at last evaluation:

CNS Leukemia

Status at transplantation:

Laboratory studies at diagnosis:

Specify cytogenetic abnormalities identified at diagnosis:

Specify cytogenetic abnormalities identified at diagnosis:

Specify molecular markers identified at diagnosis:

Laboratory studies between diagnosis and last evaluation:

Specify cytogenetic abnormalities identified between diagnosis and last evaluation:

Specify cytogenetic abnormalities identified between diagnosis and last evaluation:

Specify molecular markers identified between diagnosis and last evaluation:

Laboratory studies at last evaluation:

Specify cytogenetic abnormalities identified at last evaluation:

Specify cytogenetic abnormalities identified at last evaluation:

Specify molecular markers identified at last evaluation:

CNS Leukemia

Status at transplantation:

Status at transplantation:

Laboratory studies at diagnosis of MDS:

Specify abnormalities identified at diagnosis:

Monosomy

Trisomy

Translocation

Deletion

Inversion

Other

Laboratory studies at last evaluation prior to the start of the preparative regimen:

Specify cytogenetic abnormalities identified at last evaluation prior to the start of the preparative regimen:

Monosomy

Trisomy

Translocation

Deletion

Inversion

Other

Status at transplantation:

Status at transplantation:

Status at transplantation / infusion:

I.S.S.:

Specify cytogenetic abnormalities identified at any time prior to the start of the preparative regimen:

Trisomy

Translocation

Deletion

Other

Status at transplantation:

Center: CRID: 

Form 2402 R3.0: Disease Classification

CIBMTR Form 2402 revision 3.0 last updated Monday, January 29, 2018
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 19 / 26



Key Fields

Sequence Number:

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number:

CIBMTR Research ID:

Event date: __ __ __ __ - __ __- __ __

Primary Disease for HCT / Cellular Therapy Questions: 1 - 2

Date of diagnosis of primary disease for HCT / cellular therapy:1 __ __ __ __ - __ __- __ __

What was the primary disease for which the HCT / cellular therapy was performed?2

Acute myelogenous leukemia (AML or ANLL) (10)

Acute lymphoblastic leukemia (ALL) (20)

Acute leukemia of ambiguous lineage and other myeloid neoplasms (80)

Chronic myelogenous leukemia (CML) (40)

Myelodysplastic (MDS) / myeloproliferative (MPN) diseases (50) (Please classify all preleukemias) (If recipient has transformed to AML, indicate AML as the primary disease)

Other leukemia (30) (includes CLL)

Hodgkin lymphoma (150)

Non-Hodgkin lymphoma (100)

Multiple myeloma / plasma cell disorder (PCD) (170)

Solid tumors (200)

Severe aplastic anemia (300) (If the recipient developed MDS or AML, indicate MDS or AML as the primary disease)

Inherited abnormalities of erythrocyte differentiation or function (310)

Disorders of the immune system (400)

Inherited abnormalities of platelets (500)

Inherited disorders of metabolism (520)

Histiocytic disorders (570)

Autoimmune diseases (600)

Other disease (900)

Acute Myelogenous Leukemia (AML) Questions: 3 - 89

Specify the AML classification3

Did AML transform from MDS or MPN?4

yes - Also complete MDS Disease Classification questions

no

Is the disease (AML) therapy related?

yes no Unknown

5

Did the recipient have a predisposing condition?

yes no Unknown

6

Specify condition7

Bloom syndrome

Down syndrome

Fanconi anemia

Dyskeratosis congenita

Other condition

Specify other condition:8

Were cytogenetics tested (karyotyping or FISH)? (at diagnosis)

yes no Unknown

9

Were cytogenetics tested via FISH? (at diagnosis)

Yes No

10

Results of tests11

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities12

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

13

Specify other abnormality:14

Were cytogenetics tested via karyotyping? (at diagnosis)

Yes No

15

Results of tests16

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities17

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

18

Specify other abnormality:19

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

20

Were tests for molecular markers performed? (e.g. PCR, NGS) (at diagnosis)

yes no Unknown

21

CEBPA

Positive Negative Not Done

22

Specify CEBPA mutation23

Biallelic (homozygous)

Monoallelic (heterozygous)

Unknown

FLT3 – D835 point mutation

Positive Negative Not Done

24

FLT3 – ITD mutation

Positive Negative Not Done

25

FLT3 - ITD allelic ratio

Known Unknown

26

Specify FLT3 - ITD allelic ratio:27

IDH1

Positive Negative Not Done

28

IDH2

Positive Negative Not Done

29

KIT

Positive Negative Not Done

30

NPM1

Positive Negative Not Done

31

Other Molecular Marker (1) Questions: 32 - 33

Other molecular marker

Positive Negative Not Done

32

Specify other molecular marker:33

Were cytogenetics tested (karyotyping or FISH)? (between diagnosis and last evaluation)

yes no Unknown

34

Were cytogenetics tested via FISH? (between diagnosis and last evaluation)

Yes No

35

Results of tests36

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities37

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

38

Specify other abnormality:39

Were cytogenetics tested via karyotyping? (between diagnosis and last evaluation)

Yes No

40

Results of tests41

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities42

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

43

Specify other abnormality:44

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

45

Were tests for molecular markers performed? (e.g. PCR, NGS) (between diagnosis and last evaluation)

yes no Unknown

46

CEBPA

Positive Negative Not Done

47

Specify CEBPA mutation48

Biallelic (homozygous)

Monoallelic (heterozygous)

Unknown

FLT3 – D835 point mutation

Positive Negative Not Done

49

FLT3 – ITD mutation

Positive Negative Not Done

50

FLT3 - ITD allelic ratio

Known Unknown

51

Specify FLT3 - ITD allelic ratio:52

IDH1

Positive Negative Not Done

53

IDH2

Positive Negative Not Done

54

KIT

Positive Negative Not Done

55

NPM1

Positive Negative Not Done

56

Other Molecular Marker (1) Questions: 57 - 58

Other molecular marker

Positive Negative Not Done

57

Specify other molecular marker:58

Were cytogenetics tested (karyotyping or FISH)? (at last evaluation)

yes no Unknown

59

Were cytogenetics tested via FISH? (at last evaluation)

Yes No

60

Results of tests61

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities62

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

63

Specify other abnormality:64

Were cytogenetics tested via karyotyping? (at last evaluation)

Yes No

65

Results of tests66

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities67

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

68

Specify other abnormality:69

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

70

Were tests for molecular markers performed? (e.g. PCR, NGS) (at last evaluation)

yes no Unknown

71

CEBPA

Positive Negative Not Done

72

Specify CEBPA mutation73

Biallelic (homozygous)

Monoallelic (heterozygous)

Unknown

FLT3 – D835 point mutation

Positive Negative Not Done

74

FLT3 – ITD mutation

Positive Negative Not Done

75

FLT3 - ITD allelic ratio

Known Unknown

76

Specify FLT3 - ITD allelic ratio:77

IDH1

Positive Negative Not Done

78

IDH2

Positive Negative Not Done

79

KIT

Positive Negative Not Done

80

NPM1

Positive Negative Not Done

81

Other Molecular Marker (1) Questions: 82 - 83

Other molecular marker

Positive Negative Not Done

82

Specify other molecular marker:83

Did the recipient have central nervous system leukemia at any time prior to the start of the preparative regimen / infusion?

yes no Unknown

84

What was the disease status (based on hematological test results)?85

Primary induction failure

1st complete remission (no previous bone marrow or extramedullary relapse) (include CRi)

2nd complete remission

≥3rd complete remission

1st relapse

2nd relapse

≥3rd relapse

No treatment

How many cycles of induction therapy were required to achieve 1st complete remission? (includes CRi)

1 2 ≥ 3

86

Was the recipient in remission by flow cytometry?

Yes No Unknown Not applicable

87

Date of most recent relapse:88 __ __ __ __ - __ __- __ __

Date assessed:89 __ __ __ __ - __ __- __ __

Acute Lymphoblastic Leukemia (ALL) Questions: 90 - 151

Specify ALL classification90

Did the recipient have a predisposing condition?

yes no Unknown

91

Specify condition92

Aplastic anemia - Also complete CIBMTR Form 2028 - APL

Bloom syndrome

Down syndrome

Fanconi anemia - Also complete CIBMTR Form 2029 - FAN

Other condition

Specify other condition:93

Were tyrosine kinase inhibitors given for therapy at any time prior to the start of the preparative regimen / infusion? (e.g. imatinib mesylate, dasatinib, etc.)

yes no

94

Were cytogenetics tested (karyotyping or FISH)? (at diagnosis)

yes no Unknown

95

Were cytogenetics tested via FISH? (at diagnosis)

Yes No

96

Results of tests97

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities98

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

99

Specify other abnormality:100

Were cytogenetics tested via karyotyping? (at diagnosis)

Yes No

101

Results of tests102

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities103

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

104

Specify other abnormality:105

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

106

Were tests for molecular markers performed? (e.g. PCR, NGS) (at diagnosis)

yes no Unknown

107

BCR / ABL

Positive Negative Not Done

108

TEL-AML / AML1

Positive Negative Not Done

109

Other Molecular Marker (1) Questions: 110 - 111

Other molecular marker

Positive Negative Not Done

110

Specify other molecular marker:111

Were cytogenetics tested (karyotyping or FISH)? (between diagnosis and last evaluation)

yes no Unknown

112

Were cytogenetics tested via FISH? (between diagnosis and last evaluation)

Yes No

113

Results of tests114

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities115

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

116

Specify other abnormality:117

Were cytogenetics tested via karyotyping? (between diagnosis and last evaluation)

Yes No

118

Results of tests119

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities120

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

121

Specify other abnormality:122

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

123

Were tests for molecular markers performed? (e.g. PCR, NGS) (between diagnosis and last evaluation)

yes no Unknown

124

BCR / ABL

Positive Negative Not Done

125

TEL-AML / AML1

Positive Negative Not Done

126

Other Molecular Marker (1) Questions: 127 - 128

Other molecular marker

Positive Negative Not Done

127

Specify other molecular marker:128

Were cytogenetics tested (karyotyping or FISH)? (at last evaluation)

yes no Unknown

129

Were cytogenetics tested via FISH? (at last evaluation)

Yes No

130

Results of tests131

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities132

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

133

Specify other abnormality:134

Were cytogenetics tested via karyotyping? (at last evaluation)

Yes No

135

Results of tests136

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities137

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

138

Specify other abnormality:139

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

140

Were tests for molecular markers performed? (e.g. PCR, NGS) (at last evaluation)

yes no Unknown

141

BCR / ABL

Positive Negative Not Done

142

TEL-AML / AML1

Positive Negative Not Done

143

Other Molecular Marker (1) Questions: 144 - 145

Other molecular marker

Positive Negative Not Done

144

Specify other molecular marker:145

Did the recipient have central nervous system leukemia at any time prior to the start of the preparative regimen / infusion?

yes no Unknown

146

What was the disease status (based on hematological test results)?147

Primary induction failure

1st complete remission (no previous marrow or extramedullary relapse) (include CRi)

2nd complete remission

≥3rd complete remission

1st relapse

2nd relapse

≥3rd relapse

No treatment

How many cycles of induction therapy were required to achieve 1st complete remission? (include CRi)

1 2 ≥ 3

148

Was the recipient in remission by flow cytometry?

Yes No Unknown Not applicable

149

Date of most recent relapse:150 __ __ __ __ - __ __- __ __

Date assessed:151 __ __ __ __ - __ __- __ __

Acute Leukemias of Ambiguous Lineage and Other Myeloid Neoplasms Questions: 152 - 155

Specify acute leukemias of ambiguous lineage and other myeloid neoplasm classification152

Blastic plasmacytoid dendritic cell neoplasm (296)

Acute undifferentiated leukemia (31)

Mixed phenotype acute leukemia (MPAL) with t(9;22)(q34.1;q11.2); BCR-ABL1 (84)

Mixed phenotype acute leukemia with t(v; 11q23.3); KMT2A rearranged (85)

Mixed phenotype acute leukemia, B/myeloid, NOS (86)

Mixed phenotype acute leukemia, T/myeloid, NOS (87)

Other acute leukemia of ambiguous lineage or myeloid neoplasm (88)

Specify other acute leukemia of ambiguous lineage or myeloid neoplasm:153

What was the disease status (based on hematological test results)?154

Primary induction failure

1st complete remission (no previous marrow or extramedullary relapse)

2nd complete remission

≥3rd complete remission

1st relapse

2nd relapse

≥3rd relapse

No treatment

Date assessed:155 __ __ __ __ - __ __- __ __

Chronic Myelogenous Leukemia (CML) Questions: 156 - 166

Was therapy given prior to this HCT?

yes no

156

Combination chemotherapy

yes no

157

Hydroxyurea (Droxia, Hydrea)

yes no

158

Tyrosine kinase inhibitor (e.g. imatinib mesylate, dasatinib, nilotinib)

yes no

159

Interferon­α (Intron, Roferon) (includes PEG)

yes no

160

Other therapy

yes no

161

Specify other therapy:162

What was the disease status?163

Complete hematologic response (CHR)

Chronic phase

Accelerated phase

Blast phase

Specify level of response164

No cytogenetic response (No CyR)

Minimal cytogenetic response

Minor cytogenetic response

Partial cytogenetic response (PCyR)

Complete cytogenetic response (CCyR)

Major molecular remission (MMR)

Complete molecular remission (CMR)

Number

1st 2nd 3rd or higher

165

Date assessed:166 __ __ __ __ - __ __- __ __

Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases Questions: 167 - 260

What was the MDS / MPN subtype at diagnosis? - If transformed to AML, indicate AML as primary disease; also complete AML Disease Classification
questions

167

Was the disease (MDS/MPN) therapy related?

yes no Unknown

168

Did the recipient have a predisposing condition?

yes no Unknown

169

Specify condition

Aplastic Anemia Bloom syndrome Down syndrome Fanconi anemia Other condition

170

Specify other condition:171

WBC

Known Unknown

172

173 x 109/L (x 103/mm3)

x 106/L

Hemoglobin

Known Unknown

174

175 g/dL g/L mmol/L

Was RBC transfused ≤ 30 days before date of test?

Yes No

176

Platelets

Known Unknown

177

178 x 109/L (x 103/mm3)

x 106/L

Were platelets transfused ≤ 7 days before date of test?

Yes No

179

Neutrophils

Known Unknown

180

181 %

Blasts in bone marrow

Known Unknown

182

183 %

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

184

Results of tests185

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities186

One (1)

Two (2)

Three (3)

Four or more (4 or more)

–5

yes no

187

-7

yes no

188

–13

yes no

189

–20

yes no

190

–Y

yes no

191

+8

yes no

192

+19

yes no

193

t(1;3)

yes no

194

t(2;11)

yes no

195

t(3;3)

yes no

196

t(3;21)

yes no

197

t(6;9)

yes no

198

t(11;16)

yes no

199

del(3q) / 3q–

yes no

200

del(5q) / 5q-

yes no

201

del(7q) / 7q–

yes no

202

del(9q) / 9q–

yes no

203

del(11q) / 11q–

yes no

204

del(12p) / 12p–

yes no

205

del(13q) / 13q-

yes no

206

del(20q) / 20q–

yes no

207

inv(3)

yes no

208

i17q

yes no

209

Other abnormality

yes no

210

Specify other abnormality:211

Did the recipient progress or transform to a different MDS / MPN subtype between diagnosis and the start of the preparative regimen?

yes no

212

Specify the MDS / MPN classification after transformation:213

Specify the date of the most recent transformation:214 __ __ __ __ - __ __- __ __

Date of MDS diagnosis:215 __ __ __ __ - __ __- __ __

WBC

Known Unknown

216

217 x 109/L (x 103/mm3)

x 106/L

Hemoglobin

Known Unknown

218

219 g/dL g/L mmol/L

Was RBC transfused ≤ 30 days before date of test?

Yes No

220

Platelets

Known Unknown

221

222 x 109/L (x 103/mm3)

x 106/L

Were platelets transfused ≤ 7 days before date of test?

Yes No

223

Neutrophils

Known Unknown

224

225 %

Blasts in bone marrow

Known Unknown

226

227 %

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

228

Results of tests229

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities230

One (1)

Two (2)

Three (3)

Four or more (4 or more)

–5

yes no

231

-7

yes no

232

–13

yes no

233

–20

yes no

234

–Y

yes no

235

+8

yes no

236

+19

yes no

237

t(1;3)

yes no

238

t(2;11)

yes no

239

t(3;3)

yes no

240

t(3;21)

yes no

241

t(6;9)

yes no

242

t(11;16)

yes no

243

del(3q) / 3q–

yes no

244

del(5q) / 5q-

yes no

245

del(7q) / 7q–

yes no

246

del(9q) / 9q–

yes no

247

del(11q) / 11q–

yes no

248

del(12p) / 12p–

yes no

249

del(13q) / 13q-

yes no

250

del(20q) / 20q–

yes no

251

inv(3)

yes no

252

i17q

yes no

253

Other abnormality

yes no

254

Specify other abnormality:255

What was the disease status?256

Complete
remission
(CR)

– requires all of the following, maintained for ≥ 4 weeks: * bone marrow evaluation: <  5% myeloblasts with normal maturation of all cell lines *
peripheral blood evaluation: hemoglobin ≥ 11 g/dL untransfused and without erythropoietin support; ANC ≥ 1000/mm3  without myeloid growth factor
support; platelets ≥ 100 x 109/L without thrombopoietic support; 0% blasts

Hematologic
improvement
(HI)

– requires one measurement of the following, maintained for ≥ 8 weeks without ongoing cytotoxic therapy; specify which cell line was measured to
determine HI response: * HI­E – hemoglobin increase of ≥ 1.5 g/dL untransfused; for RBC transfusions performed for Hgb ≤ 9.0, reduction in RBC
units transfused in 8 weeks by ≥ 4 units compared to the pre­treatment transfusion number in 8 weeks * HI­P – for pre­treatment platelet count of > 20
x 109/L, platelet absolute increase of ≥ 30 x 109/L; for pre-treatment platelet count of < 20 x 109/L, platelet absolute increase of ≥ 20 x 109/L and ≥
100% from pre­treatment level  * HI­N – neutrophil count increase of ≥ 100% from pre­treatment level and an absolute increase of ≥ 500/mm3

No response (NR) / stable disease (SD) – does not meet the criteria for at least HI, but no evidence of disease progression

Progression from
hematologic improvement
(Prog from HI)

– requires at least one of the following, in the absence of another explanation (e.g., infection, bleeding, ongoing chemotherapy, etc.): *
≥ 50% reduction from maximum response levels in granulocytes or platelets * reduction in hemoglobin by ≥ 1.5 g/dL *transfusion
dependence

Relapse from complete
remission (Rel from CR)

– requires at least one of the following: * return to pre­treatment bone marrow blast percentage * decrease of ≥ 50% from maximum
response levels in granulocytes or platelets * transfusion dependence, or hemoglobin level ≥ 1.5 g/dL lower than prior to therapy

Not assessed

Specify the cell line examined to determine HI status257

HI-
E

– hemoglobin increase of ≥ 1.5 g/dL untransfused; for RBC transfusions performed for Hgb ≤ 9.0, reduction in RBC units transfused in 8 weeks by ≥ 4
units compared to the pre-treatment transfusion number in 8 weeks

HI-
P

– for pre­treatment platelet count of > 20 x 109/L, platelet absolute increase of ≥ 30 x 109/L; for pre-treatment platelet count of < 20 x 109/L, platelet
absolute increase of ≥ 20 x 109/L and ≥ 100% from pre­treatment level 

HI-N – neutrophil count increase of ≥ 100% from pre­treatment level and an absolute increase of ≥ 500/mm3

Date of progression:258 __ __ __ __ - __ __- __ __

Date of relapse:259 __ __ __ __ - __ __- __ __

Date assessed:260 __ __ __ __ - __ __- __ __

Other Leukemia (OL) Questions: 261 - 267

Specify the other leukemia classification261

Specify other leukemia:262

Was any 17p abnormality detected?

yes no

263

Did a histologic transformation to diffuse large B-cell lymphoma (Richter syndrome) occur at any time after CLL diagnosis?264

yes - Also complete NHL Disease Classification questions

no

What was the disease status? (Atypical CML)265

Primary induction failure

1st complete remission (no previous bone marrow or extramedullary relapse)

2nd complete remission

≥3rd complete remission

1st relapse

2nd relapse

≥3rd relapse

No treatment

What was the disease status? (CLL, PLL, Hairy cell leukemia)266

Complete remission (CR)

Partial remission (PR)

Stable disease (SD)

Progressive disease (Prog)

Untreated

Not assessed

Date assessed:267 __ __ __ __ - __ __- __ __

Hodgkin and Non-Hodgkin Lymphoma Questions: 268 - 285

Specify the lymphoma histology (at infusion)268

Specify other lymphoma histology:269

Assignment of DLBCL (germinal center B-cell type vs. activated B-cell type) subtype was based on270

Immunohistochemistry (e.g. Han's algorithm)

Gene expression profile

Unknown method

Is the lymphoma histology reported at transplant a transformation from CLL?

yes no

271

Was any 17p abnormality detected?

yes no

272

Is the lymphoma histology reported at transplant a transformation from a different lymphoma histology? (Not CLL)

Yes No

273

Specify the original lymphoma histology (prior to transformation)274

Specify other lymphoma histology:275

Date of original lymphoma diagnosis:276 __ __ __ __ - __ __- __ __ (report the date of diagnosis of original lymphoma subtype)

Was a PET (or PET/CT) scan performed? (at last evaluation prior to the start of the preparative regimen / infusion)

yes no

277

Was the PET (or PET/CT) scan positive for lymphoma involvement at any disease site?

yes no

278

Date of PET scan

Known Unknown

279

Date of PET (or PET/CT) scan:280 __ __ __ __ - __ __- __ __

Deauville (five-point) score of the PET (or PET/CT) scan

Known Unknown

281

Scale282

1 - no uptake or residual uptake

2 - slight uptake, but below blood pool (mediastinum)

3 - uptake above mediastinal, but below or equal to uptake in the liver

4 - uptake slightly to moderately higher than liver

5 - markedly increased uptake or any new lesions

What was the disease status?283

Total number of lines of therapy received

1 line 2 lines 3+ lines

284

Date assessed:285 __ __ __ __ - __ __- __ __

Multiple Myeloma / Plasma Cell Disorder (PCD) Questions: 286 - 317

Specify the multiple myeloma/plasma cell disorder (PCD) classification286

Specify other plasma cell disorder:287

Light chain

kappa lambda

288

What was the Durie-Salmon staging? (at diagnosis)289

Stage
I

(All of the following: Hgb > 10g/dL; serum calcium normal or <10.5 mg/dL; bone x-ray normal bone structure (scale 0), or solitary bone plasmacytoma
only; low M-component production rates IgG< 5g/dL, IgA < 3g/dL; urine light chain M-component on electrophoresis <4 g/24h)

Stage II (Fitting neither Stage I or III) 

Stage
III

(One or more of the following: Hgb < 8.5 g/dL; serum calcium > 12 mg/dL; advanced lytic bone lesions (scale 3); high M-component production rates
IgG > 7g/dL, IgA > 5 g/dL; Bence Jones protein > 12g/24h)

Unknown

What was the Durie-Salmon sub classification? (at diagnosis)290

A - relatively normal renal function (serum creatinine < 2.0 mg/dL)

B ­ abnormal renal function (serum creatinine ≥ 2.0 mg/dL)

Serum β2­microglobulin:291 μg/dL mg/L nmol/L

Serum albumin:292 g/dL g/L

Stage293

1 (β2 ­mic < 3.5, S. albumin ≥3.5)

2 (Not fitting stage 1 or 3)

3 (β2­mic ≥ 5.5; S. albumin ­)

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

294

Results of tests295

Abnormalities identified

No evaluable metaphases

No abnormalities

+3

yes no

296

+5

yes no

297

+7

yes no

298

+9

yes no

299

+11

yes no

300

+15

yes no

301

+19

yes no

302

t(4;14)

yes no

303

t(6;14)

yes no

304

t(11;14)

yes no

305

t(14;16)

yes no

306

t(14;20)

yes no

307

del(13q) / 13q-

yes no

308

del (17p) / 17p-

yes no

309

Hyperdiploid (>50)

yes no

310

Hypodiploid (<46)

yes no

311

Any abnormality at 1q

yes no

312

Any abnormality at 1p

yes no

313

Other abnormality

yes no

314

Specify other abnormality:315

What was the disease status?316

Stringent
complete
remission
(sCR)

- CR as defined, plus: normal free light chain ratio, and absence of clonal cells in the bone marrow by immunohistochemistry of immunofluorescence
(confirmation with repeat bone marrow biopsy not needed). (Presence and/or absence of clonal cells is based upon the Κ/λ ratio. An abnormal Κ/λ ratio by
immunohistochemistry and/or immunofluorescence requires a minimum of 100 plasma cells for analysis.  An abnormal ratio reflecting the presence of
an abnormal clone is Κ/λ of > 4:1 or < 1:2.) sCR requires two consecutive assessments made at any time before the institution of any new therapy, and
no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy sCR
requirements. 

Complete
remission
(CR)

- negative immunofixation on serum and urine samples, and disappearance of any soft tissue plasmacytomas, and < 5% plasma cells in the bone
marrow (confirmation with repeat bone marrow biopsy not needed).  CR requires two consecutive assessments made at any time before the institution
of any new therapy, and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not
required to satisfy CR requirements. 

Near
complete
remission
(nCR)

- serum and urine M-protein detectable by immunoelectrophoresis (IFE), but not on electrophoresis (negative SPEP & UPEP); < 5% plasma cells in
bone marrow.  nCR requires two consecutive assessments made at any time before the initiation of any new therapy, and no known evidence of
progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy nCR requirements. 

Very good
partial
remission
(VGPR)

­ serum and urine M­protein detectable by immunofixation but not on electrophoresis, or ≥ 90% reduction in serum M­protein and urine M­protein level <
100 mg/24 hours.  VGPR requires two consecutive assessments made at any time before the institution of any new therapy, and no known evidence of
progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy VGPR requirements.

Partial
remission
(PR)

­ ≥ 50% reduction in serum M­protein, and reduction in 24­hour urinary M­protein by ≥ 90% or to < 200 mg/24 hours.  If the serum and urine M­protein are
unmeasurable (i.e., do not meet any of the following criteria: • serum M­protein ≥ 1 g/dL.  Urine M­protein ≥ 200 mg/24 hours • serum free light chain
assay shows involved level ≥ 10 mg/dL, provided serum free light chain ratio is abnormal), a ≥ 50% decrease in the difference between involved and
uninvolved free light chain levels is required in place of the M-protein criteria.  If serum and urine M-protein are unmeasurable, and serum free light assay

is also unmeasurable, a ≥ 50% reduction in plasma cells is required in place of M­protein, provided the baseline bone marrow plasma cell percentage
was ≥ 30%. In addition to the above listed criteria, a ≥ 50% reduction in the size of soft tissue plasmacytomas is also required, if present at baseline. PR
requires two consecutive assessments made at any time before the institution of any new therapy, and no known evidence of progressive or new bone
lesions if radiographic studies were performed; radiographic studies are not required to satisfy PR requirements. 

Stable
disease
(SD)

- not meeting the criteria for CR, VGPR, PR or PD.  SD requires two consecutive assessments made at any time before the institution of any new therapy,
and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy SD
requirements.

Progressive
disease
(PD)

­ requires any one or more of the following:  Increase of ≥ 25% from baseline in:  serum M­component and/or (absolute increase ≥ 0.5 g/dL) (for
progressive disease, serum M­component increases of ≥ 1 g/dL are sufficient to define relapse if the starting M­component is ≥ 5 g/dL).  Urine M­
component and/or (absolute increase ≥ 200 mg/24 hours) for recipients without measurable serum and urine M­protein levels: the difference between
involved and uninvolved free light chain levels (absolute increase > 10 mg/dL).  Bone marrow plasma cell percentage (absolute percentage ≥ 10%)
(relapse from CR has a 5% cutoff vs. 10% for other categories of relapse) definite development of new bone lesions or soft tissue plasmacytomas, or
definite increase in the size of any existing  bone lesions or soft tissue plasmacytomas. Development of hypercalcemia (corrected serum calcium >
11.5 mg/dL or 2.65 mmol) that can be attributed solely to the plasma cell proliferative disorder.  PD requires two consecutive assessments made at
any time before classification as disease progression, and/or the institution of any new therapy.

Relapse
from CR
(Rel)
(untreated)

­ requires one or more of the following: reappearance of serum or urine M­protein by immunofixation or electrophoresis development of ≥ 5% plasma
cells in the bone marrow (relapse from CR has a 5% cutoff vs. 10% for other categories of relapse) appearance of any other sign of progression (e.g.,
new plasmacytoma, lytic bone lesion, hypercalcemia).  Rel requires two consecutive assessments made at any time before classification as relapse,
and/or the institution of any new therapy.

Unknown

Not applicable (Amyloidosis with no evidence of myeloma)

Date assessed:317 __ __ __ __ - __ __- __ __

Solid Tumors Questions: 318 - 319

Specify the solid tumor classification318

Specify other solid tumor:319

Severe Aplastic Anemia Questions: 320 - 321

Specify the severe aplastic anemia classification320

Specify other acquired cytopenic syndrome:321

Inherited Abnormalities of Erythrocyte Differentiation or Function Questions: 322 - 324

Specify the inherited abnormalities of erythrocyte differentiation or function classification322

Specify other constitutional anemia:323

Specify other hemoglobinopathy:324

Disorders of the Immune System Questions: 325 - 327

Specify disorder of immune system classification325

Specify other SCID:326

Specify other immunodeficiency:327

Inherited Abnormalities of Platelets Questions: 328 - 329

Specify inherited abnormalities of platelets classification328

Congenital amegakaryocytosis / congenital thrombocytopenia (501)

Glanzmann thrombasthenia (502)

Other inherited platelet abnormality (509)

Specify other inherited platelet abnormality:329

Inherited Disorders of Metabolism Questions: 330 - 331

Specify inherited disorders of metabolism classification330

Specify other inherited metabolic disorder:331

Histiocytic Disorders Questions: 332 - 333

Specify histiocytic disorder classification332

Specify other histiocytic disorder:333

Autoimmune Diseases Questions: 334 - 341

Specify autoimmune disease classification334

Specify other arthritis:335

Specify other juvenile idiopathic arthritis (JIA):336

Specify other connective tissue disease:337

Specify other vasculitis:338

Specify other autoimmune neurological disorder:339

Specify other autoimmune cytopenia:340

Specify other autoimmune bowel disorder:341

Other Disease Questions: 342 - 342

Specify other disease:342

First Name:

Last Name:

E-mail address:

Date: __ __ __ __ - __ __- __ __

OMB No: 0915-0310

Expiration Date: 1/31/2020

Public Burden Statement:  An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control
number.  The OMB control number for this project is 0915-0310.  Public reporting burden for this collection of information is estimated to average 1.0 hours per response, including the
time for reviewing instructions, searching existing data sources, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other
aspect of this collection of information, including suggestions for reducing this burden, to HRSA Reports Clearance Officer, 5600 Fishers Lane, Room 10-29, Rockville, Maryland, 20857.

Labs at diagnosis

Specify cytogenetic abnormalities identified at diagnosis:

Specify cytogenetic abnormalities identified at diagnosis:

Specify molecular markers identified at diagnosis:

Labs between diagnosis and last evaluation:

Specify cytogenetic abnormalities identified between diagnosis and last evaluation:

Specify cytogenetic abnormalities identified between diagnosis and last evaluation:

Specify molecular markers identified between diagnosis and last evaluation:

Labs at last evaluation:

Specify cytogenetic abnormalities identified at last evaluation:

Specify cytogenetic abnormalities identified at last evaluation:

Specify molecular markers identified at last evaluation:

CNS Leukemia

Status at transplantation:

Laboratory studies at diagnosis:

Specify cytogenetic abnormalities identified at diagnosis:

Specify cytogenetic abnormalities identified at diagnosis:

Specify molecular markers identified at diagnosis:

Laboratory studies between diagnosis and last evaluation:

Specify cytogenetic abnormalities identified between diagnosis and last evaluation:

Specify cytogenetic abnormalities identified between diagnosis and last evaluation:

Specify molecular markers identified between diagnosis and last evaluation:

Laboratory studies at last evaluation:

Specify cytogenetic abnormalities identified at last evaluation:

Specify cytogenetic abnormalities identified at last evaluation:

Specify molecular markers identified at last evaluation:

CNS Leukemia

Status at transplantation:

Status at transplantation:

Laboratory studies at diagnosis of MDS:

Specify abnormalities identified at diagnosis:

Monosomy

Trisomy

Translocation

Deletion

Inversion

Other

Laboratory studies at last evaluation prior to the start of the preparative regimen:

Specify cytogenetic abnormalities identified at last evaluation prior to the start of the preparative regimen:

Monosomy

Trisomy

Translocation

Deletion

Inversion

Other

Status at transplantation:

Status at transplantation:

Status at transplantation / infusion:

I.S.S.:

Specify cytogenetic abnormalities identified at any time prior to the start of the preparative regimen:

Trisomy

Translocation

Deletion

Other

Status at transplantation:

Center: CRID: 

Form 2402 R3.0: Disease Classification

CIBMTR Form 2402 revision 3.0 last updated Monday, January 29, 2018
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 20 / 26



Key Fields

Sequence Number:

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number:

CIBMTR Research ID:

Event date: __ __ __ __ - __ __- __ __

Primary Disease for HCT / Cellular Therapy Questions: 1 - 2

Date of diagnosis of primary disease for HCT / cellular therapy:1 __ __ __ __ - __ __- __ __

What was the primary disease for which the HCT / cellular therapy was performed?2

Acute myelogenous leukemia (AML or ANLL) (10)

Acute lymphoblastic leukemia (ALL) (20)

Acute leukemia of ambiguous lineage and other myeloid neoplasms (80)

Chronic myelogenous leukemia (CML) (40)

Myelodysplastic (MDS) / myeloproliferative (MPN) diseases (50) (Please classify all preleukemias) (If recipient has transformed to AML, indicate AML as the primary disease)

Other leukemia (30) (includes CLL)

Hodgkin lymphoma (150)

Non-Hodgkin lymphoma (100)

Multiple myeloma / plasma cell disorder (PCD) (170)

Solid tumors (200)

Severe aplastic anemia (300) (If the recipient developed MDS or AML, indicate MDS or AML as the primary disease)

Inherited abnormalities of erythrocyte differentiation or function (310)

Disorders of the immune system (400)

Inherited abnormalities of platelets (500)

Inherited disorders of metabolism (520)

Histiocytic disorders (570)

Autoimmune diseases (600)

Other disease (900)

Acute Myelogenous Leukemia (AML) Questions: 3 - 89

Specify the AML classification3

Did AML transform from MDS or MPN?4

yes - Also complete MDS Disease Classification questions

no

Is the disease (AML) therapy related?

yes no Unknown

5

Did the recipient have a predisposing condition?

yes no Unknown

6

Specify condition7

Bloom syndrome

Down syndrome

Fanconi anemia

Dyskeratosis congenita

Other condition

Specify other condition:8

Were cytogenetics tested (karyotyping or FISH)? (at diagnosis)

yes no Unknown

9

Were cytogenetics tested via FISH? (at diagnosis)

Yes No

10

Results of tests11

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities12

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

13

Specify other abnormality:14

Were cytogenetics tested via karyotyping? (at diagnosis)

Yes No

15

Results of tests16

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities17

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

18

Specify other abnormality:19

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

20

Were tests for molecular markers performed? (e.g. PCR, NGS) (at diagnosis)

yes no Unknown

21

CEBPA

Positive Negative Not Done

22

Specify CEBPA mutation23

Biallelic (homozygous)

Monoallelic (heterozygous)

Unknown

FLT3 – D835 point mutation

Positive Negative Not Done

24

FLT3 – ITD mutation

Positive Negative Not Done

25

FLT3 - ITD allelic ratio

Known Unknown

26

Specify FLT3 - ITD allelic ratio:27

IDH1

Positive Negative Not Done

28

IDH2

Positive Negative Not Done

29

KIT

Positive Negative Not Done

30

NPM1

Positive Negative Not Done

31

Other Molecular Marker (1) Questions: 32 - 33

Other molecular marker

Positive Negative Not Done

32

Specify other molecular marker:33

Were cytogenetics tested (karyotyping or FISH)? (between diagnosis and last evaluation)

yes no Unknown

34

Were cytogenetics tested via FISH? (between diagnosis and last evaluation)

Yes No

35

Results of tests36

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities37

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

38

Specify other abnormality:39

Were cytogenetics tested via karyotyping? (between diagnosis and last evaluation)

Yes No

40

Results of tests41

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities42

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

43

Specify other abnormality:44

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

45

Were tests for molecular markers performed? (e.g. PCR, NGS) (between diagnosis and last evaluation)

yes no Unknown

46

CEBPA

Positive Negative Not Done

47

Specify CEBPA mutation48

Biallelic (homozygous)

Monoallelic (heterozygous)

Unknown

FLT3 – D835 point mutation

Positive Negative Not Done

49

FLT3 – ITD mutation

Positive Negative Not Done

50

FLT3 - ITD allelic ratio

Known Unknown

51

Specify FLT3 - ITD allelic ratio:52

IDH1

Positive Negative Not Done

53

IDH2

Positive Negative Not Done

54

KIT

Positive Negative Not Done

55

NPM1

Positive Negative Not Done

56

Other Molecular Marker (1) Questions: 57 - 58

Other molecular marker

Positive Negative Not Done

57

Specify other molecular marker:58

Were cytogenetics tested (karyotyping or FISH)? (at last evaluation)

yes no Unknown

59

Were cytogenetics tested via FISH? (at last evaluation)

Yes No

60

Results of tests61

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities62

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

63

Specify other abnormality:64

Were cytogenetics tested via karyotyping? (at last evaluation)

Yes No

65

Results of tests66

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities67

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

68

Specify other abnormality:69

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

70

Were tests for molecular markers performed? (e.g. PCR, NGS) (at last evaluation)

yes no Unknown

71

CEBPA

Positive Negative Not Done

72

Specify CEBPA mutation73

Biallelic (homozygous)

Monoallelic (heterozygous)

Unknown

FLT3 – D835 point mutation

Positive Negative Not Done

74

FLT3 – ITD mutation

Positive Negative Not Done

75

FLT3 - ITD allelic ratio

Known Unknown

76

Specify FLT3 - ITD allelic ratio:77

IDH1

Positive Negative Not Done

78

IDH2

Positive Negative Not Done

79

KIT

Positive Negative Not Done

80

NPM1

Positive Negative Not Done

81

Other Molecular Marker (1) Questions: 82 - 83

Other molecular marker

Positive Negative Not Done

82

Specify other molecular marker:83

Did the recipient have central nervous system leukemia at any time prior to the start of the preparative regimen / infusion?

yes no Unknown

84

What was the disease status (based on hematological test results)?85

Primary induction failure

1st complete remission (no previous bone marrow or extramedullary relapse) (include CRi)

2nd complete remission

≥3rd complete remission

1st relapse

2nd relapse

≥3rd relapse

No treatment

How many cycles of induction therapy were required to achieve 1st complete remission? (includes CRi)

1 2 ≥ 3

86

Was the recipient in remission by flow cytometry?

Yes No Unknown Not applicable

87

Date of most recent relapse:88 __ __ __ __ - __ __- __ __

Date assessed:89 __ __ __ __ - __ __- __ __

Acute Lymphoblastic Leukemia (ALL) Questions: 90 - 151

Specify ALL classification90

Did the recipient have a predisposing condition?

yes no Unknown

91

Specify condition92

Aplastic anemia - Also complete CIBMTR Form 2028 - APL

Bloom syndrome

Down syndrome

Fanconi anemia - Also complete CIBMTR Form 2029 - FAN

Other condition

Specify other condition:93

Were tyrosine kinase inhibitors given for therapy at any time prior to the start of the preparative regimen / infusion? (e.g. imatinib mesylate, dasatinib, etc.)

yes no

94

Were cytogenetics tested (karyotyping or FISH)? (at diagnosis)

yes no Unknown

95

Were cytogenetics tested via FISH? (at diagnosis)

Yes No

96

Results of tests97

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities98

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

99

Specify other abnormality:100

Were cytogenetics tested via karyotyping? (at diagnosis)

Yes No

101

Results of tests102

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities103

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

104

Specify other abnormality:105

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

106

Were tests for molecular markers performed? (e.g. PCR, NGS) (at diagnosis)

yes no Unknown

107

BCR / ABL

Positive Negative Not Done

108

TEL-AML / AML1

Positive Negative Not Done

109

Other Molecular Marker (1) Questions: 110 - 111

Other molecular marker

Positive Negative Not Done

110

Specify other molecular marker:111

Were cytogenetics tested (karyotyping or FISH)? (between diagnosis and last evaluation)

yes no Unknown

112

Were cytogenetics tested via FISH? (between diagnosis and last evaluation)

Yes No

113

Results of tests114

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities115

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

116

Specify other abnormality:117

Were cytogenetics tested via karyotyping? (between diagnosis and last evaluation)

Yes No

118

Results of tests119

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities120

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

121

Specify other abnormality:122

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

123

Were tests for molecular markers performed? (e.g. PCR, NGS) (between diagnosis and last evaluation)

yes no Unknown

124

BCR / ABL

Positive Negative Not Done

125

TEL-AML / AML1

Positive Negative Not Done

126

Other Molecular Marker (1) Questions: 127 - 128

Other molecular marker

Positive Negative Not Done

127

Specify other molecular marker:128

Were cytogenetics tested (karyotyping or FISH)? (at last evaluation)

yes no Unknown

129

Were cytogenetics tested via FISH? (at last evaluation)

Yes No

130

Results of tests131

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities132

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

133

Specify other abnormality:134

Were cytogenetics tested via karyotyping? (at last evaluation)

Yes No

135

Results of tests136

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities137

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

138

Specify other abnormality:139

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

140

Were tests for molecular markers performed? (e.g. PCR, NGS) (at last evaluation)

yes no Unknown

141

BCR / ABL

Positive Negative Not Done

142

TEL-AML / AML1

Positive Negative Not Done

143

Other Molecular Marker (1) Questions: 144 - 145

Other molecular marker

Positive Negative Not Done

144

Specify other molecular marker:145

Did the recipient have central nervous system leukemia at any time prior to the start of the preparative regimen / infusion?

yes no Unknown

146

What was the disease status (based on hematological test results)?147

Primary induction failure

1st complete remission (no previous marrow or extramedullary relapse) (include CRi)

2nd complete remission

≥3rd complete remission

1st relapse

2nd relapse

≥3rd relapse

No treatment

How many cycles of induction therapy were required to achieve 1st complete remission? (include CRi)

1 2 ≥ 3

148

Was the recipient in remission by flow cytometry?

Yes No Unknown Not applicable

149

Date of most recent relapse:150 __ __ __ __ - __ __- __ __

Date assessed:151 __ __ __ __ - __ __- __ __

Acute Leukemias of Ambiguous Lineage and Other Myeloid Neoplasms Questions: 152 - 155

Specify acute leukemias of ambiguous lineage and other myeloid neoplasm classification152

Blastic plasmacytoid dendritic cell neoplasm (296)

Acute undifferentiated leukemia (31)

Mixed phenotype acute leukemia (MPAL) with t(9;22)(q34.1;q11.2); BCR-ABL1 (84)

Mixed phenotype acute leukemia with t(v; 11q23.3); KMT2A rearranged (85)

Mixed phenotype acute leukemia, B/myeloid, NOS (86)

Mixed phenotype acute leukemia, T/myeloid, NOS (87)

Other acute leukemia of ambiguous lineage or myeloid neoplasm (88)

Specify other acute leukemia of ambiguous lineage or myeloid neoplasm:153

What was the disease status (based on hematological test results)?154

Primary induction failure

1st complete remission (no previous marrow or extramedullary relapse)

2nd complete remission

≥3rd complete remission

1st relapse

2nd relapse

≥3rd relapse

No treatment

Date assessed:155 __ __ __ __ - __ __- __ __

Chronic Myelogenous Leukemia (CML) Questions: 156 - 166

Was therapy given prior to this HCT?

yes no

156

Combination chemotherapy

yes no

157

Hydroxyurea (Droxia, Hydrea)

yes no

158

Tyrosine kinase inhibitor (e.g. imatinib mesylate, dasatinib, nilotinib)

yes no

159

Interferon­α (Intron, Roferon) (includes PEG)

yes no

160

Other therapy

yes no

161

Specify other therapy:162

What was the disease status?163

Complete hematologic response (CHR)

Chronic phase

Accelerated phase

Blast phase

Specify level of response164

No cytogenetic response (No CyR)

Minimal cytogenetic response

Minor cytogenetic response

Partial cytogenetic response (PCyR)

Complete cytogenetic response (CCyR)

Major molecular remission (MMR)

Complete molecular remission (CMR)

Number

1st 2nd 3rd or higher

165

Date assessed:166 __ __ __ __ - __ __- __ __

Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases Questions: 167 - 260

What was the MDS / MPN subtype at diagnosis? - If transformed to AML, indicate AML as primary disease; also complete AML Disease Classification
questions

167

Was the disease (MDS/MPN) therapy related?

yes no Unknown

168

Did the recipient have a predisposing condition?

yes no Unknown

169

Specify condition

Aplastic Anemia Bloom syndrome Down syndrome Fanconi anemia Other condition

170

Specify other condition:171

WBC

Known Unknown

172

173 x 109/L (x 103/mm3)

x 106/L

Hemoglobin

Known Unknown

174

175 g/dL g/L mmol/L

Was RBC transfused ≤ 30 days before date of test?

Yes No

176

Platelets

Known Unknown

177

178 x 109/L (x 103/mm3)

x 106/L

Were platelets transfused ≤ 7 days before date of test?

Yes No

179

Neutrophils

Known Unknown

180

181 %

Blasts in bone marrow

Known Unknown

182

183 %

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

184

Results of tests185

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities186

One (1)

Two (2)

Three (3)

Four or more (4 or more)

–5

yes no

187

-7

yes no

188

–13

yes no

189

–20

yes no

190

–Y

yes no

191

+8

yes no

192

+19

yes no

193

t(1;3)

yes no

194

t(2;11)

yes no

195

t(3;3)

yes no

196

t(3;21)

yes no

197

t(6;9)

yes no

198

t(11;16)

yes no

199

del(3q) / 3q–

yes no

200

del(5q) / 5q-

yes no

201

del(7q) / 7q–

yes no

202

del(9q) / 9q–

yes no

203

del(11q) / 11q–

yes no

204

del(12p) / 12p–

yes no

205

del(13q) / 13q-

yes no

206

del(20q) / 20q–

yes no

207

inv(3)

yes no

208

i17q

yes no

209

Other abnormality

yes no

210

Specify other abnormality:211

Did the recipient progress or transform to a different MDS / MPN subtype between diagnosis and the start of the preparative regimen?

yes no

212

Specify the MDS / MPN classification after transformation:213

Specify the date of the most recent transformation:214 __ __ __ __ - __ __- __ __

Date of MDS diagnosis:215 __ __ __ __ - __ __- __ __

WBC

Known Unknown

216

217 x 109/L (x 103/mm3)

x 106/L

Hemoglobin

Known Unknown

218

219 g/dL g/L mmol/L

Was RBC transfused ≤ 30 days before date of test?

Yes No

220

Platelets

Known Unknown

221

222 x 109/L (x 103/mm3)

x 106/L

Were platelets transfused ≤ 7 days before date of test?

Yes No

223

Neutrophils

Known Unknown

224

225 %

Blasts in bone marrow

Known Unknown

226

227 %

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

228

Results of tests229

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities230

One (1)

Two (2)

Three (3)

Four or more (4 or more)

–5

yes no

231

-7

yes no

232

–13

yes no

233

–20

yes no

234

–Y

yes no

235

+8

yes no

236

+19

yes no

237

t(1;3)

yes no

238

t(2;11)

yes no

239

t(3;3)

yes no

240

t(3;21)

yes no

241

t(6;9)

yes no

242

t(11;16)

yes no

243

del(3q) / 3q–

yes no

244

del(5q) / 5q-

yes no

245

del(7q) / 7q–

yes no

246

del(9q) / 9q–

yes no

247

del(11q) / 11q–

yes no

248

del(12p) / 12p–

yes no

249

del(13q) / 13q-

yes no

250

del(20q) / 20q–

yes no

251

inv(3)

yes no

252

i17q

yes no

253

Other abnormality

yes no

254

Specify other abnormality:255

What was the disease status?256

Complete
remission
(CR)

– requires all of the following, maintained for ≥ 4 weeks: * bone marrow evaluation: <  5% myeloblasts with normal maturation of all cell lines *
peripheral blood evaluation: hemoglobin ≥ 11 g/dL untransfused and without erythropoietin support; ANC ≥ 1000/mm3  without myeloid growth factor
support; platelets ≥ 100 x 109/L without thrombopoietic support; 0% blasts

Hematologic
improvement
(HI)

– requires one measurement of the following, maintained for ≥ 8 weeks without ongoing cytotoxic therapy; specify which cell line was measured to
determine HI response: * HI­E – hemoglobin increase of ≥ 1.5 g/dL untransfused; for RBC transfusions performed for Hgb ≤ 9.0, reduction in RBC
units transfused in 8 weeks by ≥ 4 units compared to the pre­treatment transfusion number in 8 weeks * HI­P – for pre­treatment platelet count of > 20
x 109/L, platelet absolute increase of ≥ 30 x 109/L; for pre-treatment platelet count of < 20 x 109/L, platelet absolute increase of ≥ 20 x 109/L and ≥
100% from pre­treatment level  * HI­N – neutrophil count increase of ≥ 100% from pre­treatment level and an absolute increase of ≥ 500/mm3

No response (NR) / stable disease (SD) – does not meet the criteria for at least HI, but no evidence of disease progression

Progression from
hematologic improvement
(Prog from HI)

– requires at least one of the following, in the absence of another explanation (e.g., infection, bleeding, ongoing chemotherapy, etc.): *
≥ 50% reduction from maximum response levels in granulocytes or platelets * reduction in hemoglobin by ≥ 1.5 g/dL *transfusion
dependence

Relapse from complete
remission (Rel from CR)

– requires at least one of the following: * return to pre­treatment bone marrow blast percentage * decrease of ≥ 50% from maximum
response levels in granulocytes or platelets * transfusion dependence, or hemoglobin level ≥ 1.5 g/dL lower than prior to therapy

Not assessed

Specify the cell line examined to determine HI status257

HI-
E

– hemoglobin increase of ≥ 1.5 g/dL untransfused; for RBC transfusions performed for Hgb ≤ 9.0, reduction in RBC units transfused in 8 weeks by ≥ 4
units compared to the pre-treatment transfusion number in 8 weeks

HI-
P

– for pre­treatment platelet count of > 20 x 109/L, platelet absolute increase of ≥ 30 x 109/L; for pre-treatment platelet count of < 20 x 109/L, platelet
absolute increase of ≥ 20 x 109/L and ≥ 100% from pre­treatment level 

HI-N – neutrophil count increase of ≥ 100% from pre­treatment level and an absolute increase of ≥ 500/mm3

Date of progression:258 __ __ __ __ - __ __- __ __

Date of relapse:259 __ __ __ __ - __ __- __ __

Date assessed:260 __ __ __ __ - __ __- __ __

Other Leukemia (OL) Questions: 261 - 267

Specify the other leukemia classification261

Specify other leukemia:262

Was any 17p abnormality detected?

yes no

263

Did a histologic transformation to diffuse large B-cell lymphoma (Richter syndrome) occur at any time after CLL diagnosis?264

yes - Also complete NHL Disease Classification questions

no

What was the disease status? (Atypical CML)265

Primary induction failure

1st complete remission (no previous bone marrow or extramedullary relapse)

2nd complete remission

≥3rd complete remission

1st relapse

2nd relapse

≥3rd relapse

No treatment

What was the disease status? (CLL, PLL, Hairy cell leukemia)266

Complete remission (CR)

Partial remission (PR)

Stable disease (SD)

Progressive disease (Prog)

Untreated

Not assessed

Date assessed:267 __ __ __ __ - __ __- __ __

Hodgkin and Non-Hodgkin Lymphoma Questions: 268 - 285

Specify the lymphoma histology (at infusion)268

Specify other lymphoma histology:269

Assignment of DLBCL (germinal center B-cell type vs. activated B-cell type) subtype was based on270

Immunohistochemistry (e.g. Han's algorithm)

Gene expression profile

Unknown method

Is the lymphoma histology reported at transplant a transformation from CLL?

yes no

271

Was any 17p abnormality detected?

yes no

272

Is the lymphoma histology reported at transplant a transformation from a different lymphoma histology? (Not CLL)

Yes No

273

Specify the original lymphoma histology (prior to transformation)274

Specify other lymphoma histology:275

Date of original lymphoma diagnosis:276 __ __ __ __ - __ __- __ __ (report the date of diagnosis of original lymphoma subtype)

Was a PET (or PET/CT) scan performed? (at last evaluation prior to the start of the preparative regimen / infusion)

yes no

277

Was the PET (or PET/CT) scan positive for lymphoma involvement at any disease site?

yes no

278

Date of PET scan

Known Unknown

279

Date of PET (or PET/CT) scan:280 __ __ __ __ - __ __- __ __

Deauville (five-point) score of the PET (or PET/CT) scan

Known Unknown

281

Scale282

1 - no uptake or residual uptake

2 - slight uptake, but below blood pool (mediastinum)

3 - uptake above mediastinal, but below or equal to uptake in the liver

4 - uptake slightly to moderately higher than liver

5 - markedly increased uptake or any new lesions

What was the disease status?283

Total number of lines of therapy received

1 line 2 lines 3+ lines

284

Date assessed:285 __ __ __ __ - __ __- __ __

Multiple Myeloma / Plasma Cell Disorder (PCD) Questions: 286 - 317

Specify the multiple myeloma/plasma cell disorder (PCD) classification286

Specify other plasma cell disorder:287

Light chain

kappa lambda

288

What was the Durie-Salmon staging? (at diagnosis)289

Stage
I

(All of the following: Hgb > 10g/dL; serum calcium normal or <10.5 mg/dL; bone x-ray normal bone structure (scale 0), or solitary bone plasmacytoma
only; low M-component production rates IgG< 5g/dL, IgA < 3g/dL; urine light chain M-component on electrophoresis <4 g/24h)

Stage II (Fitting neither Stage I or III) 

Stage
III

(One or more of the following: Hgb < 8.5 g/dL; serum calcium > 12 mg/dL; advanced lytic bone lesions (scale 3); high M-component production rates
IgG > 7g/dL, IgA > 5 g/dL; Bence Jones protein > 12g/24h)

Unknown

What was the Durie-Salmon sub classification? (at diagnosis)290

A - relatively normal renal function (serum creatinine < 2.0 mg/dL)

B ­ abnormal renal function (serum creatinine ≥ 2.0 mg/dL)

Serum β2­microglobulin:291 μg/dL mg/L nmol/L

Serum albumin:292 g/dL g/L

Stage293

1 (β2 ­mic < 3.5, S. albumin ≥3.5)

2 (Not fitting stage 1 or 3)

3 (β2­mic ≥ 5.5; S. albumin ­)

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

294

Results of tests295

Abnormalities identified

No evaluable metaphases

No abnormalities

+3

yes no

296

+5

yes no

297

+7

yes no

298

+9

yes no

299

+11

yes no

300

+15

yes no

301

+19

yes no

302

t(4;14)

yes no

303

t(6;14)

yes no

304

t(11;14)

yes no

305

t(14;16)

yes no

306

t(14;20)

yes no

307

del(13q) / 13q-

yes no

308

del (17p) / 17p-

yes no

309

Hyperdiploid (>50)

yes no

310

Hypodiploid (<46)

yes no

311

Any abnormality at 1q

yes no

312

Any abnormality at 1p

yes no

313

Other abnormality

yes no

314

Specify other abnormality:315

What was the disease status?316

Stringent
complete
remission
(sCR)

- CR as defined, plus: normal free light chain ratio, and absence of clonal cells in the bone marrow by immunohistochemistry of immunofluorescence
(confirmation with repeat bone marrow biopsy not needed). (Presence and/or absence of clonal cells is based upon the Κ/λ ratio. An abnormal Κ/λ ratio by
immunohistochemistry and/or immunofluorescence requires a minimum of 100 plasma cells for analysis.  An abnormal ratio reflecting the presence of
an abnormal clone is Κ/λ of > 4:1 or < 1:2.) sCR requires two consecutive assessments made at any time before the institution of any new therapy, and
no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy sCR
requirements. 

Complete
remission
(CR)

- negative immunofixation on serum and urine samples, and disappearance of any soft tissue plasmacytomas, and < 5% plasma cells in the bone
marrow (confirmation with repeat bone marrow biopsy not needed).  CR requires two consecutive assessments made at any time before the institution
of any new therapy, and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not
required to satisfy CR requirements. 

Near
complete
remission
(nCR)

- serum and urine M-protein detectable by immunoelectrophoresis (IFE), but not on electrophoresis (negative SPEP & UPEP); < 5% plasma cells in
bone marrow.  nCR requires two consecutive assessments made at any time before the initiation of any new therapy, and no known evidence of
progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy nCR requirements. 

Very good
partial
remission
(VGPR)

­ serum and urine M­protein detectable by immunofixation but not on electrophoresis, or ≥ 90% reduction in serum M­protein and urine M­protein level <
100 mg/24 hours.  VGPR requires two consecutive assessments made at any time before the institution of any new therapy, and no known evidence of
progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy VGPR requirements.

Partial
remission
(PR)

­ ≥ 50% reduction in serum M­protein, and reduction in 24­hour urinary M­protein by ≥ 90% or to < 200 mg/24 hours.  If the serum and urine M­protein are
unmeasurable (i.e., do not meet any of the following criteria: • serum M­protein ≥ 1 g/dL.  Urine M­protein ≥ 200 mg/24 hours • serum free light chain
assay shows involved level ≥ 10 mg/dL, provided serum free light chain ratio is abnormal), a ≥ 50% decrease in the difference between involved and
uninvolved free light chain levels is required in place of the M-protein criteria.  If serum and urine M-protein are unmeasurable, and serum free light assay
is also unmeasurable, a ≥ 50% reduction in plasma cells is required in place of M­protein, provided the baseline bone marrow plasma cell percentage
was ≥ 30%. In addition to the above listed criteria, a ≥ 50% reduction in the size of soft tissue plasmacytomas is also required, if present at baseline. PR
requires two consecutive assessments made at any time before the institution of any new therapy, and no known evidence of progressive or new bone
lesions if radiographic studies were performed; radiographic studies are not required to satisfy PR requirements. 

Stable
disease
(SD)

- not meeting the criteria for CR, VGPR, PR or PD.  SD requires two consecutive assessments made at any time before the institution of any new therapy,
and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy SD
requirements.

Progressive
disease
(PD)

­ requires any one or more of the following:  Increase of ≥ 25% from baseline in:  serum M­component and/or (absolute increase ≥ 0.5 g/dL) (for
progressive disease, serum M­component increases of ≥ 1 g/dL are sufficient to define relapse if the starting M­component is ≥ 5 g/dL).  Urine M­
component and/or (absolute increase ≥ 200 mg/24 hours) for recipients without measurable serum and urine M­protein levels: the difference between
involved and uninvolved free light chain levels (absolute increase > 10 mg/dL).  Bone marrow plasma cell percentage (absolute percentage ≥ 10%)
(relapse from CR has a 5% cutoff vs. 10% for other categories of relapse) definite development of new bone lesions or soft tissue plasmacytomas, or
definite increase in the size of any existing  bone lesions or soft tissue plasmacytomas. Development of hypercalcemia (corrected serum calcium >

11.5 mg/dL or 2.65 mmol) that can be attributed solely to the plasma cell proliferative disorder.  PD requires two consecutive assessments made at
any time before classification as disease progression, and/or the institution of any new therapy.

Relapse
from CR
(Rel)
(untreated)

­ requires one or more of the following: reappearance of serum or urine M­protein by immunofixation or electrophoresis development of ≥ 5% plasma
cells in the bone marrow (relapse from CR has a 5% cutoff vs. 10% for other categories of relapse) appearance of any other sign of progression (e.g.,
new plasmacytoma, lytic bone lesion, hypercalcemia).  Rel requires two consecutive assessments made at any time before classification as relapse,
and/or the institution of any new therapy.

Unknown

Not applicable (Amyloidosis with no evidence of myeloma)

Date assessed:317 __ __ __ __ - __ __- __ __

Solid Tumors Questions: 318 - 319

Specify the solid tumor classification318

Specify other solid tumor:319

Severe Aplastic Anemia Questions: 320 - 321

Specify the severe aplastic anemia classification320

Specify other acquired cytopenic syndrome:321

Inherited Abnormalities of Erythrocyte Differentiation or Function Questions: 322 - 324

Specify the inherited abnormalities of erythrocyte differentiation or function classification322

Specify other constitutional anemia:323

Specify other hemoglobinopathy:324

Disorders of the Immune System Questions: 325 - 327

Specify disorder of immune system classification325

Specify other SCID:326

Specify other immunodeficiency:327

Inherited Abnormalities of Platelets Questions: 328 - 329

Specify inherited abnormalities of platelets classification328

Congenital amegakaryocytosis / congenital thrombocytopenia (501)

Glanzmann thrombasthenia (502)

Other inherited platelet abnormality (509)

Specify other inherited platelet abnormality:329

Inherited Disorders of Metabolism Questions: 330 - 331

Specify inherited disorders of metabolism classification330

Specify other inherited metabolic disorder:331

Histiocytic Disorders Questions: 332 - 333

Specify histiocytic disorder classification332

Specify other histiocytic disorder:333

Autoimmune Diseases Questions: 334 - 341

Specify autoimmune disease classification334

Specify other arthritis:335

Specify other juvenile idiopathic arthritis (JIA):336

Specify other connective tissue disease:337

Specify other vasculitis:338

Specify other autoimmune neurological disorder:339

Specify other autoimmune cytopenia:340

Specify other autoimmune bowel disorder:341

Other Disease Questions: 342 - 342

Specify other disease:342

First Name:

Last Name:

E-mail address:

Date: __ __ __ __ - __ __- __ __

OMB No: 0915-0310

Expiration Date: 1/31/2020

Public Burden Statement:  An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control
number.  The OMB control number for this project is 0915-0310.  Public reporting burden for this collection of information is estimated to average 1.0 hours per response, including the
time for reviewing instructions, searching existing data sources, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other
aspect of this collection of information, including suggestions for reducing this burden, to HRSA Reports Clearance Officer, 5600 Fishers Lane, Room 10-29, Rockville, Maryland, 20857.

Labs at diagnosis

Specify cytogenetic abnormalities identified at diagnosis:

Specify cytogenetic abnormalities identified at diagnosis:

Specify molecular markers identified at diagnosis:

Labs between diagnosis and last evaluation:

Specify cytogenetic abnormalities identified between diagnosis and last evaluation:

Specify cytogenetic abnormalities identified between diagnosis and last evaluation:

Specify molecular markers identified between diagnosis and last evaluation:

Labs at last evaluation:

Specify cytogenetic abnormalities identified at last evaluation:

Specify cytogenetic abnormalities identified at last evaluation:

Specify molecular markers identified at last evaluation:

CNS Leukemia

Status at transplantation:

Laboratory studies at diagnosis:

Specify cytogenetic abnormalities identified at diagnosis:

Specify cytogenetic abnormalities identified at diagnosis:

Specify molecular markers identified at diagnosis:

Laboratory studies between diagnosis and last evaluation:

Specify cytogenetic abnormalities identified between diagnosis and last evaluation:

Specify cytogenetic abnormalities identified between diagnosis and last evaluation:

Specify molecular markers identified between diagnosis and last evaluation:

Laboratory studies at last evaluation:

Specify cytogenetic abnormalities identified at last evaluation:

Specify cytogenetic abnormalities identified at last evaluation:

Specify molecular markers identified at last evaluation:

CNS Leukemia

Status at transplantation:

Status at transplantation:

Laboratory studies at diagnosis of MDS:

Specify abnormalities identified at diagnosis:

Monosomy

Trisomy

Translocation

Deletion

Inversion

Other

Laboratory studies at last evaluation prior to the start of the preparative regimen:

Specify cytogenetic abnormalities identified at last evaluation prior to the start of the preparative regimen:

Monosomy

Trisomy

Translocation

Deletion

Inversion

Other

Status at transplantation:

Status at transplantation:

Status at transplantation / infusion:

I.S.S.:

Specify cytogenetic abnormalities identified at any time prior to the start of the preparative regimen:

Trisomy

Translocation

Deletion

Other

Status at transplantation:

Center: CRID: 

Form 2402 R3.0: Disease Classification

CIBMTR Form 2402 revision 3.0 last updated Monday, January 29, 2018
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 21 / 26



Key Fields

Sequence Number:

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number:

CIBMTR Research ID:

Event date: __ __ __ __ - __ __- __ __

Primary Disease for HCT / Cellular Therapy Questions: 1 - 2

Date of diagnosis of primary disease for HCT / cellular therapy:1 __ __ __ __ - __ __- __ __

What was the primary disease for which the HCT / cellular therapy was performed?2

Acute myelogenous leukemia (AML or ANLL) (10)

Acute lymphoblastic leukemia (ALL) (20)

Acute leukemia of ambiguous lineage and other myeloid neoplasms (80)

Chronic myelogenous leukemia (CML) (40)

Myelodysplastic (MDS) / myeloproliferative (MPN) diseases (50) (Please classify all preleukemias) (If recipient has transformed to AML, indicate AML as the primary disease)

Other leukemia (30) (includes CLL)

Hodgkin lymphoma (150)

Non-Hodgkin lymphoma (100)

Multiple myeloma / plasma cell disorder (PCD) (170)

Solid tumors (200)

Severe aplastic anemia (300) (If the recipient developed MDS or AML, indicate MDS or AML as the primary disease)

Inherited abnormalities of erythrocyte differentiation or function (310)

Disorders of the immune system (400)

Inherited abnormalities of platelets (500)

Inherited disorders of metabolism (520)

Histiocytic disorders (570)

Autoimmune diseases (600)

Other disease (900)

Acute Myelogenous Leukemia (AML) Questions: 3 - 89

Specify the AML classification3

Did AML transform from MDS or MPN?4

yes - Also complete MDS Disease Classification questions

no

Is the disease (AML) therapy related?

yes no Unknown

5

Did the recipient have a predisposing condition?

yes no Unknown

6

Specify condition7

Bloom syndrome

Down syndrome

Fanconi anemia

Dyskeratosis congenita

Other condition

Specify other condition:8

Were cytogenetics tested (karyotyping or FISH)? (at diagnosis)

yes no Unknown

9

Were cytogenetics tested via FISH? (at diagnosis)

Yes No

10

Results of tests11

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities12

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

13

Specify other abnormality:14

Were cytogenetics tested via karyotyping? (at diagnosis)

Yes No

15

Results of tests16

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities17

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

18

Specify other abnormality:19

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

20

Were tests for molecular markers performed? (e.g. PCR, NGS) (at diagnosis)

yes no Unknown

21

CEBPA

Positive Negative Not Done

22

Specify CEBPA mutation23

Biallelic (homozygous)

Monoallelic (heterozygous)

Unknown

FLT3 – D835 point mutation

Positive Negative Not Done

24

FLT3 – ITD mutation

Positive Negative Not Done

25

FLT3 - ITD allelic ratio

Known Unknown

26

Specify FLT3 - ITD allelic ratio:27

IDH1

Positive Negative Not Done

28

IDH2

Positive Negative Not Done

29

KIT

Positive Negative Not Done

30

NPM1

Positive Negative Not Done

31

Other Molecular Marker (1) Questions: 32 - 33

Other molecular marker

Positive Negative Not Done

32

Specify other molecular marker:33

Were cytogenetics tested (karyotyping or FISH)? (between diagnosis and last evaluation)

yes no Unknown

34

Were cytogenetics tested via FISH? (between diagnosis and last evaluation)

Yes No

35

Results of tests36

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities37

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

38

Specify other abnormality:39

Were cytogenetics tested via karyotyping? (between diagnosis and last evaluation)

Yes No

40

Results of tests41

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities42

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

43

Specify other abnormality:44

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

45

Were tests for molecular markers performed? (e.g. PCR, NGS) (between diagnosis and last evaluation)

yes no Unknown

46

CEBPA

Positive Negative Not Done

47

Specify CEBPA mutation48

Biallelic (homozygous)

Monoallelic (heterozygous)

Unknown

FLT3 – D835 point mutation

Positive Negative Not Done

49

FLT3 – ITD mutation

Positive Negative Not Done

50

FLT3 - ITD allelic ratio

Known Unknown

51

Specify FLT3 - ITD allelic ratio:52

IDH1

Positive Negative Not Done

53

IDH2

Positive Negative Not Done

54

KIT

Positive Negative Not Done

55

NPM1

Positive Negative Not Done

56

Other Molecular Marker (1) Questions: 57 - 58

Other molecular marker

Positive Negative Not Done

57

Specify other molecular marker:58

Were cytogenetics tested (karyotyping or FISH)? (at last evaluation)

yes no Unknown

59

Were cytogenetics tested via FISH? (at last evaluation)

Yes No

60

Results of tests61

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities62

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

63

Specify other abnormality:64

Were cytogenetics tested via karyotyping? (at last evaluation)

Yes No

65

Results of tests66

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities67

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

68

Specify other abnormality:69

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

70

Were tests for molecular markers performed? (e.g. PCR, NGS) (at last evaluation)

yes no Unknown

71

CEBPA

Positive Negative Not Done

72

Specify CEBPA mutation73

Biallelic (homozygous)

Monoallelic (heterozygous)

Unknown

FLT3 – D835 point mutation

Positive Negative Not Done

74

FLT3 – ITD mutation

Positive Negative Not Done

75

FLT3 - ITD allelic ratio

Known Unknown

76

Specify FLT3 - ITD allelic ratio:77

IDH1

Positive Negative Not Done

78

IDH2

Positive Negative Not Done

79

KIT

Positive Negative Not Done

80

NPM1

Positive Negative Not Done

81

Other Molecular Marker (1) Questions: 82 - 83

Other molecular marker

Positive Negative Not Done

82

Specify other molecular marker:83

Did the recipient have central nervous system leukemia at any time prior to the start of the preparative regimen / infusion?

yes no Unknown

84

What was the disease status (based on hematological test results)?85

Primary induction failure

1st complete remission (no previous bone marrow or extramedullary relapse) (include CRi)

2nd complete remission

≥3rd complete remission

1st relapse

2nd relapse

≥3rd relapse

No treatment

How many cycles of induction therapy were required to achieve 1st complete remission? (includes CRi)

1 2 ≥ 3

86

Was the recipient in remission by flow cytometry?

Yes No Unknown Not applicable

87

Date of most recent relapse:88 __ __ __ __ - __ __- __ __

Date assessed:89 __ __ __ __ - __ __- __ __

Acute Lymphoblastic Leukemia (ALL) Questions: 90 - 151

Specify ALL classification90

Did the recipient have a predisposing condition?

yes no Unknown

91

Specify condition92

Aplastic anemia - Also complete CIBMTR Form 2028 - APL

Bloom syndrome

Down syndrome

Fanconi anemia - Also complete CIBMTR Form 2029 - FAN

Other condition

Specify other condition:93

Were tyrosine kinase inhibitors given for therapy at any time prior to the start of the preparative regimen / infusion? (e.g. imatinib mesylate, dasatinib, etc.)

yes no

94

Were cytogenetics tested (karyotyping or FISH)? (at diagnosis)

yes no Unknown

95

Were cytogenetics tested via FISH? (at diagnosis)

Yes No

96

Results of tests97

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities98

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

99

Specify other abnormality:100

Were cytogenetics tested via karyotyping? (at diagnosis)

Yes No

101

Results of tests102

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities103

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

104

Specify other abnormality:105

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

106

Were tests for molecular markers performed? (e.g. PCR, NGS) (at diagnosis)

yes no Unknown

107

BCR / ABL

Positive Negative Not Done

108

TEL-AML / AML1

Positive Negative Not Done

109

Other Molecular Marker (1) Questions: 110 - 111

Other molecular marker

Positive Negative Not Done

110

Specify other molecular marker:111

Were cytogenetics tested (karyotyping or FISH)? (between diagnosis and last evaluation)

yes no Unknown

112

Were cytogenetics tested via FISH? (between diagnosis and last evaluation)

Yes No

113

Results of tests114

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities115

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

116

Specify other abnormality:117

Were cytogenetics tested via karyotyping? (between diagnosis and last evaluation)

Yes No

118

Results of tests119

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities120

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

121

Specify other abnormality:122

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

123

Were tests for molecular markers performed? (e.g. PCR, NGS) (between diagnosis and last evaluation)

yes no Unknown

124

BCR / ABL

Positive Negative Not Done

125

TEL-AML / AML1

Positive Negative Not Done

126

Other Molecular Marker (1) Questions: 127 - 128

Other molecular marker

Positive Negative Not Done

127

Specify other molecular marker:128

Were cytogenetics tested (karyotyping or FISH)? (at last evaluation)

yes no Unknown

129

Were cytogenetics tested via FISH? (at last evaluation)

Yes No

130

Results of tests131

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities132

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

133

Specify other abnormality:134

Were cytogenetics tested via karyotyping? (at last evaluation)

Yes No

135

Results of tests136

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities137

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

138

Specify other abnormality:139

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

140

Were tests for molecular markers performed? (e.g. PCR, NGS) (at last evaluation)

yes no Unknown

141

BCR / ABL

Positive Negative Not Done

142

TEL-AML / AML1

Positive Negative Not Done

143

Other Molecular Marker (1) Questions: 144 - 145

Other molecular marker

Positive Negative Not Done

144

Specify other molecular marker:145

Did the recipient have central nervous system leukemia at any time prior to the start of the preparative regimen / infusion?

yes no Unknown

146

What was the disease status (based on hematological test results)?147

Primary induction failure

1st complete remission (no previous marrow or extramedullary relapse) (include CRi)

2nd complete remission

≥3rd complete remission

1st relapse

2nd relapse

≥3rd relapse

No treatment

How many cycles of induction therapy were required to achieve 1st complete remission? (include CRi)

1 2 ≥ 3

148

Was the recipient in remission by flow cytometry?

Yes No Unknown Not applicable

149

Date of most recent relapse:150 __ __ __ __ - __ __- __ __

Date assessed:151 __ __ __ __ - __ __- __ __

Acute Leukemias of Ambiguous Lineage and Other Myeloid Neoplasms Questions: 152 - 155

Specify acute leukemias of ambiguous lineage and other myeloid neoplasm classification152

Blastic plasmacytoid dendritic cell neoplasm (296)

Acute undifferentiated leukemia (31)

Mixed phenotype acute leukemia (MPAL) with t(9;22)(q34.1;q11.2); BCR-ABL1 (84)

Mixed phenotype acute leukemia with t(v; 11q23.3); KMT2A rearranged (85)

Mixed phenotype acute leukemia, B/myeloid, NOS (86)

Mixed phenotype acute leukemia, T/myeloid, NOS (87)

Other acute leukemia of ambiguous lineage or myeloid neoplasm (88)

Specify other acute leukemia of ambiguous lineage or myeloid neoplasm:153

What was the disease status (based on hematological test results)?154

Primary induction failure

1st complete remission (no previous marrow or extramedullary relapse)

2nd complete remission

≥3rd complete remission

1st relapse

2nd relapse

≥3rd relapse

No treatment

Date assessed:155 __ __ __ __ - __ __- __ __

Chronic Myelogenous Leukemia (CML) Questions: 156 - 166

Was therapy given prior to this HCT?

yes no

156

Combination chemotherapy

yes no

157

Hydroxyurea (Droxia, Hydrea)

yes no

158

Tyrosine kinase inhibitor (e.g. imatinib mesylate, dasatinib, nilotinib)

yes no

159

Interferon­α (Intron, Roferon) (includes PEG)

yes no

160

Other therapy

yes no

161

Specify other therapy:162

What was the disease status?163

Complete hematologic response (CHR)

Chronic phase

Accelerated phase

Blast phase

Specify level of response164

No cytogenetic response (No CyR)

Minimal cytogenetic response

Minor cytogenetic response

Partial cytogenetic response (PCyR)

Complete cytogenetic response (CCyR)

Major molecular remission (MMR)

Complete molecular remission (CMR)

Number

1st 2nd 3rd or higher

165

Date assessed:166 __ __ __ __ - __ __- __ __

Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases Questions: 167 - 260

What was the MDS / MPN subtype at diagnosis? - If transformed to AML, indicate AML as primary disease; also complete AML Disease Classification
questions

167

Was the disease (MDS/MPN) therapy related?

yes no Unknown

168

Did the recipient have a predisposing condition?

yes no Unknown

169

Specify condition

Aplastic Anemia Bloom syndrome Down syndrome Fanconi anemia Other condition

170

Specify other condition:171

WBC

Known Unknown

172

173 x 109/L (x 103/mm3)

x 106/L

Hemoglobin

Known Unknown

174

175 g/dL g/L mmol/L

Was RBC transfused ≤ 30 days before date of test?

Yes No

176

Platelets

Known Unknown

177

178 x 109/L (x 103/mm3)

x 106/L

Were platelets transfused ≤ 7 days before date of test?

Yes No

179

Neutrophils

Known Unknown

180

181 %

Blasts in bone marrow

Known Unknown

182

183 %

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

184

Results of tests185

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities186

One (1)

Two (2)

Three (3)

Four or more (4 or more)

–5

yes no

187

-7

yes no

188

–13

yes no

189

–20

yes no

190

–Y

yes no

191

+8

yes no

192

+19

yes no

193

t(1;3)

yes no

194

t(2;11)

yes no

195

t(3;3)

yes no

196

t(3;21)

yes no

197

t(6;9)

yes no

198

t(11;16)

yes no

199

del(3q) / 3q–

yes no

200

del(5q) / 5q-

yes no

201

del(7q) / 7q–

yes no

202

del(9q) / 9q–

yes no

203

del(11q) / 11q–

yes no

204

del(12p) / 12p–

yes no

205

del(13q) / 13q-

yes no

206

del(20q) / 20q–

yes no

207

inv(3)

yes no

208

i17q

yes no

209

Other abnormality

yes no

210

Specify other abnormality:211

Did the recipient progress or transform to a different MDS / MPN subtype between diagnosis and the start of the preparative regimen?

yes no

212

Specify the MDS / MPN classification after transformation:213

Specify the date of the most recent transformation:214 __ __ __ __ - __ __- __ __

Date of MDS diagnosis:215 __ __ __ __ - __ __- __ __

WBC

Known Unknown

216

217 x 109/L (x 103/mm3)

x 106/L

Hemoglobin

Known Unknown

218

219 g/dL g/L mmol/L

Was RBC transfused ≤ 30 days before date of test?

Yes No

220

Platelets

Known Unknown

221

222 x 109/L (x 103/mm3)

x 106/L

Were platelets transfused ≤ 7 days before date of test?

Yes No

223

Neutrophils

Known Unknown

224

225 %

Blasts in bone marrow

Known Unknown

226

227 %

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

228

Results of tests229

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities230

One (1)

Two (2)

Three (3)

Four or more (4 or more)

–5

yes no

231

-7

yes no

232

–13

yes no

233

–20

yes no

234

–Y

yes no

235

+8

yes no

236

+19

yes no

237

t(1;3)

yes no

238

t(2;11)

yes no

239

t(3;3)

yes no

240

t(3;21)

yes no

241

t(6;9)

yes no

242

t(11;16)

yes no

243

del(3q) / 3q–

yes no

244

del(5q) / 5q-

yes no

245

del(7q) / 7q–

yes no

246

del(9q) / 9q–

yes no

247

del(11q) / 11q–

yes no

248

del(12p) / 12p–

yes no

249

del(13q) / 13q-

yes no

250

del(20q) / 20q–

yes no

251

inv(3)

yes no

252

i17q

yes no

253

Other abnormality

yes no

254

Specify other abnormality:255

What was the disease status?256

Complete
remission
(CR)

– requires all of the following, maintained for ≥ 4 weeks: * bone marrow evaluation: <  5% myeloblasts with normal maturation of all cell lines *
peripheral blood evaluation: hemoglobin ≥ 11 g/dL untransfused and without erythropoietin support; ANC ≥ 1000/mm3  without myeloid growth factor
support; platelets ≥ 100 x 109/L without thrombopoietic support; 0% blasts

Hematologic
improvement
(HI)

– requires one measurement of the following, maintained for ≥ 8 weeks without ongoing cytotoxic therapy; specify which cell line was measured to
determine HI response: * HI­E – hemoglobin increase of ≥ 1.5 g/dL untransfused; for RBC transfusions performed for Hgb ≤ 9.0, reduction in RBC
units transfused in 8 weeks by ≥ 4 units compared to the pre­treatment transfusion number in 8 weeks * HI­P – for pre­treatment platelet count of > 20
x 109/L, platelet absolute increase of ≥ 30 x 109/L; for pre-treatment platelet count of < 20 x 109/L, platelet absolute increase of ≥ 20 x 109/L and ≥
100% from pre­treatment level  * HI­N – neutrophil count increase of ≥ 100% from pre­treatment level and an absolute increase of ≥ 500/mm3

No response (NR) / stable disease (SD) – does not meet the criteria for at least HI, but no evidence of disease progression

Progression from
hematologic improvement
(Prog from HI)

– requires at least one of the following, in the absence of another explanation (e.g., infection, bleeding, ongoing chemotherapy, etc.): *
≥ 50% reduction from maximum response levels in granulocytes or platelets * reduction in hemoglobin by ≥ 1.5 g/dL *transfusion
dependence

Relapse from complete
remission (Rel from CR)

– requires at least one of the following: * return to pre­treatment bone marrow blast percentage * decrease of ≥ 50% from maximum
response levels in granulocytes or platelets * transfusion dependence, or hemoglobin level ≥ 1.5 g/dL lower than prior to therapy

Not assessed

Specify the cell line examined to determine HI status257

HI-
E

– hemoglobin increase of ≥ 1.5 g/dL untransfused; for RBC transfusions performed for Hgb ≤ 9.0, reduction in RBC units transfused in 8 weeks by ≥ 4
units compared to the pre-treatment transfusion number in 8 weeks

HI-
P

– for pre­treatment platelet count of > 20 x 109/L, platelet absolute increase of ≥ 30 x 109/L; for pre-treatment platelet count of < 20 x 109/L, platelet
absolute increase of ≥ 20 x 109/L and ≥ 100% from pre­treatment level 

HI-N – neutrophil count increase of ≥ 100% from pre­treatment level and an absolute increase of ≥ 500/mm3

Date of progression:258 __ __ __ __ - __ __- __ __

Date of relapse:259 __ __ __ __ - __ __- __ __

Date assessed:260 __ __ __ __ - __ __- __ __

Other Leukemia (OL) Questions: 261 - 267

Specify the other leukemia classification261

Specify other leukemia:262

Was any 17p abnormality detected?

yes no

263

Did a histologic transformation to diffuse large B-cell lymphoma (Richter syndrome) occur at any time after CLL diagnosis?264

yes - Also complete NHL Disease Classification questions

no

What was the disease status? (Atypical CML)265

Primary induction failure

1st complete remission (no previous bone marrow or extramedullary relapse)

2nd complete remission

≥3rd complete remission

1st relapse

2nd relapse

≥3rd relapse

No treatment

What was the disease status? (CLL, PLL, Hairy cell leukemia)266

Complete remission (CR)

Partial remission (PR)

Stable disease (SD)

Progressive disease (Prog)

Untreated

Not assessed

Date assessed:267 __ __ __ __ - __ __- __ __

Hodgkin and Non-Hodgkin Lymphoma Questions: 268 - 285

Specify the lymphoma histology (at infusion)268

Specify other lymphoma histology:269

Assignment of DLBCL (germinal center B-cell type vs. activated B-cell type) subtype was based on270

Immunohistochemistry (e.g. Han's algorithm)

Gene expression profile

Unknown method

Is the lymphoma histology reported at transplant a transformation from CLL?

yes no

271

Was any 17p abnormality detected?

yes no

272

Is the lymphoma histology reported at transplant a transformation from a different lymphoma histology? (Not CLL)

Yes No

273

Specify the original lymphoma histology (prior to transformation)274

Specify other lymphoma histology:275

Date of original lymphoma diagnosis:276 __ __ __ __ - __ __- __ __ (report the date of diagnosis of original lymphoma subtype)

Was a PET (or PET/CT) scan performed? (at last evaluation prior to the start of the preparative regimen / infusion)

yes no

277

Was the PET (or PET/CT) scan positive for lymphoma involvement at any disease site?

yes no

278

Date of PET scan

Known Unknown

279

Date of PET (or PET/CT) scan:280 __ __ __ __ - __ __- __ __

Deauville (five-point) score of the PET (or PET/CT) scan

Known Unknown

281

Scale282

1 - no uptake or residual uptake

2 - slight uptake, but below blood pool (mediastinum)

3 - uptake above mediastinal, but below or equal to uptake in the liver

4 - uptake slightly to moderately higher than liver

5 - markedly increased uptake or any new lesions

What was the disease status?283

Total number of lines of therapy received

1 line 2 lines 3+ lines

284

Date assessed:285 __ __ __ __ - __ __- __ __

Multiple Myeloma / Plasma Cell Disorder (PCD) Questions: 286 - 317

Specify the multiple myeloma/plasma cell disorder (PCD) classification286

Specify other plasma cell disorder:287

Light chain

kappa lambda

288

What was the Durie-Salmon staging? (at diagnosis)289

Stage
I

(All of the following: Hgb > 10g/dL; serum calcium normal or <10.5 mg/dL; bone x-ray normal bone structure (scale 0), or solitary bone plasmacytoma
only; low M-component production rates IgG< 5g/dL, IgA < 3g/dL; urine light chain M-component on electrophoresis <4 g/24h)

Stage II (Fitting neither Stage I or III) 

Stage
III

(One or more of the following: Hgb < 8.5 g/dL; serum calcium > 12 mg/dL; advanced lytic bone lesions (scale 3); high M-component production rates
IgG > 7g/dL, IgA > 5 g/dL; Bence Jones protein > 12g/24h)

Unknown

What was the Durie-Salmon sub classification? (at diagnosis)290

A - relatively normal renal function (serum creatinine < 2.0 mg/dL)

B ­ abnormal renal function (serum creatinine ≥ 2.0 mg/dL)

Serum β2­microglobulin:291 μg/dL mg/L nmol/L

Serum albumin:292 g/dL g/L

Stage293

1 (β2 ­mic < 3.5, S. albumin ≥3.5)

2 (Not fitting stage 1 or 3)

3 (β2­mic ≥ 5.5; S. albumin ­)

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

294

Results of tests295

Abnormalities identified

No evaluable metaphases

No abnormalities

+3

yes no

296

+5

yes no

297

+7

yes no

298

+9

yes no

299

+11

yes no

300

+15

yes no

301

+19

yes no

302

t(4;14)

yes no

303

t(6;14)

yes no

304

t(11;14)

yes no

305

t(14;16)

yes no

306

t(14;20)

yes no

307

del(13q) / 13q-

yes no

308

del (17p) / 17p-

yes no

309

Hyperdiploid (>50)

yes no

310

Hypodiploid (<46)

yes no

311

Any abnormality at 1q

yes no

312

Any abnormality at 1p

yes no

313

Other abnormality

yes no

314

Specify other abnormality:315

What was the disease status?316

Stringent
complete
remission
(sCR)

- CR as defined, plus: normal free light chain ratio, and absence of clonal cells in the bone marrow by immunohistochemistry of immunofluorescence
(confirmation with repeat bone marrow biopsy not needed). (Presence and/or absence of clonal cells is based upon the Κ/λ ratio. An abnormal Κ/λ ratio by
immunohistochemistry and/or immunofluorescence requires a minimum of 100 plasma cells for analysis.  An abnormal ratio reflecting the presence of
an abnormal clone is Κ/λ of > 4:1 or < 1:2.) sCR requires two consecutive assessments made at any time before the institution of any new therapy, and
no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy sCR
requirements. 

Complete
remission
(CR)

- negative immunofixation on serum and urine samples, and disappearance of any soft tissue plasmacytomas, and < 5% plasma cells in the bone
marrow (confirmation with repeat bone marrow biopsy not needed).  CR requires two consecutive assessments made at any time before the institution
of any new therapy, and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not
required to satisfy CR requirements. 

Near
complete
remission
(nCR)

- serum and urine M-protein detectable by immunoelectrophoresis (IFE), but not on electrophoresis (negative SPEP & UPEP); < 5% plasma cells in
bone marrow.  nCR requires two consecutive assessments made at any time before the initiation of any new therapy, and no known evidence of
progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy nCR requirements. 

Very good
partial
remission
(VGPR)

­ serum and urine M­protein detectable by immunofixation but not on electrophoresis, or ≥ 90% reduction in serum M­protein and urine M­protein level <
100 mg/24 hours.  VGPR requires two consecutive assessments made at any time before the institution of any new therapy, and no known evidence of
progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy VGPR requirements.

Partial
remission
(PR)

­ ≥ 50% reduction in serum M­protein, and reduction in 24­hour urinary M­protein by ≥ 90% or to < 200 mg/24 hours.  If the serum and urine M­protein are
unmeasurable (i.e., do not meet any of the following criteria: • serum M­protein ≥ 1 g/dL.  Urine M­protein ≥ 200 mg/24 hours • serum free light chain
assay shows involved level ≥ 10 mg/dL, provided serum free light chain ratio is abnormal), a ≥ 50% decrease in the difference between involved and
uninvolved free light chain levels is required in place of the M-protein criteria.  If serum and urine M-protein are unmeasurable, and serum free light assay
is also unmeasurable, a ≥ 50% reduction in plasma cells is required in place of M­protein, provided the baseline bone marrow plasma cell percentage
was ≥ 30%. In addition to the above listed criteria, a ≥ 50% reduction in the size of soft tissue plasmacytomas is also required, if present at baseline. PR
requires two consecutive assessments made at any time before the institution of any new therapy, and no known evidence of progressive or new bone
lesions if radiographic studies were performed; radiographic studies are not required to satisfy PR requirements. 

Stable
disease
(SD)

- not meeting the criteria for CR, VGPR, PR or PD.  SD requires two consecutive assessments made at any time before the institution of any new therapy,
and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy SD
requirements.

Progressive
disease
(PD)

­ requires any one or more of the following:  Increase of ≥ 25% from baseline in:  serum M­component and/or (absolute increase ≥ 0.5 g/dL) (for
progressive disease, serum M­component increases of ≥ 1 g/dL are sufficient to define relapse if the starting M­component is ≥ 5 g/dL).  Urine M­
component and/or (absolute increase ≥ 200 mg/24 hours) for recipients without measurable serum and urine M­protein levels: the difference between
involved and uninvolved free light chain levels (absolute increase > 10 mg/dL).  Bone marrow plasma cell percentage (absolute percentage ≥ 10%)
(relapse from CR has a 5% cutoff vs. 10% for other categories of relapse) definite development of new bone lesions or soft tissue plasmacytomas, or
definite increase in the size of any existing  bone lesions or soft tissue plasmacytomas. Development of hypercalcemia (corrected serum calcium >
11.5 mg/dL or 2.65 mmol) that can be attributed solely to the plasma cell proliferative disorder.  PD requires two consecutive assessments made at
any time before classification as disease progression, and/or the institution of any new therapy.

Relapse
from CR
(Rel)
(untreated)

­ requires one or more of the following: reappearance of serum or urine M­protein by immunofixation or electrophoresis development of ≥ 5% plasma
cells in the bone marrow (relapse from CR has a 5% cutoff vs. 10% for other categories of relapse) appearance of any other sign of progression (e.g.,
new plasmacytoma, lytic bone lesion, hypercalcemia).  Rel requires two consecutive assessments made at any time before classification as relapse,
and/or the institution of any new therapy.

Unknown

Not applicable (Amyloidosis with no evidence of myeloma)

Date assessed:317 __ __ __ __ - __ __- __ __

Solid Tumors Questions: 318 - 319

Specify the solid tumor classification318

Specify other solid tumor:319

Severe Aplastic Anemia Questions: 320 - 321

Specify the severe aplastic anemia classification320

Specify other acquired cytopenic syndrome:321

Inherited Abnormalities of Erythrocyte Differentiation or Function Questions: 322 - 324

Specify the inherited abnormalities of erythrocyte differentiation or function classification322

Specify other constitutional anemia:323

Specify other hemoglobinopathy:324

Disorders of the Immune System Questions: 325 - 327

Specify disorder of immune system classification325

Specify other SCID:326

Specify other immunodeficiency:327

Inherited Abnormalities of Platelets Questions: 328 - 329

Specify inherited abnormalities of platelets classification328

Congenital amegakaryocytosis / congenital thrombocytopenia (501)

Glanzmann thrombasthenia (502)

Other inherited platelet abnormality (509)

Specify other inherited platelet abnormality:329

Inherited Disorders of Metabolism Questions: 330 - 331

Specify inherited disorders of metabolism classification330

Specify other inherited metabolic disorder:331

Histiocytic Disorders Questions: 332 - 333

Specify histiocytic disorder classification332

Specify other histiocytic disorder:333

Autoimmune Diseases Questions: 334 - 341

Specify autoimmune disease classification334

Specify other arthritis:335

Specify other juvenile idiopathic arthritis (JIA):336

Specify other connective tissue disease:337

Specify other vasculitis:338

Specify other autoimmune neurological disorder:339

Specify other autoimmune cytopenia:340

Specify other autoimmune bowel disorder:341

Other Disease Questions: 342 - 342

Specify other disease:342

First Name:

Last Name:

E-mail address:

Date: __ __ __ __ - __ __- __ __

OMB No: 0915-0310

Expiration Date: 1/31/2020

Public Burden Statement:  An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control
number.  The OMB control number for this project is 0915-0310.  Public reporting burden for this collection of information is estimated to average 1.0 hours per response, including the
time for reviewing instructions, searching existing data sources, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other
aspect of this collection of information, including suggestions for reducing this burden, to HRSA Reports Clearance Officer, 5600 Fishers Lane, Room 10-29, Rockville, Maryland, 20857.

Labs at diagnosis

Specify cytogenetic abnormalities identified at diagnosis:

Specify cytogenetic abnormalities identified at diagnosis:

Specify molecular markers identified at diagnosis:

Labs between diagnosis and last evaluation:

Specify cytogenetic abnormalities identified between diagnosis and last evaluation:

Specify cytogenetic abnormalities identified between diagnosis and last evaluation:

Specify molecular markers identified between diagnosis and last evaluation:

Labs at last evaluation:

Specify cytogenetic abnormalities identified at last evaluation:

Specify cytogenetic abnormalities identified at last evaluation:

Specify molecular markers identified at last evaluation:

CNS Leukemia

Status at transplantation:

Laboratory studies at diagnosis:

Specify cytogenetic abnormalities identified at diagnosis:

Specify cytogenetic abnormalities identified at diagnosis:

Specify molecular markers identified at diagnosis:

Laboratory studies between diagnosis and last evaluation:

Specify cytogenetic abnormalities identified between diagnosis and last evaluation:

Specify cytogenetic abnormalities identified between diagnosis and last evaluation:

Specify molecular markers identified between diagnosis and last evaluation:

Laboratory studies at last evaluation:

Specify cytogenetic abnormalities identified at last evaluation:

Specify cytogenetic abnormalities identified at last evaluation:

Specify molecular markers identified at last evaluation:

CNS Leukemia

Status at transplantation:

Status at transplantation:

Laboratory studies at diagnosis of MDS:

Specify abnormalities identified at diagnosis:

Monosomy

Trisomy

Translocation

Deletion

Inversion

Other

Laboratory studies at last evaluation prior to the start of the preparative regimen:

Specify cytogenetic abnormalities identified at last evaluation prior to the start of the preparative regimen:

Monosomy

Trisomy

Translocation

Deletion

Inversion

Other

Status at transplantation:

Status at transplantation:

Status at transplantation / infusion:

I.S.S.:

Specify cytogenetic abnormalities identified at any time prior to the start of the preparative regimen:

Trisomy

Translocation

Deletion

Other

Status at transplantation:

Center: CRID: 

Form 2402 R3.0: Disease Classification

CIBMTR Form 2402 revision 3.0 last updated Monday, January 29, 2018
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 22 / 26



Key Fields

Sequence Number:

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number:

CIBMTR Research ID:

Event date: __ __ __ __ - __ __- __ __

Primary Disease for HCT / Cellular Therapy Questions: 1 - 2

Date of diagnosis of primary disease for HCT / cellular therapy:1 __ __ __ __ - __ __- __ __

What was the primary disease for which the HCT / cellular therapy was performed?2

Acute myelogenous leukemia (AML or ANLL) (10)

Acute lymphoblastic leukemia (ALL) (20)

Acute leukemia of ambiguous lineage and other myeloid neoplasms (80)

Chronic myelogenous leukemia (CML) (40)

Myelodysplastic (MDS) / myeloproliferative (MPN) diseases (50) (Please classify all preleukemias) (If recipient has transformed to AML, indicate AML as the primary disease)

Other leukemia (30) (includes CLL)

Hodgkin lymphoma (150)

Non-Hodgkin lymphoma (100)

Multiple myeloma / plasma cell disorder (PCD) (170)

Solid tumors (200)

Severe aplastic anemia (300) (If the recipient developed MDS or AML, indicate MDS or AML as the primary disease)

Inherited abnormalities of erythrocyte differentiation or function (310)

Disorders of the immune system (400)

Inherited abnormalities of platelets (500)

Inherited disorders of metabolism (520)

Histiocytic disorders (570)

Autoimmune diseases (600)

Other disease (900)

Acute Myelogenous Leukemia (AML) Questions: 3 - 89

Specify the AML classification3

Did AML transform from MDS or MPN?4

yes - Also complete MDS Disease Classification questions

no

Is the disease (AML) therapy related?

yes no Unknown

5

Did the recipient have a predisposing condition?

yes no Unknown

6

Specify condition7

Bloom syndrome

Down syndrome

Fanconi anemia

Dyskeratosis congenita

Other condition

Specify other condition:8

Were cytogenetics tested (karyotyping or FISH)? (at diagnosis)

yes no Unknown

9

Were cytogenetics tested via FISH? (at diagnosis)

Yes No

10

Results of tests11

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities12

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

13

Specify other abnormality:14

Were cytogenetics tested via karyotyping? (at diagnosis)

Yes No

15

Results of tests16

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities17

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

18

Specify other abnormality:19

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

20

Were tests for molecular markers performed? (e.g. PCR, NGS) (at diagnosis)

yes no Unknown

21

CEBPA

Positive Negative Not Done

22

Specify CEBPA mutation23

Biallelic (homozygous)

Monoallelic (heterozygous)

Unknown

FLT3 – D835 point mutation

Positive Negative Not Done

24

FLT3 – ITD mutation

Positive Negative Not Done

25

FLT3 - ITD allelic ratio

Known Unknown

26

Specify FLT3 - ITD allelic ratio:27

IDH1

Positive Negative Not Done

28

IDH2

Positive Negative Not Done

29

KIT

Positive Negative Not Done

30

NPM1

Positive Negative Not Done

31

Other Molecular Marker (1) Questions: 32 - 33

Other molecular marker

Positive Negative Not Done

32

Specify other molecular marker:33

Were cytogenetics tested (karyotyping or FISH)? (between diagnosis and last evaluation)

yes no Unknown

34

Were cytogenetics tested via FISH? (between diagnosis and last evaluation)

Yes No

35

Results of tests36

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities37

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

38

Specify other abnormality:39

Were cytogenetics tested via karyotyping? (between diagnosis and last evaluation)

Yes No

40

Results of tests41

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities42

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

43

Specify other abnormality:44

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

45

Were tests for molecular markers performed? (e.g. PCR, NGS) (between diagnosis and last evaluation)

yes no Unknown

46

CEBPA

Positive Negative Not Done

47

Specify CEBPA mutation48

Biallelic (homozygous)

Monoallelic (heterozygous)

Unknown

FLT3 – D835 point mutation

Positive Negative Not Done

49

FLT3 – ITD mutation

Positive Negative Not Done

50

FLT3 - ITD allelic ratio

Known Unknown

51

Specify FLT3 - ITD allelic ratio:52

IDH1

Positive Negative Not Done

53

IDH2

Positive Negative Not Done

54

KIT

Positive Negative Not Done

55

NPM1

Positive Negative Not Done

56

Other Molecular Marker (1) Questions: 57 - 58

Other molecular marker

Positive Negative Not Done

57

Specify other molecular marker:58

Were cytogenetics tested (karyotyping or FISH)? (at last evaluation)

yes no Unknown

59

Were cytogenetics tested via FISH? (at last evaluation)

Yes No

60

Results of tests61

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities62

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

63

Specify other abnormality:64

Were cytogenetics tested via karyotyping? (at last evaluation)

Yes No

65

Results of tests66

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities67

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

68

Specify other abnormality:69

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

70

Were tests for molecular markers performed? (e.g. PCR, NGS) (at last evaluation)

yes no Unknown

71

CEBPA

Positive Negative Not Done

72

Specify CEBPA mutation73

Biallelic (homozygous)

Monoallelic (heterozygous)

Unknown

FLT3 – D835 point mutation

Positive Negative Not Done

74

FLT3 – ITD mutation

Positive Negative Not Done

75

FLT3 - ITD allelic ratio

Known Unknown

76

Specify FLT3 - ITD allelic ratio:77

IDH1

Positive Negative Not Done

78

IDH2

Positive Negative Not Done

79

KIT

Positive Negative Not Done

80

NPM1

Positive Negative Not Done

81

Other Molecular Marker (1) Questions: 82 - 83

Other molecular marker

Positive Negative Not Done

82

Specify other molecular marker:83

Did the recipient have central nervous system leukemia at any time prior to the start of the preparative regimen / infusion?

yes no Unknown

84

What was the disease status (based on hematological test results)?85

Primary induction failure

1st complete remission (no previous bone marrow or extramedullary relapse) (include CRi)

2nd complete remission

≥3rd complete remission

1st relapse

2nd relapse

≥3rd relapse

No treatment

How many cycles of induction therapy were required to achieve 1st complete remission? (includes CRi)

1 2 ≥ 3

86

Was the recipient in remission by flow cytometry?

Yes No Unknown Not applicable

87

Date of most recent relapse:88 __ __ __ __ - __ __- __ __

Date assessed:89 __ __ __ __ - __ __- __ __

Acute Lymphoblastic Leukemia (ALL) Questions: 90 - 151

Specify ALL classification90

Did the recipient have a predisposing condition?

yes no Unknown

91

Specify condition92

Aplastic anemia - Also complete CIBMTR Form 2028 - APL

Bloom syndrome

Down syndrome

Fanconi anemia - Also complete CIBMTR Form 2029 - FAN

Other condition

Specify other condition:93

Were tyrosine kinase inhibitors given for therapy at any time prior to the start of the preparative regimen / infusion? (e.g. imatinib mesylate, dasatinib, etc.)

yes no

94

Were cytogenetics tested (karyotyping or FISH)? (at diagnosis)

yes no Unknown

95

Were cytogenetics tested via FISH? (at diagnosis)

Yes No

96

Results of tests97

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities98

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

99

Specify other abnormality:100

Were cytogenetics tested via karyotyping? (at diagnosis)

Yes No

101

Results of tests102

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities103

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

104

Specify other abnormality:105

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

106

Were tests for molecular markers performed? (e.g. PCR, NGS) (at diagnosis)

yes no Unknown

107

BCR / ABL

Positive Negative Not Done

108

TEL-AML / AML1

Positive Negative Not Done

109

Other Molecular Marker (1) Questions: 110 - 111

Other molecular marker

Positive Negative Not Done

110

Specify other molecular marker:111

Were cytogenetics tested (karyotyping or FISH)? (between diagnosis and last evaluation)

yes no Unknown

112

Were cytogenetics tested via FISH? (between diagnosis and last evaluation)

Yes No

113

Results of tests114

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities115

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

116

Specify other abnormality:117

Were cytogenetics tested via karyotyping? (between diagnosis and last evaluation)

Yes No

118

Results of tests119

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities120

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

121

Specify other abnormality:122

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

123

Were tests for molecular markers performed? (e.g. PCR, NGS) (between diagnosis and last evaluation)

yes no Unknown

124

BCR / ABL

Positive Negative Not Done

125

TEL-AML / AML1

Positive Negative Not Done

126

Other Molecular Marker (1) Questions: 127 - 128

Other molecular marker

Positive Negative Not Done

127

Specify other molecular marker:128

Were cytogenetics tested (karyotyping or FISH)? (at last evaluation)

yes no Unknown

129

Were cytogenetics tested via FISH? (at last evaluation)

Yes No

130

Results of tests131

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities132

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

133

Specify other abnormality:134

Were cytogenetics tested via karyotyping? (at last evaluation)

Yes No

135

Results of tests136

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities137

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

138

Specify other abnormality:139

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

140

Were tests for molecular markers performed? (e.g. PCR, NGS) (at last evaluation)

yes no Unknown

141

BCR / ABL

Positive Negative Not Done

142

TEL-AML / AML1

Positive Negative Not Done

143

Other Molecular Marker (1) Questions: 144 - 145

Other molecular marker

Positive Negative Not Done

144

Specify other molecular marker:145

Did the recipient have central nervous system leukemia at any time prior to the start of the preparative regimen / infusion?

yes no Unknown

146

What was the disease status (based on hematological test results)?147

Primary induction failure

1st complete remission (no previous marrow or extramedullary relapse) (include CRi)

2nd complete remission

≥3rd complete remission

1st relapse

2nd relapse

≥3rd relapse

No treatment

How many cycles of induction therapy were required to achieve 1st complete remission? (include CRi)

1 2 ≥ 3

148

Was the recipient in remission by flow cytometry?

Yes No Unknown Not applicable

149

Date of most recent relapse:150 __ __ __ __ - __ __- __ __

Date assessed:151 __ __ __ __ - __ __- __ __

Acute Leukemias of Ambiguous Lineage and Other Myeloid Neoplasms Questions: 152 - 155

Specify acute leukemias of ambiguous lineage and other myeloid neoplasm classification152

Blastic plasmacytoid dendritic cell neoplasm (296)

Acute undifferentiated leukemia (31)

Mixed phenotype acute leukemia (MPAL) with t(9;22)(q34.1;q11.2); BCR-ABL1 (84)

Mixed phenotype acute leukemia with t(v; 11q23.3); KMT2A rearranged (85)

Mixed phenotype acute leukemia, B/myeloid, NOS (86)

Mixed phenotype acute leukemia, T/myeloid, NOS (87)

Other acute leukemia of ambiguous lineage or myeloid neoplasm (88)

Specify other acute leukemia of ambiguous lineage or myeloid neoplasm:153

What was the disease status (based on hematological test results)?154

Primary induction failure

1st complete remission (no previous marrow or extramedullary relapse)

2nd complete remission

≥3rd complete remission

1st relapse

2nd relapse

≥3rd relapse

No treatment

Date assessed:155 __ __ __ __ - __ __- __ __

Chronic Myelogenous Leukemia (CML) Questions: 156 - 166

Was therapy given prior to this HCT?

yes no

156

Combination chemotherapy

yes no

157

Hydroxyurea (Droxia, Hydrea)

yes no

158

Tyrosine kinase inhibitor (e.g. imatinib mesylate, dasatinib, nilotinib)

yes no

159

Interferon­α (Intron, Roferon) (includes PEG)

yes no

160

Other therapy

yes no

161

Specify other therapy:162

What was the disease status?163

Complete hematologic response (CHR)

Chronic phase

Accelerated phase

Blast phase

Specify level of response164

No cytogenetic response (No CyR)

Minimal cytogenetic response

Minor cytogenetic response

Partial cytogenetic response (PCyR)

Complete cytogenetic response (CCyR)

Major molecular remission (MMR)

Complete molecular remission (CMR)

Number

1st 2nd 3rd or higher

165

Date assessed:166 __ __ __ __ - __ __- __ __

Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases Questions: 167 - 260

What was the MDS / MPN subtype at diagnosis? - If transformed to AML, indicate AML as primary disease; also complete AML Disease Classification
questions

167

Was the disease (MDS/MPN) therapy related?

yes no Unknown

168

Did the recipient have a predisposing condition?

yes no Unknown

169

Specify condition

Aplastic Anemia Bloom syndrome Down syndrome Fanconi anemia Other condition

170

Specify other condition:171

WBC

Known Unknown

172

173 x 109/L (x 103/mm3)

x 106/L

Hemoglobin

Known Unknown

174

175 g/dL g/L mmol/L

Was RBC transfused ≤ 30 days before date of test?

Yes No

176

Platelets

Known Unknown

177

178 x 109/L (x 103/mm3)

x 106/L

Were platelets transfused ≤ 7 days before date of test?

Yes No

179

Neutrophils

Known Unknown

180

181 %

Blasts in bone marrow

Known Unknown

182

183 %

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

184

Results of tests185

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities186

One (1)

Two (2)

Three (3)

Four or more (4 or more)

–5

yes no

187

-7

yes no

188

–13

yes no

189

–20

yes no

190

–Y

yes no

191

+8

yes no

192

+19

yes no

193

t(1;3)

yes no

194

t(2;11)

yes no

195

t(3;3)

yes no

196

t(3;21)

yes no

197

t(6;9)

yes no

198

t(11;16)

yes no

199

del(3q) / 3q–

yes no

200

del(5q) / 5q-

yes no

201

del(7q) / 7q–

yes no

202

del(9q) / 9q–

yes no

203

del(11q) / 11q–

yes no

204

del(12p) / 12p–

yes no

205

del(13q) / 13q-

yes no

206

del(20q) / 20q–

yes no

207

inv(3)

yes no

208

i17q

yes no

209

Other abnormality

yes no

210

Specify other abnormality:211

Did the recipient progress or transform to a different MDS / MPN subtype between diagnosis and the start of the preparative regimen?

yes no

212

Specify the MDS / MPN classification after transformation:213

Specify the date of the most recent transformation:214 __ __ __ __ - __ __- __ __

Date of MDS diagnosis:215 __ __ __ __ - __ __- __ __

WBC

Known Unknown

216

217 x 109/L (x 103/mm3)

x 106/L

Hemoglobin

Known Unknown

218

219 g/dL g/L mmol/L

Was RBC transfused ≤ 30 days before date of test?

Yes No

220

Platelets

Known Unknown

221

222 x 109/L (x 103/mm3)

x 106/L

Were platelets transfused ≤ 7 days before date of test?

Yes No

223

Neutrophils

Known Unknown

224

225 %

Blasts in bone marrow

Known Unknown

226

227 %

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

228

Results of tests229

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities230

One (1)

Two (2)

Three (3)

Four or more (4 or more)

–5

yes no

231

-7

yes no

232

–13

yes no

233

–20

yes no

234

–Y

yes no

235

+8

yes no

236

+19

yes no

237

t(1;3)

yes no

238

t(2;11)

yes no

239

t(3;3)

yes no

240

t(3;21)

yes no

241

t(6;9)

yes no

242

t(11;16)

yes no

243

del(3q) / 3q–

yes no

244

del(5q) / 5q-

yes no

245

del(7q) / 7q–

yes no

246

del(9q) / 9q–

yes no

247

del(11q) / 11q–

yes no

248

del(12p) / 12p–

yes no

249

del(13q) / 13q-

yes no

250

del(20q) / 20q–

yes no

251

inv(3)

yes no

252

i17q

yes no

253

Other abnormality

yes no

254

Specify other abnormality:255

What was the disease status?256

Complete
remission
(CR)

– requires all of the following, maintained for ≥ 4 weeks: * bone marrow evaluation: <  5% myeloblasts with normal maturation of all cell lines *
peripheral blood evaluation: hemoglobin ≥ 11 g/dL untransfused and without erythropoietin support; ANC ≥ 1000/mm3  without myeloid growth factor
support; platelets ≥ 100 x 109/L without thrombopoietic support; 0% blasts

Hematologic
improvement
(HI)

– requires one measurement of the following, maintained for ≥ 8 weeks without ongoing cytotoxic therapy; specify which cell line was measured to
determine HI response: * HI­E – hemoglobin increase of ≥ 1.5 g/dL untransfused; for RBC transfusions performed for Hgb ≤ 9.0, reduction in RBC
units transfused in 8 weeks by ≥ 4 units compared to the pre­treatment transfusion number in 8 weeks * HI­P – for pre­treatment platelet count of > 20
x 109/L, platelet absolute increase of ≥ 30 x 109/L; for pre-treatment platelet count of < 20 x 109/L, platelet absolute increase of ≥ 20 x 109/L and ≥
100% from pre­treatment level  * HI­N – neutrophil count increase of ≥ 100% from pre­treatment level and an absolute increase of ≥ 500/mm3

No response (NR) / stable disease (SD) – does not meet the criteria for at least HI, but no evidence of disease progression

Progression from
hematologic improvement
(Prog from HI)

– requires at least one of the following, in the absence of another explanation (e.g., infection, bleeding, ongoing chemotherapy, etc.): *
≥ 50% reduction from maximum response levels in granulocytes or platelets * reduction in hemoglobin by ≥ 1.5 g/dL *transfusion
dependence

Relapse from complete
remission (Rel from CR)

– requires at least one of the following: * return to pre­treatment bone marrow blast percentage * decrease of ≥ 50% from maximum
response levels in granulocytes or platelets * transfusion dependence, or hemoglobin level ≥ 1.5 g/dL lower than prior to therapy

Not assessed

Specify the cell line examined to determine HI status257

HI-
E

– hemoglobin increase of ≥ 1.5 g/dL untransfused; for RBC transfusions performed for Hgb ≤ 9.0, reduction in RBC units transfused in 8 weeks by ≥ 4
units compared to the pre-treatment transfusion number in 8 weeks

HI-
P

– for pre­treatment platelet count of > 20 x 109/L, platelet absolute increase of ≥ 30 x 109/L; for pre-treatment platelet count of < 20 x 109/L, platelet
absolute increase of ≥ 20 x 109/L and ≥ 100% from pre­treatment level 

HI-N – neutrophil count increase of ≥ 100% from pre­treatment level and an absolute increase of ≥ 500/mm3

Date of progression:258 __ __ __ __ - __ __- __ __

Date of relapse:259 __ __ __ __ - __ __- __ __

Date assessed:260 __ __ __ __ - __ __- __ __

Other Leukemia (OL) Questions: 261 - 267

Specify the other leukemia classification261

Specify other leukemia:262

Was any 17p abnormality detected?

yes no

263

Did a histologic transformation to diffuse large B-cell lymphoma (Richter syndrome) occur at any time after CLL diagnosis?264

yes - Also complete NHL Disease Classification questions

no

What was the disease status? (Atypical CML)265

Primary induction failure

1st complete remission (no previous bone marrow or extramedullary relapse)

2nd complete remission

≥3rd complete remission

1st relapse

2nd relapse

≥3rd relapse

No treatment

What was the disease status? (CLL, PLL, Hairy cell leukemia)266

Complete remission (CR)

Partial remission (PR)

Stable disease (SD)

Progressive disease (Prog)

Untreated

Not assessed

Date assessed:267 __ __ __ __ - __ __- __ __

Hodgkin and Non-Hodgkin Lymphoma Questions: 268 - 285

Specify the lymphoma histology (at infusion)268

Specify other lymphoma histology:269

Assignment of DLBCL (germinal center B-cell type vs. activated B-cell type) subtype was based on270

Immunohistochemistry (e.g. Han's algorithm)

Gene expression profile

Unknown method

Is the lymphoma histology reported at transplant a transformation from CLL?

yes no

271

Was any 17p abnormality detected?

yes no

272

Is the lymphoma histology reported at transplant a transformation from a different lymphoma histology? (Not CLL)

Yes No

273

Specify the original lymphoma histology (prior to transformation)274

Specify other lymphoma histology:275

Date of original lymphoma diagnosis:276 __ __ __ __ - __ __- __ __ (report the date of diagnosis of original lymphoma subtype)

Was a PET (or PET/CT) scan performed? (at last evaluation prior to the start of the preparative regimen / infusion)

yes no

277

Was the PET (or PET/CT) scan positive for lymphoma involvement at any disease site?

yes no

278

Date of PET scan

Known Unknown

279

Date of PET (or PET/CT) scan:280 __ __ __ __ - __ __- __ __

Deauville (five-point) score of the PET (or PET/CT) scan

Known Unknown

281

Scale282

1 - no uptake or residual uptake

2 - slight uptake, but below blood pool (mediastinum)

3 - uptake above mediastinal, but below or equal to uptake in the liver

4 - uptake slightly to moderately higher than liver

5 - markedly increased uptake or any new lesions

What was the disease status?283

Total number of lines of therapy received

1 line 2 lines 3+ lines

284

Date assessed:285 __ __ __ __ - __ __- __ __

Multiple Myeloma / Plasma Cell Disorder (PCD) Questions: 286 - 317

Specify the multiple myeloma/plasma cell disorder (PCD) classification286

Specify other plasma cell disorder:287

Light chain

kappa lambda

288

What was the Durie-Salmon staging? (at diagnosis)289

Stage
I

(All of the following: Hgb > 10g/dL; serum calcium normal or <10.5 mg/dL; bone x-ray normal bone structure (scale 0), or solitary bone plasmacytoma
only; low M-component production rates IgG< 5g/dL, IgA < 3g/dL; urine light chain M-component on electrophoresis <4 g/24h)

Stage II (Fitting neither Stage I or III) 

Stage
III

(One or more of the following: Hgb < 8.5 g/dL; serum calcium > 12 mg/dL; advanced lytic bone lesions (scale 3); high M-component production rates
IgG > 7g/dL, IgA > 5 g/dL; Bence Jones protein > 12g/24h)

Unknown

What was the Durie-Salmon sub classification? (at diagnosis)290

A - relatively normal renal function (serum creatinine < 2.0 mg/dL)

B ­ abnormal renal function (serum creatinine ≥ 2.0 mg/dL)

Serum β2­microglobulin:291 μg/dL mg/L nmol/L

Serum albumin:292 g/dL g/L

Stage293

1 (β2 ­mic < 3.5, S. albumin ≥3.5)

2 (Not fitting stage 1 or 3)

3 (β2­mic ≥ 5.5; S. albumin ­)

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

294

Results of tests295

Abnormalities identified

No evaluable metaphases

No abnormalities

+3

yes no

296

+5

yes no

297

+7

yes no

298

+9

yes no

299

+11

yes no

300

+15

yes no

301

+19

yes no

302

t(4;14)

yes no

303

t(6;14)

yes no

304

t(11;14)

yes no

305

t(14;16)

yes no

306

t(14;20)

yes no

307

del(13q) / 13q-

yes no

308

del (17p) / 17p-

yes no

309

Hyperdiploid (>50)

yes no

310

Hypodiploid (<46)

yes no

311

Any abnormality at 1q

yes no

312

Any abnormality at 1p

yes no

313

Other abnormality

yes no

314

Specify other abnormality:315

What was the disease status?316

Stringent
complete
remission
(sCR)

- CR as defined, plus: normal free light chain ratio, and absence of clonal cells in the bone marrow by immunohistochemistry of immunofluorescence
(confirmation with repeat bone marrow biopsy not needed). (Presence and/or absence of clonal cells is based upon the Κ/λ ratio. An abnormal Κ/λ ratio by
immunohistochemistry and/or immunofluorescence requires a minimum of 100 plasma cells for analysis.  An abnormal ratio reflecting the presence of
an abnormal clone is Κ/λ of > 4:1 or < 1:2.) sCR requires two consecutive assessments made at any time before the institution of any new therapy, and
no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy sCR
requirements. 

Complete
remission
(CR)

- negative immunofixation on serum and urine samples, and disappearance of any soft tissue plasmacytomas, and < 5% plasma cells in the bone
marrow (confirmation with repeat bone marrow biopsy not needed).  CR requires two consecutive assessments made at any time before the institution
of any new therapy, and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not
required to satisfy CR requirements. 

Near
complete
remission
(nCR)

- serum and urine M-protein detectable by immunoelectrophoresis (IFE), but not on electrophoresis (negative SPEP & UPEP); < 5% plasma cells in
bone marrow.  nCR requires two consecutive assessments made at any time before the initiation of any new therapy, and no known evidence of
progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy nCR requirements. 

Very good
partial
remission
(VGPR)

­ serum and urine M­protein detectable by immunofixation but not on electrophoresis, or ≥ 90% reduction in serum M­protein and urine M­protein level <
100 mg/24 hours.  VGPR requires two consecutive assessments made at any time before the institution of any new therapy, and no known evidence of
progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy VGPR requirements.

Partial
remission
(PR)

­ ≥ 50% reduction in serum M­protein, and reduction in 24­hour urinary M­protein by ≥ 90% or to < 200 mg/24 hours.  If the serum and urine M­protein are
unmeasurable (i.e., do not meet any of the following criteria: • serum M­protein ≥ 1 g/dL.  Urine M­protein ≥ 200 mg/24 hours • serum free light chain
assay shows involved level ≥ 10 mg/dL, provided serum free light chain ratio is abnormal), a ≥ 50% decrease in the difference between involved and
uninvolved free light chain levels is required in place of the M-protein criteria.  If serum and urine M-protein are unmeasurable, and serum free light assay
is also unmeasurable, a ≥ 50% reduction in plasma cells is required in place of M­protein, provided the baseline bone marrow plasma cell percentage
was ≥ 30%. In addition to the above listed criteria, a ≥ 50% reduction in the size of soft tissue plasmacytomas is also required, if present at baseline. PR
requires two consecutive assessments made at any time before the institution of any new therapy, and no known evidence of progressive or new bone
lesions if radiographic studies were performed; radiographic studies are not required to satisfy PR requirements. 

Stable
disease
(SD)

- not meeting the criteria for CR, VGPR, PR or PD.  SD requires two consecutive assessments made at any time before the institution of any new therapy,
and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy SD
requirements.

Progressive
disease
(PD)

­ requires any one or more of the following:  Increase of ≥ 25% from baseline in:  serum M­component and/or (absolute increase ≥ 0.5 g/dL) (for
progressive disease, serum M­component increases of ≥ 1 g/dL are sufficient to define relapse if the starting M­component is ≥ 5 g/dL).  Urine M­
component and/or (absolute increase ≥ 200 mg/24 hours) for recipients without measurable serum and urine M­protein levels: the difference between
involved and uninvolved free light chain levels (absolute increase > 10 mg/dL).  Bone marrow plasma cell percentage (absolute percentage ≥ 10%)
(relapse from CR has a 5% cutoff vs. 10% for other categories of relapse) definite development of new bone lesions or soft tissue plasmacytomas, or
definite increase in the size of any existing  bone lesions or soft tissue plasmacytomas. Development of hypercalcemia (corrected serum calcium >
11.5 mg/dL or 2.65 mmol) that can be attributed solely to the plasma cell proliferative disorder.  PD requires two consecutive assessments made at
any time before classification as disease progression, and/or the institution of any new therapy.

Relapse
from CR
(Rel)
(untreated)

­ requires one or more of the following: reappearance of serum or urine M­protein by immunofixation or electrophoresis development of ≥ 5% plasma
cells in the bone marrow (relapse from CR has a 5% cutoff vs. 10% for other categories of relapse) appearance of any other sign of progression (e.g.,
new plasmacytoma, lytic bone lesion, hypercalcemia).  Rel requires two consecutive assessments made at any time before classification as relapse,
and/or the institution of any new therapy.

Unknown

Not applicable (Amyloidosis with no evidence of myeloma)

Date assessed:317 __ __ __ __ - __ __- __ __

Solid Tumors Questions: 318 - 319

Specify the solid tumor classification318

Specify other solid tumor:319

Severe Aplastic Anemia Questions: 320 - 321

Specify the severe aplastic anemia classification320

Specify other acquired cytopenic syndrome:321

Inherited Abnormalities of Erythrocyte Differentiation or Function Questions: 322 - 324

Specify the inherited abnormalities of erythrocyte differentiation or function classification322

Specify other constitutional anemia:323

Specify other hemoglobinopathy:324

Disorders of the Immune System Questions: 325 - 327

Specify disorder of immune system classification325

Specify other SCID:326

Specify other immunodeficiency:327

Inherited Abnormalities of Platelets Questions: 328 - 329

Specify inherited abnormalities of platelets classification328

Congenital amegakaryocytosis / congenital thrombocytopenia (501)

Glanzmann thrombasthenia (502)

Other inherited platelet abnormality (509)

Specify other inherited platelet abnormality:329

Inherited Disorders of Metabolism Questions: 330 - 331

Specify inherited disorders of metabolism classification330

Specify other inherited metabolic disorder:331

Histiocytic Disorders Questions: 332 - 333

Specify histiocytic disorder classification332

Specify other histiocytic disorder:333

Autoimmune Diseases Questions: 334 - 341

Specify autoimmune disease classification334

Specify other arthritis:335

Specify other juvenile idiopathic arthritis (JIA):336

Specify other connective tissue disease:337

Specify other vasculitis:338

Specify other autoimmune neurological disorder:339

Specify other autoimmune cytopenia:340

Specify other autoimmune bowel disorder:341

Other Disease Questions: 342 - 342

Specify other disease:342

First Name:

Last Name:

E-mail address:

Date: __ __ __ __ - __ __- __ __

OMB No: 0915-0310

Expiration Date: 1/31/2020

Public Burden Statement:  An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control
number.  The OMB control number for this project is 0915-0310.  Public reporting burden for this collection of information is estimated to average 1.0 hours per response, including the
time for reviewing instructions, searching existing data sources, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other
aspect of this collection of information, including suggestions for reducing this burden, to HRSA Reports Clearance Officer, 5600 Fishers Lane, Room 10-29, Rockville, Maryland, 20857.

Labs at diagnosis

Specify cytogenetic abnormalities identified at diagnosis:

Specify cytogenetic abnormalities identified at diagnosis:

Specify molecular markers identified at diagnosis:

Labs between diagnosis and last evaluation:

Specify cytogenetic abnormalities identified between diagnosis and last evaluation:

Specify cytogenetic abnormalities identified between diagnosis and last evaluation:

Specify molecular markers identified between diagnosis and last evaluation:

Labs at last evaluation:

Specify cytogenetic abnormalities identified at last evaluation:

Specify cytogenetic abnormalities identified at last evaluation:

Specify molecular markers identified at last evaluation:

CNS Leukemia

Status at transplantation:

Laboratory studies at diagnosis:

Specify cytogenetic abnormalities identified at diagnosis:

Specify cytogenetic abnormalities identified at diagnosis:

Specify molecular markers identified at diagnosis:

Laboratory studies between diagnosis and last evaluation:

Specify cytogenetic abnormalities identified between diagnosis and last evaluation:

Specify cytogenetic abnormalities identified between diagnosis and last evaluation:

Specify molecular markers identified between diagnosis and last evaluation:

Laboratory studies at last evaluation:

Specify cytogenetic abnormalities identified at last evaluation:

Specify cytogenetic abnormalities identified at last evaluation:

Specify molecular markers identified at last evaluation:

CNS Leukemia

Status at transplantation:

Status at transplantation:

Laboratory studies at diagnosis of MDS:

Specify abnormalities identified at diagnosis:

Monosomy

Trisomy

Translocation

Deletion

Inversion

Other

Laboratory studies at last evaluation prior to the start of the preparative regimen:

Specify cytogenetic abnormalities identified at last evaluation prior to the start of the preparative regimen:

Monosomy

Trisomy

Translocation

Deletion

Inversion

Other

Status at transplantation:

Status at transplantation:

Status at transplantation / infusion:

I.S.S.:

Specify cytogenetic abnormalities identified at any time prior to the start of the preparative regimen:

Trisomy

Translocation

Deletion

Other

Status at transplantation:

Center: CRID: 

Form 2402 R3.0: Disease Classification

CIBMTR Form 2402 revision 3.0 last updated Monday, January 29, 2018
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 23 / 26



Key Fields

Sequence Number:

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number:

CIBMTR Research ID:

Event date: __ __ __ __ - __ __- __ __

Primary Disease for HCT / Cellular Therapy Questions: 1 - 2

Date of diagnosis of primary disease for HCT / cellular therapy:1 __ __ __ __ - __ __- __ __

What was the primary disease for which the HCT / cellular therapy was performed?2

Acute myelogenous leukemia (AML or ANLL) (10)

Acute lymphoblastic leukemia (ALL) (20)

Acute leukemia of ambiguous lineage and other myeloid neoplasms (80)

Chronic myelogenous leukemia (CML) (40)

Myelodysplastic (MDS) / myeloproliferative (MPN) diseases (50) (Please classify all preleukemias) (If recipient has transformed to AML, indicate AML as the primary disease)

Other leukemia (30) (includes CLL)

Hodgkin lymphoma (150)

Non-Hodgkin lymphoma (100)

Multiple myeloma / plasma cell disorder (PCD) (170)

Solid tumors (200)

Severe aplastic anemia (300) (If the recipient developed MDS or AML, indicate MDS or AML as the primary disease)

Inherited abnormalities of erythrocyte differentiation or function (310)

Disorders of the immune system (400)

Inherited abnormalities of platelets (500)

Inherited disorders of metabolism (520)

Histiocytic disorders (570)

Autoimmune diseases (600)

Other disease (900)

Acute Myelogenous Leukemia (AML) Questions: 3 - 89

Specify the AML classification3

Did AML transform from MDS or MPN?4

yes - Also complete MDS Disease Classification questions

no

Is the disease (AML) therapy related?

yes no Unknown

5

Did the recipient have a predisposing condition?

yes no Unknown

6

Specify condition7

Bloom syndrome

Down syndrome

Fanconi anemia

Dyskeratosis congenita

Other condition

Specify other condition:8

Were cytogenetics tested (karyotyping or FISH)? (at diagnosis)

yes no Unknown

9

Were cytogenetics tested via FISH? (at diagnosis)

Yes No

10

Results of tests11

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities12

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

13

Specify other abnormality:14

Were cytogenetics tested via karyotyping? (at diagnosis)

Yes No

15

Results of tests16

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities17

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

18

Specify other abnormality:19

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

20

Were tests for molecular markers performed? (e.g. PCR, NGS) (at diagnosis)

yes no Unknown

21

CEBPA

Positive Negative Not Done

22

Specify CEBPA mutation23

Biallelic (homozygous)

Monoallelic (heterozygous)

Unknown

FLT3 – D835 point mutation

Positive Negative Not Done

24

FLT3 – ITD mutation

Positive Negative Not Done

25

FLT3 - ITD allelic ratio

Known Unknown

26

Specify FLT3 - ITD allelic ratio:27

IDH1

Positive Negative Not Done

28

IDH2

Positive Negative Not Done

29

KIT

Positive Negative Not Done

30

NPM1

Positive Negative Not Done

31

Other Molecular Marker (1) Questions: 32 - 33

Other molecular marker

Positive Negative Not Done

32

Specify other molecular marker:33

Were cytogenetics tested (karyotyping or FISH)? (between diagnosis and last evaluation)

yes no Unknown

34

Were cytogenetics tested via FISH? (between diagnosis and last evaluation)

Yes No

35

Results of tests36

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities37

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

38

Specify other abnormality:39

Were cytogenetics tested via karyotyping? (between diagnosis and last evaluation)

Yes No

40

Results of tests41

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities42

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

43

Specify other abnormality:44

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

45

Were tests for molecular markers performed? (e.g. PCR, NGS) (between diagnosis and last evaluation)

yes no Unknown

46

CEBPA

Positive Negative Not Done

47

Specify CEBPA mutation48

Biallelic (homozygous)

Monoallelic (heterozygous)

Unknown

FLT3 – D835 point mutation

Positive Negative Not Done

49

FLT3 – ITD mutation

Positive Negative Not Done

50

FLT3 - ITD allelic ratio

Known Unknown

51

Specify FLT3 - ITD allelic ratio:52

IDH1

Positive Negative Not Done

53

IDH2

Positive Negative Not Done

54

KIT

Positive Negative Not Done

55

NPM1

Positive Negative Not Done

56

Other Molecular Marker (1) Questions: 57 - 58

Other molecular marker

Positive Negative Not Done

57

Specify other molecular marker:58

Were cytogenetics tested (karyotyping or FISH)? (at last evaluation)

yes no Unknown

59

Were cytogenetics tested via FISH? (at last evaluation)

Yes No

60

Results of tests61

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities62

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

63

Specify other abnormality:64

Were cytogenetics tested via karyotyping? (at last evaluation)

Yes No

65

Results of tests66

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities67

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

68

Specify other abnormality:69

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

70

Were tests for molecular markers performed? (e.g. PCR, NGS) (at last evaluation)

yes no Unknown

71

CEBPA

Positive Negative Not Done

72

Specify CEBPA mutation73

Biallelic (homozygous)

Monoallelic (heterozygous)

Unknown

FLT3 – D835 point mutation

Positive Negative Not Done

74

FLT3 – ITD mutation

Positive Negative Not Done

75

FLT3 - ITD allelic ratio

Known Unknown

76

Specify FLT3 - ITD allelic ratio:77

IDH1

Positive Negative Not Done

78

IDH2

Positive Negative Not Done

79

KIT

Positive Negative Not Done

80

NPM1

Positive Negative Not Done

81

Other Molecular Marker (1) Questions: 82 - 83

Other molecular marker

Positive Negative Not Done

82

Specify other molecular marker:83

Did the recipient have central nervous system leukemia at any time prior to the start of the preparative regimen / infusion?

yes no Unknown

84

What was the disease status (based on hematological test results)?85

Primary induction failure

1st complete remission (no previous bone marrow or extramedullary relapse) (include CRi)

2nd complete remission

≥3rd complete remission

1st relapse

2nd relapse

≥3rd relapse

No treatment

How many cycles of induction therapy were required to achieve 1st complete remission? (includes CRi)

1 2 ≥ 3

86

Was the recipient in remission by flow cytometry?

Yes No Unknown Not applicable

87

Date of most recent relapse:88 __ __ __ __ - __ __- __ __

Date assessed:89 __ __ __ __ - __ __- __ __

Acute Lymphoblastic Leukemia (ALL) Questions: 90 - 151

Specify ALL classification90

Did the recipient have a predisposing condition?

yes no Unknown

91

Specify condition92

Aplastic anemia - Also complete CIBMTR Form 2028 - APL

Bloom syndrome

Down syndrome

Fanconi anemia - Also complete CIBMTR Form 2029 - FAN

Other condition

Specify other condition:93

Were tyrosine kinase inhibitors given for therapy at any time prior to the start of the preparative regimen / infusion? (e.g. imatinib mesylate, dasatinib, etc.)

yes no

94

Were cytogenetics tested (karyotyping or FISH)? (at diagnosis)

yes no Unknown

95

Were cytogenetics tested via FISH? (at diagnosis)

Yes No

96

Results of tests97

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities98

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

99

Specify other abnormality:100

Were cytogenetics tested via karyotyping? (at diagnosis)

Yes No

101

Results of tests102

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities103

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

104

Specify other abnormality:105

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

106

Were tests for molecular markers performed? (e.g. PCR, NGS) (at diagnosis)

yes no Unknown

107

BCR / ABL

Positive Negative Not Done

108

TEL-AML / AML1

Positive Negative Not Done

109

Other Molecular Marker (1) Questions: 110 - 111

Other molecular marker

Positive Negative Not Done

110

Specify other molecular marker:111

Were cytogenetics tested (karyotyping or FISH)? (between diagnosis and last evaluation)

yes no Unknown

112

Were cytogenetics tested via FISH? (between diagnosis and last evaluation)

Yes No

113

Results of tests114

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities115

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

116

Specify other abnormality:117

Were cytogenetics tested via karyotyping? (between diagnosis and last evaluation)

Yes No

118

Results of tests119

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities120

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

121

Specify other abnormality:122

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

123

Were tests for molecular markers performed? (e.g. PCR, NGS) (between diagnosis and last evaluation)

yes no Unknown

124

BCR / ABL

Positive Negative Not Done

125

TEL-AML / AML1

Positive Negative Not Done

126

Other Molecular Marker (1) Questions: 127 - 128

Other molecular marker

Positive Negative Not Done

127

Specify other molecular marker:128

Were cytogenetics tested (karyotyping or FISH)? (at last evaluation)

yes no Unknown

129

Were cytogenetics tested via FISH? (at last evaluation)

Yes No

130

Results of tests131

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities132

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

133

Specify other abnormality:134

Were cytogenetics tested via karyotyping? (at last evaluation)

Yes No

135

Results of tests136

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities137

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

138

Specify other abnormality:139

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

140

Were tests for molecular markers performed? (e.g. PCR, NGS) (at last evaluation)

yes no Unknown

141

BCR / ABL

Positive Negative Not Done

142

TEL-AML / AML1

Positive Negative Not Done

143

Other Molecular Marker (1) Questions: 144 - 145

Other molecular marker

Positive Negative Not Done

144

Specify other molecular marker:145

Did the recipient have central nervous system leukemia at any time prior to the start of the preparative regimen / infusion?

yes no Unknown

146

What was the disease status (based on hematological test results)?147

Primary induction failure

1st complete remission (no previous marrow or extramedullary relapse) (include CRi)

2nd complete remission

≥3rd complete remission

1st relapse

2nd relapse

≥3rd relapse

No treatment

How many cycles of induction therapy were required to achieve 1st complete remission? (include CRi)

1 2 ≥ 3

148

Was the recipient in remission by flow cytometry?

Yes No Unknown Not applicable

149

Date of most recent relapse:150 __ __ __ __ - __ __- __ __

Date assessed:151 __ __ __ __ - __ __- __ __

Acute Leukemias of Ambiguous Lineage and Other Myeloid Neoplasms Questions: 152 - 155

Specify acute leukemias of ambiguous lineage and other myeloid neoplasm classification152

Blastic plasmacytoid dendritic cell neoplasm (296)

Acute undifferentiated leukemia (31)

Mixed phenotype acute leukemia (MPAL) with t(9;22)(q34.1;q11.2); BCR-ABL1 (84)

Mixed phenotype acute leukemia with t(v; 11q23.3); KMT2A rearranged (85)

Mixed phenotype acute leukemia, B/myeloid, NOS (86)

Mixed phenotype acute leukemia, T/myeloid, NOS (87)

Other acute leukemia of ambiguous lineage or myeloid neoplasm (88)

Specify other acute leukemia of ambiguous lineage or myeloid neoplasm:153

What was the disease status (based on hematological test results)?154

Primary induction failure

1st complete remission (no previous marrow or extramedullary relapse)

2nd complete remission

≥3rd complete remission

1st relapse

2nd relapse

≥3rd relapse

No treatment

Date assessed:155 __ __ __ __ - __ __- __ __

Chronic Myelogenous Leukemia (CML) Questions: 156 - 166

Was therapy given prior to this HCT?

yes no

156

Combination chemotherapy

yes no

157

Hydroxyurea (Droxia, Hydrea)

yes no

158

Tyrosine kinase inhibitor (e.g. imatinib mesylate, dasatinib, nilotinib)

yes no

159

Interferon­α (Intron, Roferon) (includes PEG)

yes no

160

Other therapy

yes no

161

Specify other therapy:162

What was the disease status?163

Complete hematologic response (CHR)

Chronic phase

Accelerated phase

Blast phase

Specify level of response164

No cytogenetic response (No CyR)

Minimal cytogenetic response

Minor cytogenetic response

Partial cytogenetic response (PCyR)

Complete cytogenetic response (CCyR)

Major molecular remission (MMR)

Complete molecular remission (CMR)

Number

1st 2nd 3rd or higher

165

Date assessed:166 __ __ __ __ - __ __- __ __

Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases Questions: 167 - 260

What was the MDS / MPN subtype at diagnosis? - If transformed to AML, indicate AML as primary disease; also complete AML Disease Classification
questions

167

Was the disease (MDS/MPN) therapy related?

yes no Unknown

168

Did the recipient have a predisposing condition?

yes no Unknown

169

Specify condition

Aplastic Anemia Bloom syndrome Down syndrome Fanconi anemia Other condition

170

Specify other condition:171

WBC

Known Unknown

172

173 x 109/L (x 103/mm3)

x 106/L

Hemoglobin

Known Unknown

174

175 g/dL g/L mmol/L

Was RBC transfused ≤ 30 days before date of test?

Yes No

176

Platelets

Known Unknown

177

178 x 109/L (x 103/mm3)

x 106/L

Were platelets transfused ≤ 7 days before date of test?

Yes No

179

Neutrophils

Known Unknown

180

181 %

Blasts in bone marrow

Known Unknown

182

183 %

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

184

Results of tests185

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities186

One (1)

Two (2)

Three (3)

Four or more (4 or more)

–5

yes no

187

-7

yes no

188

–13

yes no

189

–20

yes no

190

–Y

yes no

191

+8

yes no

192

+19

yes no

193

t(1;3)

yes no

194

t(2;11)

yes no

195

t(3;3)

yes no

196

t(3;21)

yes no

197

t(6;9)

yes no

198

t(11;16)

yes no

199

del(3q) / 3q–

yes no

200

del(5q) / 5q-

yes no

201

del(7q) / 7q–

yes no

202

del(9q) / 9q–

yes no

203

del(11q) / 11q–

yes no

204

del(12p) / 12p–

yes no

205

del(13q) / 13q-

yes no

206

del(20q) / 20q–

yes no

207

inv(3)

yes no

208

i17q

yes no

209

Other abnormality

yes no

210

Specify other abnormality:211

Did the recipient progress or transform to a different MDS / MPN subtype between diagnosis and the start of the preparative regimen?

yes no

212

Specify the MDS / MPN classification after transformation:213

Specify the date of the most recent transformation:214 __ __ __ __ - __ __- __ __

Date of MDS diagnosis:215 __ __ __ __ - __ __- __ __

WBC

Known Unknown

216

217 x 109/L (x 103/mm3)

x 106/L

Hemoglobin

Known Unknown

218

219 g/dL g/L mmol/L

Was RBC transfused ≤ 30 days before date of test?

Yes No

220

Platelets

Known Unknown

221

222 x 109/L (x 103/mm3)

x 106/L

Were platelets transfused ≤ 7 days before date of test?

Yes No

223

Neutrophils

Known Unknown

224

225 %

Blasts in bone marrow

Known Unknown

226

227 %

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

228

Results of tests229

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities230

One (1)

Two (2)

Three (3)

Four or more (4 or more)

–5

yes no

231

-7

yes no

232

–13

yes no

233

–20

yes no

234

–Y

yes no

235

+8

yes no

236

+19

yes no

237

t(1;3)

yes no

238

t(2;11)

yes no

239

t(3;3)

yes no

240

t(3;21)

yes no

241

t(6;9)

yes no

242

t(11;16)

yes no

243

del(3q) / 3q–

yes no

244

del(5q) / 5q-

yes no

245

del(7q) / 7q–

yes no

246

del(9q) / 9q–

yes no

247

del(11q) / 11q–

yes no

248

del(12p) / 12p–

yes no

249

del(13q) / 13q-

yes no

250

del(20q) / 20q–

yes no

251

inv(3)

yes no

252

i17q

yes no

253

Other abnormality

yes no

254

Specify other abnormality:255

What was the disease status?256

Complete
remission
(CR)

– requires all of the following, maintained for ≥ 4 weeks: * bone marrow evaluation: <  5% myeloblasts with normal maturation of all cell lines *
peripheral blood evaluation: hemoglobin ≥ 11 g/dL untransfused and without erythropoietin support; ANC ≥ 1000/mm3  without myeloid growth factor
support; platelets ≥ 100 x 109/L without thrombopoietic support; 0% blasts

Hematologic
improvement
(HI)

– requires one measurement of the following, maintained for ≥ 8 weeks without ongoing cytotoxic therapy; specify which cell line was measured to
determine HI response: * HI­E – hemoglobin increase of ≥ 1.5 g/dL untransfused; for RBC transfusions performed for Hgb ≤ 9.0, reduction in RBC
units transfused in 8 weeks by ≥ 4 units compared to the pre­treatment transfusion number in 8 weeks * HI­P – for pre­treatment platelet count of > 20
x 109/L, platelet absolute increase of ≥ 30 x 109/L; for pre-treatment platelet count of < 20 x 109/L, platelet absolute increase of ≥ 20 x 109/L and ≥
100% from pre­treatment level  * HI­N – neutrophil count increase of ≥ 100% from pre­treatment level and an absolute increase of ≥ 500/mm3

No response (NR) / stable disease (SD) – does not meet the criteria for at least HI, but no evidence of disease progression

Progression from
hematologic improvement
(Prog from HI)

– requires at least one of the following, in the absence of another explanation (e.g., infection, bleeding, ongoing chemotherapy, etc.): *
≥ 50% reduction from maximum response levels in granulocytes or platelets * reduction in hemoglobin by ≥ 1.5 g/dL *transfusion
dependence

Relapse from complete
remission (Rel from CR)

– requires at least one of the following: * return to pre­treatment bone marrow blast percentage * decrease of ≥ 50% from maximum
response levels in granulocytes or platelets * transfusion dependence, or hemoglobin level ≥ 1.5 g/dL lower than prior to therapy

Not assessed

Specify the cell line examined to determine HI status257

HI-
E

– hemoglobin increase of ≥ 1.5 g/dL untransfused; for RBC transfusions performed for Hgb ≤ 9.0, reduction in RBC units transfused in 8 weeks by ≥ 4
units compared to the pre-treatment transfusion number in 8 weeks

HI-
P

– for pre­treatment platelet count of > 20 x 109/L, platelet absolute increase of ≥ 30 x 109/L; for pre-treatment platelet count of < 20 x 109/L, platelet
absolute increase of ≥ 20 x 109/L and ≥ 100% from pre­treatment level 

HI-N – neutrophil count increase of ≥ 100% from pre­treatment level and an absolute increase of ≥ 500/mm3

Date of progression:258 __ __ __ __ - __ __- __ __

Date of relapse:259 __ __ __ __ - __ __- __ __

Date assessed:260 __ __ __ __ - __ __- __ __

Other Leukemia (OL) Questions: 261 - 267

Specify the other leukemia classification261

Specify other leukemia:262

Was any 17p abnormality detected?

yes no

263

Did a histologic transformation to diffuse large B-cell lymphoma (Richter syndrome) occur at any time after CLL diagnosis?264

yes - Also complete NHL Disease Classification questions

no

What was the disease status? (Atypical CML)265

Primary induction failure

1st complete remission (no previous bone marrow or extramedullary relapse)

2nd complete remission

≥3rd complete remission

1st relapse

2nd relapse

≥3rd relapse

No treatment

What was the disease status? (CLL, PLL, Hairy cell leukemia)266

Complete remission (CR)

Partial remission (PR)

Stable disease (SD)

Progressive disease (Prog)

Untreated

Not assessed

Date assessed:267 __ __ __ __ - __ __- __ __

Hodgkin and Non-Hodgkin Lymphoma Questions: 268 - 285

Specify the lymphoma histology (at infusion)268

Specify other lymphoma histology:269

Assignment of DLBCL (germinal center B-cell type vs. activated B-cell type) subtype was based on270

Immunohistochemistry (e.g. Han's algorithm)

Gene expression profile

Unknown method

Is the lymphoma histology reported at transplant a transformation from CLL?

yes no

271

Was any 17p abnormality detected?

yes no

272

Is the lymphoma histology reported at transplant a transformation from a different lymphoma histology? (Not CLL)

Yes No

273

Specify the original lymphoma histology (prior to transformation)274

Specify other lymphoma histology:275

Date of original lymphoma diagnosis:276 __ __ __ __ - __ __- __ __ (report the date of diagnosis of original lymphoma subtype)

Was a PET (or PET/CT) scan performed? (at last evaluation prior to the start of the preparative regimen / infusion)

yes no

277

Was the PET (or PET/CT) scan positive for lymphoma involvement at any disease site?

yes no

278

Date of PET scan

Known Unknown

279

Date of PET (or PET/CT) scan:280 __ __ __ __ - __ __- __ __

Deauville (five-point) score of the PET (or PET/CT) scan

Known Unknown

281

Scale282

1 - no uptake or residual uptake

2 - slight uptake, but below blood pool (mediastinum)

3 - uptake above mediastinal, but below or equal to uptake in the liver

4 - uptake slightly to moderately higher than liver

5 - markedly increased uptake or any new lesions

What was the disease status?283

Total number of lines of therapy received

1 line 2 lines 3+ lines

284

Date assessed:285 __ __ __ __ - __ __- __ __

Multiple Myeloma / Plasma Cell Disorder (PCD) Questions: 286 - 317

Specify the multiple myeloma/plasma cell disorder (PCD) classification286

Specify other plasma cell disorder:287

Light chain

kappa lambda

288

What was the Durie-Salmon staging? (at diagnosis)289

Stage
I

(All of the following: Hgb > 10g/dL; serum calcium normal or <10.5 mg/dL; bone x-ray normal bone structure (scale 0), or solitary bone plasmacytoma
only; low M-component production rates IgG< 5g/dL, IgA < 3g/dL; urine light chain M-component on electrophoresis <4 g/24h)

Stage II (Fitting neither Stage I or III) 

Stage
III

(One or more of the following: Hgb < 8.5 g/dL; serum calcium > 12 mg/dL; advanced lytic bone lesions (scale 3); high M-component production rates
IgG > 7g/dL, IgA > 5 g/dL; Bence Jones protein > 12g/24h)

Unknown

What was the Durie-Salmon sub classification? (at diagnosis)290

A - relatively normal renal function (serum creatinine < 2.0 mg/dL)

B ­ abnormal renal function (serum creatinine ≥ 2.0 mg/dL)

Serum β2­microglobulin:291 μg/dL mg/L nmol/L

Serum albumin:292 g/dL g/L

Stage293

1 (β2 ­mic < 3.5, S. albumin ≥3.5)

2 (Not fitting stage 1 or 3)

3 (β2­mic ≥ 5.5; S. albumin ­)

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

294

Results of tests295

Abnormalities identified

No evaluable metaphases

No abnormalities

+3

yes no

296

+5

yes no

297

+7

yes no

298

+9

yes no

299

+11

yes no

300

+15

yes no

301

+19

yes no

302

t(4;14)

yes no

303

t(6;14)

yes no

304

t(11;14)

yes no

305

t(14;16)

yes no

306

t(14;20)

yes no

307

del(13q) / 13q-

yes no

308

del (17p) / 17p-

yes no

309

Hyperdiploid (>50)

yes no

310

Hypodiploid (<46)

yes no

311

Any abnormality at 1q

yes no

312

Any abnormality at 1p

yes no

313

Other abnormality

yes no

314

Specify other abnormality:315

What was the disease status?316

Stringent
complete
remission
(sCR)

- CR as defined, plus: normal free light chain ratio, and absence of clonal cells in the bone marrow by immunohistochemistry of immunofluorescence
(confirmation with repeat bone marrow biopsy not needed). (Presence and/or absence of clonal cells is based upon the Κ/λ ratio. An abnormal Κ/λ ratio by
immunohistochemistry and/or immunofluorescence requires a minimum of 100 plasma cells for analysis.  An abnormal ratio reflecting the presence of
an abnormal clone is Κ/λ of > 4:1 or < 1:2.) sCR requires two consecutive assessments made at any time before the institution of any new therapy, and
no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy sCR
requirements. 

Complete
remission
(CR)

- negative immunofixation on serum and urine samples, and disappearance of any soft tissue plasmacytomas, and < 5% plasma cells in the bone
marrow (confirmation with repeat bone marrow biopsy not needed).  CR requires two consecutive assessments made at any time before the institution
of any new therapy, and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not
required to satisfy CR requirements. 

Near
complete
remission
(nCR)

- serum and urine M-protein detectable by immunoelectrophoresis (IFE), but not on electrophoresis (negative SPEP & UPEP); < 5% plasma cells in
bone marrow.  nCR requires two consecutive assessments made at any time before the initiation of any new therapy, and no known evidence of
progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy nCR requirements. 

Very good
partial
remission
(VGPR)

­ serum and urine M­protein detectable by immunofixation but not on electrophoresis, or ≥ 90% reduction in serum M­protein and urine M­protein level <
100 mg/24 hours.  VGPR requires two consecutive assessments made at any time before the institution of any new therapy, and no known evidence of
progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy VGPR requirements.

Partial
remission
(PR)

­ ≥ 50% reduction in serum M­protein, and reduction in 24­hour urinary M­protein by ≥ 90% or to < 200 mg/24 hours.  If the serum and urine M­protein are
unmeasurable (i.e., do not meet any of the following criteria: • serum M­protein ≥ 1 g/dL.  Urine M­protein ≥ 200 mg/24 hours • serum free light chain
assay shows involved level ≥ 10 mg/dL, provided serum free light chain ratio is abnormal), a ≥ 50% decrease in the difference between involved and
uninvolved free light chain levels is required in place of the M-protein criteria.  If serum and urine M-protein are unmeasurable, and serum free light assay
is also unmeasurable, a ≥ 50% reduction in plasma cells is required in place of M­protein, provided the baseline bone marrow plasma cell percentage
was ≥ 30%. In addition to the above listed criteria, a ≥ 50% reduction in the size of soft tissue plasmacytomas is also required, if present at baseline. PR
requires two consecutive assessments made at any time before the institution of any new therapy, and no known evidence of progressive or new bone
lesions if radiographic studies were performed; radiographic studies are not required to satisfy PR requirements. 

Stable
disease
(SD)

- not meeting the criteria for CR, VGPR, PR or PD.  SD requires two consecutive assessments made at any time before the institution of any new therapy,
and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy SD
requirements.

Progressive
disease
(PD)

­ requires any one or more of the following:  Increase of ≥ 25% from baseline in:  serum M­component and/or (absolute increase ≥ 0.5 g/dL) (for
progressive disease, serum M­component increases of ≥ 1 g/dL are sufficient to define relapse if the starting M­component is ≥ 5 g/dL).  Urine M­
component and/or (absolute increase ≥ 200 mg/24 hours) for recipients without measurable serum and urine M­protein levels: the difference between
involved and uninvolved free light chain levels (absolute increase > 10 mg/dL).  Bone marrow plasma cell percentage (absolute percentage ≥ 10%)
(relapse from CR has a 5% cutoff vs. 10% for other categories of relapse) definite development of new bone lesions or soft tissue plasmacytomas, or
definite increase in the size of any existing  bone lesions or soft tissue plasmacytomas. Development of hypercalcemia (corrected serum calcium >
11.5 mg/dL or 2.65 mmol) that can be attributed solely to the plasma cell proliferative disorder.  PD requires two consecutive assessments made at
any time before classification as disease progression, and/or the institution of any new therapy.

Relapse
from CR
(Rel)
(untreated)

­ requires one or more of the following: reappearance of serum or urine M­protein by immunofixation or electrophoresis development of ≥ 5% plasma
cells in the bone marrow (relapse from CR has a 5% cutoff vs. 10% for other categories of relapse) appearance of any other sign of progression (e.g.,
new plasmacytoma, lytic bone lesion, hypercalcemia).  Rel requires two consecutive assessments made at any time before classification as relapse,
and/or the institution of any new therapy.

Unknown

Not applicable (Amyloidosis with no evidence of myeloma)

Date assessed:317 __ __ __ __ - __ __- __ __

Solid Tumors Questions: 318 - 319

Specify the solid tumor classification318

Specify other solid tumor:319

Severe Aplastic Anemia Questions: 320 - 321

Specify the severe aplastic anemia classification320

Specify other acquired cytopenic syndrome:321

Inherited Abnormalities of Erythrocyte Differentiation or Function Questions: 322 - 324

Specify the inherited abnormalities of erythrocyte differentiation or function classification322

Specify other constitutional anemia:323

Specify other hemoglobinopathy:324

Disorders of the Immune System Questions: 325 - 327

Specify disorder of immune system classification325

Specify other SCID:326

Specify other immunodeficiency:327

Inherited Abnormalities of Platelets Questions: 328 - 329

Specify inherited abnormalities of platelets classification328

Congenital amegakaryocytosis / congenital thrombocytopenia (501)

Glanzmann thrombasthenia (502)

Other inherited platelet abnormality (509)

Specify other inherited platelet abnormality:329

Inherited Disorders of Metabolism Questions: 330 - 331

Specify inherited disorders of metabolism classification330

Specify other inherited metabolic disorder:331

Histiocytic Disorders Questions: 332 - 333

Specify histiocytic disorder classification332

Specify other histiocytic disorder:333

Autoimmune Diseases Questions: 334 - 341

Specify autoimmune disease classification334

Specify other arthritis:335

Specify other juvenile idiopathic arthritis (JIA):336

Specify other connective tissue disease:337

Specify other vasculitis:338

Specify other autoimmune neurological disorder:339

Specify other autoimmune cytopenia:340

Specify other autoimmune bowel disorder:341

Other Disease Questions: 342 - 342

Specify other disease:342

First Name:

Last Name:

E-mail address:

Date: __ __ __ __ - __ __- __ __

OMB No: 0915-0310

Expiration Date: 1/31/2020

Public Burden Statement:  An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control
number.  The OMB control number for this project is 0915-0310.  Public reporting burden for this collection of information is estimated to average 1.0 hours per response, including the
time for reviewing instructions, searching existing data sources, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other
aspect of this collection of information, including suggestions for reducing this burden, to HRSA Reports Clearance Officer, 5600 Fishers Lane, Room 10-29, Rockville, Maryland, 20857.

Labs at diagnosis

Specify cytogenetic abnormalities identified at diagnosis:

Specify cytogenetic abnormalities identified at diagnosis:

Specify molecular markers identified at diagnosis:

Labs between diagnosis and last evaluation:

Specify cytogenetic abnormalities identified between diagnosis and last evaluation:

Specify cytogenetic abnormalities identified between diagnosis and last evaluation:

Specify molecular markers identified between diagnosis and last evaluation:

Labs at last evaluation:

Specify cytogenetic abnormalities identified at last evaluation:

Specify cytogenetic abnormalities identified at last evaluation:

Specify molecular markers identified at last evaluation:

CNS Leukemia

Status at transplantation:

Laboratory studies at diagnosis:

Specify cytogenetic abnormalities identified at diagnosis:

Specify cytogenetic abnormalities identified at diagnosis:

Specify molecular markers identified at diagnosis:

Laboratory studies between diagnosis and last evaluation:

Specify cytogenetic abnormalities identified between diagnosis and last evaluation:

Specify cytogenetic abnormalities identified between diagnosis and last evaluation:

Specify molecular markers identified between diagnosis and last evaluation:

Laboratory studies at last evaluation:

Specify cytogenetic abnormalities identified at last evaluation:

Specify cytogenetic abnormalities identified at last evaluation:

Specify molecular markers identified at last evaluation:

CNS Leukemia

Status at transplantation:

Status at transplantation:

Laboratory studies at diagnosis of MDS:

Specify abnormalities identified at diagnosis:

Monosomy

Trisomy

Translocation

Deletion

Inversion

Other

Laboratory studies at last evaluation prior to the start of the preparative regimen:

Specify cytogenetic abnormalities identified at last evaluation prior to the start of the preparative regimen:

Monosomy

Trisomy

Translocation

Deletion

Inversion

Other

Status at transplantation:

Status at transplantation:

Status at transplantation / infusion:

I.S.S.:

Specify cytogenetic abnormalities identified at any time prior to the start of the preparative regimen:

Trisomy

Translocation

Deletion

Other

Status at transplantation:

Center: CRID: 

Form 2402 R3.0: Disease Classification

CIBMTR Form 2402 revision 3.0 last updated Monday, January 29, 2018
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 24 / 26



Key Fields

Sequence Number:

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number:

CIBMTR Research ID:

Event date: __ __ __ __ - __ __- __ __

Primary Disease for HCT / Cellular Therapy Questions: 1 - 2

Date of diagnosis of primary disease for HCT / cellular therapy:1 __ __ __ __ - __ __- __ __

What was the primary disease for which the HCT / cellular therapy was performed?2

Acute myelogenous leukemia (AML or ANLL) (10)

Acute lymphoblastic leukemia (ALL) (20)

Acute leukemia of ambiguous lineage and other myeloid neoplasms (80)

Chronic myelogenous leukemia (CML) (40)

Myelodysplastic (MDS) / myeloproliferative (MPN) diseases (50) (Please classify all preleukemias) (If recipient has transformed to AML, indicate AML as the primary disease)

Other leukemia (30) (includes CLL)

Hodgkin lymphoma (150)

Non-Hodgkin lymphoma (100)

Multiple myeloma / plasma cell disorder (PCD) (170)

Solid tumors (200)

Severe aplastic anemia (300) (If the recipient developed MDS or AML, indicate MDS or AML as the primary disease)

Inherited abnormalities of erythrocyte differentiation or function (310)

Disorders of the immune system (400)

Inherited abnormalities of platelets (500)

Inherited disorders of metabolism (520)

Histiocytic disorders (570)

Autoimmune diseases (600)

Other disease (900)

Acute Myelogenous Leukemia (AML) Questions: 3 - 89

Specify the AML classification3

Did AML transform from MDS or MPN?4

yes - Also complete MDS Disease Classification questions

no

Is the disease (AML) therapy related?

yes no Unknown

5

Did the recipient have a predisposing condition?

yes no Unknown

6

Specify condition7

Bloom syndrome

Down syndrome

Fanconi anemia

Dyskeratosis congenita

Other condition

Specify other condition:8

Were cytogenetics tested (karyotyping or FISH)? (at diagnosis)

yes no Unknown

9

Were cytogenetics tested via FISH? (at diagnosis)

Yes No

10

Results of tests11

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities12

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

13

Specify other abnormality:14

Were cytogenetics tested via karyotyping? (at diagnosis)

Yes No

15

Results of tests16

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities17

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

18

Specify other abnormality:19

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

20

Were tests for molecular markers performed? (e.g. PCR, NGS) (at diagnosis)

yes no Unknown

21

CEBPA

Positive Negative Not Done

22

Specify CEBPA mutation23

Biallelic (homozygous)

Monoallelic (heterozygous)

Unknown

FLT3 – D835 point mutation

Positive Negative Not Done

24

FLT3 – ITD mutation

Positive Negative Not Done

25

FLT3 - ITD allelic ratio

Known Unknown

26

Specify FLT3 - ITD allelic ratio:27

IDH1

Positive Negative Not Done

28

IDH2

Positive Negative Not Done

29

KIT

Positive Negative Not Done

30

NPM1

Positive Negative Not Done

31

Other Molecular Marker (1) Questions: 32 - 33

Other molecular marker

Positive Negative Not Done

32

Specify other molecular marker:33

Were cytogenetics tested (karyotyping or FISH)? (between diagnosis and last evaluation)

yes no Unknown

34

Were cytogenetics tested via FISH? (between diagnosis and last evaluation)

Yes No

35

Results of tests36

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities37

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

38

Specify other abnormality:39

Were cytogenetics tested via karyotyping? (between diagnosis and last evaluation)

Yes No

40

Results of tests41

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities42

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

43

Specify other abnormality:44

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

45

Were tests for molecular markers performed? (e.g. PCR, NGS) (between diagnosis and last evaluation)

yes no Unknown

46

CEBPA

Positive Negative Not Done

47

Specify CEBPA mutation48

Biallelic (homozygous)

Monoallelic (heterozygous)

Unknown

FLT3 – D835 point mutation

Positive Negative Not Done

49

FLT3 – ITD mutation

Positive Negative Not Done

50

FLT3 - ITD allelic ratio

Known Unknown

51

Specify FLT3 - ITD allelic ratio:52

IDH1

Positive Negative Not Done

53

IDH2

Positive Negative Not Done

54

KIT

Positive Negative Not Done

55

NPM1

Positive Negative Not Done

56

Other Molecular Marker (1) Questions: 57 - 58

Other molecular marker

Positive Negative Not Done

57

Specify other molecular marker:58

Were cytogenetics tested (karyotyping or FISH)? (at last evaluation)

yes no Unknown

59

Were cytogenetics tested via FISH? (at last evaluation)

Yes No

60

Results of tests61

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities62

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

63

Specify other abnormality:64

Were cytogenetics tested via karyotyping? (at last evaluation)

Yes No

65

Results of tests66

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities67

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

68

Specify other abnormality:69

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

70

Were tests for molecular markers performed? (e.g. PCR, NGS) (at last evaluation)

yes no Unknown

71

CEBPA

Positive Negative Not Done

72

Specify CEBPA mutation73

Biallelic (homozygous)

Monoallelic (heterozygous)

Unknown

FLT3 – D835 point mutation

Positive Negative Not Done

74

FLT3 – ITD mutation

Positive Negative Not Done

75

FLT3 - ITD allelic ratio

Known Unknown

76

Specify FLT3 - ITD allelic ratio:77

IDH1

Positive Negative Not Done

78

IDH2

Positive Negative Not Done

79

KIT

Positive Negative Not Done

80

NPM1

Positive Negative Not Done

81

Other Molecular Marker (1) Questions: 82 - 83

Other molecular marker

Positive Negative Not Done

82

Specify other molecular marker:83

Did the recipient have central nervous system leukemia at any time prior to the start of the preparative regimen / infusion?

yes no Unknown

84

What was the disease status (based on hematological test results)?85

Primary induction failure

1st complete remission (no previous bone marrow or extramedullary relapse) (include CRi)

2nd complete remission

≥3rd complete remission

1st relapse

2nd relapse

≥3rd relapse

No treatment

How many cycles of induction therapy were required to achieve 1st complete remission? (includes CRi)

1 2 ≥ 3

86

Was the recipient in remission by flow cytometry?

Yes No Unknown Not applicable

87

Date of most recent relapse:88 __ __ __ __ - __ __- __ __

Date assessed:89 __ __ __ __ - __ __- __ __

Acute Lymphoblastic Leukemia (ALL) Questions: 90 - 151

Specify ALL classification90

Did the recipient have a predisposing condition?

yes no Unknown

91

Specify condition92

Aplastic anemia - Also complete CIBMTR Form 2028 - APL

Bloom syndrome

Down syndrome

Fanconi anemia - Also complete CIBMTR Form 2029 - FAN

Other condition

Specify other condition:93

Were tyrosine kinase inhibitors given for therapy at any time prior to the start of the preparative regimen / infusion? (e.g. imatinib mesylate, dasatinib, etc.)

yes no

94

Were cytogenetics tested (karyotyping or FISH)? (at diagnosis)

yes no Unknown

95

Were cytogenetics tested via FISH? (at diagnosis)

Yes No

96

Results of tests97

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities98

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

99

Specify other abnormality:100

Were cytogenetics tested via karyotyping? (at diagnosis)

Yes No

101

Results of tests102

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities103

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

104

Specify other abnormality:105

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

106

Were tests for molecular markers performed? (e.g. PCR, NGS) (at diagnosis)

yes no Unknown

107

BCR / ABL

Positive Negative Not Done

108

TEL-AML / AML1

Positive Negative Not Done

109

Other Molecular Marker (1) Questions: 110 - 111

Other molecular marker

Positive Negative Not Done

110

Specify other molecular marker:111

Were cytogenetics tested (karyotyping or FISH)? (between diagnosis and last evaluation)

yes no Unknown

112

Were cytogenetics tested via FISH? (between diagnosis and last evaluation)

Yes No

113

Results of tests114

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities115

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

116

Specify other abnormality:117

Were cytogenetics tested via karyotyping? (between diagnosis and last evaluation)

Yes No

118

Results of tests119

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities120

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

121

Specify other abnormality:122

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

123

Were tests for molecular markers performed? (e.g. PCR, NGS) (between diagnosis and last evaluation)

yes no Unknown

124

BCR / ABL

Positive Negative Not Done

125

TEL-AML / AML1

Positive Negative Not Done

126

Other Molecular Marker (1) Questions: 127 - 128

Other molecular marker

Positive Negative Not Done

127

Specify other molecular marker:128

Were cytogenetics tested (karyotyping or FISH)? (at last evaluation)

yes no Unknown

129

Were cytogenetics tested via FISH? (at last evaluation)

Yes No

130

Results of tests131

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities132

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

133

Specify other abnormality:134

Were cytogenetics tested via karyotyping? (at last evaluation)

Yes No

135

Results of tests136

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities137

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

138

Specify other abnormality:139

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

140

Were tests for molecular markers performed? (e.g. PCR, NGS) (at last evaluation)

yes no Unknown

141

BCR / ABL

Positive Negative Not Done

142

TEL-AML / AML1

Positive Negative Not Done

143

Other Molecular Marker (1) Questions: 144 - 145

Other molecular marker

Positive Negative Not Done

144

Specify other molecular marker:145

Did the recipient have central nervous system leukemia at any time prior to the start of the preparative regimen / infusion?

yes no Unknown

146

What was the disease status (based on hematological test results)?147

Primary induction failure

1st complete remission (no previous marrow or extramedullary relapse) (include CRi)

2nd complete remission

≥3rd complete remission

1st relapse

2nd relapse

≥3rd relapse

No treatment

How many cycles of induction therapy were required to achieve 1st complete remission? (include CRi)

1 2 ≥ 3

148

Was the recipient in remission by flow cytometry?

Yes No Unknown Not applicable

149

Date of most recent relapse:150 __ __ __ __ - __ __- __ __

Date assessed:151 __ __ __ __ - __ __- __ __

Acute Leukemias of Ambiguous Lineage and Other Myeloid Neoplasms Questions: 152 - 155

Specify acute leukemias of ambiguous lineage and other myeloid neoplasm classification152

Blastic plasmacytoid dendritic cell neoplasm (296)

Acute undifferentiated leukemia (31)

Mixed phenotype acute leukemia (MPAL) with t(9;22)(q34.1;q11.2); BCR-ABL1 (84)

Mixed phenotype acute leukemia with t(v; 11q23.3); KMT2A rearranged (85)

Mixed phenotype acute leukemia, B/myeloid, NOS (86)

Mixed phenotype acute leukemia, T/myeloid, NOS (87)

Other acute leukemia of ambiguous lineage or myeloid neoplasm (88)

Specify other acute leukemia of ambiguous lineage or myeloid neoplasm:153

What was the disease status (based on hematological test results)?154

Primary induction failure

1st complete remission (no previous marrow or extramedullary relapse)

2nd complete remission

≥3rd complete remission

1st relapse

2nd relapse

≥3rd relapse

No treatment

Date assessed:155 __ __ __ __ - __ __- __ __

Chronic Myelogenous Leukemia (CML) Questions: 156 - 166

Was therapy given prior to this HCT?

yes no

156

Combination chemotherapy

yes no

157

Hydroxyurea (Droxia, Hydrea)

yes no

158

Tyrosine kinase inhibitor (e.g. imatinib mesylate, dasatinib, nilotinib)

yes no

159

Interferon­α (Intron, Roferon) (includes PEG)

yes no

160

Other therapy

yes no

161

Specify other therapy:162

What was the disease status?163

Complete hematologic response (CHR)

Chronic phase

Accelerated phase

Blast phase

Specify level of response164

No cytogenetic response (No CyR)

Minimal cytogenetic response

Minor cytogenetic response

Partial cytogenetic response (PCyR)

Complete cytogenetic response (CCyR)

Major molecular remission (MMR)

Complete molecular remission (CMR)

Number

1st 2nd 3rd or higher

165

Date assessed:166 __ __ __ __ - __ __- __ __

Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases Questions: 167 - 260

What was the MDS / MPN subtype at diagnosis? - If transformed to AML, indicate AML as primary disease; also complete AML Disease Classification
questions

167

Was the disease (MDS/MPN) therapy related?

yes no Unknown

168

Did the recipient have a predisposing condition?

yes no Unknown

169

Specify condition

Aplastic Anemia Bloom syndrome Down syndrome Fanconi anemia Other condition

170

Specify other condition:171

WBC

Known Unknown

172

173 x 109/L (x 103/mm3)

x 106/L

Hemoglobin

Known Unknown

174

175 g/dL g/L mmol/L

Was RBC transfused ≤ 30 days before date of test?

Yes No

176

Platelets

Known Unknown

177

178 x 109/L (x 103/mm3)

x 106/L

Were platelets transfused ≤ 7 days before date of test?

Yes No

179

Neutrophils

Known Unknown

180

181 %

Blasts in bone marrow

Known Unknown

182

183 %

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

184

Results of tests185

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities186

One (1)

Two (2)

Three (3)

Four or more (4 or more)

–5

yes no

187

-7

yes no

188

–13

yes no

189

–20

yes no

190

–Y

yes no

191

+8

yes no

192

+19

yes no

193

t(1;3)

yes no

194

t(2;11)

yes no

195

t(3;3)

yes no

196

t(3;21)

yes no

197

t(6;9)

yes no

198

t(11;16)

yes no

199

del(3q) / 3q–

yes no

200

del(5q) / 5q-

yes no

201

del(7q) / 7q–

yes no

202

del(9q) / 9q–

yes no

203

del(11q) / 11q–

yes no

204

del(12p) / 12p–

yes no

205

del(13q) / 13q-

yes no

206

del(20q) / 20q–

yes no

207

inv(3)

yes no

208

i17q

yes no

209

Other abnormality

yes no

210

Specify other abnormality:211

Did the recipient progress or transform to a different MDS / MPN subtype between diagnosis and the start of the preparative regimen?

yes no

212

Specify the MDS / MPN classification after transformation:213

Specify the date of the most recent transformation:214 __ __ __ __ - __ __- __ __

Date of MDS diagnosis:215 __ __ __ __ - __ __- __ __

WBC

Known Unknown

216

217 x 109/L (x 103/mm3)

x 106/L

Hemoglobin

Known Unknown

218

219 g/dL g/L mmol/L

Was RBC transfused ≤ 30 days before date of test?

Yes No

220

Platelets

Known Unknown

221

222 x 109/L (x 103/mm3)

x 106/L

Were platelets transfused ≤ 7 days before date of test?

Yes No

223

Neutrophils

Known Unknown

224

225 %

Blasts in bone marrow

Known Unknown

226

227 %

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

228

Results of tests229

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities230

One (1)

Two (2)

Three (3)

Four or more (4 or more)

–5

yes no

231

-7

yes no

232

–13

yes no

233

–20

yes no

234

–Y

yes no

235

+8

yes no

236

+19

yes no

237

t(1;3)

yes no

238

t(2;11)

yes no

239

t(3;3)

yes no

240

t(3;21)

yes no

241

t(6;9)

yes no

242

t(11;16)

yes no

243

del(3q) / 3q–

yes no

244

del(5q) / 5q-

yes no

245

del(7q) / 7q–

yes no

246

del(9q) / 9q–

yes no

247

del(11q) / 11q–

yes no

248

del(12p) / 12p–

yes no

249

del(13q) / 13q-

yes no

250

del(20q) / 20q–

yes no

251

inv(3)

yes no

252

i17q

yes no

253

Other abnormality

yes no

254

Specify other abnormality:255

What was the disease status?256

Complete
remission
(CR)

– requires all of the following, maintained for ≥ 4 weeks: * bone marrow evaluation: <  5% myeloblasts with normal maturation of all cell lines *
peripheral blood evaluation: hemoglobin ≥ 11 g/dL untransfused and without erythropoietin support; ANC ≥ 1000/mm3  without myeloid growth factor
support; platelets ≥ 100 x 109/L without thrombopoietic support; 0% blasts

Hematologic
improvement
(HI)

– requires one measurement of the following, maintained for ≥ 8 weeks without ongoing cytotoxic therapy; specify which cell line was measured to
determine HI response: * HI­E – hemoglobin increase of ≥ 1.5 g/dL untransfused; for RBC transfusions performed for Hgb ≤ 9.0, reduction in RBC
units transfused in 8 weeks by ≥ 4 units compared to the pre­treatment transfusion number in 8 weeks * HI­P – for pre­treatment platelet count of > 20
x 109/L, platelet absolute increase of ≥ 30 x 109/L; for pre-treatment platelet count of < 20 x 109/L, platelet absolute increase of ≥ 20 x 109/L and ≥
100% from pre­treatment level  * HI­N – neutrophil count increase of ≥ 100% from pre­treatment level and an absolute increase of ≥ 500/mm3

No response (NR) / stable disease (SD) – does not meet the criteria for at least HI, but no evidence of disease progression

Progression from
hematologic improvement
(Prog from HI)

– requires at least one of the following, in the absence of another explanation (e.g., infection, bleeding, ongoing chemotherapy, etc.): *
≥ 50% reduction from maximum response levels in granulocytes or platelets * reduction in hemoglobin by ≥ 1.5 g/dL *transfusion
dependence

Relapse from complete
remission (Rel from CR)

– requires at least one of the following: * return to pre­treatment bone marrow blast percentage * decrease of ≥ 50% from maximum
response levels in granulocytes or platelets * transfusion dependence, or hemoglobin level ≥ 1.5 g/dL lower than prior to therapy

Not assessed

Specify the cell line examined to determine HI status257

HI-
E

– hemoglobin increase of ≥ 1.5 g/dL untransfused; for RBC transfusions performed for Hgb ≤ 9.0, reduction in RBC units transfused in 8 weeks by ≥ 4
units compared to the pre-treatment transfusion number in 8 weeks

HI-
P

– for pre­treatment platelet count of > 20 x 109/L, platelet absolute increase of ≥ 30 x 109/L; for pre-treatment platelet count of < 20 x 109/L, platelet
absolute increase of ≥ 20 x 109/L and ≥ 100% from pre­treatment level 

HI-N – neutrophil count increase of ≥ 100% from pre­treatment level and an absolute increase of ≥ 500/mm3

Date of progression:258 __ __ __ __ - __ __- __ __

Date of relapse:259 __ __ __ __ - __ __- __ __

Date assessed:260 __ __ __ __ - __ __- __ __

Other Leukemia (OL) Questions: 261 - 267

Specify the other leukemia classification261

Specify other leukemia:262

Was any 17p abnormality detected?

yes no

263

Did a histologic transformation to diffuse large B-cell lymphoma (Richter syndrome) occur at any time after CLL diagnosis?264

yes - Also complete NHL Disease Classification questions

no

What was the disease status? (Atypical CML)265

Primary induction failure

1st complete remission (no previous bone marrow or extramedullary relapse)

2nd complete remission

≥3rd complete remission

1st relapse

2nd relapse

≥3rd relapse

No treatment

What was the disease status? (CLL, PLL, Hairy cell leukemia)266

Complete remission (CR)

Partial remission (PR)

Stable disease (SD)

Progressive disease (Prog)

Untreated

Not assessed

Date assessed:267 __ __ __ __ - __ __- __ __

Hodgkin and Non-Hodgkin Lymphoma Questions: 268 - 285

Specify the lymphoma histology (at infusion)268

Specify other lymphoma histology:269

Assignment of DLBCL (germinal center B-cell type vs. activated B-cell type) subtype was based on270

Immunohistochemistry (e.g. Han's algorithm)

Gene expression profile

Unknown method

Is the lymphoma histology reported at transplant a transformation from CLL?

yes no

271

Was any 17p abnormality detected?

yes no

272

Is the lymphoma histology reported at transplant a transformation from a different lymphoma histology? (Not CLL)

Yes No

273

Specify the original lymphoma histology (prior to transformation)274

Specify other lymphoma histology:275

Date of original lymphoma diagnosis:276 __ __ __ __ - __ __- __ __ (report the date of diagnosis of original lymphoma subtype)

Was a PET (or PET/CT) scan performed? (at last evaluation prior to the start of the preparative regimen / infusion)

yes no

277

Was the PET (or PET/CT) scan positive for lymphoma involvement at any disease site?

yes no

278

Date of PET scan

Known Unknown

279

Date of PET (or PET/CT) scan:280 __ __ __ __ - __ __- __ __

Deauville (five-point) score of the PET (or PET/CT) scan

Known Unknown

281

Scale282

1 - no uptake or residual uptake

2 - slight uptake, but below blood pool (mediastinum)

3 - uptake above mediastinal, but below or equal to uptake in the liver

4 - uptake slightly to moderately higher than liver

5 - markedly increased uptake or any new lesions

What was the disease status?283

Total number of lines of therapy received

1 line 2 lines 3+ lines

284

Date assessed:285 __ __ __ __ - __ __- __ __

Multiple Myeloma / Plasma Cell Disorder (PCD) Questions: 286 - 317

Specify the multiple myeloma/plasma cell disorder (PCD) classification286

Specify other plasma cell disorder:287

Light chain

kappa lambda

288

What was the Durie-Salmon staging? (at diagnosis)289

Stage
I

(All of the following: Hgb > 10g/dL; serum calcium normal or <10.5 mg/dL; bone x-ray normal bone structure (scale 0), or solitary bone plasmacytoma
only; low M-component production rates IgG< 5g/dL, IgA < 3g/dL; urine light chain M-component on electrophoresis <4 g/24h)

Stage II (Fitting neither Stage I or III) 

Stage
III

(One or more of the following: Hgb < 8.5 g/dL; serum calcium > 12 mg/dL; advanced lytic bone lesions (scale 3); high M-component production rates
IgG > 7g/dL, IgA > 5 g/dL; Bence Jones protein > 12g/24h)

Unknown

What was the Durie-Salmon sub classification? (at diagnosis)290

A - relatively normal renal function (serum creatinine < 2.0 mg/dL)

B ­ abnormal renal function (serum creatinine ≥ 2.0 mg/dL)

Serum β2­microglobulin:291 μg/dL mg/L nmol/L

Serum albumin:292 g/dL g/L

Stage293

1 (β2 ­mic < 3.5, S. albumin ≥3.5)

2 (Not fitting stage 1 or 3)

3 (β2­mic ≥ 5.5; S. albumin ­)

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

294

Results of tests295

Abnormalities identified

No evaluable metaphases

No abnormalities

+3

yes no

296

+5

yes no

297

+7

yes no

298

+9

yes no

299

+11

yes no

300

+15

yes no

301

+19

yes no

302

t(4;14)

yes no

303

t(6;14)

yes no

304

t(11;14)

yes no

305

t(14;16)

yes no

306

t(14;20)

yes no

307

del(13q) / 13q-

yes no

308

del (17p) / 17p-

yes no

309

Hyperdiploid (>50)

yes no

310

Hypodiploid (<46)

yes no

311

Any abnormality at 1q

yes no

312

Any abnormality at 1p

yes no

313

Other abnormality

yes no

314

Specify other abnormality:315

What was the disease status?316

Stringent
complete
remission
(sCR)

- CR as defined, plus: normal free light chain ratio, and absence of clonal cells in the bone marrow by immunohistochemistry of immunofluorescence
(confirmation with repeat bone marrow biopsy not needed). (Presence and/or absence of clonal cells is based upon the Κ/λ ratio. An abnormal Κ/λ ratio by
immunohistochemistry and/or immunofluorescence requires a minimum of 100 plasma cells for analysis.  An abnormal ratio reflecting the presence of
an abnormal clone is Κ/λ of > 4:1 or < 1:2.) sCR requires two consecutive assessments made at any time before the institution of any new therapy, and
no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy sCR
requirements. 

Complete
remission
(CR)

- negative immunofixation on serum and urine samples, and disappearance of any soft tissue plasmacytomas, and < 5% plasma cells in the bone
marrow (confirmation with repeat bone marrow biopsy not needed).  CR requires two consecutive assessments made at any time before the institution
of any new therapy, and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not
required to satisfy CR requirements. 

Near
complete
remission
(nCR)

- serum and urine M-protein detectable by immunoelectrophoresis (IFE), but not on electrophoresis (negative SPEP & UPEP); < 5% plasma cells in
bone marrow.  nCR requires two consecutive assessments made at any time before the initiation of any new therapy, and no known evidence of
progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy nCR requirements. 

Very good
partial
remission
(VGPR)

­ serum and urine M­protein detectable by immunofixation but not on electrophoresis, or ≥ 90% reduction in serum M­protein and urine M­protein level <
100 mg/24 hours.  VGPR requires two consecutive assessments made at any time before the institution of any new therapy, and no known evidence of
progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy VGPR requirements.

Partial
remission
(PR)

­ ≥ 50% reduction in serum M­protein, and reduction in 24­hour urinary M­protein by ≥ 90% or to < 200 mg/24 hours.  If the serum and urine M­protein are
unmeasurable (i.e., do not meet any of the following criteria: • serum M­protein ≥ 1 g/dL.  Urine M­protein ≥ 200 mg/24 hours • serum free light chain
assay shows involved level ≥ 10 mg/dL, provided serum free light chain ratio is abnormal), a ≥ 50% decrease in the difference between involved and
uninvolved free light chain levels is required in place of the M-protein criteria.  If serum and urine M-protein are unmeasurable, and serum free light assay
is also unmeasurable, a ≥ 50% reduction in plasma cells is required in place of M­protein, provided the baseline bone marrow plasma cell percentage
was ≥ 30%. In addition to the above listed criteria, a ≥ 50% reduction in the size of soft tissue plasmacytomas is also required, if present at baseline. PR
requires two consecutive assessments made at any time before the institution of any new therapy, and no known evidence of progressive or new bone
lesions if radiographic studies were performed; radiographic studies are not required to satisfy PR requirements. 

Stable
disease
(SD)

- not meeting the criteria for CR, VGPR, PR or PD.  SD requires two consecutive assessments made at any time before the institution of any new therapy,
and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy SD
requirements.

Progressive
disease
(PD)

­ requires any one or more of the following:  Increase of ≥ 25% from baseline in:  serum M­component and/or (absolute increase ≥ 0.5 g/dL) (for
progressive disease, serum M­component increases of ≥ 1 g/dL are sufficient to define relapse if the starting M­component is ≥ 5 g/dL).  Urine M­
component and/or (absolute increase ≥ 200 mg/24 hours) for recipients without measurable serum and urine M­protein levels: the difference between
involved and uninvolved free light chain levels (absolute increase > 10 mg/dL).  Bone marrow plasma cell percentage (absolute percentage ≥ 10%)
(relapse from CR has a 5% cutoff vs. 10% for other categories of relapse) definite development of new bone lesions or soft tissue plasmacytomas, or
definite increase in the size of any existing  bone lesions or soft tissue plasmacytomas. Development of hypercalcemia (corrected serum calcium >
11.5 mg/dL or 2.65 mmol) that can be attributed solely to the plasma cell proliferative disorder.  PD requires two consecutive assessments made at
any time before classification as disease progression, and/or the institution of any new therapy.

Relapse
from CR
(Rel)
(untreated)

­ requires one or more of the following: reappearance of serum or urine M­protein by immunofixation or electrophoresis development of ≥ 5% plasma
cells in the bone marrow (relapse from CR has a 5% cutoff vs. 10% for other categories of relapse) appearance of any other sign of progression (e.g.,
new plasmacytoma, lytic bone lesion, hypercalcemia).  Rel requires two consecutive assessments made at any time before classification as relapse,
and/or the institution of any new therapy.

Unknown

Not applicable (Amyloidosis with no evidence of myeloma)

Date assessed:317 __ __ __ __ - __ __- __ __

Solid Tumors Questions: 318 - 319

Specify the solid tumor classification318

Specify other solid tumor:319

Severe Aplastic Anemia Questions: 320 - 321

Specify the severe aplastic anemia classification320

Specify other acquired cytopenic syndrome:321

Inherited Abnormalities of Erythrocyte Differentiation or Function Questions: 322 - 324

Specify the inherited abnormalities of erythrocyte differentiation or function classification322

Specify other constitutional anemia:323

Specify other hemoglobinopathy:324

Disorders of the Immune System Questions: 325 - 327

Specify disorder of immune system classification325

Specify other SCID:326

Specify other immunodeficiency:327

Inherited Abnormalities of Platelets Questions: 328 - 329

Specify inherited abnormalities of platelets classification328

Congenital amegakaryocytosis / congenital thrombocytopenia (501)

Glanzmann thrombasthenia (502)

Other inherited platelet abnormality (509)

Specify other inherited platelet abnormality:329

Inherited Disorders of Metabolism Questions: 330 - 331

Specify inherited disorders of metabolism classification330

Specify other inherited metabolic disorder:331

Histiocytic Disorders Questions: 332 - 333

Specify histiocytic disorder classification332

Specify other histiocytic disorder:333

Autoimmune Diseases Questions: 334 - 341

Specify autoimmune disease classification334

Specify other arthritis:335

Specify other juvenile idiopathic arthritis (JIA):336

Specify other connective tissue disease:337

Specify other vasculitis:338

Specify other autoimmune neurological disorder:339

Specify other autoimmune cytopenia:340

Specify other autoimmune bowel disorder:341

Other Disease Questions: 342 - 342

Specify other disease:342

First Name:

Last Name:

E-mail address:

Date: __ __ __ __ - __ __- __ __

OMB No: 0915-0310

Expiration Date: 1/31/2020

Public Burden Statement:  An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control
number.  The OMB control number for this project is 0915-0310.  Public reporting burden for this collection of information is estimated to average 1.0 hours per response, including the
time for reviewing instructions, searching existing data sources, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other
aspect of this collection of information, including suggestions for reducing this burden, to HRSA Reports Clearance Officer, 5600 Fishers Lane, Room 10-29, Rockville, Maryland, 20857.

Labs at diagnosis

Specify cytogenetic abnormalities identified at diagnosis:

Specify cytogenetic abnormalities identified at diagnosis:

Specify molecular markers identified at diagnosis:

Labs between diagnosis and last evaluation:

Specify cytogenetic abnormalities identified between diagnosis and last evaluation:

Specify cytogenetic abnormalities identified between diagnosis and last evaluation:

Specify molecular markers identified between diagnosis and last evaluation:

Labs at last evaluation:

Specify cytogenetic abnormalities identified at last evaluation:

Specify cytogenetic abnormalities identified at last evaluation:

Specify molecular markers identified at last evaluation:

CNS Leukemia

Status at transplantation:

Laboratory studies at diagnosis:

Specify cytogenetic abnormalities identified at diagnosis:

Specify cytogenetic abnormalities identified at diagnosis:

Specify molecular markers identified at diagnosis:

Laboratory studies between diagnosis and last evaluation:

Specify cytogenetic abnormalities identified between diagnosis and last evaluation:

Specify cytogenetic abnormalities identified between diagnosis and last evaluation:

Specify molecular markers identified between diagnosis and last evaluation:

Laboratory studies at last evaluation:

Specify cytogenetic abnormalities identified at last evaluation:

Specify cytogenetic abnormalities identified at last evaluation:

Specify molecular markers identified at last evaluation:

CNS Leukemia

Status at transplantation:

Status at transplantation:

Laboratory studies at diagnosis of MDS:

Specify abnormalities identified at diagnosis:

Monosomy

Trisomy

Translocation

Deletion

Inversion

Other

Laboratory studies at last evaluation prior to the start of the preparative regimen:

Specify cytogenetic abnormalities identified at last evaluation prior to the start of the preparative regimen:

Monosomy

Trisomy

Translocation

Deletion

Inversion

Other

Status at transplantation:

Status at transplantation:

Status at transplantation / infusion:

I.S.S.:

Specify cytogenetic abnormalities identified at any time prior to the start of the preparative regimen:

Trisomy

Translocation

Deletion

Other

Status at transplantation:

Center: CRID: 

Form 2402 R3.0: Disease Classification

CIBMTR Form 2402 revision 3.0 last updated Monday, January 29, 2018
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 25 / 26



Key Fields

Sequence Number:

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number:

CIBMTR Research ID:

Event date: __ __ __ __ - __ __- __ __

Primary Disease for HCT / Cellular Therapy Questions: 1 - 2

Date of diagnosis of primary disease for HCT / cellular therapy:1 __ __ __ __ - __ __- __ __

What was the primary disease for which the HCT / cellular therapy was performed?2

Acute myelogenous leukemia (AML or ANLL) (10)

Acute lymphoblastic leukemia (ALL) (20)

Acute leukemia of ambiguous lineage and other myeloid neoplasms (80)

Chronic myelogenous leukemia (CML) (40)

Myelodysplastic (MDS) / myeloproliferative (MPN) diseases (50) (Please classify all preleukemias) (If recipient has transformed to AML, indicate AML as the primary disease)

Other leukemia (30) (includes CLL)

Hodgkin lymphoma (150)

Non-Hodgkin lymphoma (100)

Multiple myeloma / plasma cell disorder (PCD) (170)

Solid tumors (200)

Severe aplastic anemia (300) (If the recipient developed MDS or AML, indicate MDS or AML as the primary disease)

Inherited abnormalities of erythrocyte differentiation or function (310)

Disorders of the immune system (400)

Inherited abnormalities of platelets (500)

Inherited disorders of metabolism (520)

Histiocytic disorders (570)

Autoimmune diseases (600)

Other disease (900)

Acute Myelogenous Leukemia (AML) Questions: 3 - 89

Specify the AML classification3

Did AML transform from MDS or MPN?4

yes - Also complete MDS Disease Classification questions

no

Is the disease (AML) therapy related?

yes no Unknown

5

Did the recipient have a predisposing condition?

yes no Unknown

6

Specify condition7

Bloom syndrome

Down syndrome

Fanconi anemia

Dyskeratosis congenita

Other condition

Specify other condition:8

Were cytogenetics tested (karyotyping or FISH)? (at diagnosis)

yes no Unknown

9

Were cytogenetics tested via FISH? (at diagnosis)

Yes No

10

Results of tests11

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities12

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

13

Specify other abnormality:14

Were cytogenetics tested via karyotyping? (at diagnosis)

Yes No

15

Results of tests16

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities17

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

18

Specify other abnormality:19

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

20

Were tests for molecular markers performed? (e.g. PCR, NGS) (at diagnosis)

yes no Unknown

21

CEBPA

Positive Negative Not Done

22

Specify CEBPA mutation23

Biallelic (homozygous)

Monoallelic (heterozygous)

Unknown

FLT3 – D835 point mutation

Positive Negative Not Done

24

FLT3 – ITD mutation

Positive Negative Not Done

25

FLT3 - ITD allelic ratio

Known Unknown

26

Specify FLT3 - ITD allelic ratio:27

IDH1

Positive Negative Not Done

28

IDH2

Positive Negative Not Done

29

KIT

Positive Negative Not Done

30

NPM1

Positive Negative Not Done

31

Other Molecular Marker (1) Questions: 32 - 33

Other molecular marker

Positive Negative Not Done

32

Specify other molecular marker:33

Were cytogenetics tested (karyotyping or FISH)? (between diagnosis and last evaluation)

yes no Unknown

34

Were cytogenetics tested via FISH? (between diagnosis and last evaluation)

Yes No

35

Results of tests36

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities37

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

38

Specify other abnormality:39

Were cytogenetics tested via karyotyping? (between diagnosis and last evaluation)

Yes No

40

Results of tests41

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities42

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

43

Specify other abnormality:44

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

45

Were tests for molecular markers performed? (e.g. PCR, NGS) (between diagnosis and last evaluation)

yes no Unknown

46

CEBPA

Positive Negative Not Done

47

Specify CEBPA mutation48

Biallelic (homozygous)

Monoallelic (heterozygous)

Unknown

FLT3 – D835 point mutation

Positive Negative Not Done

49

FLT3 – ITD mutation

Positive Negative Not Done

50

FLT3 - ITD allelic ratio

Known Unknown

51

Specify FLT3 - ITD allelic ratio:52

IDH1

Positive Negative Not Done

53

IDH2

Positive Negative Not Done

54

KIT

Positive Negative Not Done

55

NPM1

Positive Negative Not Done

56

Other Molecular Marker (1) Questions: 57 - 58

Other molecular marker

Positive Negative Not Done

57

Specify other molecular marker:58

Were cytogenetics tested (karyotyping or FISH)? (at last evaluation)

yes no Unknown

59

Were cytogenetics tested via FISH? (at last evaluation)

Yes No

60

Results of tests61

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities62

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

63

Specify other abnormality:64

Were cytogenetics tested via karyotyping? (at last evaluation)

Yes No

65

Results of tests66

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities67

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-5

-7

-17

-18

-X

-Y

+4

+8

+11

+13

+14

+21

+22

t(3;3)

t(6;9)

t(8;21)

t(9;11)

t(9;22)

t(15;17) and variants

t(16;16)

del(3q) / 3q-

del(5q) / 5q-

del(7q) / 7q-

del(9q) / 9q-

del(11q) / 11q-

del(16q) / 16q-

del(17q) / 17q-

del(20q) / 20q-

del(21q) / 21q-

inv(3)

inv(16)

(11q23) any abnormality

12p any abnormality

Other abnormality

68

Specify other abnormality:69

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

70

Were tests for molecular markers performed? (e.g. PCR, NGS) (at last evaluation)

yes no Unknown

71

CEBPA

Positive Negative Not Done

72

Specify CEBPA mutation73

Biallelic (homozygous)

Monoallelic (heterozygous)

Unknown

FLT3 – D835 point mutation

Positive Negative Not Done

74

FLT3 – ITD mutation

Positive Negative Not Done

75

FLT3 - ITD allelic ratio

Known Unknown

76

Specify FLT3 - ITD allelic ratio:77

IDH1

Positive Negative Not Done

78

IDH2

Positive Negative Not Done

79

KIT

Positive Negative Not Done

80

NPM1

Positive Negative Not Done

81

Other Molecular Marker (1) Questions: 82 - 83

Other molecular marker

Positive Negative Not Done

82

Specify other molecular marker:83

Did the recipient have central nervous system leukemia at any time prior to the start of the preparative regimen / infusion?

yes no Unknown

84

What was the disease status (based on hematological test results)?85

Primary induction failure

1st complete remission (no previous bone marrow or extramedullary relapse) (include CRi)

2nd complete remission

≥3rd complete remission

1st relapse

2nd relapse

≥3rd relapse

No treatment

How many cycles of induction therapy were required to achieve 1st complete remission? (includes CRi)

1 2 ≥ 3

86

Was the recipient in remission by flow cytometry?

Yes No Unknown Not applicable

87

Date of most recent relapse:88 __ __ __ __ - __ __- __ __

Date assessed:89 __ __ __ __ - __ __- __ __

Acute Lymphoblastic Leukemia (ALL) Questions: 90 - 151

Specify ALL classification90

Did the recipient have a predisposing condition?

yes no Unknown

91

Specify condition92

Aplastic anemia - Also complete CIBMTR Form 2028 - APL

Bloom syndrome

Down syndrome

Fanconi anemia - Also complete CIBMTR Form 2029 - FAN

Other condition

Specify other condition:93

Were tyrosine kinase inhibitors given for therapy at any time prior to the start of the preparative regimen / infusion? (e.g. imatinib mesylate, dasatinib, etc.)

yes no

94

Were cytogenetics tested (karyotyping or FISH)? (at diagnosis)

yes no Unknown

95

Were cytogenetics tested via FISH? (at diagnosis)

Yes No

96

Results of tests97

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities98

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

99

Specify other abnormality:100

Were cytogenetics tested via karyotyping? (at diagnosis)

Yes No

101

Results of tests102

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities103

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

104

Specify other abnormality:105

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

106

Were tests for molecular markers performed? (e.g. PCR, NGS) (at diagnosis)

yes no Unknown

107

BCR / ABL

Positive Negative Not Done

108

TEL-AML / AML1

Positive Negative Not Done

109

Other Molecular Marker (1) Questions: 110 - 111

Other molecular marker

Positive Negative Not Done

110

Specify other molecular marker:111

Were cytogenetics tested (karyotyping or FISH)? (between diagnosis and last evaluation)

yes no Unknown

112

Were cytogenetics tested via FISH? (between diagnosis and last evaluation)

Yes No

113

Results of tests114

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities115

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

116

Specify other abnormality:117

Were cytogenetics tested via karyotyping? (between diagnosis and last evaluation)

Yes No

118

Results of tests119

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities120

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

121

Specify other abnormality:122

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

123

Were tests for molecular markers performed? (e.g. PCR, NGS) (between diagnosis and last evaluation)

yes no Unknown

124

BCR / ABL

Positive Negative Not Done

125

TEL-AML / AML1

Positive Negative Not Done

126

Other Molecular Marker (1) Questions: 127 - 128

Other molecular marker

Positive Negative Not Done

127

Specify other molecular marker:128

Were cytogenetics tested (karyotyping or FISH)? (at last evaluation)

yes no Unknown

129

Were cytogenetics tested via FISH? (at last evaluation)

Yes No

130

Results of tests131

Abnormalities identified

No abnormalities

Specify number of distinct cytogenetic abnormalities132

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

133

Specify other abnormality:134

Were cytogenetics tested via karyotyping? (at last evaluation)

Yes No

135

Results of tests136

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities137

One (1)

Two (2)

Three (3)

Four or more (4 or more)

Specify abnormalities (check all that apply)

-7

+4

+8

+17

+21

t(1;19)

t(2;8)

t(4;11)

t(5;14)

t(8;14)

t(8;22)

t(9;22)

t(10;14)

t(11;14)

t(12;21)

del(6q) / 6q-

del(9p) / 9p-

del(12p) / 12p-

add(14q)

(11q23) any abnormality

9p any abnormality

12p any abnormality

Hyperdiploid (> 50)

Hypodiploid (< 45)

iAMP21

Other abnormality

138

Specify other abnormality:139

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

140

Were tests for molecular markers performed? (e.g. PCR, NGS) (at last evaluation)

yes no Unknown

141

BCR / ABL

Positive Negative Not Done

142

TEL-AML / AML1

Positive Negative Not Done

143

Other Molecular Marker (1) Questions: 144 - 145

Other molecular marker

Positive Negative Not Done

144

Specify other molecular marker:145

Did the recipient have central nervous system leukemia at any time prior to the start of the preparative regimen / infusion?

yes no Unknown

146

What was the disease status (based on hematological test results)?147

Primary induction failure

1st complete remission (no previous marrow or extramedullary relapse) (include CRi)

2nd complete remission

≥3rd complete remission

1st relapse

2nd relapse

≥3rd relapse

No treatment

How many cycles of induction therapy were required to achieve 1st complete remission? (include CRi)

1 2 ≥ 3

148

Was the recipient in remission by flow cytometry?

Yes No Unknown Not applicable

149

Date of most recent relapse:150 __ __ __ __ - __ __- __ __

Date assessed:151 __ __ __ __ - __ __- __ __

Acute Leukemias of Ambiguous Lineage and Other Myeloid Neoplasms Questions: 152 - 155

Specify acute leukemias of ambiguous lineage and other myeloid neoplasm classification152

Blastic plasmacytoid dendritic cell neoplasm (296)

Acute undifferentiated leukemia (31)

Mixed phenotype acute leukemia (MPAL) with t(9;22)(q34.1;q11.2); BCR-ABL1 (84)

Mixed phenotype acute leukemia with t(v; 11q23.3); KMT2A rearranged (85)

Mixed phenotype acute leukemia, B/myeloid, NOS (86)

Mixed phenotype acute leukemia, T/myeloid, NOS (87)

Other acute leukemia of ambiguous lineage or myeloid neoplasm (88)

Specify other acute leukemia of ambiguous lineage or myeloid neoplasm:153

What was the disease status (based on hematological test results)?154

Primary induction failure

1st complete remission (no previous marrow or extramedullary relapse)

2nd complete remission

≥3rd complete remission

1st relapse

2nd relapse

≥3rd relapse

No treatment

Date assessed:155 __ __ __ __ - __ __- __ __

Chronic Myelogenous Leukemia (CML) Questions: 156 - 166

Was therapy given prior to this HCT?

yes no

156

Combination chemotherapy

yes no

157

Hydroxyurea (Droxia, Hydrea)

yes no

158

Tyrosine kinase inhibitor (e.g. imatinib mesylate, dasatinib, nilotinib)

yes no

159

Interferon­α (Intron, Roferon) (includes PEG)

yes no

160

Other therapy

yes no

161

Specify other therapy:162

What was the disease status?163

Complete hematologic response (CHR)

Chronic phase

Accelerated phase

Blast phase

Specify level of response164

No cytogenetic response (No CyR)

Minimal cytogenetic response

Minor cytogenetic response

Partial cytogenetic response (PCyR)

Complete cytogenetic response (CCyR)

Major molecular remission (MMR)

Complete molecular remission (CMR)

Number

1st 2nd 3rd or higher

165

Date assessed:166 __ __ __ __ - __ __- __ __

Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases Questions: 167 - 260

What was the MDS / MPN subtype at diagnosis? - If transformed to AML, indicate AML as primary disease; also complete AML Disease Classification
questions

167

Was the disease (MDS/MPN) therapy related?

yes no Unknown

168

Did the recipient have a predisposing condition?

yes no Unknown

169

Specify condition

Aplastic Anemia Bloom syndrome Down syndrome Fanconi anemia Other condition

170

Specify other condition:171

WBC

Known Unknown

172

173 x 109/L (x 103/mm3)

x 106/L

Hemoglobin

Known Unknown

174

175 g/dL g/L mmol/L

Was RBC transfused ≤ 30 days before date of test?

Yes No

176

Platelets

Known Unknown

177

178 x 109/L (x 103/mm3)

x 106/L

Were platelets transfused ≤ 7 days before date of test?

Yes No

179

Neutrophils

Known Unknown

180

181 %

Blasts in bone marrow

Known Unknown

182

183 %

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

184

Results of tests185

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities186

One (1)

Two (2)

Three (3)

Four or more (4 or more)

–5

yes no

187

-7

yes no

188

–13

yes no

189

–20

yes no

190

–Y

yes no

191

+8

yes no

192

+19

yes no

193

t(1;3)

yes no

194

t(2;11)

yes no

195

t(3;3)

yes no

196

t(3;21)

yes no

197

t(6;9)

yes no

198

t(11;16)

yes no

199

del(3q) / 3q–

yes no

200

del(5q) / 5q-

yes no

201

del(7q) / 7q–

yes no

202

del(9q) / 9q–

yes no

203

del(11q) / 11q–

yes no

204

del(12p) / 12p–

yes no

205

del(13q) / 13q-

yes no

206

del(20q) / 20q–

yes no

207

inv(3)

yes no

208

i17q

yes no

209

Other abnormality

yes no

210

Specify other abnormality:211

Did the recipient progress or transform to a different MDS / MPN subtype between diagnosis and the start of the preparative regimen?

yes no

212

Specify the MDS / MPN classification after transformation:213

Specify the date of the most recent transformation:214 __ __ __ __ - __ __- __ __

Date of MDS diagnosis:215 __ __ __ __ - __ __- __ __

WBC

Known Unknown

216

217 x 109/L (x 103/mm3)

x 106/L

Hemoglobin

Known Unknown

218

219 g/dL g/L mmol/L

Was RBC transfused ≤ 30 days before date of test?

Yes No

220

Platelets

Known Unknown

221

222 x 109/L (x 103/mm3)

x 106/L

Were platelets transfused ≤ 7 days before date of test?

Yes No

223

Neutrophils

Known Unknown

224

225 %

Blasts in bone marrow

Known Unknown

226

227 %

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

228

Results of tests229

Abnormalities identified

No evaluable metaphases

No abnormalities

Specify number of distinct cytogenetic abnormalities230

One (1)

Two (2)

Three (3)

Four or more (4 or more)

–5

yes no

231

-7

yes no

232

–13

yes no

233

–20

yes no

234

–Y

yes no

235

+8

yes no

236

+19

yes no

237

t(1;3)

yes no

238

t(2;11)

yes no

239

t(3;3)

yes no

240

t(3;21)

yes no

241

t(6;9)

yes no

242

t(11;16)

yes no

243

del(3q) / 3q–

yes no

244

del(5q) / 5q-

yes no

245

del(7q) / 7q–

yes no

246

del(9q) / 9q–

yes no

247

del(11q) / 11q–

yes no

248

del(12p) / 12p–

yes no

249

del(13q) / 13q-

yes no

250

del(20q) / 20q–

yes no

251

inv(3)

yes no

252

i17q

yes no

253

Other abnormality

yes no

254

Specify other abnormality:255

What was the disease status?256

Complete
remission
(CR)

– requires all of the following, maintained for ≥ 4 weeks: * bone marrow evaluation: <  5% myeloblasts with normal maturation of all cell lines *
peripheral blood evaluation: hemoglobin ≥ 11 g/dL untransfused and without erythropoietin support; ANC ≥ 1000/mm3  without myeloid growth factor
support; platelets ≥ 100 x 109/L without thrombopoietic support; 0% blasts

Hematologic
improvement
(HI)

– requires one measurement of the following, maintained for ≥ 8 weeks without ongoing cytotoxic therapy; specify which cell line was measured to
determine HI response: * HI­E – hemoglobin increase of ≥ 1.5 g/dL untransfused; for RBC transfusions performed for Hgb ≤ 9.0, reduction in RBC
units transfused in 8 weeks by ≥ 4 units compared to the pre­treatment transfusion number in 8 weeks * HI­P – for pre­treatment platelet count of > 20
x 109/L, platelet absolute increase of ≥ 30 x 109/L; for pre-treatment platelet count of < 20 x 109/L, platelet absolute increase of ≥ 20 x 109/L and ≥
100% from pre­treatment level  * HI­N – neutrophil count increase of ≥ 100% from pre­treatment level and an absolute increase of ≥ 500/mm3

No response (NR) / stable disease (SD) – does not meet the criteria for at least HI, but no evidence of disease progression

Progression from
hematologic improvement
(Prog from HI)

– requires at least one of the following, in the absence of another explanation (e.g., infection, bleeding, ongoing chemotherapy, etc.): *
≥ 50% reduction from maximum response levels in granulocytes or platelets * reduction in hemoglobin by ≥ 1.5 g/dL *transfusion
dependence

Relapse from complete
remission (Rel from CR)

– requires at least one of the following: * return to pre­treatment bone marrow blast percentage * decrease of ≥ 50% from maximum
response levels in granulocytes or platelets * transfusion dependence, or hemoglobin level ≥ 1.5 g/dL lower than prior to therapy

Not assessed

Specify the cell line examined to determine HI status257

HI-
E

– hemoglobin increase of ≥ 1.5 g/dL untransfused; for RBC transfusions performed for Hgb ≤ 9.0, reduction in RBC units transfused in 8 weeks by ≥ 4
units compared to the pre-treatment transfusion number in 8 weeks

HI-
P

– for pre­treatment platelet count of > 20 x 109/L, platelet absolute increase of ≥ 30 x 109/L; for pre-treatment platelet count of < 20 x 109/L, platelet
absolute increase of ≥ 20 x 109/L and ≥ 100% from pre­treatment level 

HI-N – neutrophil count increase of ≥ 100% from pre­treatment level and an absolute increase of ≥ 500/mm3

Date of progression:258 __ __ __ __ - __ __- __ __

Date of relapse:259 __ __ __ __ - __ __- __ __

Date assessed:260 __ __ __ __ - __ __- __ __

Other Leukemia (OL) Questions: 261 - 267

Specify the other leukemia classification261

Specify other leukemia:262

Was any 17p abnormality detected?

yes no

263

Did a histologic transformation to diffuse large B-cell lymphoma (Richter syndrome) occur at any time after CLL diagnosis?264

yes - Also complete NHL Disease Classification questions

no

What was the disease status? (Atypical CML)265

Primary induction failure

1st complete remission (no previous bone marrow or extramedullary relapse)

2nd complete remission

≥3rd complete remission

1st relapse

2nd relapse

≥3rd relapse

No treatment

What was the disease status? (CLL, PLL, Hairy cell leukemia)266

Complete remission (CR)

Partial remission (PR)

Stable disease (SD)

Progressive disease (Prog)

Untreated

Not assessed

Date assessed:267 __ __ __ __ - __ __- __ __

Hodgkin and Non-Hodgkin Lymphoma Questions: 268 - 285

Specify the lymphoma histology (at infusion)268

Specify other lymphoma histology:269

Assignment of DLBCL (germinal center B-cell type vs. activated B-cell type) subtype was based on270

Immunohistochemistry (e.g. Han's algorithm)

Gene expression profile

Unknown method

Is the lymphoma histology reported at transplant a transformation from CLL?

yes no

271

Was any 17p abnormality detected?

yes no

272

Is the lymphoma histology reported at transplant a transformation from a different lymphoma histology? (Not CLL)

Yes No

273

Specify the original lymphoma histology (prior to transformation)274

Specify other lymphoma histology:275

Date of original lymphoma diagnosis:276 __ __ __ __ - __ __- __ __ (report the date of diagnosis of original lymphoma subtype)

Was a PET (or PET/CT) scan performed? (at last evaluation prior to the start of the preparative regimen / infusion)

yes no

277

Was the PET (or PET/CT) scan positive for lymphoma involvement at any disease site?

yes no

278

Date of PET scan

Known Unknown

279

Date of PET (or PET/CT) scan:280 __ __ __ __ - __ __- __ __

Deauville (five-point) score of the PET (or PET/CT) scan

Known Unknown

281

Scale282

1 - no uptake or residual uptake

2 - slight uptake, but below blood pool (mediastinum)

3 - uptake above mediastinal, but below or equal to uptake in the liver

4 - uptake slightly to moderately higher than liver

5 - markedly increased uptake or any new lesions

What was the disease status?283

Total number of lines of therapy received

1 line 2 lines 3+ lines

284

Date assessed:285 __ __ __ __ - __ __- __ __

Multiple Myeloma / Plasma Cell Disorder (PCD) Questions: 286 - 317

Specify the multiple myeloma/plasma cell disorder (PCD) classification286

Specify other plasma cell disorder:287

Light chain

kappa lambda

288

What was the Durie-Salmon staging? (at diagnosis)289

Stage
I

(All of the following: Hgb > 10g/dL; serum calcium normal or <10.5 mg/dL; bone x-ray normal bone structure (scale 0), or solitary bone plasmacytoma
only; low M-component production rates IgG< 5g/dL, IgA < 3g/dL; urine light chain M-component on electrophoresis <4 g/24h)

Stage II (Fitting neither Stage I or III) 

Stage
III

(One or more of the following: Hgb < 8.5 g/dL; serum calcium > 12 mg/dL; advanced lytic bone lesions (scale 3); high M-component production rates
IgG > 7g/dL, IgA > 5 g/dL; Bence Jones protein > 12g/24h)

Unknown

What was the Durie-Salmon sub classification? (at diagnosis)290

A - relatively normal renal function (serum creatinine < 2.0 mg/dL)

B ­ abnormal renal function (serum creatinine ≥ 2.0 mg/dL)

Serum β2­microglobulin:291 μg/dL mg/L nmol/L

Serum albumin:292 g/dL g/L

Stage293

1 (β2 ­mic < 3.5, S. albumin ≥3.5)

2 (Not fitting stage 1 or 3)

3 (β2­mic ≥ 5.5; S. albumin ­)

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

294

Results of tests295

Abnormalities identified

No evaluable metaphases

No abnormalities

+3

yes no

296

+5

yes no

297

+7

yes no

298

+9

yes no

299

+11

yes no

300

+15

yes no

301

+19

yes no

302

t(4;14)

yes no

303

t(6;14)

yes no

304

t(11;14)

yes no

305

t(14;16)

yes no

306

t(14;20)

yes no

307

del(13q) / 13q-

yes no

308

del (17p) / 17p-

yes no

309

Hyperdiploid (>50)

yes no

310

Hypodiploid (<46)

yes no

311

Any abnormality at 1q

yes no

312

Any abnormality at 1p

yes no

313

Other abnormality

yes no

314

Specify other abnormality:315

What was the disease status?316

Stringent
complete
remission
(sCR)

- CR as defined, plus: normal free light chain ratio, and absence of clonal cells in the bone marrow by immunohistochemistry of immunofluorescence
(confirmation with repeat bone marrow biopsy not needed). (Presence and/or absence of clonal cells is based upon the Κ/λ ratio. An abnormal Κ/λ ratio by
immunohistochemistry and/or immunofluorescence requires a minimum of 100 plasma cells for analysis.  An abnormal ratio reflecting the presence of
an abnormal clone is Κ/λ of > 4:1 or < 1:2.) sCR requires two consecutive assessments made at any time before the institution of any new therapy, and
no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy sCR
requirements. 

Complete
remission
(CR)

- negative immunofixation on serum and urine samples, and disappearance of any soft tissue plasmacytomas, and < 5% plasma cells in the bone
marrow (confirmation with repeat bone marrow biopsy not needed).  CR requires two consecutive assessments made at any time before the institution
of any new therapy, and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not
required to satisfy CR requirements. 

Near
complete
remission
(nCR)

- serum and urine M-protein detectable by immunoelectrophoresis (IFE), but not on electrophoresis (negative SPEP & UPEP); < 5% plasma cells in
bone marrow.  nCR requires two consecutive assessments made at any time before the initiation of any new therapy, and no known evidence of
progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy nCR requirements. 

Very good
partial
remission
(VGPR)

­ serum and urine M­protein detectable by immunofixation but not on electrophoresis, or ≥ 90% reduction in serum M­protein and urine M­protein level <
100 mg/24 hours.  VGPR requires two consecutive assessments made at any time before the institution of any new therapy, and no known evidence of
progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy VGPR requirements.

Partial
remission
(PR)

­ ≥ 50% reduction in serum M­protein, and reduction in 24­hour urinary M­protein by ≥ 90% or to < 200 mg/24 hours.  If the serum and urine M­protein are
unmeasurable (i.e., do not meet any of the following criteria: • serum M­protein ≥ 1 g/dL.  Urine M­protein ≥ 200 mg/24 hours • serum free light chain
assay shows involved level ≥ 10 mg/dL, provided serum free light chain ratio is abnormal), a ≥ 50% decrease in the difference between involved and
uninvolved free light chain levels is required in place of the M-protein criteria.  If serum and urine M-protein are unmeasurable, and serum free light assay
is also unmeasurable, a ≥ 50% reduction in plasma cells is required in place of M­protein, provided the baseline bone marrow plasma cell percentage
was ≥ 30%. In addition to the above listed criteria, a ≥ 50% reduction in the size of soft tissue plasmacytomas is also required, if present at baseline. PR
requires two consecutive assessments made at any time before the institution of any new therapy, and no known evidence of progressive or new bone
lesions if radiographic studies were performed; radiographic studies are not required to satisfy PR requirements. 

Stable
disease
(SD)

- not meeting the criteria for CR, VGPR, PR or PD.  SD requires two consecutive assessments made at any time before the institution of any new therapy,
and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy SD
requirements.

Progressive
disease
(PD)

­ requires any one or more of the following:  Increase of ≥ 25% from baseline in:  serum M­component and/or (absolute increase ≥ 0.5 g/dL) (for
progressive disease, serum M­component increases of ≥ 1 g/dL are sufficient to define relapse if the starting M­component is ≥ 5 g/dL).  Urine M­
component and/or (absolute increase ≥ 200 mg/24 hours) for recipients without measurable serum and urine M­protein levels: the difference between
involved and uninvolved free light chain levels (absolute increase > 10 mg/dL).  Bone marrow plasma cell percentage (absolute percentage ≥ 10%)
(relapse from CR has a 5% cutoff vs. 10% for other categories of relapse) definite development of new bone lesions or soft tissue plasmacytomas, or
definite increase in the size of any existing  bone lesions or soft tissue plasmacytomas. Development of hypercalcemia (corrected serum calcium >
11.5 mg/dL or 2.65 mmol) that can be attributed solely to the plasma cell proliferative disorder.  PD requires two consecutive assessments made at
any time before classification as disease progression, and/or the institution of any new therapy.

Relapse
from CR
(Rel)
(untreated)

­ requires one or more of the following: reappearance of serum or urine M­protein by immunofixation or electrophoresis development of ≥ 5% plasma
cells in the bone marrow (relapse from CR has a 5% cutoff vs. 10% for other categories of relapse) appearance of any other sign of progression (e.g.,
new plasmacytoma, lytic bone lesion, hypercalcemia).  Rel requires two consecutive assessments made at any time before classification as relapse,
and/or the institution of any new therapy.

Unknown

Not applicable (Amyloidosis with no evidence of myeloma)

Date assessed:317 __ __ __ __ - __ __- __ __

Solid Tumors Questions: 318 - 319

Specify the solid tumor classification318

Specify other solid tumor:319

Severe Aplastic Anemia Questions: 320 - 321

Specify the severe aplastic anemia classification320

Specify other acquired cytopenic syndrome:321

Inherited Abnormalities of Erythrocyte Differentiation or Function Questions: 322 - 324

Specify the inherited abnormalities of erythrocyte differentiation or function classification322

Specify other constitutional anemia:323

Specify other hemoglobinopathy:324

Disorders of the Immune System Questions: 325 - 327

Specify disorder of immune system classification325

Specify other SCID:326

Specify other immunodeficiency:327

Inherited Abnormalities of Platelets Questions: 328 - 329

Specify inherited abnormalities of platelets classification328

Congenital amegakaryocytosis / congenital thrombocytopenia (501)

Glanzmann thrombasthenia (502)

Other inherited platelet abnormality (509)

Specify other inherited platelet abnormality:329

Inherited Disorders of Metabolism Questions: 330 - 331

Specify inherited disorders of metabolism classification330

Specify other inherited metabolic disorder:331

Histiocytic Disorders Questions: 332 - 333

Specify histiocytic disorder classification332

Specify other histiocytic disorder:333

Autoimmune Diseases Questions: 334 - 341

Specify autoimmune disease classification334

Specify other arthritis:335

Specify other juvenile idiopathic arthritis (JIA):336

Specify other connective tissue disease:337

Specify other vasculitis:338

Specify other autoimmune neurological disorder:339

Specify other autoimmune cytopenia:340

Specify other autoimmune bowel disorder:341

Other Disease Questions: 342 - 342

Specify other disease:342

First Name:

Last Name:

E-mail address:

Date: __ __ __ __ - __ __- __ __

OMB No: 0915-0310

Expiration Date: 1/31/2020

Public Burden Statement:  An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control
number.  The OMB control number for this project is 0915-0310.  Public reporting burden for this collection of information is estimated to average 1.0 hours per response, including the

time for reviewing instructions, searching existing data sources, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other

aspect of this collection of information, including suggestions for reducing this burden, to HRSA Reports Clearance Officer, 5600 Fishers Lane, Room 10-29, Rockville, Maryland, 20857.

Labs at diagnosis

Specify cytogenetic abnormalities identified at diagnosis:

Specify cytogenetic abnormalities identified at diagnosis:

Specify molecular markers identified at diagnosis:

Labs between diagnosis and last evaluation:

Specify cytogenetic abnormalities identified between diagnosis and last evaluation:

Specify cytogenetic abnormalities identified between diagnosis and last evaluation:

Specify molecular markers identified between diagnosis and last evaluation:

Labs at last evaluation:

Specify cytogenetic abnormalities identified at last evaluation:

Specify cytogenetic abnormalities identified at last evaluation:

Specify molecular markers identified at last evaluation:

CNS Leukemia

Status at transplantation:

Laboratory studies at diagnosis:

Specify cytogenetic abnormalities identified at diagnosis:

Specify cytogenetic abnormalities identified at diagnosis:

Specify molecular markers identified at diagnosis:

Laboratory studies between diagnosis and last evaluation:

Specify cytogenetic abnormalities identified between diagnosis and last evaluation:

Specify cytogenetic abnormalities identified between diagnosis and last evaluation:

Specify molecular markers identified between diagnosis and last evaluation:

Laboratory studies at last evaluation:

Specify cytogenetic abnormalities identified at last evaluation:

Specify cytogenetic abnormalities identified at last evaluation:

Specify molecular markers identified at last evaluation:

CNS Leukemia

Status at transplantation:

Status at transplantation:

Laboratory studies at diagnosis of MDS:

Specify abnormalities identified at diagnosis:

Monosomy

Trisomy

Translocation

Deletion

Inversion

Other

Laboratory studies at last evaluation prior to the start of the preparative regimen:

Specify cytogenetic abnormalities identified at last evaluation prior to the start of the preparative regimen:

Monosomy

Trisomy

Translocation

Deletion

Inversion

Other

Status at transplantation:

Status at transplantation:

Status at transplantation / infusion:

I.S.S.:

Specify cytogenetic abnormalities identified at any time prior to the start of the preparative regimen:

Trisomy

Translocation

Deletion

Other

Status at transplantation:

Center: CRID: 

Form 2402 R3.0: Disease Classification

CIBMTR Form 2402 revision 3.0 last updated Monday, January 29, 2018
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 26 / 26